Symbol,Company_Name,NCTId,Phases,Status,Conditions,Interventions,Acronym,Allocation,ArmCount,ArmLabels,ArmTypes,BriefSummary,Collaborators,CompletionDate,CompletionDateType,EligibleAges,EnrollmentCount,EnrollmentType,InterventionModel,LeadSponsorClass,Masking,OfficialTitle,PrimaryCompletionDate,PrimaryCompletionDateType,PrimaryOutcomeMeasures,PrimaryPurpose,Sex,StartDate,StartDateType,StudyType
CAPR,"Capricor Therapeutics, Inc.",NCT05126758,PHASE3,ACTIVE_NOT_RECRUITING,"Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases","Deramiocel (CAP-1002), Placebo",HOPE-3,RANDOMIZED,2,Deramiocel (CAP-1002) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months o",,2026-12,ESTIMATED,10 Years - N/A,106,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy",2025-06-18,ACTUAL,Change in the upper limb function,TREATMENT,MALE,2022-06-22,ACTUAL,INTERVENTIONAL
CAPR,"Capricor Therapeutics, Inc.",NCT04428476,PHASE2,ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy,Deramiocel (CAP-1002),HOPE-2-OLE,,1,Deramiocel,OTHER,"This Phase 2, multi-center, open-label extension trial will provide deramiocel (CAP-1002) to subjects that were enrolled in the HOPE-2 trial and completed 12 months of follow-up. The trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, each separated by three months, over a period of approximately 60 months. Following completion of the initial open-label phase (Month 60), subjects who have completed all Month 60 assessments will be eligible to continue ",,2026-05,ESTIMATED,10 Years - N/A,13,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial,2022-02-16,ACTUAL,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) From Baseline Through Month 12 | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity From Baseline Through Month 12 | Change From Baseline in Functional Capacity as Assessed by Performance of the Upper Limb Test, Version 2 (PUL 2.0) Total Score.",TREATMENT,ALL,2020-08-05,ACTUAL,INTERVENTIONAL
DBVT,DBV Technologies S.A.,NCT05741476,PHASE3,ACTIVE_NOT_RECRUITING,"Allergy, Peanut","DBV712, DBV712",VITESSE,RANDOMIZED,3,DBPC Treatment Period: DBV712 250 mcg | DBPC Treatment Period: Placebo | Open Label Extension Period: DBV712 250 mcg,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.",,2029-10,ESTIMATED,4 Years - 7 Years,600,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy With DBV712 250 μg in 4-7-year-old Children With Peanut Allergy (VITESSE)",2025-11-06,ACTUAL,DBPC Treatment Period: Percentage of Treatment Responders in the DBV712 250 mcg Group Compared to Placebo Group,TREATMENT,ALL,2023-02-21,ACTUAL,INTERVENTIONAL
DBVT,DBV Technologies S.A.,NCT07003919,PHASE3,RECRUITING,"Allergy, Peanut Allergy",,,RANDOMIZED,3,DBPC Treatment Period: DBV712 250 mcg | DBPC Treatment Period: Placebo | Optional Open-Label Extension-Period: DBV712 250 mcg,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.,,2028-05,ESTIMATED,1 Year - 3 Years,480,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy With DBV712 250 mcg in 1-through 3-year-old Children With Peanut Allergy",2026-11,ESTIMATED,"DBPC Treatment Period: Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)",TREATMENT,ALL,2025-06-24,ACTUAL,INTERVENTIONAL
ANAB,"AnaptysBio, Inc.",NCT06041269,PHASE2,ACTIVE_NOT_RECRUITING,Rheumatoid Arthritis,"Rosnilimab, Placebo",,RANDOMIZED,4,Rosnilimab SC Dose 1 | Rosnilimab SC Dose 2 | Rosnilimab SC Dose 3 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)",,2025-05-30,ESTIMATED,18 Years - 65 Years,420,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis",2024-11-29,ESTIMATED,Mean change from Baseline in 28-Joint Disease Activity Score based on CRP (DAS28-CRP) at Week 12,TREATMENT,ALL,2023-08-31,ACTUAL,INTERVENTIONAL
ANAB,"AnaptysBio, Inc.",NCT06127043,PHASE2,ACTIVE_NOT_RECRUITING,Ulcerative Colitis,"Rosnilimab, Placebo",,RANDOMIZED,3,Rosnilimab SC Dose 1 | Rosnilimab SC Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)",,2026-05,ESTIMATED,18 Years - N/A,132,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis",2026-01,ESTIMATED,Mean change in modified Mayo Score (mMs) from Baseline to Week 12,TREATMENT,ALL,2023-12-04,ACTUAL,INTERVENTIONAL
INDV,"Indivior Pharmaceuticals, Inc.",NCT06576843,PHASE2,ACTIVE_NOT_RECRUITING,Moderate to Severe Opioid Use Disorder,"INDV-6001, Suboxone, Sublocade",,NON_RANDOMIZED,9,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 1a | Cohort 2a | Cohort 3a | Cohort 4a | Cohort 7,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a multicentre, open-label, multiple dose study of INDV-6001 in adult participants with moderate or severe OUD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5).

The current study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmuco",,2026-01,ESTIMATED,18 Years - 65 Years,123,ACTUAL,PARALLEL,INDUSTRY,SINGLE,"An Open-label, Multicentre Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Repeated Doses of INDV-6001 in Adults With Moderate to Severe Opioid Use Disorder",2026-01,ESTIMATED,Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the abdomen | Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the abdomen | Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the abdomen | Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the abdomen | Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the abdomen | Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the abdomen | Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injection | Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection location | Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection location | Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection location | Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection location | Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection location | Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection location | Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injection in the back of the upper arm Vs abdomen injection location | Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection location | Steady-state maximum observed plasma concentration (Cmax) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection location | Steady-state time to attain the maximum observed plasma concentration (Tmax) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection location | Steady-state minimum plasma concentration over a dosing interval (Cmin) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection location | Steady-state plasma concentration measured at the end of the dosing interval (Ctrough) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection location | Steady-state average plasma concentration over the dosing interval (Cavg) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection location | Steady-state ratio of peak to trough plasma concentrations over a dosing interval (% fluctuation) of buprenorphine following INDV-6001 injection in the Thigh Vs abdomen injection location,TREATMENT,ALL,2024-09-17,ACTUAL,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT07389590,PHASE4,NOT_YET_RECRUITING,Multiple Sclerosis,"Ublituximab, Ocrelizumab",,RANDOMIZED,2,Ublituximab | Ocrelizumab,EXPERIMENTAL | ACTIVE_COMPARATOR,"The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a ""wearing off"" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.","TG Therapeutics, Inc.",2029-03,ESTIMATED,18 Years - 65 Years,50,ESTIMATED,PARALLEL,OTHER,SINGLE,A Pilot Study of Ublituximab in People With MS Experiencing Wearing Off Phenomena While Receiving Treatment With Ocrelizumab,2028-10,ESTIMATED,Proportion of Patients with Wearing-Off,TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT07211633,PHASE3,RECRUITING,Relapsing Multiple Sclerosis,"Ublituximab, Ublituximab",,RANDOMIZED,3,Ublituximab IV | Ublituximab SC Regimen 1 | Ublituximab SC Regimen 2,ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.,,2028-12-31,ESTIMATED,18 Years - 65 Years,360,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 3, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab Versus Intravenous Ublituximab in Patients With Multiple Sclerosis",2026-12-31,ESTIMATED,Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab,TREATMENT,ALL,2025-07-09,ACTUAL,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT06143514,,RECRUITING,Relapsing Multiple Sclerosis,,PROVIDE,,1,Breast Milk Collection,,The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).,,2026-06-30,ESTIMATED,18 Years - N/A,16,ESTIMATED,,INDUSTRY,,A Post-marketing Study Evaluating the Presence and Concentration of BRIUMVI™ in Breast Milk (PROVIDE),2026-06-30,ESTIMATED,Area Under the Milk Concentration-time Curve from Time 0 to Infinity (AUC0-inf) of BRIUMVI™ | Area Under the Milk Concentration-time Curve from Time 0 to the Last Measurable Observed Concentration (AUC0-last) of BRIUMVI™ | Area Under the Milk Concentration-Time Curve from Time 0 to 24 Hours Post-Dose (AUC0-24) of BRIUMVI™ | Maximum Observed Milk Concentration of BRIUMVI™ (Cmax) | Observed Milk Concentration of BRIUMVI™ at End of Dosing Interval (Ctrough) of BRIUMVI™ | Time of Cmax (Tmax) of BRIUMVI™ in Milk,,FEMALE,2024-03-26,ACTUAL,OBSERVATIONAL
TGTX,"TG Therapeutics, Inc.",NCT06680037,PHASE1,RECRUITING,B-cell Mediated Autoimmune Disorders,Azercabtagene zapreleucel (azer-cel),,NON_RANDOMIZED,1,Azer-cel,EXPERIMENTAL,The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).,,2029-01-01,ESTIMATED,18 Years - N/A,32,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants With B-cell Mediated Autoimmune Disorders",2026-12-01,ESTIMATED,Number of Participants with Dose-Limiting Toxicities (DLTs),TREATMENT,ALL,2025-05-06,ACTUAL,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT07103746,PHASE2,NOT_YET_RECRUITING,Autoimmune Disorders,"Ublituximab, Placebo for Ublituximab",SUMMIT,RANDOMIZED,2,Initial Ublituximab Active Group | Initial Placebo of ublituximab Group,EXPERIMENTAL | EXPERIMENTAL,"This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy.

The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in treating early, active autoantibody positive immune-mediated necrotizing myopathy using the validated 2016 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Myositis Resp","Autoimmunity Centers of Excellence, TG Therapeutics, Rho Federal Systems Division, Inc.",2030-06,ESTIMATED,18 Years - N/A,30,ESTIMATED,PARALLEL,NIH,TRIPLE,"Study of Ublituximab in Early, Active, Autoantibody-Positive, IMMune-MedIated NecroTizing Myopathy (AIM01)",2029-06,ESTIMATED,The primary endpoint is the Total Improvement Score (TIS) at Week 24 reflecting the change from baseline,TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT04130997,PHASE3,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis (RMS),Ublituximab,,,1,Ublituximab Infusions,EXPERIMENTAL,The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).,,2032-05-31,ESTIMATED,18 Years - N/A,1100,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis,2032-05-31,ESTIMATED,Annualized Relapse Rate (ARR),TREATMENT,ALL,2019-11-18,ACTUAL,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT07220252,"PHASE2, PHASE3",NOT_YET_RECRUITING,Relapsing Multiple Sclerosis,"Ublituximab, Placebo, Placebo, Fingolimod",,RANDOMIZED,6,Part A: Ublituximab | Part B: Ublituximab | Part B: Placebo | Part B: Fingolimod | Part B: IV Placebo | Part C: OLE,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,The primary purpose of this study is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of ublituximab in participants ages 10 to less than (\<)18 years and body weight greater than or equal to (≥)25 kilograms (kg) to less than or equal to (≤)40 kg with RMS (Part A) and to evaluate the non-inferiority of ublituximab compared with fingolimod in pediatric RMS participants with body weight ≥ 25 kg (Part B). The study will further evaluate long-term safety and efficacy of ublituximab in,,2033-06-30,ESTIMATED,10 Years - 17 Years,240,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS),2030-01-01,ESTIMATED,Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab | Part A: Maximum Observed Concentration (Cmax) of Ublituximab | Part A: Participant B Cell Counts | Part B: Annualized Relapse Rate (ARR) | Part C: Annualized Relapse Rate (ARR),TREATMENT,ALL,2026-03-31,ESTIMATED,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT07225361,PHASE4,RECRUITING,"Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting",Ublituximab,,,1,Participants with Relapsing Multiple Sclerosis,EXPERIMENTAL,"In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims:

1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.
2. study the pre- and post-treatment change in plasma neurofilament light chain, tested at baseline pre-Ublituximab treatment, and q24 weeks for 96 weeks post Ublituximab treatment initiation.","TG Therapeutics, Inc.",2029-08-01,ESTIMATED,18 Years - 70 Years,40,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis,2029-03-15,ESTIMATED,Change in plasma neurofilament light chain,TREATMENT,ALL,2025-11-28,ACTUAL,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT06864936,,NOT_YET_RECRUITING,Multiple Sclerosis (MS) - Relapsing-remitting,Ublituximab,,NON_RANDOMIZED,2,Ublituximab | Other Disease Modifying Therapy,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use of ublituximab (Briumvi) treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. This study will evaluate the efficacy of ublituximab to modulate MS pathology in a","TG Therapeutics, Inc.",2027-06-30,ESTIMATED,18 Years - 65 Years,30,ESTIMATED,PARALLEL,OTHER,NONE,Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis,2027-03-30,ESTIMATED,Evaluation of the effect of ublituximab on macular hyperreflective foci (HRF) in MS. | Evaluation of the effect of ublituximab on inner limiting membrane (ILM) macrophage-like cells (MLC).,BASIC_SCIENCE,ALL,2026-01-01,ESTIMATED,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT05877963,PHASE3,RECRUITING,Relapsing Multiple Sclerosis,"Ublituximab, Placebo",ENHANCE,RANDOMIZED,4,Part A: Ublituximab | Part B: Ublituximab /Placebo (Treatment Arm A) | Part B: Ublituximab (Treatment Arm B) | Part C: Ublituximab (Treatment Arm C),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-bli",,2027-12-01,ESTIMATED,18 Years - 65 Years,800,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )",2027-12-01,ESTIMATED,Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 | Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab,TREATMENT,ALL,2023-06-13,ACTUAL,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT06433765,,RECRUITING,Multiple Sclerosis,,,,2,BRIUMVI® Exposed Cohort | BRIUMVI® Unexposed Cohort, | ,The primary objective of the study is to compare the prevalence rate of major congenital malformations (MCM) between 2 cohorts of pregnant participants with MS who are exposed to BRIUMVI® and who are unexposed to BRIUMVI®.,,2035-03-31,ESTIMATED,15 Years - 50 Years,728,ESTIMATED,,INDUSTRY,,BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated With BRIUMVI®,2035-03-31,ESTIMATED,Percentage of Participants with Major Congenital Malformations (MCMs),,FEMALE,2024-06-01,ACTUAL,OBSERVATIONAL
TGTX,"TG Therapeutics, Inc.",NCT04624633,PHASE2,ACTIVE_NOT_RECRUITING,"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia","Acalabrutinib, Umbralisib, Ublituximab",,NON_RANDOMIZED,2,Cohort 1-Relapsed Disease | Cohort 2-Treatment Naive,EXPERIMENTAL | EXPERIMENTAL,"This study is testing the effectiveness of the study drug combination of acalabrutinib, umbralisib, and ublituximab in participants with Chronic Lymphocytic leukemia (CLL).

The names of the study drugs involved in this study are/is:

* Acalabrutinib (CALQUENCE®, ACP-196)
* Umbralisib (TGR-1202)
* Ublituximab (TG-1101)","AstraZeneca, TG Therapeutics, Inc.",2028-01-01,ESTIMATED,18 Years - N/A,29,ACTUAL,PARALLEL,OTHER,NONE,"A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Relapsed and Previously Untreated CLL Patients",2023-12-21,ACTUAL,Complete Remission (CR) Rate After 24 Cycles,TREATMENT,ALL,2020-12-15,ACTUAL,INTERVENTIONAL
TGTX,"TG Therapeutics, Inc.",NCT06433752,,RECRUITING,"Relapsing Multiple Sclerosis, Multiple Sclerosis",,ENABLE,,1,BRIUMVI® (Ublituximab-xiiy),,"The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting",,2027-07-01,ESTIMATED,18 Years - N/A,500,ESTIMATED,,INDUSTRY,,REal World ExperieNce With BRIUMVI® (UblituximAB-xiiy) Treated Patients: A Longitudinal REgistry Study (ENABLE),2027-07-01,ESTIMATED,Annualized Relapse Rate (ARR),,ALL,2024-07-22,ACTUAL,OBSERVATIONAL
KALV,"KalVista Pharmaceuticals, Inc.",NCT05505916,PHASE3,ACTIVE_NOT_RECRUITING,Hereditary Angioedema,"KVD900 600 mg, KVD900 300 mg",,NON_RANDOMIZED,2,KVD900 600 mg | KVD900 300 mg,EXPERIMENTAL | EXPERIMENTAL,"This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.",,2026-06-30,ESTIMATED,12 Years - N/A,145,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II",2026-06-30,ESTIMATED,"Frequencies and percentages of patients with AEs, AEs within 2 days of IMP administration, serious AE's and AEs causing premature discontinuation. | Number and percentage of patients with normal or abnormal laboratory results at each scheduled visit. | Number and percentage of patients with normal or abnormal vital sign results at each scheduled visit",TREATMENT,ALL,2022-10-24,ACTUAL,INTERVENTIONAL
KALV,"KalVista Pharmaceuticals, Inc.",NCT05511922,PHASE3,ACTIVE_NOT_RECRUITING,Hereditary Angioedema,"KVD900 600 mg, Drug: KVD900 300 mg",,NON_RANDOMIZED,2,KVD900 600 mg | Experimental: KVD900 300 mg,EXPERIMENTAL | EXPERIMENTAL,This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 (sebetralstat) in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.,,2026-06-30,ESTIMATED,12 Years - 17 Years,11,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial,2026-06-30,ESTIMATED,Pharmacokinetics - Cmax | Pharmacokinetics - Tmax | Pharmacokinetics - AUC,TREATMENT,ALL,2022-10-24,ACTUAL,INTERVENTIONAL
ESPR,"Esperion Therapeutics, Inc.",NCT06300450,,RECRUITING,"Peripheral Artery Disease, Peripheral Vascular Diseases, Dyslipidemias",,PAD-ALERT,RANDOMIZED,2,Alert | No Alert,EXPERIMENTAL | NO_INTERVENTION,"This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.","Esperion Therapeutics, Inc.",2026-07-30,ESTIMATED,18 Years - N/A,400,ESTIMATED,PARALLEL,OTHER,TRIPLE,Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy,2026-02-28,ESTIMATED,Frequency of prescription of oral LDL-C-lowering therapy,TREATMENT,ALL,2023-03-01,ACTUAL,INTERVENTIONAL
ESPR,"Esperion Therapeutics, Inc.",NCT05103254,,RECRUITING,"Pregnancy, Hyperlipidemias","Bempedoic Acid, Bempedoic Acid / Ezetimibe",,,0,,,Bempedoic acid pregnancy surveillance program,,2032-05,ESTIMATED,18 Years - N/A,20,ESTIMATED,,INDUSTRY,,"A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) During Pregnancy",2032-05,ESTIMATED,Major congenital malformations (MCM),,FEMALE,2021-09-01,ACTUAL,OBSERVATIONAL
VTVT,vTv Therapeutics Inc.,NCT06334133,PHASE3,RECRUITING,"Diabetes Mellitus, Type 1","Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo",CATT1,RANDOMIZED,3,Cadisegliatin: 26 Week Double Blind Treatment Period - 800 mg QD | Cadisegliatin: 26 Week Double Blind Treatment Period - 800 mg BID | Placebo: 26 Week Double Blind Treatment Period,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.,,2026-10,ESTIMATED,18 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study",2026-09,ESTIMATED,Change in incidence of Level 2 or Level 3 hypoglycemia,TREATMENT,ALL,2024-06-14,ACTUAL,INTERVENTIONAL
ARQT,"Arcutis Biotherapeutics, Inc.",NCT07105254,PHASE2,RECRUITING,Non-segmental Vitiligo,Roflumilast topical 0.3% foam,,,1,"Open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3%",EXPERIMENTAL,"An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)","Arcutis Biotherapeutics, Inc.",2026-06-15,ESTIMATED,2 Years - 18 Years,20,ESTIMATED,SINGLE_GROUP,NETWORK,NONE,"An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)",2026-05-15,ESTIMATED,The primary endpoint of this study is the number patients achieving F-VASI 50.,TREATMENT,ALL,2025-08-01,ESTIMATED,INTERVENTIONAL
ARQT,"Arcutis Biotherapeutics, Inc.",NCT07340216,PHASE1,RECRUITING,Psoriasis,ARQ-154 Foam 0.3%,,,1,ARQ-154 Foam 0.3%,EXPERIMENTAL,This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.,,2027-02,ESTIMATED,2 Years - 12 Years,16,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open Label, Phase 1, Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% Administered QD in Pediatric Participants With Scalp and Body Psoriasis",2026-12,ESTIMATED,Concentration of Roflumilast and Roflumilast N-Oxide from plasma | Participant incidence of adverse events | Incidence of application site reactions | The incidence of changes from Baseline in the total Children's Depression Inventory 2 (CDI-2)score.,TREATMENT,ALL,2025-12-15,ACTUAL,INTERVENTIONAL
ARQT,"Arcutis Biotherapeutics, Inc.",NCT07077902,PHASE2,RECRUITING,Hidradenitis Suppurativa,Topical roflumilast 0.3% foam,,,1,HS patients arm,EXPERIMENTAL,"This is a phase 2a, open label study.

As psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on therapy for maintenance and flares in patients with moderate to severe disease. The study will include correlative analysis to study gene expression profiling before and after therapy.","Arcutis Biotherapeutics, Inc.",2026-09,ESTIMATED,18 Years - 90 Years,10,ESTIMATED,SINGLE_GROUP,OTHER,NONE,An Open Label Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam as a Mono or add-on Therapy in the Treatment of Hidradenitis Suppurativa With Correlative Analysis.,2026-09,ESTIMATED,Measure the change in gene expression profile at week 16 of using topical roflumilast vs baseline,TREATMENT,ALL,2025-09-25,ACTUAL,INTERVENTIONAL
IVVD,"Invivyd, Inc.",NCT07298434,PHASE3,RECRUITING,COVID-19,"VYD2311-SD, VYD2311-MD, Placebo",DECLARATION,RANDOMIZED,3,VYD2311-SD (single dose) | VYD2311-MD (multidose) | Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19. VYD2311 is a monoclonal antibody that attaches to the virus that causes COVID-19 and helps block it from entering your cells. It is being tested in adults and adolescents at least 12 years old. Participants in this study will be given a ""study drug"" that will be either VYD2311 or placebo.

The study drug will be given as a shot into the muscle in the",,2026-06,ESTIMATED,12 Years - 100 Years,1770,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Triple-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VYD2311 for the Prevention of COVID-19 in Adults and Adolescents",2026-03,ESTIMATED,RT-PCR-confirmed symptomatic COVID-19 through Day 90,PREVENTION,ALL,2026-01-08,ACTUAL,INTERVENTIONAL
IVVD,"Invivyd, Inc.",NCT06523153,PHASE1,ACTIVE_NOT_RECRUITING,COVID-19,VYD2311,,RANDOMIZED,2,VYD2311 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"A study to investigate the safety, tolerability, and pharmacokinetics of a SARS-CoV-2-directed monoclonal antibody in healthy participants",Novotech (Australia) Pty Limited,2025-05,ESTIMATED,18 Years - 65 Years,40,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a SARS-CoV-2-directed Monoclonal Antibody in Healthy Participants",2025-05,ESTIMATED,Incidence of TEAEs (including AEs and SAEs),OTHER,ALL,2024-08-28,ACTUAL,INTERVENTIONAL
ATAI,AtaiBeckley Inc.,NCT05660642,PHASE2,RECRUITING,Treatment Resistant Depression,BPL-003,,RANDOMIZED,2,Arm A | Arm B,EXPERIMENTAL | EXPERIMENTAL,"An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability, and pharmacodynamics of one and two doses of intranasal BPL-003 combined with psychological support, in patients with treatment resistant depression when administered as monotherapy or as adjunctive therapy with defined SSRIs (citalopram, escitalopram, sertraline or fluoxetine).",,2026-11,ESTIMATED,18 Years - 75 Years,64,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label, Phase 2a Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression",2026-11,ESTIMATED,1. To assess the safety and tolerability of single or multiple intranasal doses of BPL-003 in patients with treatment resistant depression,TREATMENT,ALL,2023-02-10,ACTUAL,INTERVENTIONAL
ATAI,AtaiBeckley Inc.,NCT05434156,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Healthy Volunteers, Major Depressive Disorder, Depression","ELE-101, ELE-101 Placebo",,RANDOMIZED,6,Cohort 1 (Part 1) | Cohort 2 (Part 1) | Cohort 3 (Part 1) | Cohort 4 (Part 1) | Cohort 5 (Part 1) | Cohort 6 (Part 2),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).,Beckley Psytech Limited,2026-03,ESTIMATED,18 Years - 65 Years,84,ESTIMATED,SEQUENTIAL,INDUSTRY,TRIPLE,"A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and Part 2, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder.",2025-12,ESTIMATED,Part 1: Percentage of participants with at least one safety event | Part 2: Subjective Drug Intensity Ratings,TREATMENT,ALL,2022-10-27,ACTUAL,INTERVENTIONAL
OCS,Oculis Holding AG,NCT05066997,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,"Dexamethasone ophthalmic suspension (OCS-01), Vehicle",,RANDOMIZED,2,OCS-01 | Vehicle Vehicle,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).,,2026-04,ESTIMATED,18 Years - 85 Years,552,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema",2026-04,ESTIMATED,Mean Change in BCVA (Best Corrected Visual Acuity),TREATMENT,ALL,2021-10-19,ACTUAL,INTERVENTIONAL
OCS,Oculis Holding AG,NCT05608837,PHASE2,ACTIVE_NOT_RECRUITING,"Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative",OCS-01,LEOPARD,RANDOMIZED,4,High Dose UME - 6 drops OCS-01 | Low Dose UME 3 drops OCS-01 and 3 drops Placebo | High dose PSME - 6 drops of OCS-01 | Low dose PSME - 3 drops of OCS-01 and 3 drops of Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01.

Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes","Global Ophthalmic Research Center (GORC), Oculis",2026-09,ESTIMATED,18 Years - N/A,28,ACTUAL,PARALLEL,OTHER,DOUBLE,Efficacy and Safety of Dexamethasone ophthaLmic Suspension Eye drOps in Uveitic and Post Surgical mAculaR eDema (The LEOPARD Study),2026-06,ESTIMATED,Central Subfield Thickness | Visual Acuity,TREATMENT,ALL,2023-05-26,ACTUAL,INTERVENTIONAL
OCS,Oculis Holding AG,NCT06172257,PHASE3,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,"Dexamethasone ophthalmic suspension (OCS-01), Vehicle",,RANDOMIZED,2,OCS-01 | Vehicle ophthalmic suspension,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).,,2026-04,ESTIMATED,18 Years - 85 Years,401,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS 01 Eye Drops in Subjects With Diabetic Macular Edema",2026-04,ESTIMATED,Mean Change from Baseline in BCVA (Best Corrected Visual Acuity),TREATMENT,ALL,2024-03-15,ACTUAL,INTERVENTIONAL
INVA,"Innoviva, Inc.",NCT06801223,PHASE1,RECRUITING,Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC),"Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)",,NON_RANDOMIZED,6,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 Subgroup 1 | Cohort 5 Subgroup 2,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections,Entasis Therapeutics,2028-05-20,ESTIMATED,1 Day - 18 Years,48,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sulbactam-Durlobactam in Hospitalized Pediatric Patients From Birth to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Acinetobacter Baumannii-calcoaceticus Complex Infection",2028-05-05,ESTIMATED,Assess the pharmacokinetic (PK) parameters for maximum concentration (Cmax) of sulbactam and durlobactam | Assess the PK parameters for area under the plasma concentration-time curve from 0 to 24 hours (AUC 0-24) of sulbactam and durlobactam,TREATMENT,ALL,2026-02-28,ESTIMATED,INTERVENTIONAL
INVA,"Innoviva, Inc.",NCT06746883,,RECRUITING,Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC),,,,1,Acinetobacter baumannii-calcoaceticus complex (ABC),,"The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex infection. Participants will be followed for approximately 28 days in order to collect safety and reaction data.",,2029-01-31,ESTIMATED,18 Years - N/A,100,ESTIMATED,,INDUSTRY,,"A Single-arm, Open-label, Prospective, Observational Study to Assess the Safety of Sulbactam-durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter Baumannii-calcoaceticus Complex Infection",2029-01-31,ESTIMATED,"Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs) defined as any event after exposure to sulbactam-durlobactam (SUL-DUR), or event already present that worsens in either intensity or frequency after exposure | Number of participants experiencing TEAEs | Incidence of maximum severity level of TEAEs | Incidence of related TEAEs as assessed by the investigator. | Incidence of serious TEAEs | Percentage of participants experiencing Adverse Events of Special Interest (AESIs) defined as an AE or SAE of concern specific to the sponsor, for which ongoing monitoring is needed. AESIs include: Hypersensitivity reactions, including anaphylaxis. | Number of participants experiencing AESIs | Incidence of maximum severity level of AESIs | Incidence of related AESIs as assessed by the investigator | Incidence of serious AESIs",,ALL,2025-04-28,ACTUAL,OBSERVATIONAL
INVA,"Innoviva, Inc.",NCT06794541,PHASE2,RECRUITING,Complicated Intra-abdominal Infections (cIAI),"Eravacycline 2mg/kg, Eravacycline 1.5mg/kg",,NON_RANDOMIZED,3,Experimental: Cohort 1 | Experimental: Cohort 2a | Experimental: Cohort 2b,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.",Innoviva Specialty Therapeutics,2029-03-19,ESTIMATED,8 Years - 17 Years,35,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients From 8 Years to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAI)",2029-02-17,ESTIMATED,Proportion of patients with Adverse Events (AEs) from the first dose of any amount of eravacycline | Change from baseline values over time in electrocardiogram (ECG) QT measurements | Change from baseline values over time in diastolic blood pressure | Change from baseline values over time in systolic blood pressure | Change from baseline values over time in liver function tests assessed by Comprehensive Metabolic Panel (CMP) | Change from baseline values over time of hemoglobin | Change from baseline values over time in white blood count | Change from baseline values over time in platelets | Change from baseline values over time in kidney function assessed by CMP,TREATMENT,ALL,2025-05-22,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT04519749,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Fabry Disease,4D-310,,NON_RANDOMIZED,4,4D-310 Dose Level 1 - AAV Neutralizing Antibody (NAb) Group A | 4D-310 Dose Level 1 - AAV NAb Titer Group B | 4D-310 Dose Level 2 - AAV NAb Titer Group A and/or B | 4D-310 Dose Expansion,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease.",,2030-06,ESTIMATED,18 Years - N/A,18,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease",2026-01,ESTIMATED,Incidence and severity of adverse events,TREATMENT,ALL,2020-09-01,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT05629559,"PHASE1, PHASE2",RECRUITING,Fabry Disease,4D-310,,NON_RANDOMIZED,4,4D-310 Dose Level -1 | 4D-310 Dose Level 2 | 4D-310 Dose Level 3 | 4D-310 Dose Level 1 (No longer enrolling),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement",,2030-06,ESTIMATED,18 Years - 65 Years,18,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"An Open-Label, Phase 1/2a Trial of Gene Therapy 4D-310 in Adults With Fabry Disease and Cardiac Involvement",2026-06,ESTIMATED,Incidence and severity of adverse events,TREATMENT,ALL,2022-10-16,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT05248230,PHASE2,RECRUITING,Cystic Fibrosis Lung,4D-710,CF,NON_RANDOMIZED,3,4D-710 Phase 1: Dose Exploration | 4D-710 Phase 2: Dose Expansion | 4D-710 Dose Exploration (Sub-Study),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.",,2030-01,ESTIMATED,18 Years - N/A,40,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults With Cystic Fibrosis",2026-12,ESTIMATED,Incidence and severity of adverse events,TREATMENT,ALL,2022-03-29,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT04517149,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,X-Linked Retinitis Pigmentosa,4D-125 IVT Injection,,NON_RANDOMIZED,3,4D-125 Dose Exploration | 4D-125 Dose Expansion | Observational,EXPERIMENTAL | EXPERIMENTAL | OTHER,"This is a Phase 1/2 multicenter study with two parallel parts: an observational natural history cohort and an open-label, prospective interventional trial in males with non-syndromic X-linked retinitis pigmentosa (XLRP) due to mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR).",,2029-05,ESTIMATED,12 Years - N/A,21,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene",2026-06,ESTIMATED,"Incidence and severity of TEAEs and serious adverse events (SAEs), including clinically significant changes in safety parameters",TREATMENT,MALE,2020-06-09,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT06864988,PHASE3,RECRUITING,Macular Neovascularization Secondary to Age-Related Macular Degeneration,"4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)",,RANDOMIZED,2,4D-150 IVT (3E10 vg/eye) | Aflibercept (AFLB) 2 mg IVT,EXPERIMENTAL | ACTIVE_COMPARATOR,"A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration",,2028-06,ESTIMATED,50 Years - N/A,480,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration",2027-06,ESTIMATED,Mean change from baseline in BCVA ETDRS letter score at Week 52,TREATMENT,ALL,2025-03-03,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT05197270,"PHASE1, PHASE2",RECRUITING,Neovascular (Wet) Age-Related Macular Degeneration,"4D-150 IVT, Aflibercept IVT",,RANDOMIZED,10,4D-150 Dose Escalation up to 4 dose levels | 4D-150 Dose Expansion Dose 1 | 4D-150 Dose Expansion Dose 2 | 4D-150 Dose Expansion Control | 4D-150 Steroid Optimization | 4D-150 Population Extension Dose 1 | 4D-150 Population Extension Dose 2 | 4D-150 Population Extension Dose 3 | 4D-150 Contralateral Eye Dose | 4D-150 Vector Shedding Dose,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.

Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.",,2031-01,ESTIMATED,50 Years - N/A,215,ESTIMATED,SEQUENTIAL,INDUSTRY,SINGLE,"A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration",2027-03,ESTIMATED,"Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parameters",TREATMENT,ALL,2021-12-09,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT05930561,PHASE2,ACTIVE_NOT_RECRUITING,"Diabetic Macular Edema, Diabetic Retinopathy","4D-150 IVT, Aflibercept IVT",,NON_RANDOMIZED,5,4D-150 Part 1 Dose Confirmation Dose Level 1 | 4D-150 Part 1 Dose Confirmation Dose Level 2 | 4D-150 Part 2 Dose Expansion Dose Level 1 | 4D-150 Part 2 Dose Expansion Dose Level 2 | 4D-150 Part 2 Dose Expansion Control,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).",,2029-02-28,ESTIMATED,18 Years - N/A,72,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2 Randomized, Active-Controlled, Double-masked Trial of Intravitreal 4D-150 Gene Therapy in Adults With Diabetic Macular Edema (SPECTRA)",2029-02-28,ESTIMATED,"Incidence and severity of TEAEs and SAEs, including clinically significant changes in safety parameters (Part 1) | Annualized number of aflibercept injections in the study eye (Part 2)",TREATMENT,ALL,2023-08-09,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT07064759,PHASE3,RECRUITING,Neovascular Age-Related Macular Degeneration (nAMD),"4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)",4FRONT-2,RANDOMIZED,2,4D-150 IVT (3E10 vg/eye) | Aflibercept (AFLB) 2 mg IVT,EXPERIMENTAL | ACTIVE_COMPARATOR,"A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration",,2029-02,ESTIMATED,50 Years - N/A,480,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration",2028-11,ESTIMATED,Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52,TREATMENT,ALL,2025-07-22,ACTUAL,INTERVENTIONAL
FDMT,"4D Molecular Therapeutics, Inc.",NCT04483440,PHASE1,ACTIVE_NOT_RECRUITING,Choroideremia,4D-110,,NON_RANDOMIZED,3,4D-110 Dose 1 | 4D-110 Dose 2 | 4D-110 Dose 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study will evaluate safety, tolerability, and preliminary efficacy of a single intravitreal (IVT) injection of a recombinant adeno-associated virus (AAV) gene therapy, 4D-110, in male patients with genetically-confirmed Choroideremia (CHM).",,2027-08-31,ESTIMATED,18 Years - N/A,13,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"Phase 1 Open-Label, Dose-Escalation Study of the Safety, Tolerability and Preliminary Efficacy of Intravitreal 4D-110 in Patients With Choroideremia",2027-05-26,ESTIMATED,Frequency and severity of ocular and systemic adverse events (AEs),TREATMENT,MALE,2020-06-02,ACTUAL,INTERVENTIONAL
FULC,"Fulcrum Therapeutics, Inc.",NCT07431398,PHASE1,RECRUITING,Sickle Cell Disease,Pociredir,,,2,Fasted Cohort | Fed Cohort,EXPERIMENTAL | EXPERIMENTAL,This clinical trial is a study to evaluate the pharmacokinetics of the tablet formulation Pociredir in fasted and fed state participants with Sickle Cell Disease (SCD).,,2026-04,ESTIMATED,18 Years - 65 Years,24,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Open-Label Study to Assess Pharmacokinetics After Single Doses of Pociredir in Participants With Sickle Cell Disease",2026-03,ESTIMATED,"Plasma concentration of pociredir under fasted and fed conditions | Maximum plasma concentration (Cmax) of pociredir under fasted and fed conditions | Area under the plasma concentration-time curve from time 0 to 24 hours (AUC(0-24)) of pociredir under fasted and fed conditions | Area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUC(0-tlast)) of pociredir under fasted and fed conditions | Area under the plasma concentration-time curve from time 0, extrapolated to infinity (AUC(0-inf)), of pociredir under fasted and fed conditions | Time to maximum plasma concentration (Tmax) of pociredir under fasted and fed conditions | Terminal disposition rate constant (λz) of pociredir under fasted and fed conditions | Terminal half-life (t1/2) of pociredir under fasted and fed conditions | Apparent volume of distribution during the terminal phase (Vz/F) of pociredir under fasted and fed conditions | Apparent clearance (CL/F) of pociredir under fasted and fed conditions",TREATMENT,ALL,2025-12-13,ACTUAL,INTERVENTIONAL
FULC,"Fulcrum Therapeutics, Inc.",NCT07401823,PHASE2,NOT_YET_RECRUITING,Sickle Cell Disease,Pociredir,,,1,Pociredir,EXPERIMENTAL,This is an open-label study to evaluate the safety and tolerability of long-term treatment with pociredir without a comparator in participants with SCD who have previously been treated and shown benefit with pociredir in feeder study 6058-SCD-101 (NCT05169580). Participants in this study will receive once daily doses of pociredir for up to 48 months.,,2030-07-05,ESTIMATED,18 Years - N/A,50,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of Pociredir in Participants With Sickle Cell Disease (SCD) Who Have Participated in a Pociredir Study,2030-02-04,ESTIMATED,Number of participants reporting Treatment Emergent Adverse Events (TEAEs) | Number of participants with clinically significant changes in 12-lead Electrocardiogram (ECGs) | Number of participants with clinically significant changes in Vital signs | Number of participants with clinically significant changes in Clinical laboratory tests,TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
PTCT,"PTC Therapeutics, Inc.",NCT05515536,PHASE3,ACTIVE_NOT_RECRUITING,Friedreich Ataxia,Vatiquinone,,,1,Vatiquinone,EXPERIMENTAL,The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.,,2027-12-31,ESTIMATED,N/A - N/A,130,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,Long-Term Open-Label Study to Assess the Safety and Efficacy of Vatiquinone in Patients With Friedreich Ataxia,2027-12-31,ESTIMATED,Number of Participants With Adverse Events (AEs),TREATMENT,ALL,2022-12-08,ACTUAL,INTERVENTIONAL
PTCT,"PTC Therapeutics, Inc.",NCT03605550,PHASE1,ACTIVE_NOT_RECRUITING,"High Grade Glioma, Diffuse Intrinsic Pontine Glioma",PTC596,,,1,Treatment (PTC596),EXPERIMENTAL,"The goal of this study is to evaluate the safety of the study drug PTC596 (Unesbulin) taken in combination with radiotherapy (RT) when given to pediatric patients newly diagnosed with High-Grade Glioma (HGG) including diffuse intrinsic pontine glioma (DIPG).

The main aims of the study are to:

* Find the safe dose of the study drug PTC596that can be given without causing serious side effects.
* Find out the amount of drug that enters blood (in all patients) and tumor (in patients who receive dr",PTC Therapeutics,2029-03-01,ESTIMATED,12 Months - 21 Years,64,ESTIMATED,SINGLE_GROUP,OTHER,NONE,A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma,2024-03-01,ACTUAL,"Establish MTD and RP2D of PTC596 | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Maximum Plasma Concentration [Cmax] of PTC596 (A, B, C, D) | Tumor Concentration of PTC596 (B) | Protein levels of BMI1 in tumor",TREATMENT,ALL,2018-08-01,ACTUAL,INTERVENTIONAL
PTCT,"PTC Therapeutics, Inc.",NCT05166161,PHASE3,ACTIVE_NOT_RECRUITING,Phenylketonuria,PTC923,,,1,PTC923,EXPERIMENTAL,"The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.",,2026-06-30,ESTIMATED,N/A - N/A,200,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria,2026-06-30,ESTIMATED,"Number of Treatment-Emergent Adverse Events (TEAEs) | Change From Baseline in Dietary Phe/Protein Consumption at Week 26, Measured During Phe Tolerance Assessment Period",TREATMENT,ALL,2022-02-14,ACTUAL,INTERVENTIONAL
PTCT,"PTC Therapeutics, Inc.",NCT04903288,PHASE2,ACTIVE_NOT_RECRUITING,AADC Deficiency,,,,1,Eladocagene Exuparvovec,EXPERIMENTAL,"This study will have a trial phase, extension phase, and a long-term extension phase. The primary objectives of the trial phase are to assess the pharmacodynamics (PD) of eladocagene exuparvovec treatment by evaluation of homovanillic acid (HVA) levels and to assess the safety of the SmartFlow® magnetic resonance (MR) Compatible Ventricular Cannula for administering eladocagene exuparvovec to pediatric participants with aromatic L-amino acid decarboxylase (AADC) deficiency. The extension phase i",,2028-04-30,ESTIMATED,1 Year - 17 Years,13,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects,2023-05-22,ACTUAL,Change From Baseline in HVA Metabolite Level at the End of the Trial Phase | Number of Participants With Adverse Events (AEs) Associated With the Surgical Administration of Eladocagene Exuparvovec Using the SmartFlow® MR-Compatible Ventricular Cannula,TREATMENT,ALL,2021-05-12,ACTUAL,INTERVENTIONAL
PTCT,"PTC Therapeutics, Inc.",NCT04014530,"PHASE1, PHASE2",RECRUITING,"Colorectal Cancer, Endometrium Cancer",Ataluren + Pembrolizumab,ATAPEMBRO,NON_RANDOMIZED,3,Phase I dMMR and pMMR | Phase II dMMR | Phase II pMMR,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Single Center, open label, Phase I-II trial designed to test the safety and efficacy of the combination of Ataluren and Pembrolizumab for the treatment of metastatic mismatch repair deficient and proficient colorectal adenocarcinoma and metastatic mismatch repair deficient endometrial carcinoma.","Merck Sharp & Dohme LLC, PTC Therapeutics",2023-08-01,ESTIMATED,18 Years - N/A,47,ESTIMATED,SEQUENTIAL,OTHER,NONE,Study of Pembrolizumab Combined With Ataluren In Patients With Metastatic pMMR and dMMR Colorectal Adenocarcinomas or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study,2023-06-01,ESTIMATED,Incidence of treatment-Emergent Adverse Event and the determination of the maximum tolerable dose of Ataluren. | Objective response rate,TREATMENT,ALL,2019-08-01,ACTUAL,INTERVENTIONAL
PTCT,"PTC Therapeutics, Inc.",NCT06302348,PHASE3,RECRUITING,Phenylketonuria,Sepiapterin,EPIPHENY,,1,Sepiapterin,EXPERIMENTAL,The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.,,2031-02-28,ESTIMATED,N/A - 10 Years,56,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin,2031-02-28,ESTIMATED,Mean Change From Baseline in Full-scale Intelligence Quotient (FSIQ) Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition (WPPSI-IV) Score | Mean Change From Baseline in FSIQ Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V) Score,TREATMENT,ALL,2024-03-04,ACTUAL,INTERVENTIONAL
QURE,uniQure N.V.,NCT05243017,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Huntington Disease,,,RANDOMIZED,3,Cohort 1 | Cohort 2 | Cohort 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration.

Cohort 3 participants will receive either high or low dose (1:1 randomization). Participants enrolled in Cohort 3 will also receive an immunosuppression regimen consisting of dexamethasone, sirolimus, and ritu",,2029-10-07,ESTIMATED,25 Years - 65 Years,14,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"A Phase Ib/II Randomized, Double-Blind Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease",2029-03,ESTIMATED,Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Adverse Events | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Vital Signs - Blood Pressure | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Vital Signs - Respiratory Rate | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Vital Signs - Heart Rate | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by Electrocardiograms | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by changes documented in the neurological examinations | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by changes documented in the physical examinations | Evaluate the safety and tolerability by number of participants with clinically significant changes in laboratory tests - Clinical Chemistry | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by number of participants with clinically significant laboratory tests - hematology | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by number of participants with clinical significant laboratory tests - urinalysis | Evaluate the safety and tolerability o by number of participants with clinical significant changes in cerebrospinal fluid (CSF) analysis | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by vector shedding | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by laboratory testing serum and CSF for biomarkers | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by cognitive assessment | Evaluate the safety and tolerability of bilateral striatal delivery of AMT-130 as a total HTT gene lowering therapy in adult subjects with early manifest HD assessed by number of participants with changes in MRI,TREATMENT,ALL,2021-10-07,ACTUAL,INTERVENTIONAL
QURE,uniQure N.V.,NCT06100276,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Amyotrophic Lateral Sclerosis,AMT-162,,NON_RANDOMIZED,2,3 single Ascending Dose Levels | EXPANSION COHORT,EXPERIMENTAL | EXPERIMENTAL,"This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.",,2031-06-30,ESTIMATED,18 Years - N/A,20,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS).",2026-09-30,ESTIMATED,To evaluate the safety and tolerability of ascending doses of intrathecally administered AMT-162 in Participants with SOD1-ALS,TREATMENT,ALL,2024-08-01,ACTUAL,INTERVENTIONAL
QURE,uniQure N.V.,NCT06063850,"PHASE1, PHASE2",RECRUITING,Mesial Temporal Lobe Epilepsy,,GenTLE,,1,AMT-260,EXPERIMENTAL,The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).,,2031-12,ESTIMATED,18 Years - 75 Years,12,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)",2026-11-30,ESTIMATED,To evaluate the safety and tolerability of AMT-260 in adults with unilateral refractory MTLE.,TREATMENT,ALL,2024-06-12,ACTUAL,INTERVENTIONAL
QURE,uniQure N.V.,NCT04120493,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Huntington's Disease,,,NON_RANDOMIZED,5,"Cohort 1 | Cohort 2 | Cohorts 1, 2 | Cohort 3 | Cohort 4",EXPERIMENTAL | EXPERIMENTAL | SHAM_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase 1/2, multicenter, first-in-human (FIH) study. The first three cohorts of the study have completed enrollment, including the randomized, double-blind, sham-controlled cohorts. Cohort 4 is open-label.

Cohort 4 participants will receive high dose AMT-130.",,2029-12,ESTIMATED,25 Years - 65 Years,43,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease",2029-06,ESTIMATED,Number and type of Adverse Events (AE),TREATMENT,ALL,2019-09-06,ACTUAL,INTERVENTIONAL
QURE,uniQure N.V.,NCT06270316,"PHASE1, PHASE2",RECRUITING,Fabry Disease,AMT-191,,NON_RANDOMIZED,3,Dose Ranging Cohort 1 | Dose Ranging Cohort 2 | Dose Ranging Cohort 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.,,2031-04-30,ESTIMATED,18 Years - 50 Years,12,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Single Dose, Dose Ranging Study of Intravenous AAV5-GLA (AMT-191) in Adult Males With Classic Fabry Disease",2027-12-01,ESTIMATED,Evaluate the safety and tolerability of different dose levels of intravenously-administered AMT-191 in Participants with FD | Incidence of Treatment-Emergent Adverse Events (TEAE),TREATMENT,MALE,2024-06-05,ACTUAL,INTERVENTIONAL
VALN,Valneva SE,NCT07163845,,ACTIVE_NOT_RECRUITING,Chikungunya Virus Infection,Live-attenuated CHIKV vaccine VLA1553,,,0,,,This is a cross-sectional serosurvey using household cluster sampling conducted before the VLA1553 pilot vaccination strategy will be implemented in about 10 municipalities in Brazil.,"Fundação Butantan, Coalition for Epidemic Preparedness Innovations",2026-12-31,ESTIMATED,2 Years - N/A,5354,ACTUAL,,INDUSTRY,,Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil,2026-07-31,ESTIMATED,To prospectively evaluate the association between vaccination uptake and previous CHIKV exposure (pre-existing immunity to CHIKV infection) after implementing a pilot vaccination in the age-group approved per label.,,ALL,2025-09-22,ACTUAL,OBSERVATIONAL
VALN,Valneva SE,NCT06334393,PHASE1,ACTIVE_NOT_RECRUITING,"Zika, Zika Virus Infection","VLA1601, CpG 1018®, 3M-052-AF",,RANDOMIZED,5,VLA1601 Low dose | VLA1601 Low dose + CpG 1018® | VLA1601 Low dose + 3M-052-AF | VLA1601 Medium dose | VLA1601 High dose,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This phase 1 clinical trial consists of an initial open-label sentinel run-in (n=25) and a randomized, double-blind, dose-finding (n=125) investigating three antigen dose levels (low, medium and high) of VLA1601 and bedside mixing of the low-dose formulation with one of the two additional adjuvants (CpG1018®, 3M-052-AF/AP 60-702). VLA1601 will be administered according to a two-dose regimen (i.e., on Day 1 and Day 29).

The primary objective of this trial is to assess the safety and tolerability",,2026-04-27,ESTIMATED,18 Years - 49 Years,150,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Phase 1 Double-blind, Randomized, Dose Finding Clinical Trial With an Open-label run-in Part to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years",2025-04-21,ACTUAL,Solicited Adverse Events | Solicited Adverse Events | Neutralizing antibodies against ZIKA virus (ZIKV),PREVENTION,ALL,2024-03-25,ACTUAL,INTERVENTIONAL
VALN,Valneva SE,NCT07414524,,NOT_YET_RECRUITING,Chikungunya Virus Infection,"Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH",,,2,VLA1553 group | Control group, | ,"This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last menstrual period. A matched comparator cohort of pregnant women vaccinated with routine, pregnancy-recommended vaccines (not exposed to VLA1553) is included. No study procedures beyond routine care are performed.","Fundação Butantan, Coalition for Epidemic Preparedness Innovations",2027-12-31,ESTIMATED,18 Years - N/A,200,ESTIMATED,,INDUSTRY,,Observational Study to Evaluate the Safety of Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Pregnant Women Exposed to the Vaccine in Brazil,2027-12-31,ESTIMATED,"Frequency (n,%) of individuals with any outcome (pregnancy and infant health), as described in the protocol. | Frequency (n,%) of specific outcomes (pregnancy and infant health), as described in the protocol.",,FEMALE,2026-03-31,ESTIMATED,OBSERVATIONAL
VALN,Valneva SE,NCT04838444,PHASE3,ACTIVE_NOT_RECRUITING,Chikungunya Virus Infection,VLA1553,,,1,VLA1553,EXPERIMENTAL,"In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).",,2031-05,ESTIMATED,18 Years - N/A,363,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label, Single Arm Trial To Evaluate Antibody Persistence And Long Term Safety Of A Live-Attenuated Chikungunya Virus Vaccine (VLA1553) In Adults Aged 18 Years and Above",2025-12,ESTIMATED,Proportion of participants with seroresponse levels post-vaccination. (defined as µPRNT50 ≥150),PREVENTION,ALL,2021-04-02,ACTUAL,INTERVENTIONAL
VALN,Valneva SE,NCT05477524,PHASE3,ACTIVE_NOT_RECRUITING,Lyme Disease,VLA15,VALOR,RANDOMIZED,4,VLA15 Lot 1 (3-dose primary vaccination series and booster dose) | VLA15 Lot 2 (3-dose primary vaccination series and booster dose) | VLA15 Lot 3 (3-dose primary vaccination series and booster dose) | Placebo (3-dose primary vaccination series and booster dose),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues) 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a",Valneva Austria GmbH,2025-12-26,ESTIMATED,5 Years - N/A,12547,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Placebo-Controlled, Randomized, Observer-Blinded Trial to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, and Lot Consistency of a 6-Valent OspA-Based Lyme Disease Vaccine in Healthy Participants ≥5 Years of Age",2025-12-26,ESTIMATED,Relative incidence rate reduction of confirmed Lyme disease cases in the VLA15 group compared to the placebo group | Percentage of participants reporting local reactions | Percentage of participants reporting systemic events | Percentage of participants reporting adverse events (AEs) | Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs) | Percentage of participants reporting serious adverse events (SAEs) | Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 1 to Lot 2 | Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 1 to Lot 3 | Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 2 to Lot 3 | Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6),PREVENTION,ALL,2022-08-04,ACTUAL,INTERVENTIONAL
MESO,Mesoblast Limited,NCT06325566,PHASE3,RECRUITING,Degenerative Disc Disease,"Rexlemestrocel-L + HA mixture, Saline",HyaluronicAcid,RANDOMIZED,2,Rexlemestrocel-L + HA | Control Group,EXPERIMENTAL | SHAM_COMPARATOR,The primary purpose of this study is to evaluate the efficacy of rexlemestrocel-L+HA compared to control in reducing low back pain at 12 months post-treatment and safety of a single injection of rexlemestrocel-L+HA injected into a lumbar intervertebral disc compared to control through 12 months post-treatment.,,2027-10,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Prospective, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Combined With HA in Subjects With Moderate to Severe Chronic Low Back Pain",2026-10,ESTIMATED,Mean Change From Baseline in Daily Average Low Back Pain at 12 Months Post-treatment Based on Visual Analog Scale (VAS) Score | Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2024-07-03,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT06924970,PHASE2,RECRUITING,Sickle Cell Disease,"Tebapivat, Tebapivat Matched Placebo",,RANDOMIZED,4,Tebapivat 2.5 milligrams (mg) | Tebapivat 5.0 mg | Tebapivat 7.5 mg | Tebapivat Matched Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.,,2027-05,ESTIMATED,16 Years - N/A,56,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease",2026-05,ESTIMATED,Percentage of Participants With Hb Response,TREATMENT,ALL,2025-05-01,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT03481738,,ACTIVE_NOT_RECRUITING,Pyruvate Kinase Deficiency,,PEAK Registry,,1,PKD Diagnosed,,"This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia.

This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospectively for a minimum of 2 years, and up to 9 years.

Data will be collected from participating Registry Physicians, participants, and, where appropriate, parents/guardians who have provided informed co",,2027-05-31,ESTIMATED,N/A - N/A,500,ACTUAL,,INDUSTRY,,Pyruvate Kinase Deficiency Global Longitudinal Registry,2027-05-31,ESTIMATED,Clinical Course of PK Deficiency,,ALL,2018-04-23,ACTUAL,OBSERVATIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT05144256,PHASE3,ACTIVE_NOT_RECRUITING,"Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia","Mitapivat, Mitapivat-matching placebo",ACTIVATE-KidsT,RANDOMIZED,2,Mitapivat | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"ACTIVATE-KidsT (AG348-C-022) is a multicenter study designed to evaluate the efficacy and safety of treatment with mitapivat compared with placebo in pediatric participants with pyruvate kinase deficiency (PK deficiency) who are regularly receiving blood transfusions. Participants will be randomized 2:1 to receive either mitapivat or matching placebo. Randomization will be stratified by age (1 to \< 6 years, 6 to \< 12 years, 12 to \< 18 years) and splenectomy status. Participants will be dosed ",,2029-06,ESTIMATED,1 Year - 17 Years,49,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension Period",2024-05-03,ACTUAL,Percentage of Participants Achieving Transfusion Reduction Response (TRR),TREATMENT,ALL,2022-06-08,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT07075640,PHASE1,RECRUITING,Healthy Participants,"AG-236, Placebo",,RANDOMIZED,3,Treatment Group A | Treatment Group B | Treatment Group C,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.,,2026-08-31,ESTIMATED,18 Years - 55 Years,24,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of AG-236 Administered as a Subcutaneous Dose in Healthy Male and Female Participants",2026-03-25,ESTIMATED,"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to Study Drug",TREATMENT,ALL,2025-07-07,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT04278781,PHASE2,ACTIVE_NOT_RECRUITING,"Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene Mutation",AG-120,,,1,Chondrosarcoma,EXPERIMENTAL,This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.,"Agios Pharmaceuticals, Inc.",2026-03,ESTIMATED,18 Years - N/A,6,ACTUAL,SINGLE_GROUP,OTHER,NONE,Phase II Study of AG-120 in IDH1 Mutant Chondrosarcoma,2026-03,ESTIMATED,Progression free survival,TREATMENT,ALL,2020-03-04,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT07055243,PHASE2,RECRUITING,Anemia,Mitapivat,SATISFY-CA,,1,Mitapivat,EXPERIMENTAL,"This is a prospective exploratory phase 2 study designed to evaluate the safety and efficacy of mitapivat in RBC membranopathies and CDAII, a rare sub type of anemia. Nine patients from Princess Margaret who are diagnosed with CDAII will be enrolled to the study. Patients will be in the trial for 57 weeks treatment weeks and a safety follow up week after 30 days from last dose. First 8 weeks will be dose escalating period followed by 48 weeks of fixed dose period. 57th week will be dose tapering","Agios Pharmaceuticals, Inc.",2027-06-30,ESTIMATED,18 Years - N/A,9,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies - Canada (SATISFY-CA),2026-06-30,ESTIMATED,To evaluate safety of mitapivat,TREATMENT,ALL,2025-06-26,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT03692052,PHASE2,ACTIVE_NOT_RECRUITING,Thalassemia,AG-348,,,1,AG-348,EXPERIMENTAL,"Study AG348-C-010 is a multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of treatment with AG-348 in adult participants with non-transfusion-dependent thalassemia (NTDT). This study includes a core period (up to 24 weeks) followed by an extension period (up to 10 years) for eligible participants. 20 participants with NTDT were enrolled. The initial dose of AG-348 was 50 milligrams (mg) twice daily (BID) with one potential dose-level increase to 100 mg BID",,2030-09-30,ESTIMATED,18 Years - N/A,20,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia",2020-08-20,ACTUAL,Percentage of Participants Achieving a Hemoglobin Response (HR),TREATMENT,ALL,2019-03-20,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT04902833,,ACTIVE_NOT_RECRUITING,"Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia",,,,2,Cohort I | Cohort 2, | ,This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.,"Agios Pharmaceuticals, Inc.",2026-12-31,ESTIMATED,18 Years - N/A,100,ESTIMATED,,OTHER,,Characterization Of Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms,2026-11-30,ESTIMATED,Overall prevalence of possible or likely acquired pyruvate kinase deficiency,,ALL,2022-02-01,ACTUAL,OBSERVATIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT07241234,PHASE1,NOT_YET_RECRUITING,Phenylketonuria,AG-181,,NON_RANDOMIZED,2,Cohort 1: AG-181 | Cohort 2 (Optional Cohort): AG-181,EXPERIMENTAL | EXPERIMENTAL,The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).,,2028-01-17,ESTIMATED,18 Years - 69 Years,20,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1b, Open-label, Multicenter, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of AG-181 in Subjects With Phenylketonuria",2028-01-17,ESTIMATED,"Number of Subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to the Study Drug",TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT04770753,PHASE3,ACTIVE_NOT_RECRUITING,"Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia","Placebo Matching Mitapivat, Mitapivat",,RANDOMIZED,2,Mitapivat | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary purpose of this study was to compare the effect of mitapivat versus placebo on hemolytic anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).,,2028-12,ESTIMATED,18 Years - N/A,194,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)",2023-11-13,ACTUAL,Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline,TREATMENT,ALL,2021-12-20,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT05490446,PHASE2,ACTIVE_NOT_RECRUITING,Myelodysplastic Syndromes,Tebapivat,,NON_RANDOMIZED,4,Core Period: Phase 2a - Tebapivat 5 mg | Core Period: Phase 2b - Tebapivat 10 mg | Core Period: Phase 2b - Tebapivat 15 mg | Core Period: Phase 2b - Tebapivat 20 mg,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.,,2029-03,ESTIMATED,18 Years - N/A,87,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes",2026-03,ESTIMATED,Phase 2a: Proportion of Participants With Hemoglobin (Hb) Response | Phase 2a: Proportion of Participants With Transfusion Independence During the Core Period | Phase 2b: Proportion of Participants With Transfusion Independence,TREATMENT,ALL,2022-11-07,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT05175105,PHASE3,ACTIVE_NOT_RECRUITING,"Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia","Mitapivat, Mitapivat-matching placebo",ACTIVATE-Kids,RANDOMIZED,3,Mitapivat | Placebo | Mitapivat (OLE period),EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"Study ACTIVATE-Kids (AG348-C-023) will evaluate the efficacy and safety of orally administered mitapivat as compared with placebo in pediatric participants with pyruvate kinase deficiency (PKD) who are not regularly receiving blood transfusions. Participants will be randomized 2:1 to receive either mitapivat or matching placebo. Randomization will be stratified by age (1 to \< 6 years, 6 to \< 12 years, 12 to \< 18 years). Participants will be dosed by age and weight during a double-blind period",,2030-01,ESTIMATED,1 Year - 17 Years,30,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused, Followed by a 5-Year Open-label Extension Period",2024-12-13,ACTUAL,Percentage of Participants Achieving a Hemoglobin (Hb) Response,TREATMENT,ALL,2022-06-06,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT04770779,PHASE3,ACTIVE_NOT_RECRUITING,"Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia","Placebo Matching Mitapivat, Mitapivat",ENERGIZE-T,RANDOMIZED,2,Mitapivat | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.,,2029-06,ESTIMATED,18 Years - N/A,258,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)",2024-04-11,ACTUAL,Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR),TREATMENT,ALL,2021-11-30,ACTUAL,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT06286046,PHASE2,NOT_YET_RECRUITING,"Sickle Cell Disease, Nephropathy",Mitapivat,,,1,Mitapivat 100 mg,EXPERIMENTAL,The primary purpose of this study is to evaluate the effect of mitapivat on albumin creatinine ratio (ACR) response in participants with sickle cell disease (SCD) and nephropathy.,,2028-12,ESTIMATED,16 Years - N/A,40,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy (RESIST)",2027-05,ESTIMATED,Percentage of Participants With Albumin Creatinine Ratio (ACR) Response,TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
AGIO,"Agios Pharmaceuticals, Inc.",NCT05031780,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,Sickle Cell Disease,Mitapivat,,RANDOMIZED,7,Phase 2: Mitapivat 50 mg BID | Phase 2: Mitapivat 100 mg BID | Phase 2: Placebo | Phase 2: Open-Label Extension Period | Phase 3: Mitapivat 100 mg BID | Phase 3: Placebo | Phase 3: Open-Label Extension Period,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the long-term effect of mitapivat on efficacy and safety will be explored in an open-label extension portion.",,2030-02,ESTIMATED,16 Years - N/A,286,ACTUAL,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease",2025-10-30,ACTUAL,Phase 2: Percentage of Participants With Hemoglobin (Hb) Response | Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious AEs (SAEs) | Phase 3: Percentage of Participants With Hb Response | Phase 3: Annualized Rate of Sickle Cell Pain Crises (SCPCs),TREATMENT,ALL,2022-02-11,ACTUAL,INTERVENTIONAL
PHAR,Pharming Group N.V.,NCT06990529,PHASE2,RECRUITING,PIDs Linked to PI3K,Leniolisib,,,1,Treatment Arm,EXPERIMENTAL,"This is an open-label extension (OLE) study to extend treatment to patients with primary immunodeficiency (PID) disorders linked to phosphoinositide 3-kinase delta signaling who participated in a prior study of leniolisib, LE 7201. The primary objective is to assess long-term safety and tolerability of leniolisib. Secondary and exploratory objectives include various efficacy and immunophenotyping measures for leniolisib.",Aixial Group,2029-04-13,ESTIMATED,12 Years - 75 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders",2028-09-18,ESTIMATED,To assess the long-term safety and tolerability of leniolisib,TREATMENT,ALL,2025-04-29,ACTUAL,INTERVENTIONAL
PHAR,Pharming Group N.V.,NCT05693129,PHASE3,ACTIVE_NOT_RECRUITING,APDS,Leniolisib,,,1,Leniolisib,EXPERIMENTAL,"This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 1 to 6 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)","CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group",2026-10-28,ESTIMATED,1 Year - 6 Years,16,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension",2026-07-09,ESTIMATED,"Part I & II: Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs) | Part I & II: Change from baseline in clinical laboratory test results | Part I & II: Change from baseline in vital signs | Part I & II: Change from baseline in physical examination findings | Part I & II: Change from baseline in electrocardiograms (ECGs) | Part I & II: Change from baseline in growth and physical development | Part I & II: Reduction in lymphadenopathy as measured by MRI or low-dose CT | Part I: A Percentage of Inhibition of Unstimulated and Stimulated pAkt Levels in B Cells",TREATMENT,ALL,2023-08-30,ACTUAL,INTERVENTIONAL
PHAR,Pharming Group N.V.,NCT05438407,PHASE3,ACTIVE_NOT_RECRUITING,APDS,Leniolisib,,,1,Leniolisib,EXPERIMENTAL,"This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).","CMIC Co, Ltd. Japan, Labcorp Central Laboratory, Fortrea, Aixial Group",2025-12-30,ESTIMATED,4 Years - 11 Years,15,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients Aged 4 to 11 Years With Activated Phosphoinositide 3-Kinase Delta Syndrome Followed by an Open-label Long-term Extension",2025-10-31,ESTIMATED,"Part I & II: Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs) | Part I & II: Change from baseline in clinical laboratory test results | Part I & II: Change from baseline in vital signs | Part I & II: Change from baseline in physical examination findings | Part I & II: Change from baseline in electrocardiograms (ECGs) | Part I & II: Change from baseline in growth and physical development | Part I & II: Reduction in lymphoproliferation as measured by MRI or low-dose CT | Part I: A Percentage of Inhibition of Unstimulated and Stimulated pAkt Levels in B Cells",TREATMENT,ALL,2023-02-01,ACTUAL,INTERVENTIONAL
LQDA,Liquidia Corporation,NCT03992755,PHASE3,ACTIVE_NOT_RECRUITING,Primary Pulmonary Hypertension,LIQ861 Inhaled Treprostinil,,,1,LIQ861 Inhaled Treprostinil,EXPERIMENTAL,The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).,"Nuventra, Inc.",2025-05-31,ESTIMATED,18 Years - N/A,92,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients",2025-05-31,ESTIMATED,Number of participants with treatment emergent adverse events (AEs).,TREATMENT,ALL,2019-07-18,ACTUAL,INTERVENTIONAL
LQDA,Liquidia Corporation,NCT07285655,PHASE3,NOT_YET_RECRUITING,Pulmonary Hypertension Due to Lung Disease (Disorder),"L606, Placebo",Re-Spire,RANDOMIZED,2,L606 (in combination with nebulizer) | Placebo (in combination with nebulizer),EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the ""six-minute walk test""). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by ",,2031-12,ESTIMATED,18 Years - 80 Years,344,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (WHO Group 3)",2029-07,ESTIMATED,Change from baseline in 6-minute walk distance (6MWD) as evaluated by the 6-minute walk test (6MWT),TREATMENT,ALL,2026-04,ESTIMATED,INTERVENTIONAL
LQDA,Liquidia Corporation,NCT06129240,,ACTIVE_NOT_RECRUITING,"Pulmonary Hypertension, Interstitial Lung Disease",LIQ861,ASCENT,,2,Cohort A | Cohort B, | ,"Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.",,2028-02-08,ESTIMATED,18 Years - 80 Years,80,ESTIMATED,,INDUSTRY,,An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension,2027-07-31,ESTIMATED,Cohort A: Incident of treatment-emergent drug/device-related adverse events and Serious Adverse Events (SAEs) | Cohort B: Number of participants with treatment-emergent drug/device-related adverse events and Serious Adverse Events (SAEs),,ALL,2023-12-28,ACTUAL,OBSERVATIONAL
LQDA,Liquidia Corporation,NCT04691154,PHASE3,ACTIVE_NOT_RECRUITING,"Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases",,,,1,L606,EXPERIMENTAL,"This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.","PPD Development, LP",2031-03-31,ESTIMATED,18 Years - 80 Years,28,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostinil Inhalation Suspension (L606) in Subjects With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease",2025-03-20,ACTUAL,Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs | Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs | Safety/Tolerability assessed by incidence of treatment-emergent AEs/SAEs (long-term),TREATMENT,ALL,2021-08-01,ACTUAL,INTERVENTIONAL
LXRX,"Lexicon Pharmaceuticals, Inc.",NCT05696366,"PHASE1, PHASE2",RECRUITING,Type 1 Diabetes,"Sotagliflozin, Volagidemab",SOTA,RANDOMIZED,3,sotagliflozin 200 mg | volagidemab 35 mg | Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This is a single site, double-blind, placebo-controlled, crossover trial to quantify the effects of combination adjunctive therapy on glycemic control, ketogenesis during insulinopenia, insulin resistance, and diabetes burden and quality of life.","Lexicon Pharmaceuticals, Breakthrough T1D",2028-01,ESTIMATED,18 Years - 70 Years,24,ESTIMATED,CROSSOVER,OTHER,DOUBLE,Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes,2028-01,ESTIMATED,Change in HbA1c,TREATMENT,ALL,2024-09-09,ACTUAL,INTERVENTIONAL
LXRX,"Lexicon Pharmaceuticals, Inc.",NCT06481891,PHASE3,RECRUITING,"Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy","Sotagliflozin, Placebo",SONATA-HCM,RANDOMIZED,2,Sotagliflozin | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compared to placebo.,,2026-08,ESTIMATED,18 Years - N/A,500,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)",2026-07,ESTIMATED,Change from Baseline to Week 26 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS),TREATMENT,ALL,2024-09-24,ACTUAL,INTERVENTIONAL
LXRX,"Lexicon Pharmaceuticals, Inc.",NCT07211802,PHASE3,NOT_YET_RECRUITING,Type 1 Diabetes (T1D),"Sotagliflozin Low Dose, Sotagliflozin High Dose",,RANDOMIZED,2,Treatment Group A | Treatment Group B,EXPERIMENTAL | EXPERIMENTAL,This research study is being conducted to learn if wearing a combination continuous glucose monitor/continuous ketone monitor (CGM/CKM) can reduce the side effects of taking sotagliflozin (study drug) in people with type 1 diabetes.,"National Institutes of Health (NIH), Abbott, Lexicon Pharmaceuticals, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",2030-12-31,ESTIMATED,18 Years - N/A,52,ESTIMATED,CROSSOVER,OTHER,TRIPLE,Utilizing Continuous Ketone Monitors to Enable Safe Use of SGLT Inhibitors in Patients With Type 1 Diabetes,2030-07-31,ESTIMATED,BHB Time Above 0.6mmol/L - 200mg | BHB Time Above 0.6mmol/L - 400mg,TREATMENT,ALL,2026-07-01,ESTIMATED,INTERVENTIONAL
LXRX,"Lexicon Pharmaceuticals, Inc.",NCT06933056,EARLY_PHASE1,RECRUITING,Platelet Function and Reactivity Tests,"Sotagliflozin (SOTA) followed by 3 drugs in a random order, Aspirin followed by 3 drugs in a random order, Clopidogrel followed by 3 drugs in a random order, Eliquis followed by 3 drugs in a random order",,,1,Platelet function in healthy subjects administered sotagliflozin vs. antiplatelet agents,EXPERIMENTAL,This study will identify the potential benefits of regulating platelet activation with sotagliflozin compared to other FDA-approved drugs known to limit platelet activation.,Lexicon Pharmaceuticals,2026-09,ESTIMATED,18 Years - 79 Years,20,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs: an Interventional Study,2026-09,ESTIMATED,Platelet aggregation,PREVENTION,ALL,2025-09-02,ACTUAL,INTERVENTIONAL
LXRX,"Lexicon Pharmaceuticals, Inc.",NCT06435156,PHASE2,RECRUITING,"Type 1 Diabetes, Heart Failure","Sotagliflozin, Placebo",SOPHIST,RANDOMIZED,2,Sotagliflozin | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"People with type 1 diabetes sometimes develop heart failure which can cause symptoms like breathlessness, tiredness or ankle swelling, reduced quality of life and lead to being admitted to hospital or suffering potential fatal consequences. This trial is investigating if a tablet called sotagliflozin, can improve quality of life in people with type 1 diabetes and heart failure. In addition, this trial will also assess the safety and tolerability of sotagliflozin in this population.

In previous ","Lexicon Pharmaceuticals, Juvenile Diabetes Research Foundation",2027-10-31,ESTIMATED,18 Years - 84 Years,320,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,A Phase 2 Double-blind Randomised Controlled Trial Studying the Effect of Sotagliflozin Versus Placebo in Individuals With Heart Failure and Type 1 Diabetes.,2027-10-31,ESTIMATED,Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score,TREATMENT,ALL,2025-01-28,ACTUAL,INTERVENTIONAL
LXRX,"Lexicon Pharmaceuticals, Inc.",NCT06217302,PHASE3,RECRUITING,"Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure","Sotagliflozin, Placebo",SUGARNSALT,RANDOMIZED,2,Sotagliflozin | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of s","Canadian Institutes of Health Research (CIHR), The Kidney Foundation of Canada, The Cleveland Clinic, University of Michigan, University of Colorado, Denver, Northwestern University, Washington University School of Medicine, State University of New York - Upstate Medical University, Providence Medical Research Center, Stanford University, Montefiore Medical Center, University of Toronto, University Health Network, Toronto, University of Calgary, University of Alberta, University of British Columbia, Institut de Recherches Cliniques de Montreal, LMC Diabetes & Endocrinology Ltd., Joslin Diabetes Center, Lexicon Pharmaceuticals, DexCom, Inc., University of Washington, Breakthrough T1D",2029-05,ESTIMATED,18 Years - 75 Years,150,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Effectiveness and Safety of Sotagliflozin in Slowing Kidney Function Decline in Persons With Type 1 Diabetes and Moderate to Severe Diabetic Kidney Disease,2028-12,ESTIMATED,eGFR at the end of the wash-out period following the treatment period,PREVENTION,ALL,2024-10-31,ACTUAL,INTERVENTIONAL
IMMX,"Immix Biopharma, Inc.",NCT06097832,"PHASE1, PHASE2",RECRUITING,Light Chain (AL) Amyloidosis,NXC-201 CAR-T,NEXICART-2,,1,NXC-201 CAR-T,EXPERIMENTAL,Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).,"Immix Biopharma, Inc.",2039-01,ESTIMATED,18 Years - 120 Years,40,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis,2026-12,ESTIMATED,Number of Participants With Treatment-Related Adverse Events | Number of Participants with Adverse Events by Severity as Assessed by CTCAE v5.0 | To confirm the maximum tolerated dose (MTD) | To confirm the recommended phase 2 dose (RP2D),TREATMENT,ALL,2024-06-05,ACTUAL,INTERVENTIONAL
ALMS,Alumis Inc.,NCT05739435,PHASE2,ACTIVE_NOT_RECRUITING,Plaque Psoriasis,ESK-001,,RANDOMIZED,2,ESK-001 Dose Level 1 | ESK-001 Dose Level 2,EXPERIMENTAL | EXPERIMENTAL,"This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.",,2026-12-30,ESTIMATED,18 Years - N/A,165,ACTUAL,PARALLEL,INDUSTRY,NONE,A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis,2026-12-01,ESTIMATED,To assess the safety and tolerability of long-term ESK-001 treatment,TREATMENT,ALL,2023-01-17,ACTUAL,INTERVENTIONAL
ALMS,Alumis Inc.,NCT06846541,PHASE3,ACTIVE_NOT_RECRUITING,"Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis","Open-Label ESK-001, Blinded ESK-001, Placebo",ONWARD3,RANDOMIZED,3,Open-Label ESK-001 | Blinded ESK-001 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are:

* How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis?
* Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis?

Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-00",,2028-11,ESTIMATED,18 Years - N/A,1680,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001",2028-11,ESTIMATED,To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study,TREATMENT,ALL,2025-01-08,ACTUAL,INTERVENTIONAL
ALMS,Alumis Inc.,NCT06588738,PHASE3,ACTIVE_NOT_RECRUITING,Plaque Psoriasis,"ESK-001, Placebo, Apremilast",ONWARD2,RANDOMIZED,3,ESK-001 | Placebo | Apremilast,EXPERIMENTAL | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:

* Does ESK-001 reduce the severity of people's psoriasis?
* How safe is ESK-001 in people with moderate to severe plaque psoriasis?

The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psorias",,2025-12,ESTIMATED,18 Years - N/A,840,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)",2025-09-23,ACTUAL,To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo,TREATMENT,ALL,2024-08-20,ACTUAL,INTERVENTIONAL
ALMS,Alumis Inc.,NCT05966480,PHASE2,ACTIVE_NOT_RECRUITING,SLE,"ESK-001, Placebo",LUMUS,RANDOMIZED,4,ESK-001 Dose Level 1 | ESK-001 Dose Level 2 | ESK-001 Dose Level 3 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.",,2027-09-01,ESTIMATED,18 Years - 70 Years,408,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus",2026-07-01,ESTIMATED,To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placebo,TREATMENT,ALL,2023-06-26,ACTUAL,INTERVENTIONAL
ALMS,Alumis Inc.,NCT06952634,PHASE1,RECRUITING,Hepatic Impairment,ESK-001,,NON_RANDOMIZED,4,Healthy Volunteer | Mild Hepatic Impairment | Moderate Hepatic Impairment | Severe Hepatic Impairment,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.",,2025-12,ESTIMATED,18 Years - 75 Years,48,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1, Open Label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of ESK001",2025-12,ESTIMATED,Maximum observed plasma concentration (Cmax) | Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] | Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)],TREATMENT,ALL,2025-04-29,ACTUAL,INTERVENTIONAL
ALMS,Alumis Inc.,NCT06586112,PHASE3,ACTIVE_NOT_RECRUITING,Plaque Psoriasis,"ESK-001, Apremilast, Placebo",ONWARD1,RANDOMIZED,3,ESK-001 | Placebo | Apremilast,EXPERIMENTAL | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:

* Does ESK-001 reduce the severity of people's psoriasis?
* How safe is ESK-001 in people with moderate to severe plaque psoriasis?

The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psorias",,2025-12,ESTIMATED,18 Years - N/A,840,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)",2025-09-19,ACTUAL,To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo,TREATMENT,ALL,2024-07-25,ACTUAL,INTERVENTIONAL
CLYM,"Climb Bio, Inc.",NCT07090655,EARLY_PHASE1,RECRUITING,Healthy Volunteers,"Budoprutug, Placebo",,RANDOMIZED,2,Budoprutug | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The main objective is to assess the safety and tolerability of subcutaneous and intravenous injection forms of budoprutug in healthy volunteers.,,2026-06,ESTIMATED,18 Years - 50 Years,38,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Injections of Budoprutug (TNT119) in Normal Healthy Volunteers",2026-04,ESTIMATED,Safety and Tolerability of Single Ascending Doses of budoprutug in Healthy Participants | Incidence of infusion-related reactions (IRRs) for IV administration | Incidence of injection site reactions (ISRs) for SC administration,BASIC_SCIENCE,ALL,2025-08-11,ACTUAL,INTERVENTIONAL
CLYM,"Climb Bio, Inc.",NCT07096843,PHASE2,RECRUITING,Primary Membranous Nephropathy,budoprutug,PrisMN,NON_RANDOMIZED,3,Cohort 1: Dose Level A | Cohort 2: Dose Level B | Cohort 3: Dose Level C,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN,,2027-10,ESTIMATED,18 Years - 70 Years,45,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN)",2027-10,ESTIMATED,Incidence of Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-08-25,ACTUAL,INTERVENTIONAL
CLYM,"Climb Bio, Inc.",NCT07011043,PHASE1,RECRUITING,Systemic Lupus Erythematosus,Budoprutug,,NON_RANDOMIZED,4,Cohort 1: Dose Level A | Cohort 2: Dose Level B | Cohort 3: Dose Level C | Cohort 4: Dose Level D,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.",,2027-04,ESTIMATED,18 Years - 65 Years,30,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1b Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Budoprutug (TNT119) in Adult Subjects With Systemic Lupus Erythematosus (SLE)",2027-04,ESTIMATED,Incidence of Treatment-Emergent Adverse Events (TEAEs) | Incidence of Clinical Laboratory Abnormalities | Change from Baseline in Systolic Blood Pressure | Change from Baseline in Diastolic Blood Pressure | Change from Baseline in Heart Rate | Change from Baseline in Respiratory Rate | Change from Baseline in Body Temperature | Change from Baseline in PR Interval | Change from Baseline in QRS Duration | Change from Baseline in QT Interval | Change from Baseline in QTc Interval,TREATMENT,ALL,2025-07-10,ACTUAL,INTERVENTIONAL
CLYM,"Climb Bio, Inc.",NCT07248865,PHASE1,RECRUITING,Healthy Volunteers,"CLYM116, Placebo",,RANDOMIZED,2,CLYM116 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 1, first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CLYM116 in healthy volunteers.",,2026-09,ESTIMATED,18 Years - 60 Years,48,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose (SAD) and Multiple-Ascending-Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injection(s) of CLYM116 in Normal Healthy Volunteers",2026-07,ESTIMATED,Safety and tolerability of single and multiple ascending doses of CLYM116 in healthy volunteers Incidence of treatment-emergent adverse events | Incidence of injection site reactions Number of injection site reactions,BASIC_SCIENCE,ALL,2025-12-02,ACTUAL,INTERVENTIONAL
CLYM,"Climb Bio, Inc.",NCT07043946,"PHASE1, PHASE2",RECRUITING,"Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19",Budoprutug,,NON_RANDOMIZED,4,Cohort 1: Dose Level A | Cohort 2: Dose Level B | Cohort 3: Dose Level C | Dose Expansion Cohort,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The main objective is to assess the safety and tolerability of budoprutug in adults with ITP. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.",,2028-08,ESTIMATED,18 Years - N/A,24,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1b/2a, Open-Label, Sequential-Cohort, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Effectiveness of Budoprutug (TNT119) in Subjects With Immune Thrombocytopenia (ITP)",2027-08,ESTIMATED,Incidence of Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-06-30,ACTUAL,INTERVENTIONAL
ZURA,Zura Bio Limited,NCT06993610,PHASE2,RECRUITING,Hidradenitis Suppurativa (HS),"Tibulizumab Dose A, Tibulizumab Dose B",TibuSHIELD,RANDOMIZED,3,Tibulizumab Dose A | Tibulizumab Dose B | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)",,2027-04,ESTIMATED,18 Years - 70 Years,225,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa",2026-11,ESTIMATED,[Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeks,TREATMENT,ALL,2025-05-16,ACTUAL,INTERVENTIONAL
ZURA,Zura Bio Limited,NCT06843239,PHASE2,RECRUITING,"Systemic Sclerosis (SSc), Scleroderma",Tibulizumab,,RANDOMIZED,2,Tibulizumab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)",,2028-01,ESTIMATED,18 Years - 75 Years,80,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Systemic Sclerosis",2027-05,ESTIMATED,[Period 1] Change from baseline in modified Rodnan Skin Score (mRSS) at 24 weeks | [Period 2] Safety and tolerability of tibulizumab,TREATMENT,ALL,2025-02-06,ACTUAL,INTERVENTIONAL
ANRO,"Alto Neuroscience, Inc.",NCT05922878,PHASE2,RECRUITING,Major Depressive Disorder,"ALTO-300, Placebo",,RANDOMIZED,2,ALTO-300 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.",,2026-12,ESTIMATED,18 Years - 70 Years,321,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder",2026-12,ESTIMATED,To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).,TREATMENT,ALL,2023-06-08,ACTUAL,INTERVENTIONAL
ANRO,"Alto Neuroscience, Inc.",NCT06656416,PHASE2,RECRUITING,Bipolar Disorder I or II With a Major Depressive Episode,"ALTO-100, Placebo",,RANDOMIZED,2,ALTO-100 | Placebo DB,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer and/or atypical antipsychotic, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.",,2026-10,ESTIMATED,18 Years - 70 Years,200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Study Followed by Open-Label Treatment of ALTO-100 in Adults With Bipolar Disorder Currently Experiencing a Major Depressive Episode",2026-08,ESTIMATED,To assess efficacy of ALTO-100 versus placebo on depression symptoms in bipolar disorder in a pre-defined subgroup of participants as measured by the mean change from Day 1 to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score,TREATMENT,ALL,2024-10-02,ACTUAL,INTERVENTIONAL
ANRO,"Alto Neuroscience, Inc.",NCT06502964,PHASE2,RECRUITING,"Schizophrenia, Cognitive Impairment","ALTO-101, Placebo",,RANDOMIZED,2,ALTO-101 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition.

Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.",,2026-03,ESTIMATED,21 Years - 55 Years,82,ESTIMATED,CROSSOVER,INDUSTRY,QUADRUPLE,"Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment",2026-02,ESTIMATED,Theta band activity,TREATMENT,ALL,2024-06-11,ACTUAL,INTERVENTIONAL
PRAX,"Praxis Precision Medicines, Inc.",NCT06999902,"PHASE2, PHASE3",RECRUITING,Focal Seizure,"20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo",POWER1,RANDOMIZED,2,"Randomized, Double-Blind 20mg/day for 6 weeks then 30mg/day for remaining 6 weeks PRAX-628 | Randomized, Double-Blind Placebo",EXPERIMENTAL | EXPERIMENTAL,"A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)",,2025-12-08,ESTIMATED,18 Years - 75 Years,230,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)",2025-11-24,ESTIMATED,To evaluate the efficacy of PRAX-628 compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs,TREATMENT,ALL,2024-12-11,ACTUAL,INTERVENTIONAL
PRAX,"Praxis Precision Medicines, Inc.",NCT06840925,PHASE1,NOT_YET_RECRUITING,Healthy,PRAX-628,,RANDOMIZED,2,Single Oral Dose 40mg PRAX-628 tablet then 4x10mg PRAX-628 capsules | Single Oral Dose 4x10mg PRAX-628 capsules then 40mg PRAX-628 tablet,EXPERIMENTAL | EXPERIMENTAL,A phase I clinical trial to evaluate the relative bioavailability of PRAX-628 tablet formulation compared to capsule formulation,,2025-06-30,ESTIMATED,18 Years - 55 Years,16,ESTIMATED,CROSSOVER,INDUSTRY,NONE,"A Phase 1, Randomized, Open-Label, 2-Way Crossover Clinical Trial in Healthy Participants to Evaluate the Relative Bioavailability of PRAX-628 Tablet Formulation Compared to Capsule Formulation",2025-05-30,ESTIMATED,To assess the relative bioavailability of single 40 mg oral doses of PRAX-628 tablet as compared to PRAX-628 capsules | To assess the relative bioavailability of single 40 mg oral doses of PRAX-628 tablet as compared to PRAX-628 capsules,TREATMENT,ALL,2025-03-24,ESTIMATED,INTERVENTIONAL
PRAX,"Praxis Precision Medicines, Inc.",NCT07019922,PHASE3,RECRUITING,"Epileptic Encephalopathy, SCN2A Encephalopathy","1mg elsunersen, 0.5mg elsunersen",,RANDOMIZED,4,Cohort 1 Arm 1: Double-Blind Treatment Period | Cohort 1 Arm 2: Double-Blind Treatment Period | Cohort 2: Open-Label Treatment Period | Cohort 3: Open-Label Treatment Period,EXPERIMENTAL | SHAM_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"A Randomized, Multi-Center, Double-Blind, Sham-Procedure-Controlled Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy",,2028-12,ESTIMATED,1 Day - 18 Years,50,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Randomized, Multi-Center, Double-Blind, Sham-Procedure-Controlled Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy",2026-06,ESTIMATED,To assess the efficacy of elsunersen on seizure frequency in participants with early-onset SCN2A DEE,TREATMENT,ALL,2025-08-13,ACTUAL,INTERVENTIONAL
PRAX,"Praxis Precision Medicines, Inc.",NCT06908356,PHASE2,RECRUITING,"Focal Onset Seizure, Primary Generalized Epilepsy",30mg PRAX-628,,,1,Open-label 30mg/day PRAX-628 for 8 weeks,EXPERIMENTAL,An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures,,2025-07,ESTIMATED,18 Years - 75 Years,50,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures,2025-07,ESTIMATED,To evaluate the efficacy of PRAX-628 on seizure frequency in adults with FOS or PGTCS currently taking ASMs,TREATMENT,ALL,2025-01-10,ACTUAL,INTERVENTIONAL
PRAX,"Praxis Precision Medicines, Inc.",NCT07010471,PHASE3,RECRUITING,Developmental and Epileptic Encephalopathy 1,"1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo",EMERALD,RANDOMIZED,3,Part A: Double-Blind Treatment Period | Part A: Double-Blind Treatment Period (Placebo) | Part B: Open-Label Extension Treatment Period,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension",,2027-07,ESTIMATED,2 Years - 65 Years,160,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants With DEE Followed by an Open-Label Extension",2026-07,ESTIMATED,To assess the effect of relutrigine on seizure frequency in participants with DEEs compared to placebo,TREATMENT,ALL,2025-07-09,ACTUAL,INTERVENTIONAL
PRAX,"Praxis Precision Medicines, Inc.",NCT05737784,"PHASE1, PHASE2",RECRUITING,"SCN2A-DEE, Epilepsy","PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses",,RANDOMIZED,8,Preliminary Safety | Dose Escalation - PRAX-222 | Dose Escalation - Placebo | Optional Dose Escalation - PRAX-222 | Optional Dose Escalation - Placebo | Confirmatory Dosing - PRAX-222 | Confirmatory Dosing - Placebo | Open-label PRAX-222,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.",,2027-09,ESTIMATED,2 Years - 18 Years,60,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy",2025-08,ESTIMATED,"Number of participants with treatment-emergent adverse events (Preliminary Safety, Dose Escalation) | Seizure frequency (Confirmatory Phase)",TREATMENT,ALL,2023-04-13,ACTUAL,INTERVENTIONAL
PRAX,"Praxis Precision Medicines, Inc.",NCT05818553,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"SCN2A Encephalopathy, SCN8A Encephalopathy",PRAX-562,EMBOLD,RANDOMIZED,4,"Part A: Randomized, Double-Blind 0.5mg/kg/day PRAX-562 or PRAX-562/Placebo | Part B: Open-Label Extension Treatment 0.5mg/kg/day PRAX-562 | Part A: Randomized, Double-Blind 1.0 mg/kg/day PRAX-562 or PRAX-562/Placebo | Open-Label Extension Treatment 1.0 mg/kg/day PRAX-562",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE),,2027-03-01,ESTIMATED,1 Year - 18 Years,77,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2,Double-Blind,Randomized Clinical Trial to Explore the Safety,Tolerability,Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants With Developmental and Epileptic Encephalopathies Followed by Open-Label Extension(OLE)",2025-11-12,ACTUAL,PART A (Cohorts 1 and 2) RDB: To evaluate the safety and tolerability of PRAX 562 in pediatric participants with SCN2A- and SCN8A- DEEs | PART B (Cohorts 1 and 2) OLE: To evaluate the long-term safety and tolerability of PRAX-562 in pediatric participants with DEEs,TREATMENT,ALL,2023-08-02,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT07241546,PHASE2,NOT_YET_RECRUITING,Asthma,"ARO-RAGE, Placebo",,RANDOMIZED,2,ARO-RAGE | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.,,2028-04,ESTIMATED,18 Years - 65 Years,36,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma",2027-12,ESTIMATED,Change from Baseline Over Time in Maximum Area of Reactance,TREATMENT,ALL,2025-12,ESTIMATED,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06347133,PHASE3,ACTIVE_NOT_RECRUITING,Hypertriglyceridemia,"Plozasiran Injection, Placebo",MUIR-3,RANDOMIZED,2,Plozasiran Injection | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.,,2026-09,ESTIMATED,18 Years - N/A,1456,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia",2026-05,ESTIMATED,Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo,TREATMENT,ALL,2024-05-21,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06131983,"PHASE1, PHASE2",RECRUITING,Facio-Scapulo-Humeral Dystrophy,"ARO-DUX4 for Injection, Placebo",,RANDOMIZED,2,ARO-DUX4 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ARO-DUX4 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1). In Part 1 of the study, participants will receive one dose of ARO-DUX4 or placebo. In Part 2 of the study, participants will receive 4 doses of ARO-DUX4 or placebo. Participants who complete Part 1 will have the option to re-screen and re-randomize into Part 2. All participants will undergo pre- ",,2026-12,ESTIMATED,16 Years - 70 Years,60,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1",2026-12,ESTIMATED,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Over Time Through End of Study (EOS),TREATMENT,ALL,2024-02-22,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT07037771,PHASE3,RECRUITING,Homozygous Familial Hypercholesterolemia,"zodasiran Injection, Placebo",,RANDOMIZED,2,zodasiran | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug durin",,2027-08-20,ESTIMATED,12 Years - N/A,60,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE),2027-08-20,ESTIMATED,Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period),TREATMENT,ALL,2025-06-17,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06347016,PHASE3,ACTIVE_NOT_RECRUITING,Severe Hypertriglyceridemia,"Plozasiran Injection, Placebo",SHASTA-4,RANDOMIZED,2,Plozasiran Injection | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After Month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.",,2026-09,ESTIMATED,18 Years - N/A,311,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia",2026-06,ESTIMATED,Percent change in fasting serum TG levels from baseline to Month 12 compared to placebo,TREATMENT,ALL,2024-07-23,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06880770,PHASE3,RECRUITING,Severe Hypertriglyceridemia,"Plozasiran, Placebo",SHASTA-5,RANDOMIZED,2,Plozasiran Injection | Placebo,EXPERIMENTAL | EXPERIMENTAL,"This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placeb",,2029-06,ESTIMATED,18 Years - N/A,288,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)",2029-03,ESTIMATED,Time to First Occurrence of Positively Adjudicated AP Event (Event Occurring More Than 10 Days After First Dose of Study Drug),TREATMENT,ALL,2025-04-24,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06138743,"PHASE1, PHASE2",RECRUITING,Myotonic Dystrophy 1,"ARO-DM1 Intravenous (IV) Infusion, Placebo Intravenous (IV) Infusion, ARO-DM1 subcutaneous (SC) injection, Placebo Subcutaneous (SC) Injection",,RANDOMIZED,4,ARO-DM1 Intravenous (IV) Infusion | Placebo by IV Infusion | ARO-DM1 Subcutaneous SC Injection | Placebo by SC Injection,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of ARO-DM1 compared to placebo in male and female subjects with type 1 myotonic dystrophy (DM1). Participants who have provided written informed consent and met all protocol eligibility requirements will be randomized to receive single (Part 1) or multiple (Part 2) doses of ARO-DM1 or placebo.",,2026-12,ESTIMATED,18 Years - 65 Years,78,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who Are ≥18 to ≤ 65 Years",2026-12,ESTIMATED,Number of Participants with Treatment -Emergent Adverse Events (TEAEs) Over Time Through End of Study (EOS),TREATMENT,ALL,2024-03-04,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06822790,PHASE3,RECRUITING,Hypertriglyceridemia,Plozasiran Injection,SHASTA-10,,1,Plozasiran Injection,EXPERIMENTAL,"This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133).

Subjects who previousl",,2028-07,ESTIMATED,18 Years - N/A,869,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study),2028-07,ESTIMATED,Number of Participants with Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-04-09,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT05217667,PHASE2,ACTIVE_NOT_RECRUITING,Homozygous Familial Hypercholesterolemia,ARO-ANG 3 Injection,Gateway,RANDOMIZED,2,ARO-ANG3 Dose 1 | ARO-ANG3 Dose 2,EXPERIMENTAL | EXPERIMENTAL,Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks. Participants who complete the first 36 week treatment period may opt to continue in an additional 24-month extension period during which they will receive up to 8 doses open-label doses of ARO-ANG3.,,2025-11,ESTIMATED,16 Years - N/A,18,ACTUAL,PARALLEL,INDUSTRY,NONE,Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH),2023-05-02,ACTUAL,Percent Change from Baseline in Fasting Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) and LDL-C by Preparative Ultracentrifugation (LDL-C [PUC]) up to Week 24,TREATMENT,ALL,2022-04-22,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06937203,"PHASE1, PHASE2",RECRUITING,"Obesity, Diabetes Mellitus, Type 2","ARO-ALK7, Placebo",,RANDOMIZED,4,Part1: ARO-ALK7 | Part 1: Placebo | Part:2: ARO-ALK7 + Tirzepatide | Part 2: Placebo + Tirzepatide,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of ARO-ALK7 in adult volunteers with obesity without Type 2 Diabetes Mellitus (T2DM) (Part 1) and the safety, tolerability, and PD of multiple doses of ARO-ALK7 in adult volunteers with obesity with and without (T2DM) receiving tirzepatide (Part 2). In Part 1A eligible participants with obesity will be randomized to receive a single dose of ARO-ALK7 or placebo (PBO) adm",,2026-07,ESTIMATED,18 Years - 65 Years,126,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1/2A Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus",2026-07,ESTIMATED,Number of Participants with Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-05-07,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT07223658,"PHASE1, PHASE2",RECRUITING,Hyperlipidemia; Mixed,"ARO-DIMERPA, Placebo",,RANDOMIZED,2,ARO-DIMERPA | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.",,2027-07,ESTIMATED,18 Years - N/A,78,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia",2026-06,ESTIMATED,Number of Participants with Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-12-22,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06700538,"PHASE1, PHASE2",RECRUITING,Obesity,"ARO-INHBE, Placebo, Tirzepatide",,RANDOMIZED,4,Part 1: ARO-INHBE | Part 1: Placebo | Part 2: ARO-INHBE + Tirzepatide | Part 2: Placebo + Tirzepatide,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (Part 1), and the safety, tolerability and PD of multiple doses of ARO-INHBE in adult participants with obesity with and without type 2 diabetes mellitus receiving tirzepatide (Part 2).",,2026-05,ESTIMATED,18 Years - 65 Years,120,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus",2026-05,ESTIMATED,Number of Participants with Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2024-12-04,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06672445,PHASE1,RECRUITING,Spinocerebellar Ataxia Type 2,"ARO-ATXN2 Injection, Placebo",,RANDOMIZED,2,ARO-ATXN2 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Adult participants with spinocerebellar ataxia type 2 (SCA2) who carry ≥33 cytosine, adenine, guanine (CAG) repeats in the ATXN2 gene, and who have met all protocol eligibility criteria will be randomized to receive a single dose of ARO-ATXN2 or placebo and be evaluated for safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) parameters.",,2026-12,ESTIMATED,18 Years - 65 Years,36,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2",2026-12,ESTIMATED,Number of Participants with Treatment -Emergent Adverse Events (TEAEs) Over Time,TREATMENT,ALL,2024-12-17,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT05089084,PHASE3,ACTIVE_NOT_RECRUITING,Familial Chylomicronemia,"Plozasiran, Placebo",PALISADE,RANDOMIZED,4,ARO-APOC3 (Plozasiran) 25 mg | Placebo for ARO-APOC3 (Plozasiran) 25 mg | ARO-APOC3 (Plozasiran) 50 mg | Placebo for ARO-APOC3 (Plozasiran) 50 mg,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.,,2026-04,ESTIMATED,18 Years - N/A,75,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome,2024-04-29,ACTUAL,Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG),TREATMENT,ALL,2021-12-14,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06347003,PHASE3,ACTIVE_NOT_RECRUITING,Severe Hypertriglyceridemia,"Plozasiran Injection, Placebo",SHASTA-3,RANDOMIZED,2,Plozasiran Injection | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.",,2026-09,ESTIMATED,18 Years - N/A,446,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia",2026-06,ESTIMATED,Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo,TREATMENT,ALL,2024-07-22,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT06209177,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,IgA Nephropathy,"ARO-CFB, Placebo",,RANDOMIZED,3,ARO-CFB (Healthy Volunteers) | Placebo (Healthy Volunteers) | ARO-CFB (Adult Patients with IgAN),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of AROCFB-1001 is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ARO-CFB Injection in adult healthy volunteers (HVs) and in adult patients with complement-mediated kidney disease (IgA Nephropathy \[IgAN\]). In Part 1 of the study, HVs will receive either one or two doses of ARO-CFB or placebo. In Part 2 of the study, adult patients with IgAN will receive 3 open-label doses of ARO-CFB. Dose levels in Part 2 will be determined based on cumulative safety ",,2026-03,ESTIMATED,18 Years - 70 Years,66,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ARO-CFB in Adult Healthy Volunteers and Adult Patients With Complement-Mediated Kidney Disease",2025-03-31,ACTUAL,Number of Participants with Treatment-Emergent Adverse Events (AEs) and/or Serious Adverse Events (SAEs),TREATMENT,ALL,2024-04-05,ACTUAL,INTERVENTIONAL
ARWR,"Arrowhead Pharmaceuticals, Inc.",NCT07221344,"PHASE1, PHASE2",RECRUITING,"Alzheimer Disease, Alzheimer Disease, Early Onset","ARO-MAPT-SC, Placebo",,RANDOMIZED,2,ARO-MAPT-SC | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.",,2027-06,ESTIMATED,18 Years - 75 Years,112,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease",2027-06,ESTIMATED,Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Over Time,TREATMENT,ALL,2025-11-18,ACTUAL,INTERVENTIONAL
GPCR,Structure Therapeutics Inc.,NCT06693843,PHASE2,ACTIVE_NOT_RECRUITING,"Obesity, Overweight, or Chronic Weight Management","Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron or Placebo, Aleniglipron, Aleniglipron, Aleniglipron, Aleniglipron",ACCESS,RANDOMIZED,7,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 1 OLE | Cohort 2 OLE | Cohort 3 OLE | Cohort 4 OLE,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treat",,2026-08,ESTIMATED,18 Years - 79 Years,220,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity",2026-07,ESTIMATED,"Percent change in body weight from Baseline to Week 36 | TEAEs and SAEs | AESI | Evaluate the safety and tolerability of participants with abnormal laboratory values, including hematology, serum chemistry, and coagulation | Evaluate long-term safety and tolerability of aleniglipron as measured through electrocardiograms (including, but not limited to, the measurements of ventricular HR, PR interval, QRS duration, QT interval, and QTcF) | Evaluate the safety and tolerability of participants with abnormal vital signs, including blood pressure, heart rate, and temperature",TREATMENT,ALL,2024-10-17,ACTUAL,INTERVENTIONAL
GPCR,Structure Therapeutics Inc.,NCT07400588,PHASE2,RECRUITING,"Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss","Aleniglipron, Placebo",GSBR-1290,RANDOMIZED,2,Arm 1: Participants will receive aleniglipron administered orally | Arm 2: Participants will receive a placebo administered orally,EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).,,2026-11,ESTIMATED,18 Years - 79 Years,50,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight",2026-10,ESTIMATED,"Incidence, severity and relationship of AEs/SAEs | Assessment of vital signs | Assessment of laboratory measures | Assessment of Electrocardiograms (ECG)",TREATMENT,ALL,2025-12-01,ACTUAL,INTERVENTIONAL
GPCR,Structure Therapeutics Inc.,NCT06139055,PHASE1,ACTIVE_NOT_RECRUITING,Healthy Volunteers,"GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)",,RANDOMIZED,5,Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet | Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule | Part 2 (Cohort 1): GSBR-1290/Placebo Tablet | Part 2 (Cohort 2): GSBR-1290/Placebo Tablet | Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.",,2024-03,ESTIMATED,18 Years - 75 Years,70,ACTUAL,CROSSOVER,INDUSTRY,QUADRUPLE,"A 2-part, Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Comparative Bioavailability of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants",2024-03,ESTIMATED,Part 1: Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) Parameters | Part 1: Analysis of Time to Maximum Observed Plasma Concentration (Tmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters | Part 1: Analysis of Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters | Part 1: Analysis of Area Under the Plasma Concentration-time Curve From 0 to infinity (AUC0-inf) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters | Part 1: Analysis of Apparent Terminal Elimination Half-life (t1/2) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters | Part 1: Analysis of Total Apparent Body Clearance (CL/F) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters | Part 1: Analysis of Apparent Volume of Distribution (Vz/F) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters | Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs | Part 2: Number of Participants With Severity of AEs | Part 2: Number of Participants With Clinically Significant Change From Baseline in Vital Signs | Part 2: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters | Part 2: Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters,TREATMENT,ALL,2023-10-02,ACTUAL,INTERVENTIONAL
GPCR,Structure Therapeutics Inc.,NCT07169942,PHASE2,ACTIVE_NOT_RECRUITING,"Obesity, Overweight, or Chronic Weight Management",aleniglipron or placebo,,RANDOMIZED,2,Cohort 1 | Cohort 2,EXPERIMENTAL | EXPERIMENTAL,"This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.",,2026-09,ESTIMATED,18 Years - 79 Years,71,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Study Evaluating the Effects of Aleniglipron (GSBR-1290) on Body Composition in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2)",2026-07,ESTIMATED,Percent change in total body fat mass by DXA,TREATMENT,ALL,2025-08-15,ACTUAL,INTERVENTIONAL
GPCR,Structure Therapeutics Inc.,NCT06703021,PHASE2,ACTIVE_NOT_RECRUITING,"Obesity, Overweight, Chronic Weight Management","aleniglipron or placebo, aleniglipron or placebo, aleniglipron or placebo, aleniglipron or placebo",ACCESS II,RANDOMIZED,4,Sentinel | Cohort 1a | Cohort 1b | Cohort 1c,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.",,2025-12,ESTIMATED,18 Years - 79 Years,82,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Efficacy of Increasing Optimal Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity (ACCESS II)",2025-11,ESTIMATED,"Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | Adverse events of special interest | Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis | Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration | Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature",TREATMENT,ALL,2024-12-20,ACTUAL,INTERVENTIONAL
MAZE,"Maze Therapeutics, Inc.",NCT06830629,PHASE2,RECRUITING,Proteinuric Kidney Disease,MZE829,,,1,MZE829,EXPERIMENTAL,"This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease",,2026-09,ESTIMATED,18 Years - 68 Years,56,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype",2026-09,ESTIMATED,Safety and tolerability as assessed by incidence of adverse events (AEs),TREATMENT,ALL,2025-02-05,ACTUAL,INTERVENTIONAL
PVLA,"Palvella Therapeutics, Inc.",NCT06653842,PHASE2,RECRUITING,Cutaneous Venous Malformations,QTORIN 3.9% rapamycin anhydrous gel,TOIVA,,1,"Single-arm, open-label",EXPERIMENTAL,"A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations",,2026-03,ESTIMATED,6 Years - N/A,15,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations",2025-12,ESTIMATED,Incidence of Treatment-Emergent Adverse Events,TREATMENT,ALL,2024-12-20,ACTUAL,INTERVENTIONAL
PVLA,"Palvella Therapeutics, Inc.",NCT05643872,PHASE3,RECRUITING,Pachyonychia Congenita,PTX-022,,,1,PTX-022,EXPERIMENTAL,"PALV-08 is a multicenter, open-label treatment (OLT) study enrolling adults with Pachyonychia Congenita (PC) with genotyped keratin mutations KRT6A, KRT6B, KRT6C or KRT16 who were previously enrolled in the PALV-05 (VAPAUS) trial.

The purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or ""PTX-022"".",,2023-11,ESTIMATED,16 Years - N/A,45,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Multicenter Open-Label Treatment Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita,2023-10,ESTIMATED,Treatment emergent adverse events,TREATMENT,ALL,2022-11-15,ACTUAL,INTERVENTIONAL
PVLA,"Palvella Therapeutics, Inc.",NCT06239480,PHASE3,RECRUITING,Microcystic Lymphatic Malformation,QTORIN 3.9% Rapamycin Anhydrous Gel,SELVA,,1,Active,EXPERIMENTAL,"SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of ",FDA Office of Orphan Products Development,2026-07,ESTIMATED,3 Years - N/A,40,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations",2026-01,ESTIMATED,Overall microcystic lymphatic malformations Investigator Global Assessment (mLM-IGA),TREATMENT,ALL,2024-07-31,ACTUAL,INTERVENTIONAL
KOD,Kodiak Sciences Inc.,NCT06990399,PHASE3,RECRUITING,Macular Edema Secondary to Inflammation,KSI-101,PEAK,RANDOMIZED,3,KSI-101 5 mg | KSI-101 10 mg | Sham,EXPERIMENTAL | EXPERIMENTAL | SHAM_COMPARATOR,A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI),,2027-07,ESTIMATED,18 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK",2026-02,ESTIMATED,Mean change in BCVA,TREATMENT,ALL,2025-07-30,ACTUAL,INTERVENTIONAL
KOD,Kodiak Sciences Inc.,NCT06270836,PHASE3,ACTIVE_NOT_RECRUITING,Diabetic Retinopathy,Tarcocimab,GLOW2,RANDOMIZED,2,Tarcocimab 5 mg (Treatment Group A) | Treatment Group B,EXPERIMENTAL | SHAM_COMPARATOR,This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with DR.,,2026-01-31,ESTIMATED,18 Years - N/A,255,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer in Participants With Diabetic Retinopathy (DR) - GLOW2",2026-01-31,ESTIMATED,Proportion of eyes improving ≥2 steps on the Early Treatment Diabetic Retinopathy Diabetic Retinopathy Severity Scale (ETDRS DRSS),TREATMENT,ALL,2024-05-01,ACTUAL,INTERVENTIONAL
KOD,Kodiak Sciences Inc.,NCT06996080,PHASE3,RECRUITING,Macular Edema Secondary to Inflammation,KSI-101,PINNACLE,RANDOMIZED,3,KSI-101 5 mg | KSI-101 10 mg | Sham,EXPERIMENTAL | EXPERIMENTAL | SHAM_COMPARATOR,A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI),,2027-07,ESTIMATED,18 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE",2026-12,ESTIMATED,Mean change in BCVA,TREATMENT,ALL,2025-07-16,ACTUAL,INTERVENTIONAL
KOD,Kodiak Sciences Inc.,NCT06556368,PHASE3,ACTIVE_NOT_RECRUITING,Wet Age-related Macular Degeneration,"Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept",DAYBREAK,RANDOMIZED,3,Tarcocimab tedromer 5 mg (KSI-301) | Tabirafusp tedromer 5 mg (KSI-501) | Aflibercept 2 mg,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD),,2027-08,ESTIMATED,50 Years - N/A,675,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)",2026-08,ESTIMATED,Best corrected visual acuity (BCVA),TREATMENT,ALL,2024-08-23,ACTUAL,INTERVENTIONAL
IRWD,"Ironwood Pharmaceuticals, Inc.",NCT05796388,,RECRUITING,Irritable Bowel Syndrome With Constipation,,IBSC-VR,RANDOMIZED,2,Sham VR | Immersive VR,SHAM_COMPARATOR | ACTIVE_COMPARATOR,The purpose of this study is to determine if adult patients with IBS-C will report an overall greater improvement in IBS symptoms and quality of life when treated with a combination of linaclotide (standard of care medication) and immersive virtual reality (VR) therapy compared to those treated with linaclotide and sham (placebo) VR therapy.,"Cedars-Sinai Medical Center, AbbVie, Ironwood Pharmaceuticals, Inc.",2026-06,ESTIMATED,18 Years - 70 Years,65,ESTIMATED,PARALLEL,OTHER,DOUBLE,A Pilot Study to Evaluate the Efficacy and Safety of Virtual Reality in Combination With Linaclotide for the Treatment of Adults With IBS and Constipation Predominance,2026-06,ESTIMATED,Changes in IBS symptoms,TREATMENT,ALL,2024-05-31,ACTUAL,INTERVENTIONAL
PEPG,PepGen Inc.,NCT06667453,PHASE2,RECRUITING,Myotonic Dystrophy 1,PGN-EDODM1,FREEDOM2-DM1,RANDOMIZED,2,PGN-EDODM1 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.",,2026-08,ESTIMATED,16 Years - 60 Years,24,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PGN-EDODM1 in Adult Participants With Myotonic Dystrophy Type 1 (FREEDOM2-DM1)",2026-08,ESTIMATED,Safety and tolerability as assessed by number of participants with Adverse Events (AEs),TREATMENT,ALL,2024-12-10,ACTUAL,INTERVENTIONAL
PEPG,PepGen Inc.,NCT07220603,PHASE2,RECRUITING,Myotonic Dystrophy 1,PGN-EDODM1,,,1,PGN-EDODM1,EXPERIMENTAL,The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.,,2029-01,ESTIMATED,N/A - N/A,48,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE),2029-01,ESTIMATED,Safety and tolerability as assessed by number of participants with Adverse Events (AEs),TREATMENT,ALL,2025-12-23,ACTUAL,INTERVENTIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT05050136,PHASE2,RECRUITING,"Primary Biliary Cholangitis, PBC","Volixibat, Placebo",VANTAGE,RANDOMIZED,5,Part 1 Arm 1: Volixibat 20mg | Part 1 Arm 2: Volixibat 80mg | Part 1 Arm 3: Placebo | Part 2 Arm 1: Volixibat Selected Dose 20mg | Part 2 Arm 2: Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.",,2027-07,ESTIMATED,18 Years - N/A,260,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis",2027-04,ESTIMATED,Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaire,TREATMENT,ALL,2021-09-22,ACTUAL,INTERVENTIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT06553768,PHASE3,RECRUITING,"Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)",Maralixibat,,RANDOMIZED,2,Maralixibat | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.",,2027-02,ESTIMATED,6 Months - N/A,90,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Participants With Cholestatic Pruritus,2026-10,ESTIMATED,Mean change in the ItchRO(Obs) severity score,TREATMENT,ALL,2024-10-14,ACTUAL,INTERVENTIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT04663308,PHASE2,ACTIVE_NOT_RECRUITING,Primary Sclerosing Cholangitis,"Volixibat, Placebo",VISTAS,RANDOMIZED,5,Part 1 Arm 1: Volixibat 20mg | Part 1 Arm 2: Volixibat 80mg | Part 1 Arm 3: Placebo | Part 2 Arm 1: Volixibat Selected Dose 20mg | Part 2 Arm 2: Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.",,2027-04,ESTIMATED,12 Years - N/A,182,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis,2026-06,ESTIMATED,Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaire,TREATMENT,ALL,2020-12-18,ACTUAL,INTERVENTIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT03115086,,ACTIVE_NOT_RECRUITING,Bile Acid Synthesis Disorders,Cholbam,,,2,Existing User | New User, | ,"This is a prospective, observational, non-interventional patient registry study designed to document product safety and effectiveness outcomes for 10 years in patients treated with Cholbam, including those who have been using Cholbam for at least 30 days (existing users) and those who are first-time initiators of Cholbam.",,2039-07,ESTIMATED,N/A - N/A,55,ESTIMATED,,INDUSTRY,,"A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry to Collect Data on Routine Clinical Care in Patients Treated With Cholbam® (Cholic Acid)",2038-07,ESTIMATED,"Number of participants with worsening cholestasis | Number of participants with new-onset cholestasis | Number of participants with steatorrhea leading to poor growth | Changes in serum levels of fat-soluble vitamins | Neuropathic signs or symptoms related to fat-soluble vitamin deficiencies | Number of participants with growth failure | Death | Adverse effects on pregnancy, pregnancy outcomes, and infant status | All Adverse Events (AEs) and Serious AEs (SAEs)",,ALL,2017-07-10,ACTUAL,OBSERVATIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT07389031,PHASE2,NOT_YET_RECRUITING,Intrahepatic Cholestasis of Pregnancy,Maralixibat,METAPHOR,,1,Maralixibat,EXPERIMENTAL,An open label phase 2a/b trial of maralixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability,"Mirum Pharmaceuticals, Inc.",2028-03-31,ESTIMATED,18 Years - 50 Years,28,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Maralixibat for the trEatment of inTrAhePatic cHOlestasis of pRegnancy (METAPHOR),2028-03-31,ESTIMATED,Assess the Safety and Tolerability of Maralixibat in Participants With ICP,TREATMENT,FEMALE,2026-04-01,ESTIMATED,INTERVENTIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT07290257,PHASE4,RECRUITING,Alagille Syndrome,Livmarli Oral Product,,,1,Patients with Alagile Syndrome treated with Livmarli,EXPERIMENTAL,"The key objectives of this low-intervention clinical study are to evaluate tolerability, long-term safety and long-term efficacy for patients with Alagille syndrome (ALGS) who are prescribed Livmarli.",,2030-12-22,ESTIMATED,2 Months - N/A,100,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU),2030-09-22,ESTIMATED,Adverse Events (AEs) | Liver function tests (LFTs) - measuring enzyme activity or concentration | Fat-Soluble Vitamins (FSV) Concentration | International Normalized Ratio (INR) | Long-Term Clinical Outcomes,OTHER,ALL,2025-09-25,ACTUAL,INTERVENTIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT07411716,,NOT_YET_RECRUITING,"PFIC - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome (ALGS), Cholestasis, Intrahepatic",,PEARL,,1,PEARL Registry,,"The purpose of this study is to create a national, multi-centre registry for children with Alagille syndrome (ALGS) and Genetic Intrahepatic Cholestasis (GIC) that follows participants long-term, ensuring standardized, high-quality data capture across all participating pediatric hepatology centres.

Inclusion criteria:

• Pediatric participants (\<18 years old) with genetically confirmed or clinically diagnosed ALGS or any of the various subtypes of GIC, each associated with a distinct genetic m","Mirum Pharmaceuticals, Inc., medison pharma",2031-12,ESTIMATED,N/A - 18 Years,220,ESTIMATED,,OTHER,,PEARL - Pediatric Evaluation and Registry for Liver Cholestasis in Canada,2031-03,ESTIMATED,PEARL Registry - Primary Outcome,,ALL,2026-03,ESTIMATED,OBSERVATIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT07209462,PHASE2,RECRUITING,Fragile X Syndrome,"Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379, Placebo, Low dose of MRM-3379 Open-Label",,RANDOMIZED,5,Arm 1: Low Dose of MRM-3379 | Arm 2: Middle dose of MRM-3379 | Arm 3: High dose of MRM-3379 | Arm 4 :Placebo | Arm 5: Low dose of MRM-3379 Open-Label,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive). In addition, a parallel cohort of participants ages 13 to \<16 will receive open-label MRM-3379. All participants will participate for 12 weeks of treatment. The study is also intended as a proof-of-concept investigation to evaluate whether MRM-3379 can improve FXS symptoms",,2027-10,ESTIMATED,13 Years - 45 Years,60,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants With Fragile X Syndrome",2027-10,ESTIMATED,Incidence and severity of treatment-emergent adverse events and Withdrawal due to adverse events and withdrawal due to adverse events,TREATMENT,MALE,2025-11-22,ACTUAL,INTERVENTIONAL
MIRM,"Mirum Pharmaceuticals, Inc.",NCT06193928,,RECRUITING,"Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis","Livmarli, Livmarli",LEAP,,2,Alagille syndrome (ALGS) | Progressive familial intrahepatic cholestasis (PFIC), | ,"The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.",,2030-09-20,ESTIMATED,N/A - N/A,70,ESTIMATED,,INDUSTRY,,Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US),2028-09-20,ESTIMATED,Incidence of Long-Term Clinical Outcomes | Liver Transplant Indication and Waitlist Status | Assessment of Growth and Development | Incidence of Clinical Events Potentially Related to Fat-Soluble Vitamin Deficiencies and Their Long-Term Sequelae,,ALL,2023-09-21,ACTUAL,OBSERVATIONAL
FBRX,"Forte Biosciences, Inc.",NCT06982963,PHASE2,RECRUITING,Celiac Disease,FB102,,RANDOMIZED,3,A | B | C,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.",,2027-02-28,ESTIMATED,18 Years - 70 Years,100,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of FB102 in Adult Participants With Celiac Disease on a Gluten Free Diet",2027-02-28,ESTIMATED,Change from baseline in the VCIEL,TREATMENT,ALL,2025-08-04,ACTUAL,INTERVENTIONAL
FBRX,"Forte Biosciences, Inc.",NCT06905873,PHASE1,RECRUITING,Vitiligo,"FB102, Placebo",,RANDOMIZED,2,FB102 | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.",,2026-12-31,ESTIMATED,18 Years - 75 Years,64,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo",2026-12-31,ESTIMATED,Number of participants with treatment-emergent adverse events (TEAEs) and Serious Adverse events (SAE) following treatment with FB102 | Percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI) | Number of participants with percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI),TREATMENT,ALL,2025-03-25,ACTUAL,INTERVENTIONAL
FBRX,"Forte Biosciences, Inc.",NCT07205159,PHASE1,RECRUITING,Alopecia Areata,"FB102, Placebo",,RANDOMIZED,2,FB102 | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).",,2027-03-10,ESTIMATED,18 Years - 75 Years,32,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.",2027-03-10,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | Change from Baseline of Severity of Alopecia Tool (SALT) score at Week 16.,TREATMENT,ALL,2025-10-23,ACTUAL,INTERVENTIONAL
STOK,"Stoke Therapeutics, Inc.",NCT04740476,PHASE2,ACTIVE_NOT_RECRUITING,Dravet Syndrome,zorevunersen (STK-001),,,1,zorevunersen (STK-001) multiple dose levels,EXPERIMENTAL,"Stoke Therapeutics is evaluating the long-term safety \& tolerability of repeated doses of zorevunersen (STK-001) in patients with Dravet syndrome who previously participated in studies of zorevunersen. Change in seizure frequency and overall clinical status, and quality of life will be measured as secondary endpoints in this open-label study.",,2029-03-31,ESTIMATED,30 Months - N/A,60,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001,2029-03-31,ESTIMATED,Safety of multiple doses of zorevunersen,TREATMENT,ALL,2021-01-20,ACTUAL,INTERVENTIONAL
STOK,"Stoke Therapeutics, Inc.",NCT06872125,PHASE3,RECRUITING,Dravet Syndrome,zorevunersen,,RANDOMIZED,2,Zorevunersen | Sham Comparator,EXPERIMENTAL | SHAM_COMPARATOR,"The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.",,2028-10,ESTIMATED,2 Years - 17 Years,170,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome",2027-03,ESTIMATED,Measurement of Seizure Change,TREATMENT,ALL,2025-06-04,ACTUAL,INTERVENTIONAL
SEPN,"Septerna, Inc.",NCT07069036,PHASE1,NOT_YET_RECRUITING,Healthy Volunteers,SEP-631,,RANDOMIZED,3,Single Ascending Dose | Multiple Ascending Dose | Food Effect,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effects of oral SEP-631 in healthy adult volunteers.",,2026-04,ESTIMATED,18 Years - 60 Years,150,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of SEP-631 in Healthy Adult Volunteers",2026-03,ESTIMATED,Frequency of treatment emergent adverse events,TREATMENT,ALL,2025-07,ESTIMATED,INTERVENTIONAL
SEPN,"Septerna, Inc.",NCT07433179,PHASE1,NOT_YET_RECRUITING,Healthy Volunteers,SEP-479,,RANDOMIZED,3,Single Ascending Dose | Multiple Ascending Dose | Food Effect,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effects of oral SEP-479 in healthy adult participants.",,2027-02,ESTIMATED,21 Years - 60 Years,150,ESTIMATED,SEQUENTIAL,INDUSTRY,TRIPLE,"A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SEP-479 in Healthy Adult Participants",2027-02,ESTIMATED,Frequency of treatment emergent adverse events,TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT05403541,PHASE3,ACTIVE_NOT_RECRUITING,Generalized Myasthenia Gravis,"Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly",,RANDOMIZED,6,Batoclimab Induction Dose 1 (Period 1) | Batoclimab Induction Dose 2 (Period 1) | Placebo Induction Dose (Period 1) | Batoclimab Maintenance Dose 1 (Period 2) | Batoclimab Maintenance Dose 2 (Period 2) | Placebo Maintenance Dose (Period 2),EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previo",,2025-04,ESTIMATED,18 Years - N/A,240,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)",2025-03,ESTIMATED,Change from Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor (AChR) Ab seropositive (AChRAb+) participants,TREATMENT,ALL,2022-06-27,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT05581199,PHASE2,ACTIVE_NOT_RECRUITING,Chronic Inflammatory Demyelinating Polyneuropathy,"Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo",,RANDOMIZED,18,"Treatment Period 1: Cohort A, Dose 1 | Treatment Period 1: Cohort A, Dose 2 | Treatment Period 1: Cohort B, Dose 1 | Treatment Period 1: Cohort B, Dose 2 | Treatment Period 1: Cohort C, Dose 1 | Treatment Period 1: Cohort C, Dose 2 | Treatment Period 1: Cohort D, Dose 1 | Treatment Period 1: Cohort D, Dose 2 | Withdrawal Period 2: Cohort A, Dose 2 | Withdrawal Period 2: Cohort A, Placebo | Withdrawal Period 2: Cohort B, Dose 2 | Withdrawal Period 2: Cohort B, Placebo | Withdrawal Period 2: Cohort C, Dose 2 | Withdrawal Period 2: Cohort C, Placebo | Withdrawal Period 2: Cohort D, Dose 2 | Withdrawal Period 2: Cohort D, Placebo | LTE Period: With Relapse in Period 2: Dose 1 and Dose 2 | LTE Period: Without Relapse in Period 2: Dose 2",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes an up to 4-week Screening Period, an up to 12-week Washout Period, a 12-week Randomized Treatment Period (Period 1), an up to 24-week Randomized Withdrawal Period (Period 2), an up to 52-week Long-term Extension (LTE) Period (optional), and Safety Follow-up 4 weeks after the last dose of study treatment. The tot",,2027-01,ESTIMATED,18 Years - N/A,277,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",2026-01,ESTIMATED,"Period 2, Cohort A: Proportion of participants who remain relapse-free at Week 36",TREATMENT,ALL,2022-12-15,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT06980805,PHASE2,RECRUITING,"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","IMVT-1402, Placebo",,RANDOMIZED,2,Period 1: Placebo | IMVT-1402 Subcutaneous (SC) Once weekly (QW),PLACEBO_COMPARATOR | EXPERIMENTAL,"The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.

The study will consist of 3 periods:

Period 1: eligible participants will be randomized 1:1 to IMVT-1402 Dose 1 or placebo SC QW for 12 weeks.

Period 2: participants who completed Period 1 will receive IMVT-1402 Dose 1 SC QW for 14 weeks.

Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 Dose",,2027-04,ESTIMATED,18 Years - N/A,56,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations",2027-04,ESTIMATED,Percent change from Period 1 Baseline in Cutaneous Lupus Erythematosus Disease area and Severity Index activity (CLASI-A) score at Week 12,TREATMENT,ALL,2025-02-19,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT07286006,PHASE2,NOT_YET_RECRUITING,Graves' Disease,IMVT-1402,,NON_RANDOMIZED,3,Group A | Group B | Group C,EXPERIMENTAL | NO_INTERVENTION | NO_INTERVENTION,"This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.",,2030-03,ESTIMATED,18 Years - N/A,372,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease",2030-03,ESTIMATED,"Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402",TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT07018323,PHASE2,RECRUITING,Graves' Disease,"IMVT-1402, IMVT-1402, Placebo",,RANDOMIZED,3,IMVT-1402 Dose 1 | IMVT-1402 Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.",,2027-05,ESTIMATED,18 Years - 75 Years,210,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease",2027-05,ESTIMATED,Percentage of participants who are euthyroid and off ATD at Week 26 (Dose 1),TREATMENT,ALL,2025-06-19,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT07032662,PHASE2,RECRUITING,Chronic Inflammatory Demyelinating Polyneuropathy,"IMVT-1402, Placebo",,RANDOMIZED,2,IMVT-1402 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.,,2030-05,ESTIMATED,18 Years - N/A,162,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",2028-08,ESTIMATED,Proportion of participants remaining Relapse-free by Week 24,TREATMENT,ALL,2025-03-18,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT06727604,PHASE2,RECRUITING,Graves' Disease,"IMVT-1402, IMVT-1402, Placebo",,RANDOMIZED,4,Group 1 Period 1 and 2: IMVT-1402 | Group 2 Period 1 and 2: IMVT-1402 | Group 2 Period 1: IMVT-1402 and Period 2: Placebo | Group 3 Period 1 and 2: Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.",,2028-06,ESTIMATED,18 Years - 75 Years,240,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease",2028-06,ESTIMATED,"Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26",TREATMENT,ALL,2024-12-17,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT07039916,PHASE3,RECRUITING,Generalized Myasthenia Gravis,"IMVT-1402, IMVT-1402, Placebo, IMVT-1402",,RANDOMIZED,3,Group 1: IMVT-1402 Dose 1 | Group 2: IMVT-1402 Dose 2 | Placebo/ IMVT-1402,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.",,2028-12,ESTIMATED,18 Years - 80 Years,231,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis",2027-12,ESTIMATED,Change from Baseline in MG-ADL Score for Antibody-positive Participants,TREATMENT,ALL,2025-05-27,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT06754462,PHASE2,ACTIVE_NOT_RECRUITING,Rheumatoid Arthritis,"IMVT-1402, Placebo",,RANDOMIZED,3,IMVT-1402 Dose 1 | IMVT-1402 Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).",,2027-09,ESTIMATED,18 Years - N/A,120,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat, ACPA-Positive Rheumatoid Arthritis",2027-09,ESTIMATED,Proportion of participants who maintain ACR20 response at Week 28,TREATMENT,ALL,2025-01-10,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT05524571,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,"Batoclimab, Placebo",,RANDOMIZED,2,Batoclimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.,,2026-03,ESTIMATED,18 Years - N/A,100,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)",2026-03,ESTIMATED,Percentage of proptosis responders,TREATMENT,ALL,2023-01-05,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT05517447,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,Batoclimab,,NON_RANDOMIZED,2,Observational cohort | Treatment Cohort,OTHER | EXPERIMENTAL,This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.,,2026-08,ESTIMATED,18 Years - N/A,180,ESTIMATED,PARALLEL,INDUSTRY,NONE,An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED),2026-08,ESTIMATED,Duration of proptosis response off treatment in study eye in batoclimab responder participants in the feeder studies,TREATMENT,ALL,2022-11-06,ACTUAL,INTERVENTIONAL
IMVT,"Immunovant, Inc.",NCT06979531,PHASE2,RECRUITING,Primary Sjögren's Syndrome,"IMVT-1402, Placebo",,RANDOMIZED,3,Group 1: IMVT-1402 Dose 1 | Group 2: IMVT-1402 Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).",,2028-07,ESTIMATED,18 Years - 74 Years,180,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity",2028-07,ESTIMATED,Change from Baseline in clinESSDAI Score at Week 24 for IMVT-1402 Dose 1 compared to Placebo,TREATMENT,ALL,2025-06-30,ACTUAL,INTERVENTIONAL
BLTE,"Belite Bio, Inc",NCT05949593,PHASE3,ACTIVE_NOT_RECRUITING,Geographic Atrophy,"Tinlarebant, Placebo",PHOENIX,RANDOMIZED,2,"LBS-008, Tinlarebant | Placebo",EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.",,2027-08-31,ESTIMATED,60 Years - 85 Years,429,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)",2027-06-30,ESTIMATED,To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size,TREATMENT,ALL,2023-07-27,ACTUAL,INTERVENTIONAL
BLTE,"Belite Bio, Inc",NCT06388083,"PHASE2, PHASE3",RECRUITING,"STGD1, Stargardt Disease 1","Tinlarebant, Placebo",DRAGON II,RANDOMIZED,2,"LBS-008, Tinlarebant | Placebo",EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease",,2028-01,ESTIMATED,12 Years - 20 Years,60,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease",2027-12,ESTIMATED,To measure the annualized rate of change from baseline lesion size in aggregate area of atrophy,TREATMENT,ALL,2024-07-31,ACTUAL,INTERVENTIONAL
NMRA,"Neumora Therapeutics, Inc.",NCT06058039,PHASE3,RECRUITING,Major Depressive Disorder,"NMRA-335140, Placebo",,RANDOMIZED,2,NMRA-335140 80 milligrams (mg) once daily (QD) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee",,2026-03,ESTIMATED,18 Years - 65 Years,332,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder",2026-02,ESTIMATED,Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score,TREATMENT,ALL,2023-12-21,ACTUAL,INTERVENTIONAL
NMRA,"Neumora Therapeutics, Inc.",NCT06058013,PHASE3,RECRUITING,Major Depressive Disorder,"NMRA-335140, Placebo",,RANDOMIZED,2,NMRA-335140 80 milligrams (mg) once daily (QD) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and ",,2026-06,ESTIMATED,18 Years - 65 Years,332,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder",2026-05,ESTIMATED,Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score,TREATMENT,ALL,2023-12-20,ACTUAL,INTERVENTIONAL
NMRA,"Neumora Therapeutics, Inc.",NCT06029439,PHASE3,RECRUITING,Major Depressive Disorder,NMRA-335140,,,1,NMRA-335140 80 milligrams (mg) once daily (QD),EXPERIMENTAL,"This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.",,2027-06,ESTIMATED,18 Years - 65 Years,1000,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Depressive Disorder,2027-06,ESTIMATED,Safety and tolerability assessments based on Treatment Emergent Adverse Events (TEAEs) and validated clinical scales,TREATMENT,ALL,2023-11-10,ACTUAL,INTERVENTIONAL
ORKA,"Oruka Therapeutics, Inc.",NCT06944379,PHASE1,ACTIVE_NOT_RECRUITING,Healthy Volunteers,ORKA-002,,RANDOMIZED,2,ORKA-002 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.",,2027-01,ESTIMATED,18 Years - 65 Years,24,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Phase 1, First-in-human, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Healthy Participants",2027-01,ESTIMATED,Incidence of Treatment-emergent Adverse Events,OTHER,ALL,2025-05-19,ACTUAL,INTERVENTIONAL
ORKA,"Oruka Therapeutics, Inc.",NCT07090330,PHASE2,RECRUITING,Plaque Psoriasis,"ORKA-001 Induction Dose, ORKA-001 Maintenance Dose",EVERLAST-A,RANDOMIZED,5,(Induction Period) ORKA-001 | (Induction Period) Placebo | (Maintenance Period - Arm 1) ORKA-001 | (Maintenance Period - Arm 2) ORKA-001 | (Maintenance Period - Arm 3) Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.",,2027-05,ESTIMATED,18 Years - N/A,80,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis",2026-09,ESTIMATED,Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16,TREATMENT,ALL,2025-07-18,ACTUAL,INTERVENTIONAL
ORKA,"Oruka Therapeutics, Inc.",NCT07290569,PHASE2,RECRUITING,Plaque Psoriasis,ORKA-001,EVERLAST-B,RANDOMIZED,7,(Induction Period - Arm 1) ORKA-001 | (Induction Period - Arm 2) ORKA-001 | (Induction Period - Arm 3) ORKA-001 | (Induction Period - Arm 4) Placebo | (Maintenance Period - Arm 1) ORKA-001 | (Maintenance Period - Arm 2) ORKA-001 | (Maintenance Period - Arm 3) Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.",,2028-12,ESTIMATED,18 Years - N/A,160,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Multicenter, Randomized, Double-blinded, Placebo-controlled, Dose-range Finding Study of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis",2027-06,ESTIMATED,Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16,TREATMENT,ALL,2025-12-03,ACTUAL,INTERVENTIONAL
ORKA,"Oruka Therapeutics, Inc.",NCT06698939,PHASE1,ACTIVE_NOT_RECRUITING,Healthy Volunteers,ORKA-001,ORKA-001-111,RANDOMIZED,2,ORKA-001 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 1, First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Healthy Participants.",,2026-06,ESTIMATED,18 Years - 65 Years,24,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, of ORKA-001 in Healthy Participants",2026-06,ESTIMATED,Number and frequency of Treatment-Emergent Adverse Events [Safety and Tolerability],OTHER,ALL,2024-12-19,ACTUAL,INTERVENTIONAL
CTNM,"Contineum Therapeutics, Inc.",NCT06810245,PHASE1,ACTIVE_NOT_RECRUITING,"Chronic Osteoarthritis Pain, Chronic Low Back Pain","PIPE-791, Placebo",,RANDOMIZED,2,Active followed by Placebo | Placebo followed by Active,EXPERIMENTAL | EXPERIMENTAL,"The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP.

Subjects will:

* Complete a washout period to stop their current pain medications.
* Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks.
* Record pain levels and track dosing in a d",,2026-02-15,ESTIMATED,18 Years - 70 Years,43,ACTUAL,CROSSOVER,INDUSTRY,QUADRUPLE,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Crossover Multicenter Study to Explore the Safety and Efficacy of Oral PIPE-791 as Treatment in Subjects With Chronic Osteoarthritis Pain (COAP) or Chronic Low Back Pain (CLBP)",2025-12-15,ESTIMATED,Number of subjects with Treatment-emergent adverse events (TEAEs),TREATMENT,ALL,2025-02-04,ACTUAL,INTERVENTIONAL
CTNM,"Contineum Therapeutics, Inc.",NCT07284459,PHASE2,RECRUITING,Idiopathic Pulmonary Fibrosis,"PIPE-791 Dose A, PIPE-791 Dose B, Placebo",,RANDOMIZED,3,PIPE-791 Dose A | PIPE-791 Dose B | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in subjects with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.",,2028-06,ESTIMATED,40 Years - N/A,324,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis",2028-05,ESTIMATED,Absolute change in forced vital capacity (FVC) (mL),TREATMENT,ALL,2026-01-08,ACTUAL,INTERVENTIONAL
MBX,"MBX Biosciences, Inc.",NCT06531941,PHASE2,ACTIVE_NOT_RECRUITING,Hypoparathyroidism,"400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection",,NON_RANDOMIZED,2,400 µg once-weekly by subcutaneous injection | 200-1600 µg once-weekly by subcutaneous injection,EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.",,2027-05-27,ESTIMATED,18 Years - 100 Years,60,ACTUAL,CROSSOVER,INDUSTRY,NONE,"An Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism Who Completed the 12-Week Treatment Period in the Phase 2 Study, MBX-2H1002 Study (Avail-Ext)",2027-05-27,ESTIMATED,To evaluate the long-term safety and tolerability of weekly MBX 2109 in patients with hypoparathyroidism.,TREATMENT,ALL,2024-10-31,ACTUAL,INTERVENTIONAL
MBX,"MBX Biosciences, Inc.",NCT07142707,PHASE1,RECRUITING,Obesity,"MBX 4291, Placebo",,RANDOMIZED,3,MBX 4291 (Part A) | MBX 4291 (Part B) | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.,,2026-05-30,ESTIMATED,18 Years - 65 Years,64,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-blind, Placebo-controlled First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of MBX 4291 in Adult Participants With Obesity",2026-05-30,ESTIMATED,Number of participants with Treatment Emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-09-03,ACTUAL,INTERVENTIONAL
MBX,"MBX Biosciences, Inc.",NCT07029412,PHASE2,RECRUITING,Postbariatric Hypoglycemia,MBX 1416 (INN imapextide),,,1,MBX 1416 (INN imapextide),EXPERIMENTAL,The purpose of this study is to assess the preliminary efficacy of single SC administration of MBX 1416 at different dose levels in patients with PBH,,2026-01-26,ESTIMATED,18 Years - 75 Years,10,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2a, Open-label, Exploratory Study to Evaluate Preliminary Efficacy of Subcutaneous MBX 1416 in Patients With Postbariatric Hypoglycemia (The STEADI Study)",2025-12-22,ESTIMATED,Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416.,TREATMENT,ALL,2025-08-26,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06588491,PHASE2,ACTIVE_NOT_RECRUITING,"Stiff-Person Syndrome, SPS",Standard lymphodepletion regimen,,,1,KYV-101 CAR-T cells with lymphodepletion conditioning,EXPERIMENTAL,A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome,,2026-12,ESTIMATED,18 Years - 75 Years,25,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"KYSA-8: A Phase 2 Open-Label, Single-Arm, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome",2026-04,ESTIMATED,To evaluate efficacy of KYV-101 | To evaluate the safety of KYV-101,TREATMENT,ALL,2024-09-25,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06400303,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria","KYV-101, Standard lymphodepletion regimen",,NON_RANDOMIZED,2,KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1) | KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2),EXPERIMENTAL | EXPERIMENTAL,A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis,,2027-03,ESTIMATED,18 Years - N/A,3,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis",2026-03,ESTIMATED,Incidence of adverse events and laboratory abnormalities (Phase 1) | Frequency of Dose-Limiting Toxicities (DLTs) at each dose level (Phase 1) | To evaluate efficacy of KYV-101(Phase 2),TREATMENT,ALL,2024-08-06,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06384976,PHASE2,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS","KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB",,RANDOMIZED,2,KYV-101 CAR-T cells with lymphodepletion conditioning | Anti- CD20 mAb,EXPERIMENTAL | ACTIVE_COMPARATOR,"A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis",,2029-01,ESTIMATED,18 Years - 60 Years,120,ESTIMATED,PARALLEL,INDUSTRY,NONE,"KYSA-7: A Phase 2, Open-Label, Randomized, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis",2027-04,ESTIMATED,To evaluate efficacy of KYV-101,TREATMENT,ALL,2024-09-20,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT05938725,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV","KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen",,NON_RANDOMIZED,2,KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1) | KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2),EXPERIMENTAL | EXPERIMENTAL,A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis,,2027-08,ESTIMATED,18 Years - N/A,6,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"KYSA-1: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",2026-08,ESTIMATED,Incidence adverse events (AEs) and laboratory abnormalities (Phase 1 and Phase 2) | Frequency of dose limiting toxicities at each dose level (Phase 1) | To Evaluate efficacy (Phase 2),TREATMENT,ALL,2023-04-28,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06193889,"PHASE2, PHASE3",RECRUITING,"Myasthenia Gravis, Generalized Myasthenia Gravis","Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101",,RANDOMIZED,3,KYV-101 CAR-T cells with lymphodepletion conditioning | KYV-101 Treatment | Standard of Care,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis,,2028-09,ESTIMATED,18 Years - 75 Years,66,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis",2027-09,ESTIMATED,Incidence and severity of adverse events (AEs) and laboratory abnormalities (Phase 2) | Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline (Phase 2) | Efficacy of KYV-101 via Myasthenia Gravis Activities of Daily Living (MG-ADL) change from baseline for KYV-101 Treatment Arm to Standard of Care Arm (Phase 3) | Efficacy of KYV-101 via Quantitative Myasthenia Gravis (QMG) change from baseline for KYV-101 Treatment arm to Standard of Care arm,TREATMENT,ALL,2024-08-28,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06342960,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV","KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen",,NON_RANDOMIZED,2,KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1) | KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2),EXPERIMENTAL | EXPERIMENTAL,A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis,,2029-01,ESTIMATED,18 Years - N/A,2,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"KYSA-3: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",2028-10,ESTIMATED,Incidence adverse events (AEs) and laboratory abnormalities (Phase 1 and Phase 2) | Frequency of dose limiting toxicities (Phase 1),TREATMENT,ALL,2022-12-01,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06138132,PHASE1,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive","KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen",,,1,KYV-101 CAR-T cells with lymphodepletion conditioning,EXPERIMENTAL,A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis,Kyverna Therapeutics,2027-06,ESTIMATED,18 Years - 65 Years,12,ESTIMATED,SEQUENTIAL,OTHER,NONE,"A Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis",2027-06,ESTIMATED,Frequency of dose limiting toxicities at each dose level,TREATMENT,ALL,2024-04-10,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06475495,"PHASE1, PHASE2",NOT_YET_RECRUITING,Rheumatoid Arthritis,"KYV101, Rituximab (active comparator)",COMPARE,RANDOMIZED,2,KYV101 | Rituximab,EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this phase I/II clinical trial is to compare B-cell depletion by rituximab and anti-CD 19 CAR-T therapy in patients with rheumatoid arthritis. The main questions it aims to answer are:

* To assess the safety of anti-CD19 CAR T cell therapy in subjects with active, ACPA positive and treatment refractory RA (Phase-I)
* To assess the safety of anti-CD19 CAR T cell therapy and of rituximab in subjects with active, ACPA positive and treatment refractory RA (Phase-II)
* To assess ACPA ser",Kyverna Therapeutics,2027-03,ESTIMATED,18 Years - 80 Years,13,ESTIMATED,PARALLEL,OTHER,NONE,"Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis. Two-stage Interventional, Prospective, Randomized, Controlled, Open Label, Parallel-group Phase I/II Trial in Patients With Active, ACPA-positive and Treatment Refractory Rheumatoid Arthritis",2027-03,ESTIMATED,Safety Phase I (1) Safety | Safety Phase I (2) Safety | Safety Phase I (3) Safety | Safety Phase I (4) Safety | Efficacy Phase II | Safety Phase II (1) | Safety Phase II (2),TREATMENT,ALL,2024-11,ESTIMATED,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT07403188,,RECRUITING,"Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)",KYV-101,KYSA-4,,1,Cohort 1,,"The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).

This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).",,2041-01,ESTIMATED,18 Years - N/A,70,ESTIMATED,,INDUSTRY,,A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101,2041-01,ESTIMATED,Number of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | Number of participants with new or recurrent malignancies as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | Number of participants with new or exacerbation of a pre-existing neurologic disorder as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | Number of participants with new or exacerbation of a prior rheumatologic or other autoimmune disorder as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | Number of participants with new hematologic disorders as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | Number of participants with new infections as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | Number of participants with positive Replication-Competent Lentivirus (RCL) laboratory test results through Year 5 of long-term follow-up (LTFU). | Number of participants with positive Chimeric Antigen Receptor (CAR) laboratory test results through Year 5 of long-term follow-up (LTFU). | Number of participants with positive Anti-Drug-Antibody (ADA) laboratory test results through Year 5 of long-term follow-up (LTFU).,,ALL,2025-11-24,ACTUAL,OBSERVATIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06152172,PHASE1,ACTIVE_NOT_RECRUITING,"Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis","KYV-101, Cyclophosphamide, Fludarabine",CARTIMMUNE,NON_RANDOMIZED,4,IIM | DCSS | SLE | AAV,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years.",Kyverna Therapeutics,2027-02,ESTIMATED,18 Years - N/A,24,ESTIMATED,PARALLEL,OTHER,NONE,CARTIMMUNE: A Single-Center Study of Patients With Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101),2027-02,ESTIMATED,Incidence and severity of AEs in IIM. | Incidence and severity of AEs in IIM. | Incidence and severity of AEs in IIM. | Incidence and severity of AEs in IIM. | Incidence and severity of AEs in DCSS | Incidence and severity of AEs in DCSS | Incidence and severity of AEs in DCSS | Incidence and severity of AEs in DCSS | Incidence and severity of AEs in SLE Nephritis | Incidence and severity of AEs in SLE Nephritis | Incidence and severity of AEs in SLE Nephritis | Incidence and severity of AEs in SLE Nephritis | Incidence and severity of AEs in AAV | Incidence and severity of AEs in AAV | Incidence and severity of AEs in AAV | Incidence and severity of AEs in AAV,TREATMENT,ALL,2024-08-05,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06451159,PHASE1,ACTIVE_NOT_RECRUITING,Progressive Multiple Sclerosis,"KYV-101 (Biological) - 0.33 ×10^8 cells, KYV-101 (Biological) - 1 ×10^8 cells, Chemotherapy: cyclophosphamide (CYC), Chemotherapy: fludarabine (FLU)",,NON_RANDOMIZED,2,Dosing Cohort #1: KYV-101 CAR+ T -- 0.33 ×10^8 cells | Dosing Cohort #2: KYV-101 CAR+ T -- 1×10^8 cells,EXPERIMENTAL | EXPERIMENTAL,"The goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are:

* What is the highest therapy dose that can be given without causing harm?
* Can this therapy enter the central nervous system?

Participants will be asked to:

* Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks.
* Complete apheresis ",Kyverna Therapeutics,2027-02,ESTIMATED,25 Years - 70 Years,10,ESTIMATED,SEQUENTIAL,OTHER,NONE,"Phase 1, Open-Label, Single Center Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis",2026-02,ESTIMATED,The presence of CAR-T cells in CSF following their peak expansion in peripheral blood. | The incidence and severity of adverse events and dose-limiting toxicities.,TREATMENT,ALL,2024-06-20,ACTUAL,INTERVENTIONAL
KYTX,"Kyverna Therapeutics, Inc.",NCT06590545,"PHASE1, PHASE2",NOT_YET_RECRUITING,ANCA-IgG-positive ANCA Associated Vasculitis,"KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy",IDEAL,,1,"KYV-101, anti-CD19 CAR T-cell immunotherapy.",EXPERIMENTAL,"The goal of this phase I/II clinical trial is to investigate anti-CD 19 chimeric antigen receptor T cell (CAR-T cell) therapy in patients with antineutrophil cytoplasmic antibodies (ANCA) immunoglobulin (IgG) positive ANCA associated vasculitis (AAV).

The main questions it aims to answer are:

* To assess the safety of anti-CD19 CAR-T cell therapy in subjects with active, treatment refractory, ANCA-IgG-positive AAV
* To assess the clinical efficacy of anti-CD19 CAR-T cell therapy in subjects wi",Kyverna Therapeutics,2027-07,ESTIMATED,18 Years - 75 Years,8,ESTIMATED,SEQUENTIAL,OTHER,NONE,"Anti-CD 19 CAR-T Cell Therapy in Patients with ANCA Vasculitis: a Two-stage Interventional, Prospective, Open-label, Phase I/II Trial in Patients with Active, Treatment Refractory, ANCA-IgG-positive Vasculitis",2027-01,ESTIMATED,number of subjects experiencing a cytokine release syndrome | antineutrophil cytoplasmic antibodies (ANCA) seroconversion rate | adverse events and serious adverse events due to investigational medical product,TREATMENT,ALL,2025-01,ESTIMATED,INTERVENTIONAL
FOLD,"Amicus Therapeutics, Inc.",NCT06303466,,ACTIVE_NOT_RECRUITING,Fabry Disease,,RWE-FABRY,,1,Danish Fabry Patients,,"Fabry is a rare X-linked metabolic lysosomal disorder caused by deficiency in the enzyme α-galactosidase A (alpha-Gal A) by mutations in the GLA gene, encoding the alpha-Gal A enzyme, which catalyses glycosphingolipids, namely globotriaosylceramide (Gb3). Reduced or absent alpha-Gal A activity leads to accumulation of Gb3 in various organs as well as cellular dysfunction and inflammation causing phsyical symptoms and eventual organ failure. Treatment has been available since 2001 for Fabry patie","Amicus Therapeutics, Rigshospitalet, Denmark",2024-12-31,ESTIMATED,18 Years - N/A,115,ESTIMATED,,OTHER,,Real World Evidence Study of Danish Fabry Patients: a >20- Year Longitudinal Retrospective Analysis of Prospectively Collected Data.,2024-08-01,ESTIMATED,Time to first individual FACE since confirmed diagnosis (Composite endpoint) | Time to first FACE after initiation of Migalastat treatment (Composite endpoint),,ALL,2023-08-01,ACTUAL,OBSERVATIONAL
FOLD,"Amicus Therapeutics, Inc.",NCT04020055,PHASE3,ACTIVE_NOT_RECRUITING,Fabry Disease,migalastat HCl 150 mg,,NON_RANDOMIZED,2,Cohort 1: Severe Renal Impairment | Cohort 2: End-Stage Renal Disease,EXPERIMENTAL | EXPERIMENTAL,An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD),,2026-12-31,ESTIMATED,18 Years - N/A,14,ESTIMATED,PARALLEL,INDUSTRY,NONE,An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or End-Stage Renal Disease Treated With Hemodialysis,2026-12-31,ESTIMATED,Maximum observed concentration (Cmax) | Time to maximum concentration (tmax) | Apparent terminal elimination half-life (t½) | Concentration at the end of a dosing interval at steady state (Ctrough) | Average plasma migalastat concentration over the dosing interval (Cavg) | Area under the concentration-time curve at steady state during the dosing interval (AUC0-τ) | Area under the concentration-time curve from zero time (pre-dose) extrapolated to infinite time (AUC0-∞) | Apparent plasma clearance (CL/F) | Apparent terminal phase volume of distribution (Vz/F) | Dialysis clearance (CLD) | Volume of dialysate collected during the interval (VD) | Mean migalastat concentration in dialysate (CD) | Amount recovered in dialysate (AeD) | Fraction of the dose recovered in dialysate (FeD) | Mean migalastat plasma concentration during the dialysis interval (P) | Mean inlet area under the curve (AUCinlet) | Mean outlet area under the curve (AUCoutlet) | Extraction ratio (ED) | Dialyzer blood flow (QD) | Cumulative amount excreted over all collection intervals (Ae0-τ) | Fraction of the dose recovered after the last measurable time point postdose (Fe0-τ) | Renal clearance (CLr),TREATMENT,ALL,2022-10-31,ACTUAL,INTERVENTIONAL
FOLD,"Amicus Therapeutics, Inc.",NCT03911505,PHASE3,ACTIVE_NOT_RECRUITING,Pompe Disease (Late-onset),"Cipaglucosidase Alfa, Miglustat",,,1,Cipaglucosidase Alfa (ATB200)/Miglustat(AT2221),EXPERIMENTAL,"This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years",,2026-06,ESTIMATED,0 Years - 17 Years,21,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years With Late-onset Pompe Disease",2026-06,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs) from baseline,TREATMENT,ALL,2020-02-13,ACTUAL,INTERVENTIONAL
FOLD,"Amicus Therapeutics, Inc.",NCT06906367,,RECRUITING,Fabry Disease,"migalastat HCl, ERT",,,3,Migalastat-treated | ERT-treated | Untreated, |  | ,"This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.",,2032-06,ESTIMATED,18 Years - N/A,450,ESTIMATED,,INDUSTRY,,"A Prospective, Observational Study of Patients With Fabry Disease (US Specific)",2032-06,ESTIMATED,Annualized rate of change in Estimated Glomerular Filtration Rate (eGFR),,ALL,2026-02-13,ACTUAL,OBSERVATIONAL
FOLD,"Amicus Therapeutics, Inc.",NCT04252066,,RECRUITING,Fabry Disease,migalastat,,,2,Cohort 1 | Cohort 2, | ,This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and/or breastfeeding. The study will evaluate outcomes of pregnancy and/or breastfeeding in women and infants exposed to migalastat.,,2030-02,ESTIMATED,N/A - N/A,20,ESTIMATED,,INDUSTRY,,A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding,2029-08,ESTIMATED,Number of major birth defects,,FEMALE,2025-03-18,ACTUAL,OBSERVATIONAL
FOLD,"Amicus Therapeutics, Inc.",NCT06121011,,RECRUITING,Pompe Disease,"Cipaglucosidase alfa, Miglustat, Alglucosidase alfa or Avalglucosidase alfa",,,3,Cipaglucosidase alfa/Miglustat-treated patients | Other Enyzme Replacement Therapy (ERT)-treated patients | Untreated patients (those who are not currently receiving any medical therapy for Pompe disease), |  | ,"This is a global, multicenter, prospective, observational registry of patients with Pompe disease, including those with late-onset pompe disease (LOPD) and infantile-onset pompe disease (IOPD). Both untreated patients and those being treated with an approved therapy for Pompe disease are eligible to participate.

The objectives of the registry are:

* To evaluate the long-term safety of Pompe disease treatments through collection of data that describe the frequency of adverse events (AEs)/seriou",,2034-12-20,ESTIMATED,N/A - N/A,500,ESTIMATED,,INDUSTRY,,A Global Prospective Observational Registry of Patients With Pompe Disease,2034-12-20,ESTIMATED,Evaluate long-term safety of Pompe disease treatments,,ALL,2024-02-16,ACTUAL,OBSERVATIONAL
FOLD,"Amicus Therapeutics, Inc.",NCT06904261,PHASE3,RECRUITING,Fabry Disease,Migalastat HCl 20 mg,,,1,Migalastat HCl 20 mg Dispersible Tablets,EXPERIMENTAL,"An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to \< 12 years of age with Fabry disease and with amenable GLA variants.",,2028-12,ESTIMATED,2 Years - 11 Years,8,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 2 to < 12 Years) With Fabry Disease and Amenable GLA Variants",2027-12,ESTIMATED,"Safety: Incidence of TEAEs, SAEs, and AEs leading to discontinuation of study drug | Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Migalastat | Pharmacokinetics (PK): Minimum Observed Plasma Concentration (Cmin) of Migalastat | Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve Over The Dosing Interval (AUCtau) of Migalastat",TREATMENT,ALL,2026-01-08,ACTUAL,INTERVENTIONAL
FOLD,"Amicus Therapeutics, Inc.",NCT04808505,PHASE3,RECRUITING,Glycogen Storage Disease Type II Infantile Onset,"Cipaglucosidase alfa, Miglustat",ROSSELLA,NON_RANDOMIZED,2,Cohort 1: Cipaglucosidase Alfa/Miglustat in ERT-experienced pediatric IOPD subjects | Cohort 2: Cipaglucosidase Alfa/Miglustat in ERT-naïve pediatric IOPD subjects,EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.",,2027-07,ESTIMATED,N/A - 17 Years,36,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to < 18 Years",2027-07,ESTIMATED,Proportion of subjects with infusion-associated reactions (IARs),TREATMENT,ALL,2023-07-18,ACTUAL,INTERVENTIONAL
IVA,Inventiva S.A.,NCT04849728,PHASE3,RECRUITING,NASH - Nonalcoholic Steatohepatitis,"IVA337, Placebo",NATiV3,RANDOMIZED,3,Lanifibranor (IVA 337) (800 mg/day) | Lanifibranor (IVA 337) (1200 mg/day) | Matching placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3,,2026-09-30,ESTIMATED,18 Years - N/A,1000,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3",2025-09-30,ESTIMATED,Resolution of NASH and improvement of fibrosis | Safety Analyses,TREATMENT,ALL,2021-08-19,ACTUAL,INTERVENTIONAL
IVA,Inventiva S.A.,NCT05651724,,RECRUITING,"MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver, Steatosis of Liver, Type 2 Diabetes, Obesity, Metabolic Syndrome, Arterial Hypertension",,GRIPonMASH,,0,,,"GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepati","UMC Utrecht, Echosens, MIMETAS BV, Nordic Bioscience A/S, Elevate BV, Leiden University, Amsterdam University Medical Center, Andaluz Health Service, National Research Council, Institute of Clinical Physiology, Italy, Leiden University Medical Center, Université Libre de Bruxelles, University Hospital, Antwerp, Catholic University of the Sacred Heart, Medical Education Research And Innovation Center S.R.L., EUROPEAN LIVER PATIENTS ASSOCIATION, Harokopio University, General University Hospital, Prague, Novo Nordisk A/S, Maastricht University, Mercodia Aktiebolag, EXIT071 BV, European Atherosclerosis Society, MetaDeq Limited, Associação para Investigação e Desenvolvimento da Faculdade de Medicina, Institute of Cardiometabolism and Nutrition, France, University Hospital, Saarland, Roche Pharma AG, Inventiva Pharma, Biocellvia, Franciscus Gasthuis & Vlietland (Hospital)",2031-03-31,ESTIMATED,18 Years - 75 Years,10000,ESTIMATED,,INDUSTRY,,Global Research Initiative for Patients Screening on MASH - Implementation of an International Transmural Patient Care Pathway,2031-03-31,ESTIMATED,"Prevalence of liver steatosis and MASLD estimated by FibroScan CAP in patients at risk | Prevalence of liver fibrosis estimated by FibroScan LSM in patients at risk | Prevalence of at-risk MASH estimated by FAST score in patients at risk | *Subset of patients: prevalence of MASH in patients at risk | Comparison of the prevalence of MASLD, liver fibrosis and (at-risk) MASH between the participating countries | Evaluate added value of a 2-step pathway as compared to FibroScan only for detection of high-risk patients",,ALL,2023-06-30,ACTUAL,OBSERVATIONAL
NVAX,"Novavax, Inc.",NCT06633835,PHASE4,ACTIVE_NOT_RECRUITING,"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine",SHIELD,NON_RANDOMIZED,2,2024-25 updated Novavax COVID-19 | Pfizer mRNA COVID-19,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine,University of Utah,2025-08-31,ESTIMATED,18 Years - N/A,660,ESTIMATED,PARALLEL,INDUSTRY,NONE,Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States,2025-06-30,ESTIMATED,Percentage of participants with solicited systemic reactogenicity symptoms.,PREVENTION,ALL,2024-09-20,ACTUAL,INTERVENTIONAL
NVAX,"Novavax, Inc.",NCT06291857,PHASE3,ACTIVE_NOT_RECRUITING,COVID-19,"CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine, Fluzone High Dose",,RANDOMIZED,4,CIC Vaccine | Novavax COVID-19 Vaccine | tNIV Vaccine | Fluzone High-Dose,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine. The researchers conducting the study won't know which vaccine each participant receives, ensuring their observations are unbiased. This study compares the new combination vaccine to an already available flu vaccine to see how well it works. It's a large-scale, final-stage study designed to thoroughly check how",,2026-09-30,ESTIMATED,65 Years - 75 Years,9320,ACTUAL,CROSSOVER,INDUSTRY,SINGLE,"A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a COVID-19 Influenza Combination Nanoparticle Vaccine and a Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants ≥ 65 Years of Age.",2026-07-26,ESTIMATED,"Numbers of participants with solicited local and systemic adverse events (AEs) | Numbers of participants reporting unsolicited AEs and medically attended adverse events (MAAEs). | Treatment-related MAAEs, serious adverse events (SAEs), and adverse events of special interest (AESIs) (including potential immune-mediated medical conditions [PIMMCs] and myocarditis and/or pericarditis) | Hemagglutination Inhibition (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as GMT | Hemagglutination Inhibition (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as GMTR | Percentage of Participants With a (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose for 3 vaccine-homologous influenza strains Expressed as SCR | Neutralizing Antibody (NAb) Responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as GMT | Neutralizing Antibody (NAb) Responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as GMTR | Percentage of Participants With a (NAb) Responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as SCR | Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of homologous influenza A and B strains expressed as GMT | Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of homologous influenza A and B strains expressed as GMTR | Percentage of Participants with (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of homologous influenza A and B strains expressed as SCR",PREVENTION,ALL,2024-12-09,ACTUAL,INTERVENTIONAL
NVAX,"Novavax, Inc.",NCT07079670,PHASE3,ACTIVE_NOT_RECRUITING,"COVID-19, SARS-CoV-2 Infection",NVX-CoV2705,COVID-19,,1,NVX-CoV2705,EXPERIMENTAL,"This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and individuals aged 12 to 64 who have existing health conditions that put them at high risk for severe COVID-19. All participants must have received a previous COVID-19 vaccine at least 90 days before joining this study. Study",Novavax,2026-06-16,ESTIMATED,12 Years - 90 Years,676,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M",2026-04-16,ESTIMATED,Pseudovirus neutralization (ID50) of Omicron JN.1 subvariant vaccine expressed as GMFR,PREVENTION,ALL,2025-10-09,ACTUAL,INTERVENTIONAL
NVAX,"Novavax, Inc.",NCT05468736,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,COVID-19,SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period),COVID-19,RANDOMIZED,12,Cohort-1(6 to < 12 y)-Part-1(Active Vaccine) | Cohort-1(6 to < 12 y)-Part-1(Placebo) | Cohort-1(6 to < 12 y)-Part-2(Active Vaccine) | Cohort-1(6 to < 12 y)-Part-2(Placebo) | Cohort-2(2 to < 6 y)-Part-1(Active Vaccine) | Cohort-2(2 to < 6 y)-Part-1(Placebo) | Cohort-2(2 to < 6 y)-Part-2(Active Vaccine) | Cohort-2(2 to < 6 y)-Part-2(Placebo) | Cohort-3(6 to < 24 m)-Part-1(Active Vaccine) | Cohort-3(6 to < 24 m)-Part-1(Placebo) | Cohort-3(6 to < 24 m)-Part-2 | Cohort-3(6 to < 24 m)-Part-2(Placebo),EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary doses of SARS-CoV-2 rS with Matrix-M™ adjuvant (NVX-CoV2373) given 21 days apart and NVX CoV2373 or a variant-based vaccine given as a booster dose or at crossover in pediatric participants (3 age cohorts; 6 to \< 12 years, 2 to \< 6 years, and 6 to \< 24 months of age). Each age cohort will be conducted in 2 parts starting with the oldest age cohor",,2025-10-25,ESTIMATED,6 Months - 11 Years,3600,ESTIMATED,CROSSOVER,INDUSTRY,TRIPLE,A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age,2024-01-16,ACTUAL,Reactogenicity Incidence and Severity | Incidence and Severity of Medically Attended Adverse Events (MAAEs) | Incidence and Severity of Unsolicited Adverse Events (AEs) | Incidence and Severity of MAAEs Attributed to Study Vaccine | Incidence and Severity of Serious Adverse Events (SAEs) | Incidence and Severity of Adverse Events of Special Interest (AESIs) | Death due to any cause,PREVENTION,ALL,2022-07-22,ACTUAL,INTERVENTIONAL
NVAX,"Novavax, Inc.",NCT07086222,PHASE4,NOT_YET_RECRUITING,"COVID-19, Sars-CoV-2 Infection","NVX-CoV2705, Placebo",COVID-19,RANDOMIZED,2,NVX-CoV2705 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19 vaccine. Approximately 6,500 healthy adults aged 50 to under 65 will be randomized to receive either the vaccine or a placebo, with follow-up for 180 days.",,2026-07-09,ESTIMATED,50 Years - 65 Years,6500,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Post-Marketing Study to Evaluate the Efficacy and Safety of an Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine Adjuvanted With Matrix-M® in Adults 50 to < 65 Years of Age Without High Risk Conditions for Severe COVID-19",2026-01-09,ESTIMATED,First episode of PCR-positive symptomatic COVID 19,PREVENTION,ALL,2025-11-10,ESTIMATED,INTERVENTIONAL
DNTH,"Dianthus Therapeutics, Inc.",NCT06282159,PHASE2,ACTIVE_NOT_RECRUITING,"Myasthenia Gravis, Generalized","DNTH103, Placebo",MAGIC,RANDOMIZED,3,Placebo | DNTH103 low dose Q2W | DNTH103 high dose Q2W,PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).",,2027-08,ESTIMATED,18 Years - 75 Years,65,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)",2025-07-28,ACTUAL,Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs),TREATMENT,ALL,2024-02-23,ACTUAL,INTERVENTIONAL
DNTH,"Dianthus Therapeutics, Inc.",NCT06858579,PHASE3,RECRUITING,Chronic Inflammatory Demyelinating Polyneuropathy,"DNTH103, DNTH103, Placebo",CAPTIVATE,RANDOMIZED,5,DNTH103 (Part A) | DNTH103 Low Dose (Part B) | DNTH103 High Dose (Part B) | Placebo (Part B) | DNTH103 (Optional OLE),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).,,2030-12-31,ESTIMATED,18 Years - 75 Years,480,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)",2028-12-31,ESTIMATED,Part B: Time From First Dose to Relapse as Assessed by the Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT),TREATMENT,ALL,2025-02-10,ACTUAL,INTERVENTIONAL
DNTH,"Dianthus Therapeutics, Inc.",NCT06537999,PHASE2,RECRUITING,Multifocal Motor Neuropathy,"DNTH103, Placebo",MOMENTUM,RANDOMIZED,3,Placebo | DNTH103 low dose Q2W | DNTH103 high dose Q2W,PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with multifocal motor neuropathy (MMN).",,2028-03-31,ESTIMATED,18 Years - 75 Years,36,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Multifocal Motor Neuropathy (MOMENTUM)",2026-06-30,ESTIMATED,Incidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs),TREATMENT,ALL,2024-09-17,ACTUAL,INTERVENTIONAL
AMLX,"Amylyx Pharmaceuticals, Inc.",NCT05021536,PHASE3,ACTIVE_NOT_RECRUITING,Amyotrophic Lateral Sclerosis,AMX0035,Phoenix,RANDOMIZED,2,Placebo | AMX0035,PLACEBO_COMPARATOR | EXPERIMENTAL,The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS,,2026-01-01,ESTIMATED,18 Years - N/A,664,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS)",2024-01-19,ACTUAL,Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope Change,TREATMENT,ALL,2021-10-28,ACTUAL,INTERVENTIONAL
AMLX,"Amylyx Pharmaceuticals, Inc.",NCT06747468,PHASE3,RECRUITING,Post Bariatric Hypoglycemia,Avexitide,LUCIDITY,RANDOMIZED,2,AVEXITIDE | PLACEBO,EXPERIMENTAL | PLACEBO_COMPARATOR,"AVX-001 (LUCIDITY) is a Phase 3 study to evaluate avexitide compared to placebo in participants with post bariatric hypoglycemia (PBH) related to Roux-en-Y gastric bypass (RYGB). The study will assess avexitide compared to placebo for safety and efficacy, measured by reduction of hypoglycemic events. The study includes a Screening period with a Run-in period (of up to 6- and 3-weeks, respectively); a randomized, double-blind, placebo-controlled study treatment period of 16 weeks; and a two-part ",,2026-10,ESTIMATED,18 Years - N/A,75,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia",2026-03,ESTIMATED,Composite rate of Level 2 and Level 3 hypoglycemic events | Safety and Tolerability of avexitide | Incidence of anti-drug antibodies (ADAb),TREATMENT,ALL,2025-04-29,ACTUAL,INTERVENTIONAL
AMLX,"Amylyx Pharmaceuticals, Inc.",NCT06122662,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism",AMX0035,ORION,RANDOMIZED,2,AMX0035 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.",,2029-11-30,ESTIMATED,40 Years - 80 Years,110,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,A Phase 2b/3 Study of the Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION),2026-04-01,ESTIMATED,Change in total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS) Score,TREATMENT,ALL,2023-12-21,ACTUAL,INTERVENTIONAL
AMLX,"Amylyx Pharmaceuticals, Inc.",NCT05676034,PHASE2,ACTIVE_NOT_RECRUITING,Wolfram Syndrome,AMX0035,,,1,AMX0035,EXPERIMENTAL,This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.,,2026-12-31,ESTIMATED,17 Years - N/A,12,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase II Study of Safety and Efficacy of AMX0035 in Adult Patients With Wolfram Syndrome,2024-07-23,ACTUAL,To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT) | To assess the safety and tolerability of AMX0035 administered orally for up to 144 weeks in adult participants with Wolfram syndrome,TREATMENT,ALL,2023-03-03,ACTUAL,INTERVENTIONAL
AMLX,"Amylyx Pharmaceuticals, Inc.",NCT06665165,PHASE1,RECRUITING,ALS,AMX0114,LUMINA,RANDOMIZED,2,Active Treatment: AMX0114 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).",,2027-10,ESTIMATED,18 Years - N/A,48,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, PK and PD of Antisense Oligonucleotide AMX0114 Administered to Adult Participants With Amyotrophic Lateral Sclerosis",2027-02,ESTIMATED,Evaluate the safety and tolerability of AMX0114 in adult participants living with ALS,TREATMENT,ALL,2025-04-07,ACTUAL,INTERVENTIONAL
VERA,"Vera Therapeutics, Inc.",NCT04716231,PHASE3,ACTIVE_NOT_RECRUITING,"IgA Nephropathy, Berger Disease",Atacicept,ORIGIN 3,RANDOMIZED,2,Atacicept Dose 150mg | Placebo to match Atacicept (Part C/D),EXPERIMENTAL | PLACEBO_COMPARATOR,A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3),,2028-07,ESTIMATED,18 Years - N/A,376,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (IgAN)",2025-05-15,ACTUAL,Change from baseline in urine protein to creatinine ratio (UPCR),TREATMENT,ALL,2023-06-29,ACTUAL,INTERVENTIONAL
VERA,"Vera Therapeutics, Inc.",NCT07020923,PHASE2,RECRUITING,"IgA Nephropathy (IgAN), Berger Disease",Atacicept,,RANDOMIZED,5,Atacicept Arm 1 | Atacicept Arm 2 | Atacicept Arm 3 | Atacicept Arm 4 | Atacicept Arm 5,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept",,2027-09,ESTIMATED,18 Years - N/A,90,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN,2026-09,ESTIMATED,Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN,TREATMENT,ALL,2025-05-29,ACTUAL,INTERVENTIONAL
VERA,"Vera Therapeutics, Inc.",NCT06983028,PHASE2,RECRUITING,"pMN, IgAN, Nephrotic Syndrome, MCD, FSGS",Atacicept,,NON_RANDOMIZED,3,IgAN or IgAVN | pMN | Primary Nephrotic Syndrome (MCD/FSGS),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.,,2027-11,ESTIMATED,10 Years - N/A,200,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER),2027-11,ESTIMATED,AE profile and results of routine clinical and laboratory tests | Percent reduction in urine protein to creatinine ratio (UPCR),TREATMENT,ALL,2025-07-07,ACTUAL,INTERVENTIONAL
NGEN,NervGen Pharma Corp.,NCT05965700,"PHASE1, PHASE2",RECRUITING,"Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury",NVG-291,,RANDOMIZED,2,NVG-291 for Injection | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects",,2026-04,ESTIMATED,18 Years - 75 Years,40,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects (CONNECT)",2026-03,ESTIMATED,Electrophysiological,TREATMENT,ALL,2023-08-08,ACTUAL,INTERVENTIONAL
HROW,"Harrow, Inc.",NCT07368595,PHASE4,NOT_YET_RECRUITING,Dry Eye Disease (DED),"Vevye®, Cyclosporine emulsion",CSAGCD,RANDOMIZED,2,Vevye® | Cyclosporine emulsion,EXPERIMENTAL | ACTIVE_COMPARATOR,"This goal of this clinical trial is to compare the effects of two approved cyclosporine eye drops that have different concentrations and vehicles on the number of mucus producing conjunctival goblet cells in patients with dry eye disease to learn which one causes the greatest increase.

The main questions it aims to answer are:

Does one drug cause a greater increase in goblet cells? How many weeks does it take to see the difference?

Participants will:

Use the eye drops every day for 2 months ",Harrow Inc,2027-06,ESTIMATED,18 Years - N/A,60,ESTIMATED,PARALLEL,OTHER,SINGLE,Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks,2027-03-31,ESTIMATED,Primary Outcome,TREATMENT,ALL,2026-04-01,ESTIMATED,INTERVENTIONAL
HROW,"Harrow, Inc.",NCT07224529,PHASE4,NOT_YET_RECRUITING,Meibomian Gland Dysfunction (MGD),Vevye(Cyclosporine 0.1% Ophthalmic Solution),,,1,Treatment,EXPERIMENTAL,"This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes.

If you join the study, after a short ""run-in"" period using artificial tears, you will receive Vevye twice a day for about 24 weeks (approximately six months). During that time you will attend several clinic visits where your eye symptoms, lid health, tear film, and meibomian gland fun",Harrow Inc,2027-02-01,ESTIMATED,18 Years - N/A,48,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction,2027-02-01,ESTIMATED,Change in Meibomian Gland Expressibility Score | Change in Visual Analog Scale (VAS) Dryness Score | Change in Corneal Fluorescein Staining (NEI Scale),TREATMENT,ALL,2026-02-01,ESTIMATED,INTERVENTIONAL
DRUG,Bright Minds Biosciences Inc.,NCT06401538,PHASE2,RECRUITING,"Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome, Lennox Gastaut Syndrome",BMB-101,,,1,BMB-101,EXPERIMENTAL,"The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then up to 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 ",,2025-11-30,ESTIMATED,18 Years - 65 Years,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults With Either Classic Absence Epilepsy (With or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), OR Developmental Epileptic Encephalopathy (DEE).",2025-09-15,ESTIMATED,Change from baseline in seizure frequency in DEE subjects | Change from baseline in the number of generalized spike-wave discharges (GSWD) on the 24 hr EEG in Absence subjects.,TREATMENT,ALL,2024-12-05,ACTUAL,INTERVENTIONAL
DRUG,Bright Minds Biosciences Inc.,NCT07266324,PHASE2,NOT_YET_RECRUITING,Prader-Willi Syndrome,"BMB-101, Placebo",,RANDOMIZED,2,BMB-101 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to evaluate the safety and effects of a new drug called BMB-101 in people with Prader-Willi Syndrome (PWS). This study is designed as a multi-centre, double-blind, randomized, placebo controlled 2-part study with a blinded main phase followed up an open label extension phase.",,2027-03,ESTIMATED,18 Years - 65 Years,16,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Efficacy, Safety and Tolerability of BMB-101 Oral Solution for the Treatment of Patients With Prader-Willi Syndrome (PWS)",2026-11,ESTIMATED,Change from Baseline in Hyperphagia Questionnaire for Clinical Trials scores over time in Prader-Willi Syndrome participants.,TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
DSGN,"Design Therapeutics, Inc.",NCT07024693,PHASE2,RECRUITING,"Fuchs Endothelial Corneal Dystrophy, Fuchs",DT-168,,,1,Active,EXPERIMENTAL,"The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.",,2026-12,ESTIMATED,30 Years - N/A,28,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty",2026-09,ESTIMATED,FECD Biomarkers: Splicing Panel,TREATMENT,ALL,2025-07-30,ACTUAL,INTERVENTIONAL
DSGN,"Design Therapeutics, Inc.",NCT06772870,PHASE1,NOT_YET_RECRUITING,Friedreich Ataxia,"DT-216P2, Saline",,RANDOMIZED,2,DT-216P2 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.",,2025-12,ESTIMATED,18 Years - 45 Years,36,ESTIMATED,CROSSOVER,INDUSTRY,DOUBLE,"A Phase 1, Double-Masked, Randomized, Placebo-Controlled, Single Ascending Dose Crossover Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Normal Healthy Participants",2025-09,ESTIMATED,Frequency of treatment emergent adverse events (TEAEs),TREATMENT,ALL,2025-02,ESTIMATED,INTERVENTIONAL
DSGN,"Design Therapeutics, Inc.",NCT06874010,"PHASE1, PHASE2",RECRUITING,Friedreich Ataxia,DT-216P2,,,1,DT-216P2,EXPERIMENTAL,"The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.",,2027-03,ESTIMATED,18 Years - 65 Years,20,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Patients With Friedreich's Ataxia",2026-12,ESTIMATED,Frequency of treatment-emergent adverse events (TEAE),TREATMENT,ALL,2025-06,ESTIMATED,INTERVENTIONAL
DFTX,"Definium Therapeutics, Inc.",NCT06741228,PHASE3,RECRUITING,Generalized Anxiety Disorder,MM120 (LSD D-Tartrate),,RANDOMIZED,2,Arm 1 - Placebo | Arm 2 - 100µg MM120 (LSD D-Tartrate),PLACEBO_COMPARATOR | EXPERIMENTAL,"A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage",,2026-11,ESTIMATED,18 Years - 74 Years,200,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage",2026-05,ESTIMATED,Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12,TREATMENT,ALL,2024-12-11,ACTUAL,INTERVENTIONAL
DFTX,"Definium Therapeutics, Inc.",NCT07303907,PHASE2,RECRUITING,"Autism Spectrum Disorder, ASD","MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))",,,1,200 mg MM402 (R-MDMA),EXPERIMENTAL,A Phase 2A Trial of MM402 Open-Label Study in Adults with Autism Spectrum Disorder,,2027-08,ESTIMATED,18 Years - 45 Years,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-label Study Evaluating MM402 in Adults With Autism Spectrum Disorder,2027-08,ESTIMATED,Change from Baseline in 11-point Numerical Rating Scale (NRS) scores,TREATMENT,ALL,2025-12-03,ACTUAL,INTERVENTIONAL
DFTX,"Definium Therapeutics, Inc.",NCT06809595,PHASE3,RECRUITING,Generalized Anxiety Disorder,MM120 (LSD D-Tartrate),,RANDOMIZED,3,Arm 1 - Placebo | Arm 2 - 50µg MM120 (LSD D-Tartrate) | Arm 3 - 100µg MM120 (LSD D-Tartrate),PLACEBO_COMPARATOR | SHAM_COMPARATOR | EXPERIMENTAL,"A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama",,2027-05,ESTIMATED,18 Years - 74 Years,250,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama",2026-11,ESTIMATED,Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12,TREATMENT,ALL,2025-01-29,ACTUAL,INTERVENTIONAL
DFTX,"Definium Therapeutics, Inc.",NCT06941844,PHASE3,RECRUITING,Major Depressive Disorder,MM120 (LSD D-Tartrate),,RANDOMIZED,2,Arm 1 - Placebo | Arm 2 - 100µg MM120 (LSD D-Tartrate),PLACEBO_COMPARATOR | EXPERIMENTAL,"A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge",,2027-05,ESTIMATED,18 Years - 74 Years,140,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Emerge",2026-11,ESTIMATED,Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6,TREATMENT,ALL,2025-04-14,ACTUAL,INTERVENTIONAL
OMER,Omeros Corporation,NCT06298955,PHASE2,RECRUITING,Paroxysmal Nocturnal Hemoglobinuria,OMS906 study drug,,,1,OMS906 study drug,EXPERIMENTAL,The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.,,2027-04,ESTIMATED,18 Years - 99 Years,25,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",2026-12,ESTIMATED,To assess overall safety and tolerability of OMS906 administration at 8-week intervals in PNH patients.,TREATMENT,ALL,2024-02-19,ACTUAL,INTERVENTIONAL
OMER,Omeros Corporation,NCT05855083,PHASE2,RECRUITING,"Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation",Biological: narsoplimab,,,1,Narsoplimab single arm-treatment,EXPERIMENTAL,The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).,,2025-12,ESTIMATED,28 Days - 17 Years,18,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic Microangiopathy",2025-12,ESTIMATED,100-day survival rate following high-risk HSCT-TMA diagnosis.,TREATMENT,ALL,2023-05-01,ACTUAL,INTERVENTIONAL
OMER,Omeros Corporation,NCT06209736,PHASE2,RECRUITING,"C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis",OMS906 study drug,,,1,Study Drug OMS906,EXPERIMENTAL,"The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)",,2026-04,ESTIMATED,18 Years - 99 Years,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients With C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)",2026-01,ESTIMATED,To assess OMS906 5mg/kg IV administration at 4-week intervals in patients with C3G and ICGN.,TREATMENT,ALL,2024-03-01,ACTUAL,INTERVENTIONAL
CABA,"Cabaletta Bio, Inc.",NCT06121297,"PHASE1, PHASE2",RECRUITING,"Systemic Lupus Erythematosus, Lupus Nephritis","CABA-201, CABA-201",,NON_RANDOMIZED,2,"CABA-201 with FLU/CY Preconditioning | CABA-201, No Preconditioning",EXPERIMENTAL | EXPERIMENTAL,RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus,,2029-12,ESTIMATED,18 Years - 65 Years,28,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus",2029-12,ESTIMATED,To evaluate incidence of adverse events,TREATMENT,ALL,2024-02-16,ACTUAL,INTERVENTIONAL
CABA,"Cabaletta Bio, Inc.",NCT04422912,"PHASE1, PHASE2",RECRUITING,Pemphigus Vulgaris,"DSG3-CAART, CABA-201",,NON_RANDOMIZED,2,DSG3-CAART | CABA-201,EXPERIMENTAL | EXPERIMENTAL,"A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells \[DSG3-CAART\] or CD19-specific Chimeric Antigen Receptor T cells \[CABA-201\]) in subjects with active, pemphigus vulgaris",,2029-01,ESTIMATED,18 Years - N/A,40,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris",2029-01,ESTIMATED,"Adverse events, including Dose Limit Toxicity | For CABA-201 Sub-study: To evaluate adverse events reported by subjects",TREATMENT,ALL,2020-09-29,ACTUAL,INTERVENTIONAL
CABA,"Cabaletta Bio, Inc.",NCT06328777,"PHASE1, PHASE2",RECRUITING,"Systemic Sclerosis, Scleroderma",CABA-201,,,1,CABA-201,EXPERIMENTAL,"RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis",,2029-07,ESTIMATED,18 Years - 75 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis",2029-07,ESTIMATED,To evaluate incidence of adverse events,TREATMENT,ALL,2024-07-02,ACTUAL,INTERVENTIONAL
CABA,"Cabaletta Bio, Inc.",NCT07006805,"PHASE1, PHASE2",NOT_YET_RECRUITING,"Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS), Multiple Sclerosis - Relapsing Remitting, Multiple Sclerosis, Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis (MS) - Relapsing-remitting, Progressive Multiple Sclerosis",CABA-201,,NON_RANDOMIZED,2,Relapsing MS Cohort | Progressive MS Cohort,EXPERIMENTAL | EXPERIMENTAL,RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis,,2029-10,ESTIMATED,18 Years - 60 Years,12,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis",2028-09,ESTIMATED,Primary (Part A: Dose Escalation) incidence and severity of adverse events | Primary (Part B: Dose Expansion) incidence of and severity of adverse events in order to confirm the dose(s) of CABA-201,TREATMENT,ALL,2026-06,ESTIMATED,INTERVENTIONAL
CABA,"Cabaletta Bio, Inc.",NCT06154252,"PHASE2, PHASE3",RECRUITING,"Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis",CABA-201 following preconditioning with fludarabine and cyclophosphamide,,NON_RANDOMIZED,3,CABA-201 Phase 1/2 | CABA-201 Phase 2b - Sub-study 1 | CABA-201 Phase 2b - Sub-study 2,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy,,2028-07,ESTIMATED,6 Years - 75 Years,74,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy",2028-07,ESTIMATED,Phase 1/2: Incidence and severity of adverse events (AEs) | Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids | Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids,TREATMENT,ALL,2023-12-20,ACTUAL,INTERVENTIONAL
CABA,"Cabaletta Bio, Inc.",NCT06359041,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Generalized Myasthenia Gravis (gMG),CABA-201,,,1,CABA-201,EXPERIMENTAL,RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis,,2029-09,ESTIMATED,18 Years - 70 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis",2029-09,ESTIMATED,To evaluate incidence and severity of adverse events (AEs),TREATMENT,ALL,2024-12-17,ACTUAL,INTERVENTIONAL
TSHA,"Taysha Gene Therapies, Inc.",NCT04798235,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Infantile GM2 Gangliosidosis (Disorder),TSHA-101,,,1,TSHA-101,EXPERIMENTAL,"GM2 gangliosidoses are a group of autosomal recessive neurodegenerative diseases characterized by a deficiency of the Hex A enzyme to catabolize GM2, thereby causing GM2 accumulation within cellular lysosomes.Hex A is composed of 2 subunits, α- and β-, coded by the HEXA and HEXB genes, respectively. The primary purpose of the current study is to assess the safety and tolerability of TSHA101 administered via IT injection.","Taysha Gene Therapies, Inc., GlycoNet",2027-03-12,ESTIMATED,N/A - 15 Months,3,ACTUAL,SINGLE_GROUP,OTHER,NONE,"Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis",2027-03-12,ESTIMATED,Safety and tolerability: Treatment-emergent Adverse Events (TEAEs) | Safety and Tolerability: Number of participants with abnormal Laboratory assessments | Safety and Tolerability: Electrocardiogram (ECG),TREATMENT,ALL,2021-03-12,ACTUAL,INTERVENTIONAL
TSHA,"Taysha Gene Therapies, Inc.",NCT05606614,PHASE3,RECRUITING,Rett Syndrome,,,NON_RANDOMIZED,3,Part A Cohort 1 | Part A Cohort 2 | Part B Pivotal Cohort,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The primary objectives of this study are to evaluate the safety of a single intrathecal (IT) dose of TSHA-102 in females with typical Rett syndrome, to select the TSHA-102 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the efficacy and safety of TSHA-102 at the selected dose.",,2031-06,ESTIMATED,6 Years - 21 Years,15,ESTIMATED,SEQUENTIAL,INDUSTRY,SINGLE,"An Open-label Phase 1/2/3 Study Consisting of a Phase 1/2 Safety and Dose-escalation and Phase 3 Dose-expansion Study to Evaluate Safety and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy in Females With Rett Syndrome",2031-06,ESTIMATED,Part A: Safety and Tolerability of TSHA-102 | Part B: Efficacy of TSHA-102,TREATMENT,FEMALE,2023-03-06,ACTUAL,INTERVENTIONAL
TSHA,"Taysha Gene Therapies, Inc.",NCT06152237,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Rett Syndrome,,,RANDOMIZED,2,Cohort 1 | Cohort 2,EXPERIMENTAL | EXPERIMENTAL,"The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome.

The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is up to 6 years.",,2031-11-02,ESTIMATED,5 Years - 8 Years,6,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"A Multicenter, Open Label, Randomized, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, and Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females With Rett Syndrome",2028-11-02,ESTIMATED,Primary Safety,TREATMENT,FEMALE,2023-12-12,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT05461170,PHASE2,ACTIVE_NOT_RECRUITING,"Hepatitis D, Chronic","VIR-2218, VIR-3434, NRTI",,RANDOMIZED,9,Cohort 1a (VIR-2218) | Cohort 1b (VIR-3434) | Cohort 2a (VIR-2218) | Cohort 2b1 (VIR-3434) | Cohort 2b2 (VIR-3434) | Cohort 2c (VIR-2218 + VIR-3434) | Cohort 3 (VIR-3434) | Cohort 4 (NRTI) | Cohort 5 (VIR-2218),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy",,2029-08,ESTIMATED,18 Years - 69 Years,95,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of VIR-2218 and VIR-3434 in Participants With Chronic Hepatitis D Virus Infection (SOLSTICE)",2029-08,ESTIMATED,Proportion of participants with undetectable HDV RNA (< limit of detection [LOD]) or ≥ 2 log10 decrease in HDV RNA from baseline and alanine aminotransferase (ALT) normalization (ALT < upper limit of normal [ULN]) at Week 24 | Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs),TREATMENT,ALL,2022-09-17,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT05970289,PHASE2,ACTIVE_NOT_RECRUITING,Chronic Hepatitis B Virus Infection,"PEG-IFNα, BRII-835",,RANDOMIZED,4,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.,"Vir Biotechnology, Inc.",2026-02,ESTIMATED,18 Years - 60 Years,86,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection",2025-07-16,ACTUAL,Proportion of participants with HBsAg loss at end of treatment | Proportion of participants with HBsAg loss at 24 weeks post-end of treatment | Proportion of participants with treatment-emergent adverse events (TEAEs) | Proportion of participants with serious adverse events (SAEs),TREATMENT,ALL,2023-08-22,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT05997615,PHASE1,RECRUITING,Hormone-refractory Prostate Cancer,VIR-5500,,NON_RANDOMIZED,4,Part 1: VIR-5500 Monotherapy Dose Escalation | Part 2: VIR-5500 Monotherapy Dose Expansion | Part 3a: VIR-5500 in combination with an ARSI for Dose Escalation | Part 4a: VIR-5500 in combination with an ARSI for Dose Expansion,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a).

* Part 1 (Monotherapy Dose Escalation): Single-agent VIR-5500 dose escalation
* Part 2 (Monotherapy Dose Expansion): Single-agent VIR-5500 dose expansion
* Part 3 (Combination Dose Escalation): VIR-5500 plus another therapeutic agent dose escalation

  o Par",,2027-09-29,ESTIMATED,18 Years - N/A,390,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer",2027-09-29,ESTIMATED,Part 1 and 3a: Number of participants with treatment-emergent Adverse Events (AEs) | Part 1 and 3a: Incidence of Dose Limiting Toxicities (DLTs) | Part 2 and 4a: Prostate-Specific Antigen (PSA) response rate | Part 2 and 4a: Objective Response Rate (ORR),TREATMENT,MALE,2023-08-10,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT07142811,PHASE2,ACTIVE_NOT_RECRUITING,Viral Hepatitis,"Tobevibart, Elebsiran, Bulevirtide",,RANDOMIZED,2,Arm 1 | Arm 2,EXPERIMENTAL | EXPERIMENTAL,A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection,,2030-07,ESTIMATED,18 Years - 70 Years,100,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)",2026-11,ESTIMATED,"HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 48 | HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment | Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 48",TREATMENT,ALL,2025-08-05,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT07128550,PHASE3,RECRUITING,Viral Hepatitis,"Tobevibart, Elebsiran, Bulevirtide",,RANDOMIZED,2,Arm 1 | Arm 2,EXPERIMENTAL | EXPERIMENTAL,"This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide",,2031-07,ESTIMATED,18 Years - 70 Years,150,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)",2026-12,ESTIMATED,"HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24 | HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) 24 weeks after end of treatment.",TREATMENT,ALL,2025-07-30,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT06903338,PHASE3,ACTIVE_NOT_RECRUITING,Viral Hepatitis,"Tobevibart, Elebsiran",,RANDOMIZED,2,Arm 1 (Tobevibart + Elebsiran) | Arm 2 (Tobevibart + Elebsiran),EXPERIMENTAL | EXPERIMENTAL,"This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.",,2031-05,ESTIMATED,18 Years - 70 Years,124,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)",2026-12-31,ESTIMATED,"HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2 | Incidence of Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through Week 12",TREATMENT,ALL,2025-03-12,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT04856085,PHASE2,ACTIVE_NOT_RECRUITING,"Hepatitis B, Chronic","VIR-2218, VIR-3434, PEG-IFNα",MARCH,NON_RANDOMIZED,13,Cohort 1a (VIR-2218 + VIR-3434) | Cohort 2a (VIR-2218 + VIR-3434) | Cohort 3a (VIR-2218 + VIR-3434) | Cohort 4a (VIR-2218 + VIR-3434) | Cohort 5a (VIR-2218 + VIR-3434) | Cohort 6a (VIR-2218 + VIR-3434) | Cohort 7a (VIR-2218 + VIR-3434) | Cohort 8a (VIR-2218 + VIR-3434) | Cohort 1b (VIR-3434) | Cohort 2b (VIR-3434) | Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα) | Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα) | Cohort 1d (VIR-3434 + PEG-IFNα),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy",,2026-03,ESTIMATED,18 Years - 65 Years,244,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection",2026-03,ESTIMATED,Proportion of participants with treatment-emergent adverse events (TEAEs) | Proportion of participants with serious adverse events (SAEs) | Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment | Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment,TREATMENT,ALL,2021-07-11,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT06960395,PHASE1,RECRUITING,"Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR","VIR-5525, Pembrolizumab",,NON_RANDOMIZED,4,Part 1: VIR-5525 Monotherapy Dose Escalation | Part 2: VIR-5525 Monotherapy Dose Expansion | Part 3: VIR-5525 Combination Dose Escalation | Part 4: VIR-5525 Combination Dose Expansion,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in participants with solid tumors that are known to express EGFR.

The study will be conducted in the following 4 parts:

* Part 1: VIR-5525 monotherapy dose escalation
* Part 2: VIR-5525 monotherapy dose expansion
* Part 3: VIR-5525 plus pembrolizumab dose escalation
* Part 4: V",,2029-08,ESTIMATED,18 Years - N/A,450,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5525 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",2029-08,ESTIMATED,Primary Safety Objectives (Parts 1 and 3) | Primary Safety Objectives (Parts 1 and 3) | Primary Efficacy Objectives (Parts 2 and 4),TREATMENT,ALL,2025-07-22,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT05356741,"PHASE1, PHASE2",RECRUITING,Locally Advanced or Metastatic HER2-Expressing Cancers,"VIR-5818, pembrolizumab",,NON_RANDOMIZED,4,Part 1 (dose escalation) | Part 2 (dose escalation) | Part 3 (dose expansion) | Part 4 (dose expansion,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity of VIR-5818 (Formerly AMX-818) as a single agent and in combination with pembrolizumab in participants with HER2+ tumors across multiple tumor types. The study will be conducted in four parts:

* Part 1 (dose escalation): Single-agent VIR-5818
* Part 2 (dose escalation): VIR-5818 plus pembrolizumab
* Part 3 (dose expansio",Merck Sharp & Dohme LLC,2027-08-16,ESTIMATED,18 Years - N/A,645,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of VIR-5818 Alone and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers",2027-08-16,ESTIMATED,"Incidence of dose-limiting toxicity - Part 1 and Part 2 | Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)- Parts 1, 2, 3, and 4 | Objective Response Rate (ORR) - Part 3 and Part 4 | Duration of Response (DOR) - Part 3 and Part 4",TREATMENT,ALL,2022-04-13,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT06491563,PHASE2,ACTIVE_NOT_RECRUITING,For Treatment of Chronic Hepatitis B Virus Infection,"BRII-179, BRII-835 (VIR-2218), PEG-IFNα",,NON_RANDOMIZED,2,BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα | BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα,EXPERIMENTAL | EXPERIMENTAL,"This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.","Vir Biotechnology, Inc.",2027-06,ESTIMATED,18 Years - 60 Years,150,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)",2026-12,ESTIMATED,Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepoint,TREATMENT,ALL,2024-08-06,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT05484206,PHASE1,RECRUITING,"Hepatic Impairment, Cirrhosis","VIR-2218, VIR-3434",,NON_RANDOMIZED,9,Cohort 1: CPT-B (moderate HI) participants and matched healthy participants will be evaluated first | Cohort 2: CPT-C (severe HI) participants and matched healthy participants | Cohort 3: CPT-A (mild HI) participants and matched healthy participants | Cohort 4: CPT-A (mild HI) participants and matched healthy participants | Cohort 5: CPT-B (moderate HI) participants and matched healthy participants | Cohort 6: CPT-C (severe HI) participants and matched healthy participants | Cohort 7: CPT-A (mild HI) and matched healthy participants | Cohort 8: CPT-B (moderate HI) and matched healthy participants | Cohort 9: CPT-C (severe HI) and matched healthy participants,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.",,2027-04-30,ESTIMATED,18 Years - 70 Years,144,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment",2026-09-25,ESTIMATED,Maximum observed Plasma concentration (Cmax) of VIR-2218 and metabolite AS(N-1)3'VIR2218 | Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and metabolite AS(N-1)3'VIR2218 | Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 metabolite AS(N-1)3'VIR2218 | Maximum observed Plasma concentration (Cmax) of VIR-3434 | Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-3434 | Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-3434,TREATMENT,ALL,2022-09-21,ACTUAL,INTERVENTIONAL
VIR,"Vir Biotechnology, Inc.",NCT06070051,PHASE1,ACTIVE_NOT_RECRUITING,Chronic Hepatitis B,"VRON-0200-AdC6, VRON-0200-AdC7, VIR-2218, VIR-3434",,RANDOMIZED,6,"Cohort 1a: Low Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost | Cohort 1b: Low Dose VRON-0200-AdC6 Prime, No Boost | Cohort 2a: High Dose VRON-0200-AdC7 Prime, VRON-0200-AdC6 Boost | Cohort 2b: High Dose VRON-0200-AdC6 Prime, No Boost | Cohort 3a: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, VRON-0200-AdC6 Boost | Cohort 3b: High Dose VRON-0200-AdC7 Prime, 6 Doses VIR-2218 + VIR-3434, No Boost",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This Phase 1b clinical study is a multi-center, open-label, dose escalation, prime only, and prime plus boost therapeutic vaccination study of 2 distinct chimpanzee adenoviral vectors (AdC6 and AdC7), containing parts of hepatitis B virus (HBV) core and polymerase antigens fused within glycoprotein D in a cohort of chronic hepatitis B (CHB)-infected adult participants who are currently receiving entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine","Vir Biotechnology, Inc.",2026-03-31,ESTIMATED,18 Years - 55 Years,56,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime And Boost Vaccination Evaluation of VRON-0200 Using Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)Ide Reverse Transcriptase Inhibitors",2026-03-31,ESTIMATED,Treatment Emergent Adverse Events | Grade 3 Adverse Events | Clinically Significant Changes in Lab Values | Serious Adverse Events | Medically Attended Adverse Events,TREATMENT,ALL,2023-09-26,ACTUAL,INTERVENTIONAL
EWTX,"Edgewise Therapeutics, Inc.",NCT05257473,,ACTIVE_NOT_RECRUITING,"Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker",,GRASP-01-002,,0,,,"This is a 24-month, observational study of 50 participants with Becker muscular dystrophy (BMD)","Edgewise Therapeutics, Inc.",2026-05,ESTIMATED,6 Years - N/A,80,ESTIMATED,,OTHER,,Defining Endpoints in Becker Muscular Dystrophy,2026-05,ESTIMATED,To assess the natural history of measures of muscle function in BMD | 4-Stair Climb | 100-Meter Timed Test | PERFORMANCE OF UPPER LIMB 2.0 (PUL) | HAND HELD DYNAMOMETRY (HHD) AND GRIP | TIMED UP-AND-GO (TUG) | Measures of Pulmonary Function (Seated and supine FVC) | Measures of Pulmonary Function (MEP and MIP) | Measures of Pulmonary Function (other) | Measure of ejection fraction (ECHO) | Measure of systolic and diastolic function (ECHO),,MALE,2022-04-13,ACTUAL,OBSERVATIONAL
EWTX,"Edgewise Therapeutics, Inc.",NCT06100887,PHASE2,ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy,"Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Placebo",FOX,RANDOMIZED,3,Cohort 1 | Cohort 2 | Cohort 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.",,2027-03,ESTIMATED,6 Years - 17 Years,43,ACTUAL,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy",2027-03,ESTIMATED,Number of adverse events during treatment with sevasemten or placebo | Severity of adverse events during treatment with sevasemten or placebo,TREATMENT,MALE,2024-03-22,ACTUAL,INTERVENTIONAL
EWTX,"Edgewise Therapeutics, Inc.",NCT07034768,PHASE1,RECRUITING,Renal Impairments,EDG-7500,,,4,Healthy Volunteers | Severe Renal Impairment | Moderate Renal Impairment | Mild Renal Impairment,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.,,2025-12-31,ESTIMATED,18 Years - 75 Years,48,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1, 2-Part, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Renal Function",2025-12-31,ESTIMATED,Area under the curve from time zero to last quantifiable concentration (AUC0-last) | Area under the curve from time zero to extrapolated infinite time (AUC0-inf) | Maximum observed plasma concentration (Cmax) | Observed plasma concentration at the end of the dosing interval (C24) | Time to reach maximum observed plasma concentration (Tmax) | Plasma elimination half-life (T1/2),BASIC_SCIENCE,ALL,2025-07-22,ACTUAL,INTERVENTIONAL
EWTX,"Edgewise Therapeutics, Inc.",NCT07324616,PHASE1,NOT_YET_RECRUITING,Hepatic Impairment (HI),EDG-7500,,,3,Healthy Adults | Mild Hepatic Impairment | Moderate Hepatic Impairment,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.,,2026-05,ESTIMATED,18 Years - N/A,32,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Hepatic Function",2026-05,ESTIMATED,Area under the plasma concentration time-curve from time zero to the last measured concentration (AUC0-last) | Area under the plasma concentration time-curve from time zero extrapolated to infinity (AUC0-inf) | Maximum observed plasma concentration (Cmax),TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
EWTX,"Edgewise Therapeutics, Inc.",NCT07177066,PHASE1,RECRUITING,Healthy Adults,"EDG-15400, Placebo",,RANDOMIZED,3,Part A: Healthy Adult (Ages ≥18 to <60 years) Single Ascending Dose | Part B: Healthy Adult (Ages ≥18 to <60 years) Multiple Ascending Doses | Part C: Healthy Adult (Ages ≥18 to <60 years) Food Effect and Relative Bioavailability,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purposes of this Phase 1 study of EDG-15400 are to:

1. Learn about the safety of EDG-15400 after single and multiple doses in healthy adults
2. Learn about how EDG-15400 is tolerated after single and multiples doses in healthy adults
3. Evaluate the amount of EDG-15400 in the blood and urine after single and multiple doses in healthy adults
4. Evaluate the effect of a meal on the amount of EDG-15400 that is in the blood in healthy adults
5. Evaluate whether the amount of EDG-15400 in the bl",,2026-05,ESTIMATED,18 Years - 59 Years,108,ESTIMATED,SEQUENTIAL,INDUSTRY,TRIPLE,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Healthy Adults",2026-05,ESTIMATED,Safety: incidence of treatment-emergent adverse events,BASIC_SCIENCE,ALL,2025-08-20,ACTUAL,INTERVENTIONAL
EWTX,"Edgewise Therapeutics, Inc.",NCT06347159,PHASE2,ACTIVE_NOT_RECRUITING,Hypertrophic Cardiomyopathy,"EDG-7500, EDG-7500",,NON_RANDOMIZED,4,Part A: EDG-7500 Single Dose | Part B: EDG-7500 Multiple Dose in Adults with Obstructive Hypertrophic Cardiomyopathy | Part C: EDG-7500 Multiple Dose in Adults with Nonobstructive Hypertrophic Cardiomyopathy | Part D: EDG-7500 Multiple Dose in Adults with Hypertrophic Cardiomyopathy,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy (nHCM).,,2026-12,ESTIMATED,18 Years - N/A,100,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-7500 in Adults With Hypertrophic Cardiomyopathy",2026-06,ESTIMATED,Incidence of treatment-emergent adverse events,TREATMENT,ALL,2024-04-11,ACTUAL,INTERVENTIONAL
EWTX,"Edgewise Therapeutics, Inc.",NCT05291091,PHASE2,ACTIVE_NOT_RECRUITING,Becker Muscular Dystrophy,"Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo",,RANDOMIZED,5,Adult Cohort 1 | Adult Cohort 2 | Adult Cohort 6 | Adolescent Cohort 4 | Adolescent Cohort 5,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker.

CANYON and GRAND CANYON are fully enrolled.","Medpace, Inc., ImagingNMD, SYSNAV",2026-09,ESTIMATED,12 Years - 50 Years,244,ACTUAL,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy",2026-09,ESTIMATED,Number of adverse events in those treated with sevasemten or placebo | Severity of adverse events in those treated with sevasemten or placebo | Change from Baseline in serum Creatine Kinase | Change from Baseline in the North Star Ambulatory Assessment scale,TREATMENT,MALE,2022-11-10,ACTUAL,INTERVENTIONAL
EWTX,"Edgewise Therapeutics, Inc.",NCT05540860,PHASE2,ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy,"Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3, Sevasemten Dose 4, Sevasemten Dose 5, Placebo",,RANDOMIZED,6,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 2NS,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.",,2027-01,ESTIMATED,4 Years - 9 Years,76,ACTUAL,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B",2027-01,ESTIMATED,Number of adverse events during treatment with sevasemten or placebo | Severity of adverse events during treatment with sevasemten or placebo,TREATMENT,MALE,2022-10-24,ACTUAL,INTERVENTIONAL
RAPP,"Rapport Therapeutics, Inc.",NCT07219407,PHASE2,RECRUITING,"Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure",RAP-219,,,1,RAP-219,EXPERIMENTAL,This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.,,2028-02-03,ESTIMATED,18 Years - 70 Years,30,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures",2028-02-03,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs),TREATMENT,ALL,2025-12-15,ACTUAL,INTERVENTIONAL
RAPP,"Rapport Therapeutics, Inc.",NCT07046494,PHASE2,RECRUITING,Bipolar 1 Disorder,RAP-219,,RANDOMIZED,2,Active Arm | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.,,2026-12,ESTIMATED,18 Years - 65 Years,224,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder",2026-10,ESTIMATED,Young Mania Rating Scale (YMRS),TREATMENT,ALL,2025-07-25,ACTUAL,INTERVENTIONAL
OCGN,"Ocugen, Inc.",NCT05203939,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Retinitis Pigmentosa, Leber Congenital Amaurosis","OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing",,NON_RANDOMIZED,8,Cohort 1 (Low Dose) | Cohort 2 (Mid Dose) | Cohort 3 (High Dose) | Pediatric Arm | Phase 2 (High and Medium Dose) | Adult Arm | Second Eye Dosing | Natural History Study (OCU400-104),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,"This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects Investigators will also conduct a Natural History Study (OCU400-104)i

This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 24 subjects in the OCU400-101 and 100 subjects i",,2027-03,ESTIMATED,6 Years - N/A,22,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 and RHO Mutations and Leber Congenital Amaurosis With Mutation(s) in CEP290 Gene,2027-03,ESTIMATED,Study Drug-related adverse events (SDAE) | Treatment-Emergent adverse events (TEAEs) | Serious adverse events (SAEs),TREATMENT,ALL,2022-01-24,ACTUAL,INTERVENTIONAL
OCGN,"Ocugen, Inc.",NCT05956626,"PHASE2, PHASE3",RECRUITING,Stargardt Disease,OCU410ST,GARDian3,RANDOMIZED,2,Phase 2/3 Randomized Treatment Arm | Phase 2/3 Randomized Control Arm,EXPERIMENTAL | NO_INTERVENTION,"Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects).

Phase 1 is complete and closed for enrollment. It was a multicenter, open-label, dose ranging/dose escalation study that enrolled 9 subjects.",,2026-09-28,ESTIMATED,5 Years - N/A,51,ESTIMATED,SEQUENTIAL,INDUSTRY,SINGLE,A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIVOTAL CONFIRMATORY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE,2026-09-28,ESTIMATED,Change from baseline in atrophic lesion size as measured by Fundus Auto Fluorescence | Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)),TREATMENT,ALL,2023-08-25,ACTUAL,INTERVENTIONAL
OCGN,"Ocugen, Inc.",NCT06388200,PHASE3,ACTIVE_NOT_RECRUITING,Retinitis Pigmentosa,,liMeliGhT,RANDOMIZED,4,RHO Arm | Gene Agnostic Arm | Control for RHO Arm | Control for Gene Agnostic Arm,EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION | NO_INTERVENTION,"This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP.

This is a multicenter, assessor blinded and randomized study which will enroll 150 subjects.",,2026-12-31,ESTIMATED,3 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Phase 3, Multi-Center, Randomized Study to Assess The Efficacy, Safety and Tolerability of Subretinal OCU400 Gene Therapy for the Treatment of Retinitis Pigmentosa",2026-12-31,ESTIMATED,Number of participants with change in functional vision in the study eye of RP subjects as assessed by LDNA | Number of participants with change in functional vision in the study eye in Gene Agnostic group as assessed by LDNA,TREATMENT,ALL,2024-06-18,ACTUAL,INTERVENTIONAL
OCGN,"Ocugen, Inc.",NCT06018558,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Geographic Atrophy,,ArMaDa,RANDOMIZED,6,Phase1 Dose Escalation- Low Dose (2.5×10E10 vg/mL): | Phase1 Dose Escalation- Medium Dose (5×10E10 vg/mL): | Phase1 Dose Escalation- High Dose (1.5×10E11 vg/mL): | Phase 2 Dose Expansion: Maximum tolerated dose (MTD) from Phase 1-Randomized Arm | Phase 2 Dose Expansion: Lower Dose from Phase 1-Randomized Arm | Control Arm,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,"This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD).

This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 60 subjects.",,2026-05-29,ESTIMATED,50 Years - N/A,60,ACTUAL,SEQUENTIAL,INDUSTRY,SINGLE,A Phase 1/2 Study to Assess the Safety And Efficacy Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration,2026-02-17,ESTIMATED,Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) | Change in anatomy of ocular structures using Slit Lamp Biomicroscopy | Change in anatomy of ocular structures using Indirect ophthalmoscopy | Change from baseline in BCVA (Best Corrected Visual Acuity) | Change in Low Luminance Visual Acuity | Change in the Intraocular Pressure (mmHg),TREATMENT,ALL,2023-02-23,ACTUAL,INTERVENTIONAL
OCGN,"Ocugen, Inc.",NCT05802329,PHASE1,RECRUITING,"Center Involved Diabetic Macular Edema, Diabetic Macular Edema",OCU200,DME,NON_RANDOMIZED,4,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema,,2026-07-31,ESTIMATED,18 Years - N/A,24,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,A Phase 1 Study To Assess The Safety And Efficacy Of OCU200 For Center-Involved Diabetic Macular Edema,2026-07-31,ESTIMATED,Study Drug-related adverse events (SDAE) | Treatment-emergent adverse events (TEAEs) | Serious adverse events (SAEs),TREATMENT,ALL,2024-01-13,ACTUAL,INTERVENTIONAL
VRDN,"Viridian Therapeutics, Inc.",NCT07155668,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,VRDN-003,,RANDOMIZED,3,VRDN-003 every 4 weeks using autoinjector | VRDN-003 every 8 weeks using autoinjector | VRDN-003 every 8 weeks using vial and syringe,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a clinical trial assessing the safety, tolerability and pharmacokinetics (PK) of an investigational drug, VRDN-003, in participants with TED (Thyroid Eye Disease)",,2026-11,ESTIMATED,18 Years - 75 Years,87,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Randomized, Open-label Study Evaluating the Safety, Tolerability and Pharmacokinetics of VRDN-003 Administered Subcutaneously in Participants With Thyroid Eye Disease (TED)",2026-07,ESTIMATED,Treatment Emergent Adverse Event (TEAE) incidence rate,TREATMENT,ALL,2025-07-01,ACTUAL,INTERVENTIONAL
VRDN,"Viridian Therapeutics, Inc.",NCT06625398,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,"VRDN-003, Placebo",REVEAL-2,RANDOMIZED,3,VRDN-003 every 4 weeks | VRDN-003 every 8 weeks | Placebo every 4 weeks,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).",,2026-12-15,ESTIMATED,18 Years - 75 Years,195,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"REVEAL-2 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)",2026-04-01,ESTIMATED,Title: Proptosis Responder Rate in the study eye,TREATMENT,ALL,2024-08-27,ACTUAL,INTERVENTIONAL
VRDN,"Viridian Therapeutics, Inc.",NCT06812325,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease (TED),"VRDN-003, Placebo",,RANDOMIZED,2,VRDN-003 every 4 weeks | VRDN-003 every 8 weeks,EXPERIMENTAL | EXPERIMENTAL,"This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).",,2026-10,ESTIMATED,18 Years - 75 Years,321,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)",2026-04,ESTIMATED,Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24,TREATMENT,ALL,2025-02-03,ACTUAL,INTERVENTIONAL
VRDN,"Viridian Therapeutics, Inc.",NCT06625411,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,"VRDN-003, Placebo",REVEAL-1,RANDOMIZED,3,VRDN-003 every 4 weeks | VRDN-003 every 8 weeks | Placebo every 4 weeks,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).",,2026-11-15,ESTIMATED,18 Years - 75 Years,117,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"REVEAL-1 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)",2026-03-01,ESTIMATED,Proptosis Responder Rate in the study eye,TREATMENT,ALL,2024-08-27,ACTUAL,INTERVENTIONAL
CPRX,"Catalyst Pharmaceuticals, Inc.",NCT06564974,,RECRUITING,Duchenne Muscular Dystrophy,Vamorolone,,,0,,,The goal of this observational study is to follow patients being treated with the FDA approved drug AGAMREE® in male patients 2 years of age or older with Duchenne's Muscular Dystrophy for long term safety and quality of life.,,2030-11,ESTIMATED,2 Years - N/A,250,ESTIMATED,,INDUSTRY,,Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy,2030-09,ESTIMATED,Change in BMI Z score at the End-of-Registry ( 5 years) or Early-Termination. | Change in Height Z-score at the End-of-Registry ( 5 years) or Early-Termination. | Change in Puberty development using the Tanner Stage at the End-of-Registry ( 5 years) or Early-Termination. | Number of Fractures based on Spine x-rays at the End-of-Registry ( 5 years) or Early-Termination. | Presence or absence of Cataracts at the End-of-Registry ( 5 years) or Early-Termination. | Presence of Cardiomyopathy at the End-of-Registry ( 5 years) or Early-Termination. | Evaluation of Hormonal status based on Cortisol levels at enrollment. | Presence or absence of Glaucoma at the End-of-Registry ( 5 years) or Early-Termination. | Number of patients experiencing any Adverse Events (AEs) or Serious Adverse Events (SAEs) after signing the Informed Consent Form. | Change in Pediatric Quality of Life Inventory Duchenne Muscular Dystrophy (PedsQL DMD) Module at the End-of-Registry ( 5 years) or Early-Termination. | Change in Duchenne Muscular Dystrophy Quality of Life (DMD-QoL)at the End-of-Registry ( 5 years) or Early-Termination. | Change in Euro Qol 5 Dimensions (EQ-5D) at the End-of-Registry ( 5 years) or Early-Termination. | Change in Patient Reported Outcome Measure for the Upper Limb (PROM UL) at the End-of-Registry ( 5 years) or Early-Termination. | Change in North Star Ambulatory Assessment (NSAA) at the End-of-Registry ( 5 years) or Early-Termination. | Change in Performance of Upper Limb (PUL) at the End-of-Registry ( 5 years) or Early-Termination.,,MALE,2024-07-31,ACTUAL,OBSERVATIONAL
MLYS,"Mineralys Therapeutics, Inc.",NCT05968430,PHASE3,ACTIVE_NOT_RECRUITING,Hypertension,"lorundrostat, Placebo",,NON_RANDOMIZED,3,Open-Label Arm | RTW Substudy | Optional Continuation Period,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension",,2026-12,ESTIMATED,18 Years - N/A,1076,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension",2025-12-30,ACTUAL,Change from MLS-101-301 baseline automated office blood pressure | Change at MLS-101-901 Week 16 (RTW Week 4) from MLS 101-901 Week 12 (RTW substudy baseline) in AOBP SBP in subjects enrolled in RTW,TREATMENT,ALL,2023-07-14,ACTUAL,INTERVENTIONAL
TBPH,"Theravance Biopharma, Inc.",NCT05696717,PHASE3,ACTIVE_NOT_RECRUITING,"Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy","Ampreloxetine, Placebo",CYPRESS,RANDOMIZED,3,Ampreloxetine (Open Label) | Ampreloxetine (Randomized Withdrawal) | Long-Term Extension Period,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).",,2028-01,ESTIMATED,30 Years - N/A,102,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy",2026-01,ESTIMATED,Change in OHSA composite score at Week 8 during the double-blind RW period,TREATMENT,ALL,2023-06-27,ACTUAL,INTERVENTIONAL
TBPH,"Theravance Biopharma, Inc.",NCT07133880,PHASE4,RECRUITING,COPD (Chronic Obstructive Pulmonary Disease),"umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ), Placebo DPI",,RANDOMIZED,2,DPI Treatment Group | Nebulizer Treatment Group,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).

The investigators hypothesize that, in patients with symptomatic COPD, therapy with a long-acting anti muscarinic agent/long-acting beta agonist (LAMA/LABA) combination admin",Theravance Biopharma,2025-12-01,ESTIMATED,40 Years - N/A,72,ESTIMATED,PARALLEL,OTHER,TRIPLE,Differentiating the Effects of Long-acting Bronchodilators Administered by Nebulizer Versus Dry Powder Inhaler in Symptomatic Patients With Chronic Obstructive Pulmonary Disease,2025-12-01,ESTIMATED,Difference Between the Values of Area Under the Response Curve for Inspiratory Capacity (IC),TREATMENT,ALL,2023-12-05,ACTUAL,INTERVENTIONAL
KNSA,"Kiniksa Pharmaceuticals International, plc",NCT07010159,"PHASE2, PHASE3",RECRUITING,"Pericarditis, Pericarditis Acute, Recurrent Pericarditis","KPL-387, Placebo",,RANDOMIZED,7,Phase 2 KPL-387 100mg SC q2wk | Phase 2 KPL-387 100mg SC q4wk | Phase 2 KPL-387 300mg SC q2wk | Phase 2 KPL-387 300mg SC q4wk | Phase 3 KPL-387 SC | Phase 3 Placebo SC | Long-Term Extension,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.,"Kiniksa Pharmaceuticals, GmbH",2029-12-31,ESTIMATED,18 Years - 80 Years,165,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis,2027-12-31,ESTIMATED,Phase 2: Time to Treatment Response by Week 24 | Phase 3: Time to Pericarditis Recurrence | Long-Term Extension: Annualized rate of Pericarditis Recurrence,TREATMENT,ALL,2025-07-25,ACTUAL,INTERVENTIONAL
KNSA,"Kiniksa Pharmaceuticals International, plc",NCT04687358,,ACTIVE_NOT_RECRUITING,Recurrent Pericarditis,,RESONANCE,,2,Active RP | Inactive RP, | ,"The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.","Kiniksa Pharmaceuticals (UK), Ltd.",2029-03,ESTIMATED,7 Years - N/A,500,ESTIMATED,,INDUSTRY,,Registry of the Natural History of Recurrent Pericarditis in Pediatric and Adult Patients,2029-03,ESTIMATED,Patients using 1 or more RP treatments,,ALL,2021-03-16,ACTUAL,OBSERVATIONAL
KNSA,"Kiniksa Pharmaceuticals International, plc",NCT07288216,PHASE2,RECRUITING,"Recurrent Pericarditis, Heart Diseases, Pericarditis",KPL-387,,NON_RANDOMIZED,2,Posology KPL-387 | Long-Term Extension,EXPERIMENTAL | EXPERIMENTAL,The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.,"Kiniksa Pharmaceuticals, GmbH",2029-12-31,ESTIMATED,18 Years - 80 Years,80,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies,2027-12-31,ESTIMATED,Posology: Proportion of participants free from Pericarditis Recurrence by Week 16 | Long-Term Extension: Annualized rate of Pericarditis Recurrence through the end of the LTE.,TREATMENT,ALL,2026-01-31,ESTIMATED,INTERVENTIONAL
AVIR,"Atea Pharmaceuticals, Inc.",NCT07314346,PHASE1,NOT_YET_RECRUITING,Healthy Volunteer Study,"Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR",,NON_RANDOMIZED,2,(n=16) buprenorphine/naloxone + BEM/RZR | (n=16) methadone + BEM/RZR,EXPERIMENTAL | EXPERIMENTAL,Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone,,2026-05-29,ESTIMATED,18 Years - 65 Years,32,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Open-Label, Two-Part, Single-Sequence Study to Evaluate the Effect of Multiple Oral Doses of BEM/RZR FDC on the Pharmacokinetics of Buprenorphine/Naloxone or Methadone in Participants on Stable Maintenance Therapy for Opiate Withdrawal",2026-05-29,ESTIMATED,"Effect of BEM/RZR on PK of buprenorphine,norbuprenorphine and naloxone | Effect of BEM/RZR on PK of buprenorphine,norbuprenorphine and naloxone | Effect of BEM/RZR on PK of methadone | Effect of BEM/RZR on PK of methadone",TREATMENT,ALL,2025-12,ESTIMATED,INTERVENTIONAL
AVIR,"Atea Pharmaceuticals, Inc.",NCT07272889,PHASE1,NOT_YET_RECRUITING,Healthy Volunteer Study,"Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG)",,NON_RANDOMIZED,3,EE/LNG | BEM/RZR | BEM/RZR + EE/LNG,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,Drug-drug interaction study between Ethinyl Estradioll/Levonorgestrel and Bemnifosbuvir/Ruzasvir,,2025-12,ESTIMATED,18 Years - 65 Years,24,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Oral Doses of Bemnifosbuvir/Ruzasvir Fixed-dose Combination on the Single-Dose Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/ Levonorgestrel) in Healthy Adult Female Participants of Non-Childbearing Potential",2025-12,ESTIMATED,PK of EE/LNG (Cmax) | PK of EE/LNG (AUC),TREATMENT,FEMALE,2025-12,ESTIMATED,INTERVENTIONAL
AVIR,"Atea Pharmaceuticals, Inc.",NCT06911320,PHASE1,RECRUITING,"Healthy Volunteer Study, Hepatic Impairment, Renal Impairment",Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination,,NON_RANDOMIZED,3,Group 1 - Severe Renal Impairment | Group 2 - Severe Hepatic Impairment | Group 3 - Matched Healthy Subjects,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose,,2025-11,ESTIMATED,18 Years - 80 Years,28,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of Bemnifosbuvir and Ruzasvir Administered as a Fixed-Dose Combination in Adult Participants With Severe Renal or Hepatic Impairment in Comparison to Healthy Participants",2025-11,ESTIMATED,Pharmacokinetics (PK) of BEM/RZR Maximum plasma concentration (Cmax) | Pharmacokinetics (PK) of BEM/RZR Area under the plasma concentration-time curve (AUC) | Pharmacokinetics (PK) of BEM/RZR AUC,TREATMENT,ALL,2025-04-09,ACTUAL,INTERVENTIONAL
AVIR,"Atea Pharmaceuticals, Inc.",NCT07037277,PHASE3,RECRUITING,"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C","Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir",,RANDOMIZED,2,Bemnifosbuvir - Ruzasvir (BEM/RZR) | Sofosbuvir-Velpatasvir (SOF/VEL),EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.,,2027-03,ESTIMATED,18 Years - 85 Years,880,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study",2026-12,ESTIMATED,Portion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at week 24,TREATMENT,ALL,2025-06-02,ACTUAL,INTERVENTIONAL
AVIR,"Atea Pharmaceuticals, Inc.",NCT06868264,PHASE3,ACTIVE_NOT_RECRUITING,HEPATITIS C VIRUS CHRONIC INFECTION,"Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)",,RANDOMIZED,2,Bemnifosbuvir-Ruzasvir (BEM/RZR) | Sofosbuvir-Velpatasvir (SOF/VEL),EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.,,2026-12,ESTIMATED,18 Years - 85 Years,880,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects With Chronic Hepatitis C Virus (HCV) Infection",2026-09,ESTIMATED,Proportion of subjects achieving HCV RNA less than the lower limit of quantitation (LLOQ) at study week 24.,TREATMENT,ALL,2025-04-07,ACTUAL,INTERVENTIONAL
EYPT,"EyePoint, Inc.",NCT05191706,PHASE4,RECRUITING,Cataract,"Dexamethasone, Prednisolone Acetate Ophthalmic",,RANDOMIZED,2,DEXYCU (dexamethasoneintraocular suspension) 9% | Prednisolone acetate ophthalmic suspension (USP) 1%,EXPERIMENTAL | ACTIVE_COMPARATOR,"A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract",,2026-02,ESTIMATED,N/A - 3 Years,60,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract",2026-01,ESTIMATED,Grade of anterior chamber cells (ACC),TREATMENT,ALL,2022-01-04,ACTUAL,INTERVENTIONAL
EYPT,"EyePoint, Inc.",NCT06683742,PHASE3,ACTIVE_NOT_RECRUITING,"Wet Age Related Macular Degeneration, wAMD","EYP-1901, Aflibercept (2.0 mg)",wAMD,RANDOMIZED,2,EYP-1901 2686 µg | Aflibercept,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.",,2027-10,ESTIMATED,50 Years - N/A,400,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD",2026-10,ESTIMATED,Average change in best corrected visual acuity (BCVA),TREATMENT,ALL,2024-11-27,ACTUAL,INTERVENTIONAL
EYPT,"EyePoint, Inc.",NCT06668064,PHASE3,ACTIVE_NOT_RECRUITING,"Wet Age Related Macular Degeneration, wAMD","EYP-1901, Aflibercept (2.0 mg)",wAMD,RANDOMIZED,2,EYP-1901 2686 µg | Aflibercept,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.",,2027-08,ESTIMATED,50 Years - N/A,400,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD",2026-08,ESTIMATED,Average change in best corrected visual acuity (BCVA),TREATMENT,ALL,2024-10-22,ACTUAL,INTERVENTIONAL
CMPS,COMPASS Pathways plc,NCT05624268,PHASE3,ACTIVE_NOT_RECRUITING,Treatment Resistant Depression,Psilocybin,,RANDOMIZED,2,25 mg COMP360 Psilocybin | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)",,2026-04,ESTIMATED,18 Years - N/A,255,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression",2025-05-28,ACTUAL,COMP360 25 mg versus placebo for the change from baseline in MADRS total score,TREATMENT,ALL,2023-01-19,ACTUAL,INTERVENTIONAL
CMPS,COMPASS Pathways plc,NCT05711940,PHASE3,ACTIVE_NOT_RECRUITING,Treatment Resistant Depression,Psilocybin,,RANDOMIZED,3,25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)",,2026-12,ESTIMATED,18 Years - N/A,572,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression",2026-02,ESTIMATED,COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score.,TREATMENT,ALL,2023-02-14,ACTUAL,INTERVENTIONAL
CMPS,COMPASS Pathways plc,NCT05733546,PHASE2,ACTIVE_NOT_RECRUITING,Major Depressive Disorder,Psilocybin,,RANDOMIZED,3,25 mg COMP360 Psilocybin | 10 mg COMP360 Psilocybin | 1 mg COMP360 Psilocybin,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.",,2025-09,ESTIMATED,18 Years - N/A,102,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder",2025-09,ESTIMATED,Safety and tolerability of COMP360 Psilocybin,TREATMENT,ALL,2023-01-30,ACTUAL,INTERVENTIONAL
CMPS,COMPASS Pathways plc,NCT04433858,PHASE2,ACTIVE_NOT_RECRUITING,Treatment Resistant Depression,Psilocybin,,,1,Psilocybin,EXPERIMENTAL,"The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.",COMPASS Pathways,2026-05-01,ESTIMATED,18 Years - 65 Years,27,ACTUAL,SINGLE_GROUP,OTHER,NONE,An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD),2025-06-01,ESTIMATED,Montgomery Asberg Depression Rating Scale (MADRS),TREATMENT,ALL,2021-03-01,ACTUAL,INTERVENTIONAL
CMPS,COMPASS Pathways plc,NCT06247839,PHASE3,RECRUITING,Major Depressive Disorder,Psilocybin,,,1,Psilocybin,EXPERIMENTAL,This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.,COMPASS Pathways,2026-06-30,ESTIMATED,18 Years - 55 Years,20,ESTIMATED,SINGLE_GROUP,OTHER,NONE,The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder,2026-06-30,ESTIMATED,Change in Massachusetts General Hospital Rumination Questionnaire (MGH-RQ) | Change in Resting-State Functional Connectivity | Change in Self-Attribution Task performance | Change in Task-Based Activity during Self-Attribution Task,TREATMENT,ALL,2024-09-10,ACTUAL,INTERVENTIONAL
WVE,Wave Life Sciences Ltd.,NCT06842186,PHASE1,RECRUITING,Obesity and Overweight,WVE-007,INLIGHT,RANDOMIZED,5,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.",,2026-10,ESTIMATED,18 Years - 60 Years,136,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity",2026-10,ESTIMATED,The proportion of participants with adverse events,TREATMENT,ALL,2025-01-31,ACTUAL,INTERVENTIONAL
WVE,Wave Life Sciences Ltd.,NCT04906460,"PHASE1, PHASE2",RECRUITING,Duchenne Muscular Dystrophy,WVE-N531,,,1,WVE-N531,EXPERIMENTAL,"This is a Phase 1b/2 open-label study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical effects of intravenous (IV) WVE-N531 in patients with Duchenne muscular dystrophy (DMD). To participate in the study, patients must have a documented mutation of the DMD gene that is amenable to exon 53 skipping intervention. This study has 3 parts, Part A, Part B, including Part B Extension Arm, and Part C. Part A is completed. Part B is completed. Following compl",,2027-04-24,ESTIMATED,4 Years - 18 Years,26,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-label Phase 1b/2 Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy,2026-06-27,ESTIMATED,Part A: Safety: Proportion of patients with adverse events (AEs) | Part B: Pharmacodynamics: Dystrophin level (% normal dystrophin) as assessed by Western blot of muscle tissue following multiple doses of WVE-N531 | Part C: Pharmacodynamics: Change from baseline dystrophin level (% normal dystrophin) as assessed by a validated assay analysis in muscle tissue following multiple doses of WVE-N531,TREATMENT,MALE,2021-09-28,ACTUAL,INTERVENTIONAL
WVE,Wave Life Sciences Ltd.,NCT07209332,PHASE2,NOT_YET_RECRUITING,Duchenne Muscular Dystrophy,WVE-N531,,,1,WVE-N531,EXPERIMENTAL,"This is a Phase 2 open-label extension (OLE) study to evaluate the long-term safety, tolerability, efficacy, pharmacokinetics, and the pharmacodynamics (PD) through potential exploratory biomarker(s) of intravenous (IV) WVE-N531 in patients with DMD who participated in another study of WVE-N531. All patients will have rolled over from a previous study of WVE-N531.",,2029-03,ESTIMATED,N/A - N/A,175,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, Pharmacokinetics, and Efficacy of WVE-N531 in Patients With Duchenne Muscular Dystrophy Who Participated in Another Study of WVE-N531",2029-03,ESTIMATED,Number of participants with treatment related adverse events as assessed by the following parameters:,TREATMENT,MALE,2025-11,ESTIMATED,INTERVENTIONAL
WVE,Wave Life Sciences Ltd.,NCT06405633,"PHASE1, PHASE2",RECRUITING,Alpha-1 Antitrypsin Deficiency,WVE-006,,NON_RANDOMIZED,3,WVE-006 (Dose 1) | WVE-006 (Dose 2) | WVE-006 (Dose 3),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.",,2026-09,ESTIMATED,18 Years - 70 Years,24,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)",2026-09,ESTIMATED,The proportion of participants with adverse events,TREATMENT,ALL,2024-07-19,ACTUAL,INTERVENTIONAL
PHAT,"Phathom Pharmaceuticals, Inc.",NCT06851559,PHASE2,RECRUITING,Eosinophilic Esophagitis,"Vonoprazan, Placebo",,RANDOMIZED,2,Vonoprazan 20 mg | Placebo,EXPERIMENTAL | EXPERIMENTAL,The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.,,2027-03,ESTIMATED,18 Years - N/A,80,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects With Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Up to 24 Weeks",2026-12,ESTIMATED,Number of Participants at Week 12 Achieving Peak Esophageal Intraepithelial Eosinophil Count <15 eos/hpf.,TREATMENT,ALL,2025-10-30,ACTUAL,INTERVENTIONAL
PHAT,"Phathom Pharmaceuticals, Inc.",NCT07224035,PHASE4,ACTIVE_NOT_RECRUITING,"H Pylori Infection, H Pylori Gastritis, Gastric Cancer","PYTEST® 14C-Urea Breath Test, VOQUEZNA® Triple Pak®",,,1,Helicobacter Pylori Screening and Treatment,EXPERIMENTAL,"H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for the infection. By treating those who are positive for H. pylori, there is an opportunity to prevent gastritis, peptic ulcer disease, and even gastric cancer.","Phathom Pharmaceuticals, NRG Oncology",2027-11-06,ESTIMATED,18 Years - N/A,500,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1,2027-11-06,ESTIMATED,Percent of participants diagnosed with Helicobacter pylori using PYTEST® breath test at baseline,SCREENING,ALL,2022-10-15,ACTUAL,INTERVENTIONAL
PHAT,"Phathom Pharmaceuticals, Inc.",NCT07224048,PHASE4,ACTIVE_NOT_RECRUITING,"H. Pylori Infection, Gastric Cancer, Gastritis H Pylori","PYTEST® 14C-Urea Capsule Breath Test (at Home), PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person)",,RANDOMIZED,2,At-Home Retesting Strategy | Standard Care Retesting Strategy,EXPERIMENTAL | ACTIVE_COMPARATOR,"H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for the infection. By treating those who are positive for H. pylori, there is an opportunity to prevent gastritis, peptic ulcer disease, and even gastric cancer.","Phathom Pharmaceuticals, NRG Oncology",2027-11-06,ESTIMATED,18 Years - N/A,75,ESTIMATED,PARALLEL,OTHER,NONE,Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2,2027-11-06,ESTIMATED,Standard vs At-Home Retesting for eradication,HEALTH_SERVICES_RESEARCH,ALL,2024-11-06,ACTUAL,INTERVENTIONAL
PHAT,"Phathom Pharmaceuticals, Inc.",NCT06660342,,RECRUITING,"Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection",Vonoprazan,,,2,Exposed Cohort | Unexposed Cohort, | ,"The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are unexposed to vonoprazan during pregnancy but who may be exposed to other products for the treatment of conditions for which vonoprazan may be prescribed.",,2034-09,ESTIMATED,15 Years - 50 Years,728,ESTIMATED,,INDUSTRY,,Vonoprazan Pregnancy Registry: An Observational Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring,2034-09,ESTIMATED,Number of Participants with Major Congenital Malformations (MCMs),,FEMALE,2025-05-15,ACTUAL,OBSERVATIONAL
PCVX,"Vaxcyte, Inc.",NCT07365826,PHASE3,RECRUITING,Pneumococcal Vaccines,"31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo",,RANDOMIZED,2,VAX-31 + SIV | Placebo + SIV,EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately.",,2027-03,ESTIMATED,50 Years - N/A,1300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older",2027-03,ESTIMATED,"For each of the 32 serotypes (the 31 serotypes included in VAX-31, and serotype 20B), the ratio (co-administration group to sequential administration group) of opsonophagocytic activity (OPA) geometric mean titers (GMT) in evaluable participants | For each of the strains in SIV, the ratio (co-administration group to sequential administration group) of hemagglutination inhibition (HAI) GMT in evaluable participants | Percentage of participants reporting solicited local adverse events (AE) within 7 days after Day 1 and Month 1 vaccination (redness, swelling, and pain at injection site) in each group | Percentage of participants reporting solicited systemic AE within 7 days after Day 1 and Month 1 vaccination (fever, headache, fatigue, muscle pain, and joint pain) in each group | Percentage of participants reporting unsolicited AE within 1 month after Day 1 and Month 1 vaccination in each group | Percentage of participants reporting NOCI, MAAE, and SAE within 6 months after last vaccination in each group",PREVENTION,ALL,2026-01-12,ACTUAL,INTERVENTIONAL
PCVX,"Vaxcyte, Inc.",NCT06720038,PHASE2,ACTIVE_NOT_RECRUITING,Pneumococcal Vaccines,"0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31",,RANDOMIZED,5,VAX-31 Low | VAX-31 Mid | VAX-31 High | PCV20 | VAX-31 High-PFS,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL,"The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll approximately 352 subjects. Stage 3 of the study will enroll approximately 500 subjects.",,2027-12,ESTIMATED,42 Days - 89 Days,905,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age Concomitantly With Routine Pediatric Vaccines",2027-12,ESTIMATED,Percentage of subjects with any solicited local injection site adverse events (AE) within 7 days after each vaccination | Percentage of subjects with any solicited systemic AE within 7 days after each vaccination | Percentage of subjects with any unsolicited AE within 1 month after each vaccination | Percentage of subjects with any medically attended adverse events (MAAE) within 6 months after last vaccination | Percentage of subjects with any Serious Adverse Events (SAE) within 6 months after last vaccination | Percentage of subjects with any new onset of chronic illness (NOCI) within 6 months after last vaccination,PREVENTION,ALL,2024-11-25,ACTUAL,INTERVENTIONAL
PCVX,"Vaxcyte, Inc.",NCT07284654,PHASE3,RECRUITING,Pneumococcal Vaccines,"31 valent pneumococcal conjugate vaccine, PCV20, PCV21",,RANDOMIZED,5,"Cohort 1 (VAX-31), participant ≥ 50 years of age | Cohort 1 (PCV21), participant ≥ 50 years of age | Cohort 1 (PCV20), participant ≥ 50 years of age | Cohort 2 (VAX-31), participant 18-49 years of age | Cohort 2 (PCV20), participant 18-49 years of age",EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR,"The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.",,2027-01,ESTIMATED,18 Years - N/A,4000,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age",2027-01,ESTIMATED,"Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and above | Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site) | Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain) | Percentage of subjects reporting unsolicited AE | Percentage of subjects reporting serious adverse events (SAE), new onset of chronic illness (NOCI), and medically attended adverse events (MAAE) | Serotype-specific OPA geometric mean titers (GMT) in 18 to 49 year olds and 50 to 64 year olds",PREVENTION,ALL,2025-12-01,ACTUAL,INTERVENTIONAL
PCVX,"Vaxcyte, Inc.",NCT07425392,PHASE3,RECRUITING,Pneumococcal Vaccines,"31-valent pneumococcal conjugate vaccine, PCV20",,RANDOMIZED,6,Cohort 1 (VAX-31): Prior PPSV23 | Cohort 1 (PCV20): Prior PPSV23 | Cohort 2 (VAX-31): Prior PCV20 | Cohort 2 (PCV20): Prior PCV20 | Cohort 3 (VAX-31): Other prior licensed pneumococcal vaccine or combination | Cohort 3 (PCV20): Other prior licensed pneumococcal vaccine or combination,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR,"The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.",,2027-03,ESTIMATED,50 Years - N/A,720,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination",2027-03,ESTIMATED,"Serotype-specific OPA geometric mean titers (GMT) | Serotype-specific OPA geometric mean fold rise (GMFR) from baseline | Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site) | Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain) | Percentage of subjects reporting unsolicited AE | Percentage of subjects reporting new onset of chronic illness (NOCI), medically attended AE (MAAE), and serious adverse events (SAE)",PREVENTION,ALL,2026-02-09,ACTUAL,INTERVENTIONAL
PTGX,"Protagonist Therapeutics, Inc.",NCT06033586,PHASE3,ACTIVE_NOT_RECRUITING,Polycythemia Vera,Open-label rusfertide,THRIVE,,1,Open-label rusfertide,EXPERIMENTAL,"The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.",,2027-04-01,ESTIMATED,18 Years - N/A,46,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,An Extension Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (THRIVE),2026-04-01,ESTIMATED,Hematocrit | Phlebotomies,TREATMENT,ALL,2024-01-22,ACTUAL,INTERVENTIONAL
PTGX,"Protagonist Therapeutics, Inc.",NCT05210790,PHASE3,ACTIVE_NOT_RECRUITING,Polycythemia Vera,"Placebo, Rusfertide",VERIFY,RANDOMIZED,2,Rusfertide | Placebo,EXPERIMENTAL | EXPERIMENTAL,The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.,,2027-06,ESTIMATED,18 Years - N/A,293,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera,2025-02-21,ACTUAL,Proportion of subjects achieving a response who receive rusfertide compared to placebo.,TREATMENT,ALL,2022-04-01,ACTUAL,INTERVENTIONAL
PTGX,"Protagonist Therapeutics, Inc.",NCT07153146,PHASE1,RECRUITING,Healthy Volunteer,"PN-881 Oral Solution, PN-881 Oral Tablet, Placebo",,RANDOMIZED,6,PN-881 Oral Solution Single Ascending Dose | Placebo Oral Solution Single Ascending Dose | PN-881 Oral Solution Multiple Ascending Dose | Placebo Oral Solution Multiple Ascending Dose | PN-881 Oral Tablet Single Dose | PN-881 Oral Tablet Multiple Dose,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"The goal of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PN-881 in healthy adult participants.",,2026-06-15,ESTIMATED,18 Years - 65 Years,142,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of PN-881 in Healthy Subjects",2026-06-15,ESTIMATED,Incidence and severity of treatment-emergent adverse events (TEAEs),TREATMENT,ALL,2025-10-07,ACTUAL,INTERVENTIONAL
APGE,"Apogee Therapeutics, Inc.",NCT06395948,PHASE2,ACTIVE_NOT_RECRUITING,Atopic Dermatitis,"APG777, Placebo",,RANDOMIZED,6,Part A: Induction Period: APG777 | Part A: Induction Period: Placebo | Part A: Maintenance Period: APG777 | Part B: Induction Period: APG777 | Part B: Induction Period: Placebo | Part B: Maintenance Period: APG777,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants ra",,2028-06,ESTIMATED,18 Years - N/A,470,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis",2026-11,ESTIMATED,Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI) | Part B: Proportion of participants who achieve EASI 75 at Week 16,TREATMENT,ALL,2024-04-29,ACTUAL,INTERVENTIONAL
APGE,"Apogee Therapeutics, Inc.",NCT07027527,PHASE1,RECRUITING,Atopic Dermatitis,"APG777, APG990, Dupilumab",,RANDOMIZED,2,APG777 + APG990 | Dupilumab,EXPERIMENTAL | ACTIVE_COMPARATOR,"The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).",,2027-12,ESTIMATED,18 Years - N/A,80,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis",2026-12,ESTIMATED,Number of Participants with Treatment Emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-06-04,ACTUAL,INTERVENTIONAL
APGE,"Apogee Therapeutics, Inc.",NCT06920901,PHASE1,ACTIVE_NOT_RECRUITING,Asthma,"APG777, Placebo",,RANDOMIZED,2,APG777 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma.

The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.",,2027-03,ESTIMATED,18 Years - 65 Years,31,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APG777 in Adults With Mild-to-Moderate Asthma",2026-09,ESTIMATED,Number of Participants with Treatment Emergent Adverse Events (TEAEs) | Number of Participants with Abnormal Laboratory Findings | Number of Participants with Abnormal Vital Signs | Number of Participants with Abnormal Electrocardiograms (ECGs) | Number of Participants with Abnormal Physical Examination Findings,TREATMENT,ALL,2025-03-27,ACTUAL,INTERVENTIONAL
APGE,"Apogee Therapeutics, Inc.",NCT07003425,PHASE2,RECRUITING,Atopic Dermatitis,"APG777, APG777, APG777",,NON_RANDOMIZED,3,APG777 - Long Term Extension Treatment - 12 Weeks | APG777 - Long Term Extension Treatment - 24 Weeks | APG777 - Open Label Escape Arm,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).

The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

This study will be conducted in participants with atopic de",,2029-12,ESTIMATED,18 Years - N/A,350,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777,2029-12,ESTIMATED,Number of Participants with Treatment Emergent Adverse Events,TREATMENT,ALL,2025-05-14,ACTUAL,INTERVENTIONAL
ANNX,"Annexon, Inc.",NCT06510816,PHASE3,ACTIVE_NOT_RECRUITING,Geographic Atrophy,Vonaprument,ARCHER II,RANDOMIZED,2,Vonaprument | Sham Group,EXPERIMENTAL | SHAM_COMPARATOR,The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).,,2027-10-31,ESTIMATED,50 Years - N/A,659,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)",2026-10-31,ESTIMATED,Proportion of patients experiencing a best corrected visual acuity (BCVA) ≥15-letter loss from baseline through the primary timepoint as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at any two consecutive visits.,TREATMENT,ALL,2024-07-30,ACTUAL,INTERVENTIONAL
ANNX,"Annexon, Inc.",NCT07020819,PHASE3,RECRUITING,Guillain-Barre Syndrome,Tanruprubart,,,1,Tanruprubart,EXPERIMENTAL,"The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.",,2028-06-30,ESTIMATED,12 Years - 85 Years,30,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)",2026-12-31,ESTIMATED,Area Under the Tanruprubart Serum Concentration-time Curve to the Last Sample (AUC0-t) | Observed Time to Maximum Observed Serum Concentration (Cmax) (Tmax) of Tanruprubart,TREATMENT,ALL,2025-09-12,ACTUAL,INTERVENTIONAL
CYTK,"Cytokinetics, Incorporated",NCT07054073,,NOT_YET_RECRUITING,Hypertrophic Cardiomyopathy (HCM),,,,2,Obstructive HCM | Non-obstructive HCM, | ,"This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system.

This study is looking to enroll patients that were previously part of a research project called ""HCMR - Novel Predictors of Outcome in Hypertrophi","Brigham and Women's Hospital, Mayo Clinic, Tufts Medical Center, Northwestern University, University of Michigan, The Cleveland Clinic, University Hospital Birmingham NHS Foundation Trust, Glenfield Hospital, Leicester, London Chest Hospital, Cytokinetics, Toronto General Hospital",2026-07,ESTIMATED,18 Years - 65 Years,314,ESTIMATED,,OTHER,,HCMR Re-Imaging Study,2026-03,ESTIMATED,Change in % LGE mass,,ALL,2025-07-30,ESTIMATED,OBSERVATIONAL
CYTK,"Cytokinetics, Incorporated",NCT06736574,PHASE3,RECRUITING,"Heart Failure, Heart Failure With Reduced Ejection Fraction","Omecamtiv Mecarbil (OM), Placebo",COMET-HF,RANDOMIZED,2,Omecamtiv Mecarbil | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.",,2027-12,ESTIMATED,18 Years - 85 Years,1800,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)",2027-09,ESTIMATED,"Time to the first of event of CV death, HF event, LVAD implantation/cardiac transplantation, or stroke",TREATMENT,ALL,2024-12-19,ACTUAL,INTERVENTIONAL
CYTK,"Cytokinetics, Incorporated",NCT06793371,PHASE2,RECRUITING,Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF),"CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586",AMBER-HFpEF,RANDOMIZED,6,CK-4021586 - Cohort 1 | Placebo - Cohort 1 | CK-4021586 - Cohort 2 | Placebo - Cohort 2 | CK-4021586 - Cohort 3 | Placebo - Cohort 3,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.,,2026-09,ESTIMATED,40 Years - 85 Years,60,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-4021586 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction",2026-09,ESTIMATED,Incidence of early drug discontinuation | Incidence of LVEF < 40% | Incidence of AEs,TREATMENT,ALL,2025-02-06,ACTUAL,INTERVENTIONAL
CYTK,"Cytokinetics, Incorporated",NCT06081894,PHASE3,ACTIVE_NOT_RECRUITING,Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy,"Aficamten, Placebo",ACACIA-HCM,RANDOMIZED,2,Aficamten | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.","Sanofi, Bayer",2026-09,ESTIMATED,18 Years - 85 Years,500,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy",2026-06,ESTIMATED,Change in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) | Change in pVO2,TREATMENT,ALL,2023-08-30,ACTUAL,INTERVENTIONAL
CYTK,"Cytokinetics, Incorporated",NCT06412666,"PHASE2, PHASE3",RECRUITING,"Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy","Aficamten, Placebo",CEDAR-HCM,RANDOMIZED,2,Aficamten | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).",,2030-01,ESTIMATED,12 Years - 17 Years,55,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Trial to Evaluate the Efficacy and Safety of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy",2030-01,ESTIMATED,Change from baseline in Valsalva left ventricular outflow tract gradient (LVOT-G),TREATMENT,ALL,2024-05-29,ACTUAL,INTERVENTIONAL
ARDX,"Ardelyx, Inc.",NCT05643534,PHASE3,RECRUITING,Irritable Bowel Syndrome With Constipation (IBS-C),"Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo",,RANDOMIZED,3,Tenpanor 50 mg BID | Tenpanor 25 mg BID | Placebo Comparator,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.",,2026-06-01,ESTIMATED,12 Years - 17 Years,180,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 12 to Less Than 18 Years Old",2026-06-01,ESTIMATED,6/12-week APS (abdominal pain and SBM) +2 response,TREATMENT,ALL,2022-11-15,ACTUAL,INTERVENTIONAL
ARDX,"Ardelyx, Inc.",NCT06553547,PHASE2,RECRUITING,Irritable Bowel Syndrome With Constipation (IBS-C),"Tenapanor, Placebo",,RANDOMIZED,7,Tenapanor Cohort 1 | Tenapanor Cohort 2 | Tenapanor Cohort 3 | Tenapanor Cohort 4 | Tenapanor Cohort 5 | Tenapanor Cohort 6 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a randomized, double-blind, placebo-controlled dose-ranging study to assess the safety and efficacy of tenapanor for treatment of the IBS-C in pediatric patients 6 to less than 12 year old.",,2026-06,ESTIMATED,6 Years - 11 Years,72,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"4-Week, Multi-Center, Randomized, Db-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety & Efficacy of Tenapanor for the T/t of IBS-C in Pts. 6 to < 12 Yrs. Old",2026-06,ESTIMATED,Average weekly SBM (week 4),TREATMENT,ALL,2024-07-24,ACTUAL,INTERVENTIONAL
ARDX,"Ardelyx, Inc.",NCT06460038,PHASE2,RECRUITING,"Synucleinopathy, Parkinson's Disease","Tenapanor, Placebo",,RANDOMIZED,2,Tenapanor | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation,Ardelyx,2027-03,ESTIMATED,50 Years - 89 Years,30,ESTIMATED,PARALLEL,OTHER,DOUBLE,Efficacy and Safety of Tenapanor in Synucleinopathy-Related Constipation,2026-12,ESTIMATED,Complete spontaneous bowel movements (CSBM),TREATMENT,ALL,2025-01-01,ACTUAL,INTERVENTIONAL
ARDX,"Ardelyx, Inc.",NCT05995899,PHASE4,ACTIVE_NOT_RECRUITING,"IBS, IBS - Irritable Bowel Syndrome",Tenapanor,,,1,Patients with IBS-C,EXPERIMENTAL,"The aim of this study is to better understand how tenapanor affects the metagenomics and metabolomics of patients with irritable bowel syndrome with constipation (IBS-C). Tenapanor is the newest FDA-approved agent for IBS-C. It is a small molecule that inhibits the NHE3 receptor, leading to impaired sodium and water absorption in the intestine. Previous clinical trials comparing tenapanor to placebo showed that a 50 mg dose of tenapanor led to increased bowel movements and decreased abdominal pa",Ardelyx,2026-01,ESTIMATED,18 Years - 75 Years,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"An Open-label, Single Center Investigator Sponsored Study Assessing the Effect of Tenapanor on Metagenomic and Metabolomic Markers in Patients With Irritable Bowel Syndrome With Constipation",2026-01,ESTIMATED,Measuring metagenomics of stool samples using whole genome shotgun sequencing (WGS) | Measuring metabolomics of stool samples using the DiscoveryHD4TM Platform,TREATMENT,ALL,2024-02-06,ACTUAL,INTERVENTIONAL
ARDX,"Ardelyx, Inc.",NCT07382167,PHASE3,RECRUITING,Chronic Idiopathic Constipation (CIC),"Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BID, Placebo",,RANDOMIZED,4,Tenapanor 5 mg BID | Tenapanor 25 mg BID | Tenapanor 50 mg BID | Placebo Comparator,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.",,2027-06-04,ESTIMATED,18 Years - 80 Years,692,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults",2027-02-26,ESTIMATED,Durable CSBM response,TREATMENT,ALL,2026-01-13,ACTUAL,INTERVENTIONAL
ARDX,"Ardelyx, Inc.",NCT06810167,PHASE3,RECRUITING,"Cystic Fibrosis, Constipation",Tenapanor,,,1,Cystic fibrosis patients with CF-related constipation,EXPERIMENTAL,"Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. They will also complete three questionnaires, the PAC-SYM, PAC-QoL, and IBS-SSS, and daily diaries to characterize GI symptom burden and spontaneous bowel movement (SBM) frequency.",Ardelyx,2027-06-30,ESTIMATED,18 Years - 75 Years,25,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"An Open-label, Single Center Study Assessing Tenapanor as a Non-CFTR-mediated Treatment of CF-related Constipation in People With CF.",2026-02-01,ESTIMATED,Increase in SBM frequency,TREATMENT,ALL,2025-06-01,ACTUAL,INTERVENTIONAL
SVRA,Savara Inc.,NCT04544293,PHASE3,ACTIVE_NOT_RECRUITING,Autoimmune Pulmonary Alveolar Proteinosis,"Molgramostim, Placebo, Molgramostim Open-label",IMPALA-2,RANDOMIZED,3,Molgramostim | Placebo | Molgramostim Open-label Extension,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.,,2027-05-30,ESTIMATED,18 Years - N/A,164,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)",2023-11-30,ACTUAL,Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24,TREATMENT,ALL,2021-05-19,ACTUAL,INTERVENTIONAL
SVRA,Savara Inc.,NCT06431776,PHASE3,RECRUITING,Autoimmune Pulmonary Alveolar Proteinosis,Molgramostim,,,1,molgramostim,EXPERIMENTAL,"The goal of this open-label study is to study molgramostim as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP) in pediatric patients between age 6 and 18. The main questions it aims to answer are:

The effect of molgramostim on breathing tests and activity in pediatric patients with aPAP and the safety of molgramostim in pediatric patients with aPAP.

This is an open-label study: all participants will receive treatment with molgramostim.

Patients will:

* Take molgramostim once ",,2027-12,ESTIMATED,6 Years - 18 Years,5,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).",2027-06,ESTIMATED,DLCO,TREATMENT,ALL,2025-10-22,ACTUAL,INTERVENTIONAL
TRVI,"Trevi Therapeutics, Inc.",NCT07036029,PHASE1,RECRUITING,Idiopathic Pulmonary Fibrosis,"NAL ER, Placebo",,,1,NAL ER,EXPERIMENTAL,The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.,,2026-02,ESTIMATED,18 Years - N/A,10,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open Label, In-Clinic Study to Assess Respiratory Function and Safety of Escalating Doses of Nalbuphine Extended-Release Tablets (NAL ER) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)",2026-02,ESTIMATED,"Respiratory Function and Safety Assessed by Number of Participants With Increase in End Tidal Partial Pressure of Carbon Dioxide by Capnography (PetCO2) of at Least 10 Millimetres of Mercury (mmHg) From Baseline, or PetCO2>55 mmHg, for at Least 1 Minute | Respiratory Function and Safety as Assessed by Number of Participants With a Decrease in Blood Oxygen Saturation (SpO2) to <88% for at Least 1 Minute | Respiratory Function and Safety as Assessed by Number of Participants With a Decrease in Respiratory Rate (RR) to <6 Breaths per Minute | Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs)",TREATMENT,ALL,2025-08-21,ACTUAL,INTERVENTIONAL
BEAM,Beam Therapeutics Inc.,NCT05456880,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Sickle Cell Disease,BEAM-101,BEACON,,1,BEAM-101,EXPERIMENTAL,"This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD",,2028-02,ESTIMATED,12 Years - 35 Years,15,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial),2028-02,ESTIMATED,"Change in annualized number of severe VOCs (Vascular-occlusive Crisis) relative to baseline | Proportion of patients with successful neutrophil engraftment | Time to neutrophil engraftment | Time to platelet engraftment | Transplant-related mortality within 100 days after beam-101 treatment | Safety and tolerability assessments based on frequency, severity and seriousness of adverse events (AE's)",TREATMENT,ALL,2022-08-30,ACTUAL,INTERVENTIONAL
BEAM,Beam Therapeutics Inc.,NCT07304791,PHASE1,RECRUITING,"Healthy Subjects, Healthy Participant Study","BEAM-103, Placebo Comparator",,RANDOMIZED,2,BEAM-103 Drug Product | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this Phase I single ascending dose study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of BEAM-103 in healthy subjects between the ages of 18 and 55. The main questions the study aims to answer are:

* Safety and tolerability of BEAM-103
* The pharmacokinetic (PK) profile and pharmacodynamic (PD) characteristics of EAM-103
* The effect of BEAM-103 on hematologic parameters
* To assess the immunogenicity of BEAM-103

Researchers will determine and esta",,2026-05-29,ESTIMATED,18 Years - 55 Years,30,ESTIMATED,SEQUENTIAL,INDUSTRY,SINGLE,"A Randomized, Single-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BEAM-103 in Healthy Subjects",2026-01-29,ESTIMATED,To determine the safety and tolerability of single ascending doses of BEAM-103,BASIC_SCIENCE,ALL,2025-10-27,ACTUAL,INTERVENTIONAL
BEAM,Beam Therapeutics Inc.,NCT06934382,PHASE1,RECRUITING,T-Cell Acute Lymphoblastic Leukemia/Lymphoma,Allogeneic anti-CD7 CAR-T cells (BEAM-201),24CT015,NON_RANDOMIZED,2,Dose Escalation Arm | Dose Expansion Arm,EXPERIMENTAL | EXPERIMENTAL,"This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.",Beam Therapeutics Inc.,2031-05-30,ESTIMATED,0 Years - 29 Years,33,ESTIMATED,SEQUENTIAL,OTHER,NONE,A Phase 1 Study of Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) or T-cell Lymphoblastic Lymphoma (T-LLy),2029-05-30,ESTIMATED,Determine the Maximum Tolerate Dose of Beam 201 Cells | Frequency of Adverse Events Following Beam-201 administration,TREATMENT,ALL,2025-04-29,ACTUAL,INTERVENTIONAL
BEAM,Beam Therapeutics Inc.,NCT07373639,,RECRUITING,"Hemoglobinopathy, Sickle Cell Disease",Long-Term Follow-up Study of patients who received BEAM-101,,,1,BTX-101-002 Long-term Follow-up on Patients who received BEAM-101,,This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).,,2043-02-12,ESTIMATED,14 Years - 37 Years,50,ESTIMATED,,INDUSTRY,,A Long-term Follow-up Study in Patients With Hemoglobinopathy Who Received Autologous CD34+ Edited Hematopoietic Stem Cells,2043-02-12,ESTIMATED,Long-Term Safety Monitoring and Mortality Assessment,,ALL,2025-12-15,ACTUAL,OBSERVATIONAL
BEAM,Beam Therapeutics Inc.,NCT05885464,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia",BEAM-201,,NON_RANDOMIZED,2,"Fludarabine, cyclophosphamide and alemtuzumab | Fludarabine, cyclophosphamide without alemtuzumab",EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.",,2026-12,ESTIMATED,18 Years - 50 Years,5,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)",2026-12,ESTIMATED,"Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events, including serious adverse events (SAEs) and dose-limiting toxicities (DLTs; in Phase 1 only) | Overall response rate as defined as proportion of T-ALL patients achieving complete response (CR) or complete response with incomplete hematologic recovery (CRi) or T-LL patients achieving CR or PR at any point after BEAM-201 infusion",TREATMENT,ALL,2023-05-25,ACTUAL,INTERVENTIONAL
BEAM,Beam Therapeutics Inc.,NCT06735755,"PHASE1, PHASE2",RECRUITING,Glycogen Storage Disease Type Ia,BEAM-301: Single dose of BEAM-301 administered by IV,,,1,BEAM-301,EXPERIMENTAL,"This is a Phase 1/2, multicenter, open-label, single-ascending-dose study to evaluate the safety, tolerability, and efficacy of BEAM-301 in adult patients with GSDIa homozygous or compound heterozygous for the G6PC1 c.247C\>T (p.R83C) variant and to determine the optimal biological dose.",,2027-12-30,ESTIMATED,18 Years - N/A,36,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) Homozygous or Compound Heterozygous for the G6PC1 c.247C>T (p.R83C) Variant",2027-12-30,ESTIMATED,To evaluate the safety and tolerability of BEAM-301 in patients with GSDIa with a G6PC1 c.247C>T (p.R83C) variant by measuring incidence of treatment-emergent adverse events (TEAEs) including serious adverse events (SAEs) and dose-limiting toxicities (DL,TREATMENT,ALL,2024-12-06,ACTUAL,INTERVENTIONAL
BEAM,Beam Therapeutics Inc.,NCT06389877,"PHASE1, PHASE2",RECRUITING,Alpha 1-Antitrypsin Deficiency,BEAM-302,,,1,BEAM-302 Drug Product,EXPERIMENTAL,"This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).",,2027-08,ESTIMATED,18 Years - 70 Years,106,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease,2027-06,ESTIMATED,Phase 1 Dose Exploration: Rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | Phase 2 Dose Expansion: Absolute blood levels of total AAT,TREATMENT,ALL,2024-06-19,ACTUAL,INTERVENTIONAL
BEAM,Beam Therapeutics Inc.,NCT06071377,,RECRUITING,Sickle Cell Trait,,,,1,Individuals with sickle cell trait,,"The main purpose of this study is to create a longitudinal cohort of those with Sickle Cell Trait (SCT) to better understand the hematologic phenotype for those that carry HbS, assess for differences in those with varying quantities of HbS and assess for potential clinical complications of SCT.",Beam Therapeutics Inc.,2027-02,ESTIMATED,18 Years - N/A,1000,ESTIMATED,,OTHER,,Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT),2026-12,ESTIMATED,Hemoglobin variant quantification,,ALL,2023-04-01,ACTUAL,OBSERVATIONAL
ALKS,Alkermes plc,NCT06843590,PHASE2,RECRUITING,Idiopathic Hypersomnia,"ALKS 2680, Placebo",Vibrance-3,RANDOMIZED,4,"ALKS 2680, 10 mg | ALKS 2680, 14 mg | ALKS 2680, 18 mg | Placebo",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets,,2026-06,ESTIMATED,18 Years - 70 Years,96,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)",2026-06,ESTIMATED,Change in Epworth Sleepiness Scale (ESS) from baseline to Week 8 by dose level,TREATMENT,ALL,2025-05-22,ACTUAL,INTERVENTIONAL
ALKS,Alkermes plc,NCT06767683,"PHASE2, PHASE3",RECRUITING,"Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia","ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg",,NON_RANDOMIZED,3,Narcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2) | Idiopathic Hypersomnia (IH),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.",,2028-06,ESTIMATED,18 Years - 70 Years,256,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia",2028-06,ESTIMATED,Incidence of Treatment-Emergent Adverse Events,TREATMENT,ALL,2025-01-27,ACTUAL,INTERVENTIONAL
ALKS,Alkermes plc,NCT05495984,,RECRUITING,Opioid Use Disorder,,,NON_RANDOMIZED,2,Primary Objective: Event-Related Potentials (ERPs) | Secondary Objective: ERPs + Mothering from the Inside Out (MIO),EXPERIMENTAL | EXPERIMENTAL,"Opioid use disorder (OUD) remains a major public health problem particularly for mothers in the perinatal period, for whom stress, relapse rates, and risk for overdose are elevated. The perinatal period is characterized by significant neural reorganization that determines outcomes for mothers and infants. OUD is also associated with neural reorganization, specifically neural circuitry implicated in stress regulation and reward processes. Interventions should therefore take advantage of this chan","Alkermes, Inc.",2026-06,ESTIMATED,21 Years - 45 Years,15,ESTIMATED,SEQUENTIAL,OTHER,NONE,Neuroplasticity in Maternal Opioid Use Disorder (OUD),2026-06,ESTIMATED,Change in mothers' Event-related potentials (ERPs) elicited by unknown infant face and cry stimuli | Change in maternal mentalization measured by coding of reflective functioning (RF) on the one-hour Parent Development Interview (PDI) | Change in mothers' reflective functioning assessed using the self-report Parental Reflective Functioning Questionnaire (PRFQ) | Change in mothers' certainty about mental states assessed using the self-report Certainty about Mental States Questionnaire (CAMSQ) | Change in mothers' mind-mindedness assessed using the Five-Minute Speech Sample (MM),TREATMENT,FEMALE,2023-01-01,ACTUAL,INTERVENTIONAL
ALKS,Alkermes plc,NCT05303064,PHASE3,RECRUITING,"Schizophrenia, Bipolar I Disorder","OLZ/SAM, Olanzapine",,RANDOMIZED,2,Group 1 OLZ/SAM | Group 2 Olanzapine,EXPERIMENTAL | ACTIVE_COMPARATOR,To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine,,2026-09,ESTIMATED,10 Years - 17 Years,220,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth)",2026-09,ESTIMATED,Change from baseline in body mass index (BMI) Zscore at week 12,TREATMENT,ALL,2022-06-30,ACTUAL,INTERVENTIONAL
ALKS,Alkermes plc,NCT05028062,PHASE4,RECRUITING,"Alcohol Use Disorder, Alcoholism","XR-NTX 380 mg, intramuscular injection, Placebo intramuscular injection",,RANDOMIZED,2,"XR-NTX 380 mg, intramuscular injection | Inactive placebo intramuscular injection",ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This study is a phase IV, two-arm, randomized, double-blind, placebo-controlled study to assess whether individuals identified as primarily reward drinkers are significantly more likely to reduce heavy drinking if they receive XR-NTX than a matching placebo injection.

Study subjects will receive monthly injections of long-acting injectable naltrexone 380 mg (4 mL) or matching placebo. All subjects will also receive 4 sessions of Medical Management (MM). Post-treatment follow-up visits will be c","Alkermes, Inc.",2028-07,ESTIMATED,18 Years - 65 Years,60,ESTIMATED,PARALLEL,OTHER,TRIPLE,Testing the Reward-Drinker Hypothesis of Naltrexone Using an Extended-Release Formulation,2027-07,ESTIMATED,Frequency of heavy drinking days by medication group (timeline follow back calendar).,TREATMENT,ALL,2022-03-07,ACTUAL,INTERVENTIONAL
ALKS,Alkermes plc,NCT01246765,,RECRUITING,"Pregnant Women, Psychotropic Drugs",,,,5,Atypical Antipsychotic Cohort | Antidepressant Medications | ADHD Medications | Sedative Hypnotic Medications | Other Psychiatric Medications, |  |  |  | ,"The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.","Alkermes, Inc., Eisai Inc., Otsuka America Pharmaceutical, Supernus Pharmaceuticals, Inc., Sage Therapeutics, Bristol-Myers Squibb",2033-12,ESTIMATED,18 Years - 45 Years,5000,ESTIMATED,,OTHER,,National Pregnancy Registry for Psychiatric Medications,2033-12,ESTIMATED,Major Malformations in Infants,,FEMALE,2008-11,ACTUAL,OBSERVATIONAL
ALKS,Alkermes plc,NCT06555783,PHASE2,ACTIVE_NOT_RECRUITING,Narcolepsy Type 2,"ALKS 2680, Placebo",Vibrance-2,RANDOMIZED,4,"ALKS 2680, 10 mg | ALKS 2680, 14 mg | ALKS 2680, 18 mg | Placebo",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.,,2025-11,ESTIMATED,18 Years - 70 Years,80,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2",2025-11,ESTIMATED,Change in Mean Sleep Latency (MSL) on the Maintenance Wakefulness Test (MWT) | Change in Epworth Sleepiness Scale (ESS),TREATMENT,ALL,2024-07-26,ACTUAL,INTERVENTIONAL
DNLI,Denali Therapeutics Inc.,NCT07328451,PHASE1,RECRUITING,"Alzheimer Disease, Early Onset","DNL628, Placebo",,RANDOMIZED,2,Experimental Arm | Placebo Arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloid positivity.",,2027-02,ESTIMATED,18 Years - 75 Years,68,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease",2027-02,ESTIMATED,Incidence and severity of treatment-emergent adverse events (TEAEs) throughout the double-blind period,TREATMENT,ALL,2026-01-30,ACTUAL,INTERVENTIONAL
DNLI,Denali Therapeutics Inc.,NCT05262023,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Frontotemporal Dementia,"DNL593, Placebo",,RANDOMIZED,4,DNL593 (Healthy Participant) | Placebo (Healthy Participant) | DNL593 (Participants with FTD) | Placebo (Participants with FTD),EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period.

Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and",Takeda,2028-11,ESTIMATED,18 Years - 80 Years,85,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension",2026-12,ESTIMATED,"Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs) | Incidence of treatment-emergent clinically significant abnormalities in safety laboratory values | Change from baseline in vital sign measurements: systolic and diastolic blood pressure | Change from baseline in vital sign measurements: heart rate | Change from baseline in vital sign measurements: respiratory rate | Change from baseline in vital sign measurements: body temperature | Change from baseline in electrocardiogram (ECG) results including PR, QRS, and QTcF intervals | Incidence of treatment-emergent clinically significant abnormalities in physical/neurological examination findings | Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS; Parts B and C only)",TREATMENT,ALL,2022-02-01,ACTUAL,INTERVENTIONAL
DNLI,Denali Therapeutics Inc.,NCT07354724,PHASE1,NOT_YET_RECRUITING,Late-onset Pompe Disease,DNL952,,NON_RANDOMIZED,6,Cohort A1 | Cohort A2 | Cohort A3 (Optional) | Cohort A4 (Optional) | Cohort B1 (Optional) | Cohort B2 (Optional),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 1, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL952 in adult participants with late-onset Pompe disease. The principal aim of this study is to obtain safety and tolerability data across varous dose levels of DNL952 in participants with late-onset Pompe disease (LOPD).",,2028-08,ESTIMATED,18 Years - 75 Years,32,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease",2028-08,ESTIMATED,"Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs) | Incidence and severity of infusion-related reacations (IRRs)",TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
DNLI,Denali Therapeutics Inc.,NCT06181136,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Mucopolysaccharidosis Type IIIA,DNL126,,NON_RANDOMIZED,5,Cohort A1 | Cohort A2 | Cohort A3 | Cohort B1 | Cohort B2,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a multicenter, open-label, Phase 1/2 study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of DNL126 in participants with Sanfilippo syndrome Type A (MPS IIIA). The core study period is 25 weeks (approximately 6 months); followed by an open-label extension (OLE), which extends through Week 97 (approximately 18 months); and a long-term extension (LTE), which extends through Week 193 (Year 4). Participants with MPS IIIA will be enrolle",,2028-08,ESTIMATED,0 Years - 18 Years,20,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)",2028-08,ESTIMATED,Percentage change from baseline in cerebrospinal fluid (CSF) concentration of heparan sulfate (HS),TREATMENT,ALL,2023-12-07,ACTUAL,INTERVENTIONAL
DNLI,Denali Therapeutics Inc.,NCT04251026,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Mucopolysaccharidosis II,tividenofusp alfa,,NON_RANDOMIZED,5,Cohort A | Cohort B | Cohort C | Cohort D | Cohort E,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome).

Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extensio",,2031-02,ESTIMATED,N/A - 18 Years,47,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome",2031-02,ESTIMATED,Incidence and severity of treatment-emergent adverse events (TEAEs) | Change from baseline in urine total glycosaminoglycan (GAG) concentrations | Incidence and severity of infusion-related reactions (IRRs) | Change from baseline in concomitant medications,TREATMENT,MALE,2020-07-16,ACTUAL,INTERVENTIONAL
DNLI,Denali Therapeutics Inc.,NCT05348785,PHASE2,ACTIVE_NOT_RECRUITING,Parkinson Disease,"BIIB122, BIIB122-Matching Placebo",LUMA,RANDOMIZED,2,BIIB122 225 mg | BIIB122 Matching Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"In this study, researchers will learn more about BIIB122 in participants with early-stage Parkinson's disease (PD). The study will include adults aged 30 to 80 who were diagnosed with PD within 2 years of starting the study.

The main objective of the study is to learn about the effect BIIB122 has on slowing down the worsening of PD symptoms. The main question researchers want to answer is:

\- How long does it take for PD symptoms to worsen during BIIB122 treatment?

Researchers will answer thi",Denali Therapeutics Inc.,2026-03-09,ESTIMATED,30 Years - 80 Years,650,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease",2026-02-25,ESTIMATED,Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment Period,TREATMENT,ALL,2022-04-19,ACTUAL,INTERVENTIONAL
DNLI,Denali Therapeutics Inc.,NCT05371613,"PHASE2, PHASE3",RECRUITING,Mucopolysaccharidosis II,"tividenofusp alfa, idursulfase",COMPASS,RANDOMIZED,3,Cohort A: Participants with nMPS II | Cohort B: Participants with nnMPS II | Open-label Treatment Phase,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II).

Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.",,2027-12,ESTIMATED,2 Years - 25 Years,63,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II",2027-12,ESTIMATED,"Percent change from baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) | Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A)",TREATMENT,ALL,2022-07-21,ACTUAL,INTERVENTIONAL
DNLI,Denali Therapeutics Inc.,NCT06602193,PHASE2,RECRUITING,Parkinson Disease,BIIB122 225 mg,,RANDOMIZED,2,BIIB122 225 mg | BIIB122 Matching Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.",Biogen,2028-02-28,ESTIMATED,30 Years - N/A,50,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)",2026-04-30,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) with BIIB122 compared with placebo over the 12-week double-blind period,TREATMENT,ALL,2024-10-24,ACTUAL,INTERVENTIONAL
PRTA,Prothena Corporation plc,NCT04777331,PHASE2,ACTIVE_NOT_RECRUITING,Parkinsons Disease,"Prasinezumab, Placebo",PADOVA,RANDOMIZED,2,Prasinezumab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.",Prothena Biosciences Limited,2026-12-30,ESTIMATED,50 Years - 85 Years,586,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease",2024-09-11,ACTUAL,DBT Period: Time to Confirmed Motor Progression Event Assessed by Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III,TREATMENT,ALL,2021-05-05,ACTUAL,INTERVENTIONAL
PRTA,Prothena Corporation plc,NCT07174310,PHASE3,RECRUITING,Parkinson's Disease,"Prasinezumab, Placebo",PARAISO,RANDOMIZED,2,Prasinezumab | Placebo,EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.",Prothena Biosciences Limited,2031-06-30,ESTIMATED,50 Years - 85 Years,900,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease",2029-06-30,ESTIMATED,Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Score,TREATMENT,ALL,2025-11-24,ACTUAL,INTERVENTIONAL
PRTA,Prothena Corporation plc,NCT03100149,PHASE2,ACTIVE_NOT_RECRUITING,Parkinson's Disease,"RO7046015, RO7046015, Placebo",PASADENA,RANDOMIZED,6,Part 1: RO7046015 High Dose | Part 1: RO7046015 Low Dose | Part 1: Placebo | Part 2: RO7046015 High Dose | Part 2: RO7046015 Low Dose | Part 3: RO7046015 Low Dose,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participa",Prothena Biosciences Limited,2031-12-01,ESTIMATED,40 Years - 80 Years,316,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 11-Year All-Participants-on-Treatment Extension",2019-11-27,ACTUAL,"Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52",TREATMENT,ALL,2017-06-27,ACTUAL,INTERVENTIONAL
PRTA,Prothena Corporation plc,NCT06699680,PHASE1,RECRUITING,Healthy Participants Study,"PRX019, Placebo",,RANDOMIZED,2,"PRX019, single dose | PRX019, multiple dose",EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to assess the safety and tolerability of PRX019 in healthy adult participants.,,2026-01-23,ESTIMATED,18 Years - 65 Years,48,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending and Multiple Doses of PRX019 in Healthy Adults",2026-01-23,ESTIMATED,Number of participants with adverse events | Number of participants with clinical laboratory assessment abnormalities,TREATMENT,ALL,2024-11-08,ACTUAL,INTERVENTIONAL
EPRX,Eupraxia Pharmaceuticals Inc.,NCT05608681,"PHASE1, PHASE2",RECRUITING,Eosinophilic Esophagitis,EP-104GI,RESOLVE,RANDOMIZED,12,EP-104GI 4 mg | EP-104GI 8 mg | EP-104GI 20 mg | EP-104GI 30 mg | EP-104GI 48 mg | EP-104GI 64 mg | EP-104GI 80 mg | EP-104GI 96 mg | EP-104GI 120 mg | EP-104GI Dose A or matching vehicle control | EP-104GI 160 mg | EP-104GI Dose B or matching vehicle control,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"A Phase 1b/2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE). Endoscopic and histologic assessments will also be evaluated to understand the local effects of EP-104GI on eosinophilic EoE disease activity. Approximately 27 to 33 participants will be enrolled in dose escalation: 3-6 participants per dose cohort. The number of participants enrolled in escalation will depend on the number of dose escalation cohorts evaluated, and d",,2026-12,ESTIMATED,18 Years - 75 Years,117,ESTIMATED,CROSSOVER,INDUSTRY,QUADRUPLE,"A Phase 1b/2 Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104GI in Adults With Eosinophilic Esophagitis (RESOLVE)",2026-12,ESTIMATED,"Dose Escalation- Incidence of treatment emergent adverse events (TEAEs) | Dose Escalation- Severity of treatment emergent adverse events (TEAEs) | Dose Escalation- Change from baseline in morning serum cortisol levels | Dose Escalation- Plasma concentrations of fluticasone propionate | Dose Escalation- Change from baseline in physical examination results, BMI and weight change. | Randomised Dose Optimization- Change from baseline in EoEHSS grade and stage scored in 3 regions of the esophagus within the injection area (proximal, mid, distal)",TREATMENT,ALL,2023-03-31,ACTUAL,INTERVENTIONAL
SION,"Sionna Therapeutics, Inc.",NCT07108153,PHASE2,RECRUITING,Cystic Fibrosis (CF),"SION-719, Placebo-to-match SION-719",PreciSION CF,RANDOMIZED,2,Crossover Treatment Sequence 1: SION-719 followed by placebo-to-match SION-719 | Crossover Treatment Sequence 2: Placebo-to-match SION-719 followed by SION-719,EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.",,2026-07,ESTIMATED,18 Years - 65 Years,16,ESTIMATED,CROSSOVER,INDUSTRY,QUADRUPLE,"A Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed Trikafta® in People With Cystic Fibrosis Who Are Homozygous for the F508del Mutation",2026-07,ESTIMATED,To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] when SION-719 is administered to people with cystic fibrosis (CF) who are taking a standard stable dose of physician-prescribed Trikafta,TREATMENT,ALL,2025-11-03,ACTUAL,INTERVENTIONAL
SION,"Sionna Therapeutics, Inc.",NCT07035990,PHASE1,RECRUITING,Cystic Fibrosis (CF),"SION-451, SION-2222, SION-109, Placebo SION-451, Placebo SION-2222, Placebo SION-109",,RANDOMIZED,4,SION-451 + SION-2222 | Placebo matched to SION-451 and SION-2222 | SION 451 + SION 109 | Placebo matched to SION-451 and SION-109,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of Parts D and E of this Phase 1 study are to evaluate the safety, tolerability, and pharmacokinetics of multiple dose combinations of SION-451 and complementary modulators SION-2222 and SION-109 in healthy participants.",,2026-06,ESTIMATED,18 Years - 55 Years,144,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of SION-451, and Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.",2026-06,ESTIMATED,To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-109 when administered in combination to healthy participants | To evaluate the incidence of treatment emergent adverse events [Safety and Tolerability] of SION-451 and SION-2222 when administered in combination to healthy participants,TREATMENT,ALL,2025-07-23,ACTUAL,INTERVENTIONAL
ACAD,ACADIA Pharmaceuticals Inc.,NCT06159673,"PHASE2, PHASE3",RECRUITING,Alzheimer's Disease Psychosis,"ACP-204, Placebo",,RANDOMIZED,3,ACP-204 30 mg | ACP-204 60 mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP

* Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first.
* Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B wi",,2028-02,ESTIMATED,55 Years - 95 Years,1074,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis",2028-01,ESTIMATED,"Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D) total score change from baseline (Substudies 1, 2A, 2B)",TREATMENT,ALL,2023-11-14,ACTUAL,INTERVENTIONAL
ACAD,ACADIA Pharmaceuticals Inc.,NCT06173531,PHASE3,ACTIVE_NOT_RECRUITING,Hyperphagia in Prader-Willi Syndrome,"Carbetocin, Placebo",,RANDOMIZED,2,Carbetocin | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)",,2025-11,ESTIMATED,5 Years - 30 Years,170,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome",2025-10,ESTIMATED,Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score,TREATMENT,ALL,2023-11-27,ACTUAL,INTERVENTIONAL
ACAD,ACADIA Pharmaceuticals Inc.,NCT05357612,PHASE4,RECRUITING,"Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis",Pimavanserin,,,1,Pimavanserin,EXPERIMENTAL,It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.,ACADIA Pharmaceuticals Inc.,2026-08,ESTIMATED,50 Years - 85 Years,75,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases,2026-06,ESTIMATED,Change in 5HT2A receptor density measured using the PET radioligand MH.MZ | Change in 5HT2A receptor binding occupancy measured using the PET radioligand MH.MZ,BASIC_SCIENCE,ALL,2023-01-23,ACTUAL,INTERVENTIONAL
ACAD,ACADIA Pharmaceuticals Inc.,NCT05999240,PHASE2,RECRUITING,Autism Spectrum Disorder,"Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Placebo",,RANDOMIZED,2,Pimavanserin tartrate | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 2 study examines the safety, tolerability, and preliminary efficacy of pimavanserin in individuals with Autism Spectrum Disorder. Male or female participants aged 16 to 40 years of age will be randomized to receive single doses of either placebo or pimavanserin in this randomized, placebo-controlled, cross-over designed study, followed by open label extension.","ACADIA Pharmaceuticals Inc., University of Kansas Medical Center, Research Foundation for Mental Hygiene, Inc., Weill Medical College of Cornell University",2026-12-31,ESTIMATED,16 Years - 40 Years,30,ESTIMATED,CROSSOVER,OTHER,TRIPLE,A Target Engagement Study of Pimavanserin for Behavioral Inflexibility With Open Label Trial for Rigid Rigid-compulsive Behavior in Adolescents and Adults With Autism,2026-12-31,ESTIMATED,Evaluate the impact of a single dose of pimavanserin 34 mg versus placebo | Evaluate pimavanserin for treatment of restricted/repetitive behavior in ASD,TREATMENT,ALL,2025-10-01,ACTUAL,INTERVENTIONAL
ACAD,ACADIA Pharmaceuticals Inc.,NCT05895513,PHASE2,RECRUITING,Intermittent Explosive Disorder,"Pimavanserin 34 mg, Placebo",,RANDOMIZED,2,Pimavanserin | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The investigators are studying how certain drugs can reduce anger outbursts in people with anger problems. In this study the investigators seek to determine if a single 34 mg (two 17 mg tablets) oral dose of the 5-HT2a receptor blocker, pimavanserin, will reduce aggressive responding in individuals with impulsive aggression (Intermittent Explosive Disorder: IED) on a laboratory task that assesses aggression (Taylor Aggression Paradigm: TAP). We will also be examining how this drug impacts hostil",ACADIA Pharmaceuticals Inc.,2028-01,ESTIMATED,21 Years - 55 Years,35,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Effect of Pimavanserin on Aggression and Social Cognition.,2027-01,ESTIMATED,Aggressive Responding on the Taylor Aggression Paradigm (TAP),BASIC_SCIENCE,ALL,2024-08-01,ACTUAL,INTERVENTIONAL
ACAD,ACADIA Pharmaceuticals Inc.,NCT07029581,PHASE2,RECRUITING,Lewy Body Dementia Psychosis,"ACP-204, Placebo",,RANDOMIZED,3,ACP-204 30 mg | ACP-204 60 mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.",,2028-03,ESTIMATED,55 Years - 84 Years,180,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)",2028-02,ESTIMATED,Change from Baseline in SAPS-LBDP total score at Week 6,TREATMENT,ALL,2025-08-06,ACTUAL,INTERVENTIONAL
ACAD,ACADIA Pharmaceuticals Inc.,NCT07284667,PHASE2,RECRUITING,"Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant","ACP-211, Placebo",NORLIGHT,RANDOMIZED,3,ACP-211 600 mg | ACP-211 300 mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).

The main questions the study aims to answer are:

* Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression?
* What adverse events do participants have when taking ACP-211?",,2027-09,ESTIMATED,18 Years - 65 Years,153,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment",2027-08,ESTIMATED,Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 28,TREATMENT,ALL,2025-11-14,ACTUAL,INTERVENTIONAL
PHVS,Pharvaris N.V.,NCT06679881,PHASE3,RECRUITING,Hereditary Angioedema (HAE),Deucrictibant,CHAPTER-4,,1,Deucrictibant,EXPERIMENTAL,"This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema",,2028-12,ESTIMATED,12 Years - N/A,130,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema",2028-12,ESTIMATED,"Treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs), adverse events of special interest (AESIs), and TEAEs leading to study drug discontinuation | Change in heart rate | Change in blood pressure | Change in body temperature | Change in clinical laboratory tests from baseline | Change in electrocardiograms (ECGs) from baseline",TREATMENT,ALL,2025-02-01,ACTUAL,INTERVENTIONAL
PHVS,Pharvaris N.V.,NCT05834777,PHASE3,RECRUITING,Intradialytic Hypotension,"Icatibant, Placebo",,RANDOMIZED,2,Icatibant | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Currently, there is no medication available to adequately treat patients undergoing hemodialysis who are suffering from intradialytic hypotension (IDH). Medical interventions such as Trendelenburg positioning, saline bolus administration, reduction of ultrafiltration rate, interruption of the hemodialysis, and other medical treatments are the methods of choice to treat the hypotensive condition of these patients and thus to maintain the systolic blood pressure. Patients suffering from IDH have a","Pharvaris Netherlands B.V., Renal Research Institute",2026-04-01,ESTIMATED,18 Years - 80 Years,26,ESTIMATED,CROSSOVER,OTHER,QUADRUPLE,"Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor A Randomized, Double-blind, Placebo-controlled, Cross Over Explorative Study",2026-02-01,ESTIMATED,Blood pressure during hemodialysis,HEALTH_SERVICES_RESEARCH,ALL,2023-12-11,ACTUAL,INTERVENTIONAL
PHVS,Pharvaris N.V.,NCT06669754,PHASE3,ACTIVE_NOT_RECRUITING,Hereditary Angioedema (HAE),"Deucrictibant, Placebo",CHAPTER-3,RANDOMIZED,2,Active | Placebo,EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.",,2026-08,ESTIMATED,12 Years - N/A,81,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema",2026-08,ESTIMATED,Time-normalized (per 4 weeks) number of Investigator-confirmed HAE attacks during the 24-week Treatment Period,TREATMENT,ALL,2024-12-01,ACTUAL,INTERVENTIONAL
PHVS,Pharvaris N.V.,NCT07266805,PHASE3,RECRUITING,Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH),"Deucrictibant, Placebo, Deucrictibant, Placebo, Deucrictibant",CREAATE,RANDOMIZED,5,Part 1 - Arm 1 - Active | Part 1 - Arm 2 - Placebo | Part 2 - Arm 1 | Part 2 - Arm 2 | Part 3 - Open-label,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.",,2027-06,ESTIMATED,18 Years - N/A,32,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release (XR) Tablet for Prophylaxis and Deucrictibant Immediate-release (IR) Capsule for On-demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency",2027-06,ESTIMATED,"Part 1 (Prophylaxis, Double-blind Treatment Phase) | Part 2 (On-demand, Double-blind Treatment Phase) | Part 3 (On-demand, Open-label Extension Treatment Phase)",TREATMENT,ALL,2025-10-16,ACTUAL,INTERVENTIONAL
NAMS,NewAmsterdam Pharma Company N.V.,NCT07219602,PHASE3,NOT_YET_RECRUITING,"Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)","obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg",RUBENS,RANDOMIZED,4,Obicetrapib/Ezetimibe | Obicetrapib | Placebo | Open-Label Extension,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.",,2028-06,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (RUBENS Trial)",2028-03,ESTIMATED,The percent change from Baseline to Day 84 in LDL-C compared with placebo for the following treatment groups: - obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group; and - obicetrapib 10 mg monotherapy treatment group,PREVENTION,ALL,2025-12,ESTIMATED,INTERVENTIONAL
NAMS,NewAmsterdam Pharma Company N.V.,NCT05972278,PHASE1,ACTIVE_NOT_RECRUITING,Lipid Metabolism,Obicetrapib,,RANDOMIZED,2,Obicetrapib placebo | Obicetrapib 10 mg,PLACEBO_COMPARATOR | EXPERIMENTAL,To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).,University of Pennsylvania,2024-10-14,ESTIMATED,18 Years - 75 Years,22,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Placebo-Controlled, Phase 1 Study to Investigate the Effect of Obicetrapib on Lipoprotein Metabolism.",2024-09-26,ESTIMATED,Treatment with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).,TREATMENT,ALL,2023-12-01,ACTUAL,INTERVENTIONAL
NAMS,NewAmsterdam Pharma Company N.V.,NCT06305559,PHASE3,RECRUITING,"Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic",obicetrapib 10 mg + ezetimibe 10 mg FDC daily,REMBRANDT,RANDOMIZED,2,Obicetrapib/Ezetimibe | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).",,2027-03,ESTIMATED,45 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial)",2026-12,ESTIMATED,• To evaluate the effect of obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) daily on total non-calcified coronary atherosclerotic plaque volume (NCPV) at 18 months.,PREVENTION,ALL,2024-05-16,ACTUAL,INTERVENTIONAL
NAMS,NewAmsterdam Pharma Company N.V.,NCT05202509,PHASE3,ACTIVE_NOT_RECRUITING,Atherosclerotic Cardiovascular Disease,"Obicetrapib, Placebo",PREVAIL,RANDOMIZED,2,obicetrapib 10mg | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.",Monash University,2026-11,ESTIMATED,18 Years - N/A,9541,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Placebo Controlled, Double Blind, Randomized Cardiovascular Outcome Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With ASCVD Not Adequately Controlled Despite Maximally Tolerated Lipid Modifying Therapies",2026-11,ESTIMATED,Major Adverse Cardiovascular Effect (MACE),TREATMENT,ALL,2022-02-07,ACTUAL,INTERVENTIONAL
NAMS,NewAmsterdam Pharma Company N.V.,NCT06982508,PHASE2,RECRUITING,Antioxidant Absorption,"Obicetrapib 10mg, Placebo",VERMEER,RANDOMIZED,2,Obicetrapib 10mg | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to learn if Obicetrapib works to change antioxidant levels in HDL and plasma, as well as retinal tissue. The main questions it aims to answer are:

Do Obicetrapib effect absorption of antioxidants in a person's blood or their eye tissue? Researchers will compare Obicetrapib to a placebo (a look-alike substance that contains no drug) to see if Obicetrapib helps improve a person's ability to absorb antioxidants.

Participants will:

Take Obicetrapib or a placebo ",MB Clinical Research and Consulting LLC,2026-12,ESTIMATED,18 Years - 75 Years,100,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study",2026-09,ESTIMATED,Sum of Percent Change of Antioxidant Levels within HDL,BASIC_SCIENCE,ALL,2025-09-09,ACTUAL,INTERVENTIONAL
NAMS,NewAmsterdam Pharma Company N.V.,NCT06496243,PHASE2,RECRUITING,Dyslipidemias,obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks,VINCENT,,1,obicetrapib/evolocumab combination,EXPERIMENTAL,"The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab

Patients will:

Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16",,2026-02,ESTIMATED,18 Years - 75 Years,69,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study,2025-11,ESTIMATED,To evaluate the effect of evolocumab in combination with obicetrapib on lipoprotein (a) (Lp[a]).,TREATMENT,ALL,2024-12-02,ACTUAL,INTERVENTIONAL
AXSM,"Axsome Therapeutics, Inc.",NCT06223880,PHASE4,RECRUITING,Major Depressive Disorder,"AXS-05, Bupropion",,RANDOMIZED,2,AXS-05 | Bupropion,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.",,2026-03,ESTIMATED,18 Years - 65 Years,350,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms",2026-03,ESTIMATED,Time from randomization to relapse of depressive symptoms,TREATMENT,ALL,2023-12-27,ACTUAL,INTERVENTIONAL
AXSM,"Axsome Therapeutics, Inc.",NCT06170970,PHASE2,RECRUITING,"Multiple Sclerosis, Multiple Sclerosis Fatigue","Solriamfetol, Placebo",SOLARIMS,RANDOMIZED,2,solriamfetol then placebo first | placebo then solriamfetol first,EXPERIMENTAL | EXPERIMENTAL,"Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for MS patients with concomitant excessive daytime sleepiness. This study uses a randomized, double-blind, placebo-controlled crossover design. Participants will undergo a 10-day lead-in with he medicati","National Multiple Sclerosis Society, Axsome Therapeutics, Inc.",2027-03-01,ESTIMATED,18 Years - 60 Years,46,ESTIMATED,CROSSOVER,OTHER,TRIPLE,Solriamfetol for the Treatment of Fatigue in Patients With Multiple Sclerosis and Excessive Daytime Sleepiness,2026-12-01,ESTIMATED,Modified Fatigue Impact Scale (MFIS) Score,TREATMENT,ALL,2024-06-01,ACTUAL,INTERVENTIONAL
AXSM,"Axsome Therapeutics, Inc.",NCT06413433,PHASE3,RECRUITING,Binge-Eating Disorder,"Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo",ENGAGE,RANDOMIZED,3,Solriamfetol 150 mg | Solriamfetol 300 mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.",,2025-12,ESTIMATED,18 Years - 55 Years,450,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)",2025-12,ESTIMATED,Change from Baseline to Week 12 in number of binge eating episodes,TREATMENT,ALL,2024-04-26,ACTUAL,INTERVENTIONAL
AXSM,"Axsome Therapeutics, Inc.",NCT07398417,PHASE3,RECRUITING,Fibromyalgia,"AXS-14 (Esreboxetine), Placebo",FORWARD,RANDOMIZED,2,AXS-14 (esreboxetine) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.",,2028-03,ESTIMATED,18 Years - N/A,620,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia",2028-03,ESTIMATED,Time from randomization to loss of therapeutic response,TREATMENT,ALL,2026-01-14,ACTUAL,INTERVENTIONAL
AXSM,"Axsome Therapeutics, Inc.",NCT05838430,PHASE4,ACTIVE_NOT_RECRUITING,Insomnia,Solriamfetol 75 MG,,RANDOMIZED,4,Solriamfetol+ CBT-I | Solriamfetol Only | Placebo + CBT-I | Placebo Only,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Medication is FDA approved. The objective of this project is to test the efficacy of solriamfetol for treating insomnia (alone and in combination with Cognitive Behavioral Therapy for Insomnia \[CBT-I\]). Ultimately, this study will test whether wake extension (regardless of how it is achieved) will consolidate sleep and improve sleep continuity.","Axsome Therapeutics, Inc.",2026-04-30,ESTIMATED,25 Years - 60 Years,60,ESTIMATED,FACTORIAL,OTHER,QUADRUPLE,"The Effects of Solriamfetol and CBT-I (Alone and in Combination) on Sleep Continuity, Sleepiness, Fatigue, and Performance in Patients With Insomnia Disorder",2026-01-31,ESTIMATED,Sleep Continuity,TREATMENT,ALL,2023-07-31,ACTUAL,INTERVENTIONAL
AXSM,"Axsome Therapeutics, Inc.",NCT06413420,,RECRUITING,"Narcolepsy, Obstructive Sleep Apnea, Pregnant Women and Their Offspring","Sunosi (solriamfetol), Other prescription wake-promoting medications or stimulants",,,5,Cohort 1: Solriamfetol-exposed participants with narcolepsy or OSA | Cohort 2: Unexposed participants with narcolepsy or OSA | Cohort 3: Other-exposed participants with narcolepsy or OSA | Cohort 4: Solriamfetol-exposed participants without narcolepsy or OSA | Cohort 5: Other-exposed participants without narcolepsy or OSA, |  |  |  | ,"The SUNOSI (solriamfetol) Pregnancy Registry is a prospective, multi-country, observational study to evaluate the safety of solriamfetol exposure during pregnancy in women with a diagnosis of narcolepsy or obstructive sleep apnea (OSA).",,2029-09,ESTIMATED,N/A - N/A,1731,ESTIMATED,,INDUSTRY,,SUNOSI® (Solriamfetol) Pregnancy Registry: An Observational Study on the Safety of Solriamfetol Exposure in Pregnant Women and Their Offspring,2029-09,ESTIMATED,Long-term Safety,,FEMALE,2019-07-31,ACTUAL,OBSERVATIONAL
AXSM,"Axsome Therapeutics, Inc.",NCT06568367,PHASE3,RECRUITING,"Excessive Sleepiness, Shift-work Disorder","Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo",,RANDOMIZED,3,Solriamfetol 150mg | Solriamfetol 300mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).",,2026-12,ESTIMATED,18 Years - 65 Years,520,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder",2026-12,ESTIMATED,Change from Baseline to Week 12 in the mean sleep latency time as measured by the Maintenance of Wakefulness Test (MWT). | Change from Baseline to Week 12 in the Clinical Global Impressions of Severity of Illness (CGI-S) for sleepiness during the night shift.,TREATMENT,ALL,2024-08-01,ACTUAL,INTERVENTIONAL
ZBIO,"Zenas BioPharma, Inc.",NCT07067463,PHASE3,RECRUITING,Multiple Sclerosis (MS) Primary Progressive,"Orelabrutinib, Placebo",,RANDOMIZED,2,Orelabrutinib Group | Placebo Group,EXPERIMENTAL | PLACEBO_COMPARATOR,"Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS. Patients will be treated for approximately 30 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 705 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.",,2030-07,ESTIMATED,18 Years - 60 Years,705,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis",2030-06,ESTIMATED,"Time to onset of composite confirmed disability progression (cCDP) , confirmed over at least 12 weeks (12-week cCDP)",TREATMENT,ALL,2025-12,ESTIMATED,INTERVENTIONAL
ZBIO,"Zenas BioPharma, Inc.",NCT06564311,PHASE2,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis,"Obexelimab, Placebo",,RANDOMIZED,2,Obexelimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis,,2026-02,ESTIMATED,18 Years - 60 Years,93,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Relapsing Multiple Sclerosis",2025-08-28,ACTUAL,Cumulative number of new GdE T1 hyperintense lesions,TREATMENT,ALL,2024-08-26,ACTUAL,INTERVENTIONAL
ZBIO,"Zenas BioPharma, Inc.",NCT07299019,PHASE3,NOT_YET_RECRUITING,Secondary Progressive Multiple Sclerosis,"Orelabrutinib, Placebo",,RANDOMIZED,2,Orelabrutinib Group | Placebo Group,EXPERIMENTAL | PLACEBO_COMPARATOR,"Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.",,2030-07,ESTIMATED,18 Years - 60 Years,990,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-active Secondary Progressive Multiple Sclerosis",2030-06,ESTIMATED,"Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks",TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
ZBIO,"Zenas BioPharma, Inc.",NCT05786573,PHASE3,ACTIVE_NOT_RECRUITING,Warm Autoimmune Hemolytic Anemia,"Obexelimab, Obexelimab",,RANDOMIZED,3,Safety and Dose Confirmation Run-in Period (SRP): Obexelimab | Randomized Control Period (RCP): Obexelimab | Randomized Control Period (RCP): Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).,,2026-08-31,ESTIMATED,18 Years - N/A,134,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety and Dose Confirmation Run-In Period, To Evaluate the Efficacy and Safety of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)",2026-06-30,ESTIMATED,Safety and Dose Confirmation Run-in Period (SRP) | Randomized Control Period (RCP),TREATMENT,ALL,2023-09-25,ACTUAL,INTERVENTIONAL
ZBIO,"Zenas BioPharma, Inc.",NCT06559163,PHASE2,RECRUITING,Systemic Lupus Erythematosus,"Obexelimab, Placebo",SunStone,RANDOMIZED,2,Obexelimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).,,2026-09,ESTIMATED,18 Years - 70 Years,190,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Systemic Lupus Erythematosus",2026-06,ESTIMATED,Primary Outcome Measure,TREATMENT,ALL,2024-09-17,ACTUAL,INTERVENTIONAL
ZBIO,"Zenas BioPharma, Inc.",NCT05638854,PHASE1,RECRUITING,"Healthy Volunteers, Rheumatoid Arthritis","ZB002, Placebo, ZB002, Placebo",,RANDOMIZED,2,Part A: SAD in Healthy Volunteers | Part B: MAD in RA Participants,EXPERIMENTAL | EXPERIMENTAL,"This double-blind, randomized, placebo-controlled study will assess the safety and pharmacokinetics of ZB002 in healthy participants and in participants with rheumatoid arthritis (RA). The study consists of 2 parts. Part A: Single Ascending Dose (SAD), which will include only healthy volunteers. Part B: Multiple Ascending Dose (MAD), will commence after completion of the SAD study and will include RA participants.",,2025-07,ESTIMATED,18 Years - 70 Years,72,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1, 2-Part, Single Ascending Dose (SAD) Study to Evaluate the Safety and Pharmacokinetics (PK) of ZB002 in Healthy Volunteers (HVs) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety and PK of ZB002 in Participants With Rheumatoid Arthritis (RA)",2025-07,ESTIMATED,Part A: Safety and Tolerability in HVs | Part B: Safety and Tolerability of multiple doses of ZB002 in participants with RA,TREATMENT,ALL,2022-12-08,ACTUAL,INTERVENTIONAL
ZBIO,"Zenas BioPharma, Inc.",NCT05662241,PHASE3,ACTIVE_NOT_RECRUITING,IgG4 Related Disease,Obexelimab,INDIGO,RANDOMIZED,2,ZB012 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD),Bristol-Myers Squibb,2029-02-15,ESTIMATED,18 Years - N/A,194,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO)",2025-11-13,ACTUAL,Primary outcome measure,TREATMENT,ALL,2023-01-09,ACTUAL,INTERVENTIONAL
XENE,Xenon Pharmaceuticals Inc.,NCT07172516,PHASE3,RECRUITING,"Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder","Azetukalner, Placebo",X-CEED,RANDOMIZED,2,Azetukalner | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).",,2028-08,ESTIMATED,18 Years - 74 Years,400,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)",2028-06,ESTIMATED,Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6.,TREATMENT,ALL,2025-08-08,ACTUAL,INTERVENTIONAL
XENE,Xenon Pharmaceuticals Inc.,NCT07076407,PHASE3,RECRUITING,Major Depressive Disorder,"Azetukalner, Placebo",X-NOVA3,RANDOMIZED,2,Azetukalner | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)",,2027-07,ESTIMATED,18 Years - 74 Years,450,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder",2027-05,ESTIMATED,"Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6",TREATMENT,ALL,2025-07-08,ACTUAL,INTERVENTIONAL
XENE,Xenon Pharmaceuticals Inc.,NCT05716100,PHASE3,RECRUITING,Focal Onset Seizures,"XEN1101, Placebo",,RANDOMIZED,3,XEN1101 25 mg/day | XEN1101 15 mg/day | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.",Worldwide Clinical Trials,2026-12,ESTIMATED,18 Years - N/A,360,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures",2026-10,ESTIMATED,Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo.,TREATMENT,ALL,2023-05-09,ACTUAL,INTERVENTIONAL
XENE,Xenon Pharmaceuticals Inc.,NCT05667142,PHASE3,RECRUITING,Primary Generalized Tonic-Clonic Seizures,"XEN1101, Placebo",X-ACKT,RANDOMIZED,3,XEN1101 25 mg/day | XEN1101 15 mg/day | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).",Worldwide Clinical Trials,2027-06,ESTIMATED,12 Years - N/A,160,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures",2027-04,ESTIMATED,Median percent change (MPC) in monthly (28 days) PGTCS frequency,TREATMENT,ALL,2023-02-14,ACTUAL,INTERVENTIONAL
XENE,Xenon Pharmaceuticals Inc.,NCT05614063,PHASE3,ACTIVE_NOT_RECRUITING,Focal Onset Seizures,"XEN1101, Placebo",X-TOLE2,RANDOMIZED,3,XEN1101 25 mg/day | XEN1101 15 mg/day | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.",Worldwide Clinical Trials,2026-02,ESTIMATED,18 Years - N/A,360,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures",2025-12,ESTIMATED,Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo.,TREATMENT,ALL,2022-11-18,ACTUAL,INTERVENTIONAL
XENE,Xenon Pharmaceuticals Inc.,NCT03796962,PHASE2,ACTIVE_NOT_RECRUITING,Focal Epilepsy,XEN1101,X-TOLE,RANDOMIZED,4,25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).",Novotech Health Holdings Pte. Ltd.,2028-10,ESTIMATED,18 Years - 75 Years,325,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, With an Open-label Extension",2021-09-02,ACTUAL,Median Percent Change in Focal Seizure Frequency,TREATMENT,ALL,2019-01-30,ACTUAL,INTERVENTIONAL
XENE,Xenon Pharmaceuticals Inc.,NCT06775379,PHASE3,RECRUITING,Major Depressive Disorder,"Azetukalner, Placebo",X-NOVA2,RANDOMIZED,2,Azetukalner | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)",,2026-10,ESTIMATED,18 Years - 74 Years,450,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder",2026-08,ESTIMATED,"Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6",TREATMENT,ALL,2024-12-20,ACTUAL,INTERVENTIONAL
TRDA,"Entrada Therapeutics, Inc.",NCT07038824,"PHASE1, PHASE2",RECRUITING,Duchenne Muscular Dystrophy (DMD),"ENTR-601-45, ENTR-601-45 - matching placebo",ELEVATE-45,RANDOMIZED,2,ENTR-601-45 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a study of the investigational medicine ENTR-601-45 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition. The researchers want to: Test how safe ENTR-601-45 is, learn about any side effects, and look at the potential positive effects of ENTR-601-45, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-45 and placebo are both called study treatments.

The study has 2 parts:",,2029-03-01,ESTIMATED,4 Years - 20 Years,24,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)",2029-03-01,ESTIMATED,Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period).,TREATMENT,MALE,2025-08-30,ACTUAL,INTERVENTIONAL
TRDA,"Entrada Therapeutics, Inc.",NCT07037862,"PHASE1, PHASE2",RECRUITING,Duchenne Muscular Dystrophy (DMD),"ENTR-601-44, ENTR-601-44 - matching placebo",ELEVATE-44,RANDOMIZED,2,ENTR-601-44 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a study of the investigational medicine ENTR-601-44 in participants who have Duchenne muscular dystrophy (DMD), a rare genetic condition.

The researchers want to: Test how safe ENTR-601-44 is, learn about any side effects, and look at the potential positive effects of ENTR-601-44, compared to placebo. Placebo looks like the investigational medicine but does not contain any active ingredient. In this summary ENTR-601-44 and placebo are both called study treatments.

The study has 2 parts",,2029-03-28,ESTIMATED,4 Years - 20 Years,24,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping With an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-44, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-44 (ELEVATE-44)",2029-03-28,ESTIMATED,Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and Open Label (OL) Period),TREATMENT,MALE,2025-06-30,ACTUAL,INTERVENTIONAL
MNKD,MannKind Corporation,NCT07344558,PHASE1,RECRUITING,Idiopathic Pulmonary Fibrosis (IPF),"MNKD-201(Nintenadib DPI), Placebo",,RANDOMIZED,3,Cohort 1: MNKD-201 Target Dose or placebo | Cohort 2: MNKD-201 High Dose or placebo | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.",,2026-04-01,ESTIMATED,40 Years - 75 Years,24,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Clinical Study of the Safety, Tolerability, and Pharmacokinetics of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis",2026-04-01,ESTIMATED,(Cohort 1) Events of Bronchospasm | (Cohort 2) Events of Bronchospasm | (Cohort 1) Changes in FEV1 (mL) from pre-dose to post-dose | (Cohort 2) Changes in FEV1 (mL) from pre-dose to post-dose | (Cohort 1) Changes in FEV1 / FVC ratio from pre-dose to post-dose | (Cohort 2) Changes in FEV1 / FVC ratio from pre-dose to post-dose | (Cohort 1) Rate of Study Drug Discontinuations | (Cohort 2) Rate of Study Drug Discontinuations | (Cohort 1) Rate of Study Drug Dose Reductions | (Cohort 2) Rate of Study Drug Dose Reductions | (Cohort 1) Rate of Treatment Emergent Adverse Events (TEAEs) | (Cohort 2) Rate of Treatment Emergent Adverse Events (TEAEs) | (Cohort 1) Rate of Treatment Related Adverse Events (TRAEs) | (Cohort 2) Rate of Treatment Related Adverse Events (TRAEs) | (Cohort 1) Rate of Serious Adverse Events (SAEs) | (Cohort 2) Rate of Serious Adverse Events (SAEs),TREATMENT,ALL,2025-12-22,ACTUAL,INTERVENTIONAL
MNKD,MannKind Corporation,NCT06532942,PHASE1,RECRUITING,Healthy Volunteers,"(Part A) MKND-201, Placebo, (Part B) MKND-201",,RANDOMIZED,3,(Part A) MKND-201 SAD | (Part B) MKND-201 MAD | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"MKC-NI-001 is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in healthy adult volunteers. The trial consists of a Single Ascending Dose (SAD), followed by a Multiple Ascending Dose (MAD) with a primary objective to evaluate the safety, tolerability, and pharmacokinetics (PK) of MNKD-201 compared to placebo in healthy adult participants.",,2024-10-31,ESTIMATED,40 Years - 65 Years,40,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Nintedanib Inhalation Powder (MNKD-201) in Healthy Volunteers",2024-10-31,ESTIMATED,"(Part A) Incidence of inhaled intolerability | (Part B) Incidence of inhaled intolerability | (Part A) Incidence of participants with reductions in FEV1 ≥ 15% from baseline at any time postdose | (Part B) Incidence of participants with reductions in FEV1 ≥ 15% from baseline at any time postdose | (Part A) Incidence of participants with reductions in FEV1 ≥ 15% following administration of a dose of study drug, compared to the corresponding predose measurement | (Part B) Incidence of participants with reductions in FEV1 ≥ 15% following administration of a dose of study drug, compared to the corresponding predose measurement | (Part A) Incidence of treatment-emergent adverse events (TEAEs) | (Part B) Incidence of treatment-emergent adverse events (TEAEs) | (Part A) Incidence of serious adverse events (SAEs) | (Part B) Incidence of serious adverse events (SAEs) | (Part A) Incidence of abnormal clinically significant vital signs | (Part B) Incidence of abnormal clinically significant vital signs | (Part A) Changes from baseline in liver enzymes and bilirubin | (Part B) Changes from baseline in liver enzymes and bilirubin | (Part A) Changes from baseline in coagulation parameters, INR and aPTT | (Part B) Changes from baseline in coagulation parameters, INR and aPTT",TREATMENT,ALL,2024-05-28,ACTUAL,INTERVENTIONAL
MNKD,MannKind Corporation,NCT06535789,"PHASE2, PHASE3",RECRUITING,"Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy",Inhaled Technosphere Insulin,INHALE-GDM,RANDOMIZED,2,technosphere insulin (TI) | Rapid-acting insulin analog,EXPERIMENTAL | NO_INTERVENTION,"Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin ",Mannkind Corporation,2025-07,ESTIMATED,18 Years - 40 Years,30,ESTIMATED,CROSSOVER,OTHER,NONE,The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes,2025-07,ESTIMATED,Post-prandial AUC120,TREATMENT,FEMALE,2025-05,ESTIMATED,INTERVENTIONAL
MNKD,MannKind Corporation,NCT07224321,PHASE2,RECRUITING,Type 1 Diabetes Mellitus,"Technosphere Insulin, Technosphere Insulin, Basal insulin",INHALE-1st,,1,Afrezza (Technosphere Insulin) + Basal Insulin,EXPERIMENTAL,"INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 10 to \<18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of an Afrezza plus BI reigmen on participant and parent/legally authorized representative satisfaction. Participants will be followed for 13 weeks during the main phase followed by an optional Extension",Jaeb Center for Health Research,2027-07,ESTIMATED,10 Years - 17 Years,100,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,INHALE-1st: Technosphere Insulin (Afrezza®) In Combination With Basal Insulin For Youth With Newly-Diagnosed Type 1 Diabetes,2026-11,ESTIMATED,Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70%,TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
MNKD,MannKind Corporation,NCT06880835,,RECRUITING,"Diabetes Mellitus, Type 1",,INHALE-AIDEx,RANDOMIZED,3,Control IQ + sleep activity with TI | Control IQ + sleep activity with Rapid-Acting Analogue (RAA) Comparator | Control IQ + exercise activity with Rapid-acting analogue (RAA) Control,EXPERIMENTAL | NO_INTERVENTION | NO_INTERVENTION,"This investigator-initiated study will enroll about 30 adults 18 to 65 years of age with type 1 diabetes (T1D) who are using the Tandem t:slim X2 insulin pump or Tandem Mobi insulin pump with Control-IQ or Control-IQ+ technology (""Control-IQ"" which will refer to either Control-IQ or Control-IQ+). The study is being done to find out if inhaled insulin given for a meal is safer and better to use than a bolus of insulin through your pump when you exercise following a meal. Participants are asked to","Mannkind Corporation, Tandem Diabetes Care, Inc., The Leona M. and Harry B. Helmsley Charitable Trust",2026-05-31,ESTIMATED,18 Years - 65 Years,30,ESTIMATED,CROSSOVER,OTHER,NONE,INHALE-AIDEx: A Randomized Crossover Trial Evaluating the Effect of Inhaled Technosphere Insulin (Afrezza®) vs Rapid Acting Analogue Insulin on Exercise-Induced Hypoglycemia in Adults With Type 1 Diabetes Using Automated Insulin Delivery,2026-05-31,ESTIMATED,Blood glucose <70 mg/dL,TREATMENT,ALL,2025-06-05,ACTUAL,INTERVENTIONAL
TARS,"Tarsus Pharmaceuticals, Inc.",NCT06054217,PHASE2,ACTIVE_NOT_RECRUITING,"Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis",Vehicle of TP-03,Rhea,RANDOMIZED,3,Study Cohort 1 | Study Cohort 2 | Study Cohort 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.",,2024-06-15,ESTIMATED,18 Years - N/A,36,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,Evaluating the Effect of Two Dosing Regimens of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex Lid Infestation,2024-06-15,ESTIMATED,Treatment Emergent Adverse Events (TEAEs),TREATMENT,ALL,2023-08-01,ACTUAL,INTERVENTIONAL
PROK,ProKidney Corp.,NCT05918523,,RECRUITING,"Diabetic Kidney Disease, Chronic Kidney Diseases",Renal Autologous Cell Therapy (REACT),,,1,CKD patients previously treated with REACT,,The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).,,2028-03,ESTIMATED,30 Years - 80 Years,80,ESTIMATED,,INDUSTRY,,"A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004",2028-01,ESTIMATED,Primary Endpoint: Long-term safety of REACT,,ALL,2023-12-11,ACTUAL,OBSERVATIONAL
PROK,ProKidney Corp.,NCT05099770,PHASE3,RECRUITING,"Type 2 Diabetes Mellitus, Chronic Kidney Diseases",Renal Autologous Cell Therapy (REACT),,RANDOMIZED,2,Sham Procedure | Experimental (REACT/rilparencel injections),SHAM_COMPARATOR | EXPERIMENTAL,The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT/rilparencel injections given 12 weeks (-14 days to +28 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.,,2027-02,ESTIMATED,30 Years - 80 Years,685,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease (REGEN-006),2027-02,ESTIMATED,Clinical Endpoint,TREATMENT,ALL,2022-01-05,ACTUAL,INTERVENTIONAL
DMAC,DiaMedica Therapeutics Inc.,NCT05065216,"PHASE2, PHASE3",RECRUITING,"Acute Stroke, Ischemic Stroke, Stroke",Recombinant human tissue kallikrein,ReMEDy2,RANDOMIZED,2,DM199 | Placebo for DM199 Solution for Injection,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unl",,2026-12,ESTIMATED,18 Years - 90 Years,728,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)",2026-12,ESTIMATED,Stroke Recovery,TREATMENT,ALL,2021-11-07,ACTUAL,INTERVENTIONAL
PRGO,Perrigo Company plc,NCT07391059,,NOT_YET_RECRUITING,Headlice,,,RANDOMIZED,3,"INVESTIGATIONAL DEVICE Paranix ® shampoo , 2 MINUTES | INVESTIGATIONAL DEVICE Paranix ® shampoo, 5 MINUTES | COMPARATOR DEVICE, Pouxit ® shampoo",EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice). The most common symptom of infestation is pruritus (itching) on the head which normally intensifies 3 to 4 weeks after the initial infestation.

The test item has been developed with the ambition to offer a complete head lice treatment, whilst also offering ultimate convenience in use - making treatment of head lice i",,2026-05,ESTIMATED,2 Years - N/A,180,ESTIMATED,PARALLEL,INDUSTRY,NONE,Randomized Medical Device Class IIa Clinical Investigation to Assess the Safety and Efficacy of a New Shampoo for Head Lice Treatment,2026-05,ESTIMATED,Cure Rate after complete treatment | Cure Rate after complete treatment,TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT07219121,PHASE4,RECRUITING,"Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant",Sparsentan,SPARX,,1,Drug: Sparsentan,EXPERIMENTAL,To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.,,2027-05,ESTIMATED,18 Years - N/A,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)",2027-03,ESTIMATED,Urinary protein/creatinine ratio (UPCR),TREATMENT,ALL,2025-10-07,ACTUAL,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT04663204,PHASE2,ACTIVE_NOT_RECRUITING,"Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis, Autoimmune Diseases, Immune System Diseases",Sparsentan,SPARTAN,,1,Sparsentan,EXPERIMENTAL,"To determine the nephroprotective potential of treatment with sparsentan in patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy.","Travere Therapeutics, Inc.",2025-03-31,ESTIMATED,18 Years - N/A,12,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"A Multi-centre, Open-label, Single-group Exploratory Trial of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy",2025-03-31,ESTIMATED,Urine protein/creatinine ratio (UP/C) at Week 36,TREATMENT,ALL,2020-12-10,ACTUAL,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT02998710,,RECRUITING,Homocystinuria Due to CBS Deficiency,,,,0,,,The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices,,2026-08,ESTIMATED,1 Year - 65 Years,150,ESTIMATED,,INDUSTRY,,"A Multicenter, Observational, Prospective, Natural History Study of Homocystinuria Due to Cystathionine Beta-synthase Deficiency in Pediatric and Adult Patients (ACAPPELLA)",2026-04,ESTIMATED,Changes in Met cycle metabolites levels - tHcy | Changes in Met cycle metabolites levels - total Cys | Changes in Met cycle metabolites levels - Met | Changes in Met cycle metabolites levels - Cth | Patient Reported Outcome (PRO): Quality of Life in Neurological Disorders [Neuro-QoL] | Patient Reported Outcome (PRO): Quality of Life by 36-Item Short Form Survey [SF-36] | National Institutes of Health (NIH) Toolbox Cognition Battery | EuroQol EQ-5D™ questionnaire to measure health and quality-of-life | Dual-Energy X-Ray Absorptiometry to measure bone mineral density | Eye assessments to evaluate ocular health: Visual acuity examination will be performed to determine the clarity or sharpness of vision | Eye assessments to evaluate ocular health: Slit lamp eye examination will be performed to look for any diseases or abnormalities in the anterior portion of the eye,,ALL,2017-01,ACTUAL,OBSERVATIONAL
TVTX,"Travere Therapeutics, Inc.",NCT03493685,PHASE3,ACTIVE_NOT_RECRUITING,Focal Segmental Glomerulosclerosis,"sparsentan, Irbesartan",DUPLEX,RANDOMIZED,2,sparsentan for double-blind and open-label extension | Irbesartan,EXPERIMENTAL | ACTIVE_COMPARATOR,To determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).,,2026-02,ESTIMATED,8 Years - 75 Years,371,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS",2023-03-20,ACTUAL,Slope of Estimated Glomerular Filtration Rate (eGFR) | Percentage of Participants Achieving FSGS Partial Remission Endpoint (FPRE),TREATMENT,ALL,2018-04-17,ACTUAL,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT06247085,PHASE3,ACTIVE_NOT_RECRUITING,Homocystinuria,Pegtibatinase,HARMONY,RANDOMIZED,2,pegtibatinase | placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to measure efficacy and safety of pegtibatinase treatment compared with placebo in participants with classical HCU receiving standard of care who have not achieved tHcy target levels. Study details include:

* Total Study duration: up to 38 weeks
* Screening:

  * Initial Screening duration: up to 4 weeks
  * Pre-treatment Diet Standardization Period duration: up to 6 weeks
* Blinded Treatment Duration: 24 weeks

  * 2-week blinded dose titration period
  * 22-week b",,2026-01,ESTIMATED,12 Years - 65 Years,70,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study To Assess The Efficacy And Safety Of Pegtibatinase Administered Subcutaneously In Addition To Standard Of Care In Participants With Classical Homocystinuria Due To Cystathionine Beta Synthase Deficiency (HARMONY)",2025-12,ESTIMATED,Change from baseline in plasma tHcy levels,TREATMENT,ALL,2023-12-28,ACTUAL,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT07224776,PHASE1,NOT_YET_RECRUITING,"Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range","sparsentan, No sparsentan",,NON_RANDOMIZED,2,"Treatment with sparsentan, an endothelin-1 antagonist | Historical controls with high-grade proteinuria not treated with sparsentan",ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors","Travere Therapeutics, Inc.",2028-12-01,ESTIMATED,18 Years - N/A,20,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria,2026-12-01,ESTIMATED,Change in urine to protein creatinine ratio (UPCR),TREATMENT,ALL,2025-12-01,ESTIMATED,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT05630612,PHASE2,ACTIVE_NOT_RECRUITING,"ANCA Associated Vasculitis, Cardiovascular Diseases, Kidney Diseases",Sparsentan,SPARVASC,RANDOMIZED,2,Sparsentan | Irbesartan,EXPERIMENTAL | ACTIVE_COMPARATOR,"ANCA-associated vasculitis is an autoimmune disease that causes damage to blood vessels. This leads to organ damage with the number of organs affected and the severity of damage varying significantly between patients.

Vasculitis patients also have a very high risk of heart attacks and strokes, called cardiovascular disease. A chemical called 'endothelin', produced by the blood vessels, causes vessels to stiffen and raises blood pressure and this associates with cardiovascular risk.

The investi","Travere Therapeutics, Inc.",2027-09-01,ESTIMATED,18 Years - N/A,32,ACTUAL,PARALLEL,OTHER,QUADRUPLE,Effects of Simultaneous ETA & AT1 Receptor Antagonism on Endothelial Function & Vascular Stiffness in ANCA-associated Vasculitis (SPARsentan in VASCulitis - SPARVASC),2024-07-18,ACTUAL,Forearm blood flow,TREATMENT,ALL,2022-12-08,ACTUAL,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT05003986,PHASE2,RECRUITING,"Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome","Sparsentan, Sparsentan, Sparsentan",EPPIK,NON_RANDOMIZED,3,"Population 1: FSGS and/or MCD | Population 2: IgAN, IgAV, or AS | Population 3: IgAN",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.",,2027-04-12,ESTIMATED,1 Year - 17 Years,67,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases",2027-03-12,ESTIMATED,"Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), AEs leading to treatment discontinuation, and adverse events of interest (AEOIs) | Urine protein/creatinine ratio (UP/C) at week 108",TREATMENT,ALL,2021-08-12,ACTUAL,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT03406611,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Homocystinuria,"Pegtibatinase, Placebo",,RANDOMIZED,2,Pegtibatinase | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Homocystinuria caused by Cystathionine Beta-Synthase (CBS) Deficiency is a rare autosomal-recessive metabolic condition characterized by an excess of homocysteine (Hcy) in the plasma, tissues and urine. It is due to reduced or absent activity of the CBS enzyme, and is also known as classical homocystinuria. The symptoms associated with homocystinuria are variable in severity and time of onset across patients. Some affected individuals may have mild signs of the disorder; others may have multi-sy",,2026-12,ESTIMATED,12 Years - 65 Years,32,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double Blind, Randomized, Placebo-controlled, Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058), Administered Subcutaneously in Patients with Cystathionine Beta-Synthase Deficient Homocystinuria (COMPOSE)",2026-06,ESTIMATED,Incidence of AEs | Anti-pegtibatinase antibodies | Anti-PEG antibodies,TREATMENT,ALL,2019-01-22,ACTUAL,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT03762850,PHASE3,ACTIVE_NOT_RECRUITING,Immunoglobulin A Nephropathy,"sparsentan, irbesartan, Dapagliflozin",PROTECT,RANDOMIZED,4,sparsentan | irbesartan | dapagliflozin + sparsentan (Sub study) | sparsentan (Sub Study),EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).,,2026-07,ESTIMATED,18 Years - N/A,406,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy",2023-08-07,ACTUAL,Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at Week 36,TREATMENT,ALL,2018-12-11,ACTUAL,INTERVENTIONAL
TVTX,"Travere Therapeutics, Inc.",NCT06548022,,ACTIVE_NOT_RECRUITING,"Anxiety, Depressive Symptoms, Post-traumatic Stress Disorder, Problems Psychosocial",,Group PM+,,1,Rare Group PM Plus,EXPERIMENTAL,"Participants are being asked to be in the study if they are the parent or legal guardian of a child (\>1 year or \<18 years old) with a rare condition.

The group based psychoeducational intervention is called Rare Group Problem Management Plus.

Rare Group PM Plus may help adults with practical and emotional problems. It is a group program (there will be other men or women with similar problems) It happens once a week for 5 weeks (each session lasts 90 minutes)

Participants will complete asses","Travere Therapeutics, Inc.",2025-11-30,ESTIMATED,18 Years - 99 Years,8,ACTUAL,SINGLE_GROUP,OTHER,NONE,Rare Group Problem Management Plus,2025-06-25,ACTUAL,Acceptability,TREATMENT,ALL,2024-02-05,ACTUAL,INTERVENTIONAL
BCRX,"BioCryst Pharmaceuticals, Inc.",NCT06539507,PHASE1,RECRUITING,Netherton Syndrome,"BCX17725, Placebo",,RANDOMIZED,6,Part 1 - BCX17725 single dose | Part 1 - placebo single dose | Part 2 - BCX17725 multiple doses | Part 2 - placebo multiple doses | Part 3 - BCX17725 multiple doses | Part 4 - BCX17725 multiple doses,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adoles",,2026-12,ESTIMATED,12 Years - 65 Years,78,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome",2026-10,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs) | Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12 (Part 4),TREATMENT,ALL,2024-09-26,ACTUAL,INTERVENTIONAL
BCRX,"BioCryst Pharmaceuticals, Inc.",NCT07228559,PHASE1,RECRUITING,Diabetic Macular Edema (DME),avoralstat,,,1,Single dose suprachoroidal injection of avoralstat,EXPERIMENTAL,The goal of this study is to assess the safety and therapeutic potential of a single dose of avoralstat in adult participants with DME.,,2026-09,ESTIMATED,18 Years - N/A,9,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1b Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Suprachoroidal Injection of Avoralstat In Participants With Diabetic Macular Edema",2026-05,ESTIMATED,The safety and tolerability of avoralstat in participants with DME. Incidence and severity of ocular (study eye) and systemic treatment emergent adverse events (TEAEs).,TREATMENT,ALL,2025-10-02,ACTUAL,INTERVENTIONAL
BCRX,"BioCryst Pharmaceuticals, Inc.",NCT05453968,PHASE3,ACTIVE_NOT_RECRUITING,"Hereditary Angioedema, Pediatric",Berotralstat,APeX-P,NON_RANDOMIZED,4,Cohort 1: ≥ 40 kg body weight (Berotralstat 150 mg) | Cohort 2: 32 to < 40 kg body weight (Berotralstat 108 mg) | Cohort 3: 24 to < 32 kg body weight (Berotralstat 96 mg) | Cohort 4: 12 to <24 kg body weight (Berotralstat 78 mg),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the pharmacokinetics (PK), safety and effectiveness of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to \< 12 years of age for prophylactic treatment to prevent attacks of hereditary angioedema (HAE).",,2027-02,ESTIMATED,2 Years - 11 Years,29,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3 Study to Evaluate the Safety and Pharmacokinetics of Berotralstat Prophylaxis in Children With Hereditary Angioedema Who Are 2 to < 12 Years of Age,2024-09-11,ACTUAL,Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of Berotralstat | Area Under the Plasma Concentration-Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6) of Berotralstat | Concentration at the End of the Dosing Interval (Ctrough) of Berotralstat | Maximum Observed Plasma Concentration (Cmax) of Berotralstat | Time of Last Measurable Plasma Concentration (Tlast) of Berotralstat | Time to Maximum Plasma Concentration (Tmax) of Berotralstat,PREVENTION,ALL,2022-10-25,ACTUAL,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT06220084,,ACTIVE_NOT_RECRUITING,Parkinson Disease,,UPGRADE-PD,RANDOMIZED,3,Live DfPD® | Remote DfPD® | Control,EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,"Dance for Parkinson's Disease® (DfPD®) is a specially designed dance program for individuals with PD. This study assesses the efficacy, safety and feasibility of a culturally adapted DfPD® program offered both live and online in Greek PD patients.

A total of 40 early-to-mid-stage PD Greek patients have been enrolled to underwent a total of 16 60-min classes twice weekly over 8 weeks both live and online as well as to be part of the non-intervention control group in a 3-arms crossover randomized",World in Harmony/Mundo en Armonia,2024-07-31,ESTIMATED,18 Years - N/A,40,ACTUAL,CROSSOVER,OTHER,NONE,Therapeutic Dance in Parkinson's Disease: The UPbeating GReek Application of DancE in Parkinson's Disease (UPGRADE-PD) Clinical Trial,2024-07-11,ESTIMATED,Change in total score of Parkinson's Disease Questionnaire-8 (PDQ-8),TREATMENT,ALL,2023-05-02,ACTUAL,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT05066217,PHASE3,RECRUITING,Lennox Gastaut Syndrome,"Clemizole HCl, Placebo",,RANDOMIZED,3,Placebo | Double-blind clemizole HCl | Open-label clemizole HCl,PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole HCL (EPX-100) as adjunctive therapy in children and adult participants with Lennox-Gastaut syndrome (LGS).","Harmony Biosciences Management, Inc.",2029-11-01,ESTIMATED,2 Years - 55 Years,260,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients With Lennox-Gastaut Syndrome",2026-11-01,ESTIMATED,Percent Change in CMMS-28,TREATMENT,ALL,2025-04-09,ACTUAL,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT07047378,,RECRUITING,"Child Abuse, Parental Burnout",,,RANDOMIZED,2,ACT Intervention Group | Control Group,EXPERIMENTAL | OTHER,"The purpose of the proposed randomized controlled trial is to evaluate the feasibility, acceptability, and potential effectiveness of Acceptance and Commitment Therapy (ACT) in reducing parental burnout and improving children's emotional and behavioral adjustment in families in Hong Kong over 3 months after the intervention. The findings will provide valuable and scientific insights to inform better parenting interventions and child protection policies.","Harmony House, Hong Kong Jockey Club",2028-04-30,ESTIMATED,3 Years - 65 Years,120,ESTIMATED,PARALLEL,OTHER,SINGLE,Acceptance and Commitment Therapy-Based Training Programme for Reducing Parental Burnout and Improving Emotional and Behavioural Issues in Children: A Pilot Randomised Controlled Trial,2027-04-30,ESTIMATED,Parental Burnout | Children's emotional and behavioral adjustment,TREATMENT,ALL,2025-04-22,ACTUAL,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT06880237,,NOT_YET_RECRUITING,"Dementia, Nursing Homes Residents",,SOL,RANDOMIZED,2,Singing group | Waitlist Control group,EXPERIMENTAL | NO_INTERVENTION,"We intend to investigate whether a singing programme for nursing home residents living with dementia can reduce the mental and physiological effects of dementia. The main questions it aims to answer are:

1. Does participating in the Sing Out Loud (SOL) singing intervention lead to an improvement in the physiological well-being (increase in oxytocin and reduction in cortisol levels) of persons living with dementia (PWDs) in nursing homes?
2. Will participation in the SOL singing intervention res","Esplanade, APEX Harmony Lodge",2025-07,ESTIMATED,21 Years - 90 Years,56,ESTIMATED,PARALLEL,OTHER,NONE,Sing Out Loud: a Choral Singing Program for Persons Living with Dementia,2025-06,ESTIMATED,Changes from baseline in Oxytocin and Cortisol levels at 8 weeks | Change from baseline in the severity and distress of neuropsychiatric symptoms at 8 weeks,SUPPORTIVE_CARE,ALL,2025-03-12,ESTIMATED,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT04257929,PHASE2,ACTIVE_NOT_RECRUITING,Prader-Willi Syndrome,"Pitolisant oral tablets, Placebo oral tablet",,RANDOMIZED,4,Double-Blind Treatment Phase Lower Dose Pitolisant | Double-Blind Treatment Phase Higher Dose Pitolisant | Double-Blind Treatment Phase Placebo | Open-Label Pitolisant,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | OTHER,The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Prader Willi syndrome (PWS) ages 6 to 65 years.,,2028-09-07,ESTIMATED,6 Years - 65 Years,65,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension",2022-08-17,ACTUAL,Excessive Daytime Sleepiness,TREATMENT,ALL,2020-12-09,ACTUAL,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT06366464,PHASE3,RECRUITING,Prader-Willi Syndrome,Pitolisant tablet,,RANDOMIZED,3,Double-Blind Treatment Period Pitolisant | Double-Blind Treatment Period Placebo | Open-Label Extension Period Pitolisant,EXPERIMENTAL | PLACEBO_COMPARATOR | OTHER,"This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome.

The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome.

Secondary objectives include assessing the impact of pitolisant on:

Irritable and disruptive behaviors Hyperphagia Other ",,2027-07,ESTIMATED,6 Years - N/A,134,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Label Extension in Patients With Prader-Willi Syndrome",2026-07,ESTIMATED,Change in severity of EDS as measured by Patient-Reported Outcomes Measurement Information System Bank v1.0 - Sleep-Related Impairment (PROMIS-SRI) T-score,TREATMENT,ALL,2024-05-28,ACTUAL,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT05536011,,RECRUITING,"Pregnancy Related, Narcolepsy","Pitolisant, Comparator Products",,,5,Pitolisant-exposed participants with narcolepsy | Unexposed participants with narcolepsy | Comparator-exposed participants with narcolepsy | Pitolisant-exposed participants without narcolepsy | Comparator-exposed participants without narcolepsy, |  |  |  | ,"The WAKIX (pitolisant) Pregnancy Registry is a US-based, prospective, observational cohort study designed to evaluate the association between pitolisant exposure during pregnancy and subsequent maternal, fetal, and infant outcomes.",,2030-06-30,ESTIMATED,N/A - N/A,1329,ESTIMATED,,INDUSTRY,,WAKIX® (Pitolisant) Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring,2030-06-30,ESTIMATED,Major congenital malformation,,FEMALE,2021-08-24,ACTUAL,OBSERVATIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT06451978,,ACTIVE_NOT_RECRUITING,"Dementia, Mild Cognitive Impairment",,,RANDOMIZED,2,Intervention group | Waitlist-control group,EXPERIMENTAL | ACTIVE_COMPARATOR,"Background: Nature positively affects people living with dementia. However, there are a lack of nature-based interventions for people living with mild cognitive impairment or dementia who reside in the community.

Aim: This study is testing a caregiver-led nature-based intervention, which has been co-developed with people living with dementia, supporters/caregivers and professionals, and the study design and set-up will also be evaluated. The results will help provide evidence for whether or not",,2025-11,ESTIMATED,18 Years - N/A,48,ESTIMATED,PARALLEL,OTHER,SINGLE,"You, Me and Nature: A Randomised Pilot Study of a Manualised, Caregiver-led Nature-based Intervention to Improve the Wellbeing of People Living With Mild Cognitive Impairment or Dementia and Their Supporters or Caregivers",2025-10,ESTIMATED,Change in wellbeing of the person living with dementia or mild cognitive impairment and their caregiver,SUPPORTIVE_CARE,ALL,2025-01-29,ACTUAL,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT07109453,,NOT_YET_RECRUITING,"Normal, Sensitive Skin",,,,1,18 Test Products along with Positive and Negative Control,EXPERIMENTAL,To Check Dermatological Safety of Test Products by 24 Hours Patch Testing,Skin Harmony Lifescience Pvt. Ltd,2025-09,ESTIMATED,18 Years - 65 Years,26,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Dermatological Safety Assessment of Test Products Using Primary Irritation Patch Test (PIPT) in Healthy Adult Human Subjects,2025-09,ESTIMATED,To evaluate the dermatological safety of the test products by 24 Hours Patch,OTHER,ALL,2025-08-25,ESTIMATED,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT04462770,PHASE3,RECRUITING,Dravet Syndrome,"Clemizole HCl, Placebo",ARGUS,RANDOMIZED,3,Double-blind clemizole HCl | Placebo | Open-label clemizole HCl,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).","Harmony Biosciences Management, Inc.",2029-05-01,ESTIMATED,2 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)",2026-04-01,ESTIMATED,Percent Change in Countable Motor Seizures Per 28 Days (CMS-28) in the Titration Plus Maintenance Periods Relative to Baseline | European Union: Percent Change in Countable Motor Seizures Per 28 Days in the Maintenance Period Relative to Baseline,TREATMENT,ALL,2020-09-15,ACTUAL,INTERVENTIONAL
HRMY,"Harmony Biosciences Holdings, Inc.",NCT06014281,,ACTIVE_NOT_RECRUITING,"Healthy, Well-Being, Psychological",,,RANDOMIZED,2,Meditation group | Waitlist control,EXPERIMENTAL | EXPERIMENTAL,The study will examine the effects of online meditation training on stress and anxiety in healthy participants. It will also examine the dose-response relationship between the amount of daily focused attention meditation practice and established mental health outcome measures.,"Institute for Meditation and Inner Harmony, Feldman Foundation CA",2025-07-30,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,OTHER,NONE,"An Internet-administered Randomized Control Trial to Examine the Effects of Regular, Brief Meditation Practice on Mental Health and Well Being",2025-06-30,ESTIMATED,Change in Generalize Anxiety Disorder Questionnaire Score | Change in Pittsburgh Sleep Quality Index Questionnaire Score | Change in Mind Wandering Questionnaire Score | Resting Heart Rate | Heart Rate Variability | Change in Stroop Test Score | Change in N-back Test Score,TREATMENT,ALL,2023-11-01,ACTUAL,INTERVENTIONAL
ASMB,"Assembly Biosciences, Inc.",NCT06385327,PHASE1,ACTIVE_NOT_RECRUITING,Recurrent Genital Herpes Simplex Type 2,"ABI-5366, ABI-5366 Placebo",,RANDOMIZED,5,"Part A: SAD Cohorts 1-5, ABI-5366 | Part A: SAD Cohorts 1-5, Placebo | Part A: SAD Fed Cohort 6, ABI-5366 | Part B: MAD Cohorts 1-4 ABI-5366 | Part B: MAD Cohorts 1-4 Placebo",EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.",,2026-02,ESTIMATED,18 Years - 60 Years,115,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple-Ascending Doses of ABI-5366 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes",2026-02,ESTIMATED,"Area Under the Plasma Concentration Time Curve (AUC) of ABI-5366 | Maximum Observed Plasma Concentration (Cmax) of ABI-5366 | Time to Cmax (Tmax) of ABI-5366 | Apparent Terminal Elimination Half Life (t 1/2) of ABI-5366 | Apparent Systemic Clearance (CL/F) of ABI-5366 | Apparent Volume of Distribution (Vz/F) of ABI-5366 | Dose normalized AUCs and Cmax of ABI-5366 | Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AEs, and abnormal laboratory results",TREATMENT,ALL,2024-05-30,ACTUAL,INTERVENTIONAL
ASMB,"Assembly Biosciences, Inc.",NCT06698575,PHASE1,ACTIVE_NOT_RECRUITING,Recurrent Genital Herpes Simplex Type 2,"ABI-1179, ABI-1179 Placebo",,RANDOMIZED,5,"Part A: SAD Cohorts 1-5, ABI-1179 | Part A:SAD Cohorts 1-5, Placebo | Part A: (SAD) Fed Cohort 6 or 7, ABI-1179 | Part B: MAD Cohorts 1-4, ABI-1179 | Part B: MAD Cohorts 1-4 Placebo",EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-1179 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-1179 in Part B in participants seropositive for Herpes Simplex Virus Type 2 (HSV-2) with recurrent genital herpes. Effect of food will also be evaluated in Part A.",,2026-01,ESTIMATED,18 Years - 60 Years,146,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 1a/1b, Blinded, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Single- and Multiple Ascending Doses of ABI-1179 in Healthy Subjects and in Subjects Who Are Seropositive for Herpes Simplex Virus Type 2 With Recurrent Genital Herpes",2025-12,ESTIMATED,"Area Under the Plasma Concentration Time Curve, (AUC) of ABI-1179 | Maximum Observed Plasma Concentration (Cmax) of ABI-1179 | Time to Cmax (Tmax) of ABI-1179 | Apparent Terminal Elimination Half Life ( t 1/2) ABI-1179 | Apparent Systemic Clearance (CL/F) of ABI-1179 | Apparent Volume of Distribution (Vz/F) of ABI-1179 | Dose normalized AUCs and Cmax of ABI-1179 | Proportion of subjects with adverse events (AEs), premature treatment discontinuation due to AE's and abnormal laboratory results.",TREATMENT,ALL,2024-12-08,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT06271265,PHASE1,RECRUITING,Postoperative Pain,"EXPAREL, bupivacaine",,RANDOMIZED,2,EXPAREL | bupivacaine,EXPERIMENTAL | ACTIVE_COMPARATOR,"This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).",,2027-01,ESTIMATED,0 Years - 6 Years,48,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter, Open-label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery",2027-01,ESTIMATED,The following model-predicted PK endpoint will be determined: | The following model-predicted PK endpoint will be determined: | The following model-predicted PK endpoint will be determined: | The following model-predicted PK endpoint will be determined: | The following model-predicted PK endpoint will be determined: | The following model-predicted PK endpoint will be determined:,TREATMENT,ALL,2024-03-29,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT06884865,PHASE2,RECRUITING,Osteoarthritis (OA) of the Knee,"Enekinragene Inzadenovec (PCRX-201), Placebo",,RANDOMIZED,6,"Part A Dose A | Part A, Placebo | Part B Dose A | Part B Dose B | Part B Placebo | Part A, Dose B",EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is.

Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse e",,2032-03,ESTIMATED,45 Years - 80 Years,135,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee",2027-03,ESTIMATED,Incidence (number and percent) of treatment-emergent adverse events (TEAEs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52 | Incidence (number and percent) of adverse events of special interest (AESIs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52 | Incidence (number and percent) of serious adverse events (SAEs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52,TREATMENT,ALL,2025-02-26,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT06340451,,RECRUITING,"Spasticity, Cerebral or Spinal Condition",,,RANDOMIZED,2,iovera° system treatment | sham iovera° system treatment,ACTIVE_COMPARATOR | SHAM_COMPARATOR,"This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approximately 132 subjects will be enrolled; 88 subjects will receive treatment with the iovera° system and 44 subjects will receive sham treatment (sham iovera° system treatment).",,2026-03,ESTIMATED,18 Years - N/A,132,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity",2026-03,ESTIMATED,"Change from baseline in the Modified Ashworth Scale score for elbow measured (0 to 4, where lower scores represent normal muscle tone and higher scores represent spasticity)",TREATMENT,ALL,2024-07-11,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT03739021,"PHASE2, PHASE3",NOT_YET_RECRUITING,Chronic Shoulder Pain,"Exparel, Ropivacaine",ETSP,RANDOMIZED,2,Group 1 (30 participants) | Group 2 (30 participants),EXPERIMENTAL | EXPERIMENTAL,"Total shoulder surgery (arthroplasty) is a widely successful method of treating shoulder arthritis. Although the goal of the procedure is pain relief, post-operative pain is unavoidable. Pain is a common side effect that many patients undergo while in the clinical setting and is a vital factor in influencing the length of hospital stay, narcotic usage, as well as overall patient satisfaction. Post-operative pain management typically involves elevated usage of narcotics, which is a concern among ","Pacira Pharmaceuticals, Inc",2020-11-15,ESTIMATED,18 Years - N/A,60,ESTIMATED,PARALLEL,OTHER,NONE,Analgesic Requirements for Post-operative Pain Control in Total Shoulder Replacement Patients: Comparison of Interscalene Single Shot Exparel (Bupivacaine Liposome) Injections to Cervical Paravertebral Catheter With Ropivacaine (0.2% Continuous Infusion),2020-03-01,ESTIMATED,Duration of Surgery (in minutes) | Post-Operative VAS Scores (10 cm scale) | Intraoperative Narcotics Usage (in Milligrams Morphine Equivalent; MME) | Length of Post-Anesthesia Care Unit (PACU) stay (in minutes) | Post-Operative Narcotics Usage during PACU Stay (in Milligrams Morphine Equivalent; MME) | Post-Operative Narcotics Usage during first 72 hours after PACU discharge (Milligrams in Morphine Equivalents | Length of Hospital Stay (in hours),TREATMENT,ALL,2019-11,ESTIMATED,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT07212114,PHASE3,RECRUITING,"Total Ankle Arthroplasty, Postsurgical Analgesia","EXPAREL, 0.25% bupivacaine (HCl): 50 ml, 0.25% bupivacaine (HCl): 30 ml",,RANDOMIZED,2,Admix | Reference,EXPERIMENTAL | EXPERIMENTAL,"The goal of this clinical study is to learn about pain management strategies in subjects undergoing total ankle replacement. arthroplasty surgery The primary objective is to compare the magnitude of the analgesic effect following a single dose injection of EXPAREL vs. 0.25% bupivacaine (HCl).

Secondary objectives are to:

Compare the total opioid consumption (in oral morphine equivalents) from 0 to 96 hours following a single dose injection of EXPAREL vs. 0.25% bupivacaine HCl

* Compare the ti","Pacira Pharmaceuticals, Inc",2029-08,ESTIMATED,18 Years - N/A,104,ESTIMATED,PARALLEL,OTHER,DOUBLE,"A Randomized, Double-blind, Active Controlled, Single-center Study to Evaluate the Efficacy of EXPAREL vs. Bupivacaine HCl Administered as Combined Sciatic (in the Popliteal Fossa) and Saphenous (in the Adductor Canal) Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Total Ankle Arthroplasty",2029-08,ESTIMATED,Magnitude of the analgesic effect,TREATMENT,ALL,2025-11-17,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT04119687,PHASE1,ACTIVE_NOT_RECRUITING,"Osteoarthritis, Knee",FX201,,NON_RANDOMIZED,3,Low Dose FX201 | Mid Dose FX201 | High Dose FX201,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This two-part study will be conducted in male and female patients, 30 - 80 years of age with painful OA of the index knee with Kellgren-Lawrence (K-L) Grade 2, 3 or 4.

Part 1 - Single Ascending Dose (SAD) Phase: Up to three ascending doses of FX201 will be tested in cohorts of 5-8 patients. Each patient will only receive one injection of FX201. An independent Data Monitoring Committee (DMC) will review safety and guide the conduct of the study.

Part 2 - Expansion Phase: Up to an additional 35 ",,2026-11-28,ESTIMATED,30 Years - 80 Years,72,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee",2023-11-28,ACTUAL,Primary Outcome Measure: Incidence of treatment emergent adverse events after a single intra-articular (IA) injection of FX201 (safety and tolerability),TREATMENT,ALL,2020-03-02,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT06269705,PHASE3,RECRUITING,Glenohumeral Osteoarthritis,ZILRETTA,,RANDOMIZED,2,ZILRETTA | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo

Secondary Objective:

* To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, and normal saline placebo
* To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline plac",,2026-08,ESTIMATED,50 Years - 80 Years,150,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,A Study to Evaluate the Efficacy and Safety of ZILRETTA in Subjects With Glenohumeral Osteoarthritis,2026-08,ESTIMATED,"Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 12 for ZILRETTA relative to placebo",TREATMENT,ALL,2024-02-05,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT07125833,,RECRUITING,Degenerative Joint Disease of Shoulder,,,RANDOMIZED,2,Control | Intervention,ACTIVE_COMPARATOR | EXPERIMENTAL,"The main purpose of this research is to find out if a treatment called cryoneurolysis can reduce pain after reverse total shoulder replacement surgery. This treatment uses cold to temporarily block a nerve in the shoulder. The study will compare people who receive the treatment to those who do not, to see if it helps lower pain and reduce the need for opioid pain medications after a reverse total shoulder surgery (RTSA).","Pacira Pharmaceuticals, Inc",2026-08,ESTIMATED,30 Years - 85 Years,20,ESTIMATED,PARALLEL,OTHER,NONE,A Randomized Pilot Trial for Cryoneurolysis of the Suprascapular Nerve for Perioperative Pain Control After Receiving a Reverse Total Shoulder Arthroplasty,2026-07,ESTIMATED,The primary endpoint for the primary objective would be decreased opioid utilization in the post-operative period after a reverse total shoulder arthroplasty (RTSA) as measured by Morphine Milligram Equivalents (MME).,TREATMENT,ALL,2025-07-30,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT06946368,,RECRUITING,Total Knee Arthroplasty,,,RANDOMIZED,3,Group 1 | Group 2-Control (Standard of Care) | Group 3,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL,"Intra-articular Posteromedial Surgeon Administered (IPSA) Block in this study describes a new type of medical procedure where a surgeon provides anesthetic medication directly into a specific area inside a knee joint to numb the pain during knee surgery. Intra-articular refers to inside of knee joint, posteromedial refers to the back and inner side of a knee joint, and surgeon administered means a surgeon is performing the procedure.

Patients You will be randomly assigned to one of these three ","Pacira Pharmaceuticals, Inc",2026-12-11,ESTIMATED,N/A - N/A,60,ESTIMATED,PARALLEL,OTHER,NONE,"A Single-Center, Randomized, Pilot Study to Assess the Clinical Effectiveness of EXPAREL as an Intra-articular Posteromedial Surgeon Administered (IPSA) Block in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty",2026-12-11,ESTIMATED,Questionnaires to assess the Pain levels of subjects enrolled in the study | Evaluate safety and any side effects | Medication usage | Subject Satisfaction Assessments | Knee and general health survey | Body Mass Index,TREATMENT,ALL,2025-08-18,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT06603051,,RECRUITING,ACL Repair,,,RANDOMIZED,2,Arm A: ACL reconstruction usual care | Arm B: Usual care plus pre-operative cryoneurolysis,NO_INTERVENTION | EXPERIMENTAL,"The purpose of the research is to investigate the effect of preoperative Cryoneurolysis of the knee on postoperative pain management in patients undergoing autograft anterior cruciate ligament (ACL) reconstruction (a surgical procedure that makes a new ACL using the patient's own tendon). Cryoneurolysis is an approved process of applying extreme cold temperatures to targeted nerves in order to decrease or eliminate pain. . If you take part in the research, you will be randomly assigned (assigned","Pacira Pharmaceuticals, Inc",2026-02,ESTIMATED,14 Years - N/A,20,ESTIMATED,PARALLEL,OTHER,NONE,The Effect of Pre-Operative Cryoneurolysis on Post-Operative Narcotic Consumption in Patients Undergoing Autograft ACL Reconstruction,2026-02,ESTIMATED,Post-operative opioid consumption,TREATMENT,ALL,2024-08-28,ACTUAL,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT07214844,,RECRUITING,"Low Back Pain, Chronic",,,RANDOMIZED,2,iovera cryoneurolysis | Radiofrequency ablation (RFA),EXPERIMENTAL | ACTIVE_COMPARATOR,"A research study is being conducted to compare two treatments for long-term low back pain:

* One uses the iovera° system, which applies cold to certain nerves in the lower back.
* The other is the standard treatment called radiofrequency ablation, which uses heat.

The primary objective is to find out which treatment works better to reduce back pain. Participants in this study will be randomly placed in one of the two treatment groups. The clinical research team will check on participant pain l","Pacira Pharmaceuticals, Inc",2027-03,ESTIMATED,18 Years - N/A,110,ESTIMATED,PARALLEL,OTHER,DOUBLE,"A Prospective, Randomized, Assessor Blind, Active-controlled, Single-center Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Facet-mediated Chronic Low Back Pain",2027-03,ESTIMATED,Numeric rating scale (NRS) pain intensity score,TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT06935539,,NOT_YET_RECRUITING,Chronic Sacroiliac Joint Pain,,,RANDOMIZED,2,Cryoneurolysis | Radiofrequency ablation,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This is a single-center, randomized, open-label, pilot study in adult subjects with chronic sacroiliac joint (SIJ) pain. Thirty (30) subjects are planned for initial enrollment and will be randomized 1:1 to receive ioveraº cryoneurolysis or radiofrequency ablation.","Pacira Pharmaceuticals, Inc",2026-08,ESTIMATED,18 Years - N/A,30,ESTIMATED,PARALLEL,OTHER,NONE,"A Prospective, Single-center, Open-label, Pilot Randomized Controlled Study Evaluating the Clinical Effectiveness of Lateral Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Sacroiliac Joint Pain",2026-07,ESTIMATED,Safety and Clinical Effectiveness of Cryoneurolysis as Compared to Radiofrequency Ablation (RFA),TREATMENT,ALL,2025-05,ESTIMATED,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT06958289,,NOT_YET_RECRUITING,Spasticity as Sequela of Stroke,,,,1,Intervention,EXPERIMENTAL,"Spasticity can make regular daily activities difficult or impossible. Cryoneurolysis is a new technique to treat spasticity that is currently being tested. For this technique, a needle is inserted alongside a nerve implicated in spasticity. The needle then freezes and causes the nerve to break down. The nerve breaking down seems to provide relief for spasticity. The investigators are interested in testing the long-term effects of cryoneurolysis on the function of the brain over six months after ","Pacira Pharmaceuticals, Inc",2028-05-01,ESTIMATED,18 Years - N/A,25,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Cryoneurolysis for Spasticity Treatment: Quantifying Long-term Clinical Outcomes and Exploring Mechanisms Within the Central Nervous System,2027-12-01,ESTIMATED,TMS | fNIRS,OTHER,ALL,2025-05-01,ESTIMATED,INTERVENTIONAL
PCRX,"Pacira BioSciences, Inc.",NCT05495334,,RECRUITING,Knee Osteoarthritis,,iGOR,,1,All participants,,"The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs \[NSAIDs\]).",,2033-12-30,ESTIMATED,N/A - N/A,10000,ESTIMATED,,INDUSTRY,,Innovations in Genicular Outcomes Registry,2032-06-30,ESTIMATED,Pain intensity and interference scores via NRS (Numeric Rating Scale) | Pain intensity and interference scores via BPI-sf (Brief Pain Inventory-short form) | Opioid use via pre-and post-treatment analgesic medication use log | Functional status via KOOS-JR (Knee injury and Osteoarthritis Outcome Score for Joint Replacement) | Functional status via SANE (Single Assessment Numeric Evaluation) | Quality of Sleep via PROMIS-SD (PROMIS - Sleep Disturbance - Short Form 8b) | Adverse events related to pain therapies | General HRQOL via PROMIS-10 (PROMIS GLOBAL-10) | Patient Satisfaction | Physical therapy utilization and work productivity via PT/Work Productivity | Emergency Department (ED) visits | Reimbursement status | Post-operative pain scores NRS (Numeric Rating Scale) | Post-operative opioid consumption (analgesic medication use log) | Length of facility stay,,ALL,2021-09-23,ACTUAL,OBSERVATIONAL
GHRS,GH Research PLC,NCT06511947,PHASE1,RECRUITING,Healthy Volunteers,"5 Methoxy N,N Dimethyltryptamine",,NON_RANDOMIZED,6,"Part 1, Cohort A | Part 1, Cohort B | Part 1, Cohort C | Part 1, Cohort D (optional) | Part 1, Cohort E (optional) | Part 2, Cohort F",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration and a single-day individualized dosing regimen (IDR). As secondary objectives, the mebufotenin PK/ pharmacodynamic (PD) relationship, the PD profile of GH001 as evaluated by its psychoactive effects (PsE), the impact on cognitive performance, and the TCmax/2 and TCma",,2025-02,ESTIMATED,18 Years - 64 Years,52,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Open-label Phase 1 Trial to Determine the Pharmacokinetics, Pharmacodynamics, and Safety of GH001 Administered Via a Proprietary Aerosol Delivery Device in Healthy Subjects",2025-02,ESTIMATED,"Serum PK parameters of mebufotenin - maximum observed concentration (Cmax) | Serum PK parameters of mebufotenin - time of maximum observed concentration (Tmax) | Serum PK parameters of mebufotenin - terminal elimination half-life (t1/2) | Serum PK parameters of mebufotenin - area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUC0-t) | Serum PK parameters of mebufotenin - area under the serum concentration-time curve extrapolated to infinity (AUC0-∞) | Serum PK parameters of mebufotenin - terminal elimination rate constant (λz) | Serum PK parameters of mebufotenin - apparent total body clearance (CL/F) | Serum PK parameters of mebufotenin - apparent steady-state volume of distribution (VSS/F) | Serum PK parameters of mebufotenin - Cmax/AUC0-∞ | Safety and tolerability: incidence of treatment-emergent adverse events | Safety and tolerability: clinically significant changes from baseline in electrocardiogram (ECG), vital signs, spirometry and safety laboratory assessments | Safety and tolerability: assessment of sedation (Modified Observer's Assessment of Alertness and Sedation [MOAA/S]) following each dose and as part of the discharge evaluation on Day 0 | Safety and tolerability: change from baseline in Clinician Administered Dissociative States Scale (CADSS) | Safety and tolerability: assessment of subject discharge readiness at discharge on Day 0 | Safety and tolerability: Columbia-Suicide Severity Rating Scale (C-SSRS) categorization. | Safety and tolerability: Change from baseline in Brief Psychiatric Rating Scale (BPRS).",TREATMENT,ALL,2024-08-01,ACTUAL,INTERVENTIONAL
SLNO,"Soleno Therapeutics, Inc.",NCT05701774,PHASE3,ACTIVE_NOT_RECRUITING,Prader-Willi Syndrome,DCCR,,,1,DCCR,EXPERIMENTAL,The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.,,2028-06,ESTIMATED,4 Years - N/A,83,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Prader-Willi Syndrome,2028-06,ESTIMATED,Safety of DCCR (adverse events. Safety analyses will be conducted in all subjects who receive at least one dose of DCCR in the C614 study. ( Adverse events),TREATMENT,ALL,2023-01-31,ACTUAL,INTERVENTIONAL
TECX,"Tectonic Therapeutic, Inc.",NCT06616974,PHASE2,RECRUITING,"Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction","TX000045- Dose A, TX000045- Dose B, Placebo",,RANDOMIZED,3,TX000045 Dose A | TX000045 Dose B | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).",,2026-11-20,ESTIMATED,18 Years - 83 Years,180,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)",2026-10-09,ESTIMATED,"Mean change from baseline in Pulmonary Vascular Resistance (PVR) in participants with a combined pre- and post-capillary pulmonary hypertension (CpcPH). | Assess safety of TX000045 by the incidence of adverse events, adverse events of special interest and SAEs. | Number of participants with abnormal laboratory values and/or adverse events that are related to treatment. | Number of participants with treatment-related adverse events. | Number of participants with changes in the physical examination findings.",TREATMENT,ALL,2024-09-04,ACTUAL,INTERVENTIONAL
AMRN,Amarin Corporation plc,NCT06637657,,RECRUITING,Acute Coronary Syndrome,,GOLDEN,,2,'Current practice' group | 'First-time-right' (FTR) group, | ,"The goal of this observational study is to evaluate the implementation of a 'first-time-right' pharmacological treatment strategy in patients hospitalized with coronary artery disease.

The main question it aims to answer is:

Does early (immediately post-event) initiation of a full set of guideline-based, individualized, preventive medication lead to reductions in cardiovascular events compared to current practice (incremental titration strategies)?

Researchers will compare the 'first-time-rig","Dutch Network for Cardiovascular Research (WCN), Utrecht, Novartis Pharmaceuticals, Amarin Pharma Inc.",2029-01,ESTIMATED,18 Years - N/A,5586,ESTIMATED,,OTHER,,Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD (GOLDEN). A Prospective Observational Study of Long-term Outcomes.,2029-01,ESTIMATED,4-point MACE,,ALL,2024-07-09,ACTUAL,OBSERVATIONAL
AMRN,Amarin Corporation plc,NCT03428477,PHASE3,ACTIVE_NOT_RECRUITING,"Liver Metastasis, Colon Cancer",Icosapent Ethyl,EMT2,RANDOMIZED,2,Icosapent Ethyl (EPA-EE) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop disease recurrence and die from the disease. A previous small study (the EMT study) suggested a possible survival benefit in patients who took the naturally-occurring omega-3 fatty acid EPA (a fish oil supplement) before liver surgery. The EMT2 study is a larger study which will recruit 448 men and women with liver metastases from bowel cancer. Trial participant,"Yorkshire Cancer Research, Amarin Pharma Inc.",2026-04-30,ESTIMATED,18 Years - N/A,418,ACTUAL,PARALLEL,OTHER,QUADRUPLE,A Randomised Placebo-controlled Phase III Trial of the Effect of the Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) on Colorectal Cancer Recurrence and Survival After Surgery for Resectable Liver Metastases,2025-11-30,ESTIMATED,Progression Free Survival (PFS),PREVENTION,ALL,2018-05-02,ACTUAL,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT07219927,,RECRUITING,Parkinson Disease,,,,0,,,"Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease",,2027-08-01,ESTIMATED,18 Years - N/A,120,ESTIMATED,,INDUSTRY,,"Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease",2027-08-01,ESTIMATED,Titration Duration and Time to Optimized Dose | Concomitant Parkinson's Disease (PD) Medication Adjustments | The number of titration visits or dose adjustments required to reach the final optimized dose. This is a count of a specific event,,ALL,2025-03-31,ACTUAL,OBSERVATIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT06798896,PHASE2,RECRUITING,Focal Onset Seizures,"SPN-817, Placebo",,RANDOMIZED,2,SPN-817 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.",,2026-10,ESTIMATED,18 Years - 70 Years,258,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"RENAISSANCE 2: a Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures",2026-10,ESTIMATED,Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period,TREATMENT,ALL,2024-12-30,ACTUAL,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT02736656,PHASE3,ACTIVE_NOT_RECRUITING,Attention-Deficit/Hyperactivity Disorder,SPN-812,,,1,Open-Label Treatment,EXPERIMENTAL,"Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients",,2026-09,ESTIMATED,4 Years - 18 Years,1400,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD),2026-09,ESTIMATED,Incidence of adverse events,TREATMENT,ALL,2016-02-02,ACTUAL,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT01246765,,RECRUITING,"Pregnant Women, Psychotropic Drugs",,,,5,Atypical Antipsychotic Cohort | Antidepressant Medications | ADHD Medications | Sedative Hypnotic Medications | Other Psychiatric Medications, |  |  |  | ,"The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.","Alkermes, Inc., Eisai Inc., Otsuka America Pharmaceutical, Supernus Pharmaceuticals, Inc., Sage Therapeutics, Bristol-Myers Squibb",2033-12,ESTIMATED,18 Years - 45 Years,5000,ESTIMATED,,OTHER,,National Pregnancy Registry for Psychiatric Medications,2033-12,ESTIMATED,Major Malformations in Infants,,FEMALE,2008-11,ACTUAL,OBSERVATIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT04781140,PHASE4,RECRUITING,Attention-Deficit/Hyperactivity Disorder,"100mg SPN-812, Placebo",,RANDOMIZED,2,Placebo | SPN-812,PLACEBO_COMPARATOR | EXPERIMENTAL,This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.,,2026-06,ESTIMATED,48 Months - 69 Months,286,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 Years Old) With Attention-Deficit/Hyperactivity Disorder (ADHD)",2026-06,ESTIMATED,"Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)",TREATMENT,ALL,2024-03-19,ACTUAL,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT06185985,PHASE4,ACTIVE_NOT_RECRUITING,Attention-Deficit/Hyperactivity Disorder,SPN-812,,,1,Open-Label Treatment,EXPERIMENTAL,"Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.",,2025-01,ESTIMATED,18 Years - N/A,750,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase IV, Open-Label, Decentralized Clinical Trial to Evaluate the Efficacy and Safety of Qelbree® in Adults With Attention-Deficit/Hyperactivity Disorder and Mood Symptoms",2025-01,ESTIMATED,Change from baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total score by visit.,TREATMENT,ALL,2024-03-28,ACTUAL,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT07226661,PHASE2,NOT_YET_RECRUITING,Major Depressive Disorder (MDD),"SPN-821 2400 mg, Placebo",,RANDOMIZED,2,SPN-821 2400 mg | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder,,2027-01-31,ESTIMATED,18 Years - 70 Years,230,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SPN-821 as an Adjunctive Therapy in Adults With Major Depressive Disorder",2026-12-31,ESTIMATED,Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.,TREATMENT,ALL,2026-01-01,ESTIMATED,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT03474770,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Focal Impaired Awareness Seizures,BIS-001ER,FIAS,,1,BIS-001ER,EXPERIMENTAL,The purpose of this study is to examine safety signals and demonstrate seizure reduction in adults with FIAS treated with BIS-001ER as an add-on therapy in an in-patient and out-patient study design.,,2026-12-30,ESTIMATED,18 Years - 65 Years,16,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures,2026-12-30,ESTIMATED,Effect of BIS-001ER on Seizure Count,TREATMENT,ALL,2018-04-10,ACTUAL,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT07125222,PHASE2,NOT_YET_RECRUITING,Radiation Encephalopathy,Gocovri (extended-release amantidine),,,1,Gocovri (extended-release amantidine),EXPERIMENTAL,A study to assess the effect of Gocovri (extended-release amantidine) to improve disability as assessed by the disability rating scale (DRS) and cognition as assessed by the Montreal Cognitive Assessment (MoCA) test in patients with radiation encephalopathy.,Supernus Pharmaceuticals,2028-08,ESTIMATED,18 Years - N/A,24,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Use of Gocovri to Improve Disability Due to Radiation Encephalopathy,2028-08,ESTIMATED,Change in the level of disability as measured by the Disability Rating Scale(DRS),TREATMENT,ALL,2025-09,ESTIMATED,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT02339064,PHASE3,ACTIVE_NOT_RECRUITING,Idiopathic Parkinson's Disease,apomorphine infusion,INFUS-ON,,1,Apomorphine infusion,EXPERIMENTAL,"This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.",,2025-12,ESTIMATED,30 Years - N/A,99,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy",2018-12,ACTUAL,"Percent of daily ""off"" time during the waking day",TREATMENT,ALL,2015-02,,INTERVENTIONAL
SUPN,"Supernus Pharmaceuticals, Inc.",NCT07141329,PHASE2,RECRUITING,Focal Onset Seizures,SPN-817,,,1,SPN-817,EXPERIMENTAL,This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.,,2027-12-31,ESTIMATED,18 Years - N/A,100,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures",2027-12-31,ESTIMATED,Incidence of treatment-emergent adverse events,TREATMENT,ALL,2025-07-30,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT04930783,PHASE1,RECRUITING,"Melanoma, Metastatic Melanoma","CDX-301, NEOVAX, Nivolumab, Pembrolizumab",,NON_RANDOMIZED,2,CDX-301 + Neovax + Nivolumab | CDX-301 + Neovax + Pembrolizumab,EXPERIMENTAL | EXPERIMENTAL,"This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab or Pembrolizumab as a possible treatment for melanoma.

The names of the study drugs involved in this study are:

* Personalized Neoantigen peptides (which combined with poly-ICLC make the vaccine NeoVax)
* Poly-ICLC (Hiltonol)
* CDX-301
* Nivolumab (Opdivo)
* Pembrolizumab (Keytruda)",Celldex Therapeutics,2030-09-30,ESTIMATED,18 Years - N/A,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With Melanoma,2026-12-31,ESTIMATED,Rate of Dose Limiting Toxicity (DLT) | Recommended maximum tolerated dose (MTD),TREATMENT,ALL,2022-01-03,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT07266402,PHASE3,RECRUITING,"Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria, Symptomatic Dermographism","Barzolvolimab, Matching Placebo",,RANDOMIZED,4,barzolvolimab 450mg loading dose followed by 150mg in patients with Cold Induced Urticaria | Placebo comparator in patients with Cold Induced Urticaria | barzolvolimab 450mg loading dose followed by 150mg in patients with Symptomatic Dermographism | Placebo comparator in patients with Symptomatic Dermographism,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this Phase 3, randomized, double-blind, placebo-controlled study is to assess the activity and safety of barzolvolimab compared to placebo in participants with cold induced urticaria or symptomatic dermographism who remain symptomatic despite the use of H1-antihistamines.",,2028-10,ESTIMATED,18 Years - N/A,240,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study of Barzolvolimab in Participants With Cold Induced Urticaria and Symptomatic Dermographism (EMBARQ-COLDU and SD)",2028-06,ESTIMATED,Complete response to provocation testing at Week 12,TREATMENT,ALL,2026-01-15,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT05029999,PHASE1,RECRUITING,"HER2-negative Breast Cancer, Metastatic Breast Cancer","PLD Chemotherapy, CDX-1140, CDX-301",,RANDOMIZED,2,Cohort A | Cohort C,EXPERIMENTAL | EXPERIMENTAL,"This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs. This research study will also test how your immune system responds to ","Celldex Therapeutics, Gateway for Cancer Research, National Institutes of Health (NIH)",2026-04-20,ESTIMATED,18 Years - 99 Years,30,ESTIMATED,PARALLEL,OTHER,NONE,Phase 1 Pilot Study With Dose Expansion of Chemotherapy in Combination With CD40 Agonist and Flt3 Ligand in Metastatic HER2 Negative Breast Cancer,2026-04-20,ESTIMATED,"Safety (tolerability) of the drug combination of CDX-1140, CDX-301 and PLD as measured by the number of participants with Dose Limiting Toxicity (DLT)",TREATMENT,ALL,2022-04-20,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT06727552,PHASE2,ACTIVE_NOT_RECRUITING,Atopic Dermatitis,"Barzolvolimab, Matching placebo",,RANDOMIZED,4,Barzolvolimab 150 mg | Barzolvolimab 300 mg | Placebo then barzolvolimab 150 mg | Placebo then barzolvolimab 300 mg,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis,,2027-05,ESTIMATED,18 Years - N/A,131,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Moderate to Severe Atopic Dermatitis",2026-10,ESTIMATED,Percent change from Baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16,TREATMENT,ALL,2024-12-18,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT03688178,PHASE2,ACTIVE_NOT_RECRUITING,Glioblastoma,"Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Varlilumab, Td, Unpulsed DCs",DERIVe,RANDOMIZED,3,Gr1: DC vaccine (DC pre-conditioning) | Gr2: DC Vaccine (Td pre-conditioning) | Gr3:DC Vaccine+varlilumab(Td pre-conditioning),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Patients with newly diagnosed glioblastoma will be consented following tumor resection then undergo leukapheresis for harvest of peripheral blood leukocytes for generation of dendritic cells. Subjects will then receive standard of care (planned 6 weeks) radiation therapy (RT) and concurrent temozolomide (TMZ) at a standard targeted dose of 75 mg/m2/day.

The study cycle of TMZ comprises a targeted dose of 150-200mg/m2/day for 5 days every 4 (+2) weeks for up to 12 cycles (patients with unmethyla",Celldex Therapeutics,2026-03,ESTIMATED,18 Years - N/A,43,ACTUAL,PARALLEL,OTHER,TRIPLE,DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab,2026-03,ESTIMATED,"Median Overall Survival (OS) of Subjects Receiving Td pre-conditioning | Safety of administering Varlilumab to GBM patients receiving temozolomide and dendritic cell vaccines ± Td pre-conditioning as measured by the percentage of patients with unacceptable toxicity regardless of attribution | Median percent change between baseline, assessed on day 14, and nadir levels of Treg before the time that the second cycle of adjuvant TMZ would be administered. Treg determined by flow cytometry (CD3+ CD4+ CD25+ Foxp3+).",TREATMENT,ALL,2020-08-26,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT03804944,PHASE2,RECRUITING,Breast Cancer,"Pembrolizumab (200mg IV for 30 minutes, CDX-301",CBCV,RANDOMIZED,4,ARM 1 | ARM 2 | ARM 3 | ARM 4,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.","United States Department of Defense, Merck Sharp & Dohme LLC, Celldex Therapeutics",2027-12-31,ESTIMATED,18 Years - 90 Years,100,ESTIMATED,PARALLEL,OTHER,NONE,Converting HR+ Breast Cancer Into an Individualized Vaccine,2026-12-31,ESTIMATED,"Tolerability will be demonstrated if no grade 3 or higher toxicities are observed in the first 8 patients, of each arm. | Clinical response rate to tumor radiation +/-immunotherapy during standard endocrine therapy for HR+ breast cancer will be measured. | Pathological response rate to tumor radiation +/-immunotherapy during standard endocrine therapy for HR+ breast cancer will be measured.",TREATMENT,FEMALE,2020-03-17,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT07256392,PHASE3,RECRUITING,Chronic Spontaneous Urticaria,barzolvolimab,,NON_RANDOMIZED,2,Group 1 Observation Group | Group 2 Barzolvolimab Retreatment Group,EXPERIMENTAL | EXPERIMENTAL,"The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials.

This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable.",,2028-09,ESTIMATED,18 Years - N/A,1370,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13,2028-09,ESTIMATED,Time to disease worsening or treatment failure through Week 52 based on the occurrence of UAS7 (Urticaria Activity Score) of 16 or greater. | Time to disease worsening or treatment failure through Week 52 based on the occurrence of the discontinuation of barzolvolimab in Group 2 due to lack of efficacy or to a treatment related adverse event. | Time to disease worsening or treatment failure through Week 52 based on the occurrence of first use of strongly confounding prohibited medication (Group 1 or 2) or use of barzolvolimab in Group 1.,TREATMENT,ALL,2025-11-25,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT06650761,PHASE1,ACTIVE_NOT_RECRUITING,Healthy Participants,"CDX-622, Normal Saline",,RANDOMIZED,2,CDX-622 | Normal Saline,EXPERIMENTAL | PLACEBO_COMPARATOR,This is a study to determine the safety of CDX-622 in healthy participants.,,2026-04,ESTIMATED,18 Years - 55 Years,85,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Three-Part, Phase 1a Dose Escalation Clinical Trial to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-622 in Healthy Participants",2026-04,ESTIMATED,Safety as assessed by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials. Infusion reactions will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.,TREATMENT,ALL,2024-11-01,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT05231122,PHASE2,RECRUITING,"Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma","Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab",,RANDOMIZED,2,"Arm I (pembrolizumab, bevacizumab) | Arm II (pembrolizumab, bevacizumab, CDX-1140)",ACTIVE_COMPARATOR | EXPERIMENTAL,"This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, an","Merck Sharp & Dohme LLC, Celldex Therapeutics, United States Department of Defense",2026-12-30,ESTIMATED,18 Years - N/A,80,ESTIMATED,PARALLEL,OTHER,SINGLE,Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer,2026-12-30,ESTIMATED,Incidence of adverse events | Objective response rate (ORR),TREATMENT,FEMALE,2024-03-12,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT05349890,PHASE1,ACTIVE_NOT_RECRUITING,Malignant Epithelial Neoplasms,"TCR-transduced T cells, CDX-1140, Pembrolizumab",,,1,CDX-1140 + TCR-T + Pembro,EXPERIMENTAL,"This is a phase I/Ib study of adoptively transferred T-cell receptor gene-engineered T cells (TCR-T) targeting tumor-specific antigens, with in vivo CD40 activation and PD-1 blockade, for patients with incurable cancers. The study design is a safety lead-in TCR-T with CD40/PD-1 (3+3), followed by Simon's Two-Stage expansion design, 80% power and 5% one-sided alpha: stage-one futility assessment at n = 10; stage-two assessment at n = 22, (accrual up to 24 to allow for potential study drop-out).","Celldex Therapeutics, Providence Cancer Center, Earle A. Chiles Research Institute",2028-04-15,ESTIMATED,N/A - N/A,1,ACTUAL,SINGLE_GROUP,OTHER,NONE,"A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Patient-unique Tumor-specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers",2026-04-15,ESTIMATED,Incidence of adverse events | Severity of adverse events,TREATMENT,ALL,2023-04-03,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT06445023,PHASE3,RECRUITING,Chronic Spontaneous Urticaria,"barzolvolimab, Matching placebo",EMBARQ-CSU1,RANDOMIZED,4,barzolvolimab 150 mg | barzolvolimab 300 mg | Placebo then barzolvolimab 150 mg | Placebo then barzolvolimab 300 mg,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.",,2027-04,ESTIMATED,18 Years - N/A,915,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU1)",2026-10,ESTIMATED,Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score),TREATMENT,ALL,2024-07-11,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT06366750,PHASE2,ACTIVE_NOT_RECRUITING,Prurigo Nodularis,barzolvolimab,,RANDOMIZED,3,"Barzolvolimab 450 mg, then 150 mg Q4W | Barzolvolimab 450 mg, then 300 mg Q4W | Placebo",EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.,,2027-03,ESTIMATED,18 Years - N/A,140,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Patients With Prurigo Nodularis",2026-06,ESTIMATED,Proportion of participants with improvement in Worst Itch Numeric Rating Scale (WI-NRS) by ≥ 4 from baseline to Week 12.,TREATMENT,ALL,2024-04-12,ACTUAL,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT07330778,PHASE1,RECRUITING,Mild to Moderate Asthma,CDX-622,,,1,CDX-622,EXPERIMENTAL,"This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.",,2027-03,ESTIMATED,18 Years - N/A,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma",2027-03,ESTIMATED,To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma.,TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
CLDX,"Celldex Therapeutics, Inc.",NCT06455202,PHASE3,RECRUITING,Chronic Spontaneous Urticaria,"barzolvolimab, Matching placebo",EMBARQ-CSU2,RANDOMIZED,4,barzolvolimab 150 mg | barzolvolimab 300 mg | Placebo then barzolvolimab 150 mg | Placebo then barzolvolimab 300 mg,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.",,2027-04,ESTIMATED,18 Years - N/A,915,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)",2026-10,ESTIMATED,Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score),TREATMENT,ALL,2024-07-19,ACTUAL,INTERVENTIONAL
ZVRA,"Zevra Therapeutics, Inc.",NCT06773026,PHASE2,RECRUITING,Medium-chain Acyl-CoA Dehydrogenase Deficiency,Sodium phenylbutyrate,,,1,4.0 g/m2/day BID sodium phenylbutyrate,EXPERIMENTAL,"This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD) caused by the common ACADM c.985 A\>G (K304E) mutation. The medication is sodium phenylbutyrate (ACER-001), which is currently FDA approved for the treatment of Urea Cyle Disorders. Previous research suggests that sodium phenylbutyrate may also be effective in the treatment MCADD. This study will investigate the safety and efficac",Zevra Therapeutics,2027-07,ESTIMATED,4 Years - N/A,24,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"A Phase 2, Open-label, Fixed-dose Study to Assess the Efficacy of Sodium Phenylbutyrate (ACER-001) in Treating Pediatric and Adult Patients With Medium Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency Resulting From the Prevalent ACADM c.985 A>G (K304E) Mutation",2027-01,ESTIMATED,Number of participants with treatment related adverse events as assessed by CTCAE v5.0,TREATMENT,ALL,2025-06-30,ACTUAL,INTERVENTIONAL
APLS,"Apellis Pharmaceuticals, Inc.",NCT03531255,PHASE3,ACTIVE_NOT_RECRUITING,PNH,Pegcetacoplan,,,1,"1,080 mg pegcetacoplan administered subcutaneously",EXPERIMENTAL,"This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.",,2025-06,ESTIMATED,18 Years - N/A,160,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)",2025-06,ESTIMATED,Incidence and severity of treatment-emergent adverse events,TREATMENT,ALL,2018-08-27,ACTUAL,INTERVENTIONAL
APLS,"Apellis Pharmaceuticals, Inc.",NCT04572854,PHASE2,ACTIVE_NOT_RECRUITING,"C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis",Pegcetacoplan,NOBLE,RANDOMIZED,2,Group 1 | Group 2,EXPERIMENTAL | OTHER,"This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.",,2026-01,ESTIMATED,18 Years - N/A,13,ACTUAL,PARALLEL,INDUSTRY,NONE,"An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN",2023-02-27,ACTUAL,Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12,TREATMENT,ALL,2021-09-07,ACTUAL,INTERVENTIONAL
APLS,"Apellis Pharmaceuticals, Inc.",NCT07213960,"PHASE2, PHASE3",NOT_YET_RECRUITING,FSGS,APL2,,RANDOMIZED,3,Phase 2 - APL2 | Phase 3 - APL2 | Phase 3 - Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.",,2029-12,ESTIMATED,18 Years - N/A,270,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of APL2 in Adults and Adolescents With Focal Segmental Glomerulosclerosis",2029-10,ESTIMATED,Phase 2: Evaluate the efficacy of APL2 in terms of change from baseline in log-transformed urine protein to creatinine ratio (uPCR) | Phase 3: Change from baseline in log-transformed urine protein to creatinine ratio (uPCR),TREATMENT,ALL,2025-12,ESTIMATED,INTERVENTIONAL
APLS,"Apellis Pharmaceuticals, Inc.",NCT05809531,PHASE3,ACTIVE_NOT_RECRUITING,"C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)",Pegcetacoplan,VALE,,1,Pegcetacoplan administered subcutaneously,EXPERIMENTAL,"This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN).",,2027-07,ESTIMATED,12 Years - N/A,100,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis",2027-07,ESTIMATED,Proportion of participants with a reduction in urine protein-to-creatinine ratio (uPCR) of at least 50% from the pretreatment value over time.,TREATMENT,ALL,2023-05-29,ACTUAL,INTERVENTIONAL
APLS,"Apellis Pharmaceuticals, Inc.",NCT04901936,PHASE2,RECRUITING,"Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria",Pegcetacoplan,,,1,Pegcetacoplan,EXPERIMENTAL,"The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).",,2028-12,ESTIMATED,12 Years - 17 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria",2028-12,ESTIMATED,"Pegcetacoplan serum concentrations over the course of the 16-week treatment period | Change from baseline to Wk 16 in hemoglobin (Hb) | Incidence and severity of treatment-emergent adverse events (TEAEs) over the course of the 16-week treatment period, including monitoring bacterial infections | Change from baseline to wk 16 lactate dehydrogenase (LDH) | Change from baseline to wk 16 absolute reticulocyte count (ARC)",TREATMENT,ALL,2021-02-04,ACTUAL,INTERVENTIONAL
APLS,"Apellis Pharmaceuticals, Inc.",NCT07215390,PHASE2,RECRUITING,Geographic Atrophy Secondary to Age-related Macular Degeneration,"APL-3007, pegcetacoplan (APL-2), APL-3007, pegcetacoplan (APL-2)",,RANDOMIZED,3,Group 1 (APL-3007 Dose/Frequency 1 ) | Group 2 (APL-3007 Dose/Frequency 2) | Group 3 (placebo),EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration",,2027-11,ESTIMATED,60 Years - N/A,240,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration",2027-06,ESTIMATED,Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the study eye,TREATMENT,ALL,2025-06-23,ACTUAL,INTERVENTIONAL
APLS,"Apellis Pharmaceuticals, Inc.",NCT06161584,,ACTIVE_NOT_RECRUITING,Geographic Atrophy,Pegcetacoplan,,,1,Observation,,"A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration",,2028-06,ESTIMATED,60 Years - N/A,300,ESTIMATED,,INDUSTRY,,"A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration",2028-06,ESTIMATED,Incidence of ocular AEs in treated eyes overall and according to physician-directed treatment interval based on US prescribing information | Incidence of other events of interest,,ALL,2023-09-28,ACTUAL,OBSERVATIONAL
APLS,"Apellis Pharmaceuticals, Inc.",NCT07020832,PHASE3,NOT_YET_RECRUITING,"Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant",Pegcetacoplan,,RANDOMIZED,2,Pegceptacoplan | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULTS AT HIGH RISK OF DELAYED GRAFT FUNCTION (DGF) FOLLOWING KIDNEY ALLOGRAFT TRANSPLANTATION,,2028-08,ESTIMATED,18 Years - N/A,320,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation",2027-08,ESTIMATED,Time to freedom from dialysis through Day 90,TREATMENT,ALL,2025-09,ESTIMATED,INTERVENTIONAL
ABUS,Arbutus Biopharma Corporation,NCT05960240,PHASE1,ACTIVE_NOT_RECRUITING,Chronic Hepatitis b,"AB-101, Placebo, Nucleos(t)ide Analogue",,RANDOMIZED,3,Part 1 | Part 2 | Part 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects.

Part 3 will be a Phase 1b dose-ranging assessment of AB-101 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.",,2026-04,ESTIMATED,18 Years - 60 Years,128,ACTUAL,PARALLEL,INDUSTRY,SINGLE,"A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, PK and PD of AB-101, an Oral PD-L1 Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection.",2026-01,ESTIMATED,"Parts 1 and 2: Incidence of adverse events (AEs), serious AEs (SAEs), immune related AEs (irAEs) and discontinuations due to AEs and irAEs. | Part 3: Incidence of AEs, SAEs, irAEs and discontinuations due to AEs and irAEs | Parts 1 and 2: Incidence of clinically significant laboratory abnormalities Parts 1 and 2: Incidence of clinically significant laboratory abnormalities | Parts 1 and 2: Incidence of clinically significant changes in vital signs (heart rate, blood pressure, temperature, respiratory rate), physical examinations and electrocardiograms (ECGs) | Part 3: Incidence of clinically significant laboratory abnormalities | Part 3: Incidence of clinically significant changes in vital signs (heart rate, blood pressure, temperature, respiratory rate), physical examinations and electrocardiograms (ECGs)",TREATMENT,ALL,2023-08-30,ACTUAL,INTERVENTIONAL
ABUS,Arbutus Biopharma Corporation,NCT06154278,PHASE2,RECRUITING,Chronic Hepatitis B,Imdusiran (AB-729),i-LIVER,,1,Imdusiran (AB-729),EXPERIMENTAL,"The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are:

* how well is it working in the liver
* how does Imdusiran affect the hepatitis B virus

Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran, and the second 8 weeks after the last dose of Imdusir",Arbutus Biopharma Corporation,2027-07-01,ESTIMATED,18 Years - N/A,10,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Pilot Study to Evaluate Intrahepatic and Peripheral Responses to Small Interfering RNA, Imdusiran (AB-729), Among People With Chronic Hepatitis B",2026-12-01,ESTIMATED,Intrahepatic concentration of Imdusiran (AB-729),BASIC_SCIENCE,ALL,2024-07-25,ACTUAL,INTERVENTIONAL
ABUS,Arbutus Biopharma Corporation,NCT06277037,,RECRUITING,Long Term Follow-up,,,,0,,,"This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study \[EOS\] visit) from their imdusiran clinical trial (the ""parent study""). No interventions will be performed in this study other than blood sample collections, review of curren",,2029-10-30,ESTIMATED,20 Years - 70 Years,50,ESTIMATED,,INDUSTRY,,A Long-Term Follow-up Study for Subjects With Chronic Hepatitis B Previously Treated With Imdusiran (AB-729),2029-08-30,ESTIMATED,To evaluate the durability of effect of imdusiran on HBV parameters | To evaluate the durability of effect of imdusiran on HBV parameters | To evaluate the durability of effect of imdusiran on HBV parameters,,ALL,2024-07-11,ACTUAL,OBSERVATIONAL
DYN,"Dyne Therapeutics, Inc.",NCT04635891,,RECRUITING,FSHD,,MOVE FSHD,,1,MOVE FSHD Study Visits,,"The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD.

M","FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche, Springbok Analytics",2028-01,ESTIMATED,N/A - N/A,450,ESTIMATED,,OTHER,,Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD),2027-12,ESTIMATED,"10m walk/run | Shoulder and Arm Range of Motion | Shoulder and Arm Function | Spirometry (FVC, FEV1, PCF)",,ALL,2020-12-15,ACTUAL,OBSERVATIONAL
DYN,"Dyne Therapeutics, Inc.",NCT05524883,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy (DMD),"DYNE-251, Placebo",DELIVER,RANDOMIZED,3,Placebo-Controlled MAD Period - DYNE-251 | Placebo-Controlled MAD Period - Placebo | Open-Label and Long-Term Extension Period - DYNE-251,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The primary purpose of this study is to evaluate the safety, tolerability, and dystrophin protein levels in muscle tissue following multiple intravenous (IV) doses of DYNE-251 in participants with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping.

The study consists of 3 periods: a multiple-ascending dose (MAD) / placebo-controlled period (24 weeks), an open-label period (24 weeks) and a long-term extension (LTE) period (192 weeks).",,2029-11,ESTIMATED,4 Years - 16 Years,86,ACTUAL,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping",2029-11,ESTIMATED,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Change From Baseline in Dystrophin Protein Levels in Muscle Tissue at Week 25,TREATMENT,MALE,2022-08-12,ACTUAL,INTERVENTIONAL
DYN,"Dyne Therapeutics, Inc.",NCT05481879,"PHASE1, PHASE2",RECRUITING,Myotonic Dystrophy Type 1 (DM1),"DYNE-101, Placebo",ACHIEVE,RANDOMIZED,8,MAD Cohort: Placebo-Controlled Period: DYNE-101 | MAD Cohort: Placebo-Controlled Period: Placebo | MAD Cohort: Treatment Period: DYNE-101 | MAD Cohort: Long-Term Extension Period: DYNE-101 | Dose Expansion Cohort: Placebo-Controlled Period: DYNE-101 | Dose Expansion Cohort: Placebo-Controlled Period: Placebo | Dose Expansion Cohort: Treatment Period: DYNE-101 | Dose Expansion Cohort: Long-Term Extension Period: DYNE-101,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1).

The study consists of 4 periods: A Screening Period (up to 8 weeks), a Placebo-Controlled Period (24 weeks), a Treatment Period (24 weeks) and a Long-Term Extension (LTE) Period (168 weeks) in both multiple-ascending dose (MAD) and dose expansion cohorts.",,2029-07,ESTIMATED,18 Years - 65 Years,116,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants With Myotonic Dystrophy Type 1",2029-07,ESTIMATED,MAD Cohorts: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Dose Expansion Cohorts: Change From Baseline in Myotonia as Measured by Video Hand Opening Time (vHOT),TREATMENT,ALL,2022-09-05,ACTUAL,INTERVENTIONAL
DYN,"Dyne Therapeutics, Inc.",NCT03458832,,RECRUITING,Facioscapulohumeral Muscular Dystrophy,,ReSolve,,1,FSHD-COM,,"The primary cause of facioscapulohumeral muscular dystrophy (FSHD), a common adult-onset dystrophy, was recently discovered identifying targets for therapy. As multiple drug companies pursue treatments for FSHD, there is an urgent need to define the clinical trial strategies which will hasten drug development, including creating disease-relevant outcome measures and optimizing inclusion criteria. This proposal will develop two new outcome measures (FSHD-COM and EIM) and optimize eligibility crit","National Institute of Neurological Disorders and Stroke (NINDS), FSHD Society, Friends Research Institute, Inc., Muscular Dystrophy Association, AFM Telethon, University of Rochester, Leiden University Medical Center, Dyne Therapeutics",2027-12,ESTIMATED,18 Years - 75 Years,320,ESTIMATED,,OTHER,,Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD,2027-06,ESTIMATED,FSHD composite (FSHD-COM) | Electrical Impedance Myography (EIM),,ALL,2018-03-05,ACTUAL,OBSERVATIONAL
ANIP,"ANI Pharmaceuticals, Inc.",NCT05486468,PHASE3,RECRUITING,"Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate",Yutiq 0.18 MG Drug Implant,TYNI,RANDOMIZED,2,Treatment Arm | Control Arm,EXPERIMENTAL | SHAM_COMPARATOR,The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial),"Eye Point Pharmaceuticals, ANI Pharmaceuticals",2026-12,ESTIMATED,18 Years - N/A,30,ESTIMATED,PARALLEL,OTHER,DOUBLE,The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial),2026-07,ESTIMATED,Recurrence rate of uveitis will be assessed at the 6-month visit,TREATMENT,ALL,2022-10-05,ACTUAL,INTERVENTIONAL
ANIP,"ANI Pharmaceuticals, Inc.",NCT07346079,PHASE4,RECRUITING,"Gout Arthritis, Gout Flare, Gout","Purified Cortophin Gel, 40 U, Purified Cortophin Gel 80 U",,RANDOMIZED,2,Purified Cortophin Gel 40 U | Purified Cortophin Gel 80 U,EXPERIMENTAL | EXPERIMENTAL,"This is a randomized, multicenter, double-blind, single administration study to investigate the efficacy and safety of 2 dosing regimens of Purified Cortrophin® Gel in the treatment of an acute gouty arthritis flare.

The study consists of three periods: an optional pre-screening period, a double-blind treatment period, and a 7-day follow-up period.

The treatment period is double-blind, and the patients will be randomized to treatment with 40 U Purified Cortrophin® Gel or 80 U Purified Cortroph",ANI Pharmaceuticals,2027-08-31,ESTIMATED,18 Years - 90 Years,150,ESTIMATED,PARALLEL,OTHER,DOUBLE,"A Randomized, Multicenter, Double-blind, Efficacy and Safety Study of 2 Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares",2027-08-31,ESTIMATED,Change in gout pain intensity from baseline in target join to 72 hours post-injection,TREATMENT,ALL,2025-12-20,ACTUAL,INTERVENTIONAL
ANIP,"ANI Pharmaceuticals, Inc.",NCT05322070,PHASE4,ACTIVE_NOT_RECRUITING,"Uveitis, Posterior",Fluocinolone Acetonide Intravitreal Implant 0.18 mg,,,1,Fluocinolone Acetonide 0.18 mg,EXPERIMENTAL,A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.,CBCC Global Research,2025-11,ESTIMATED,18 Years - N/A,125,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Phase 4 Study of YUTIQ® (Fluocinolone Acetonide Intravitreal Implant) 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis (Intraocular Inflammation Study),2025-11,ESTIMATED,Change in BCVA | Change in CST,TREATMENT,ALL,2022-06-06,ACTUAL,INTERVENTIONAL
ANIP,"ANI Pharmaceuticals, Inc.",NCT06539481,PHASE4,RECRUITING,Non-infectious Uveitis Affecting the Posterior Segment of the Eye,fluocinolone acetonide 190 micrograms,,,1,ILUVIEN® 190μg,EXPERIMENTAL,"The main aim is to test how safe and effective the medicine ILUVIEN® (190μg) is for children and adolescents, who have non-infectious uveitis that keeps coming back and affects the back of the eye.

The main thing Alimera wants to find out is how well the implant works for treating non-infectious uveitis in the back of the eye. Treatment success will be measured after 6 months of using the implant.

The treatment will be considered successful if two things happen:

1. No swelling in the back of ",,2028-10-31,ESTIMATED,6 Years - 17 Years,25,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Non-randomised, Open-label, Uncontrolled, Multi-centre, Phase IIIb Study Evaluating the Safety and Efficacy of Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Paediatric Subjects From 6 Years to Less Than 18 Years With Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye",2026-07-15,ESTIMATED,"Absence of cystoid macular oedema on Optical Coherence Tomography and a decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze. | Rate of cataract formation and Rate of IOP elevation",PREVENTION,ALL,2024-08-31,ESTIMATED,INTERVENTIONAL
ANIP,"ANI Pharmaceuticals, Inc.",NCT04469595,PHASE4,ACTIVE_NOT_RECRUITING,Diabetic Macular Edema,"Iluvien 0.19 MG Drug Implant, Aflibercept",NEW DAY,RANDOMIZED,2,ILUVIEN Arm | Aflibercept Arm,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compa",,2024-12-31,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)",2024-12-31,ESTIMATED,The mean total number of supplemental aflibercept injections needed during the study,TREATMENT,ALL,2020-08-31,ACTUAL,INTERVENTIONAL
SPRY,"ARS Pharmaceuticals, Inc.",NCT06927999,PHASE2,RECRUITING,Urticaria Chronic,"Placebo, 0.5 mg epinephrine, 1 mg epinephrine",,RANDOMIZED,3,Placebo | 0.5 mg | 1 mg,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).",,2026-06,ESTIMATED,18 Years - 65 Years,42,ESTIMATED,CROSSOVER,INDUSTRY,DOUBLE,"An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria",2026-06,ESTIMATED,Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch and hive,TREATMENT,ALL,2025-07-09,ACTUAL,INTERVENTIONAL
SPRY,"ARS Pharmaceuticals, Inc.",NCT06834165,PHASE4,RECRUITING,Allergic Reactions,"Neffy, Adrenaline",,RANDOMIZED,2,Neffy | IM adrenaline,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The study is to assess the safety of neffy or IM Adrenalin in patients who are experiencing allergic reactions after an OFC, allergen Immunotherapy (AIT), or other allergy challenge that may require epinephrine intervention.",,2026-06,ESTIMATED,4 Years - N/A,600,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy,2026-04,ESTIMATED,AEs after epinephrine treatment within 2 hours,TREATMENT,ALL,2025-05-20,ACTUAL,INTERVENTIONAL
VKTX,"Viking Therapeutics, Inc.",NCT07104500,PHASE3,ACTIVE_NOT_RECRUITING,Weight Loss,VK2735,VANQUISH 1,RANDOMIZED,4,Placebo Assignment | Active Assignment (Dose 1) | Active Assignment (Dose 2) | Active Assignment (Dose 3),PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.",,2027-08-01,ESTIMATED,18 Years - N/A,4500,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition",2027-07-01,ESTIMATED,Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment,TREATMENT,ALL,2025-06-23,ACTUAL,INTERVENTIONAL
VKTX,"Viking Therapeutics, Inc.",NCT07104383,PHASE3,RECRUITING,Weight Loss,VK2735,,RANDOMIZED,4,Placebo Assignment | Active Assignment (Dose #1) | Active Assignment (Dose #2) | Active Assignment (Dose #3),PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight",,2027-08-01,ESTIMATED,18 Years - N/A,1100,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight",2027-07-01,ESTIMATED,Percent change in body weight from baseline to Week 78 in body weight,TREATMENT,ALL,2025-06-23,ACTUAL,INTERVENTIONAL
LXEO,"Lexeo Therapeutics, Inc.",NCT05445323,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Friedreich Ataxia, Cardiomyopathy, Secondary",,,,1,Cohort 1/ Cohort 2/ Cohort 3,EXPERIMENTAL,"This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver the human frataxin (hFXN) gene to cardiac cells over a 52-week period. Long-term safety and efficacy will be evaluated for an additional 4-years ",,2029-09,ESTIMATED,18 Years - 50 Years,8,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,A Phase 1/2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich's Ataxia,2029-09,ESTIMATED,Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious events (TESAEs),TREATMENT,ALL,2022-08-24,ACTUAL,INTERVENTIONAL
LXEO,"Lexeo Therapeutics, Inc.",NCT06976606,,RECRUITING,"Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC",,SNAPSHOT- PKP2,,0,,,An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.,,2027-09,ESTIMATED,18 Years - 65 Years,40,ESTIMATED,,INDUSTRY,,"An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)",2027-07,ESTIMATED,Premature ventricular contractions (PVC),,ALL,2024-01-23,ACTUAL,OBSERVATIONAL
LXEO,"Lexeo Therapeutics, Inc.",NCT05400330,PHASE1,ACTIVE_NOT_RECRUITING,Alzheimer Disease,LX1001,LEADLTFU,,1,Previously administered LX1001,EXPERIMENTAL,"The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4. Additional secondary outcomes include amyloid PET scan, CSF markers (including Aβ42, Aβ42/Aβ40 ratio T--tau, and P-tau), and quantitative MRI (",,2028-11,ESTIMATED,50 Years - N/A,10,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,Long-Term Follow-Up to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease,2028-11,ESTIMATED,Incidence of treatment emergent adverse events | Incidence of serious adverse events,TREATMENT,ALL,2023-05-08,ACTUAL,INTERVENTIONAL
LXEO,"Lexeo Therapeutics, Inc.",NCT06865482,,RECRUITING,"Friedreich Ataxia, Cardiomyopathy",,,,2,Cohort 1: Participants ≥16 years of age with FA-CM | Cohort 2: Participants ≥6 to <16 years of age with FA-CM, | ,Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA),,2027-09,ESTIMATED,6 Years - N/A,65,ESTIMATED,,INDUSTRY,,Characteristics And Clinical Course Of Disease In Participants With Cardiomyopathy Associated With Friedreich Ataxia (CLARITY-FA),2027-09,ESTIMATED,Characterize cardiac disease presentation and progression among participants,,ALL,2025-09-30,ACTUAL,OBSERVATIONAL
LXEO,"Lexeo Therapeutics, Inc.",NCT06109181,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC",,,,1,LX2020,EXPERIMENTAL,"This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM",,2027-03,ESTIMATED,18 Years - 65 Years,10,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant,2026-12,ESTIMATED,Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).,TREATMENT,ALL,2024-02-29,ACTUAL,INTERVENTIONAL
RYTM,"Rhythm Pharmaceuticals, Inc.",NCT06239064,,ACTIVE_NOT_RECRUITING,"Obesity, Childhood, Hyperphagia, Retinopathy, Syndactyly, Polydactyly, Cognitive Impairment, Bardet-Biedl Syndrome, POMC Deficiency",,WEGIO,,1,Participants suspected to genetic obesity,,"TITLE: Whole genetic approach in Early Genetic Identification of Obesity (WEGIO)

DESIGN: Multicenter epidemiological study

STUDY POPULATION: Participants at risk for a syndromic or a monogenic genetic obesity, incl. participants clinically diagnosed with Bardet-Biedl-Syndrome (BBS)

NUMBER OF PARTICIPANTS: 1000 for initial genetic sequencing and app. 40 for the follow-up documentation

COORDINATING INVESTIGATOR: Prof. Dr. Arndt Rolfs","Rhythm Pharmaceuticals, Inc.",2027-03-01,ESTIMATED,2 Years - N/A,1000,ESTIMATED,,NETWORK,,Whole Genetic Approach in Early Genetic Identification of Obesity (WEGIO),2026-03-01,ESTIMATED,BBS prevalence,,ALL,2024-01-24,ACTUAL,OBSERVATIONAL
RYTM,"Rhythm Pharmaceuticals, Inc.",NCT06420622,,RECRUITING,"Gene Abnormality, Child Obesity, Hunger",,INDICATOR,,0,,,"The study investigates the genetic backgrounds of extreme childhood obesity (using saliva sample) and contains short online questionnaires on family history, phenotypical characteristics and hunger behavior. It is an observational study in a predefined cohort (subjects with data in CrescNet aged 0-18 with BMI measurement(s) above the 99.5th percentile). Recruitment will initially be from CrescNet data through the cooperating pediatric and adolescent medical institutions associated with these ini","Rhythm Pharmaceuticals, Inc.",2026-03-31,ESTIMATED,2 Years - 18 Years,1000,ESTIMATED,,OTHER,,INDIcators for Clarifying the bAckground of exTreme Obesity in childRen (INDICATOR),2025-10-31,ESTIMATED,Prevalence of each monogenetic obesity | Typical patterns of weight gain for each form of obesity,,ALL,2024-04-15,ACTUAL,OBSERVATIONAL
RYTM,"Rhythm Pharmaceuticals, Inc.",NCT05093634,PHASE3,ACTIVE_NOT_RECRUITING,"Obesity, Genetic Obesity","Setmelanotide, Placebo",,RANDOMIZED,4,POMC or PCSK1 variant | LEPR variant | NCOA1 (SRC1) variant | SH2B1 variant,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

* POMC or PCSK1 (Sub-study 035a)
* LEPR (Sub-study 035b)
* SRC1 (Sub-study 035c)
* SH2B1 (Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.",,2026-12-31,ESTIMATED,6 Years - 65 Years,296,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway",2025-12-22,ACTUAL,"Difference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMI",TREATMENT,ALL,2021-12-10,ACTUAL,INTERVENTIONAL
RYTM,"Rhythm Pharmaceuticals, Inc.",NCT06239116,"PHASE1, PHASE2",RECRUITING,"Hypothalamic Obesity, Prader-Willi Syndrome, PWS","Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718, Part D: RM-718",,RANDOMIZED,17,RM-718 (Cohort A1) | RM-718 (Cohort A2) | RM-718 (Cohort A3) | RM-718 (Cohort A4) | RM-718 (Cohort A5) | RM-718 (Cohort A6) | RM-718 (Cohort A7) | RM-718 (Cohort A8) | RM-718 (Cohort A9) | RM-718 (Cohort B1) | RM-718 (Cohort B2) | RM-718 (Cohort B3) | RM-718 (Cohort B4) | RM-718 (Cohort B5) | RM-718 (Cohort B6) | RM-718 (Cohort C1) | RM-718 (Cohort D1),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with MC4R Pathway Impairment",,2028-11-01,ESTIMATED,12 Years - 65 Years,150,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Obesity Due to MC4R Impairment,2027-11-01,ESTIMATED,"Parts A, B, C, D: Safety and Tolerability Assessed by Number of Study Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)",TREATMENT,ALL,2024-03-05,ACTUAL,INTERVENTIONAL
RYTM,"Rhythm Pharmaceuticals, Inc.",NCT05774756,PHASE3,ACTIVE_NOT_RECRUITING,Hypothalamic Obesity,"Setmelanotide, Placebo",,RANDOMIZED,2,Setemelanotide | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for 52 weeks on a therapeutic regimen.

A separate sub-study in patients with congenital HO is detailed under NCT06760546.",,2027-04-16,ESTIMATED,4 Years - N/A,120,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity",2025-03-18,ACTUAL,Mean % change in BMI,TREATMENT,ALL,2023-04-26,ACTUAL,INTERVENTIONAL
RYTM,"Rhythm Pharmaceuticals, Inc.",NCT06760546,PHASE3,RECRUITING,"Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome","Setmelanotide, Placebo",,RANDOMIZED,2,Setemelanotide | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a sub-study of Study RM-493-040 (NCT05774756).

The goal of this sub-study is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with congenital Hypothalamic Obesity (cHO). To determine how well setmelanotide works and how safe it is, patients with cHO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 26 weeks on a therapeutic regimen.",,2028-03-13,ESTIMATED,4 Years - N/A,39,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity",2027-03-13,ESTIMATED,Mean % change in BMI,TREATMENT,ALL,2025-09-23,ACTUAL,INTERVENTIONAL
RYTM,"Rhythm Pharmaceuticals, Inc.",NCT06772597,PHASE2,ACTIVE_NOT_RECRUITING,"Prader-Willi Syndrome, Obesity, Hyperphagia",Setmelanotide,,,1,Setmelanotide (Open-label),EXPERIMENTAL,"This is a Phase 2, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 52 weeks.",,2027-10-31,ESTIMATED,6 Years - 65 Years,18,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2 Open-label Study of Setmelanotide in Patients With Prader-Willi Syndrome,2026-10-31,ESTIMATED,Frequency and severity of adverse events (AEs),TREATMENT,ALL,2025-03-04,ACTUAL,INTERVENTIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT07137338,PHASE1,NOT_YET_RECRUITING,Dilated Cardiomyopathy (DCM),,,,1,Single ascending dose of RP-A701 in up to 2 consecutive cohorts,EXPERIMENTAL,"This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.",,2029-06,ESTIMATED,18 Years - 65 Years,8,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human BCL2-associated Athanogene 3 (BAG3) Gene Coding Sequence (RP-A701) in Subjects With Dilated Cardiomyopathy Arising From Pathogenic BAG3 Variants (BAG3-DCM),2029-06,ESTIMATED,Incidence of Treatment-emergent Adverse Events (TEAE) | Incidence of Treatment-emergent Serious Adverse Events (SAE). | Incidence of Dose Limiting Toxicities (DLT).,TREATMENT,ALL,2026-06,ESTIMATED,INTERVENTIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT06214507,,RECRUITING,Danon Disease,,,,2,Prospective Cohort | Retrospective Cohort, | ,The goal of this international observational study is to learn about the natural history of Danon disease in male patients (≥8 years of age) and female patients (8 to 50 years of age).,,2030-03,ESTIMATED,8 Years - N/A,60,ESTIMATED,,INDUSTRY,,"An Observational Study of Genetic Cardiomyopathy, Danon Disease",2029-12,ESTIMATED,Left Ventricular Mass Index (LVMI) by echocardiogram,,ALL,2023-12-20,ACTUAL,OBSERVATIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT04248439,PHASE2,ACTIVE_NOT_RECRUITING,Fanconi Anemia Complementation Group A,RP-L102,,,1,RP-L102,EXPERIMENTAL,"The objective of this study is to assess the therapeutic efficacy of a hematopoietic cell-based gene therapy for patients with Fanconi anemia, subtype A (FA-A).

Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will be infused intravenously back to the patient with the goal of preventing bone marrow failure.",,2026-05-05,ESTIMATED,1 Year - N/A,5,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects With Fanconi Anemia Subtype A,2026-05-05,ESTIMATED,Bone Marrow (BM) Colony-Forming Cell (CFC) Mitomycin-C (MMC) resistance,TREATMENT,ALL,2020-07-15,ACTUAL,INTERVENTIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT06282432,,ACTIVE_NOT_RECRUITING,Leukocyte Adhesion Deficiency,,,,1,Subjects that received RP-L201 on the RP-L201-0318 Parent Study,,This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene,,2036-10-04,ESTIMATED,3 Months - N/A,9,ACTUAL,,INDUSTRY,,Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector Encoding the ITGB2 Gene,2036-10-04,ESTIMATED,Hematopoietic stem cell transplant (HSCT) free survival,,ALL,2022-03-09,ACTUAL,OBSERVATIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT06092034,PHASE2,RECRUITING,Danon Disease,,,,1,RP-A501,EXPERIMENTAL,"This is a single arm Phase 2 trial to evaluate the efficacy and safety of RP-A501, a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene, in male patients with Danon Disease.",,2032-04,ESTIMATED,8 Years - N/A,14,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients With Danon Disease,2028-04,ESTIMATED,Evaluation of efficacy via primary endpoint comprised of LAMP2 myocardial tissue expression and left ventricular mass index,TREATMENT,MALE,2023-09-05,ACTUAL,INTERVENTIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT06644742,,RECRUITING,"Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Genetic Diseases",,,,1,Prospective Cohort,,The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.,,2028-12,ESTIMATED,12 Years - N/A,36,ESTIMATED,,INDUSTRY,,The Natural History of Arrhythmogenic Cardiomyopathy With Pathogenic Plakophilin-2 Variants (PKP2-ACM): An Observational Cohort Study,2028-12,ESTIMATED,Heart rhythm and rate monitoring measures | Cardiac biomarkers,,ALL,2025-09,ESTIMATED,OBSERVATIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT04069533,PHASE2,ACTIVE_NOT_RECRUITING,Fanconi Anemia Complementation Group A,RP-L102,,,1,RP-L102,EXPERIMENTAL,"This is an open-label Phase II clinical trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for pediatric patients with Fanconi Anemia, subtype A (FA-A).

Hematopoietic stem cells from mobilized peripheral blood of patients with FA-A will be transduced ex vivo (outside the body) with a lentiviral vector carrying the FANCA gene. After transduction, the corrected stem cells will be infused intravenously back to the patient with the goal of preventing bone marrow failure.",,2025-02,ESTIMATED,1 Year - 17 Years,7,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients With Fanconi Anemia Subtype A,2025-02,ESTIMATED,Phenotypic correction of bone marrow colony forming units after infusion of RP-L102,TREATMENT,ALL,2019-11-28,ACTUAL,INTERVENTIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT06422351,PHASE2,NOT_YET_RECRUITING,Pyruvate Kinase Deficiency,RP-L301,,,1,Participant Group/Arm,EXPERIMENTAL,This is an open-label Phase II trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).,,2029-01,ESTIMATED,8 Years - 55 Years,10,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Subjects With Pyruvate Kinase Deficiency,2026-11,ESTIMATED,Improvement in Anemia,TREATMENT,ALL,2024-08,ESTIMATED,INTERVENTIONAL
RCKT,"Rocket Pharmaceuticals, Inc.",NCT05885412,PHASE1,RECRUITING,PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM),,,,1,RP-A601,EXPERIMENTAL,This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.,,2026-09,ESTIMATED,18 Years - N/A,9,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-Associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human Plakophilin-2a (PKP2a) Coding Sequence (RP-A601; AAVrh.74-PKP2a) in Subjects With Arrhythmogenic Cardiomyopathy Arising From Pathogenic PKP2 Variants (PKP2-ACM),2025-09,ESTIMATED,Evaluation of safety associated with RP-A601,TREATMENT,ALL,2023-08-29,ACTUAL,INTERVENTIONAL
PBH,Prestige Consumer Healthcare Inc.,NCT05141149,"PHASE1, PHASE2",RECRUITING,Pancreatic Cancer,"PBP1510 (400mg/16mL), Gemcitabine (1000 mg/m^2)",,NON_RANDOMIZED,10,Cohort 1M | Cohort 1C | Cohort 2M | Cohort 2C | Cohort 3M | Cohort 3C | Cohort 4M | Cohort 4C | Cohort 5M | Cohort 5C,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The first in human clinical study is planned as an open-label, dose-escalation, and dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Part 1 as a PBP1510 single agent dose-escalation, and PBP1510 dose-escalation in combination with gemcitabine, and Part 2 as PBP1510 dose-expansion at the RP2D in combination with gemcitabine.",,2026-12,ESTIMATED,18 Years - N/A,80,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer",2026-02,ESTIMATED,PART 1 (PHASE 1): To evaluate safety and tolerability of PBP1510 | PART 1 (PHASE 1): Dose limiting toxicity (DLT) evaluation | PART 2 (PHASE 2a): To establish safety of PBP1510 in combination with gemcitabine | PART 2 (PHASE 2a): To assess the efficacy of PBP1510 in combination with gemcitabine | PART 1 (PHASE 1): Determine the recommended Phase 2a dose (R2PD) of PBP1510,TREATMENT,ALL,2023-06-05,ACTUAL,INTERVENTIONAL
PBH,Prestige Consumer Healthcare Inc.,NCT05108259,PHASE1,RECRUITING,Healthy Volunteers,"PBP1502, EU-licensed Humira, US-licensed Humira",,RANDOMIZED,3,PBP1502 | EU-licensed Humira | US-licensed Humira,EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The main purpose of the study is to demonstrate pharmacokinetic (PK) equivalence of PBP1502 to the European (EU) and American (US) Humira reference products, following a single subcutaneous (SC) dose of 40 mg in healthy volunteers.",,2026-05,ESTIMATED,18 Years - 55 Years,324,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1, Double-blind, Randomized, Three-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of a Single Subcutaneous Dose of PBP1502, EU-Humira®, and US-Humira® in Healthy Male and Female Subjects.",2026-02,ESTIMATED,Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) | Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) | Maximum Serum Concentration (Cmax),TREATMENT,ALL,2022-03-30,ACTUAL,INTERVENTIONAL
PBH,Prestige Consumer Healthcare Inc.,NCT03390686,PHASE3,ACTIVE_NOT_RECRUITING,"Lung Cancer, Non-small Cell Lung Cancer","Bevacizumab, HD204, Carboplatin, Paclitaxel",,RANDOMIZED,2,HD204 (Bevacizumab biosimilar) | Avastin (Bevacizumab),EXPERIMENTAL | ACTIVE_COMPARATOR,"In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy, safety, pharmacokinetics and immunogenicity.",,2025-12,ESTIMATED,18 Years - N/A,650,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer",2024-07-01,ACTUAL,Overall Response Rate (ORR) at Week 18,TREATMENT,ALL,2019-11-15,ACTUAL,INTERVENTIONAL
VCEL,Vericel Corporation,NCT03588975,PHASE3,RECRUITING,"Chondral Defect, Osteochondritis Dissecans (OCD), Articular Cartilage Defect, Articular Cartilage Disorder of Knee",MACI,PEAK,RANDOMIZED,2,MACI | microfracture,EXPERIMENTAL | ACTIVE_COMPARATOR,The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of patients aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.,,2027-06,ESTIMATED,10 Years - 17 Years,45,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee",2027-06,ESTIMATED,Proportion of Patients Who Achieve at Least a 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Scores,TREATMENT,ALL,2018-10-24,ACTUAL,INTERVENTIONAL
VCEL,Vericel Corporation,NCT06915233,PHASE3,RECRUITING,"Chondral Defect, Articular Cartilage Defect",autologous cultured chondrocytes on porcine collagen membrane,MASCOT,RANDOMIZED,2,MACI | Bone Marrow Stimulation,EXPERIMENTAL | ACTIVE_COMPARATOR,The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus.,,2030-07,ESTIMATED,17 Years - 65 Years,309,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients With Symptomatic Chondral or Osteochondral Lesions of the Talus (MASCOT)",2030-07,ESTIMATED,Change from Baseline to Week 104 in the FAOS Pain and Function (SRA) subscale scores,TREATMENT,ALL,2025-12,ESTIMATED,INTERVENTIONAL
ALDX,"Aldeyra Therapeutics, Inc.",NCT07402876,PHASE3,RECRUITING,Primary Vitreoretinal Lymphoma,"ICM ADX-2191 injection, Monthly ADX-2191 injection",,RANDOMIZED,2,Induction/Consolidation/Maintenance (ICM) ADX-2191 injection | Monthly ADX-2191 injection,EXPERIMENTAL | ACTIVE_COMPARATOR,"A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma",,2026-12,ESTIMATED,21 Years - N/A,20,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Prospective, Randomized, Double-masked, Dosing-frequency-controlled, Multicenter Clinical Trial Evaluating the Safety and Activity of Intravitreally Injected ADX-2191 (Methotrexate Injection USP) in Patients With Primary Vitreoretinal Lymphoma",2026-12,ESTIMATED,Proportion of clearance of lymphomatous vitreous cells compared across ICM and monthly ADX-2191 treatment groups after eight weeks of treatment,TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
IRON,"Disc Medicine, Inc.",NCT05745883,PHASE1,ACTIVE_NOT_RECRUITING,"Chronic Kidney Diseases, Anemia of Chronic Kidney Disease","DISC-0974, Placebo",,RANDOMIZED,4,Phase 1b Single Dose | Single Dose of Placebo | Phase 1b Multiple Doses | Multiple Doses of Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.",,2026-05,ESTIMATED,18 Years - N/A,50,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants With Non-Dialysis Dependent Chronic Kidney Disease and Anemia",2026-01,ESTIMATED,Incidence of treatment-emergent adverse events | Incidence of clinically abnormal vital signs | Incidence of abnormal laboratory test results | Incidence of clinically abnormal physical exam | Incidence of clinically abnormal electrocardiograms,TREATMENT,ALL,2023-04-04,ACTUAL,INTERVENTIONAL
IRON,"Disc Medicine, Inc.",NCT06985147,PHASE2,RECRUITING,Polycythemia Vera (PV),DISC-3405,,,1,Within-participant dose escalation,EXPERIMENTAL,"This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).",,2029-02,ESTIMATED,18 Years - N/A,60,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants With Polycythemia Vera (PV)",2027-02,ESTIMATED,Number of participants with treatment-related adverse events as assessed by CTCAE | Incidence of clinically abnormal vital signs | Incidence of clinically abnormal physical exam | Incidence of clinically abnormal electrocardiograms | Incidence of abnormal laboratory test results,TREATMENT,ALL,2025-08-12,ACTUAL,INTERVENTIONAL
IRON,"Disc Medicine, Inc.",NCT05320198,"PHASE1, PHASE2",RECRUITING,"Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes",DISC-0974,,RANDOMIZED,2,Phase 1b: Dose Escalation | Phase 2: Expansion,EXPERIMENTAL | EXPERIMENTAL,"This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.",,2026-09,ESTIMATED,18 Years - N/A,150,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia",2026-09,ESTIMATED,"Incidence of treatment-emergent adverse events (Phase 1b only) | Incidence of clinically abnormal vital signs (Phase 1b only) | Incidence of clinically abnormal physical exam (Phase 1b only) | Incidence of clinically abnormal electrocardiograms (Phase 1b only) | Incidence of abnormal laboratory test results (Phase 1b only) | Transfusion-dependent (TD) high cohort: transfusion independence, defined as the absence of packed red blood cell (PRBC) transfusions over any rolling 12-week interval during the treatment period with a minimum hemoglobin (Hgb) of 7 g/dL (Phase 2 only) | TD low cohort: transfusion independence, defined as the absence of PRBC transfusions over any rolling 16 week interval during the treatment period with a minimum Hgb of 7 g/dL (Phase 2 only) | Non-transfusion-dependent (nTD) cohort: anemia response, defined as the composite of the absence of transfusions over any rolling 12 week period and a concomitant mean Hgb increase of ≥1.5 g/dL over baseline (Phase 2 only)",TREATMENT,ALL,2022-06-06,ACTUAL,INTERVENTIONAL
IRON,"Disc Medicine, Inc.",NCT07368972,PHASE2,RECRUITING,"Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia","DISC-0974, Placebo",,RANDOMIZED,2,Active | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2, multicenter, randomized, double-blind placebo-controlled study of DISC-0974 to evaluate safety, tolerability, and efficacy in participants with IBD and anemia of inflammation.",,2027-03,ESTIMATED,18 Years - N/A,21,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"RALLY-IBD: A Phase 2 Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of DISC-0974 in Participants With Inflammatory Bowel Disease and Anemia of Inflammation",2026-10,ESTIMATED,Maximal change from baseline in Hgb through Day 85,TREATMENT,ALL,2026-02-20,ACTUAL,INTERVENTIONAL
IRON,"Disc Medicine, Inc.",NCT06910358,PHASE3,RECRUITING,"Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)","Placebo, DISC-1459",APOLLO,RANDOMIZED,2,Placebo | DISC-1459 oral dose,PLACEBO_COMPARATOR | EXPERIMENTAL,"The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are:

* Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP.
* How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment.

Researchers will compare bitopertin to a placebo look-alike substance that contains no drug.

Partici",,2026-11,ESTIMATED,12 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)",2026-10,ESTIMATED,"Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatment | Percent change from baseline in whole-blood metal-free PPIX levels at 6 months | Safety and tolerability, as assessed by adverse events (AEs) and laboratory results, over the 6-month treatment period",TREATMENT,ALL,2025-04-04,ACTUAL,INTERVENTIONAL
IRON,"Disc Medicine, Inc.",NCT07187973,PHASE1,RECRUITING,Sickle Cell Disease,DISC-3405,,,1,Within-participant dose escalation,EXPERIMENTAL,"This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.",,2027-10,ESTIMATED,18 Years - N/A,24,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease",2027-06,ESTIMATED,Safety and tolerability of DISC-3405 administration in participants with SCD,TREATMENT,ALL,2026-01-06,ACTUAL,INTERVENTIONAL
SRPT,"Sarepta Therapeutics, Inc.",NCT05881408,PHASE3,ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy,,ENVISION,RANDOMIZED,2,Delandistrogene Moxeparvovec followed by Placebo | Placebo followed by Delandistrogene Moxeparvovec,EXPERIMENTAL | PLACEBO_COMPARATOR,"The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study. Participants will be in the study for approximately 128 weeks. All participants will have the opportunity to receive intravenous (IV) delandistrogene moxeparvovec in either Part 1 or Part 2.",Hoffmann-La Roche,2028-06-30,ESTIMATED,N/A - N/A,148,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP- 9001 in Non-Ambulatory and Ambulatory Subjects With Duchenne Muscular Dystrophy (ENVISION)",2027-05-31,ESTIMATED,Part 1: Change From Baseline in the Total Score of Performance of Upper Limb (PUL) (Version 2.0) at Week 72,TREATMENT,MALE,2023-05-31,ACTUAL,INTERVENTIONAL
SRPT,"Sarepta Therapeutics, Inc.",NCT06246513,PHASE3,ACTIVE_NOT_RECRUITING,Limb-girdle Muscular Dystrophy,"SRP-9003, Glucocorticoid",EMERGENE,,1,SRP-9003,EXPERIMENTAL,"This is a multicenter, global study of the effects of a single systemic dose of SRP-9003 on beta-sarcoglycan (β-SG) gene expression in participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). This study will consist of both ambulatory participants (Cohort 1) and non-ambulatory participants (Cohort 2).",,2029-11-30,ESTIMATED,4 Years - N/A,17,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects With Limb Girdle Muscular Dystrophy 2E/R4",2025-03-04,ACTUAL,Cohort 1: Change from Baseline in β-SG Expression at Day 60 Post-dose as Measured by Immunofluorescence (IF) Percent β-SG Positive Fibers,TREATMENT,ALL,2024-01-15,ACTUAL,INTERVENTIONAL
SRPT,"Sarepta Therapeutics, Inc.",NCT06128564,PHASE2,ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy,,ENVOL,,1,Delandistrogene Moxeparvovec,EXPERIMENTAL,"This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.","Sarepta Therapeutics, Inc.",2034-01-30,ESTIMATED,2 Years - 3 Years,13,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Two-Part, Open-Label Systemic Gene Delivery Study to Evaluate the Safety and Expression of RO7494222 (SRP-9001) in Subjects Under the Age of Four With Duchenne Muscular Dystrophy",2030-02-28,ESTIMATED,"Percentage of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI)",TREATMENT,MALE,2023-11-29,ACTUAL,INTERVENTIONAL
SRPT,"Sarepta Therapeutics, Inc.",NCT04626674,PHASE1,RECRUITING,"Muscular Dystrophy, Duchenne",,ENDEAVOR,,1,Delandistrogene Moxeparvovec,EXPERIMENTAL,This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with DMD. The maximum participant duration for this study is 156 weeks.,Hoffmann-La Roche,2028-02-29,ESTIMATED,2 Years - N/A,83,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)",2027-12-31,ESTIMATED,"Part 1 (Cohorts 1 to 5): Change from Baseline in Quantity of Delandistrogene Moxeparvovec Dystrophin Expression at Week 12, as Measured by Western Blot | Part 1 (Cohorts 6 to 8): Quantity of Delandistrogene Moxeparvovec Dystrophin Expression at Week 12 as Measured by Western Blot | Cohort 8: Number of Participants with Acute Liver Injury (ALI)",TREATMENT,MALE,2020-11-23,ACTUAL,INTERVENTIONAL
SRPT,"Sarepta Therapeutics, Inc.",NCT05876780,PHASE1,ACTIVE_NOT_RECRUITING,Limb Girdle Muscular Dystrophy,,,,1,SRP-9003,EXPERIMENTAL,"The primary purpose of this study is to evaluate the safety of SRP-9003 and to quantify expression of β-SG in the skeletal muscle of participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). The study will include both ambulatory (Cohort 1) and non-ambulatory (Cohort 2) participants.",,2028-08-28,ESTIMATED,4 Years - 50 Years,6,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter, Open-label, Single-dose, Systemic Gene Transfer Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9003 on Subjects With Limb Girdle Muscular Dystrophy, Type 2E/R4 (β-Sarcoglycan Deficiency)",2028-08-28,ESTIMATED,Number of Treatment-Emergent Adverse Events (AEs) and Treatment-Emergent Serious Adverse Events (SAEs) | Change from Baseline in β-SG Protein Expression Quantity Assessed by Immunofluorescence (IF) Fiber Intensity at Day 60 | Change from Baseline in β-SG Protein Expression Quantity Assessed by IF Percent Protein Fibers (PPF) at Day 60 | Change from Baseline in β-SG Protein Expression Quantity Assessed by Western Blot at Day 60,TREATMENT,ALL,2022-12-19,ACTUAL,INTERVENTIONAL
SRPT,"Sarepta Therapeutics, Inc.",NCT06581887,,RECRUITING,"DMD, BMD",,D-BRAIN,,1,Cohort,,"Study aims to develop and to evaluate the neurophysiological and physiological response to a classical conditioning task.To better understand how Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) impacts mental health and how to assess it. Participants invited to complete questionnaires about behaviour, cognitive function and social interactions, complete computer tasks and have an optional MRI brain scan,","Sarepta Therapeutics, Inc.",2024-12-31,ESTIMATED,7 Years - 17 Years,100,ESTIMATED,,OTHER,,Defining Outcome Measures for Behavioural and Emotional Problems in Dystrophinopathies,2024-11-19,ESTIMATED,"Group differences between DMD, BMD and controls in the initial aversive unconditioned stimulus.",,MALE,2022-09-13,ACTUAL,OBSERVATIONAL
SRPT,"Sarepta Therapeutics, Inc.",NCT03992430,PHASE3,ACTIVE_NOT_RECRUITING,"Muscular Dystrophy, Duchenne",Eteplirsen,MIS51ON,RANDOMIZED,4,Part 1: Eteplirsen | Part 2: Eteplirsen 30 mg/kg | Part 2: Eteplirsen 100 mg/kg | Part 2: Eteplirsen 200 mg/kg,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in approximately 10 participants with DMD; Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 200 mg/kg) of eteplirsen compared with that of the 30 mg/kg dose of eteplirsen, in approximately 144 participants with genetically confirmed deletion mutations amenable to treatment by skipping exon 51.",,2026-10-31,ESTIMATED,4 Years - 13 Years,160,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients With Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping",2026-10-31,ESTIMATED,Part 1: Incidence of Adverse Events (AEs) | Part 2: Change From Baseline at Week 144 in the NSAA Total Score (for Final Analysis) | Part 2: Change from Baseline at Week 72 or Week 96 in NSAA Total Score (for Conditional Efficacy Interim Analysis),TREATMENT,MALE,2020-07-13,ACTUAL,INTERVENTIONAL
SRPT,"Sarepta Therapeutics, Inc.",NCT04475926,,ACTIVE_NOT_RECRUITING,Limb-girdle Muscular Dystrophy,,,,4,LGMD2E/R4 Cohort | LGMD2D/R3 Cohort | LGMD2C/R5 Cohort | LGMD2A/R1 Cohort, |  |  | ,"This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1).

These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 5 years after enrollment for participants with LGMD2C/R5, LGMD2D/R3, and LGMD2E/R4 with a Nort",,2030-09-05,ESTIMATED,4 Years - N/A,205,ACTUAL,,INDUSTRY,,"Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), Type 2C (LGMD2C/R5), and Type 2A (LGMD2A/R1)",2030-09-05,ESTIMATED,NSAD Total Score | Time to Rise from the Floor | Time of 10-Meter Walk/Run [10MWR] | Time to Ascend 4 Steps | Ankle Range of Motion (ROM) | Dimension of the Performance of the Upper Limb (PUL) | Timed Up and Go (TUG) | Time of 100-Meter Walk/Run (100MWR) | Pulmonary Function Test: Forced Vital Capacity (FVC),,ALL,2021-04-22,ACTUAL,OBSERVATIONAL
HELP,Cybin Inc.,NCT06564818,PHASE3,RECRUITING,Major Depressive Disorder,"CYB003, Placebo",APPROACH,RANDOMIZED,2,Experimental Arm A: CYB003 in 2 of 2 Dosing Sessions | Placebo Comparator Arm B: Placebo in 2 of 2 Dosing Sessions,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.",,2026-09,ESTIMATED,18 Years - 85 Years,220,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder",2026-08,ESTIMATED,Montgomery-Åsberg Depression Rating Scale (MADRS),TREATMENT,ALL,2024-12-17,ACTUAL,INTERVENTIONAL
HELP,Cybin Inc.,NCT06605105,PHASE3,RECRUITING,Major Depressive Disorder,CYB003,EXTEND,,1,CYB003,EXPERIMENTAL,This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.,Worldwide Clinical Trials,2028-03-15,ESTIMATED,18 Years - 85 Years,468,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase III Long-Term Extension Trial With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major Depressive Disorder (EXTEND),2028-03-15,ESTIMATED,Montgomery-Asberg Depression Rating Scale (MADRS),TREATMENT,ALL,2025-07-18,ACTUAL,INTERVENTIONAL
HELP,Cybin Inc.,NCT06051721,PHASE2,ACTIVE_NOT_RECRUITING,Generalized Anxiety Disorder,CYB004,,RANDOMIZED,2,Arm A: Active | Arm B: Control,EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.",Worldwide Clinical Trials,2026-09,ESTIMATED,18 Years - 65 Years,36,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2a, Randomized, Double-Blind, Active-Controlled Study to Assess the Preliminary Clinical Efficacy, Safety, Tolerability, and Pharmacokinetics, of CYB004 in Participants With Generalized Anxiety Disorder (GAD)",2025-10-14,ACTUAL,Hamilton Anxiety Rating Scale (HAM-A),TREATMENT,ALL,2024-05-10,ACTUAL,INTERVENTIONAL
HELP,Cybin Inc.,NCT06793397,PHASE3,RECRUITING,"Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression",CYB003,EMBRACE,RANDOMIZED,3,Experimental Arm A CYB003 in 2 of 2 Dosing Sessions | Experimental Arm B CYB003 in 2 of 2 Dosing Sessions | Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.",Worldwide Clinical Trials,2027-05-08,ESTIMATED,18 Years - 85 Years,330,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder",2027-03-18,ESTIMATED,Montgomery-Asberg Depression Scale (MADRS),TREATMENT,ALL,2025-12-10,ACTUAL,INTERVENTIONAL
ALT,"Altimmune, Inc.",NCT06987513,PHASE2,ACTIVE_NOT_RECRUITING,Alcohol Use Disorder (AUD),Pemvidutide,,RANDOMIZED,2,Pemvidutide 2.4mg (Active) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms:

* Pemvidutide: 2.4 mg SC once weekly
* Placebo: Placebo SC once weekly",,2026-06,ESTIMATED,18 Years - 75 Years,100,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight",2026-05,ESTIMATED,"Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the TLFB method",TREATMENT,ALL,2025-05-15,ACTUAL,INTERVENTIONAL
ALT,"Altimmune, Inc.",NCT07009860,PHASE2,RECRUITING,Alcohol Liver Disease,Pemvidutide,,RANDOMIZED,2,Pemvidutide 2.4 mg | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.

* Pemvidutide: 2.4 mg SC once weekly
* Placebo: Placebo SC once weekly",,2027-08-31,ESTIMATED,18 Years - 75 Years,100,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)",2027-03-31,ESTIMATED,Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24,TREATMENT,ALL,2025-06-16,ACTUAL,INTERVENTIONAL
BNTC,Benitec Biopharma Inc.,NCT06185673,"PHASE1, PHASE2",RECRUITING,Oculopharyngeal Muscular Dystrophy,,,,1,BB-301 Treatment,EXPERIMENTAL,"Subjects who have enrolled in the oculopharyngeal muscular dystrophy (OPMD) natural history study (Study BNTC-OPMD-NH-001) and have completed at least 6 months of follow up in Study BNTC-OPMD-NH-001 may be eligible to participate in this study, where all subjects will be treated with a single dose of BB-301. BB-301 will be injected directly into the middle pharyngeal constrictor muscle and the inferior pharyngeal constrictor muscle of the throat through the use of an open surgical procedure cond",,2040-11,ESTIMATED,N/A - 65 Years,30,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1b/2a, Open-label, Dose Escalation Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia",2030-11,ESTIMATED,Incidence of dose-limiting toxicities (DLTs) in phase 1b | Incidence of adverse events (AEs) according to NCI CTCAE v5.0 in phase 1b and in phase 2a | Phase 1b: Swallowing efficiency as measured by Vallecular Residue %(C2-4)^2 | Phase 1b: Swallowing efficiency as measured by Pyriform Sinus Residue %(C2-4)^2 | Phase 1b: Swallowing efficiency as measured by Other Pharyngeal Residue %(C2-4)^2 | Phase 1b: Swallowing efficiency as measured by Total Pharyngeal Residue %(C2-4)^2 | Phase 1b: Pharyngeal constrictor muscle function as estimated by the pharyngeal area at maximum constriction (PhAMPC) | Phase 2a: Swallowing efficiency as measured by Vallecular Residue %(C2-4)^2 | Phase 2a: Swallowing efficiency as measured by Pyriform Sinus Residue %(C2-4)^2 | Phase 2a: Swallowing efficiency as measured by Other Pharyngeal Residue %(C2-4)^2 | Phase 2a: Swallowing efficiency as measured by Total Pharyngeal Residue %(C2-4)^2 | Phase 2a: Pharyngeal constrictor muscle function as estimated by PhAMPC,TREATMENT,ALL,2023-11-28,ACTUAL,INTERVENTIONAL
MLTX,MoonLake Immunotherapeutics,NCT06768671,PHASE3,RECRUITING,Hidradenitis Suppurativa,Sonelokimab,,,1,sonelokimab,EXPERIMENTAL,This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.,,2026-03-27,ESTIMATED,12 Years - 17 Years,35,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents Aged ≥12 to ≤17 Years at the Time of Study Inclusion With Active Moderate to Severe Hidradenitis Suppurativa",2026-03-27,ESTIMATED,Pharmacokinetics (PK) of sonelokimab in adolescents | Adverse events (AEs) following treatment with sonelokimab in adolescents | Discontinuation of sonelokimab treatment due to AEs | Clinically significant changes in clinical laboratory parameters | Clinically significant changes in vital signs | Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervals,TREATMENT,ALL,2024-12-30,ACTUAL,INTERVENTIONAL
MLTX,MoonLake Immunotherapeutics,NCT06411379,PHASE3,ACTIVE_NOT_RECRUITING,Hidradenitis Suppurativa,"Sonelokimab, Placebo",,RANDOMIZED,2,sonelokimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.,,2026-06-17,ESTIMATED,18 Years - N/A,418,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",2025-06-17,ESTIMATED,Hidradenitis Suppurativa Clinical Response 75,TREATMENT,ALL,2024-05-14,ACTUAL,INTERVENTIONAL
MLTX,MoonLake Immunotherapeutics,NCT06641089,PHASE3,RECRUITING,"Arthritis, Psoriatic","Sonelokimab, Placebo, Risankizumab",IZAR-2,RANDOMIZED,4,sonelokimab dose 1 with an induction regimen | sonelokimab dose 2 with an induction regimen | Placebo | risankizumab,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.,,2027-01-15,ESTIMATED,18 Years - N/A,600,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study With Risankizumab as Active Reference Arm, to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumor Necrosis Factor-α Inhibitors",2027-01-15,ESTIMATED,Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50),TREATMENT,ALL,2024-10-15,ACTUAL,INTERVENTIONAL
MLTX,MoonLake Immunotherapeutics,NCT06411899,PHASE3,ACTIVE_NOT_RECRUITING,Hidradenitis Suppurativa,"Sonelokimab, Placebo",,RANDOMIZED,2,sonelokimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.,,2026-06-17,ESTIMATED,18 Years - N/A,422,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",2025-06-17,ESTIMATED,Hidradenitis Suppurativa Clinical Response 75,TREATMENT,ALL,2024-05-15,ACTUAL,INTERVENTIONAL
MLTX,MoonLake Immunotherapeutics,NCT06641076,PHASE3,ACTIVE_NOT_RECRUITING,"Arthritis, Psoriatic","Sonelokimab, Placebo",IZAR-1,RANDOMIZED,3,sonelokimab dose with an induction regimen | sonelokimab dose without an induction regimen | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drug therapy.,,2027-02-04,ESTIMATED,18 Years - N/A,960,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs",2027-02-04,ESTIMATED,Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50),TREATMENT,ALL,2024-10-15,ACTUAL,INTERVENTIONAL
RGNX,REGENXBIO Inc.,NCT06942520,PHASE2,RECRUITING,Diabetic Macular Edema,Aflibercept (2.0 mg),ELAAVATE,RANDOMIZED,3,RGX-314 Treatment Arm (Dose 1) | Treatment Arm (Dose 2) | Aflibercept Treatment Arm,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)",REGENXBIO Inc.,2027-12,ESTIMATED,25 Years - 89 Years,18,ESTIMATED,PARALLEL,OTHER,NONE,"A Randomized, Open Label, Controlled, Phase 2 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 AAV Gene Therapy Administered Via Subretinal Delivery in Participants With Center Involved Diabetic Macular Edema",2027-12,ESTIMATED,Mean change from baseline in BCVA in the study eye at Week 52,TREATMENT,ALL,2025-03-18,ACTUAL,INTERVENTIONAL
RGNX,REGENXBIO Inc.,NCT07236606,PHASE3,RECRUITING,"MPS II, Hunter Syndrome (MPS II)",,,,1,2.9×1011 GC/g brain mass of RGX 121,EXPERIMENTAL,"RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety, efficacy, and pharmacodynamic dose ranging study to determine whether RGX-121 is safe, effective and well-tolerated by patients with MPS II (Hunter Syndrome)",,2031-05-30,ESTIMATED,4 Months - 5 Years,2,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RGX 121 in Pediatric Participants With Neuronopathic MPS II (Hunter Syndrome)",2028-04-30,ESTIMATED,"Efficacy of RGX-121 on Neurodevelopmental Function (as measured by the Bayley Scales of Infant and Toddler Development, 3rd Edition) | Efficacy of RGX-121 on Neurodevelopmental Function (as measured by Kaufman Assessment Battery for Children, 2nd Edition) | Long-term Safety of RGX-121",TREATMENT,MALE,2025-11-25,ACTUAL,INTERVENTIONAL
RGNX,REGENXBIO Inc.,NCT05693142,"PHASE2, PHASE3",RECRUITING,Duchenne Muscular Dystrophy,,,NON_RANDOMIZED,2,"Part 1: Cohort 1 and 1b: RGX-202 Dose 1 | Part 1: Cohort 2, 2c;, and Part 2; and Part 3: RGX-202 Dose 2",EXPERIMENTAL | EXPERIMENTAL,"RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain.

This is a multicenter, open-label dose evaluation clinical study to assess the safety, tolerability, and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in participants with Duchenne.

For additional information on how to participate (or be considered for the study), please follow this lin",,2028-08,ESTIMATED,1 Year - N/A,65,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1/2/3 Open-label Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Intravenous RGX-202 Gene Therapy in Males With Duchenne Muscular Dystrophy (DMD)",2026-02,ESTIMATED,Part 1 Safety measured by incidence of Adverse Events and Serious Adverse Events | Part 2 and 3 Pharmacodynamic,TREATMENT,MALE,2023-01-04,ACTUAL,INTERVENTIONAL
RGNX,REGENXBIO Inc.,NCT05683379,,RECRUITING,Duchenne Muscular Dystrophy,,,,0,,,This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).,,2026-09,ESTIMATED,0 Years - 25 Years,200,ESTIMATED,,INDUSTRY,,Anti-AAV8 Antibody Assessment Study of Males With Duchenne Muscular Dystrophy Aged 0 to <25 Years,2026-09,ESTIMATED,Prevalence of anti-AAV8 antibodies in patients with DMD,,MALE,2022-12-20,ACTUAL,OBSERVATIONAL
RGNX,REGENXBIO Inc.,NCT04567550,PHASE2,ACTIVE_NOT_RECRUITING,"Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)","Topical Steroid, Aflibercept",ALTITUDE®,RANDOMIZED,6,Part 1: Observation Control Arm | Part 1: ABBV-RGX-314 Treatment Arm (Dose 1) | Part 1: ABBV-RGX-314 Treatment Arm (Dose 2) | Part 1: ABBV-RGX-314 Treatment Arm (Dose 3) and Topical Steroid | Part 2: ABBV-RGX-314 Treatment Arm (Dose 4) and Topical Steroid | Part 2: Aflibercept Control,NO_INTERVENTION | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME). DR is a chronic and progressive complication of diabetes mellitus. It is a sight-threatening disease characterized in the early stages by neuronal and vascular dysfunction in the retina, and later by neovascularization that leads to further deterioration of functional vision. Despite the availability",REGENXBIO Inc.,2026-12,ESTIMATED,25 Years - 89 Years,139,ACTUAL,PARALLEL,INDUSTRY,SINGLE,"A Phase 2, Randomized, Controlled, Dose-escalation Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via a Single Suprachoroidal Space (SCS) Injections in Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)(ALTITUDE)",2026-06,ESTIMATED,Part 1: Proportion of participants achieving a 2-step or greater improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography at Week 48 | Part 2: Mean change from baseline in Best Corrected Visual Acuity (BCVA) in the study eye at Week 54.,TREATMENT,ALL,2020-11-20,ACTUAL,INTERVENTIONAL
RGNX,REGENXBIO Inc.,NCT05407636,PHASE3,RECRUITING,"AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV",Aflibercept (EYLEA®),ASCENT,RANDOMIZED,3,ABBV-RGX-314 Dose 1 | ABBV-RGX-314 Dose 2 | Control Arm,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha",REGENXBIO Inc.,2027-11,ESTIMATED,50 Years - 89 Years,660,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD",2026-10,ESTIMATED,Mean change from baseline in Best Corrected Visual Acuity (BCVA) | Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEs,TREATMENT,ALL,2022-01-13,ACTUAL,INTERVENTIONAL
RGNX,REGENXBIO Inc.,NCT04514653,PHASE2,RECRUITING,Neovascular Age-Related Macular Degeneration (nAMD),"Ranibizumab, Local Steroid, Topical Steroid",AAVIATE,RANDOMIZED,7,Ranibizumab control | ABBV-RGX-314 Treatment Arm (Dose 1) | ABBV-RGX-314 Treatment Arm (Dose 2) | ABBV-RGX-314 Treatment Arm (Dose 3) | ABBV-RGX-314 Treatment Arm (Dose 3) and Local Steroid | ABBV-RGX-314 Treatment Arm (Dose 3) and Topical Steroid | ABBV-RGX-314 Treatment Arm (Dose 4) and Topical Steroid,ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This interventional study is being conducted with an investigational gene therapy treatment called ABBV-RGX-314 (also known as RGX-314) and is being developed as a potential one-time gene therapy treatment for neovascular (wet) age-related macular degeneration (wet AMD or nAMD). The typical treatment for nAMD is frequent injections of anti-VEGF therapy. Researchers are testing ABBV-RGX-314 to see if it has similar effects as the current approved standard of care, such as Lucentis® or Eylea® inje",REGENXBIO Inc.,2027-02,ESTIMATED,50 Years - 89 Years,140,ESTIMATED,SEQUENTIAL,INDUSTRY,SINGLE,"A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)",2026-08,ESTIMATED,Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score,TREATMENT,ALL,2020-08-25,ACTUAL,INTERVENTIONAL
RGNX,REGENXBIO Inc.,NCT04704921,"PHASE2, PHASE3",RECRUITING,"AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization",Ranibizumab (LUCENTIS®),ATMOSPHERE,RANDOMIZED,3,ABBV-RGX-314 Dose 1 | ABBV-RGX-314 Dose 2 | Control Arm,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF)",REGENXBIO Inc.,2027-11,ESTIMATED,50 Years - 89 Years,630,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)",2026-12,ESTIMATED,Mean change from baseline in Best Corrected Visual Acuity (BCVA) | Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEs,TREATMENT,ALL,2020-12-29,ACTUAL,INTERVENTIONAL
RGNX,REGENXBIO Inc.,NCT03566043,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,Mucopolysaccharidosis Type II (MPS II),,,NON_RANDOMIZED,6,Part 1: RGX-121 Dose 1 | Part 1: RGX-121 Dose 2 | Part 1: RGX-121 Dose 2 Expanded Cohort | Part 1: RGX-121 Dose 3 | Part 1: RGX-121 Dose 3 Expanded Cohort | Part 2: RGX-121 Pivotal Expansion,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety and efficacy, dose ranging study to determine whether RGX-121 is safe, effective and well-tolerated by patients with MPS II.",,2025-08,ESTIMATED,4 Months - 5 Years,48,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1/2/3 Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)",2023-11-27,ACTUAL,Part 1 Safety | Part 2 Biomarkers | Part 2 Biomarkers | Part 2 Neurodevelopmental parameters | Part 2 Neurodevelopmental parameters,TREATMENT,MALE,2018-09-27,ACTUAL,INTERVENTIONAL
CGC,Canopy Growth Corporation,NCT05324982,PHASE1,RECRUITING,Behavioral Pharmacology of Cannabis,"Oral Placebo, Oral CBG Cannabis",,RANDOMIZED,5,Placebo | Oral administration of 25mg CBG | Oral administration of 50mg CBG | Oral administration of 100mg CBG | Oral administration of 200mg CBG,PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of cannabigerol (CBG; CHI-914), a naturally occurring chemical constituent of the cannabis plant formulated for oral consumption, in healthy adults. The study will utilize a within-subjects, placebo-controlled, double-blind, ascending-dose design.Upon enrollment, participants will complete 5 oral dosing conditions (placebo, 25, 50, 100, and 200 mg CBG). Each condition will consist of a single acute drug expo",Canopy Growth Corporation,2025-12,ESTIMATED,18 Years - 55 Years,30,ESTIMATED,CROSSOVER,OTHER,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled Study, Pharmacokinetics, and Pharmacodynamics of CHI-914 in Healthy Participants",2025-12,ESTIMATED,Self-reported Drug Effect ratings on the Drug Effect Questionnaire (DEQ) | Heart rate | Blood Pressure | Divided Attention as assessed by the DAT | Digit Symbol Substitution Task (DSST) score | Paced Auditory Serial Addition Task (PASAT) score | Behavioral task performance as assessed by the DRUID app | Digit Vigilance Test (response time) | Digit Vigilance Test (number of incorrect responses) | Go/No-Go Task (response time) | Go/No-Go Task (number of incorrect responses) | Quantitative levels of CHI-914 (CBG) in blood | Quantitative levels of CHI-914 (CBG) in urine,BASIC_SCIENCE,ALL,2022-08-09,ACTUAL,INTERVENTIONAL
CRMD,CorMedix Inc.,NCT06714864,PHASE4,RECRUITING,Catheter-Related Infections,"(taurolidine and heparin) catheter lock solution, Standard of Care",,RANDOMIZED,2,DefenCath® | Control,EXPERIMENTAL | ACTIVE_COMPARATOR,This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.,,2026-03,ESTIMATED,N/A - 17 Years,36,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter",2026-01,ESTIMATED,"Time to first clinical diagnosis of Catheter-related Bloodstream Infections (CRBSI) | Descriptive analysis characterizing the relative rates of deaths, AEs, and SAEs",PREVENTION,ALL,2025-07-08,ACTUAL,INTERVENTIONAL
CRMD,CorMedix Inc.,NCT06822426,PHASE3,RECRUITING,Central Line Associated Blood Stream Infections (CLABSI),"(taurolidine and heparin) catheter lock solution, Heparin",,RANDOMIZED,2,DefenCath® | Control,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.",,2027-01,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonstrate The Safety And Efficacy Of DEFENCATH® In Reducing Central Line-Associated Bloodstream Infections (CLABSIs) In Adult Participants Receiving Total Parenteral Nutrition (TPN) Via Central Venous Catheter (CVC)",2027-01,ESTIMATED,Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study,PREVENTION,ALL,2025-05-14,ACTUAL,INTERVENTIONAL
AKBA,"Akebia Therapeutics, Inc.",NCT07429006,PHASE1,NOT_YET_RECRUITING,Healthy Volunteers,AKB-9090,,RANDOMIZED,2,AKB-9090 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants. The study consists of two stages: Stage 1, a single ascending dose (SAD) phase with five dose cohorts, and Stage 2, a multiple ascending dose (MAD) phase with three dose cohorts. Approximately 40 participants in SAD and 30 in MAD are planned to be enrolled.",Emerald Clinical Trials,2026-12,ESTIMATED,18 Years - 60 Years,70,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Single (SAD) and Multiple Ascending-Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AKB-9090 Administered Intravenously to Healthy Adult Participants",2026-10,ESTIMATED,Number of participants who will report serious Treatment emergent adverse events (TEAEs) and TEAEs | Number of Participants with Clinically Significant Changes in Physical Examinations | Number of Participants with Clinically Significant Changes in Vital Signs | Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG) | Number of Participants with Clinically Significant Changes in Chemistry parameters | Number of Participants with Clinically Significant Changes in Hematology Parameters | Number of Participants with Clinically Significant Changes in Lipid Parameters | Number of Participants with Clinically Significant Changes in Coagulation Parameters | Number of Participants with Clinically Significant Changes in Urinalysis Parameters,TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
AKBA,"Akebia Therapeutics, Inc.",NCT06901505,PHASE3,ACTIVE_NOT_RECRUITING,Anemia of Chronic Kidney Disease,"Erythropoiesis-Stimulating Agent (ESA), Vadadustat",,RANDOMIZED,2,Vadadustat | Erythropoiesis-Stimulating Agent (ESA),EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the efficacy of vadadustat administered three times a week compared to standard of care erythropoiesis-stimulating agent for the treatment of anemia in in-center hemodialysis participants with end-stage kidney disease (ESKD). A subset of sites will participate in a red blood cell (RBC) sub-study where changes in the phenotype of RBCs in response to vadadustat treatment relative to methoxy polyethylene gly",,2026-08,ESTIMATED,18 Years - N/A,353,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis",2026-08,ESTIMATED,Change in hemoglobin (Hb),TREATMENT,ALL,2025-07-24,ACTUAL,INTERVENTIONAL
AKBA,"Akebia Therapeutics, Inc.",NCT07268638,PHASE2,RECRUITING,Focal Segmental Glomerulosclerosis,Praliciguat,,RANDOMIZED,2,Praliciguat | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.",,2028-01,ESTIMATED,18 Years - N/A,60,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis",2027-06,ESTIMATED,Change from Baseline in urine protein-to-creatinine ratio (UPCR),TREATMENT,ALL,2025-12-03,ACTUAL,INTERVENTIONAL
AKBA,"Akebia Therapeutics, Inc.",NCT07086755,"PHASE2, PHASE3",RECRUITING,"Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury","Vadadustat 900mg, Vadadustat 1200mg, Placebo",,RANDOMIZED,3,Vadadustat 900mg | Vadadustat 1200mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.,Akebia Therapeutics Inc.,2026-07-01,ESTIMATED,18 Years - N/A,1100,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury,2026-07-01,ESTIMATED,"Win ratio for hierarchical composite endpoint based on death, duration of mechanical ventilation or ECMO, and duration of high-flow nasal oxygenation or non-invasive ventilation",TREATMENT,ALL,2025-10-23,ACTUAL,INTERVENTIONAL
AKBA,"Akebia Therapeutics, Inc.",NCT06520826,PHASE3,RECRUITING,Anemia of Chronic Kidney Disease,"Vadadustat, Erythropoiesis Stimulating Agent",VOICE,RANDOMIZED,2,Vadadustat | Erythropoiesis-stimulating agent (ESA) - Standard of Care (SOC),EXPERIMENTAL | ACTIVE_COMPARATOR,"This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will obtain long-term safety data in a large sample of subjects receiving in-center hemodialysis to support adoption of three times per week vadadustat dosing.",Akebia Therapeutics,2026-06-30,ESTIMATED,18 Years - N/A,2200,ESTIMATED,PARALLEL,NETWORK,NONE,Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience,2026-06-30,ESTIMATED,All-cause mortality,TREATMENT,ALL,2024-11-20,ACTUAL,INTERVENTIONAL
UPB,"Upstream Bio, Inc.",NCT06196879,PHASE2,ACTIVE_NOT_RECRUITING,Severe Asthma,"Verekitug (UPB-101), Placebo",,RANDOMIZED,4,Verekitug (UPB-101): 100 mg Q12W / Placebo | Verekitug (UPB-101): 400 mg Q24W / Placebo | Verekitug (UPB-101): 100 mg Q24W / Placebo | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.",,2026-06-11,ESTIMATED,18 Years - 80 Years,479,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study to Evaluate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)",2025-12-16,ACTUAL,Annual Asthma Exacerbation Rate (AAER),TREATMENT,ALL,2024-02-27,ACTUAL,INTERVENTIONAL
UPB,"Upstream Bio, Inc.",NCT06966479,PHASE2,RECRUITING,Severe Asthma,"Verekitug, Placebo",,RANDOMIZED,2,Verekitug 100 mg Q12W and Placebo | Verekitug 400 mg Q24W and Placebo,EXPERIMENTAL | EXPERIMENTAL,The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).,,2027-09,ESTIMATED,18 Years - N/A,436,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,A Long-Term Extension Study to Evaluate Safety and Efficacy of Verekitug (UPB-101) in Adult Participants With Severe Asthma Who Completed the VALIANT Trial,2027-09,ESTIMATED,Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2025-05-21,ACTUAL,INTERVENTIONAL
UPB,"Upstream Bio, Inc.",NCT06981078,PHASE2,RECRUITING,Chronic Obstructive Pulmonary Disease,Verekitug,,RANDOMIZED,3,Verekitug (UPB-101) 100 mg and Placebo | Verekitug (UPB-101) 400 mg and Placebo | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.",,2028-07,ESTIMATED,40 Years - 85 Years,666,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)",2028-04,ESTIMATED,Annualized rate of moderate or severe COPD exacerbation events,TREATMENT,ALL,2025-07-02,ACTUAL,INTERVENTIONAL
AGMB,AgomAb Therapeutics NV,NCT05843578,PHASE2,ACTIVE_NOT_RECRUITING,Fibrostenotic Crohn's Disease,"AGMB-129, Placebo",,RANDOMIZED,3,AGMB-129 High | AGMB-129 Low | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Many patients with Crohn's disease develop fibrotic narrowing (strictures) in their bowel, causing obstructive symptoms such as abdominal pain, cramping, or vomiting after meals. Because of these symptoms, patients often require bowel resection surgery. The objective of this clinical trial is to evaluate the safety, pharmacokinetics, and pharmacodynamics of AGMB-129 in patients with Crohn's disease and symptomatic strictures, and whether it can have a beneficial effect on intestinal strictures.
",,2026-09,ESTIMATED,18 Years - N/A,103,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients With Fibrostenotic Crohn's Disease",2026-09,ESTIMATED,Number of participants with adverse events (Part A and B) | Number of participants with abnormal clinical laboratory values (Part A and B) | Number of participants with abnormal ECG parameters (Part A and B) | Number of participants with abnormal vital signs (Part A and B) | Number of participants with abnormal physical exams (Part A and B) | Number of participants with abnormal 2D-echocardiography (Part A and B),TREATMENT,ALL,2023-08-01,ACTUAL,INTERVENTIONAL
AGMB,AgomAb Therapeutics NV,NCT06181370,PHASE1,RECRUITING,IPF,AGMB-447,,RANDOMIZED,2,AGMB-447 | placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to measure the safety, tolerability PK and PD of inhaled AGMB-477 compared with placebo in healthy participants and participants with IPF. This is an integrated phase 1, single center, 3-part, double-blind, randomized, placebo-controlled SAD (Part A) and MAD (Part B) study in healthy participants and multiple dose study in IPF participants (Part C).

Safety, tolerability PK and PD will be assessed following single ascending, multiple ascending and multiple dosing of ",,2026-06,ESTIMATED,18 Years - 55 Years,145,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of Inhaled AGMB-447 in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis",2026-06,ESTIMATED,Number of participants with adverse events | Number of participants with abnormal clinical laboratory values | Number of participants with abnormal ECG parameters | Number of participants with abnormal vital signs | Number of participants with abnormal physical exams | Number of participants with abnormal spirometry parameters,TREATMENT,ALL,2023-12-01,ACTUAL,INTERVENTIONAL
AGYTF,Allergy Therapeutics plc,NCT05186025,,ACTIVE_NOT_RECRUITING,"Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, Allergic Asthma",MATA trees or MATA grass,,,2,Adults | Children, | ,The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial posology.,Bencard Allergie GmbH,2026-10,ESTIMATED,5 Years - N/A,320,ACTUAL,,INDUSTRY,,"A Long-term, Prospective, Open, Multi-centre, Non-interventional Study to Evaluate the Effectiveness After Treatment With TA Bäume Top (Trees) and TA Gräser Top (Grass) Following a Perennial Posology in Children and Adults, as Well as Proofing the Non-inferiority of Children Compared to Adults",2026-06,ESTIMATED,change in the combined symptom medication score (CSMS),,ALL,2020-11-06,ACTUAL,OBSERVATIONAL
AGYTF,Allergy Therapeutics plc,NCT00031408,,ACTIVE_NOT_RECRUITING,HIV Infections,,,,0,,,"The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other tissues) for future studies that may include genetic testing.",National Institute of Allergy and Infectious Diseases (NIAID),2027-12-31,ESTIMATED,N/A - N/A,17444,ACTUAL,,NETWORK,,Plan for Obtaining Informed Consent to Use Stored Human Biological Materials (HBM) for Currently Unspecified Analyses,2027-12-31,ESTIMATED,,,ALL,2002-02-13,ACTUAL,OBSERVATIONAL
AGYTF,Allergy Therapeutics plc,NCT07103746,PHASE2,NOT_YET_RECRUITING,Autoimmune Disorders,"Ublituximab, Placebo for Ublituximab",SUMMIT,RANDOMIZED,2,Initial Ublituximab Active Group | Initial Placebo of ublituximab Group,EXPERIMENTAL | EXPERIMENTAL,"This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive immune-mediated necrotizing myopathy.

The primary objective is to estimate the effect of ublituximab as first add-on combination therapy at 24 weeks compared to placebo in treating early, active autoantibody positive immune-mediated necrotizing myopathy using the validated 2016 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Myositis Resp","Autoimmunity Centers of Excellence, TG Therapeutics, Rho Federal Systems Division, Inc.",2030-06,ESTIMATED,18 Years - N/A,30,ESTIMATED,PARALLEL,NIH,TRIPLE,"Study of Ublituximab in Early, Active, Autoantibody-Positive, IMMune-MedIated NecroTizing Myopathy (AIM01)",2029-06,ESTIMATED,The primary endpoint is the Total Improvement Score (TIS) at Week 24 reflecting the change from baseline,TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
AGYTF,Allergy Therapeutics plc,NCT05985642,,RECRUITING,HIV-1-infection,,,,1,Observational PIC Destination Cohort,,This study is being done to see if people who control HIV without antiretroviral therapy (ART) after receiving an intervention can remain off ART safely. The information collected in this study is also being used to try to understand how people control HIV without ART after receiving an intervention.,National Institute of Allergy and Infectious Diseases (NIAID),2029-09-03,ESTIMATED,18 Years - N/A,30,ESTIMATED,,NETWORK,,An Observational Post-Intervention Control Destination Cohort,2029-07-03,ESTIMATED,Occurrence of an SAE or Grade ≥3 AE that is related to ATI | Change in CD4 percentage from parent study (pre-ATI) to Step 1 timepoints | Occurrence of new diagnoses of interest | Time from ATI to sustained HIV-1 RNA ≥1000 copies/mL | HIV RNA below 200 copies/mL | Change in CD4% from pre-ATI to Step 2 | Measurements of reservoir,,ALL,2024-03-19,ACTUAL,OBSERVATIONAL
AGYTF,Allergy Therapeutics plc,NCT06031272,PHASE1,ACTIVE_NOT_RECRUITING,HIV-1-infection,"3BNC117-LS-J, 10-1074-LS-J, Placebo for 3BNC117-LS-J, Placebo for 10-1074-LS-J",PAUSE,RANDOMIZED,2,Arm A: 30 mg/kg 3BNC117-LS-J + 10 mg/kg 10-1074-LS-J | Arm B: Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The main purpose of this study is to see if it is safe to give the study antibodies (3BNC117-LS-J and 10-1074-LS-J) by intravenous infusion to people with HIV (PWH), and to see if they cause any side effects. In addition, to see how the study antibodies affect the level of HIV in the blood when participants are not taking regular HIV treatment for an extended period. This extended period of not taking regular HIV treatment is called an analytical treatment interruption (ATI).",National Institute of Allergy and Infectious Diseases (NIAID),2026-04-05,ESTIMATED,18 Years - 70 Years,32,ACTUAL,PARALLEL,NETWORK,DOUBLE,"A Phase I, Randomized, Placebo-Controlled Study of the Safety, Antiviral & Immunomodulatory Activity of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in Sub-Saharan Africa Living With HIV During a Monitored Analytical Treatment Interruption",2026-04-05,ESTIMATED,Occurrence of a Grade ≥3 or higher systemic AE or any AE (regardless of grade) leading to premature study or treatment discontinuation | Viral suppression,TREATMENT,ALL,2024-05-28,ACTUAL,INTERVENTIONAL
AGYTF,Allergy Therapeutics plc,NCT06205602,PHASE2,RECRUITING,HIV-1-infection,"3BNC117-LS, 10-1074-LS, Placebo for 3BNC117-LS, Placebo for 10-1074-LS",ACACIA,RANDOMIZED,2,Broadly neutralizing antibodies (bNAbs) infusions with antiretroviral therapy (ART) | Placebo infusions with ART,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"For people living with HIV, antiretroviral therapy (ART) helps to stop the virus from multiplying. The goal of current HIV treatment is to have such a small amount of the virus in the blood that it does not show up on regular tests. HIV is also hidden in cells throughout the body and can start multiplying when ART is stopped.

This research study will test two new study drugs: 10-1074-LS and 3BNC117-LS. Both of these study drugs are antibodies against HIV. An antibody is generally a substance th",National Institute of Allergy and Infectious Diseases (NIAID),2029-02-16,ESTIMATED,18 Years - 60 Years,135,ESTIMATED,PARALLEL,NETWORK,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Two Long-Acting Broadly Neutralizing Antibodies at ART Initiation in Adults Living With HIV-1 in Sub-Saharan Africa: The ACACIA Study",2029-02-16,ESTIMATED,Occurrence of Grade ≥2 Adverse Events (AE) or Serious Adverse Events (SAE) | Time from antiretroviral therapy (ART) discontinuation to sustained HIV-1 RNA ≥ 1000 copies/mL over a 4-week period (through step 2),TREATMENT,ALL,2025-01-17,ACTUAL,INTERVENTIONAL
AGYTF,Allergy Therapeutics plc,NCT06205589,PHASE2,NOT_YET_RECRUITING,"Tuberculosis, Pulmonary","ID93 + GLA-SE vaccine, Placebo vaccine",,RANDOMIZED,10,Group 1/Phase 2a: ID93+GLA-SE 4 months and 6 months after start of TB treatment | Group 2/Phase 2a: ID93+GLA-SE 3 months and 5 months after start of TB treatment | Group 3/Phase 2a: ID93+GLA-SE 2 months and 4 months after start of TB treatment | Group 4/Phase 2a: ID93+GLA-SE 1 month and 3 months after start of TB treatment | Group 5/Phase 2b: ID93+GLA-SE schedule based on Group 3 and 4 safety and immunogenicity data | Group 1/Phase 2a: Placebo vaccine 4 months and 6 months after start of TB treatment | Group 2/Phase 2a: Placebo vaccine 3 months and 5 months after start of TB treatment | Group 3/Phase 2a: Placebo vaccine 2 months and 4 months after start of TB treatment | Group 4/Phase 2a: Placebo vaccine 1 month and 3 months after start of TB treatment | Group 5/Phase 2b: Placebo vaccine schedule based on Group 3 and 4 safety and immunogenicity data,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,This study is being done to test an experimental study vaccine compared to a placebo. The experimental study vaccine is called ID93 + GLA-SE. ID93 + GLA-SE has been used in humans in research but has not been approved for use in medical care. This study will be the first to test ID93 + GLA-SE in people living with HIV (PLWH). The injections during the study will be given to different groups of participants while they are using standard TB treatment. One of the research questions is to understand,National Institute of Allergy and Infectious Diseases (NIAID),2029-10-13,ESTIMATED,18 Years - 65 Years,1500,ESTIMATED,SEQUENTIAL,NETWORK,DOUBLE,"A Phase 2a/2b Study Evaluating Safety, Immunogenicity, and Therapeutic Efficacy of ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB",2028-10-31,ESTIMATED,"Safety (Phase 2a and Phase 2b): Vaccine-related serious adverse event (SAE) | Safety (Phase 2a and Phase 2b): Grade ≥3 vaccine-related unsolicited adverse event (AE) | Safety (Phase 2a and Phase 2b): Grade ≥3 local or systemic reactogenicity AE | Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response relative to the negative control stimulation | Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response relative to the negative control stimulation and relative to the pre-vaccine response | Cellular immunogenicity (Phase 2a and Phase 2b): ID93-specific CD4+ T cell response magnitude relative to the negative control stimulation | Efficacy (Phase 2b): Bacteriologically confirmed TB-related unfavorable outcome (treatment failure, TB recurrence, or death due to TB)",TREATMENT,ALL,2026-02-15,ESTIMATED,INTERVENTIONAL
AGYTF,Allergy Therapeutics plc,NCT06856174,PHASE4,NOT_YET_RECRUITING,"HIV Infection, Menopause","Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone",HoT,RANDOMIZED,2,Arm A: Hormone Therapy | Arm B: Hormone Therapy Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Women living with HIV have been shown to experience more frequent and severe hot flashes and night sweats (collectively known as vasomotor symptoms) as compared to women living without HIV. This correlates with disturbed sleep, increased depressive symptoms, increased anxiety, worse mental function, interference with activities of daily living including work, and worse overall quality of life.

Hormone therapy is considered to be the most effective therapy for hot flashes and night sweats and th","National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Aging (NIA), Exeltis, Xiromed LLC",2027-09-20,ESTIMATED,40 Years - 60 Years,105,ESTIMATED,PARALLEL,NETWORK,DOUBLE,Menopausal Hormone Therapy for Women Living With HIV (HoT),2027-09-20,ESTIMATED,Change in vasomotor symptoms (VMS) frequency,TREATMENT,FEMALE,2026-01-19,ESTIMATED,INTERVENTIONAL
AGYTF,Allergy Therapeutics plc,NCT07412990,,NOT_YET_RECRUITING,Grass Pollen Allergy,Grassmuno®,GRASS,,1,Grass Allergic adults,,Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.,"Bencard Allergie GmbH, ClinCompetence Cologne GmbH",2028-10-02,ESTIMATED,18 Years - N/A,1000,ESTIMATED,,INDUSTRY,,"Eine Prospektive, Offene, Multizentrische, Nicht-interventionelle Studie Zur Erhebung Von Daten Zur Anwendung Von Grass MATA MPL 27 600 SU Und Compliance in Der täglichen Klinischen Praxis Bei Erwachsenen Gräserpollen- Allergikern",2028-10-02,ESTIMATED,Treatment adherence,,ALL,2026-02-16,ESTIMATED,OBSERVATIONAL
AGYTF,Allergy Therapeutics plc,NCT05476497,PHASE1,RECRUITING,Peanut Allergy,"VLP Peanut, Placebo, VLP Peanut",PROTECT,RANDOMIZED,3,Part A - Group A1 | Part A - Group A2 | Part B - Cohorts 1-4,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.,,2025-10,ESTIMATED,18 Years - 50 Years,46,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,A Phase I Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy and to Explore Preliminary Signals of Its Efficacy (PROTECT),2025-10,ESTIMATED,Number and severity of Adverse Events (AEs) (including local and systemic AEs). | Number of subjects discontinuing prematurely from treatment due to AEs,TREATMENT,ALL,2022-10-17,ACTUAL,INTERVENTIONAL
AKBLF,ALK-Abelló A/S,NCT05440643,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Peanut Allergy,Peanut SLIT-tablet,,RANDOMIZED,13,Part 1: Cohort 1 | Part 1: Cohort 2 | Part 1: Cohort 3 | Part 1: Cohort 4 | Part 1: Cohort 5 | Part 2: Cohort 6 | Part 2: Cohort 7 | Part 2: Cohort 8 | Part 2: Cohort 9 | Part 2: Cohort 10 | Part 3: Maintenance A | Part 3: Maintenance B | Part 3: Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This clinical research study investigates the safety, tolerability and efficacy of a peanut SLIT-tablet in adults, adolescents, and children with peanut allergy.",Parexel,2026-04,ESTIMATED,4 Years - 65 Years,192,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase I/II Trial in 3 Parts Assessing the Safety, Tolerability, and Efficacy of a Once-daily Peanut Sublingual Immunotherapy (SLIT) Tablet in Adults, Adolescents, and Children With Peanut Allergy",2026-03,ESTIMATED,Part 1 and 2: Dose tolerability response rate | Part 3: TD-600 response rate,TREATMENT,ALL,2022-09-07,ACTUAL,INTERVENTIONAL
AKBLF,ALK-Abelló A/S,NCT07060885,PHASE3,RECRUITING,"Allergic Rhinoconjunctivitis, Allergic Rhinitis",HDM SLIT-tablet (12 SQ-HDM),,RANDOMIZED,2,Active treatment | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.,,2026-08,ESTIMATED,12 Years - 65 Years,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,A Randomised Double-blind Placebo-controlled Phase III Field Trial Evaluating the Efficacy and Safety of the House Dust Mite (HDM) SLIT-tablet in Chinese Participants Aged 12-65 Years With HDM Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma,2026-07,ESTIMATED,Average daily total combined rhinitis score (TCRS) during the primary efficacy assessment period.,TREATMENT,ALL,2025-09-01,ACTUAL,INTERVENTIONAL
AKBLF,ALK-Abelló A/S,NCT07013123,PHASE3,NOT_YET_RECRUITING,"Severe Asthma, Allergy to House Dust Mites","Tezepelumab, Acarizax, Placebo",TEZEPAIT,RANDOMIZED,2,Tezepelumab + Acarizax | Tezepelumab + Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The aim of this drug trial is to evaluate the annualized asthma exacerbation rate under treatment with Acarizax versus placebo. The trial is intended for adults aged 18 to 65 with severe uncontrolled asthma and a house dust mite allergy. The study will involve 32 patients (up to 38 with study dropouts) recruited from French hospitals, in pulmonology and allergology departments.

Initially, all participants will receive Tezepelumab for 3 to 6 months (M-3/-6) to control asthma symptoms. If asthma ","AstraZeneca, ALK-Abelló A/S, University hospital of Nîmes, ThermoFisher Scientific Brahms Biomarkers France",2029-08-18,ESTIMATED,18 Years - 65 Years,38,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab",2029-08-18,ESTIMATED,Annualized total number of asthma exacerbations under acarizax/placebo treatment,SUPPORTIVE_CARE,ALL,2025-07-15,ESTIMATED,INTERVENTIONAL
APNHY,Aspen Pharmacare Holdings Limited,NCT06491030,PHASE4,RECRUITING,"Proximal Junctional Kyphosis, Adult Spinal Deformity Surgery, Thoracolumbosacral Orthosis",,,RANDOMIZED,2,Thoracolumosacral Orthosis | No brace,EXPERIMENTAL | PLACEBO_COMPARATOR,"Proximal junctional kyphosis (PJK) is a common post-operative radiographic finding after surgery for adult spinal deformity (ASD) patients. Although the clinical relevance of isolated PJK is unclear, PJK can progress to symptomatic proximal junctional failures which requires a large revision surgery. Currently, post-operative bracing with a thoracolumbosacral orthosis (TLSO) is common practice after spinal deformity surgery, however the efficacy of this in preventing PJK is unknown. This multi-c",Aspen Medical Products,2026-12,ESTIMATED,30 Years - 75 Years,84,ESTIMATED,PARALLEL,OTHER,NONE,The Use of a Novel Post-Operative Thoracolumosacral Orthosis for Prevention of Proximal Junctional Kyphosis After Adult Spinal Deformity Surgery,2026-12,ESTIMATED,The incidence of proximal junctional kyphosis development,PREVENTION,ALL,2024-12-02,ACTUAL,INTERVENTIONAL
BIESF,Biotest Aktiengesellschaft Preference Shares,NCT03334006,PHASE2,RECRUITING,"Peritonitis, Sepsis, Septic Shock",Pentaglobin®/Standard of Care,PEPPER,RANDOMIZED,2,Control arm | Verum arm,NO_INTERVENTION | ACTIVE_COMPARATOR,"The aim of this prospective, randomized, controlled trial is to provide evidence for adjuvant IgGAM treatment with regard to

1. Improvement of patient outcomes for peritonitis. Improvement in outcome will be determined by scores such as MOF, SOFA and survival.
2. Identification of biomarkers (including immunoglobulin levels, HLA-DR, NF-kB1 and other immunological biomarkers) to identify patient subpopulations that benefit most from IgGAM treatment. These patients will form the basis for a furth",Biotest,2028-03,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,OTHER,NONE,"Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis",2027-09,ESTIMATED,"Change in Multiple Organ Failure (MOF) score (measured in lung, heart, kidney, liver, blood) from baseline to day 7 after surgical infectious source control in the context of peritonitis.",TREATMENT,ALL,2017-11-20,ACTUAL,INTERVENTIONAL
BIESF,Biotest Aktiengesellschaft Preference Shares,NCT05722938,PHASE3,RECRUITING,Community-acquired Pneumonia,"Trimodulin, Placebo (human albumin 1%)",ESsCAPE,RANDOMIZED,2,Trimodulin | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV).

Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.",,2028-07-31,ESTIMATED,18 Years - N/A,590,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)",2028-07-31,ESTIMATED,28-day all-cause mortality rate,TREATMENT,ALL,2023-09-09,ACTUAL,INTERVENTIONAL
BJTRF,Beijing Tong Ren Tang Chinese Medicine Company Limited,NCT06331923,,RECRUITING,Comprehensive Complication Index,,,RANDOMIZED,2,CGM group | Control group,EXPERIMENTAL | NO_INTERVENTION,"The goal of this multi-center, pragmatic, randomized controlled trial is to assess the effectiveness of continuous glucose monitoring (CGM) compared with conventional monitoring in enhancing surgical outcomes for diabetic patients. The main questions it aims to answer are:

* To assess the effectiveness of CGM compared with conventional monitoring in reducing the comprehensive complication index (CCI) for patients with diabetes or impaired glucose tolerance (IGT) within 30 days after surgery.
* ","Peking University International Hospital, Wang Jing Hospital, ZhuHai Hospital, Beijing Hospital, Siyang County Hospital of Traditional Chinese Medicine, Second Hospital of Shanxi Medical University, Henan Provincial Chest Hospital, Fuzhou First Hospital, Pinggu Hospital of Beijing Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Mindong Hospital of Ningde, The Fifth Hospital of Xiamen, People's Hospital of Ningxia Hui Autonomous Region, The First People's Hospital of Changzhou, The Fifth hospital of Deyang, Suzhou Municipal Hospital, Tang-Du Hospital, Yiyang Central Hospital, First Affiliated Hospital of Xinjiang Medical University, Peng Ding Shan Shi Zhong Yi Yi Yuan, Yueyang Central Hospital, The First People's Hospital of Lianyungang, Haimen District Traditional Chinese Medicine Hospital, The 910th Hospital, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Beijing Tiantan Hospital, Affiliated Hospital of Jiangsu University, Liaocheng People's Hospital, Beijing Chao Yang Hospital, Jilin City Hospital of Chemical Industry, Creen Hospital-465, Wuhan Central Hospital, Air Force Military Medical University, China, Shanghai Tong Ren Hospital, Beijing Anzhen Hospital, Emergency General Hospital, Beijing Tongren Hospital, Civil Aviation General Hospital, Peking University Shougang Hospital, The First Affiliated Hospital of Anhui Medical University, Chinese PLA Central Hospital",2025-12-31,ESTIMATED,18 Years - N/A,10168,ESTIMATED,PARALLEL,OTHER,SINGLE,"Assessing the Effectiveness of Continuous Glucose Monitoring Compared with Conventional Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes: a Multi-center, Parallel-arm, Randomized, Pragmatic Trial in China",2025-10-31,ESTIMATED,Comprehensive complication index,TREATMENT,ALL,2024-04-12,ACTUAL,INTERVENTIONAL
BORAY,"Bora Pharmaceuticals Co., Ltd.",NCT07310160,,NOT_YET_RECRUITING,"Pressure Injury, Simulation Based Learning, Nursing",,DT-HIMRS,RANDOMIZED,2,Digital Twin Haptic Integrated Simulation Group | High-Fidelity Simulation Group,EXPERIMENTAL | ACTIVE_COMPARATOR,"The responsibility for the management of pressure injuries belongs to nurses; the development of pressure injuries indicates that nursing care is not adequate. Pressure injury management should be addressed starting from undergraduate education in line with current guidelines. However, programs in which traditional education methods are used in pressure injury management are insufficient. Therefore, pressure injuries should be addressed with a structured simulation practice integrated with advan",The Scientific and Technological Research Council of Turkey,2026-05-29,ESTIMATED,N/A - N/A,130,ESTIMATED,PARALLEL,OTHER,SINGLE,Development of a Digital Twin-Haptic Integrated Mixed Reality Simulation for Pressure Injury Management,2026-02-02,ESTIMATED,Pressure Injury Management Skill Level | Pressure Injury Management Knowledge Level,TREATMENT,ALL,2026-02-02,ESTIMATED,INTERVENTIONAL
BPMUF,Basilea Pharmaceutica AG,NCT06925321,PHASE3,RECRUITING,Invasive Mold Infections,"Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet",,RANDOMIZED,3,Cohort A: Experimental Treatment | Cohort A: Comparator Antifungal Treatment | Cohort B,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL,"The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections. The study is looking for patients who have been diagnosed with invasive mold infections. The maximum study duration will be approximately 8 months, including a target study treatment duration of 84 days which can be extended up to 180 days and follow-up period.

The patient will be assigned to one of two treatment cohorts:

",Biomedical Advanced Research and Development Authority,2028-02,ESTIMATED,18 Years - N/A,219,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections Caused by Aspergillus Spp., Fusarium Spp., Lomentospora Prolificans, Mucorales Fungi, or Other Multidrug Resistant Molds",2028-02,ESTIMATED,Day 42 all-cause mortality rate,TREATMENT,ALL,2025-08-26,ACTUAL,INTERVENTIONAL
BPMUF,Basilea Pharmaceutica AG,NCT01731353,,RECRUITING,Invasive Fungal Disease,,FungiScope,,1,Emerging fungal infections,,"The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.","Pfizer, Basilea Pharmaceutica, Cidara Therapeutics Inc., F2G Biotech GmbH, Matinas Biopharma, Inc",2026-12,ESTIMATED,N/A - N/A,1000,ESTIMATED,,OTHER,,FungiScope - A Global Emerging Fungal Infection Registry,2026-12,ESTIMATED,Treatment efficacy of emerging fungal infections,,ALL,2003-03,,OBSERVATIONAL
BPMUF,Basilea Pharmaceutica AG,NCT05421858,PHASE3,RECRUITING,"Candidemia, Candidiasis, Invasive","Fosmanogepix, Fosmanogepix, Caspofungin, Fluconazole, Placebo, Placebo, Placebo, Placebo",,RANDOMIZED,2,Fosmanogepix IV/oral | Caspofungin IV/ Fluconazole oral,EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida.

The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis.

Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosma",Biomedical Advanced Research and Development Authority,2028-01-30,ESTIMATED,18 Years - N/A,450,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis,2028-01-30,ESTIMATED,Proportion of patients alive at Day 30 | Proportion of patients with an overall response of treatment success at end of study treatment (EOST),TREATMENT,ALL,2024-12-11,ACTUAL,INTERVENTIONAL
BPMUF,Basilea Pharmaceutica AG,NCT06733675,PHASE1,RECRUITING,"Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC","Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole",,NON_RANDOMIZED,4,Part 1 | Part 2 Group 1 | Part 2 Group 2 | Part 2 Group 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 1, open-label, two-part, study in approximately 46 healthy adult participants between 18 and 55 years of age (both inclusive) (at least 16 participants in Part 1 and up to 30 participants in Part 2). The study will be conducted at one clinical site in the United States. Participants in Part 1 and Part 2 may be conducted in parallel. The duration of an individual participation will be approximately 46 days for Part 1 and 43 days for Part 2. All participants will be screened within",Biomedical Advanced Research and Development Authority,2026-06-30,ESTIMATED,18 Years - 55 Years,46,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1, Open-label Study to Evaluate the Safety and to Characterize the Pharmacokinetics of a Fixed-Dose Combination Formulation of Ceftibuten-Ledaborbactam Etzadroxil",2026-06-30,ESTIMATED,"Part 1 Plasma PK AUC0-∞ (ceftibuten, ledaborbactam, and ledaborbactam etzadroxil) | Part 1 Plasma PK Cmax (ceftibuten, ledaborbactam, and ledaborbactam etzadroxil) | Proportion of participants of Part 2 experiencing Treatment-emergent adverse events (TEAEs), Serious TEAEs, or TEAEs leading to discontinuation.",TREATMENT,ALL,2025-01-07,ACTUAL,INTERVENTIONAL
BRCTF,BioArctic AB (publ),NCT06671938,PHASE2,RECRUITING,"Parkinson Disease, Multiple System Atrophy","exidavnemab, Placebo Comparator",EXIST,RANDOMIZED,2,exidavnemab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.,Worldwide Clinical Trials,2026-03-16,ESTIMATED,40 Years - 85 Years,36,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients With Mild to Moderate Parkinson's Disease on Stable Symptomatic Parkinson's Disease Medication and in Patients With Multiple System Atrophy",2026-03-16,ESTIMATED,Number of participants with adverse events (AEs) and serious adverse events (SAEs).,TREATMENT,ALL,2024-10-24,ACTUAL,INTERVENTIONAL
BTTAY,Biotest Aktiengesellschaft,NCT03334006,PHASE2,RECRUITING,"Peritonitis, Sepsis, Septic Shock",Pentaglobin®/Standard of Care,PEPPER,RANDOMIZED,2,Control arm | Verum arm,NO_INTERVENTION | ACTIVE_COMPARATOR,"The aim of this prospective, randomized, controlled trial is to provide evidence for adjuvant IgGAM treatment with regard to

1. Improvement of patient outcomes for peritonitis. Improvement in outcome will be determined by scores such as MOF, SOFA and survival.
2. Identification of biomarkers (including immunoglobulin levels, HLA-DR, NF-kB1 and other immunological biomarkers) to identify patient subpopulations that benefit most from IgGAM treatment. These patients will form the basis for a furth",Biotest,2028-03,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,OTHER,NONE,"Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis",2027-09,ESTIMATED,"Change in Multiple Organ Failure (MOF) score (measured in lung, heart, kidney, liver, blood) from baseline to day 7 after surgical infectious source control in the context of peritonitis.",TREATMENT,ALL,2017-11-20,ACTUAL,INTERVENTIONAL
BTTAY,Biotest Aktiengesellschaft,NCT05722938,PHASE3,RECRUITING,Community-acquired Pneumonia,"Trimodulin, Placebo (human albumin 1%)",ESsCAPE,RANDOMIZED,2,Trimodulin | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV).

Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.",,2028-07-31,ESTIMATED,18 Years - N/A,590,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)",2028-07-31,ESTIMATED,28-day all-cause mortality rate,TREATMENT,ALL,2023-09-09,ACTUAL,INTERVENTIONAL
BVNRY,Bavarian Nordic A/S,NCT06007183,PHASE3,ACTIVE_NOT_RECRUITING,Chikungunya Virus Infection,"CHIKV VLP vaccine booster, Placebo booster",,RANDOMIZED,7,Group 1a | Group 1b | Group 2a | Group 2b | Group 3a | Group 3b | Group 4,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | NO_INTERVENTION,"The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3, 4, or 5 years post-initial CHIKV VLP vaccination.",,2028-08,ESTIMATED,12 Years - N/A,800,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen,2028-04,ESTIMATED,Proportion of participants maintaining a preboost anti-CHIKV SNA titer ≥100 at yearly intervals up to 5 years post-initial vaccination | Proportion of vaccine boosted participants with composite booster response at 21 days after booster vaccination,PREVENTION,ALL,2023-08-30,ACTUAL,INTERVENTIONAL
BVNRY,Bavarian Nordic A/S,NCT07003984,PHASE3,RECRUITING,Chikungunya Virus,"CHIKV VLP vaccine, Placebo",,RANDOMIZED,4,Arm 1 | Arm 2 | Arm 3 | Arm 4,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to \<12 years of age.",,2028-12,ESTIMATED,2 Years - 11 Years,720,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age",2028-12,ESTIMATED,"Primary Immunogenicity Endpoint: Day 22 anti-CHIKV SNA seroresponse rate in seronegative children | Safety Endpoint 1: Incidence of solicited adverse events through Day 8 | Safety Endpoint 2: Incidence of unsolicited AEs through Day 29 | Safety Endpoint 3: Incidence of AESI, MAAEs, and SAEs",PREVENTION,ALL,2025-06-05,ACTUAL,INTERVENTIONAL
BVNRY,Bavarian Nordic A/S,NCT06844500,PHASE3,ACTIVE_NOT_RECRUITING,"Neonate, Maternal Transmission, Mpox, Vaccination, Immunogenicity, Safety, Pregnancy, Postpartum","MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP)",PregInPoxVac,RANDOMIZED,4,Maternal Group 1 | Maternal Group 2 | Maternal Group 3 | Historical Arm,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | OTHER,"This Phase 3 open-label study aims to assess the safety and immune response of the MVA-BN mpox vaccine when administered subcutaneously to pregnant and postpartum women in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection. The study will be conducted in Boende, Tshuapa Province, DRC.

A total of 359 maternal participants, aged 16 to 35 and in their second or third trimester of pregnancy, will be enrolled. Participants will be randomly assigned to receive two","PENTA Foundation, Ace Africa, European and Developing Countries Clinical Trials Partnership (EDCTP), Bavarian Nordic, University of Kinshasa",2027-05,ESTIMATED,16 Years - 35 Years,359,ESTIMATED,PARALLEL,OTHER,NONE,"Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo",2026-06,ESTIMATED,"Main study: Neutralising antibody response post-dose 2 vaccination with MVA-BN | Safety and reactogenicity of the MVA-BN vaccine in pregnant women | Neonatal/infant safety outcomes in offspring of vaccinated mothers | Maternal, fetal, and neonatal outcomes in vaccinated women | Sub-study. Maternal immunity transferred via breastmilk | Immunogenicity in maternal serum post-vaccination | Maternal immunity transferred via breastmilk (IgA antibodies) | Maternal immunity transferred via breastmilk (IgG antibodies) | Persistence of maternal immunity in infants",PREVENTION,FEMALE,2025-06-23,ACTUAL,INTERVENTIONAL
BVNRY,Bavarian Nordic A/S,NCT06844487,PHASE3,RECRUITING,"Mpox (Monkeypox), Vaccination, Immunogenicity, Safety, Infants, Children","MVA-BN standard regimen, MVA-BN half-dose regimen",PregInPoxVac,RANDOMIZED,3,Child group 1 | Child group 2 | Historical arm,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | OTHER,"This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection and complications. The study will compare the safety and immunogenicity of a full-dose regimen versus a half-dose regimen in this population. A hierarchical testing strategy will be applied as follo","Ace Africa, PENTA Foundation, Bavarian Nordic, European and Developing Countries Clinical Trials Partnership (EDCTP), University of Kinshasa, CEPI",2026-11,ESTIMATED,4 Months - 24 Months,344,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo",2025-12,ESTIMATED,Immunogenicity of Full-Dose vs. Half-Dose MVA-BN Vaccine in Infants/Children. | Safety and Reactogenicity of the MVA-BN Vaccine in Infants/Children Compared to Adults from the POX-MVA-045 Study,PREVENTION,ALL,2025-05-29,ACTUAL,INTERVENTIONAL
BVNRY,Bavarian Nordic A/S,NCT06549530,PHASE2,ACTIVE_NOT_RECRUITING,Monkeypox (Mpox),MVA-BN,,,1,MVA-BN,EXPERIMENTAL,"All participants will receive 2 vaccinations of the same dose of Modified Vaccinia Ankara Virus (MVA-BN) vaccine 4 weeks apart (standard regimen).

Serum samples for assessment of immune response will be collected at baseline (visit of first vaccination) and at 2 weeks (week 6), 6 months (week 30), and 1 year after the second (last) vaccination.",Coalition for Epidemic Preparedness Innovations,2026-05-07,ESTIMATED,2 Years - 50 Years,460,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections",2026-05-01,ESTIMATED,Immunogenicity of 2 doses of MVA BN | Occurrence of Safety Adverse Events (SAE) & Adverse of Event of Special Interest (AESI) events,TREATMENT,ALL,2024-10-21,ACTUAL,INTERVENTIONAL
BVNRY,Bavarian Nordic A/S,NCT07199569,PHASE2,RECRUITING,Monkeypox (Mpox),"Jynneos, MVA-BN (Quail)",,RANDOMIZED,2,Group 1 | Group 2,ACTIVE_COMPARATOR | EXPERIMENTAL,"andomized, double-blind, phase 2b trial to assess comparability in immunogenicity, safety, and reactogenicity of MVA-BN vaccine manufactured in primary chicken

embryo fibroblast (CEF) cells and the CCX.E10 quail cell line in adults",ICON plc,2026-10-31,ESTIMATED,18 Years - 49 Years,744,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Phase 2b Comparability Trial in Adults 18 to 49 Years of Age to Assess Immunogenicity, Safety, and Reactogenicity of the MVA-BN Vaccine Manufactured in Different Production Cells",2026-10-31,ESTIMATED,"Immunogenicity of 2 doses of MVA-BN | Number of Participants with Serious Adverse Events (SAE) | Number of Participants with Adverse Events of Special Interest (AESI) | Number of Participants with Medically Attended Adverse Events (MAAE) | Number of Participants with a Grade 3 or higher adverse event (AE) | Number of Participants with Solicited Local AE | Number of Participants with Solicited Systemic AE (body temperature, headache, fatigue, myalgia, nausea, chills) | Number of Participants with Unsolicited AE",OTHER,ALL,2025-10-27,ACTUAL,INTERVENTIONAL
BVNRY,Bavarian Nordic A/S,NCT06899802,PHASE2,ACTIVE_NOT_RECRUITING,Encephalitis,MVA-BN-WEV,,RANDOMIZED,3,MVA-BN-WEV Low Dose | MVA-BN-WEV High Dose | Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by VEEV and EEEV, in persons aged 18 years and older at high risk of exposure.",JPM CBRN Medical,2027-03,ESTIMATED,18 Years - 50 Years,411,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Two-stage, Randomized, Double-blind, Dose Ranging Phase 2 Trial in Healthy Adult Participants to Investigate Optimal Dose and Dosing Regimen, and to Evaluate Safety and Immunogenicity of the Recombinant MVA-BN-WEV Vaccine",2027-02,ESTIMATED,Optimal dose of MVA-BN-WEV vaccine in adult participants in terms of immunogenicity based on eastern equine encephalitis virus (EEEV)- and Venezuelan equine encephalitis virus (VEEV)-specific humoral immune responses to the MVA-BN-WEV vaccination. | Booster response of MVA-BN-WEV versus placebo in terms of immunogenicity based on EEEV- and VEEV- specific humoral immune responses to the MVA-BN-WEV vaccine.,PREVENTION,ALL,2025-03-10,ACTUAL,INTERVENTIONAL
BVNRY,Bavarian Nordic A/S,NCT02977715,PHASE3,ACTIVE_NOT_RECRUITING,Monkeypox Virus Infection,"JYNNEOS (Liquid Formulation), JYNNEOS (Lyophilized Formulation)",,NON_RANDOMIZED,3,Intervention (Liquid Formulation) | Intervention (Lyophilized Formulation) | Single booster dose (Liquid Formulation),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Mpox is a febrile rash illness caused by the monkeypox virus. Its natural occurrence in the DRC puts healthcare and frontline workers at high risk of acquiring monkeypox virus infections that can prevent them from performing work duties, compromise the overall healthcare delivery in an already fragile system, and can result in death (case fatality estimates are approximately 10%).

This is an open-label prospective cohort study in up to 1,600 eligible healthcare workers at risk of mpox infection","Ministry of Public Health, Democratic Republic of the Congo, Kinshasa School of Public Health, Bavarian Nordic",2025-12-31,ESTIMATED,18 Years - N/A,1600,ACTUAL,SEQUENTIAL,FED,NONE,An Open-Label Prospective Cohort Study of JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo,2025-12-31,ESTIMATED,Monkeypox virus infection | Monkeypox virus exposure | Orthopoxvirus Antibody Response | Distribution of Geometric Means Titers (GMTs) | Adverse event and serious adverse event information,PREVENTION,ALL,2017-02-23,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06700148,PHASE3,ACTIVE_NOT_RECRUITING,Meningococcal Meningitis,"MCV4, MPSV4",,RANDOMIZED,2,ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197)(MCV4) | ACYW135 Group Meningococcal Polysaccharide Vaccine (MPSV4),EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a randomized, blinded, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups, afterwards some subjects entered the immune persistence group.",,2025-08-30,ESTIMATED,7 Years - 17 Years,840,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Blinded, Peer-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7-17 Year Olds",2025-08-30,ESTIMATED,"Meningococcal Antibody Positive Conversion Rates and GMT for Groups A, C, Y, and W135 in All Subjects | Geometric Mean Titer (GMT) for Groups A, C, Y, and W135 in All Subjects | Incidence of adverse reactions in all subjects | Incidence of adverse reactions/events in all subjects | Incidence of adverse reactions/events in all subjects",PREVENTION,ALL,2024-12-14,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06857370,PHASE3,ACTIVE_NOT_RECRUITING,"Diphtheria, Tetanus and Acellular Pertussis","Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 1), Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 2), Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP Lot 3)",,RANDOMIZED,3,"Experimental vaccine group A, 2 months old | Experimental vaccine group B, 2 months old | Experimental vaccine group C, 2 months old",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a randomized, blinded, peer-controlled study. There will be 3 treatment groups, screened subjects were randomized in a 1:1:1 ratio to receive three batches of the DTcP trial vaccine, and completed the primary immunization according to the procedure of one dose each at 2, 4, and 6 months of age.",,2026-01,ESTIMATED,60 Days - 89 Days,780,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine,2026-01,ESTIMATED,"Geometric Mean Concentration (GMC) of serum anti-PT, FHA, PRN, DT, and TT antibodies in 2-month-old subjects with three different batches of the trial vaccine.",PREVENTION,ALL,2025-03-23,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT05951725,PHASE3,ACTIVE_NOT_RECRUITING,"Diphtheria, Tetanus and Acellular Pertussis","Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (DTcP), Diphtheria，Tetanus and Acellular Pertussis Combined Vaccine，DTaP, Diphtheria,tetanus,pertussis(acellular,component),Inactivated polio vaccine(adsorbed）and Haemophilus influenzae type b conjugate vaccine,adsorbed,DTaP-IPV-Hib, DTcP, DTaP-IPV-Hib, DTcP",,RANDOMIZED,6,Experimental vaccine group A，3 months old | Control vaccine group B，3 months old | Control vaccine group C，3 months old | Experimental vaccine group D，2 months old | Control vaccine group E，2 months old | Experimental vaccine group F，2 months old,EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL,"The combined pertussis, diphtheria and tetanus vaccine, the first vaccine to be included in the Expanded Programme of Immunization(EPI) of World Health Organization(WHO), has played an important role in the prevention and control of these three infectious diseases. The (diphtheria，tetanus and acellular pertussis combined vaccine，DTaP) vaccine was successfully developed in China in 1993, and its safety and serological effects were confirmed by the observation of human safety, with mild vaccinatio",,2025-04-01,ESTIMATED,2 Months - 3 Months,2520,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Blinded, Positive Vaccine-controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of DTcP in Infants and Children at 2 and 3 Months of Age",2025-04-01,ESTIMATED,"Serum anti-Pertussis Toxoid(PT), Filamentous hemagglutmin(FHA), Pertactin(PRN), DT(Diphtheria Toxoid), TT(Tetanus Toxoid) antibody positive conversion rate,GMC 30 days after completion of basal immunization in subjects in the 3-month-old group | Serum anti-PT, FHA, PRN, DT, TT antibody positive conversion rate, Geometric Mean Concentration(GMC) 30 days after completion of basal immunization in subjects in the 2-month-old group | Incidence of adverse reactions within 0-30 days after each dose of vaccination in subjects in the 3-month-old group | Incidence of adverse reactions within 0-30 days after each dose of vaccination in subjects in the 2-month-old group",PREVENTION,ALL,2023-08-11,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06226714,PHASE3,ACTIVE_NOT_RECRUITING,Meningococcal Meningitis,"MCV4, MPSV4",,RANDOMIZED,2,ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4) | ACYW135 Group Meningococcal Polysaccharide Vaccine (MPSV4),EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups.",,2025-08,ESTIMATED,18 Years - 59 Years,840,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Blinded, Peer-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 18-59 Years",2024-09-26,ACTUAL,"Meningococcal antibody positive conversion rates for groups A, C, Y, and W135 in all subjects | Geometric mean titer (GMT) of antibodies to groups A, C, Y, and W135 in all subjects | Incidence of adverse reactions in all subjects | Incidence of adverse reactions/events in all subjects | Incidence of adverse reactions/events in all subjects",PREVENTION,ALL,2024-03-01,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06056050,PHASE1,ACTIVE_NOT_RECRUITING,"Diphtheria, Tetanus, Pertussis","Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp), 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）, Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)",,RANDOMIZED,6,"Experimental vaccine group 1A,≥18 years old | Control vaccine group 1B,≥18 years old | Experimental vaccine group 2A,12~17 years old | Control vaccine group 2B,12~17 years old | Experimental vaccine group 3A,6~11 years old | Control vaccine group 3B,6~11 years old",EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR,"Pertussis is an acute respiratory infectious disease caused by Bordetella pertussis, diphtheria is an acute upper respiratory infectious disease caused by Gram-positive Corynebacterium diphtheriae, and tetanus is a highly fatal disease caused by Clostridium tetani infection. Currently, there is no clinical trial registration of Diphtheria, tetanus, and pertussis (DPT) vaccine applicable to ≥6 years of age in China, therefore, the five-component acellular DPT combination vaccine developed by our ",,2025-09-28,ESTIMATED,6 Years - N/A,180,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Blinded, Controlled Phase I Clinical Trial for Preliminary Evaluation of the Safety and Immunogenicity of Adsorbed Cell-free DPT Vaccine (for People Aged 6 Years and Above)",2024-04-13,ACTUAL,Incidence of adverse reactions 0-30 days after vaccination,PREVENTION,ALL,2023-12-06,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06621654,PHASE1,ACTIVE_NOT_RECRUITING,Haemophilus Influenzae Type B Infection,"Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine, Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine, Haemophilus Influenzae Type b Conjugate Vaccine, Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine, Haemophilus Influenzae Type b Conjugate Vaccine, Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine, Haemophilus Influenzae Type b Conjugate Vaccine",,RANDOMIZED,7,Experimental vaccine group 1A | Experimental vaccine group 2A | Control vaccine group 2B | Experimental vaccine group 3A | Control vaccine group 3B | Experimental vaccine group 4A | Control vaccine group 4B,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR,"This trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of age groups, from the oldest to the youngest, and the initial safety assessment will be conducted on the 8th day after the first dose of vaccination for each age group, and the next group will be enrolled only after the ",,2026-10,ESTIMATED,2 Months - 59 Years,160,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Partially Blinded, Positively Controlled Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine in a Population Aged 2 Months and Older",2026-10,ESTIMATED,Adverse reactions in all subjects,PREVENTION,ALL,2024-11-15,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06577298,"PHASE1, PHASE2",RECRUITING,Poliomyelitis,"Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) (VLP-Polio) low adjuvant dose, VLP-Polio medium dose, VLP-Polio high dose, Vaccine Poliomyelitis Inactivated (IPV)",,RANDOMIZED,14,"Phase I, Toddler Group A, Experimental vaccine, High dose, IM | Phase I, Toddler Group A, Control vaccine, IM | Phase I, Infant Group B, Experimental vaccine, Low-adjuvant dose, IM | Phase I, Infant Group B, Control vaccine, IM | Phase I, Infant Group C, Experimental vaccine, Medium dose, IM | Phase I, Infant Group C, Control vaccine, IM | Phase I, Infant Group D, Experimental vaccine, High dose, IM | Phase I, Infant Group D, Control vaccine, IM | Phase II, Infant Group E, Experimental vaccine, Low-adjuvant dose, IM | Phase II, Infant Group E, Control vaccine, IM | Phase II, Infant Group F, Experimental vaccine, Medium dose, IM | Phase II, Infant Group F, Control vaccine, IM | Phase II, Infant Group G, Experimental vaccine, High dose, IM | Phase II, Infant Group G, Control vaccine, IM",EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to receive either investigational vaccine (Low-adjuvant dose VLP-Polio, Medium dose VLP-Polio, or High dose VLP-Polio or control vaccine in a ratio of 3:1. Phase II infant cohort will have 4 arms randomly assigned to recei",,2026-12,ESTIMATED,6 Weeks - 18 Months,480,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase I/II Randomized, Double-blind, Positive-controlled Dose-exploration Study to Evaluate the Safety and Immunogenicity of a Virus-like Particle (VLP) Based Vaccine Against Poliomyelitis (VLP-Polio) in Infants From 6 Weeks of Age and Toddlers 12-18 Months of Age",2026-10,ESTIMATED,"Phase I: Percentage of participants with solicited adverse events (AEs) | Phase II: Percentage of participants with solicited adverse events (AEs) | Phase II: Seroconversion rate of neutralizing antibodies against Sabin and wild-type poliovirus type 1, 2, and 3",PREVENTION,ALL,2024-12-19,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06708286,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Diphtheria, Tetanus, Pertussis","Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)), 23-valent Pneumococcal Polysaccharide Vaccine (PPV23), Tdcp, PPV23, Tdcp, PPV23, Tdcp, PPV23, Tdcp, Diphtheria-tetanus-acellular pertussis vaccine (DTaP)",,RANDOMIZED,10,"Phase II, ≥18 years old, Experimental vaccine | Phase II, ≥18 years old, Control vaccine | Phase II, 7-17 years old, Experimental vaccine | Phase II, 7-17 years old, Control vaccine | Phase III, ≥18 years old, Experimental vaccine | Phase III, ≥18 years old, Control vaccine | Phase III, 7-17 years old, Experimental vaccine | Phase III, 7-17 years old, Control vaccine | Phase III, 6 years old, Experimental vaccine | Phase III, 6 years old, Control vaccine",EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a randomized, blinded, controlled phase II and III clinical trial evaluating the immunogenicity and safety of adsorbed cell-free DPT vaccine. 320 subjects aged 7 years and older in the phase II were divided into two age groups, the ≥18 years group and the 7-17 years group, and randomized 3:1 to receive the trial vaccine Tdcp versus the control vaccine PPV23. 1500 subjects in the phase III were divided into 3 age subgroups. 780 subjects were planned to be enrolled in the 6-year-old group ",,2025-05-30,ESTIMATED,6 Years - N/A,1820,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Blinded, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Adsorbed Cell-free DTP Vaccine (Five-component)",2025-05-30,ESTIMATED,"Phase II: Incidence of adverse reactions | Phase III: Geometric mean concentration (GMC) of serum anti-PT, FHA, PRN, FIM 2&3, DT, TT antibodies | Phase III: Proportion of serum anti-DT and TT antibodies ≥ 0.1IU/ml | Phase III: Incidence of adverse reactions",PREVENTION,ALL,2024-12-20,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06732583,PHASE1,RECRUITING,Tuberculosis,"Tuberculosis (TB) vaccine (Ad5-105K), Placebo, Ad5-105K, Placebo",,RANDOMIZED,4,"Experimental vaccine group, Low dose | Placebo Group, Low dose | Experimental vaccine group, High dose | Placebo Group, High dose",EXPERIMENTAL | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a ratio of 2:1. The distribution of participant's gender and age should be balanced in each group.",PT Etana Biotechnologies Indonesia,2026-08,ESTIMATED,18 Years - 49 Years,36,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase I Randomized, Double-blind, Placebo-controlled and Dose Escalation Study to Evaluate the Safety and Immunogenicity of a Viral Vector-based Tuberculosis (TB) Vaccine Ad5-105K Against TB Disease in Adults Aged 18 to 49 Years",2026-08,ESTIMATED,Occurrence of solicited adverse events (AEs),PREVENTION,ALL,2025-11-13,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT07203755,PHASE1,RECRUITING,"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, DTcP-Hib-MCV4, DTcP-Hib-MCV4, DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP), Haemophilus influenzae type b (Conjugate) (Hib), Meningococcal Group ACYW135 (Conjugate) (MCV4), MCV4, MCV4",,RANDOMIZED,11,"Part I, 1A, low dose, 6 year-old | Part I, 2A, low dose, 18~24 month-old | Part I, 2B, high dose, 18~24 month-old | Part I, 3A, low dose, 2 month-old | Part I, 3B, high dose, 2 month-old | Part I, 3C, 2 month-old | Part I, 3D, 2 month-old | Part I, 3E, 2 month-old | Part I, 4A, 3 month-old | Part II, Vaccine Group, 2 month-old | Part II, Placebo Group, 2 month-old",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design. Part One is divided into four stages based on age and vaccine dose levels. Part Two consists of the 2-month-old vaccine/placebo groups.",,2029-02,ESTIMATED,2 Months - 6 Years,260,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Partially Blinded, Dose-Exploratory, Active/Placebo-Controlled Phase I Clinical Trial Evaluating the Safety and Immunogenicity of the Adsorbed Acellular Pertussis (Tricomponent) DPT-Hib (Conjugate)-ACYW135-Group B Meningococcal (Conjugate) Combined Vaccine in Individuals Aged 2 Months to 6 Years",2029-02,ESTIMATED,Incidence of adverse reactions,PREVENTION,ALL,2025-12-19,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06131554,PHASE3,ACTIVE_NOT_RECRUITING,Meningococcal Meningitis,"batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4, Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",,RANDOMIZED,4,"batch 1 of MCV4 | batch 2 of MCV4 | batch 3 of MCV4 | Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55 years. Subjects will be randomized to receive investigational Lot 1, Lot 2, Lot 3 vaccine or control vaccine in a 1:1:1:1 ratio, with the subjects in experimental group randomly and equally assigned to three different batches of MCV4 for single-dose vaccination.",,2025-12,ESTIMATED,18 Years - 55 Years,1480,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-blinded, Positive-controlled Phase Ⅲ Clinical Trial to Evaluate Lot-to-lot Consistency, Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years",2024-07-12,ACTUAL,"The geometric mean titer (GMT) of serogroup A, C, Y and W135 meningococcal rSBA titer in all participants. | The seroconversion rate of serogroup A, C, Y, and W135 meningococcal rSBA titer. | The incidence of adverse reactions (ARs) in all participants.",PREVENTION,ALL,2024-03-20,ACTUAL,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT07017777,PHASE3,NOT_YET_RECRUITING,"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","PCV13i, Prevnar 13",,RANDOMIZED,2,13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (PCV13i) | Pneumococcal 13-valent Conjugate Vaccine (Prevnar 13),EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a Phase 3 randomized, observation-blinded, active-controlled, parallel-group clinical trial designed to evaluate the immunogenicity, safety, and functional antibody response of the experimental vaccine versus the control vaccine in healthy Thailand infants vaccinated at a 2+1 schedule (2 months, 4 months and 12-15 months). The trial will enroll approximately 600 healthy infants aged 2 months (at least 6 weeks) who will be randomly assigned in a 1:1 ratio to receive either the experimenta",,2028-05-15,ESTIMATED,6 Weeks - 2 Months,600,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)",2027-02-15,ESTIMATED,Proportion of participants achieving serotype-specific IgG antibody concentrations ≥ 0.35 µg/mL | Incidence of solicited local and systemic adverse events (AEs),PREVENTION,ALL,2025-10-15,ESTIMATED,INTERVENTIONAL
CASBF,CanSino Biologics Inc.,NCT06389513,PHASE4,ACTIVE_NOT_RECRUITING,Epidemic Meningitis,MCV4,,,1,ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (MCV4),EXPERIMENTAL,"This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.",,2025-12,ESTIMATED,3 Months - 3 Months,3011,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,Phase IV Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants,2025-12,ESTIMATED,Incidence of localized adverse reactions in subjects | Incidence of systemic adverse reactions in subjects,PREVENTION,ALL,2024-06-12,ACTUAL,INTERVENTIONAL
CBPHF,"Clover Biopharmaceuticals, Ltd.",NCT05426369,PHASE1,ACTIVE_NOT_RECRUITING,Chemotherapy-induced Thrombocytopenia (CIT),Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein,,NON_RANDOMIZED,3,Dose Escalation | Dose Expansion - Group A: First-line CIT treatment / Prophylactic administration for CIT (as needed) | Dose Expansion - Group B: Previously treated or refractory CIT,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Preliminary Efficacy and Pharmacokinetics of SCB-219M in the patients with chemotherapy-induced thrombocytopenia (CIT)",,2025-12,ESTIMATED,18 Years - 75 Years,36,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Preliminary Efficacy and Pharmacokinetics of SCB-219M in the Patients With Chemotherapy-induced Thrombocytopenia",2025-07-02,ACTUAL,Dose escalation: Occurrence of DLT. | Dose escalation: Frequency of DLT. | Dose escalation and Dose expansion:Occurrence of AE.,TREATMENT,ALL,2022-06-14,ACTUAL,INTERVENTIONAL
CBPHF,"Clover Biopharmaceuticals, Ltd.",NCT06984094,PHASE1,RECRUITING,"Respiratory Syncytial Virus Vaccination, Human Metapneumovirus Vaccination, Parainfluenza Vaccination","SCB-1019T, SCB-1022, SCB-1033",,RANDOMIZED,8,Group 1 (SCB-1022 dose level 1) | Group 2 (SCB-1022 dose level 2) | Group 3 (SCB-1033 dose level 1) | Group 4 (SCB-1019T) | Group 5 (SCB-1022 dose level 3) | Group 6 (SCB-1033 dose level 2) | Group 7 (SCB-1033 dose level 3) | Group 8 (SCB-1019T),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"This phase 1 study will evaluate the safety, reactogenicity, and immunogenicity of 3 different dose levels of SCB-1022 and SCB-1033 in healthy adults aged 60-85 years.",,2026-06-30,ESTIMATED,65 Years - 80 Years,192,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Observer-blind, First-in-human Study to Describe the Safety, Reactogenicity and Immunogenicity of SCB-1022 and SCB-1033 in Healthy Older Adults Aged 60-85 Years",2026-03-03,ESTIMATED,To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T. | To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T. | To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T. | To evaluate the safety and reactogenicity of SCB-1022 and SCB 1033 compared to SCB-1019T.,PREVENTION,ALL,2025-06-18,ACTUAL,INTERVENTIONAL
CBPHF,"Clover Biopharmaceuticals, Ltd.",NCT06843317,PHASE1,RECRUITING,RSV Infection,"Candidate vaccine, SCB-1019T, AREXVY",,RANDOMIZED,4,Group 1 (SCB-1019T) | Group 2 (SCB-1019T) | Group 3 (AREXVY) | Group 4 (Placebo),EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.",,2026-06-03,ESTIMATED,60 Years - 85 Years,160,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before",2026-03-03,ESTIMATED,To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccine | To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccine | To evaluate the safety and reactogenicity of revaccination with SCB-1019T vaccine,PREVENTION,ALL,2025-03-21,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07237828,,NOT_YET_RECRUITING,Breast Cancer,,DRAIN,RANDOMIZED,2,Intervention group | Control group,EXPERIMENTAL | NO_INTERVENTION,"Breast cancer is a malignant tumor that seriously threatens the health of women, with an increasing incidence rate. The current main treatment methods include multidisciplinary diagnosis and treatment such as surgery, radiotherapy, chemotherapy, and endocrine therapy, among which surgery is the key. Postoperative care is also very important. Traditional breast surgery requires long-term placement of drainage tubes after the operation. However, long-term placement of drainage tubes increases the ","The First Affiliated Hospital of Shanxi Medical University, West China Fourth Hospital, Sichuan University, Bethune Hospital of Shanxi Medical University, The First Hospital of Jilin University, Shanxi Province Cancer Hospital, Suining Central Hospital, The Second Affiliated Hospital of Kunming Medical University, Zhengzhou Central Hospital, Deyang People's Hospital, Suzhou Municipal Hospital, Chengdu Fifth People's Hospital, Hunan University of Traditional Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, The Fourth People's Hospital of Sichuan Province, China-Japan Union Hospital, Jilin University, Guangzhou First People's Hospital, Xinjiang Medical University Affiliated Cancer Hospital, Fujian Medical University Union Hospital, Central Hospital of Taiyuan, West China Tianfu Hospital of Sichuan University",2032-06-30,ESTIMATED,18 Years - 70 Years,379,ESTIMATED,PARALLEL,OTHER,NONE,"Drainage Removal After Reverse-Sequence Endoscopic Nipple-Sparing Mastectomy With Direct-to-Implant Prepectoral Breast Reconstruction on Postoperative Safety and Patient Satisfaction : A National Multicenter, Open, Randomized Controlled Study",2032-06-30,ESTIMATED,Aesthetic outcome evaluation--BREAST-Q scores,TREATMENT,FEMALE,2025-12-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06527547,,RECRUITING,"Transcutaneous Electric Nerve Stimulation, Rheumatoid Arthritis, Sleep Quality",,,RANDOMIZED,2,taVNS Group | Sham Stimulation Group,EXPERIMENTAL | SHAM_COMPARATOR,"The purpose of this clinical trial is to determine whether transcutaneous auricular vagus nerve stimulation (taVNS) is suitable for improving sleep disorders in patients with rheumatoid arthritis (RA). It will also evaluate the safety of taVNS. The main questions it aims to answer are:

Can taVNS improve the sleep quality of RA patients? What medical issues might RA patients experience while receiving taVNS treatment? Researchers will compare taVNS with a placebo (a similar substance that does n","Hebei Provincial Hospital of Traditional Chinese Medicine, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Shenzhen Futian Hospital of TCM, Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine",2025-12-31,ESTIMATED,18 Years - 72 Years,52,ESTIMATED,PARALLEL,OTHER,DOUBLE,Effect of Transcutaneous Auricular Electroacupuncture on Sleep Disturbances in Patients With Rheumatoid Arthritis: A Randomized Double-Blind Clinical Trial,2025-12-31,ESTIMATED,Pittsburgh Sleep Quality Index(PSQI),TREATMENT,ALL,2024-06-06,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07077382,,RECRUITING,Pneumoconiosis,,PANDECT,,3,Patients with pneumoconiosis | Dust exposure group | Healthy control group, |  | ,The primary objective of this study is to characterize the demographic and clinical features of patients with occupational pneumoconiosis (hereinafter referred to as pneumoconiosis) in China. Secondary objectives include: 1) to describe the natural course of pneumoconiosis; 2) to evaluate the prognosis of pneumoconiosis patients; and 3) to assess complications and comorbidities in pneumoconiosis patients.,"KaiLuan General Hospital, The First Affiliated Hospital of Shanxi Medical University, Weifang Respiratory Disease Hospital, Hubei Hospital of Traditional Chinese Medicine, Hunan Prevention and Treatment Institute for Occupational Diseases, China, The first affiliated hospital of chongqing medical and pharmaceutical college, Centers for Disease Control and Prevention, China, Shandong Gold Mining Company Occupational Disease Precention Hospital, Shandong Province Hospital of occupational diseases, The Second Hospital of Heilongjiang Province",2030-05-31,ESTIMATED,N/A - N/A,2000,ESTIMATED,,OTHER,,Pneumoconiosis and Dust Exposure China Cohort,2026-03-31,ESTIMATED,Pulmonary function test,,ALL,2021-05-28,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07295938,PHASE2,RECRUITING,Mycobacterium Abscessus Pulmonary Disease,"Chinese herbs-I, Chinese herbs-I placebo, Chinese herbs-II, Chinese herbs-II placebo",,RANDOMIZED,4,Treatment Group-I | Control Group-I | Treatment Group-II | Control Group-II,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"Chinese herbs can facilitate sputum culture conversion, promote lesion absorption, and enhance clinical symptoms and quality of life for patients with Mycobacterium abscessus pulmonary disease (MAB-PD). The investigators aimed to evaluate the efficacy of Chinese herbs as adjunct therapy to improve cure rates or reduce recurrence rates during the continuation phase of MAB-PD treatment.","Shanghai Pulmonary Hospital, Shanghai, China, Anhui Chest Hospital, Guangzhou Chest Hospital., Jiangxi Chest Hospital, Beijing Chest Hospital, China-Japan Friendship Hospital, Huashan Hospital",2028-11,ESTIMATED,18 Years - 75 Years,352,ESTIMATED,PARALLEL,OTHER,TRIPLE,A Study to Assess the Traditional Chinese Medicine as Adjunctive Therapy to Improve Cure Rates During the Continuation Phase in Mycobacterium Abscessus Pulmonary Disease,2028-11,ESTIMATED,Clinical cure rate | Relapse or reinfection rates,TREATMENT,ALL,2025-09-08,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06515964,,RECRUITING,Early Esophageal Cancer,,,,0,,,"With the development of endoscopy, more and more patients with superficial esophageal squamous cell carcinoma (ESCC) receive endoscopic resection rather than traditional surgery. However, there is still no complete consensus on the risk factors for lymph node metastasis (LNM) and recurrence of ESCC after endoscopic resection. The existing curative resection criteria are strict to a certain extent, and a considerable number of patients are overtreated according to the current standard of addition","Lianshui People's Hospital, The second affiliated hospital of Xuzhou medical university, The second people's hospital of Nanyang, Nanchong Central Hospital, Tongliao City Hospital, Yancheng First People's Hospital, The Second Hospital of Hebei Medical University, The Second Affiliated Hospital of Baotou Medical College, Affiliated Hospital of Southwest Medical University, Sichuan Cancer Hospital and Research Institute, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Zhongda Hospital, The First Affiliated Hospital with Nanjing Medical University, West China Hospital, The First Affiliated Hospital of Soochow University, Jiangsu Province Hospital of Traditional Chinese Medicine, Shandong Provincial Hospital, Shanxi Provincial People's Hospital, Henan Provincial People's Hospital, Anyang Cancer Hospital",2025-10-01,ESTIMATED,15 Years - 85 Years,1000,ESTIMATED,,OTHER,,Development and Validation of a Curability Evaluation Model for Endoscopic Resection of Early Esophageal Squamous Cell Carcinoma Based on China Early Esophageal Cancer Cohort,2025-10-01,ESTIMATED,Noncurative Resection,,ALL,2022-10-01,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT03131427,,RECRUITING,Genetic/Metabolic Liver Diseases,Standard of care,,,5,Wilson's Disease | Hereditary Hemochromatosis | Hereditary Hyperbilirubinemias | Inherited Cholestatic Liver Disease | Other genetic/metabolic liver diseases, |  |  |  | ,"CR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. Patients' whole blood and serum were collected for genetic testing and future researches. These patients will be followed-up every six to twelve months.","Beijing YouAn Hospital, Henan Provincial People's Hospital, Beijing Ditan Hospital, Hebei Medical University Third Hospital, Peking University First Hospital, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Nanfang Hospital, Southern Medical University, Logistics University of Chinese People's Armed Police Forces, Beijing Anzhen Hospital, West China Second University Hospital, Jinshan Hospital Fudan University, Fudan University",2027-04-28,ESTIMATED,N/A - N/A,20000,ESTIMATED,,OTHER,,A Nation-wide Hospital-based Registry:China Registry for Genetic / Metabolic Liver Diseases,2022-04-28,ESTIMATED,rate of liver-related events of each disease.,,ALL,2015-06-13,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07231523,PHASE3,NOT_YET_RECRUITING,"Efgartigimod, Intravenous Immunoglobulin, Myasthenia Gravis Associated With Thymoma",,,RANDOMIZED,2,Efgartigimod + Thymectomy | Intravenous immunglobulin + Thymectomy,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the perioperative application for acetylcholine receptor (AChR) antibody-positive thymoma patients with myasthenia gravis in order to provide reliable evidence for clinical decision-making.","The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tang-Du Hospital, West China Hospital, Second Affiliated Hospital of Soochow University, Huashan Hospital, The Affiliated Brain Hospital of Nanjing Medical University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Wuhan TongJi Hospital",2027-12-01,ESTIMATED,18 Years - 75 Years,64,ESTIMATED,PARALLEL,OTHER,NONE,"Perioperative Efficacy and Safety of Efgartigimod Versus Intravenous Immunoglobulin for Thymoma Associated Myasthenia Gravis: a Prospective, Multicenter, Randomized Controlled Study",2027-06-01,ESTIMATED,Quantitative Myasthenia Gravis (QMG) reduction,TREATMENT,ALL,2025-12-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05598528,,RECRUITING,"Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation, Primary Resistance, Circulating Tumor DNA",,PRECISE,,1,EGFR-positive lung patients recieving 3rd generation EGFR-TKIs as first-line therapy,,"Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), especially the 3rd-generation EGFR-TKIs have demonstrated strong antitumor effects in EGFR-positive patients.

However, approximately 20% of EGFR-positive were primarily resistant to 3rd generation EGFR-TKIs, i.e., clinical non-response or disease progression in the short ter","Xiangya Hospital of Central South University, Shanghai Chest Hospital, West China Hospital, Hunan Cancer Hospital, The Third Xiangya Hospital of Central South University, The First Affiliated Hospital of Xiamen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, China-Japan Friendship Hospital, Fudan University, First Affiliated Hospital of Kunming Medical University, Loudi Central Hospital, ZhuZhou Central Hospital, Xiangtan Central Hospital, First People's Hospital of Chenzhou, Yueyang Central Hospital, Yongzhou Central Hospital, The First Affiliated Hospital of University of South China, Hunan Provincial People's Hospital, Shaoyang Central Hospital, Yiyang Central Hospital, Changsha Central Hospital, The first people's hospital of Guiyang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, The First People's Hospital of Changde City, Zhuzhou Second Hospital, First Hospital of Changsha, Hengyang Central Hospital, Huaihua first people's Hospital, The First People's Hospital of Xiangtan, University of South China Affiliated Nanhua Hospital, Xiangxi Autonomous Prefecture People's Hospital, People's Hospital of Zhangjiajie, Second People's Hospital Of Huaihua, Hunan Academy of Traditional Chinese Medicine Affiliated Hospital, The Third Hospital of Changsha, Xiangya Changde Hospital, Changsha County first People's Hospital, Hunan Provincial Straight Hospital of Traditional Chinese Medicine, Liuyang Hospital of traditional Chinese Medicine, Second People's Hospital of Hunan, First Affiliated Hospital of Guangxi Medical University, Guiyang Public Health Treatment Center, The Affiliated Bethune Hospital of Shanxi Medical University, Hunan University of Traditional Chinese Medicine, Tongji Hospital, The First Affiliated Hospital of Nanchang University",2026-12-31,ESTIMATED,18 Years - N/A,210,ESTIMATED,,OTHER,,A Multicenter Clinical Study to Explore the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study),2025-12-31,ESTIMATED,Objective Response Rate (ORR) | Progression-free survival (PFS) | Differences in genomic profiles of tumor tissues and ctDNA clearance of third-generation EGFR-TKIs sensitive and primary drug-resistant NSCLC.,,ALL,2021-09-28,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07333053,,RECRUITING,Unresectable Colorectal Cancer,,,RANDOMIZED,2,TAIC Group | IVC group,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).","Liaoning Cancer Hospital & Institute, The Rocket Force Characteristic Medical Center, Second Affiliated Hospital of Nanchang University, The Affiliated Hospital of Hebei University, The First Hospital of Qinhuangdao, The Central Hospital of Handan City, The First People's Hospital of Jiujiang City, Changzhi Medical College, Zibo Boshan District Traditional Chinese Medicine Hospital, Linshu County People's Hospital, Hebei Yixian Hospital, Baoding Mancheng District People's Hospital",2027-12-31,ESTIMATED,18 Years - N/A,30,ESTIMATED,PARALLEL,OTHER,NONE,"FOLFOX-Based Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer: An Open-Label, Multicenter, Randomized, Controlled, Phase Ⅱ Trial",2027-12-31,ESTIMATED,ORR | DCR,TREATMENT,ALL,2026-01-31,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06591078,,NOT_YET_RECRUITING,Cervical Cancer,,,RANDOMIZED,2,experimental group | control group,EXPERIMENTAL | NO_INTERVENTION,"In a prospective, multicenter, randomized, controlled study, patients with metastatic, recurrent, or persistent cervical cancer who were ineligible for surgery and/or radiotherapy were randomly assigned in a 1:1 ratio to either an experimental group or a control group."" The control group was treated with apatinib combined with callizumab/callizumab combined with chemotherapy, and the experimental group was treated with electroacupuncture on the basis of the treatment. Anti-tumor efficacy, immune","Peking Union Medical College Hospital, Beijing Obstetrics and Gynecology Hospital, Peking University Cancer Hospital & Institute, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sichuan Cancer Hospital and Research Institute, Shanghai University of Traditional Chinese Medicine, Hunan Cancer Hospital, Chongqing University Cancer Hospital",2026-11-01,ESTIMATED,18 Years - 70 Years,90,ESTIMATED,PARALLEL,OTHER,DOUBLE,Clinical Efficacy Evaluation and Mechanism Study of Potential Advantageous Diseases of Acupuncture - Evaluation of Clinical Efficacy of Acupuncture in Improving Immune Response in Patients With Cervical Cancer,2026-11-01,ESTIMATED,objective remission rate,TREATMENT,FEMALE,2024-09-15,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06375824,,NOT_YET_RECRUITING,Preserved Ratio Impaired Spirometry,"Bufei Recipe, Bufei Recipe placebo",,RANDOMIZED,2,Bufei Recipe | Bufei Recipe placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,Establish early TCM prevention and treatment program to reduce the incidence rate of COPD.,"West China Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University",2027-10-31,ESTIMATED,18 Years - 80 Years,1100,ESTIMATED,PARALLEL,OTHER,DOUBLE,"Bufei Recipe Reduces the Incidence Rate of COPD: A Multicenter, Randomized, Double Blind, Placebo Controlled Study",2027-04-30,ESTIMATED,Incidence rate of COPD,TREATMENT,ALL,2024-05-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07177586,,RECRUITING,Supraglottic Airway Devices Position,,,RANDOMIZED,2,Inflatable LMA Group | GMA Group,ACTIVE_COMPARATOR | EXPERIMENTAL,"This study aims to compare the new-generation GMA laryngeal mask airway (LMA) with the traditional inflatable LMA in patients undergoing elective surgery under general anesthesia. The primary objectives are to evaluate the safety, effectiveness, stability, ease of use, and patient comfort of the GMA LMA, providing practical guidance for clinical airway management. Additionally, this research will analyze the anatomical positioning and sealing mechanism of the LMA to identify factors influencing ","The Second Affiliated Hospital of Zhejiang Chinese Medical University, Red Cross Hospital, Hangzhou, China, Hangzhou Hospital of Traditional Chinese Medicine, Lanxi People's Hospital, Ningbo Medical Center Lihuili Hospital, The Second Affiliated Hospital of Jiaxing University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Ruijin Hospital, The Central Hospital of Lishui City, Lishui Country People's Hospital, Sir Run Run Shaw Hospital",2027-07-31,ESTIMATED,18 Years - 75 Years,1384,ESTIMATED,PARALLEL,OTHER,NONE,"A Multicenter, Randomized Controlled Study Comparing the Effectiveness of the New Generation GMA Laryngeal Mask and Conventional Laryngeal Mask in Airway Management During General Anesthesia",2027-07-31,ESTIMATED,Success rate of anatomical alignment of laryngeal mask,OTHER,ALL,2025-09-18,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT03657732,,RECRUITING,"Alzheimer Disease, Familial Alzheimer Disease (FAD)",,CFAN,,2,Familial Alzheimer's disease group | Normal control group, | ,"This research will establish and continuously improve the FAD research network in conjunction with multi-center institutions nationwide. By collecting information on the family's demography, genetics, neuropsychology, neuroimaging, biomarkers and other information, we can understand the current FAD population in China, clarify the genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of AD in China; which will lay the foundation for ameliorating clinic","Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Henan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, Zhongnan Hospital, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Afﬁliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital",2038-01-01,ESTIMATED,18 Years - N/A,40000,ESTIMATED,,OTHER,,A Multi-center Longitudinal Cohort Study of Familial Alzheimer's Disease in China,2038-01-01,ESTIMATED,"The prevalence of gene mutations in familial Alzheimer's disease in China. | The development patterns of genetic, biofluid, imaging, and neuropsychological markers of FAD.",,ALL,2005-01-10,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07032116,,NOT_YET_RECRUITING,Diabetic Kidney Disease (DKD),,,,2,Exposed group | Non-exposed group, | ,"In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease（DKD） patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based on a preliminary DKD cohort of 13,000 patients. The exposure factor was supplementing and reducing the kidney turbidity-Huoxue Tongluo method represented by the addition and subversion of Shenzhuo prescription, and the incidence of end-stage renal disease was the main t","Guang'anmen Hospital of China Academy of Chinese Medical Sciences, First Affiliated Hospital, Sun Yat-Sen University, Tianjin Medical University Chu Hsien-I Memorial Hospital, Changchun University of Chinese Medicine, EFONG PHARMRCEUTICRL, Xinxiang Central Hospital of Henan province, Xiamen Hospital of Traditional Chinese Medicine, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Beijing Tiantan Hospital, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Hubei Zhongshan Hospital Affiliated to Wuhan University",2028-07-31,ESTIMATED,18 Years - 80 Years,4472,ESTIMATED,,OTHER,,Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 1,2028-07-31,ESTIMATED,The incidence of end-stage renal disease,,ALL,2025-08-01,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07019714,,NOT_YET_RECRUITING,Idiopathic Pulmonary Fibrosis,,,RANDOMIZED,2,Daoyin Technique in addition to the guideline - directed treatment. | Routine Comprehensive Training in addition to the guideline - directed treatment.,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study is based on the previously constructed digital rehabilitation management platform, scientifically evaluating the clinical efficacy of guided technology in improving IPF exercise endurance, and forming high-quality clinical evidence.","The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Xiyuan Hospital of China Academy of Chinese Medical Sciences",2028-12-30,ESTIMATED,40 Years - 85 Years,236,ESTIMATED,PARALLEL,OTHER,DOUBLE,Clinical Research on the Improvement of Exercise Endurance in Idiopathic Pulmonary Fibrosis by Daoyin Technique,2028-06-30,ESTIMATED,6 Six Minute Walk Distance(6MWD) | the 30 - second sit - to - stand test(30s STS),TREATMENT,ALL,2025-06-30,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT02958020,,RECRUITING,Osteoporosis,,,,0,,,"This is a multicenter cohort study on osteoporosis in nine cities of China which locate in the east, south, north, west, middle of China. At least 3000 middle-aged and elderly permanent residents (women aged from 45 to 79, and men aged from 50 to 79) in every city will be enrolled. Residents with severe mental diseases, physical diseases or acute infectious diseases who could not cooperate with the survey as well as lactating or pregnant women were excluded. All the enrolled residents who signed","Wangjing Hospital, China Academy of Chinese Medical Sciences, Dongzhimen Hospital, Beijing, The First Affiliated Hospital of Guangzhou University of TCM, Guangdong Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Gansu Provincial Hospital, Guangzhou Kingmed Diagnostics Co., Ltd., Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Yunnan Provincial Hospital of Traditional Chinese Medicine, Shenzhen Pingle Orthopedic Hospital, First People's Hospital of Nankang District, Ganzhou City",2028-10,ESTIMATED,45 Years - 79 Years,50000,ESTIMATED,,OTHER,,"Multicenter Cohort Study on Osteoporosis in the Middle-aged and Elderly People in Shanghai, China",2026-10,ESTIMATED,"changes in bone mineral density from baseline to 2, 4, 6, 8 and 10 years after enrollment",,ALL,2016-11,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07296614,PHASE3,NOT_YET_RECRUITING,"Diminished Ovarian Reserve (DOR), Infertility","Western Medicine, Traditional Chinese Medicine, Placebo",,RANDOMIZED,2,Western medicine group | Integrated traditional Chinese and Western medicine,PLACEBO_COMPARATOR | EXPERIMENTAL,"This study aims to evaluate the superiority of an integrated traditional Chinese and Western medicine regimen (""Xiehe DOR Bushen Tongzhi Formula"" + ovulation induction therapy with ovulation monitoring and timed intercourse) compared to standard treatment alone (placebo + ovulation induction therapy with ovulation monitoring and timed intercourse) in improving the natural cumulative clinical pregnancy rate in infertile patients with kidney deficiency-type diminished ovarian reserve (DOR).","Dongfang Hospital Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Hunan University of Traditional Chinese Medicine, Shandong University, Xiamen University, Beijing Obstetrics and Gynecology Hospital, Xiyuan Hospital of China Academy of Chinese Medical Sciences, The Third Affiliated Hospital of Beijing University of Chinese Medicine, Hunan Provincial Maternal and Child Health Care Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Institute of Basic Medical Sciences CAMS, First Affiliated Hospital of Heilongjiang Chinese Medicine University, Shunde Women and Children's Hospital (Maternity and Child Healthcare Hospital of Shunde Foshan), The First Affiliated Hospital of Zhengzhou University, Shenyang Women's and Children's Hospital",2028-07-30,ESTIMATED,22 Years - 39 Years,320,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Integrative Chinese and Western Medicine for Diminished Ovarian Reserve-Associated Infertility in Natural Conception Population,2028-07-30,ESTIMATED,Cumulative clinical pregnancy rate,TREATMENT,FEMALE,2025-12-25,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT04370925,PHASE3,RECRUITING,Colorectal Cancer,Systemic chemotherapy,,RANDOMIZED,2,Matched control | HIPEC,ACTIVE_COMPARATOR | EXPERIMENTAL,The purpose of this study is to determine the efficacy of adjuvant HIPEC with Mitomycin C after colectomy in the treatment of colorectal cancer patients at high risk of peritoneal carcinomatosis.,"Nanfang Hospital, Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Peking University Cancer Hospital & Institute, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People's Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi Zhuang Autonomous Region, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University",2026-04-30,ESTIMATED,18 Years - 70 Years,688,ESTIMATED,PARALLEL,OTHER,NONE,A Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy After Colectomy in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis,2024-04-30,ESTIMATED,Peritoneal recurrence free survival,TREATMENT,ALL,2020-06-04,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05439135,,RECRUITING,"Malnutrition, Gastroenterostomy",,,RANDOMIZED,2,midgut | colonic,EXPERIMENTAL | EXPERIMENTAL,"This is a prospective, randomized, multicenter study to evaluate WMT in improving nutritional status in malnourished patients who underwent nonphysiological reconstruction of the upper gastrointestinal tract. In this multicenter trial, sixty-two patients will be enrolled in forteen Chinese sites. Participants will be randomized at a ratio of 1:1 to receive three WMTs through either mid-gut tube or colonic TET. After WMT, each participant will receive free diet plus home enteral nutrition. Home e","The First Affiliated Hospital of Guangdong Pharmaceutical University, Nanjing Medical University, Wuxi No. 2 People's Hospital, Jiangxi University of Chinese Medicine Affiliated Hospital, Hubei Hospital of Traditional Chinese Medicine, The Affiliated Hospital Of Southwest Medical University, Tang-Du Hospital, Huzhou Central Hospital, West China Forth University Hospitalï¼ŒSichuan University, The Affiliated People's hospital of Ningbo Univercity, Guangzhou First People Hospital of Guangzhou Medical University, The First Affiliated Hospital of Anhui University of Chinese Medicine, Beijing Rectum Hospital, Dazhou Central Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Affiliated Hospital of Guangzhou Medical University, The 901th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, YI'AN PEOPLE'S HOSPITAL, Hunan Aerospace Hospital, Jiamusi City Hospital of Traditional Chinese Medicine, The First People's Hospital of Kunshan, LanZhou University, Jingxing xian yiyuan, TAIHE country people's hospital, Tailai County People's Hospital, Armed Police Characteristic Medical Center, First Affiliated Hospital Xi'an Jiaotong University",2025-10-31,ESTIMATED,18 Years - N/A,62,ESTIMATED,PARALLEL,OTHER,NONE,"An Open-label, Multicenter, Randomized Clinical Trial for Malnutrition After Nonphysiological Reconstruction of the Upper Gastrointestinal Tract: Washed Microbiota Transplantation Via Mid-gut Tube Versus Colonic Transendoscopic Enteral Tube",2025-10-31,ESTIMATED,Changes of weight and height | Changes of the third lumbar vertebrae skeletal muscle mass and height | Changes of weight,TREATMENT,ALL,2024-10-20,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06709885,PHASE2,RECRUITING,Colon Adenocarcinoma,"Chidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX",,RANDOMIZED,2,Chidamide + Tislelizumab + chemotherapy (CapeOX ) | Neoadjuvant chemotherapy (CapeOX),EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.

The main questions it aims to answer are:

Can HDAC inhibitors combined with neoadjuvant immunochemotherapy improve the rate of pCR and complete resection in patients? Are HDAC inhibitors combined with neoadjuvant immunochemotherapy safe and reliable? Does the combination of","Southwest Hospital, China, Xinqiao Hospital of Chongqing, First Affiliated Hospital of Chongqing Medical University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing University Cancer Hospital, Chongqing General Hospital, Chongqing Traditional Chinese Medicine Hospital, Chongqing Shapingba District People's Hospital, Chongqing Seventh People's Hospital, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The 13th People's Hospital of Chongqing",2027-09-30,ESTIMATED,18 Years - N/A,100,ESTIMATED,PARALLEL,OTHER,NONE,"HDAC Inhibitor Combination with Immunochemotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer: a Multicenter, Double-arm, Phase II Randomized Controlled Study",2025-09-30,ESTIMATED,pCR,TREATMENT,ALL,2024-10-15,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05709249,PHASE3,RECRUITING,Colon Cancer,"XLJDOD compound granule, placebo (XLJDOD mimetic agent)",,RANDOMIZED,2,intervention group | control group,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).","Jiangsu Province Hospital of Traditional Chinese Medicine, Ministry of Science and Technology of the People´s Republic of China",2028-04-01,ESTIMATED,20 Years - 80 Years,730,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,Efficacy of Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Stage IIIB/IIIC Colon Cancer：a Study Protocol for a Randomized Controlled Trial,2027-04-01,ESTIMATED,Two-year disease-free survival (DFS),PREVENTION,ALL,2022-12-01,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06685315,,NOT_YET_RECRUITING,"Asthma Bronchiale, Chronic Obstructive Pulmonary Disease (COPD)",,,,0,,,"This study will to investigate the correlation between the characteristics of the population with chronic airway diseases (asthma, chronic obstructive pulmonary disease) and syndromes, in order to reveal the disease and syndrome features of the population; Secondly, screening and identifying biomarkers for asthma and chronic obstructive pulmonary disease to provide a basis for precise prevention and treatment of the disease.","West China Hospital, Beijing Yikang Medical Technology Co., Ltd, Tongji Hospital",2028-07-31,ESTIMATED,12 Years - 80 Years,10545,ESTIMATED,,OTHER,,"Research on the Syndrome Characteristics of Chronic Airway Diseases (asthma, Chronic Obstructive Pulmonary Disease) Based on Intelligent Algorithm Fusion of Phenotype Omics",2027-12-31,ESTIMATED,Inflammatory Phenotype of Chronic Airway Diseases | The Traditional Chinese Medicine Syndromes of Athma | The Traditional Chinese Medicine Syndromes of COPD | General Demographic Data | Asthma Control Test (ACT) | COPD Assessment Test (CAT) | Clinical Symptoms and Signs Questionnaire | modified Medical Research Council (mMRC) | Forced Expiratory Volume in One Second (FEV1) | Forced Vital Capacity (FVC) | Diffusing capacity of the lungs for carbon monoxide (DLCO) | Cough and Sputum Assessment Questionnaire （CASA-Q） | Sputum Characteristic Score | Sputum Viscosity Grading | mucin 5B（MUC5B） | mucin 5AC（MUC5AC）,,ALL,2024-12-01,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06874738,,NOT_YET_RECRUITING,Menopausal Syndrome,Liuwei Dihuang pills,,,1,Liuwei Dihuang Pills,,"To evaluate the clinical efficacy of the real-world Liuwei Dihuang pills for the treatment of female menopausal syndromes, and to provide a basis for effective, safe and rational clinical use of the drug.","Lanxi Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Harbin Medical University",2026-12-30,ESTIMATED,45 Years - 55 Years,1000,ESTIMATED,,OTHER,,A Real-world Clinical Study on the Treatment of Menopausal Syndrome With Liuwei Dihuang Pills,2026-12-30,ESTIMATED,Change of Menopausal Symptoms | Change of Hormone Levels,,FEMALE,2025-03-08,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06359418,,RECRUITING,"Obesity, Abdominal Obesity, PreDiabetes",,,RANDOMIZED,2,Acupuncture | Sham acupuncture,EXPERIMENTAL | SHAM_COMPARATOR,The clinical trial aims to evaluate the efficacy and safety of acupuncture in reducing weight and waist circumference while modulating glucose and lipid metabolism in Prediabetes with Combined Obesity.,"Hubei Hospital of Traditional Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Zhuhai, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Dongfang Hospital Beijing University of Chinese Medicine, Linyi Hospital of Traditional Chinese Medicine, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Xi'an Traditional Chinese Medicine Hospital, Qingdao Traditional Chinese Medicine Hospital, Xi'an Hospital of Traditional Chinese Medicine, Heilongjiang Academy of traditional Chinese Medicine, The Affiliated Hospital of Qingdao University, Yantai Hospital of Traditional Chinese Medicine, Shaanxi Hospital of Traditional Chinese Medicine",2028-04-01,ESTIMATED,18 Years - 64 Years,260,ESTIMATED,PARALLEL,OTHER,TRIPLE,Acupuncture for Prediabetes With Combined Obesity: a Multicenter Randomized Controlled Trial,2027-06-01,ESTIMATED,The percentage change in body weight from baseline to week 12 | The percentage change in waist circumference from baseline to week 12,TREATMENT,ALL,2025-03-01,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07338396,,NOT_YET_RECRUITING,Non Small Cell Lung Cancer NSCLC,EGFR-TKI,,,2,Advanced Cohort | Postoperative Cohort, | ,"The goal of this observational study is to learn about the relationship between TCM body constitution patterns (called ""syndromes"") and the effectiveness of EGFR-TKI targeted drugs in patients with lung cancer. Approximately 3000 patients with EGFR-mutant non-small cell lung cancer who are about to start or are already taking EGFR-TKI drugs as part of their regular medical care will be invited to join. Participants will be followed for up to 5 years. During routine clinic visits, researchers wil","Beijing Chest Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Sichuan Cancer Hospital and Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Affiliated Hospital of Xinxiang Medical University, Henan province",2031-07,ESTIMATED,18 Years - N/A,3000,ESTIMATED,,OTHER,,A Clinical Study on the Patterns of Traditional Chinese Medicine Syndromes and Efficacy Differences in Lung Cancer Patients Treated With EGFR-TKI,2029-07,ESTIMATED,Progression-Free Survival | Disease-Free Survival,,ALL,2026-01,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06717009,,NOT_YET_RECRUITING,"Kidney Neoplasms / Surgery, Robotic Surgical Procedures, Imaging, Three-Dimensional / Methods, Nephrectomy / Methods",,,RANDOMIZED,2,3D trial group | Conventional group,EXPERIMENTAL | NO_INTERVENTION,"The goal of this clinical trial is to learn the evidence-based medical value of 3D visualization techniques to improve tumor control, preservation of renal function, and perioperative safety in robot-assisted nephron sparing surgery for complex renal tumors. The main question it aims to answer is:

Is 3D visualization techniques more effective in improving robot-assisted nephron sparing surgery for complex renal tumors in terms of tumor control, renal function preservation, and perioperative saf","Sir Run Run Shaw Hospital, The First Affiliated Hospital of Zhengzhou University, Peking University First Hospital, Liaoning Cancer Hospital & Institute, The Second Affiliated Hospital of Dalian Medical University, First Affiliated Hospital of Chongqing Medical University, Qilu Hospital of Shandong University, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Hebei Medical University Fourth Hospital, West China Hospital, Tongji Hospital, Sun Yat-sen University Tumor Hospital, Shanghai Cancer Hospital, China, Shengjing Hospital",2027-10,ESTIMATED,18 Years - 75 Years,350,ESTIMATED,PARALLEL,OTHER,NONE,"A Prospective, Multicenter, Randomized Controlled Study of Three-dimensional Visualization Techniques to Improve the Quality and Safety of Robot-assisted Nephron Sparing Surgery for Complex Renal Tumors",2026-09,ESTIMATED,warm ischemia time,DIAGNOSTIC,ALL,2025-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06331923,,RECRUITING,Comprehensive Complication Index,,,RANDOMIZED,2,CGM group | Control group,EXPERIMENTAL | NO_INTERVENTION,"The goal of this multi-center, pragmatic, randomized controlled trial is to assess the effectiveness of continuous glucose monitoring (CGM) compared with conventional monitoring in enhancing surgical outcomes for diabetic patients. The main questions it aims to answer are:

* To assess the effectiveness of CGM compared with conventional monitoring in reducing the comprehensive complication index (CCI) for patients with diabetes or impaired glucose tolerance (IGT) within 30 days after surgery.
* ","Peking University International Hospital, Wang Jing Hospital, ZhuHai Hospital, Beijing Hospital, Siyang County Hospital of Traditional Chinese Medicine, Second Hospital of Shanxi Medical University, Henan Provincial Chest Hospital, Fuzhou First Hospital, Pinggu Hospital of Beijing Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Mindong Hospital of Ningde, The Fifth Hospital of Xiamen, People's Hospital of Ningxia Hui Autonomous Region, The First People's Hospital of Changzhou, The Fifth hospital of Deyang, Suzhou Municipal Hospital, Tang-Du Hospital, Yiyang Central Hospital, First Affiliated Hospital of Xinjiang Medical University, Peng Ding Shan Shi Zhong Yi Yi Yuan, Yueyang Central Hospital, The First People's Hospital of Lianyungang, Haimen District Traditional Chinese Medicine Hospital, The 910th Hospital, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Beijing Tiantan Hospital, Affiliated Hospital of Jiangsu University, Liaocheng People's Hospital, Beijing Chao Yang Hospital, Jilin City Hospital of Chemical Industry, Creen Hospital-465, Wuhan Central Hospital, Air Force Military Medical University, China, Shanghai Tong Ren Hospital, Beijing Anzhen Hospital, Emergency General Hospital, Beijing Tongren Hospital, Civil Aviation General Hospital, Peking University Shougang Hospital, The First Affiliated Hospital of Anhui Medical University, Chinese PLA Central Hospital",2025-12-31,ESTIMATED,18 Years - N/A,10168,ESTIMATED,PARALLEL,OTHER,SINGLE,"Assessing the Effectiveness of Continuous Glucose Monitoring Compared with Conventional Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes: a Multi-center, Parallel-arm, Randomized, Pragmatic Trial in China",2025-10-31,ESTIMATED,Comprehensive complication index,TREATMENT,ALL,2024-04-12,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06533410,,RECRUITING,Fibromyalgia,,,,2,chronic widespread pain | Fibromyalgia, | ,This study aimed to evaluate the specificity and sensitivity of the diagnostic criteria for fibromyalgia after conducting local validation in China.,"Hebei Provincial Hospital of Traditional Chinese Medicine, BAODING NO.1 HOSPITAL OF TCM, Inner Mongolia Hospital of Traditional Chinese Medicine, Shenzhen Hospital of Traditional Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine",2025-05-31,ESTIMATED,18 Years - N/A,59,ESTIMATED,,OTHER,,Using the Chinese Indigenization FS Scale in the Diagnosis of Fibromyalgia： Specificity and Sensitivity in Clinical Practice,2025-03-31,ESTIMATED,Diagnosis of fibromyalgia with the Polysymptomatic Distress Scale(PDS),,ALL,2024-05-21,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06713421,,RECRUITING,"Esophageal Cancer, Gastric Cancer","Dimethicone+Pronase, Dimethicone",,RANDOMIZED,4,A1:Dimeticone+Pronase+Postural Exercise group | A2:Dimeticone+Pronase group | B1:Dimeticone+Postural Exercise group | B2:Dimeticone group,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"Gastric cancer and esophageal cancer are common malignant tumors that threaten people's life and health. Esophagogastroduodenoscopy (EGD) is an important tool for screening upper gastrointestinal tumors, especially early tumors, and an effective method for detecting other upper gastrointestinal lesions, including ulcers and polyps. However, during EGD examination, mucus and foam can reduce the cleanliness of the mucosa and limit the operator's visual field, resulting in missed lesions and misdia","Fujian Provincial Hospital, Huashan Hospital, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Red Cross Hospital, Hangzhou, China, The Affiliated Hospital of Inner Mongolia Medical University, Yuebei People's Hospital, Longgang District People's Hospital of Shenzhen, Huadu District People's Hospital of Guangzhou, Liaocheng People's Hospital, Qilu Hospital of Shandong University, The Second Affiliated Hospital of Shandong First Medical University, Anqing Municipal Hospital, Jiujiang No.1 People's Hospital, Kunshan Hospital of Traditional Chinese Medicine, Nanjing Gaochun People's Hospital, Taizhou First People's Hospital, Hengshui People's Hospital, Affiliated Hospital of Hebei University, Second Affiliated Hospital of Xi'an Jiaotong University, Taihe Hospital, ZhuZhou Central Hospital, The Second Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Kunming Medical University, Subei People's Hospital of Jiangsu Province, The Affiliated Hospital Of Southwest Medical University, The Second Affiliated Hospital of Chongqing Medical University, Loudi Central Hospital, Beijing Tiantan Hospital, Peking Union Medical College Hospital, The First People's Hospital of Lin'an District, Hangzhou, Zhejiang Provincial People's Hospital, Jining Medical University, Ningbo Medical Center Lihuili Hospital, Zhoushan Hospital, Zhejiang, General Hospital of Ningxia Medical University, Yunnan Cancer Hospital, Xinghua City People's Hospital, Beijing Friendship Hospital, Captial Medical University, Beijing Chao-Yang Hospital, Captial Medical University, The People's Hospital of JiangMen, The First People's Hospital of TianMen in Hubei Province, THE FIRST AFFILIATED HOSPITAL OF SHIHEZI UNIVERSITY",2025-09-01,ESTIMATED,18 Years - 70 Years,3000,ESTIMATED,FACTORIAL,OTHER,NONE,"The Effects of Premedication With Pronase and Postural Exercise on Mucosal Cleanliness During Painless Esophagogastroduodenoscopy: A Prospective, Multicenter, Randomized Controlled Study Based on Artificial Intelligence Assessment",2025-09-01,ESTIMATED,Mucosal Cleanliness Scores,OTHER,ALL,2024-12-01,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07162870,,NOT_YET_RECRUITING,Idiopathic Pulmonary Fibrosis (IPF),"Traditional Chinese medicine (TCM), Non-traditional Chinese medicine (non-TCM)",,,2,Traditional Chinese Medicine cohort | Non-Traditional Chinese Medicine cohort, | ,"This study, based on past registration records, evaluates the clinical efficacy of traditional Chinese medicine in treating IPF in the real world, identifies advantageous populations and clinical targets, and provides references for precision traditional Chinese medicine treatment.","The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, China-Japan Friendship Hospital, The First Affiliated Hospital of Zhengzhou University, Shanghai Pulmonary Hospital, Shanghai, China",2028-11-30,ESTIMATED,40 Years - N/A,1000,ESTIMATED,,OTHER,,Idiopathic Pulmonary Fibrosis Cohort Studies of Chinese Medicine,2028-10-30,ESTIMATED,Annual acute exacerbation rate,,ALL,2025-09-05,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06995118,,RECRUITING,Breast Cancer Early Stage Breast Cancer (Stage 1-3),,HUAXI-h-01,RANDOMIZED,2,HH-01 group | Control group,EXPERIMENTAL | NO_INTERVENTION,"This study is a multicenter, open-label, randomized controlled trial. It will prospectively compare outcomes between patients undergoing reverse-sequence endoscopic NSM (R-E-NSM) with direct-to-implant breast reconstruction (DIBR) with the ""HUAXI Hole 1"" versus without the ""HUAXI Hole 1"". The study aims to evaluate differences in operative efficiency, surgical safety, postoperative aesthetics, and oncological safety between the two groups.","West China Tianfu Hospital, Sichuan University, West China Fourth Hospital, Sichuan University, The Fourth People's Hospital of Sichuan Province, The First Affiliated Hospital of Zhengzhou University, The First Hospital of Jilin University, Shanxi Bethune Hospital, Chengdu Fifth People's Hospital, Suzhou Municipal Hospital, Taiyuan Central Hospital of Shanxi Medical University, The People's Hospital of DAZU ，Chongqing, Anyang City Tumor Hospital, Mianyang Hospital of Traditional Chinese Medicine, Sichuan Cancer Hospital and Research Institute, Deyang People's Hospital, Hunan University of Traditional Chinese Medicine, The Affiliated Hospital of lnner Mongolia Medical University, Guangzhou First People's Hospital, Fujian Medical University Union Hospital, Nanchang People's Hospital",2031-12-31,ESTIMATED,18 Years - 70 Years,337,ESTIMATED,PARALLEL,OTHER,NONE,"The Application of ""HUAXI Hole 1"" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction: A National Multicenter, Open-Label, Randomized Controlled Trial (HUAXI-h-01)",2026-06-01,ESTIMATED,Operative time,TREATMENT,FEMALE,2025-06-17,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06528197,,RECRUITING,Primary Sjögren Syndrome,,,,2,Exposed group | Control group, | ,"This study aims to establish a large sample cohort of patients with primary sjogren's syndrome, collect multi-omics information of patients with primary sjogren's syndrome, and construct disease diagnosis model and disease prognosis prediction model.","Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing Hospital of Traditional Chinese Medicine, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital",2026-12-31,ESTIMATED,18 Years - 75 Years,1000,ESTIMATED,,OTHER,,Construction of Clinical Model of Primary Sjogren's Syndrome Combined Traditional Chinese Medicine and Western Medicine Based on Multi-omics,2025-12-31,ESTIMATED,Number of participants with system involvement,,ALL,2024-07-04,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07277218,,NOT_YET_RECRUITING,Femoropopliteal In-Stent Restenosis (ISR),,,NON_RANDOMIZED,1,Drug-coated Balloons vs Drug-eluting Stents for Femoropopliteal In-Stent Restenosis,EXPERIMENTAL,"Brief Summary: Defier Study What is this study about? Femoropopliteal artery disease (a type of peripheral arterial disease) often requires stenting to restore blood flow to the legs. However, a common challenge after stenting is in-stent restenosis (ISR)-the treated blood vessel narrows again over time. Two advanced treatments for ISR are available: drug-coated balloons (DCBs) and drug-eluting stents (DESs). Both deliver medication to prevent vessel narrowing, but there is limited direct eviden","Department of Vascular Surgery, The First Affiliated Hospital of Medicine College of Zhejiang University, Hangzhou, China., Department of Vascular Surgery, Liyuan Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China., Department of Vascular Surgery, Qingdao Haici Hospital Affiliated to Qingdao University, Qingdao, China., Department of Vascular Surgery, School of Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University, Hangzhou, China., Department of Vascular Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China., Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China., Department of Vascular Surgery, Huashan Hospital, Fudan University, Shanghai, China., Department of Cardiovascular Surgery, Xiamen Cardiovascular Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China., Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China., Biomedical Informatics and Statistics Center, School of Public Health.Fudan University, Shanghai, China., Department of Vascular Surgery, Xuanwu Hospital Capital MedicalUniversity, Beijing, China.",2028-01-01,ESTIMATED,N/A - N/A,578,ESTIMATED,PARALLEL,OTHER,NONE,"Title: Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis: A Prospective, Multicenter, Cohort Study (The Defier Study)",2028-01-01,ESTIMATED,Clinically-Driven Target Lesion Revascularization (CD-TLR) | Clinically-Driven Target Lesion Revascularization (CD-TLR),TREATMENT,ALL,2026-01-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07099157,PHASE4,RECRUITING,Herpes Zoster,"Brivudine, Famciclovir",,RANDOMIZED,2,Brivudine Group | Famciclovir Group,EXPERIMENTAL | ACTIVE_COMPARATOR,"This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.","Peking University First Hospital, Air Force Military Medical University, China, Beijing Hospital of Traditional Chinese Medicine, Xuanwu Hospital, Beijing",2027-12-31,ESTIMATED,18 Years - N/A,140,ESTIMATED,PARALLEL,OTHER,SINGLE,"Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster: A Multicenter, Randomized, Prospective Clinical Trial",2026-12-31,ESTIMATED,Day 30 numeric pain rating scale (NPRS),TREATMENT,ALL,2025-08-25,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06770296,PHASE1,RECRUITING,Breast Cancer,"Pyrotinib low dose group, Pyrotinib normal dose group",,RANDOMIZED,2,Pyrotinib low dose group | Pyrotinib normal dose group,EXPERIMENTAL | ACTIVE_COMPARATOR,Evaluate the safety and efficacy of Pyrotinib at different doses in combination with trastuzumab and paclitaxel chemotherapy for first-line treatment of HER2-positive advanced breast cancer.,"The First People's Hospital of Xuzhou, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The Second People's Hospital of Changshu, Shuyang County Traditional Chinese Medicine Hospital, Affiliated Hospital of Nantong University, Affiliated Hospital of Jiangsu University, The Affiliated Hospital of Xuzhou Medical University",2028-11-01,ESTIMATED,18 Years - 75 Years,200,ESTIMATED,SEQUENTIAL,OTHER,NONE,"Pyrotinib at Different Doses in Combination With Trastuzumab and Paclitaxel Chemotherapy for First-Line Treatment of HER2-Positive Advanced Breast Cancer: A Multicenter, Randomized, Double-Cohort Study",2026-11-01,ESTIMATED,Objective Response Rate,TREATMENT,ALL,2024-11-01,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05834413,,NOT_YET_RECRUITING,Lung Cancer,"chemotherapy plus TCM 1&ICIs plusTCM2 placebo, chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo",,RANDOMIZED,2,chemotherapy plus TCM 1&ICIs plusTCM2 placebo | chemotherapy plus TCM 1 placebo&ICIs plus TCM2 placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This project adopts a prospective, multicenter, randomized controlled clinical study to investigate the treatment of TCM in postoperative patients with driver gene negative lung cancer, according to two phases of postoperative adjuvant therapy: (i) chemotherapy phase immunotherapy phase. In this study, 367 patients (183 in the control group and 184 in the trial group) will be observed over 4 years, and the quality of life, toxic effects and safety of this therapy will be investigated. This study","Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital",2026-06-30,ESTIMATED,18 Years - 74 Years,367,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors,2026-06-30,ESTIMATED,Disease-free Survival(DFS),TREATMENT,ALL,2023-05-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06201455,,RECRUITING,"Glaucoma, Open-Angle, Cataract Complicated, Goniotomy",,ECO,RANDOMIZED,2,PEI+GT | PEI+MED,EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this multicenter non-inferiority randomized controlled trial is to compare the efficacy of phacoemulsification with intraocular lens implantation (PEI) combined with goniotomy (GT) and PEI combined with medical therapy (MED) in the treatment of medically-controlled primary open-angle glaucoma (POAG) with cataract. The main questions it aims to answer are:

* Whether the PEI+GT was non-inferior to PEI+MED with regard to the intraocular pressure lowering effect in medically-controlled ","West China Hospital, Chongqing Medical University, The Second Hospital of Anhui Medical University, Handan City Eye Hospital, Shijiazhuang People's Hospital, Chengdu First People's Hospital, Guangdong Hospital of Traditional Chinese Medicine, Zhuhai, Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Huizhou Municipal Central Hospital",2029-12-31,ESTIMATED,40 Years - 85 Years,100,ESTIMATED,PARALLEL,OTHER,NONE,Efficacy of Phacogoniotomy in Medically-controlled Primary Open-angle Glaucoma With Cataract a Multicenter Non-inferiority Randomized Controlled Trial,2026-09-30,ESTIMATED,IOP at 12 months after surgery.,TREATMENT,ALL,2023-09-28,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06833541,,RECRUITING,"Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease",,,,4,Type 2 Diabetes Kidney Disease | Type 2 Diabetes Mellitus | Chronic Kidney Disease | healthy people, |  |  | ,"Diabetic kidney disease (DKD) is characterized by high prevalence, multiple pathogenesis, and lack of effective treatment and management strategies. Early detection helps overcome treatment inertia, enables timely medical intervention, maximizes renal function in diabetic patients, and is essential to avoid renal failure and improve clinical outcomes. The gold standard for diagnosis of DKD is renal biopsy, which has the highest accuracy. However, due to the trauma of renal biopsy, the patient ac",National Natural Science Foundation of China,2025-12-01,ESTIMATED,18 Years - 75 Years,720,ESTIMATED,,OTHER,,Research on Gut-kidney Axis Regulation of Diabetic Kidney Disease Based on Multi-omics and Bacterio-drug Interaction Control Mechanism,2025-02-28,ESTIMATED,UACR | eGFR | BUN | Scr | FBG | HbA1c | GSP,,ALL,2022-04-18,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07115641,,NOT_YET_RECRUITING,Rheumatoid Arthritis,"Huoluo Pills, Iguratimod Tablets",,RANDOMIZED,2,Trial group | Control group,EXPERIMENTAL | OTHER,"This study aims to systematically evaluate the efficacy and safety of Huoluo Pills combined with Iguratimod Tablets in the treatment of rheumatoid arthritis (RA). A total of 240 patients with RA belonging to the syndromes of Wind - Damp Obstruction or Cold - Damp Obstruction will be enrolled in 8 centers (randomly assigned to groups). The experimental group will receive oral Huoluo Pills combined with Iguratimod Tablets, while the control group will receive oral Iguratimod Tablets alone. Both gr","Institute of Science, Beijing Tongrentang Co., Ltd., Beijing Leadingpharm Medicine Technology Development, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, The First Affiliated Hospital of Henan university of CM, Xi'an No.5 Hospital, Liaoning University of Traditional Chinese Medicine Affiliated Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Affiliated Hospital of Shanxi University of Chinese Medicine",2026-08-31,ESTIMATED,18 Years - 70 Years,240,ESTIMATED,PARALLEL,OTHER,NONE,A Multicenter Clinical Randomized Controlled Trial on the Efficacy and Safety of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis,2026-05-31,ESTIMATED,The proportion of subjects achieving ACR20,TREATMENT,ALL,2025-08-11,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07280429,,NOT_YET_RECRUITING,Immune Checkpoint Inhibitors Related Myocarditis,,,RANDOMIZED,2,Rehab Arm | Control Arm,EXPERIMENTAL | NO_INTERVENTION,"Immunotherapy has become a cornerstone in oncology; however, managing its associated adverse events poses a significant clinical challenge. Cardiotoxicity represents a major concern, among which myocarditis accounts for a considerable proportion. This condition is characterized by poor prognosis, highly heterogeneous outcomes, and a high prevalence of persistent cardiac dysfunction after the acute phase. The dual impact of myocardial injury and underlying malignancy severely compromises patients","Weifang Hospital of Traditional Chinese Medicine, Chinese Academy of Medical Sciences, Fuwai Hospital, Second Affiliated Hospital of Nanchang University",2028-07-31,ESTIMATED,18 Years - 80 Years,60,ESTIMATED,PARALLEL,OTHER,SINGLE,A Study on Rehabilitation Study for Immune Checkpoint Inhibitors-Associated Myocarditis: A Randomized Controlled Trial,2028-07-31,ESTIMATED,MACE | NT-proBNP/BNP levels | EQ-5D,TREATMENT,ALL,2026-01-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT04212494,,RECRUITING,ST-segment Elevation Myocardial Infarction (STEMI),,,RANDOMIZED,2,Thrombus aspiration | PCI Alone,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a prospective, multicenter, open-label, randomized, controlled, parallel group study, in which ST-segment Elevation Myocardial Infarction (STEMI) patients with high thrombus burden(TIMI thrombus grade ≥3) are included. Patients are randomized to be treated with or without manual thrombus aspiration(TA) during primary percutaneous coronary intervention(PPCI) by a ratio of 1:1.","Zhongshan People's Hospital, Guangdong, China, Kaiping Central Hospital, Second Affiliated Hospital of Shantou University Medical College, The Third Xiangya Hospital of Central South University, Sihui City People's Hospital, Shenzhen Baoan District Shiyan People's Hospital, People's Hospital of Nanxiong County, Yuebei People's Hospital, Weifang Medical University, Wuzhou Gongren Hospital, Dafeng Hospital of Chaoyang District in Shantou City, Shenzhen Baoan People's Hospital, Dongguan People's Hospital, Yangchun People's Hospital, Taishan People's Hospital, The Second People's Hospital of Foshan, Guangzhou Hospital of integrated Traditional and West Medicine, Guangning People's Hospital, Foshan Sanshui District People's Hospital, Qingyuan People's Hospital, Luhe County People's Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The Fourth People's Hospital of Chenzhou, People's Hospital of Dapu County, Shenzhen People's Hospital, Heyuan people's Hospital, Huaiji People's Hospital, People's Hospital of Yingde City, Qingyuan Hospital of Traditional Chinese Medicine Affiliated To Guangzhou University of Traditional Chinese Medicine, Zhongshan Hospital Of Traditional Chinese Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Lianzhou People's Hospital, Lianping Xian Ren Ming Yi Yuan, Guangxi Zhuang Autonomous Region Nationalities Hospital, Liuzhou Municipal Liutie Central Hospital, Chen Zhou 3RD People's Hospital, Longgang District People's Hospital of Shenzhen, The Affiliated Shunde Hospital of Jinan University, Shenzhen Longhua District Central Hospital, Shantou Central Hospital, Tongxiang First People's Hospital, Bobai County People's Hospital, Guangxi, Meizhou Traditional Chinese Medicine Hospital, The Third Affiliated Hospital of Sun Yat-Sen University, Yuedong Hospital, Shenzhen Third People's Hospital, Yangjiang People's Hospital, Jiangmen Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, The First People's Hospital of Kashgar Erea, First People's Hospital of Foshan, Zhaoqing Gaoyao People's Hospital, People's Hospital of Nanhai District, Foshan, The Second Affiliated Hospital of Dalian Medical University, Nanning Second People's Hospital, The Second People's Hospital of Nanhai District of Foshan, Shangyou People's Hospital",2026-02-28,ESTIMATED,18 Years - N/A,3838,ESTIMATED,PARALLEL,OTHER,NONE,Thrombus Aspiration in Primary Percutaneous Coronary Intervention for STEMI Patients With High Thrombus Burden,2025-08-31,ESTIMATED,Major adverse cardiovascular events,TREATMENT,ALL,2020-08-30,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07020429,,NOT_YET_RECRUITING,Premature Ovarian Insufficiency,"Huanjingjian decoction, Hormone replacement therapy, Placebo",EAST-HOPE,RANDOMIZED,2,Huanjingjian decoction + Hormone replacement therapy | Placebo + Hormone replacement therapy,EXPERIMENTAL | ACTIVE_COMPARATOR,"Study Summary

This clinical trial aims to evaluate the efficacy and safety of the traditional Chinese herbal formula Huanjingjian decoction in women with premature ovarian insufficiency (POI). The study is designed to address the following key questions:

1. Does Huanjingjian decoction improve clinical symptoms in patients with POI?
2. What adverse medical events, if any, occur during the treatment with Huanjingjian decoction? To answer these questions, researchers will compare Huanjingjian dec","Shanghai University of Traditional Chinese Medicine, Shanghai Geriatric Institute of Chinese Medicine, Shanghai Institute of Acupuncture and Anesthesia, Shanghai, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Jingan Hospital of Traditional Chinese Medicine",2030-07-30,ESTIMATED,18 Years - 39 Years,276,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Efficacy and Safety of the Traditional Chinese Herbal Formula Huanjingjian Decoction in Women With Premature Ovarian Insufficiency: a Randomised Controlled Trial,2030-07-30,ESTIMATED,Disease-Specific Quality of Life Assessment,TREATMENT,FEMALE,2025-09-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06320249,,NOT_YET_RECRUITING,Cervical Radiculopathy,,,RANDOMIZED,3,The high-frequency manipulation group | The low-frequency manipulation group | The cervical traction group,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,The evidence for different frequencies of rotation-traction manipulation treatment in cervical radiculopathy is insufficient. This study determined whether 3 sessions per week of rotation-traction manipulation treatment are superior to 1 session per week for symptomatic outcomes in cervical radiculopathy based on a multicenter randomized controlled trial.,"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Dongzhimen Hospital, Beijing",2025-06-30,ESTIMATED,40 Years - 65 Years,216,ESTIMATED,PARALLEL,OTHER,SINGLE,Rotation-traction Manipulation of Different Treatment Frequency in Cervical Radiculopathy: A Multicenter Randomized Controlled Trial,2025-04-30,ESTIMATED,The Visual Analog Scale for Pain,TREATMENT,ALL,2024-04-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07360002,,NOT_YET_RECRUITING,IgA Nephropathy (IgAN),"Shenqi Yishen Granules, Placebo",,RANDOMIZED,2,Treatment group | Control Group,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to learn if Shenqi Yishen Granules works to treat IgA Nephropathy in adults. It will also learn about the safety of Shenqi Yishen Granules. The main questions it aims to answer are:

Does Shenqi Yishen Granules lower 24-hour urinary protein quantification of participants? What medical problems do participants have when taking Shenqi Yishen Granules? Researchers will compare Shenqi Yishen Granules to a placebo (a look-alike substance that contains no drug) to se","The First Affiliated Hospital of Zhejiang Chinese Medical University, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Red Cross Hospital, Hangzhou, China, Hangzhou Traditional Chinese Medicine Hospital, Zhenhai District Traditional Chinese Medicine Hospital, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Shao Yifu Hospital of Zhejiang Medical University, Hangzhou First People's Hospital, School of Medicine, Zhejiang Universiry, Yuyao City Traditional Chinese Medicine Hospital, First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Affiliated Hospital of Jiaxing University, Hangzhou Xiaoshan First People's Hospital, Shanghai 6th People's Hospital",2026-12,ESTIMATED,18 Years - 75 Years,102,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy,2026-12,ESTIMATED,24-hour urinary protein quantification | Protein-to-creatinine rati,TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05496582,,RECRUITING,Asthma,,,,2,Asthma | Control, | ,"Asthma is one of the most common chronic respiratory diseases. Previous study found a series of differentially expressed genes and proteins (transgelin-2, metallothionein-2, ezrin) in asthmatic rat. The aim of the study is to investigate the changes and associations of these gene with asthma in human.","Xiangya Hospital of Central South University, National Natural Science Foundation of China",2026-12,ESTIMATED,14 Years - 75 Years,100,ESTIMATED,,OTHER,,"The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma: A Case-control Study",2026-08,ESTIMATED,"Difference in gene expression of transgelin-2, metallothionein-2 and ezrin between controls and asthmatic patients | Association of transgelin-2, metallothionein-2 and ezrin with asthma",,ALL,2022-11-01,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07170345,,RECRUITING,"Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)",,HCC-MVI-CAD,,19,"Peking Union Medical College Hospital | First Affiliated Hospital of Kunming Medical University | Beijing YouAn Hospital | Zhujiang Hospital | Meng Chao Hepatobiliary Hospital of Fujian Medical University | First Affiliated Hospital of Wenzhou Medical University | Fifth Affiliated Hospital, Sun Yat-Sen University | Henan Provincial People's Hospital | Guangdong Provincial Hospital of Traditional Chinese Medicine | Shengjing Hospital | Beijing Tsinghua Changgeng Hospital | Yunnan Cancer Hospital | The First People's Hospital of Yunnan Province | Guizhou Provincial People's Hospital | First Affiliated Hospital of Guangxi Medical University | West China Hospital | Zhuhai People's Hospital | Dazhou Central Hospital | Eastern Hepatobiliary Surgery Hospital", |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ,"Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Its early recurrence and long-term prognosis are closely associated with tumor aggressiveness. Microvascular invasion (MVI), defined as the presence of tumor cells within small branches of the portal or hepatic veins, is a key indicator of malignant biological behavior in HCC. Clinically, MVI is strongly correlated with postoperative early recurrence and serves as an important factor in determining surgica","Peking Union Medical College Hospital, First Affiliated Hospital of Kunming Medical University, Beijing YouAn Hospital, Zhujiang Hospital, Meng Chao Hepatobiliary Hospital of Fujian Medical University, First Affiliated Hospital of Wenzhou Medical University, Fifth Affiliated Hospital, Sun Yat-Sen University, Henan Provincial People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shengjing Hospital, Beijing Tsinghua Changgeng Hospital, Yunnan Cancer Hospital, The First People's Hospital of Yunnan, Guizhou Provincial People's Hospital, First Affiliated Hospital of Guangxi Medical University, West China Hospital, ZhuHai Hospital, Dazhou Central Hospital, Eastern Hepatobiliary Surgery Hospital",2027-09-01,ESTIMATED,18 Years - 18 Years,400,ESTIMATED,,OTHER_GOV,,Development of a Computer-Aided Diagnosis System for Hepatocellular Carcinoma Microvascular Invasion Based on Preoperative Image Analysis,2026-09-01,ESTIMATED,Area Under the Receiver Operating Characteristic Curve (AUC) | Accuracy,,ALL,2025-09-01,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06612216,,NOT_YET_RECRUITING,Cancer,,,,6,healthy individuals and cancer patients | Patients with different traditional Chinese medicine cancer toxicity syndrome types | Patients with different traditional Chinese medicine constitutions | Patients with different tumor burden | Patients with different symptom burdens | Patients with different treatment and outcome outcomes, |  |  |  |  | ,The study aims to investigate the potential mechanisms by which the interaction between the microbiota and tumors leads to the occurrence and development of cancer by collecting clinical information and biological samples from healthy individuals and cancer patients.,"Xiyuan Hospital of China Academy of Chinese Medical Sciences, Dongzhimen Hospital, Beijing, Beijing Chest Hospital, Capital Medical University, Shanghai University of Traditional Chinese Medicine, Shaanxi Hospital of Traditional Chinese Medicine, Leling Traditional Chinese Medicine Hospital, Henan Medical University",2027-02-28,ESTIMATED,18 Years - N/A,500,ESTIMATED,,OTHER,,Research on the Scientific Connotation of Cancer Toxin Pathogenesis Based on the Interaction Between Flora and Tumor-Establishment of Cohort Under the Guidance of the Pathogenesis of Cancer Toxin in Traditional Chinese Medicine,2027-02-28,ESTIMATED,16S rDNA,,ALL,2024-09-22,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07353749,PHASE4,NOT_YET_RECRUITING,"Unruptured Intracranial Aneurysms, Cerebrovascular Event, Hemorrhagic Stroke, Methylprednisolone, Flow Diverter","Methylprednisolone (Injectable Form), Placebo Injection",,RANDOMIZED,2,Methylprednisolone Group | Placebo Control Group,EXPERIMENTAL | PLACEBO_COMPARATOR,"Study Title: Testing Methylprednisolone to Prevent Strokes After a Stent Procedure for Brain Aneurysms

What is the purpose of this study? This study aims to find out if a short course of a steroid medicine called methylprednisolone can help prevent strokes and other brain-related complications in patients who have a ""flow diverter"" stent placed to treat an unruptured brain aneurysm. The main goal is to see if this treatment reduces the combined number of new strokes (both clot-related and bleed","Nanfang Hospital, Southern Medical University, Guangdong Provincial People's Hospital, Beijing Tiantan Hospital, First Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Southwest Medical University, Guangdong 999 Brain Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, ZhuHai Hospital, First Affiliated Hospital of Harbin Medical University, Henan Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Second Affiliated Hospital of Nanchang University, West China Hospital, Shengjing Hospital, Tongji Hospital, Zunyi Medical College, Qilu Hospital of Shandong University, Second Affiliated Hospital of Xi'an Jiaotong University, The First Affiliated Hospital of Zhengzhou University, Guangdong Provincial Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Southern Medical University, Dongguan People's Hospital, Shantou Central Hospital, the Affiliated hospital of Guilin medical university, China, Huizhou Third People's Hospital, Guangzhou Medical University, Guangdong Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Qingyuan People's Hospital, Guigang People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The First Affiliated Hospital of Guangzhou Medical University, First Affiliated Hospital of Jinan University, Shenzhen People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan",2027-09-01,ESTIMATED,18 Years - N/A,864,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"Efficacy and Safety of Methylprednisolone in Preventing Adverse Cerebrovascular Events After Flow-Diverter Stent Implantation in Patients With Unruptured Intracranial Aneurysms: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial",2027-08-31,ESTIMATED,Incidence of the Composite Outcome of Any New Cerebrovascular Adverse Event and Neurologic Death within 30 Days,PREVENTION,ALL,2026-01-30,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07361783,,RECRUITING,"Primary PCI, ST-elevation Myocardial Infarction (STEMI)",Unfractionated heparin,HELP-PCI 2,RANDOMIZED,2,Administration of Heparin at the first medical contact | Administration of Heparin in the catheterization laboratory,EXPERIMENTAL | ACTIVE_COMPARATOR,"This randomized, multicenter, prospective trial will enroll 6,294 participants in approximately 80 centers. STEMI patients with onset time within 12 hours and scheduled for primary PCI will be randomly assigned to two groups in a 1:1 ratio. Patients meeting the criteria were randomly assigned. It is recommended that loading doses of dual antiplatelet therapy be administered immediately after electrocardiogram diagnosis. The experimental group was required to be given an intravenous injection of ","Renmin Hospital of Wuhan University, Xianning Central Hospital, Hubei University of Medicine, Yichang Central People's Hospital, Xiangyang Central Hospital, Caidian District People's Hospital, Chibi People's Hospital, Jiangxia First People's Hospital, Anlu Pu'ai Hospital, Jingzhou Central Hospital, The Fifth Hospital of Wuhan, Shiyan People's Hospital, The Third People's Hospital of Hubei Province, China Resources Wugang General Hospital, Wuhan Puren Hospital, Sinopharm Dongfeng General Hospital, Changjiang Shipping General Hospital, Wuhan No.1 Hospital, Wuhan No.3 Hospital, Xishui County People's Hospital, Xiangyang Hospital of Traditional Chinese Medicine, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Jiangling People's Hospital, Wuhan No.6 Hospital, The Central Hospital of Huanggang, Laohekou First Hospital, Wuxue First People's Hospital, Hanyang University, The First People's Hospital of Tianmen, Xianning First People's Hospital, Wuhan Hospital of Traditional Chinese Medicine, Wuhan Central Hospital, The Second Affiliated Hospital of Harbin Medical University, Second Xiangya Hospital of Central South University, Tongcheng People's Hospital of Anhui province, Songzi People's Hospital, Xiantao First People's Hospital, Ezhou Central Hospital, People's Hospital of Jingshan",2030-04-01,ESTIMATED,18 Years - N/A,6294,ESTIMATED,PARALLEL,OTHER,DOUBLE,"The Impact of Injection of a Loading Dose of Unfractionated Heparin on Patients With Acute ST-segment Elevation Myocardial Infarction Scheduled for Primary PCI at Initial Medical Contact: A Multicenter, Prospective, Randomized Controlled Study（HELP-PCI 2）",2029-12-31,ESTIMATED,"The composite endpoint of all-cause death, recurrent myocardial infarction, urgent coronary revascularization, stent thrombosis, or stroke within 30 days after randomization | Primary safety endpoint: Major bleeding (BARC type 3~5) within 30 days",TREATMENT,ALL,2025-08-13,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07321795,,NOT_YET_RECRUITING,"OVCF Database, Cohort Study",,,,4,normal bone mass group | osteopenia group | osteoporosis group | Osteoporotic Vertebral Compression Fracture group, |  |  | ,The study aims to construct an early warning model for Osteoporotic Vertebral Compression Fracture (OVCF) by integrating TCM syndrome patterns with modern risk factors. This is a multi-center cohort study on OVCF integrated with disease and syndrome differentiation in Traditional Chinese Medicine (TCM).,"Hunan University of Traditional Chinese Medicine, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Shandong Wendeng Orthopedic Hospital",2027-12-31,ESTIMATED,50 Years - 80 Years,200,ESTIMATED,,OTHER,,Osteoporotic Vertebral Compression Fractures: A Multi-center Cohort Study Based on Disease and Syndrome Differentiation,2027-09-30,ESTIMATED,Bone Mineral Density (BMD),,ALL,2026-01-10,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05623722,,RECRUITING,"Sepsis, Acute Gastrointestinal Injury, Organ Dysfunction Syndrome",,,RANDOMIZED,2,Control Group | Erector Spinae Plane Block Group,NO_INTERVENTION | EXPERIMENTAL,"This study is a prospective, multicenter, parallel-group, open-label, randomized controlled clinical trial. Sepsis is defined as organ dysfunction induced by infections. And sepsis and gastrointestinal injury can be the leading cause for each other. Our previous study showed erector spinae plane block improved the organ dysfunctions in patients with AGI. The aim of the clinical trial is to investigate erector pinae plane block improves the organ dysfunction in septic patients with acute gastroin","Zhongshan People's Hospital, Guangdong, China, Zhongshan Hospital Of Traditional Chinese Medicine",2026-12-31,ESTIMATED,18 Years - N/A,116,ESTIMATED,PARALLEL,OTHER,NONE,Erector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury: a Randomized Clinical Trial,2026-11-30,ESTIMATED,Sequential Organ Failure Assessment (SOFA) score,TREATMENT,ALL,2022-12-29,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07370116,PHASE2,NOT_YET_RECRUITING,"Pancreaticoduodenectomy, Nasogastric Tube Decompression, Minimally Invasive Surgical Procedures",,,RANDOMIZED,2,routine nasogastric tube | routine omission of the nasogastric tube,ACTIVE_COMPARATOR | EXPERIMENTAL,"This study will evaluate two perioperative nasogastric tube strategies in patients undergoing laparoscopic pancreatoduodenectomy. The goal is to determine whether routine omission of a nasogastric tube is not worse than routine nasogastric tube placement in terms of overall complications and postoperative recovery.

Participants will be randomly assigned to one of two groups. Each group will receive the assigned nasogastric tube strategy during and after surgery, and will be followed during the ","Zhejiang Provincial People's Hospital, Shanghai Cancer Centre, The Second Hospital of Hebei Medical University, People's Hospital of Chongqing, Shanghai Zhongshan Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shandong Provincial Hospital, The Second Affiliated Hospital of the Army Medical University, West China Hospital, Shanxi Province Cancer Hospital",2026-08,ESTIMATED,18 Years - 75 Years,200,ESTIMATED,PARALLEL,OTHER,NONE,Safety and Feasibility of Omitting Nasogastric Decompression in Minimally Invasive Pancreaticoduodenectomy: a Multicenter Randomized Controlled Trial,2026-06-30,ESTIMATED,Comprehensive Complication Index,TREATMENT,ALL,2026-03-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06514339,EARLY_PHASE1,RECRUITING,Sepsis,"shenhuang granule, placebo",,RANDOMIZED,2,Treatment group | Control group,EXPERIMENTAL | SHAM_COMPARATOR,"Sepsis is a life-threatening organ dysfunction caused by the body's dysfunctional response to infection, most patients require treatment in the ICU, and is the leading cause of death worldwide. Over the years, the development of new drugs for the treatment of sepsis has failed without significant benefit in reducing mortality, and there is currently no effective drug treatment. Therefore, sepsis is a serious disease threatening the life and health of patients, causing a huge burden to society, a","Zhejiang University, Red Cross Hospital, Hangzhou, China, Ningbo Hospital of Traditional Chinese Medicine",2026-07-01,ESTIMATED,18 Years - N/A,410,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis: a Randomized, Double-blind, Placebo-controlled, Effective Clinical Trial",2026-03-01,ESTIMATED,28-day mortality rate,TREATMENT,ALL,2024-07-01,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07178392,,NOT_YET_RECRUITING,Idiopathic Pulmonary Fibrosis (IPF),,,,1,Participants fill out the questionnaire,,"This study, based on previous registration records, aims to explore the syndrome patterns, disease characteristics, and their interrelationships of IPF at different stages, grades, and in its natural course, thus providing a multidimensional interpretation of the syndrome patterns and characteristics of IPF.","The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, China-Japan Friendship Hospital, The First Affiliated Hospital of Zhengzhou University, Shanghai Pulmonary Hospital, Shanghai, China",2028-11-30,ESTIMATED,18 Years - N/A,2864,ESTIMATED,,OTHER,,Research on the Disease-syndrome Characteristics of Idiopathic Pulmonary Fibrosis,2028-09-30,ESTIMATED,"Disease Stage | Gender, age and physiologic variables (GAP)stage | Pulmonary function classification | Natural course | The Traditional Chinese Medicine(TCM) Syndromes | 6 Six Minute Walk Distance(6MWD) | The 30 - second sit - to - stand test(30s STS) | A Tool to Assess Quality of life (ATAQ-IPF) total scores | St. George's respiratory questionnaire (SGRQ) total scores | Dyspnea | C-reactive protein (CRP) | Krebs Von den Lungen-6（KL-6） | The pulmonary artery systolic pressure(PASP) | The diameter of the pulmonary artery | Forced vital capacity (FVC) | FVC as the percentage of the predicted value (FVC%) | Diffusing capacity of the lungs for carbon monoxide (DLCO) | DLCO as the percentage of the predicted value (DLCO%)",,ALL,2025-09-15,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05730595,,NOT_YET_RECRUITING,"Colorectal Neoplasms, Fluorescence, Lymph Node Excision",,FLORA-01,RANDOMIZED,2,D2 lymph node dissection | D3 lymph node dissection,EXPERIMENTAL | ACTIVE_COMPARATOR,To explore the short-term and long-term outcomes of fluorescence laparoscopic navigation D2 lymph node dissection for colorectal cancer surgery by comparing it with D3 lymph node dissection.,"Fudan University, Fujian Province Tumor Hospital, Guangdong Provincial People's Hospital, Shengjing Hospital, Affiliated Hospital of Qinghai University, Hebei Medical University Fourth Hospital, The Second Affiliated Hospital of Harbin Medical University, Jiangxi Provincial Cancer Hospital, The First Hospital of Jilin University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Shanxi Province Cancer Hospital, Nanfang Hospital, Southern Medical University, Second People's Hospital of Yunnan Province, Binzhou Medical University, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chengdu Medical College, The Second People's Hospital of Yibin, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",2027-06-01,ESTIMATED,18 Years - 75 Years,550,ESTIMATED,PARALLEL,OTHER,TRIPLE,A Randomized Controlled Trial of Fluorescence Laparoscopic Navigation of the Extent of Lymph Node Dissection for High Rectal Cancer and Sigmoid Colon Cancer,2026-12-01,ESTIMATED,Disease-free survival | Overall survival,TREATMENT,ALL,2023-09-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07321535,,NOT_YET_RECRUITING,Sarcopenia,"Huangjing Yangji Formula Granules, Placebo Granules for Huangjing Yangji Formula",,RANDOMIZED,2,Huangjing Yangji Formula + Training | Placebo + Training,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to learn if a traditional Chinese medicine formula called ""Huangjing Yangji Formula,"" combined with elastic band resistance training, works better than exercise alone to improve physical function and muscle strength in older adults with sarcopenia (age-related muscle loss). The main questions it aims to answer are:

Does the combined treatment improve participants' overall physical performance scores more than exercise with a placebo?

Does it lead to better ou","The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Hunan University of Traditional Chinese Medicine",2026-12-31,ESTIMATED,50 Years - 75 Years,106,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"Huangjing Yangji Formula Combined With Resistance Training for Sarcopenia: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial",2026-09-30,ESTIMATED,Short Physical Performance Battery (SPPB) Score,TREATMENT,ALL,2026-01-15,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05937178,,RECRUITING,"Hepatitis B, Chronic","ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF",,,3,"Recommend to initiate treatment in 2022 Chinese Guideline, but not in 2019 Chinese Guideline | Recommend to initiate treatment in 2019 and 2022 Chinese Guideline, but not in AASLD/EASL guidelines | Treatment experienced and with partial response", |  | ,"The goal of this multicenter, observational, prospective study is to observe and compare different anti-viral treatment strategies in a real-world cohort of patients with CHB managed in routine clinical settings in China. The main questions it aims to answer are:

1. To evaluate the benefits of initiating first-line nucleos(t)ide analogue in patients with chronic HBV infection who are recommended in the updated Chinese Guideline 2022, but not recommended in the Chinese Guideline 2019.
2. To eval","The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital",2029-01-31,ESTIMATED,18 Years - 80 Years,20000,ESTIMATED,,OTHER,,A Real-world Study of Optimizing Nucleotide-analogues-based Treatment for Chronic Hepatitis B,2029-01-31,ESTIMATED,The proportion of patients with HBV DNA <20 IU/ml | The proportion of patients with HBV DNA <20 IU/ml | The proportion of patients with HBV DNA <20 IU/ml | Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG) | Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG) | Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG) | Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG),,ALL,2023-01-31,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06890143,PHASE3,RECRUITING,Pediatric Hereditary Kidney Diseases,"Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks",,RANDOMIZED,2,Early Dapagliflozin Group | Delayed Dapagliflozin Group,EXPERIMENTAL | EXPERIMENTAL,"This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children","Guangzhou Women and Children's Medical Center, Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Shandong Provincial Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Wuhan Children's Hospital, Xuzhou Children Hospital, First Affiliated Hospital, Sun Yat-Sen University, Kunming Children's Hospital, The Children's Hospital of Zhejiang University School of Medicine, Children's Hospital of Nanjing Medical University, Zhengzhou Children's Hospital, China, Xiamen Women's and Children's Hospital, Guiyang Maternity and Child Health Care Hospital, Maternal and Child Health Care Hospital of Hainan Province, Children's Hospital of The Capital Institute of Pediatrics, Second Affiliated Hospital of Wenzhou Medical University, Xian Children's Hospital, The Second Hospital of Hebei Medical University, Wuxi Women's & Children's Hospital, First People's Hospital of Urumqi",2027-03-31,ESTIMATED,6 Years - 18 Years,44,ESTIMATED,CROSSOVER,OTHER,SINGLE,"The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial",2026-12-31,ESTIMATED,Changes in 24-hour urinary protein excretion from baseline to week 12,TREATMENT,ALL,2025-03-22,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT04320979,PHASE3,ACTIVE_NOT_RECRUITING,Breast Cancer,,,RANDOMIZED,2,internal mammary nodal irradiation | no-internal mammary nodal irradiation,EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of this study is to evaluate the impact of internal mammary nodal irradiation on disease-free survival in high-risk breast cancer patients treated with mastectomy or breast-conserving surgery.,"Hebei Medical University Fourth Hospital, Shanghai Zhongshan Hospital, Zhejiang Cancer Hospital, Beijing Hospital, Liaoning Cancer Hospital & Institute, Jilin Provincial Tumor Hospital, Tangshan People's Hospital, The First Hospital of Jilin University, West China Hospital, Peking Union Medical College Hospital, Henan Cancer Hospital, Zhongnan Hospital, Peking University Cancer Hospital & Institute, Fudan University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Air Force Military Medical University, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Chinese Academy of Medical Sciences, Fuwai Hospital, Lanzhou University First Hospital, Jiangsu Province Hospital of Traditional Chinese Medicine, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center",2030-05,ESTIMATED,18 Years - 70 Years,2400,ACTUAL,PARALLEL,OTHER,NONE,Postmastectomy Prophylactic Internal Mammary Nodal Irradiation for High-risk Patients With Non-metastatic Breast Cancer,2025-11-01,ACTUAL,disease-free survival,TREATMENT,FEMALE,2020-05-08,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06824376,,RECRUITING,Asymptomatic Hyperuricemia,,HUA，SUA，MA,RANDOMIZED,2,Manual acupuncture group | Sham acupuncture group,EXPERIMENTAL | SHAM_COMPARATOR,Assess the effectiveness of manual acupuncture in modulating serum uric acid levels among patients diagnosed with asymptomatic hyperuricemia.,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Xianning Hospital of Traditional Chinese Medicine, China, Beijing Hospital of Traditional Chinese Medicine, Qianjiang Central Hospital, China, Hainan General Hospital, Yichang Central People's Hospital, Wuhan No.1 Hospital, The Second Hospital of Huangshi, Puyang Hospital of Traditional Chinese Medicine",2026-12,ESTIMATED,18 Years - N/A,260,ESTIMATED,PARALLEL,OTHER,TRIPLE,"Efficacy and Safety Study of Manual Acupuncture (MA) on Serum Uric Acid (SUA) Outcomes in Patients With Asymptomatic Hyperuricemia (HUA): a Multi-center, Randomized, Sham-controlled Trial",2026-10,ESTIMATED,Serum uric acid (SUA),TREATMENT,ALL,2025-03-25,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05540938,PHASE4,RECRUITING,Rheumatoid Arthritis,"Wangbi granules, Wangbi granules simulant",,RANDOMIZED,2,treatment group | control group,EXPERIMENTAL | ACTIVE_COMPARATOR,"The group used a randomized controlled trial to conduct a post-marketing re-evaluation study of Wangbi granules. The study was conducted to observe the degree of clinical remission in rheumatoid arthritis patients with low disease activity after standard methotrexate and tofacitinib citrate treatment, using a combination of Chinese and Western medicine treatment with Wangbi granules. The study aims to provide evidence-based medical evidence to improve the clinical efficacy of rheumatoid arthriti","Peking Union Medical College Hospital, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, The 980th Hospital of PLA Joint Logistics Support Force, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Southwest Hospital, China",2026-03-31,ESTIMATED,18 Years - 75 Years,340,ESTIMATED,PARALLEL,OTHER,TRIPLE,Reevaluation of Original Research Results of Integrated Traditional Chinese and Western Medicine and Transformation of Hospital Preparations: Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis,2025-12-31,ESTIMATED,DAS28,TREATMENT,ALL,2023-05-23,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06647940,PHASE2,RECRUITING,Diffuse Large B Cell Lymphoma (DLBCL),"Orelabrutinib Oral Tablet, R-CHOP Protocol",,,1,Orelabrutinib in combination with R-CHOP,EXPERIMENTAL,"This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.","Fifth Affiliated Hospital, Sun Yat-Sen University, Gansu Cancer Hospital, First Affiliated Hospital of Shantou University Medical College, Southern Medical University, China, Guangdong Provincial Hospital of Traditional Chinese Medicine, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shenzhen People's Hospital, Guangzhou First People's Hospital, Dongguan People's Hospital, The First People's Hospital of Zhaoqing",2027-03-01,ESTIMATED,18 Years - N/A,39,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients: a Single-arm, Multicenter, Phase II Clinical Trial（Rocket Trial）",2026-11-01,ESTIMATED,2-year event-free survival (EFS) rate,TREATMENT,ALL,2024-11-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT04443478,,RECRUITING,Gastric Cancer,,,,2,Laparoscopic Surgery | Open Surgery, | ,"Mediastinal lymph node dissection has been adopted as standard treatment for adenocarcinoma of esophagogastric junction(AEJ). This multi-center, exploratory, prospective, cohort study aims at provide standard technical details of laparoscopic mediastinal lymph node dissection, and explore the potential clinical effects, gather key information for following study regarding sample size calculation, primary outcome and feasibility.","Peking University Cancer Hospital & Institute, Changzhi People's Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Shanghai Zhongshan Hospital, Fudan University, Guangdong Provincial People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Hebei Medical University Fourth Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The First Hospital of Jilin University, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Air Force Medicial University, Nanfang Hospital, Southern Medical University, The Affiliated Hospital of Qingdao University, Affiliated Hospital of Qinghai University, The First Affiliated Hospital of Xiamen University, Shandong Provincial Hospital, Shanxi Province Cancer Hospital, RenJi Hospital, Ruijin Hospital, Beijing Friendship Hospital, West China Hospital, Tianjin Medical University Cancer Institute and Hospital, First Affiliated Hospital Xi'an Jiaotong University, Zhejiang Cancer Hospital, Chinese PLA General Hospital, First Hospital of China Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Sun Yat-sen University",2026-07-01,ESTIMATED,18 Years - 80 Years,1036,ESTIMATED,,OTHER,,"Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Siewert Type II/III Adenocarcinoma of Esophagogastric Junction: an Exploratory, Prospective, Observational, IDEAL Stage 2, Cohort Study",2023-07-01,ESTIMATED,The number of lower mediastinal lymph nodes retrieved,,ALL,2020-08-01,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06093932,PHASE4,RECRUITING,"Hypertension,Essential","Songling Xuemaikang Capsules, Placebo",ESCIHP,RANDOMIZED,2,Lifestyle intervention + Songling Xuemaikang Capsules | Lifestyle intervention + placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is:

1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension.
2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension.
3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.","China Academy of Chinese Medical Sciences Xiyuan Hospital Shanxi Hospital, Suzhou Hosptial of Traditional Chinese Medicine, China Academy of Chinese Medical Sciences Xiyuan Hospital Jining Hospital, Shandong University of Traditional Chinese Medicine",2027-12,ESTIMATED,35 Years - 65 Years,100,ESTIMATED,PARALLEL,OTHER,DOUBLE,"Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized, Multicenter, Double-blind, Placebo-controlled Trial",2024-12,ESTIMATED,"Change from Baseline in the Mean 24h Systolic Blood Pressure at 4,12 weeks",TREATMENT,ALL,2024-04-07,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT03865914,,RECRUITING,Diabetic Kidney Disease,,,,1,Type 2 diabetic nephropathy,,"With the rapid increase of diabetic nephropathy worldwide, type 2 diabetes mellitus(DM) is the leading cause of end-stage renal disease(ESRD). Pathological types of diabetic kidney disease(DKD) could be mainly divided into diabetic nephropathy（DN）and non-diabetic renal diseases（NDRD）. There are no accurate renal biopsy indications and standardized operation procedures for type 2 diabetic nephropathy. The clinical stages of type 2 diabetic nephropathy still referred to the Mogensen stage of type ","Beijing Municipal Science & Technology Commission, China-Japan Friendship Hospital, Beijing Friendship Hospital, Beijing Hospital, Fourth Medical Center of PLA General Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Third Medical Center of PLA General Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, The First Affiliated Hospital of Dalian Medical University, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Dongzhimen Hospital, Beijing, Shanghai University of Traditional Chinese Medicine",2030-12-31,ESTIMATED,18 Years - N/A,2000,ESTIMATED,,OTHER,,Correlation Study Between Clinical Phenotype and Pathology of Type 2 Diabetic Nephropathy,2027-11-30,ESTIMATED,change in eGFR and urine protein from baseline,,ALL,2017-11-30,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07153744,PHASE4,NOT_YET_RECRUITING,"Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)","Aspirin, Shexiang Baoxin Pill",MUST Ⅱ,RANDOMIZED,2,the Shexiang Baoxin Pill Group | the Conventional Treatment Group,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study. It seeks to validate its efficacy in reducing cardiovascular event risk during the peri-PCI period, as well as its effects on cardiac function, quality of life , and relevant biomarkers. Through this research, we expect to provide higher-quality evidence for the application of SBP in AMI ","Shanghai Zhongshan Hospital, Huashan Hospital, Shanghai 10th People's Hospital, Shanghai 6th People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai East Hospital, Longhua Hospital, Second Affiliated Hospital of Soochow University, Affiliated Hospital of Jiangsu University, The First Affiliated Hospital with Nanjing Medical University, The First People's Hospital of Lianyungang, Huai'an First People's Hospital, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Ningbo University, Shandong Provincial Hospital, Qianfoshan Hospital, Weihai Municipal Hospital, Weifang People's Hospital, Rizhao People's Hospital, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Linyi People's Hospital, Xiangya Hospital of Central South University, Second Xiangya Hospital of Central South University, Yueyang Central Hospital, The First Affiliated Hospital of University of South China, The Central Hospital of Shaoyang, The First People's Hospital of Changde City, Wuxi People's Hospital, Jinhua Central Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, ZhuZhou Central Hospital, First People's Hospital of Chenzhou, People's Hospital of Quzhou, Xuzhou New Health Hospital, Taizhou Enze Medical Center Group, Beijing Chao Yang Hospital, Civil Aviation General Hospital, Xuanwu Hospital, Beijing, Beijing Friendship Hospital, Peking University People's Hospital, Beijing Electric Power Hospital, Renmin Hospital of Wuhan University, Wuhan No.1 Hospital, Jingzhou Central Hospital, The First Affiliated Hospital of Dalian Medical University, Ansteel Group General Hospital, General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group, The First Affiliated Hospital of Zhengzhou University, Huaihe Hospital of Henan University, Zhoukou Central Hospital, The First Affiliated Hospital of Henan University of Science and Technology, First Affiliated Hospital of Nanyang Medical College, Jiaozuo Second People's Hospital, Anyang Area Hospital of Puyang City, Shijiazhuang People's Hospital, Cangzhou Central Hospital, The First Hospital of Hebei Medical University, Handan Central Hospital, The People's Hospital of Langfang City, Xingtai Central Hospital, North China University of Science and Technology, The First Affiliated Hospital of Anhui Medical University, the First Hospital of Anhui University of Science and Technology, Chaohu Hospital of Anhui Medical University, Tongling People's Hospital, Huang Shan People's Hospital, Huaibei Miners General Hospital, The Second Affiliated Hospital of Fujian Medical University, Changzhi Medical College, LinFen People's Hospital, Shanxi Cardiovascular Hospital, Dazhou First People's Hospital, The Affiliated Hospital Of Southwest Medical University, The Third Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University, Yangchun People's Hospital, Shaoguan People's Hospital, Guilin People's Hospital, The First Affiliated Hospital of Nanchang University, Ji'an Central People's Hospital, Jiangxi Provincial People's Hopital, People's Hospital of Chongqing, Ankang Central Hospital, Xiangyang Central Hospital, Tianjin Third Central Hospital, General Hospital of Ningxia Medical University, The Second Affiliated Hospital of Hainan Medical University, Lanzhou University Second Hospital, Jilin Province People's Hospital, Inner Mongolia Autonomous Region People's Hospital, Yan'an Hospital of Kunming City, The People's Hospital of Jizhou District, Tianjin, The Southwest Hospital of Army Medical University, The First People's Hospital of Nanning, The People' s Hospital of Jiangmen, The second People's Hospital of Guiyang, The Third People's Hospital of Chengdu, The Tirst People's Hospital of Mianyang, First Affiliated Hospital of Fujian Medical University, The First People's Hospital of Chu Zhou, Xuancheng people's hospital",2029-12-31,ESTIMATED,18 Years - N/A,9588,ESTIMATED,PARALLEL,INDUSTRY,NONE,"Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction: A Prospective, Multicenter, Pragmatic Randomized Controlled Real-World Study",2028-12,ESTIMATED,Incidence of major adverse cardiovascular and cerebrovascular events (MACE),TREATMENT,ALL,2025-09-01,ESTIMATED,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07319338,,NOT_YET_RECRUITING,"Chronic Atrophic Gastritis, Depressive Symptoms, Depression, Gastrointestinal Diseases",,,,1,Patients with Chronic Atrophic Gastritis (CAG),,"Depressive symptoms are highly prevalent in patients with chronic atrophic gastritis (CAG) but are frequently under-detected due to stigma and reliance on subjective questionnaires. This multicenter, cross-sectional observational study aims to validate a novel clinical triage workflow. It repurposes routine vascular assessments (specifically dorsalis pedis artery ultrasound and arterial stiffness metrics) as objective ""biological entry points"" to facilitate mental health referrals. The study wil","Beijing Anzhen Hospital, Hengshui Hospital of Traditional Chinese Medicine, Liyang Hospital of Traditional Chinese Medicine",2026-08-30,ESTIMATED,20 Years - 60 Years,520,ESTIMATED,,OTHER,,Implementing Objective Vascular Biomarkers as a Non-stigmatizing Triage Workflow for Depression in Gastroenterology Settings: a Multicenter Study Protocol for a Hybrid Effectiveness-implementation Study,2026-06-20,ESTIMATED,Depressive Symptom Screening-Positive Status (PHQ-9 ≥10),,ALL,2026-02-01,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06358209,,RECRUITING,Central Nervous System Infections,,,RANDOMIZED,2,Control group | Ventricular irrigation group,NO_INTERVENTION | EXPERIMENTAL,"Ventriculitis is a severe infectious disease of the central nervous system with diverse etiologies. Currently, the treatment for ventriculitis is challenging, with poor prognosis. The mortality rate of ventriculitis is generally reported to be higher than 30%, with the highest reaching over 75%. Even among survivors, over 60% suffer from a variety of neurological sequelae, including cognitive impairment, gait disturbances, paralysis, behavioral disorders, and epilepsy.

Currently, treatments for","Southern Medical University, China, First Affiliated Hospital of Zhejiang University, 904th Hospital of the Joint Logistics Support Force of the PLA, Shenzhen Second People's Hospital, Shanghai East Hospital, Xuanwu Hospital, Beijing, South Taihu Hospital Affiliated to Huzhou College, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, Yangzhou University, The First Affiliated Hospital of Soochow University, Zhongshan Hospital Of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, First Affiliated Hospital of Xinjiang Medical University, West China Hospital, The Second Affiliated Hospital of Air Force Medical University, Qilu Hospital of Shandong University, The Fourth Affiliated Hospital of China Medical University, Ganzhou People's Hospital, Xiangya Hospital of Central South University, Tongji Hospital, First Affiliated Hospital of Harbin Medical University, Henan Provincial People's Hospital, The Second People's Hospital of Anhui Province, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Fujian Medical University, Shanghai Donglei Brain Hospital, The Affiliated People's Hospital of Ningbo University, Inner Mongolia People's Hospital, Second Affiliated Hospital of Nanchang University, Affiliated Hospital of Nantong University, The First Affiliated Hospital of Wannan Medical College（Yijishan Hospital of Wannan Medical College）, The Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital), Shanghai 10th People's Hospital",2028-12-31,ESTIMATED,18 Years - 65 Years,310,ESTIMATED,PARALLEL,OTHER,SINGLE,Safety and Efficacy of Ventricular Irrigation for Ventriculitis: a Randomized Controlled Trial,2028-06-30,ESTIMATED,Clinical cure rate,TREATMENT,ALL,2025-07-01,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07034326,"PHASE2, PHASE3",RECRUITING,"Non-Small Cell Lung Cancer, Electroacupuncture, Immune Checkpoint Inhibitors","Zilongjin tablet combined with immunotherapy, Immunotherapy",,RANDOMIZED,3,Electroacupuncture combined with immunotherapy | Zilongjin tablet combined with immunotherapy | Immunotherapy,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"Postoperative immunoadjuvant therapy has been proven to significantly reduce the risk of recurrence after resectable NSCLC, and has become a new standard of postoperative adjuvant therapy for stage II-III NSCLC. Immunotherapy faces challenges such as immune resistance, heterogeneity of biomarker expression, and limitation of immune-suitable population. How to reduce the rate of recurrence and metastasis after surgery, enhance the therapeutic effect of immunotherapy, and then prolong the survival",Ministry of Science and Technology of the People´s Republic of China,2028-12-31,ESTIMATED,18 Years - 80 Years,405,ESTIMATED,PARALLEL,OTHER,NONE,Observation on the Clinical Efficacy of Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer,2028-12-31,ESTIMATED,Disease free survival(DFS),TREATMENT,ALL,2025-01-01,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06078930,,RECRUITING,"Gastric Cancer, Tongue Images, Diagnosis",,,,2,Patients with gastric cancer | Healthy participants, | ,"In this study, the investigators will prospectively recruit 100,000 individuals, including gastric cancer patients who have not undergone any anti-tumor treatment and non-gastric cancer participants. The investigators will construct a diagnostic model for malignant tumors based on the combination of tongue imaging, tongue coating, saliva, gastric juice, and fecal multi-omics data (including metagenomics, proteomics, metabolomics, etc.). Additionally, the study will explore the relationship betwe","Sichuan Cancer Hospital and Research Institute, The First Affiliated Hospital of Zhejiang Chinese Medical University, Wenzhou Medical University, Fujian Cancer Hospital, RenJi Hospital, Tongde Hospital of Zhejiang, Kecheng District People's Hospital, Yueyang Central Hospital, Shandong Cancer Hospital and Institute, Shanxi Province Cancer Hospital, Liaoning Cancer Hospital & Institute, Harbin Cancer Hospital, Yuhang District People's Hospital, Hainan Cancer Hospital, Zigong Fourth People's Hospital, Henan University of Science and Technology, Shangyu People's Hospital of Shaoxing City, Red Cross Hospital, Hangzhou, China, The Affiliated Hospital of Hangzhou Normal University, Xiaoshan District First People's Hospital, Xianju County People's Hospital, Lin'an District First People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Leqing City People's Hospital, The Affiliated Hospital of Medical School of Ningbo University, Cixi City People's Hospital, Mingzhou Hospital, Zhejiang University, Fourth Hospital of Ningbo City, Fenghua District People's Hospital, Fenghua Traditional Chinese Medicine Hospital, Ningbo City, Xikou Hospital, Fenghua District, Ningbo City, Chengdu University of Traditional Chinese Medicine, Guang'an Hospital, Affiliated to Chengdu University of Traditional Chinese Medicine, Jiangsu Cancer Institute & Hospital, Jiangsu Provincial People's Hospital, The First People's Hospital of Changzhou, The First Affiliated Hospital of Soochow University, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Zidong Campus of Jiangsu Provincial Hospital of TCM, Wuxi Traditional Chinese Medicine Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Anhui Medical University, Peking University Cancer Hospital & Institute, Xijing Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Xiangya Hospital of Central South University, Yunnan Cancer Hospital, Chongqing University Cancer Hospital, Gansu Cancer Hospital, Fudan University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, First Affiliated Hospital of Guangxi Medical University, Tianjin Medical University Cancer Institute and Hospital, Huzhou Central Hospital, Zhoushan Hospital, Zhejiang",2026-12-31,ESTIMATED,18 Years - 90 Years,100000,ESTIMATED,,OTHER,,A Multi-center Observational Clinical Study on the Development of Artificial Intelligence-Based Gastric Cancer Screening and Diagnosis Technology Using Multi-Omics Analysis of Tongue Imaging and Tongue Coating,2025-06-01,ESTIMATED,"The differences in tongue images, tongue coating, saliva, gastric juice, and fecal samples between patients with gastric cancer and healthy individuals will be systematically analyzed. | The differences of the clinical information between patients with gastric cancer and healthy participants. | Overall Survival (OS)",,ALL,2021-06-01,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06743867,PHASE1,RECRUITING,Peritoneal Carcinoma Metastatic,Pressurized Intraperitoneal Aerosol Chemotherapy,,,1,Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC),EXPERIMENTAL,"This research is a prospective, multi-center, single-arm clinical trial aimed at assessing the standard pressurized intraperitoneal aerosol chemotherapy (PIPAC) utilizing a novel nebulized drug delivery system (NDDS) for patients with peritoneal metastatic adenocarcinoma (PMA) originating from gastric, colorectal, appendiceal, or ovarian cancer.

The primary objectives of this study are to assess the safety and efficacy of PIPAC with the novel NDDS in the treatment of PMA. Primary endpoints incl","Tianjin Third Central Hospital, Peking University Cancer Hospital & Institute, Second Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Henan Cancer Hospital, Tongji Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiangxi Provincial Cancer Hospital, The First Affiliated Hospital of Air Force Medicial University, Nanfang Hospital, Southern Medical University, Southern Medical University, China, Affiliated Hospital of Qinghai University, Ruijin Hospital, Shenzhen Second People's Hospital, West China Hospital, Tianjin Nankai Hospital, Wannan Medical College Yijishan Hospital, Second Affiliated Hospital of Wenzhou Medical University, Changzhi People's Hospital, First Hospital of China Medical University, Xiangya Hospital of Central South University, Sixth Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen University, Fujian Medical University Union Hospital",2026-09-30,ESTIMATED,18 Years - 75 Years,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"A Prospective, Multi-center, Single-arm Clinical Research Evaluating the Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastatic Adenocarcinoma",2026-09-30,ESTIMATED,"Adverse Events (AE) and serious AE associated with Treatment | Incidences of device defects | Postoperative pain scores | Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Version 3.0)",TREATMENT,ALL,2024-12-11,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07003191,,ACTIVE_NOT_RECRUITING,Type 2 Diabetes,Metformin Hydrochloride and Empagliflozin tables (Fixed-Dose Combination),,,0,,,"The main objective of this study is to evaluate the efficacy and safety of Metformin Hydrochloride and Empagliflozin Tablets in the treatment of type 2 diabetes in real-world clinical settings. A total of 2,600 type 2 diabetes patients were included in the study. The study observed the clinical glycemic control rate and adverse events over a period of at least 6 months from the prescription date to the end of continuous clinical follow-up.","First Affiliated Hospital, Sun Yat-Sen University, Liaoning Health Industry Group Fushun Mining General Hospital, Liaoning Health Industry Group Benxi Steel General Hospital, Changsha Fourth Hospital, Second Hospital of Shanxi Medical University, The First People's Hospital of Kunshan, Suzhou Ninth People's Hospital, the First Affiliated Hospital of Anhui University of Science and Technology, Mingguang People's Hospital, the People's Hospital Longhua Shenzhen, Afﬁliated Hospital of North Sichuan Medical College, Yiyang County People's Hospital, THE SECOND PEOPLE'S HOSPITAL, WUHU, The First People's Hospital of Zhangjiagang, Yixing People's Hospital, Shijiazhuang People's Hospital, Guiyang First People's Hospital, Lanzhou University Second Hospital, Tiefa Coal Industry Group General Hospital, Southern Medical University Shenzhen Hospital, The Second Hospital of Shijiazhuang, Ningbo University Affiliated People's Hospital, Dongyang People's Hospital, Xiangyang Central Hospital, Li Hui Li Hospital, Nanning Second People's Hospital, Hunan Provincial People's Hospital Ma Wang Dui Branch, The Second Affiliated Hospital of Bengbu Medical College, Ruyang County People's Hospital, Kaifeng People's Hospital, Dingzhou People's Hospital, The Second People's Hospital of Changshu, The Second Affiliated Hospital of Henan University of Science and Technology, Dengzhou People's Hospital, Taizhou First People's Hospital, Red Cross Hospital, Hangzhou, China, The First People's Hospital of Lin'an District, China Resources Wugang General Hospital, Yiwu Central Hospital, The First People's Hospital of Jiashan County, The First People's Hospital of Tongxiang City, Shaoxing Central Hospital, The First People's Hospital of Jiande City, Beilun District People's Hospital, Huantai County People's Hospital, Fifth Affiliated Hospital of Guangzhou Medical University, Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, The Affiliated Hospital of Shaanxi University of Chinese Medicine, Zhangjiagang Traditional Chinese Medicine Hospital",2025-12-31,ESTIMATED,18 Years - N/A,2600,ESTIMATED,,OTHER,,"Multicenter, Prospective, Observational Study of Metformin Hydrochloride and Empagliflozin Tablets (Enshuangping) in the Treatment of Type 2 Diabetes",2025-12-31,ESTIMATED,6-month clinical glycemic control rate,,ALL,2023-08-02,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06427018,,RECRUITING,"Asthma, Protein",,,,2,Asthma group | Non-asthma group, | ,"Asthma, a prevalent chronic respiratory affliction, significantly impinges upon the quality of life for affected individuals. Timely and appropriate diagnostic measures, coupled with efficacious therapeutic interventions, are paramount in mitigating exacerbations of symptoms and enhancing the life quality of patients.

Ezrin plays an important role in maintaining cell morphology, cell migration, cell adhesion and polarisation, but Ezrin expression in airway smooth muscle remains unclear.

Pip5k1","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai 6th People's Hospital, Xiangya Hospital of Central South University, Baoshan Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai Pulmonary Hospital, Shanghai, China",2026-12-31,ESTIMATED,18 Years - 70 Years,120,ESTIMATED,,OTHER,,"Assessing the Expressions of Ezrin, Phosphorylated Ezrin, and Pip5k1α in the Airway Smooth Muscle of Asthmatic Patient",2026-12-31,ESTIMATED,Immunofluorescence results | Immunohistochemistry results,,ALL,2024-05-28,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06898723,PHASE4,RECRUITING,"Septic Cardiomyopathy, Septic Shock",Shenfu Injection,SHIELD Trail,RANDOMIZED,2,Shenfu Injection Group | Control Group,EXPERIMENTAL | NO_INTERVENTION,"This study focuses on improving heart function in patients with life-threatening blood infections (septic shock). When the body fights severe infections, the heart sometimes struggles to pump blood effectively, which can lead to dangerous complications. Current treatments like intravenous fluids and blood pressure medications have limitations in protecting heart function.

This multicenter clinical trial aims to evaluate whether adding Shenfu Injection - a traditional Chinese medicine preparatio","Suzhou Municipal Hospital of Anhui Province, the Second of Affiliated Hospital of Wannan Medical College, Wuhu, China, Wuhu County Traditional Chinese Medicine Hospital, Wuhu first people's hospital, Wuhu City Second People's Hospital, Xuancheng people's hospital, Tongling People's Hospital, The Second Hospital of Anhui Medical University, The Fourth Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Anhui Medical University, The Third People's Hospital of Bengbu, Fuyang people's hospital, Chaohu Hospital of Anhui Medical University, The First People's Hospital of Bengb, Guangde people's hospital, Fuyang Traditional Chinese Medicine Hospital, Taihe County Traditional Chinese Medicine Hospital",2026-09-30,ESTIMATED,18 Years - N/A,440,ESTIMATED,PARALLEL,OTHER,TRIPLE,"The Preventive Effect of Shenfu Injection on Myocardial Dysfunction in Sepsis: a Multicenter, Randomized Controlled Study",2026-09-30,ESTIMATED,The incidence of septic cardiomyopathy | Duration of vasopressor administration,TREATMENT,ALL,2024-10-01,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT03649503,,RECRUITING,Parkinsonian Disorders,,ForPDCN,,0,,,"The overall goal of this project is to identify, assess and longitudinally monitor subjects who are interested in participating in this study. Participants will enroll through a platform named PaWei, and provide informed consent prior to any study activities. PaWei will collect a variety of information, including participants' demographic information, overall health, family history of Parkinson's Disease, other clinical information (clinical drug use, drug efficacy, and comorbid disorders), mood","First Affiliated Hospital, Sun Yat-Sen University, Tianjin Medical University General Hospital, Peking Union Medical College Hospital, Chinese PLA General Hospital, Shanghai Zhongshan Hospital, The First Affiliated Hospital of the Fourth Military Medical University, Afﬁliated Hospital of North Sichuan Medical College, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Changshu Hospital of Traditional Chinese Medicine, The Affiliated Hospital of Qingdao University, Guangxi Ruikang Hospital, Xi'an Central Hospital, First Affiliated Hospital of Chongqing Medical University, The First Hospital of Hebei Medical University, Jieyang People's Hospital, Luoyang Central Hospital, Taian City Central Hospital, Gansu Provincial Hospital, First Affiliated Hospital of Harbin Medical University, Daqing Oil Field Hospital, Fujian Provincial Hospital, The Affiliated Hospital of Xuzhou Medical University, Taizhou Hospital, Zhejiang Hospital, The 101st Hospital of Chinese People's Liberation Army, The First Affiliated Hospital of Zhengzhou University, The First Affiliated Hospital of Dalian Medical University, China-Japan Union Hospital, Jilin University, Wuhan No.1 Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Northern Jiangsu People's Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 5th People's Hospital, Third People's Hospital, Huzhou City, Zhejiang Province, China, Suzhou Municipal Hospital, Ningbo No. 1 Hospital, The First People's Hospital of Changzhou, Affiliated Hospital of Jiangsu University, The Second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital with Nanjing Medical University, Fujian Medical University Union Hospital, Shanghai Changzheng Hospital, Second Affiliated Hospital of Nanchang University, Jingjiang People's Hospital, Qingdao Municipal Hospital, Xi'an No.3 Hospital, Lianyungang Hospital Affiliated Bengbu Medical College, Jinzhou Medical University, Shanghai 10th People's Hospital, Huadong Hospital, No. 102 Hospital of Chinese People's Liberation Army, Shandong Provincial Hospital, Anhui Provincial Hospital, Affiliated Hospital of Guangdong Medical University",2033-09-30,ESTIMATED,N/A - N/A,100000,ESTIMATED,,OTHER,,The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China (ForPDCN),2028-09-30,ESTIMATED,Change from Baseline in the Short-Form 8-Item Parkinson's Disease Questionnaire (PDQ-8) Score,,ALL,2018-10-01,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06161701,,RECRUITING,Nephrotic Syndrome,,,,1,Blood glucose management in patients with kidney disease after using glucocorticoids,,"If steroid diabetes is not recognized in time, it will cause irreversible damage to the body. Nephropathy patients are more likely to have steroid diabetes ,the incidence rate up to 25%,due to hypoalbuminemia, high-dose hormone and other reasons, so they need to be closely followed up, identified and intervened in time.","The Third Affiliated Hospital of Wenzhou Medical University, The First People's Hospital of Xiaoshan District, Hangzhou City, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Nanxun District People's Hospital of Huzhou City，China, Wenling Traditional Chinese Medicine Hospital, Affiliated Hospital of Jiaxing University, Taizhou Hospital, The First People's Hospital of Chun'an",2027-02-28,ESTIMATED,18 Years - 75 Years,300,ESTIMATED,,OTHER,,A Study on the Influencing Factors of Glucocorticoid Induced Elevated Blood Glucose in Nephrotic Patients,2026-12-31,ESTIMATED,Incidence of steroid diabetes in nephrotic patients after glucocorticoid use,,ALL,2024-01-10,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05845372,,NOT_YET_RECRUITING,Acute Ischemic Stroke,,,,2,Stress Ulcer Prophylaxis | Control Group, | ,"Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ","Guangzhou Medical University, The Affiliated Hospital of Inner Mongolia Medical University, Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Guangxi Medical University, Fujian Medical University Union Hospital, Huizhou Municipal Central Hospital, Haikou People's Hospital, Kashgar 1st People's Hospital, Ganzhou City People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Huadu District People's Hospital of Guangzhou, Dongguan donghua hospital, Sinopharm North Hospital, Heyuan people's Hospital, Hainan People's Hospital, Hainan Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, The Second Hospital University of South China, Dongguan People's Hospital, Yueyang People's Hospital",2027-01-01,ESTIMATED,18 Years - N/A,2592,ESTIMATED,,OTHER,,"Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy: a Prospective, Multicenter, Observational Cohort Study",2027-01-01,ESTIMATED,90-day mortality after onset | Incidence of stroke-associated pneumonia,,ALL,2023-05-01,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT03653156,,RECRUITING,"Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD), Normal Control, Non-Alzheimer Degenerative Dementia",,COAST,,6,Mild cognitive impairment (MCI) and its subtypes | Sporadic Alzheimer's disease (SAD) | Familial Alzheimer's disease (FAD) | Vascular dementia(VaD） | Normal control | Non-Alzheimer degenerative dementia, |  |  |  |  | ,"The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and diagnosis and treatment status of dementia and its subtypes in China. It is of great significance to establish a relatively comprehensive national database of cognitive disorders, improve the clinical diagnosis and treatment level of cognitive disorders, and formulate preven","Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Hunan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, Zhongnan Hospital, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Afﬁliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital",2038-01-01,ESTIMATED,18 Years - N/A,100000,ESTIMATED,,OTHER,,"China Cognition and Aging Study: a Multi-center, National-wide, Longitudinal Study in China",2038-01-01,ESTIMATED,"The prevalence of MCI and AD measured using a population-based cross-sectional survey with a multistage cluster sampling design | The conversion rate of normal to MCI to AD in Chinese | The biomarkers for normal (pre-MCI), MCI and AD diagnosis | The risk factors (genetic and environmental factors) for MCI, AD and VCI at genomic and expression levels | The effective non-pharmacologic treatment(NPT) intervention",,ALL,2000-01-01,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07309705,,ACTIVE_NOT_RECRUITING,"Intracranial Atherosclerosis ICAS, Hemodynamic, Stroke",Standardized medical therapy targeting vascular risk factors and stroke prevention,CASSISS-DPR,,1,CASSISS-DPR,,"The goal of this observational study is to learn whether a digital angiography derived fractional flow reserve (DPR) measurement can improve the prediction of stroke risk in adults with symptomatic intracranial atherosclerotic stenosis, defined as 50 to 99 percent narrowing.

The main questions it aims to answer are:

Does DPR identify patients who are at higher risk of recurrent stroke despite receiving standard medical treatment? Is DPR more accurate than traditional angiographic stenosis meas","Suining Hospital of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical University, The First Affiliated Hospital of Zhengzhou University, Xuanwu Jinan Hospital, The First Affiliated Hospital of University of Science and Technology of China, First Affiliated Hospital of Chongqing Medical University, Jiangmen Central Hospital, Hebi People's Hospital, Shanghai Sixth People's Hospital Anhui Branch",2028-01-01,ESTIMATED,18 Years - 80 Years,400,ESTIMATED,,OTHER,,Digital Angiography-Based Hemodynamic Assessment for Stroke Risk Stratification in Intracranial Arterial Stenosis,2027-01-01,ESTIMATED,ischemic stroke in the qualifying artery territory or related death within 1 year after enrollment.,,ALL,2025-12-01,ACTUAL,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07278817,,NOT_YET_RECRUITING,Immune Checkpoint Inhibitor-Related Myocarditis,,,,1,ICIACI-Rehab Cohort,,"Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding the disease characteristics and recovery status of patients during the ICIACI convalescent phase. The objectives of this study are to establish a national, multicenter cohort for this patient population and to comprehensively describe their clinical profiles from an integrated Traditional Chinese and Western medicine standpoint, as well as","Weifang Hospital of Traditional Chinese Medicine, Chinese Academy of Medical Sciences, Fuwai Hospital, Second Affiliated Hospital of Nanchang University",2028-07-31,ESTIMATED,18 Years - 80 Years,340,ESTIMATED,,OTHER,,Study on the Monitoring of Traditional Chinese and Western Medicine Characteristics and Rehabilitation Program for ICIAM：A Cohort Study,2028-07-31,ESTIMATED,MACE,,ALL,2025-12-30,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT06876597,,RECRUITING,Stroke,,,RANDOMIZED,3,Motor-cognitive interactive robot-assisted training | Motor-focused robot-assisted training | Conventional rehabilitation training,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study aims to investigate the effects of motor-cognitive interactive robot-assisted training on improving upper limb motor dysfunction after stroke. By observing different combinations of motor and cognitive components in the training, the study will clarify the relationship between the proportion of motor and cognitive elements and the recovery of upper limb motor function. The goal is to optimize the training protocol for upper limb rehabilitation robots and enhance their therapeutic outc","Fujian University of Traditional Chinese Medicine Affiliated Rehabilitation Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, China Rehabilitation Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China, Shanghai Sunshine Rehabilitation Center",2026-12-31,ESTIMATED,40 Years - 80 Years,1047,ESTIMATED,PARALLEL,OTHER,SINGLE,Motor-Cognitive Interactive Upper Limb Rehabilitation Robot Intervention for Post-Stroke Motor Dysfunction: A Multicenter Randomized Controlled Study,2026-12-31,ESTIMATED,Fugl-Meyer Upper Extremity Scale,TREATMENT,ALL,2025-04-08,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05914272,,NOT_YET_RECRUITING,Stroke,Osmotic drugs,,,2,trement group | control group, | ,"Stroke remains the second leading cause of death worldwide, with 2%-8% of these being large hemispheric infarction (LHI) with an occupying effect and the worst prognosis. Even with medical and surgical treatment, the mortality of LHI with cerebral edema is as high as 20% to 30%. Current guidelines recommend supportive supervision, osmotic drugs, and decompressive hemicraniectomy (DHC) for the treatment of LHI, but not all patients with LHI are suitable for DHC, and not all of them can afford the","The Second Hospital University of South China, The Affiliated Hospital of Inner Mongolia Medical University, Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Guangxi Medical University, Fujian Medical University Union Hospital, Huizhou Municipal Central Hospital, Haikou People's Hospital, Kashgar 1st People's Hospital, Ganzhou City People's Hospital, Guangzhou Medical University, Dongguan People's Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Hainan Traditional Chinese Medicine Hospital, Hainan People's Hospital, Sinopharm North Hospital, Huadu District People's Hospital of Guangzhou, Guangdong Provincial Hospital of Traditional Chinese Medicine",2027-01-01,ESTIMATED,18 Years - N/A,2592,ESTIMATED,,OTHER,,"Association of Osmotic Drugs With Clinical Outcomes in Acute Large Hemispheric Infarction: a Prospective, Multicenter, Observational Cohort Study",2027-01-01,ESTIMATED,90-day mortality | Incidence of acute renal impairment,,ALL,2023-07-01,ESTIMATED,OBSERVATIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT05470777,PHASE2,RECRUITING,B-cell Acute Lymphoblastic Leukemia,,,,1,CD22/CD19 CAR T and auto-HSCT sandwich strategy as consolidation therapy for B-ALL,EXPERIMENTAL,"Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, relapse after CAR-T has been a major issue. Multi-antigen CAR T and combination with other regimens may reduce the relapse rate. The investigators first conducted CD22/CD19 CAR T-cells and auto-HSCT ""sandwich "" strategy as consolidation therapy in patients with B-ALL. The main Purpose of this study was to observe the safety and efficacy of this new strategy.","National Natural Science Foundation of China(Grant No. 81970138), Jiangsu Province Natural Science Foundation of China (Grant No. BK20210091), Jining Medical University, The Second People's Hospital of Huai'an, The First Affiliated Hospital of Bengbu Medical University, Northern Jiangsu People's Hospital, Affiliated Hospital of Nantong University, Suzhou Hospital of Traditional Chinese Medicine",2039-07-21,ESTIMATED,15 Years - 65 Years,37,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Safety and Efficacy of CD22/CD19 CAR T-cells and Autologous HSCT Sandwich Strategy as Consolidation Therapy for B-cell Acute Lymphoblastic Leukemia,2026-07-21,ESTIMATED,Overall survival (OS),TREATMENT,ALL,2020-01-19,ACTUAL,INTERVENTIONAL
CHIZF,China Traditional Chinese Medicine Holdings Co. Limited,NCT07277686,,RECRUITING,"Coronary Artery Disease (CAD), Artificial Intelligence Algorithms, Face, Screening",,,,2,Diagnostic Test Cohort | Real-world Observational Cohort, | ,"This study aims to evaluate the effectiveness of this facial image-based AI algorithm for screening CAD in high-risk community populations (specifically individuals with diabetes, hypertension, or aged over 65). The main objectives are:

1. To verify if the AI algorithm can accurately distinguish between high-risk and low-risk groups by comparing the actual prevalence of CAD in these groups.
2. To compare the CAD detection rate using this AI screening strategy against the natural detection rate ","Zhoukou Specialized Disease Hospital, Zhoukou Chuanhui District Hospital of Traditional Chinese Medicine, Chinese Academy of Medical Sciences, Fuwai Hospital, Zhoukou Central Hospital",2026-08-01,ESTIMATED,18 Years - N/A,1392,ESTIMATED,,OTHER_GOV,,AI Facial Analysis Algorithm to Screening Coronary Artery Disease in High-Risk Community Population,2026-04-01,ESTIMATED,Difference in Prevalence of CAD Between AI-Stratified High-Risk and Low-Risk Groups,,ALL,2025-12-11,ACTUAL,OBSERVATIONAL
CLBPF,"Caliway Biopharmaceuticals Co., Ltd.",NCT07140939,PHASE3,NOT_YET_RECRUITING,Subcutaneous Fat,CBL-514 Injection,SUPREME-01,RANDOMIZED,2,CBL-514 injection | Injectable 0.9% Sodium Chloride solution,EXPERIMENTAL | PLACEBO_COMPARATOR,"A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.",,2026-09,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.",2026-07,ESTIMATED,Percentage of participants with at least 13% abdominal fat change and at least a 2-grade improvement on Patient Reported Abdominal Fat Rating Scale (PR-AFRS) in the CBL-514 group versus the placebo group.,TREATMENT,ALL,2025-09,ESTIMATED,INTERVENTIONAL
CLBPF,"Caliway Biopharmaceuticals Co., Ltd.",NCT06303570,PHASE2,RECRUITING,Dercum's Disease,"CBL-514 injection, 0.9% Sodium chloride",,RANDOMIZED,2,CBL-514 injection | 0.9% Sodium Chloride,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.",,2026-04,ESTIMATED,18 Years - 64 Years,20,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Single-Blind, Placebo-Control, Randomized Phase 2 Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas",2026-03,ESTIMATED,"To estimate the treatment effect, as measured by Partial Response (PR), between CBL-514 and placebo in participants with Dercum's disease (DD).",TREATMENT,ALL,2024-11-27,ACTUAL,INTERVENTIONAL
CLVLY,Clinuvel Pharmaceuticals Limited,NCT06109649,PHASE3,ACTIVE_NOT_RECRUITING,Vitiligo,Afamelanotide and NB-UVB Light,,RANDOMIZED,2,Afamelanotide and NB-UVB Light | NB-UVB Light,EXPERIMENTAL | OTHER,The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.,,2026-06,ESTIMATED,12 Years - N/A,200,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo",2025-12,ESTIMATED,Percentage of patients achieving T-VASI 50 on the body,TREATMENT,ALL,2023-10-11,ACTUAL,INTERVENTIONAL
CPHGF,Consun Pharmaceutical Group Limited,NCT07021157,PHASE1,RECRUITING,Chronic Kidney Disease(CKD),"SK-08, Placebo",SK-08,RANDOMIZED,2,SK-08 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The trial is conducted in a single-center, randomized, double-blind, placebo-controlled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) ,and pharmacodynamics (PD) characteristics of SK-08 in healthy participants.",,2025-08-07,ESTIMATED,18 Years - 45 Years,48,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Single-dose Increasing of SK-08 Tablets in Healthy Participants",2025-08-07,ESTIMATED,Safety Evaluation,TREATMENT,ALL,2025-03-09,ACTUAL,INTERVENTIONAL
CPHGF,Consun Pharmaceutical Group Limited,NCT07267026,PHASE1,NOT_YET_RECRUITING,"FSGS, MCD","SK-09, Placebo",,RANDOMIZED,2,SK-09 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 1 trial consists of two parts: Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study. Both parts adopt a randomized, double-blind, placebo-controlled design.",,2026-08-31,ESTIMATED,18 Years - 55 Years,72,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of SK-09 in Healthy Adult Participants",2026-08-31,ESTIMATED,Safety Evaluation,TREATMENT,ALL,2025-12-15,ESTIMATED,INTERVENTIONAL
DMPHF,Dermapharm Holding SE,NCT07096440,,NOT_YET_RECRUITING,"Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus",,NOVUS-UP,,0,,,"The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.

Novo-Helisen Depot is an approved allergen immunotherapy used to treat allergies to house dust mites. For allergen immunotherapy, it is important that the allergen dose is gradually increased, a process known as up-dosing to induce immune tolerance to the allergen. The recently approved One Strength up-dosing scheme for Novo-Helisen Depot allows ",,2026-06-30,ESTIMATED,5 Years - N/A,105,ESTIMATED,,INDUSTRY,,"NOVo-Helisen Depot HoUSe Dust Mites - A Prospective, Multicenter, Noninterventional Clinical Study on the Tolerability and Safety of Short One Strength UP-dosing in Children, Adolescents, and Adults in Daily Practice",2026-06-30,ESTIMATED,Safety of the One Strength dose escalation scheme in daily practice | Tolerability of the One Strength dose escalation scheme in daily practice,,ALL,2025-07-30,ESTIMATED,OBSERVATIONAL
DMPHF,Dermapharm Holding SE,NCT06778213,PHASE4,RECRUITING,Allergic Rhinoconjunctivitis,NovoHelisen Depot,RANSES,RANDOMIZED,2,verum | placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,The main objective of the study is to measure and correlate clinical parameters suitable for the assessment of allergen immunotherapy (AIT) with an aluminum hydroxide-adsorbed preparation of house dust mite (Dermatophagoides pteronyssinus/ Dermatophagoides farinae) allergens in adults with moderate to severe allergic rhinitis/rhinoconjunctivitis with or without controlled allergic bronchial asthma caused by house dust mite (HDM) allergens. The assessment of clinical responses will be evaluated f,"ALL-MED Medical Research Institute, Wroclaw, Poland, Allergopharma GmbH & Co. KG",2026-12-01,ESTIMATED,18 Years - 65 Years,67,ESTIMATED,PARALLEL,OTHER,DOUBLE,A Randomized Placebo-controlled Double-blind Clinical Study for Evaluation of the Efficacy of Allergen-specific Immunotherapy Using Clinical and Biomarker Assessment in an Allergen Exposure Chamber and During Natural Exposure in Patients With House Dust Mite-triggered Allergic Rhinoconjunctivitis RANSES,2026-04-02,ESTIMATED,Total nasal symptom score,TREATMENT,ALL,2024-11-02,ACTUAL,INTERVENTIONAL
ELTP,"Elite Pharmaceuticals, Inc.",NCT06986317,,RECRUITING,"Trigger Point Pain, Myofascial",,,RANDOMIZED,2,positional release technique | graston technique,EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of the study is to evaluate comparative effectiveness of positional release techniques and graston technique In trapezius trigger point,,2025-07-12,ESTIMATED,18 Years - 55 Years,34,ESTIMATED,PARALLEL,OTHER,NONE,Effectiveness of Positional Release Techniques and Graston Technique In Trapezius Trigger Point,2025-07-12,ESTIMATED,Visual Analogue Scale | Neck Disability Index,TREATMENT,ALL,2025-04-27,ACTUAL,INTERVENTIONAL
EVMN,"Evommune, Inc.",NCT06873516,PHASE2,RECRUITING,Chronic Spontaneous Urticaria,"EVO756, EVO756, EVO756, Placebo control",,RANDOMIZED,4,Dose 1 | Dose 2 | Dose 3 | Placebo control,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).,,2026-05,ESTIMATED,18 Years - N/A,160,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria",2026-05,ESTIMATED,Mean change from baseline in UAS7,TREATMENT,ALL,2025-03-20,ACTUAL,INTERVENTIONAL
EVMN,"Evommune, Inc.",NCT07150845,PHASE2,RECRUITING,Atoptic Dermatitis,"EVO756, EVO756, EVO756, Placebo control",,RANDOMIZED,4,Dose 1 | Dose 2 | Dose 3 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.,,2026-07,ESTIMATED,18 Years - N/A,120,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis",2026-07,ESTIMATED,Percentage change in Eczema Area and Severity Index (EASI) from Baseline,TREATMENT,ALL,2025-08-26,ACTUAL,INTERVENTIONAL
EVMN,"Evommune, Inc.",NCT06645821,EARLY_PHASE1,RECRUITING,Hidradenitis Suppurativa (HS),EVO101,,,1,Open label EVO101 topical cream 0.1%,EXPERIMENTAL,"The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are:

Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit.

What medical problems do participants have when applying drug EVO101 Does a participant perceive a change in their hidradenitis suppurativa symptoms based on patient reported outcome questionnaires.

Participants will:

A","Evommune, Inc.",2025-05,ESTIMATED,18 Years - N/A,15,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Open-label, Investigator-initiated, Single-site Proof of Concept Trial Evaluating EVO101 in Adult Subjects with Mild to Moderate Hidradenitis Suppurativa.",2025-03,ESTIMATED,The efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO) | The efficacy of EVO101 on hidradenitis suppurativa will be evaluated using two parameters: decrease in lesion count and change in patient reported outcomes (PRO),TREATMENT,ALL,2024-12-03,ACTUAL,INTERVENTIONAL
GERNW,Geron Corporation WT EXP 123125,NCT05583552,PHASE2,ACTIVE_NOT_RECRUITING,"Myelodysplastic Syndromes, Acute Myeloid Leukemia",Imetelstat sodium,IMpress,,1,Single-arm imetelstat,EXPERIMENTAL,"The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.","Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group",2026-06,ESTIMATED,18 Years - N/A,46,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy,2025-09-30,ESTIMATED,Overall Hematological Response Rate of Participants after Treatment with Imetelstat,TREATMENT,ALL,2023-06-05,ACTUAL,INTERVENTIONAL
GERNW,Geron Corporation WT EXP 123125,NCT05371964,PHASE1,RECRUITING,Myelofibrosis,"Imetelstat sodium, Ruxolitinib",,,2,Part 1: Imetelstat sodium + Ruxolitinib | Part 2: Imetelstat sodium + Ruxolitinib,EXPERIMENTAL | EXPERIMENTAL,"The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib in participants with MF in Part 2.",,2028-08,ESTIMATED,18 Years - N/A,36,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis",2027-02,ESTIMATED,"Part 1: Incidence, Type, and Severity of Adverse Events, Including Dose-limiting Toxicity (DLT) During the DLT Observation Period and/or Study Treatment | Part 2: Number of Participants With Treatment-emergent Adverse Event (AE) | Part 2: Symptom Response Rate at Week 24",TREATMENT,ALL,2022-05-04,ACTUAL,INTERVENTIONAL
GERNW,Geron Corporation WT EXP 123125,NCT07320235,PHASE1,RECRUITING,Relapsed Acute Myeloid Leukemia,"Imetelstat, Azacitidine, Venetoclax",IMAGINE,NON_RANDOMIZED,2,Part A Safety Run-In phase: Imetelstat in combination with Azacitidine | Part B Combination Therapy: Imetelstat in combination with Azacitidine with or without Venetoclax,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML. The trial will consist of a safety run-in phase (Part A) employing a 3+3 design to monitor dose-limiting toxicities of imetelstat when administered in combination with a fixed dose of azacitidine. Part B will consist of a phase 1b trial employing a BOIN12 design to determine the optimal biological dose of,Geron Corporation,2035-06-15,ESTIMATED,18 Years - N/A,36,ESTIMATED,SEQUENTIAL,OTHER,NONE,IMetelstat and Azacitidine With or Without Venetoclax GIveN in rElapsed Acute Myeloid Leukemia (IMAGINE Trial),2030-06-17,ESTIMATED,Dose Limiting Toxicity (DLT),TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
GERNW,Geron Corporation WT EXP 123125,NCT04576156,PHASE3,ACTIVE_NOT_RECRUITING,Myelofibrosis,"Imetelstat, Best Available Therapy (BAT)",,RANDOMIZED,2,Imetelstat | Best Available Therapy (BAT),EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.,,2028-06-30,ESTIMATED,18 Years - N/A,327,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor",2028-06-30,ESTIMATED,Overall survival (OS),TREATMENT,ALL,2021-04-12,ACTUAL,INTERVENTIONAL
GERNW,Geron Corporation WT EXP 123125,NCT06247787,PHASE1,RECRUITING,"Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia","Cytarabine, Fludarabine, Hydrocortisone Sodium Succinate, Imetelstat, Leucovorin Calcium, Methotrexate",,,1,"Treatment (Imetelstat, fludarabine, cytarabine)",EXPERIMENTAL,"This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs","Geron Corporation, National Cancer Institute (NCI)",2026-06-30,ESTIMATED,1 Year - 18 Years,36,ESTIMATED,SEQUENTIAL,NETWORK,NONE,A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy,2026-06-30,ESTIMATED,Dose limiting toxicities of imetelstat administered in combination with fludarabine and cytarabine,TREATMENT,ALL,2025-02-04,ACTUAL,INTERVENTIONAL
GERNW,Geron Corporation WT EXP 123125,NCT02598661,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,Myelodysplastic Syndromes,"Imetelstat Sodium, Placebo",,RANDOMIZED,7,Phase 2: Imetelstat Sodium | Phase 3: Imetelstat Sodium | Phase 3: Placebo | QTc Substudy: Imetelstat Sodium | QTc Substudy: Placebo | Extension Phase: Imetelstat Sodium | Extension Phase: Extended Follow-up,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment in Phase 2 study and to compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat sodium to placebo in transfusion-dependent participants with low or intermediate-1 risk MDS that is relapsed/",,2026-10-13,ESTIMATED,18 Years - N/A,289,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,2023-10-13,ACTUAL,Phase 2: Percentage of Participants Without Any Red Blood Cell (RBC) Transfusion During Any Consecutive 8-Weeks Period (All Participants) | Phase 2: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks Period in Target Population | Phase 3: Percentage of Participants Without Any RBC Transfusion During Any Consecutive 8-Weeks Period,TREATMENT,ALL,2016-01-12,ACTUAL,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT05905172,PHASE3,RECRUITING,Liver Fibrosis,"Hydronidone capsules, The placebo capsules",,RANDOMIZED,2,Hydronidone group | The placebo group,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is a Phase IIIb extension trial following the ""A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase III Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B"".

The main objective of this study is to evaluate the effectiveness and the safety of hydronidone capsules for long-term treatment of patients with chronic viral hepatitis B liver fibrosis.",,2028-10-20,ESTIMATED,18 Years - 65 Years,248,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase IIIb Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated With Chronic Hepatitis B",2028-06-20,ESTIMATED,Cumulative incidence of clinical endpoint events (defined as the occurrence of any clinical endpoint event).,TREATMENT,ALL,2023-08-12,ACTUAL,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07412236,PHASE3,NOT_YET_RECRUITING,"Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B","Hydronidone (270mg), Hydronidone (Placebo Group)",,RANDOMIZED,2,Hydronidone Capsule Group (270 mg) | Hydronidone Capsule Group (Placebo Group),EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy. It aims to evaluate the clinical benefits of Hydronidone Capsules in patients with liver fibrosis due to chronic hepatitis B. The study consists of a Screening/Baseline Period (4 weeks) and a Dosing/Observation Period (planned duration of 5 years, including a 52-week primary treatment phase and a 208-week long-term treatment phase).","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",2028-12-30,ESTIMATED,18 Years - 65 Years,1208,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIIc Clinical Study Evaluating the Long-term Treatment of Hepatic Fibrosis in Chronic Hepatitis B With Hydronidone Capsules.",2028-12-30,ESTIMATED,Incidence of Clinical Endpoint Events,TREATMENT,ALL,2026-01-30,ESTIMATED,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07263152,PHASE1,NOT_YET_RECRUITING,Hepatic Fibrosis,"Hydronidone, Placebo",,RANDOMIZED,6,Group A1 | Placebo Group A1 | Group A2 | Placebo Group A2 | Group A3 | Placebo Group A3,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study was designed with three dose cohorts (A1-A3): a 90 mg cohort, a 270 mg cohort, and a 540 mg cohort. Each cohort enrolled 16 healthy Chinese participants, with 12 receiving the investigational product Hydronidone Capsules and 4 receiving placebo (i.e., matching placebo for Hydronidone Capsules). A total of 48 healthy Chinese subjects were planned for enrollment, and all participants received a single dose under fasting conditions.",,2026-01-30,ESTIMATED,18 Years - 50 Years,48,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Effect of Single-Dose Hydronidone Capsules on QTc Interval in Chinese Healthy Subjects",2026-01-30,ESTIMATED,The relationship between plasma drug concentration and placebo-corrected change from baseline in QTc interval (ΔΔQTc) following single-dose administration of Hydroxynidone Capsules,TREATMENT,ALL,2025-12-01,ESTIMATED,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT05288179,PHASE3,RECRUITING,Pneumoconiosis,"Pirfenidone Capsules, placebo capsules",,RANDOMIZED,2,Pirfenidone group | placebo group,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is a randomized, double-blind, placebo-controlled, multicenter clinical study.

The main purpose of this study was to confirm the efficacy and safety of pirfenidone capsules in the treatment of pneumoconiosis.",,2026-09-30,ESTIMATED,18 Years - 70 Years,272,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial of Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis",2026-09-30,ESTIMATED,Changes in pulmonary function FVC%,TREATMENT,ALL,2022-06-07,ACTUAL,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07388680,"PHASE2, PHASE3",NOT_YET_RECRUITING,"Radiation-induced Lung Injury, Immune-related Pneumonia","Pirfenidone Capsules （400 mg）, Pirfenidone Capsules（600mg）, Pirfenidone Capsules（0mg）",,RANDOMIZED,3,Low-dose group | High-dose group | Placebo group,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"Radiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %. Multiple studies have shown that RILI can adversely affect patient prognosis by disrupting treatment schedules. Moreover, the widespread clinical use of immune-checkpoint inhibitors (ICIs) has further increased pulmonary toxicity when radiotherapy (RT) is combined with ICIs. Checkpoint-inhibitor-related pneumonitis (CIP)-i.e., immune-mediated lung injury-may ne",Sun Yat-sen University,2026-10-30,ESTIMATED,18 Years - 75 Years,298,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Efficacy and Safety of Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune-related Pneumonia",2026-10-30,ESTIMATED,Phase II and Phase III: The absolute value of the change in the predicted percentage of lung carbon monoxide diffusion capacity (DLCO% predicted) from the baseline at week 24.,TREATMENT,ALL,2026-02-28,ESTIMATED,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07394309,PHASE1,NOT_YET_RECRUITING,Liver Fibrosis,Hydronidone capsules,,NON_RANDOMIZED,3,"Group One A(mild hepatic impairment group) | Group Two B(moderate hepatic impairment group) | Group Three C（control group, normal hepatic function group）",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal hepatic function matched for sex, age, and BMI. The administration method is a single oral dose of 90 mg hydroxynidone capsules under fasting conditions.

Participants meeting the inclusion criteria with corresponding degrees of hepatic impairment and those with normal hepati",The First Affiliated Hospital of Bengbu Medical University,2026-10-30,ESTIMATED,18 Years - 75 Years,30,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Phase I Pharmacokinetic Study of Hydronidone Capsules in Patients With Varying Degrees of Hepatic Impairment and Normal Hepatic Function.,2026-02-15,ESTIMATED,Pharmacokinetic Parameter of Hydronidone: Cmax | Pharmacokinetic Parameter of Hydronidone: AUC0-t | Pharmacokinetic Parameter of Hydronidone:AUC0-∞ | Pharmacokinetic Parameter of Hydronidone:Tmax | Pharmacokinetic Parameter of Hydronidone:t1/2 | Pharmacokinetic Parameter of Hydronidone:λz | Pharmacokinetic Parameter of Hydronidone:CL/F | Pharmacokinetic Parameter of Hydronidone:MRT | Pharmacokinetic Parameter of Hydronidone:Vz/F | Pharmacokinetic Parameter of Hydronidone:Ratio of free drugsRatio of free drugs | Difference in the main parameters AUC₀-t between patients with hepatic impairment and participants with normal hepatic function. | Difference in the main parameters AUC₀-∞ between patients with hepatic impairment and participants with normal hepatic function. | Difference in the main parameters Cmax between patients with hepatic impairment and participants with normal hepatic function.,TREATMENT,ALL,2026-02-15,ESTIMATED,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07262346,PHASE1,NOT_YET_RECRUITING,Liver Fibrosis,"Hydronidone capsules, Placebo capsules",,RANDOMIZED,13,SAD:180mg drug group | SAD:120mg drug group | SAD:240mg drug group | SAD:300mg drug group | SAD:360mg drug group | SAD:420mg drug group | MAD: drug group1 (dosage to be determined) | MAD: drug group 2 (dosage to be determined) | MAD: drug group 3 (dosage to be determined) | Study on the Interaction between Food and Drugs:drug group1 (dosage to be determined) | Study on the Interaction between Food and Drugs:drug group2 (dosage to be determined) | SAD:Placebo group | MAD:Placebo group,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"Based on the Phase I (Ia, Ib, Ic) clinical pharmacokinetic study of Hydronidone Capsules, a clinical pharmacokinetic trial of Hydronidone Capsules (specification: 30 mg/capsule) was conducted, including single-dose administration, multiple-dose administration, and a food-effect study. The aim was to investigate the safety, tolerability, and pharmacokinetic characteristics of higher doses of Hydronidone Capsules (specification: 30 mg/capsule) in healthy subjects, in preparation for future expansi","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2026-05-05,ESTIMATED,18 Years - 45 Years,138,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Clinical Pharmacokinetic Study of Hydronione Capsules in Healthy Chinese Subjects (Ⅰd),2026-05-05,ESTIMATED,SAD :Blood drug PK parameters(Cmax) | SAD:Blood drug PK parameters（Tmax） | SAD:Blood drug PK parameters（AUC0-t） | SAD:Blood drug PK parameters( t1/2) | SAD:Blood drug PK parameters(AUC0-∞) | SAD:Blood drug PK parameters(λz) | SAD:Blood drug PK parameters(Vd/F) | SAD:Blood drug PK parameters(CL/F) | SAD:Blood drug PK parameters(AUC_%Extrap) | SAD:Blood drug PK parameters(MRT) | MAD:Blood drug PK parameters(ss) | MAD :Blood drug PK parameters(Cmax) | MAD:Blood drug PK parameters（Tmax） | MAD:Blood drug PK parameters（AUC0-t） | MAD:Blood drug PK parameters( t1/2) | MAD:Blood drug PK parameters(AUC0-∞) | MAD:Blood drug PK parameters(λz) | MAD:Blood drug PK parameters(Vd/F) | MAD:Blood drug PK parameters(CL/F) | MAD:Blood drug PK parameters(AUC_%Extrap) | MAD:Blood drug PK parameters(MRT) | The influence of food on the parameters of single-dose pharmacokinetics(Tlag) | The influence of food on the parameters of single-dose pharmacokinetics(Cmax) | The influence of food on the parameters of single-dose pharmacokinetics(Tmax) | The influence of food on the parameters of single-dose pharmacokinetics(AUC0-t) | The influence of food on the parameters of single-dose pharmacokinetics(AUC0-∞),TREATMENT,ALL,2025-12-05,ESTIMATED,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07262333,PHASE1,RECRUITING,Renal Insufficiency Chronic,Hydronidone capsules,,NON_RANDOMIZED,4,Control group (healthy individuals) | The group of patients with mild renal insufficiency(eGFR 60~89 mL/min) | The group of patients with moderate renal insufficiency(eGFR 30~59 mL/min) | The group of patients with severe renal insufficiency(eGFR 15~29 mL/min),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally. The applicant has completed the preliminary Phase I and Phase II clinical trials. The results showed that Hydronidone is a safe and effective drug for treating liver fibrosis in chronic hepatitis B, and it has good safety and tolerability.

Based on the preliminary clinical research, a special population study has been initiated. The aim","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",2026-07-01,ESTIMATED,18 Years - 70 Years,56,ESTIMATED,PARALLEL,INDUSTRY,NONE,Safety and Pharmacokinetics of Single-dose Hydroxynidone Capsules in Patients With Renal Insufficiency,2026-07-01,ESTIMATED,The plasma drug concentrations of hydronidone and its metabolites M3 and M4(AUC0-∞) | The free plasma concentration of hydronidone | The urine drug concentrations of hydronidone and its metabolites M3 and M4 | The plasma drug concentrations of hydronidone and its metabolites M3 and M4(AUC%Extrap) | The plasma drug concentrations of hydronidone and its metabolites M3 and M4( AUC0-t) | The plasma drug concentrations of hydronidone and its metabolites M3 and M4(CL/F) | The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Vd/F) | The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Cmax) | The plasma drug concentrations of hydronidone and its metabolites M3 and M4(T1/2) | The plasma drug concentrations of hydronidone and its metabolites M3 and M4(λz) | The plasma drug concentrations of hydronidone and its metabolites M3 and M4(Tmax),OTHER,ALL,2025-12-25,ACTUAL,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07417553,PHASE2,NOT_YET_RECRUITING,Chronic Hepatitis B-related Liver Fibrosis,Hydronidone capsules,,,1,Hydronidone Capsule Group (270 mg),EXPERIMENTAL,"This trial employs a single-arm, open-label, multicenter clinical trial design. All study participants who meet the inclusion/exclusion criteria will receive Hydronidone treatment for 4 weeks. The study includes a screening period (up to 21 days) to assess the eligibility of participants. Eligible participants will enter the treatment period and receive Hydronidone capsules at a dosage of 270 mg TID (30 mg/capsule, 3 capsules each time, three times daily, taken orally half an hour before meals) ",The Second Affiliated Hospital of Chongqing Medical University,2026-07-30,ESTIMATED,18 Years - 70 Years,150,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis",2026-07-30,ESTIMATED,Incidence of adverse events (AEs) and serious adverse events (SAEs). | Severity of adverse events (AEs) and serious adverse events (SAEs).,TREATMENT,ALL,2026-03-15,ESTIMATED,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07343778,PHASE3,NOT_YET_RECRUITING,Chronic Hepatitis B With Hepatic Fibrosis,Hydronidone Capsules,,,1,Hydronitone Capsules group,EXPERIMENTAL,"This is a single-arm, multicenter, open-label Phase III clinical trial to evaluate the safety and tolerability of high-dose hydronidone capsules in patients with hepatic fibrosis and cirrhosis. Eligible participants will be sequentially enrolled to receive hydronidone capsules 120 mg three times daily (TID) for 28 consecutive days. Participants will return to the hospital on Day 28 after the first dose for a follow-up safety assessment. All adverse events (AEs) and concomitant medications must b",,2026-10-30,ESTIMATED,18 Years - N/A,300,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Single-Arm, Open-Label, Multicenter Phase III Clinical Trial to Evaluate the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis",2026-10-30,ESTIMATED,Any adverse events occurring in study participants following drug administration.,TREATMENT,ALL,2026-01-20,ESTIMATED,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT06899815,PHASE1,RECRUITING,Pulmonary Hypertension,F230 tablets,,RANDOMIZED,3,SAD single dose group | MAD multiple dose group | Research on the effects of food on drugs,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"F230 is a new Class 1 chemical drug jointly developed by Beijing Contini Pharmaceutical Co., Ltd. for the treatment of pulmonary hypertension (Notification number: 2024LP01242, 2024LP01243). The in vitro activity and in vivo toxicology tests of F230, the lead compound for the treatment of PAH developed by Beijing Contini Pharmaceutical Co., LTD., showed that F230 had the same in vitro activity as the endothelin antagonist on the market. The pharmacodynamics of F230 in rats with nephrogenic hyper",,2026-07-01,ESTIMATED,18 Years - 45 Years,136,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of Single and Multiple Administration of F230 Tablets in Healthy Adult Volunteers",2026-07-01,ESTIMATED,"Single dose:PK parameters: Cmax | Single dose:PK parameters: Tmax | Single dose:PK parameters: AUC0-t | Single dose:PK parameters: AUC0-∞ | Single dose:PK parameters: t1/2 | Single dose:PK parameters: λz | Single dose:PK parameters: Vz/F | Single dose:PK parameters: CL/F | Single dose:PK parameters: AUC_%Extrap | Single dose:PK parameters: MRT | Single dose:PK parameters: Ae_u (t1-t2) | Single dose:PK parameters: Ae_u (0-t) | Single dose:PK parameters: Rate_u (max) | Single dose:PK parameters:Fe_u (0-t) | Multiple administration: PK parameters:Cmax,ss | Multiple administration: PK parameters:Tmax,ss | Multiple administration: PK parameters: AUC0-τ,ss | Multiple administration: PK parameters: AUC0-t | Multiple administration: PK parameters: AUC0-∞ | Multiple administration: PK parameters:Cmin,ss | Multiple administration: PK parameters: Cav,ss | Multiple administration: PK parameters: t1/2 | Multiple administration: PK parameters: λz | Multiple administration: PK parameters: CLss/F | Multiple administration: PK parameters: AUC_%Extrap | Multiple administration: PK parameters: MRT | Multiple administration: PK parameters: DF | Multiple administration: PK parameters: Rac | Effects of food on single pharmacokinetic parameters: Cmax | Effects of food on single pharmacokinetic parameters: Tmax | Effects of food on single pharmacokinetic parameters: AUC",TREATMENT,ALL,2025-05-15,ACTUAL,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT05704166,PHASE2,RECRUITING,"Acute Lung Injury, Prevention",Pirfenidone/Placebo,,RANDOMIZED,2,Pirfenidone | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The incidence of chest CT manifestations of lung injury after radiotherapy for breast cancer is more than 50%. Although the prognosis and quality of life of patients are rarely affected, it is still necessary to prevent the occurrence of minor radiation lung injury with the use of more novel drugs and subsequent salvage treatment may aggravate the radiation injury. This study intends to conduct a randomized, double-blind, single-center clinical study of pirfenidone versus placebo in the preventi","Beijing Continent Pharmaceutical Co, Ltd.",2026-05-31,ESTIMATED,18 Years - 75 Years,214,ESTIMATED,PARALLEL,OTHER,DOUBLE,"Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating",2025-12-31,ESTIMATED,Changes in lung injury grading on chest computerized tomography within 3 months after radiotherapy,PREVENTION,FEMALE,2023-03-16,ACTUAL,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT05689645,PHASE2,RECRUITING,"Acute Liver Failure, Acute-On-Chronic Liver Failure","F573 for injection, Sterilizing water for injection",,RANDOMIZED,2,F573 for injection groups | Placebo Comparator,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial .

The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury (DILI), chronic hepatitis B (CHB), intrahepatic cholestatic liver injury, etc.).",,2026-09-01,ESTIMATED,18 Years - 60 Years,97,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"F573 for Injection for the Treatment of Liver Injury/Failure : Randomized, Double-blind, Placebo-controlled Phase Ⅱa Clinical Trial",2026-09-01,ESTIMATED,"Adverse events (AE), serious adverse events (SAE) | Adverse events (AE), serious adverse events (SAE) | clinical laboratory tests ：blood routine | clinical laboratory tests ：blood routine | clinical laboratory tests ：blood biochemistry | clinical laboratory tests ：blood biochemistry | clinical laboratory tests : urine routine | clinical laboratory tests : urine routine | clinical laboratory tests ：blood coagulation function | clinical laboratory tests ：blood coagulation function | 12-lead electrocardiogram (ECG) | 12-lead electrocardiogram (ECG) | All-cause mortality | All-cause mortality",TREATMENT,ALL,2023-03-24,ACTUAL,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07295873,PHASE1,NOT_YET_RECRUITING,"Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)","Entecavir, Tenofovir Disoproxil Fumarate（TDF）, Tenofovir alafenamide（TAF）, Tenofovir Amibufenamide(TMF)",,NON_RANDOMIZED,4,Queue 1: Drug-Drug Interaction Study of Hydronidone Capsules and Entecavir | Queue 2: Drug-Drug Interaction Study of honyinone capsules and Tenofovir Disoproxil Fumarate; | Drug-Drug Interaction Study of Fuzuloprim Capsules with Tenofovir Alafenamide | Queue 4: Drug-Drug Interaction Study of Hydronidone Capsules and Tenofovir Amibufenamide,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The proposed indication for Hydronidone Capsules is chronic hepatitis B-associated liver fibrosis, which in clinical practice typically requires concomitant use with antiviral agents for chronic hepatitis B. The commonly used chronic hepatitis B antiviral agents include Entecavir, Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF), and Tenofovir Amibufenamide (TMF).

This study aims to evaluate the drug-drug interaction (DDI) of Hydronidone Capsules 90 mg with Entecavir, Tenofovir ",,2026-06-30,ESTIMATED,18 Years - 50 Years,64,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Single-Center, Open-Label, Single-Arm, Self-Controlled Phase I Clinical Study to Evaluate Drug-Drug Interactions of Hydronidone With Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide in Healthy Chinese Subjects",2026-06-30,ESTIMATED,"Plasma hydronidone PK parameters of hydronidone capsules : steady-state peak concentration (Cmax,ss); | Plasma hydronidone PK parametersof hydronidone capsules : Area under the plasma concentration-time curve from time zero to 24 hours at steady state (AUC0-24h,ss) | Primary PK parameters of plasma of entecavir : AUC0-24h,ss. | Primary PK parameters of plasma of entecavir : Cmax,ss . | Primary PK parameters of plasma tenofovir alafenamide (TAF) : AUC0-24h,ss. | Primary PK parameters of plasma tenofovir alafenamide (TAF) : Cmax,ss . | Primary PK parameters of tenofovir disoproxil fumarate tablets (TDF): Cmax,ss . | Primary PK parameters of tenofovir disoproxil fumarate tablets (TDF): AUC0-24h,ss. | Primary PK parameters of plasma tenofovir amibufenamide (TMF) : Cmax,ss . | Primary PK parameters of plasma tenofovir amibufenamide (TMF) : AUC0-24h,ss.",TREATMENT,ALL,2025-12-30,ESTIMATED,INTERVENTIONAL
GNIIF,GNI Group Ltd.,NCT07364448,PHASE2,NOT_YET_RECRUITING,Chronic Hepatitis B With Hepatic Fibrosis,Hydronidone capsules,,,1,Hydronidone Capsule Group,EXPERIMENTAL,"This is an open-label, single-arm study designed to collect safety data on hydronidone capsules in patients with chronic hepatitis B virus infection accompanied by liver fibrosis or fatty liver disease accompanied by liver fibrosis .

Approximately 200 subjects will be enrolled, all of whom will receive hydronidone capsules three times daily, with three capsules per dose, resulting in a total daily treatment dose of 270 mg. The medication will be administered orally half an hour before meals for",The First Hospital of Jilin University,2026-08-30,ESTIMATED,18 Years - N/A,200,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Single-arm Clinical Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis",2026-07-30,ESTIMATED,Any adverse events occurring in study participants following drug administration.,TREATMENT,ALL,2026-01-30,ESTIMATED,INTERVENTIONAL
HAWPY,Haw Par Corporation Limited,NCT06899308,,RECRUITING,"Social Isolation or Loneliness, Anxiety, Anxiety Depression (Mild or Not Persistent), Health Behavior, Observational Study, Stress, Psychological, Emotional Stress, Life Stress, Psychological Stress, Stress, Emotional, Stress (Psychology), Substance Abuse, Substance Addiction, Substance Dependence, Substance Use",,CUB-HS2025,,1,students,,"The aim of Health Surveillance is to analyze and describe the state of health of students at Constructor University, key influencing factors and individual resources by using mixed-method design.",Hamburg University of Applied Sciences/Hochschule für Angewandte Wissenschaften Hamburg (HAW Hamburg),2026-12-31,ESTIMATED,18 Years - N/A,363,ESTIMATED,,OTHER,,Health Surveillance at Constructor University Bremen (CUB) to Assess Students' and HAW-Hamburg Employees' Health and Wellbeing - Explanatory Sequential Mixed-Methods Approach,2026-06-30,ESTIMATED,Loneliness | Health literacy,,ALL,2025-03-17,ACTUAL,OBSERVATIONAL
HAWPY,Haw Par Corporation Limited,NCT07089914,,ACTIVE_NOT_RECRUITING,"Social Isolation or Loneliness, Anxiety, Anxiety Acute, Anxiety Depression, Health Behavior, Health Behavior Change, Observational Study, Working Adults, Conditions Influencing Health Status, Anxiety Depression (Mild or Not Persistent), Social Isolation",,HAW-HS 2025,,1,employees,,"The aim of Health Surveillance 2025 is to analyze and describe the state of health of employees at University of Applied Science Hamburg, key influencing factors and individual resources.",Hamburg University of Applied Sciences/Hochschule für Angewandte Wissenschaften Hamburg (HAW Hamburg),2025-12-31,ESTIMATED,18 Years - N/A,700,ESTIMATED,,OTHER,,Health Surveillance at University of Applied Science Hamburg (HAW) in the Year 2025 to Assess Employees Health and Wellbeing,2025-07-30,ACTUAL,Health literacy | Loneliness,,ALL,2025-05-14,ACTUAL,OBSERVATIONAL
HAWPY,Haw Par Corporation Limited,NCT07265427,,RECRUITING,"Digital Health, Artificial Intelligence (AI)",,TRUST-AI,,3,Rehabilitation Center Oldenburg patients and employees | training course participants | Students, |  | ,"This study aims to investigate differences in perception of barriers and facilitators of digitalization and Artificial Intelligence (AI) usage in healthcare across different generational groups (youth, working-age adults, and seniors). The results will help create practical recommendations for public health projects and consultants to support fair and inclusive use of new digital tools in healthcare. A cross-sectional online survey will be conducted among students at HAW, patients and employees ",Hamburg University of Applied Sciences/Hochschule für Angewandte Wissenschaften Hamburg (HAW Hamburg),2026-12-30,ESTIMATED,18 Years - N/A,250,ESTIMATED,,OTHER,,"Acceptance and Perceived Benefits of Digitalization by Medical Assistants and Other Generational Groups (ANDI-MFA-2): ""Trust in AI and Digitalization in Healthcare Across Generational Groups: A Comparative Study of Barriers and Facilitators Toward Equitable Adoption""",2026-03-30,ESTIMATED,Trust in digitalization and AI in healthcare | Perceived barriers to adoption of AI and digitalization in healthcare | Perceived facilitators to the adoption of AI and digitalization in healthcare,,ALL,2025-11-24,ACTUAL,OBSERVATIONAL
HLBBF,H. Lundbeck A/S,NCT05669950,"PHASE1, PHASE2",RECRUITING,Congenital Adrenal Hyperplasia,Lu AG13909,,,1,Lu AG13909,EXPERIMENTAL,"This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.",,2027-12-31,ESTIMATED,18 Years - 70 Years,42,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Multi-site, Open-label, Sequential-group, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia",2026-09-30,ESTIMATED,Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Parts A and B: Number of Participants With Anti-Drug Antibodies (ADAs) | Parts A and B: Cmax: Maximum Observed Serum Concentration of Lu AG13909 | Parts A and B: Tmax: Nominal Time Corresponding to the Occurrence of Cmax | Parts A and B: Ctrough: Minimum Observed Serum Concentration of Lu AG13909 | Parts A and B: t½: Apparent Elimination Half-life of Lu AG13909 | Parts A and B: AUC0-infinity: Area under the plasma concentration curve of x from zero to infinity of Lu AG13909 | Parts A and B: CL: Apparent Total Serum Clearance of Lu AG13909 | Parts A and B: Vz: Volume of Distribution During the Terminal Elimination Phase After IV Administration of Lu AG13909 | Parts A and B: Change From Baseline After Each Dose of Lu AG13909 in Blood Concentrations of 17-hydroxyprogesterone (17-OHP) and Androstenedione (A4) | Parts A and B: AUC0-tau: Area under the curve over a dosing interval | Part C: Morning Concentration of A4 in Blood <Upper Limit of Normal (ULN),TREATMENT,ALL,2022-12-19,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT06557850,PHASE1,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,Lu AG22515,,,1,Lu AG22515,EXPERIMENTAL,"This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease (TED). TED is an autoimmune condition closely related to Graves' Disease.

In people with TED, the healthy tissue behind and around the eye becomes inflamed and swollen. One of the key symptoms of TED is proptosis (bulging eyes). The main goal of this trial is to learn whether treatment with Lu AG22515 improves proptosis in participants with moderate-to-severe TED.",,2026-09-29,ESTIMATED,18 Years - N/A,20,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"Interventional, Open-label, Single-group, Long-term Follow-up Trial of Lu AG22515 in Patients With Moderate-to-severe Thyroid Eye Disease",2026-03-30,ESTIMATED,Change in Proptosis from Baseline to Week 24 in the Trial Eye Using the Hertel Exophthalmometer,TREATMENT,ALL,2024-09-19,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT06471829,PHASE2,RECRUITING,Cushing's Disease,Lu AG13909,BalanCeD,,1,Lu AG13909,EXPERIMENTAL,"This trial will evaluate the effects of Lu AG13909 in adult participants with Cushing's disease (CD). CD is a rare and serious disorder where the body makes too much of a hormone called cortisol. The main goals of this trial are to learn about

1. the effect of Lu AG13909 on cortisol levels.
2. the safety and tolerability of Lu AG13909.
3. the pharmacokinetic parameters of Lu AG13909 (how the drug is absorbed, distributed, and processed by the body).",,2027-11-30,ESTIMATED,18 Years - 70 Years,18,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease",2026-09-15,ESTIMATED,Part A & Part B: Urinary Free Cortisol (UFC) Complete Response: mean UFC (mUFC) ≤ Upper Limit of Normal (ULN) at the end of the IV/SC Titration Period,TREATMENT,ALL,2024-06-19,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT07035197,,RECRUITING,"Migraine, Treatment, Treatment Refusal",Eptinezumab,FACEpi,,3,People with episodic or chronic migraine who have NEVER received CGRP mAb therapy | People with episodic or chronic migraine who have received CGRP mAb therapy | Healthcare Provider, |  | ,"This research study is designed as a longitudinal prospective descriptive study using mixed-method data collection. Eptinezumab, an anti-calcitonin gene-related peptide monoclonal antibody (anti-CGRP mAb), is administered by intravenous (IV) infusion every 3 months as preventive medication for individuals with migraine who have been diagnosed based on theInternational Classification of Headache Disorders, 3rd edition (ICHD-3) by headache specialist neurologists. The goal of this study is to unde",H. Lundbeck A/S,2027-07,ESTIMATED,18 Years - N/A,30,ESTIMATED,,OTHER,,Facilitators and Barriers to Eptinezumab Administration in Thailand: Real-World Experiences and Perspectives From Mixed-method Design and In-Depth Interviews (FACEpi),2026-07,ESTIMATED,Migraine patients' experiences after receiving eptinezumab | Facilitators and barriers of integrating the use of eptinezumab in the headache specialty clinic in Thailand from the perspective of migraine patients | Facilitators and barriers of integrating the use of eptinezumab in the headache specialty clinic in Thailand from the perspective of healthcare providers,,ALL,2025-08-25,ACTUAL,OBSERVATIONAL
HLBBF,H. Lundbeck A/S,NCT05164172,PHASE3,RECRUITING,Migraine,Eptinezumab,REJOIN,RANDOMIZED,2,Eptinezumab 300 mg | Eptinezumab 100 mg,EXPERIMENTAL | EXPERIMENTAL,The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.,,2028-04-30,ESTIMATED,6 Years - 17 Years,600,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Long-term, Open-label (Dose-blinded), Extension Study of Eptinezumab in Children and Adolescents With Chronic or Episodic Migraine",2028-04-30,ESTIMATED,Number of Participants With Treatment Emergent Adverse Events,TREATMENT,ALL,2021-12-01,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT04291859,PHASE1,ACTIVE_NOT_RECRUITING,Parkinson Disease,Lu AF28996,,,1,Lu AF28996,EXPERIMENTAL,"The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.",,2026-02-04,ESTIMATED,35 Years - 85 Years,57,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease",2025-10-14,ACTUAL,Number of Participants with Treatment-emergent Adverse Events | Cmax of Lu AF28996 | Tmax of Lu AF28996,TREATMENT,ALL,2020-02-26,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT06428838,PHASE3,NOT_YET_RECRUITING,"Migraine, Chronic Migraine",Eptinezumab,,RANDOMIZED,2,Standard of Care | Standard of Care + Eptinezumab,OTHER | EXPERIMENTAL,"The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again. The results of this study may help inform better ways to manage patients with migraines in the ED.

Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine, but its short-term effectiveness in the ED context is unknown. Unlike other migraine treatments used in the ED, eptin","H. Lundbeck A/S, Centre for Neurology Studies, Surrey Neuroplasticity Clinic Inc., Royal Columbian Hospital Foundation, Surrey Memorial Hospital",2025-12-30,ESTIMATED,19 Years - 75 Years,102,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,Eptinezumab as an Adjunct to Standard of Care for MIGRANE in an Acute EmeRgency Context (Migraine ERase Study),2025-12-30,ESTIMATED,Number of migraine days at week 1,PREVENTION,ALL,2024-09-30,ESTIMATED,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT06706622,PHASE3,ACTIVE_NOT_RECRUITING,Multiple System Atrophy,"Amlenetug, Placebo",MASCOT,RANDOMIZED,3,Amlenetug Low Dose | Amlenetug High Dose | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).,,2029-10-25,ESTIMATED,40 Years - 75 Years,357,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Interventional, Randomized, Double-blind, Placebo-controlled, Optional Open-label Extension Trial of Lu AF82422 in Participants With Multiple System Atrophy",2028-02-17,ESTIMATED,Rest of the World (RoW; All Countries Except European Union [EU] and Japan [JP]) Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression | EU and JP Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression,TREATMENT,ALL,2024-12-03,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT05453058,,ACTIVE_NOT_RECRUITING,Multiple System Atrophy,,TALISMAN,,1,Patients diagnosed with possible or probable MSA,,"Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union \[EU\]). There will be common study objectives between China and EU regions (including prospective assessments for MSA disease progression during routine clinical visits for MSA), and this will allow for data (on common objectives) to be presented overall and stratified by region. There will also be study objectives specific to each region: 1) th",,2031-05-30,ESTIMATED,40 Years - 75 Years,90,ESTIMATED,,INDUSTRY,,TALISMAN - Tracking Longitudinal Changes in MSA - International Natural History Study,2024-03-12,ACTUAL,"To describe early MSA disease progression changes in 6-month intervals over 12-months (i.e., baseline, 6-months, 12-months) | Changes from baseline to approx. 6-months after baseline and approx.12- months after baseline in plasma NfL concentrations. | Percentage change in brain volume in brain regions-of-interest (ROIs), as measured by volumetric MRI (vMRI). | Percentage change in tissue integrity in ROIs, as measured by diffusion-tensor imaging (DTI) MRI.",,ALL,2022-06-25,ACTUAL,OBSERVATIONAL
HLBBF,H. Lundbeck A/S,NCT04789915,PHASE1,RECRUITING,"Psychosis, Negative Symptoms With Primary Psychotic Disorder","Memantine, Placebo",AMEND,RANDOMIZED,2,Memantine + aripiprazole | Placebo + aripiprazole,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Antipsychotics affects the brain's dopamine system, and the drugs reduce delusions, hallucinations, and disorganized thinking, which are cardinal symptoms of psychotic disorders. However, negative symptoms e.g. anhedonia, avolition, and social withdrawal, as well as cognitive deficits, are not sufficiently treated.

Memantine is used to treat Alzheimer's disease and affects the brain's glutamate system. AMEND is a 12-week, double-blind, placebo-controlled, randomized clinical trial (RCT) testing","Lundbeck Foundation, Danish Research Centre for Magnetic Resonance",2026-12-31,ESTIMATED,18 Years - 45 Years,46,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,AMEND - Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis,2025-07-01,ESTIMATED,"Negative Symptom change, PANSS negative subscore | Negative Symptom change, Brief Negative Symptom Scale (BNSS)",TREATMENT,ALL,2021-05-26,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT06701526,PHASE4,RECRUITING,Migraine,Eptinezumab,,,1,Eptinezumab,EXPERIMENTAL,The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).,,2026-06-05,ESTIMATED,18 Years - 75 Years,150,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting Therapies",2026-06-05,ESTIMATED,"Number of Participants with Response of ""Much Improved"" or ""Very Much Improved"" on the Patient Global Impression of Change (PGIC) Scale",TREATMENT,ALL,2024-12-18,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT05897320,PHASE3,RECRUITING,Episodic Migraine,"Eptinezumab, Placebo",PROSPECT-1,RANDOMIZED,3,Eptinezumab 300 mg | Placebo | Eptinezumab 100 mg,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.,,2027-08-31,ESTIMATED,6 Years - 17 Years,315,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine",2027-07-06,ESTIMATED,Change From Baseline in the Number of Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12,TREATMENT,ALL,2023-06-08,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT04965675,PHASE3,RECRUITING,Chronic Migraine in Children,"Eptinezumab, Placebo",PROSPECT-2,RANDOMIZED,3,Eptinezumab 300 mg | Eptinezumab 100 mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.,,2026-10-31,ESTIMATED,12 Years - 17 Years,285,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 Years) for the Preventive Treatment of Chronic Migraine",2026-09-05,ESTIMATED,Change From Baseline in Monthly Migraine Days (MMDs) Averaged Over Weeks 1-12,TREATMENT,ALL,2021-06-30,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT05104476,PHASE2,ACTIVE_NOT_RECRUITING,Multiple System Atrophy,"Lu AF82422, Placebo",AMULET,RANDOMIZED,2,Lu AF82422 | Placebo,EXPERIMENTAL | EXPERIMENTAL,To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.,,2028-03-07,ESTIMATED,40 Years - 75 Years,64,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of Lu AF82422 in Patients With Multiple System Atrophy",2023-11-16,ACTUAL,Percentage Slowing of Clinical Progression Based on Change From Baseline in the UMSARS TS at the End of Treatment (EOT) DB Period (DBP),TREATMENT,ALL,2021-11-16,ACTUAL,INTERVENTIONAL
HLBBF,H. Lundbeck A/S,NCT06323928,PHASE2,ACTIVE_NOT_RECRUITING,Migraine,"Lu AG09222, Placebo",PROCEED,RANDOMIZED,9,Group A: Placebo SC (closed for recruitment) | Group B: Lu AG09222 SC (closed for recruitment) | Group C: Lu AG09222 SC (closed for recruitment) | Group D: Lu AG09222 SC (closed for recruitment) | Group E: Lu AG09222 SC (closed for recruitment) | Group F: Placebo IV | Group G: Lu AG09222 IV | Group H: Lu AG09222 IV | Group I: Lu AG09222 IV,PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.",,2026-04-30,ESTIMATED,18 Years - 65 Years,874,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-finding Trial of Lu AG09222 for the Prevention of Migraine in Participants With Unsuccessful Prior Preventive Treatments",2026-01-16,ACTUAL,Change From Baseline in the Number of Monthly Migraine Days (MMDs),PREVENTION,ALL,2024-04-01,ACTUAL,INTERVENTIONAL
HLOSF,Healios K.K.,NCT04533464,PHASE2,RECRUITING,"Trauma, Adult Stem Cells","MultiStem, Placebo",,RANDOMIZED,2,MultiStem | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Single center, prospective, randomized, double-blind, pragmatic Phase 2 clinical study in severely injured trauma patients within hours of hospitalization who have survived initial resuscitation.","Memorial Hermann Hospital, United States Department of Defense",2025-12,ESTIMATED,18 Years - N/A,156,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome,2025-12,ESTIMATED,A composite of the highest Acute Kidney Injury stage (based on KDIGO guidelines),TREATMENT,ALL,2020-11-09,ACTUAL,INTERVENTIONAL
HNSBF,Hansa Biopharma AB (publ),NCT05714514,,ACTIVE_NOT_RECRUITING,Kidney Transplantation in Highly Sensitized Patients,Imlifidase administered in the ConfIdeS study,ConfIdeSLTFU,,2,Imlifidase administered in the ConfIdeS study | Best available treatment administered in the ConfIdeS study, | ,"The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).",,2029-12-31,ESTIMATED,N/A - N/A,64,ESTIMATED,,INDUSTRY,,"A Prospective, Long-term Confirmatory Follow up Trial in Highly Sensitized Patients Treated With Imlifidase or Standard of Care in the ConfIdeS (20-HMedIdeS-17) Trial",2027-12-31,ESTIMATED,Proportion of patients alive and free of dialysis at 3 years,,ALL,2023-04-21,ACTUAL,OBSERVATIONAL
HNSBF,Hansa Biopharma AB (publ),NCT05679401,PHASE3,ACTIVE_NOT_RECRUITING,"Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome","Imlifidase, Cyclophosphamide (CYC), Glucocorticoids",GOOD-IDES-02,RANDOMIZED,2,Imlifidase and Standard-of-Care (SoC) | Standard-of-Care (SoC),EXPERIMENTAL | ACTIVE_COMPARATOR,"An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.",,2026-11,ESTIMATED,18 Years - N/A,50,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)",2025-06-23,ACTUAL,Renal function as evaluated by estimated glomerular filtration rate (eGFR) at 6 months,TREATMENT,ALL,2022-12-22,ACTUAL,INTERVENTIONAL
HNSBF,Hansa Biopharma AB (publ),NCT05937750,PHASE3,RECRUITING,Long Term Efficacy and Safety,Imlifidase administered in the 20-HMedIdeS-19 (PAES) study,PAES-LTFU,NON_RANDOMIZED,2,Imlifidase | Non-Comparative Concurrent Reference Cohort,EXPERIMENTAL | EXPERIMENTAL,"A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.",,2030-04-30,ESTIMATED,19 Years - 76 Years,150,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort",2030-04-30,ESTIMATED,Graft failure-free survival (%) up to 5 years after imlifidase enabled transplantation (imlifidase cohort only),OTHER,ALL,2023-07-03,ACTUAL,INTERVENTIONAL
HNSBF,Hansa Biopharma AB (publ),NCT06518005,PHASE2,RECRUITING,Crigler-Najjar Syndrome,"Imlifidase, GNT0003",,NON_RANDOMIZED,2,Treatment with imlifidase | Treatment with GNT0003,EXPERIMENTAL | EXPERIMENTAL,"Clinical trial rationale:

CNS is an ultra-rare (\<1/1 million newborns), autosomal recessive disorder of bilirubin conjugation caused by mutation in the gene coding for uridine 5'-diphosphate glucuronosyltransferase (UGT1A1), that causes the accumulation of neurotoxic unconjugated bilirubin (UCB).

Reduction of UCB is managed with phenobarbital in mild CNS, and daily phototherapy in severe CNS.

There is no authorized curative medical treatment for CNS. Liver transplantation is currently the on",Hansa Biopharma AB,2030-09-30,ESTIMATED,18 Years - N/A,3,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"An Open-label, Phase 2 Trial to Evaluate the Efficacy and Safety of a Single Intravenous Administration of GNT0003 (an Adeno-associated Viral (AAV) Vector Expressing the UGT1A1 Transgene) Following Imlifidase Pre-treatment in Adult Participants With Severe Crigler-Najjar Syndrome (CNS) Requiring Daily Phototherapy and Presenting Pre-existing Anti-AAV8 Antibodies",2026-09-30,ESTIMATED,"Proportion of participants with serum total bilirubin ≤ 300 μmol/L, 48 weeks after GNT0003 infusion and without phototherapy from Week 16",TREATMENT,ALL,2024-11-08,ACTUAL,INTERVENTIONAL
HNSBF,Hansa Biopharma AB (publ),NCT05753930,PHASE2,RECRUITING,Kidney Transplantation in Highly Sensitized Patients,Imlifidase,DINKY,,1,Imlifidase,EXPERIMENTAL,"The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD).

The main questions it aims to answer are:

* Does imlifidase treatment result in crossmatch conversion that enables transplantation?
* How is the function of the transplanted kidney?

The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive me",,2031-08-31,ESTIMATED,1 Year - 17 Years,10,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment",2027-02-28,ESTIMATED,Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatment,TREATMENT,ALL,2023-06-02,ACTUAL,INTERVENTIONAL
HNSBF,Hansa Biopharma AB (publ),NCT05369975,PHASE3,ACTIVE_NOT_RECRUITING,Kidney Transplantation in Highly Sensitized Patients,Imlifidase,PAES,NON_RANDOMIZED,3,Imlifidase | Non-Comparative Concurrent Reference Cohort | Non-Comparative Historical Reference Cohort,EXPERIMENTAL | OTHER | OTHER,An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive crossmatch (XM) against a deceased donor prior to desensitized with imlifidase and subsequent kidney transplantation. Two non-comparative reference cohorts are included to assess the impact of differences in post-transplantation management and outcome in less sensitized patients.,,2026-04,ESTIMATED,18 Years - 75 Years,225,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Controlled, Open-label PA Efficacy and Safety Study in Imlifidase Desensitised Kidney Tx Patients With Positive XM Against a Deceased Donor Prior to Imlifidase Treatment, Including Non-comparative Registry and Concurrent Reference Cohorts",2026-04,ESTIMATED,Graft failure-free survival 1 year after transplantation following imlifidase treatment,TREATMENT,ALL,2022-04-19,ACTUAL,INTERVENTIONAL
HUMDF,Hua Medicine (Shanghai) Ltd.,NCT07279987,,NOT_YET_RECRUITING,Vascular Calcification,,CRUSH-CALC,RANDOMIZED,2,Rotational Atherectomy + Super High-Pressure Balloon | Rotational Atherectomy + Intravascular Lithotripsy,EXPERIMENTAL | ACTIVE_COMPARATOR,"Study Design Prospective, multicenter, single-blind, randomized controlled trial

Hypothesis In patients with severely calcified coronary lesions undergoing rotational atherectomy (Rota), post-rotational lesion optimization using intravascular lithotripsy (IVL) is non-inferior to super high-pressure balloon (SHPB) in terms of final minimal lumen diameter (MLD), with potential differences in acute lumen gain, stent expansion, and periprocedural complications.

Inclusion Criteria

* Age ≥ 18 years","China-Japan Friendship Hospital, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine",2028-12-31,ESTIMATED,18 Years - N/A,162,ESTIMATED,PARALLEL,OTHER,SINGLE,Comparison of Combined Rotational Atherectomy With Intravascular Lithotripsy Versus Super-High Pressure Balloon Angioplasty for Heavily Calcified Coronary Lesions (CRUSH-CALC Study),2027-12-31,ESTIMATED,Minimum Lumen Diameter (MLD) assessed by intravascular imaging,TREATMENT,ALL,2026-01-01,ESTIMATED,INTERVENTIONAL
HUMDF,Hua Medicine (Shanghai) Ltd.,NCT05418218,,RECRUITING,"Headache Disorders, Primary, Headache Disorders, Secondary, Migraine, Tension-Type Headache, Vertigo, Vestibular Migraine, Fibromyalgia",,IHRS,,5,Migraine | Other Primary Headache Disorders | Vertigo | Secondary Headache Disorders | Normal control, |  |  |  | ,"In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were st","Zhejiang University, First People's Hospital of Hangzhou, Affiliated Hospital of Shaoxing Wenli University, Tiantai People's Hospital, People's Hospital of Lin 'an City, Deqing County People's Hospital, Jiaxing No.1 Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Shaoxing People's Hospital, Huzhou Central Hospital, The Affiliated Hospital of Hangzhou Normal University, Quzhou City People's Hospital, Xin Hua Hospital of Zhejiang Province, The First People's Hospital of Huzhou, Zhongshan Hospital Of Traditional Chinese Medicine, Jiaxing Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Wenzhou Medical University, Affiliated Wenling Hospital of Wenzhou Medical University, Hangzhou Hospital of Traditional Chinese Medicine, Linhai First People's Hospital, Pain Management Center, Stanford University, USA, The Second Affiliated Hospital of Jiaxing University, The Fourth Affiliated Hospital of Medical College of Zhejiang University, Chongqing Xinqiao Hospital",2082-12-31,ESTIMATED,4 Years - 99 Years,200000,ESTIMATED,,OTHER,,International Headache and Vertigo Registration Study,2082-12-31,ESTIMATED,Days of Migraine | Moderate / Severe Headache Days | Migraine Attack,,ALL,2021-07-12,ACTUAL,OBSERVATIONAL
HUMDF,Hua Medicine (Shanghai) Ltd.,NCT04934982,,RECRUITING,Cervical Cancer,,LAUNCH 1,RANDOMIZED,2,1 | 2,EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this study is to confirm whether there is a difference between laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in patient survival for Cervical Cancer (Stage IA1 with LVSI, IA2)","Children's Hospital of Fudan University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, RenJi Hospital, Taizhou Hospital, Affiliated Cancer Hospital of the University of Chinese Academy of Sciences, First Affiliated Hospital of Wenzhou Medical University",2026-06,ESTIMATED,21 Years - 70 Years,690,ESTIMATED,PARALLEL,OTHER,NONE,"A Multicenter Noninferior Randomized Controlled Study Comparing the Efficacy of Laparoscopic Versus Abdominal Radical Hysterectomy for Cervical Cancer (Stage IA1 With LVSI, IA2)",2024-06,ESTIMATED,the rate of PFS at 5 years,TREATMENT,FEMALE,2021-09-24,ACTUAL,INTERVENTIONAL
HUMDF,Hua Medicine (Shanghai) Ltd.,NCT06263348,PHASE4,RECRUITING,Type2diabetes,Dorzagliatin tablets,,,1,Dorzagliatin group,EXPERIMENTAL,The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.,"Shanghai Branch, KunTuo Medical Research and Development (Beijing) Co., Ltd.",2026-04-30,ESTIMATED,18 Years - N/A,2000,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Multicenter Post-Marketing Observational Study to Evaluate the Long-Term Safety of Dorzagliatin in Patients With Type 2 Diabetes Mellitus,2026-04-30,ESTIMATED,Incidences of ADRs and SAEs,TREATMENT,ALL,2023-12-20,ACTUAL,INTERVENTIONAL
HUMDF,Hua Medicine (Shanghai) Ltd.,NCT07203248,,NOT_YET_RECRUITING,"Vestibular Migraine, Dizziness, Vertigo","CGRP R Inhibitor; CGRP Inhibitor, none-CGRP",,,4,A1 | A2 | B1 | B2, |  |  | ,"Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment. Acute treatment aims to reduce the severity and duration of a single episode, while preventive treatment aims to decrease the frequency, severity, and duration of attacks. Current acute treatments are primarily divided into pain relief and anti-dizziness, with specific drugs such ","First People's Hospital of Hangzhou, Sir Run Run Shaw Hospital, Affiliated Hospital of Jiaxing University, The People's Hospital of Quzhou, The First People Hospital of Hangzhou Lin An District, Shaoxing People's Hospital, Jiaxing Hospital of T.C.M, Hangzhou Hospital of Traditional Chinese Medicine, Affiliated Wenling Hospital of Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Zhongshan Hospital Of Traditional Chinese Medicine, The First People's Hospital of Huzhou, Xin Hua Hospital of Zhejiang Province, The Affiliated Hospital of Hangzhou Normal University, Huzhou Central Hospital, Chinese Medical University, Tiantai People Hospital, Zhejiang University",2028-12,ESTIMATED,18 Years - 75 Years,2000,ESTIMATED,,OTHER,,A Real-world Study on the Use of CGRP-targeted Medications for the Treatment of Vestibular Migraine in Chinese Patients,2027-12,ESTIMATED,The average scores of the most severe vestibular symptom post-dose measured by VAS scale to evaluate the effectiveness of CGRP medication in the acute treatment of vestibular migraine | Change in number of Moderate/Severe vestibular symptom days as defined by Bárány Society for participants measured daily from the observational phase compared to baseline between group B1 and B2,,ALL,2025-12,ESTIMATED,OBSERVATIONAL
HUMDF,Hua Medicine (Shanghai) Ltd.,NCT04939922,,RECRUITING,"Headache Disorders, Primary, Headache Disorders, Secondary, Migraine, Tension-Type Headache, Cluster Headache, Vertigo, Constant, Vestibular Migraine, Fibromyalgia",,CHRS,,5,Migraine | Other Primary Headache Disorders | Vertigo | Secondary Headache Disorders | Normal control, |  |  |  | ,"In the Chinese Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied,","Zhejiang University, Tiantai People Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Huzhou Central Hospital, The Affiliated Hospital of Hangzhou Normal University, Xin Hua Hospital of Zhejiang Province, The First People's Hospital of Huzhou, Zhongshan Hospital Of Traditional Chinese Medicine, First Affiliated Hospital of Wenzhou Medical University, Affiliated Wenling Hospital of Wenzhou Medical University, Hangzhou Hospital of Traditional Chinese Medicine, Jiaxing Hospital of T.C.M, Shaoxing People's Hospital, The First People Hospital of Hangzhou Lin An District, The People's Hospital of Quzhou, Affiliated Hospital of Jiaxing University, First People's Hospital of Hangzhou, SIR RUNRUN Hospital",2050-12-12,ESTIMATED,4 Years - 99 Years,10000,ESTIMATED,,OTHER,,China Headache and Vertigo Registry Study,2050-12-12,ESTIMATED,Days of Migraine | Moderate / Severe Headache Days | Vertigo attack,,ALL,2017-06-12,ACTUAL,OBSERVATIONAL
IDRSF,Idorsia Ltd,NCT06816433,PHASE2,NOT_YET_RECRUITING,Post Traumatic Stress Disorder,"Intervention D SLS-002, Intervention D Placebo",,RANDOMIZED,2,Intervention D: SLS-002 | Intervention D: Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for Post Traumatic Stress Disorder (PTSD) utilizing an adaptive platform trial (APT) design.

Intervention D - SLS-002 will assess the safety and efficacy of SLS-002 in participants with PTSD.

Please see NCT05422612 for information on the S-21-02 Master Protocol.","U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline",2026-09,ESTIMATED,18 Years - 65 Years,200,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD",2026-03,ESTIMATED,Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/Early termination Visit). | Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline.,TREATMENT,ALL,2025-11,ESTIMATED,INTERVENTIONAL
IDRSF,Idorsia Ltd,NCT05948540,PHASE2,RECRUITING,Post Traumatic Stress Disorder,"Intervention C Daridorexant, Intervention C Placebo",,RANDOMIZED,2,Intervention C Daridorexant | Intervention C Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.

Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD.

Please see NCT05422612 for information on the S-21-02 Master Protocol.","U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline",2026-09,ESTIMATED,18 Years - 65 Years,200,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD",2026-03,ESTIMATED,Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/Early termination Visit). | Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline.,TREATMENT,ALL,2023-11-02,ACTUAL,INTERVENTIONAL
IDRSF,Idorsia Ltd,NCT05422612,PHASE2,RECRUITING,Post Traumatic Stress Disorder,"Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo",,RANDOMIZED,8,Intervention A: Fluoxetine HCl | Intervention A Placebo | Intervention B Vilazodone | Intervention B Placebo | Intervention C Daridorexant | Intervention C Placebo | Intervention D SLS-002 | Intervention D Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the multiple cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). This master protocol describes the default procedures and analyses for all cohorts;","U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline",2026-09,ESTIMATED,18 Years - 65 Years,800,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD",2026-03,ESTIMATED,Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/Early termination Visit). | Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline.,TREATMENT,ALL,2023-11-02,ACTUAL,INTERVENTIONAL
IDRSF,Idorsia Ltd,NCT05924425,PHASE4,RECRUITING,"Alzheimer Disease, Insomnia Disorder, Sleep","Daridorexant 50 mg, Placebo",DARIDOR-ALZ,RANDOMIZED,2,Daridorexant 50 mg | Placebo-controlled arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and orexin-2 receptors, in selected populations of MCI and mild-to-moderate AD patients with insomnia complaints.",Idorsia Pharmaceuticals Ltd.,2027-03-13,ESTIMATED,60 Years - 85 Years,62,ESTIMATED,CROSSOVER,OTHER,QUADRUPLE,Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease,2026-05-13,ESTIMATED,Change in Total Sleep Time (TST).,TREATMENT,ALL,2024-03-13,ACTUAL,INTERVENTIONAL
IDRSF,Idorsia Ltd,NCT05423717,PHASE2,ACTIVE_NOT_RECRUITING,Insomnia,"Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo",,RANDOMIZED,4,Daridorexant 10 mg | Daridorexant 25 mg | Daridorexant 50 mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to \< 18 years with insomnia disorder.",,2026-04,ESTIMATED,10 Years - 17 Years,150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder",2026-03,ESTIMATED,Change from baseline to Day 1 in Total Sleep Time (TST) as measured by polysomnography (PSG).,TREATMENT,ALL,2022-09-06,ACTUAL,INTERVENTIONAL
IDRSF,Idorsia Ltd,NCT05948553,PHASE2,RECRUITING,Post Traumatic Stress Disorder,"Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo",,RANDOMIZED,2,Intervention A: Fluoxetine HCl | Intervention A Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.

Intervention A - Fluoxetine will assess the safety and efficacy of fluoxetine in participants with PTSD.

Please see NCT05422612 for information on the S-21-02 Master Protocol.","U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline",2026-09,ESTIMATED,18 Years - 65 Years,200,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD",2026-03,ESTIMATED,Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/Early termination Visit). | Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline.,TREATMENT,ALL,2023-11-02,ACTUAL,INTERVENTIONAL
IDRSF,Idorsia Ltd,NCT03737214,PHASE3,ACTIVE_NOT_RECRUITING,Fabry Disease,Lucerastat,,,1,Lucerastat,EXPERIMENTAL,A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease. This study includes a sub-study evaluating kidney Gb3 inclusions (and other histologic lesions) in male participants with classic Fabry disease who have been treated for at least 2 years with lucerastat monotherapy in study ID-069A302.,,2029-11,ESTIMATED,18 Years - N/A,107,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multi-center, Open-label, Uncontrolled, Single-arm, Extension Study to Determine the Long-term Safety and Tolerability of Oral Lucerastat in Adult Subjects With Fabry Disease",2029-08,ESTIMATED,Treatment-emergent adverse events (AEs),TREATMENT,ALL,2018-12-18,ACTUAL,INTERVENTIONAL
IDRSF,Idorsia Ltd,NCT05948579,PHASE2,NOT_YET_RECRUITING,Post Traumatic Stress Disorder,"Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo",,RANDOMIZED,2,Intervention B Vilazodone | Intervention B Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.

Intervention B - Vilazodone will assess the safety and efficacy of vilzodone in participants with PTSD.

Please see NCT05422612 for information on the S-21-02 Master Protocol.","U.S. Army Medical Research and Development Command, PPD Development, LP, Berry Consultants, Idorsia Pharmaceuticals Ltd., Cambridge Cognition Ltd, Citeline",2026-09,ESTIMATED,18 Years - 65 Years,200,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PTSD",2026-03,ESTIMATED,Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/Early termination Visit). | Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline.,TREATMENT,ALL,2025-11,ESTIMATED,INTERVENTIONAL
IDRSF,Idorsia Ltd,NCT06393504,,ACTIVE_NOT_RECRUITING,Insomnia Disorder,"Daridorexant, Non-orexin receptor antagonist insomnia medication",,,3,QUVIVIQ-exposed group | Active comparator group | Unexposed comparator group, |  | ,"Healthcare claims database study to provide safety information on maternal, fetal and infant outcomes among women exposed to QUVIVIQ (daridorexant) during pregnancy",Carelon Research,2028-04,ESTIMATED,15 Years - 50 Years,2095,ESTIMATED,,INDUSTRY,,"Healthcare Claims Database Study to Provide Safety Information on Maternal, Fetal and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant) During Pregnancy",2028-04,ESTIMATED,Prevalence of major congenital malformations (MCMs),,FEMALE,2023-11-30,ACTUAL,OBSERVATIONAL
IDRSF,Idorsia Ltd,NCT06498128,,RECRUITING,Insomnia,"Daridorexant, Non-orexin receptor antagonist medications for insomnia",,,3,QUIVIQ (Cohort A) | Non-orexin receptor antagonist medications for insomnia (Cohort B1) | No insomnia medications (Cohort B2), |  | ,"This study will investigate pregnancy, neonatal, and infant outcomes in women exposed to QUVIVIQ during pregnancy compared to women unexposed to QUVIVIQ during pregnancy.",Iqvia Pty Ltd,2033-03,ESTIMATED,15 Years - 50 Years,785,ESTIMATED,,INDUSTRY,,QUVIVIQ® Pregnancy Registry,2033-03,ESTIMATED,Major congenital malformations classified according to MACDP,,FEMALE,2024-11-21,ACTUAL,OBSERVATIONAL
JBIO,"Jade Biosciences, Inc.",NCT07059312,PHASE1,ACTIVE_NOT_RECRUITING,Healthy Volunteers,"JADE101, Placebo",,RANDOMIZED,2,JADE101 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 1, first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE101 compared to placebo in healthy participants.",,2026-10,ESTIMATED,18 Years - 55 Years,32,ACTUAL,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Volunteers",2026-10,ESTIMATED,Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy Participants,BASIC_SCIENCE,ALL,2025-08-17,ACTUAL,INTERVENTIONAL
KKPCF,"Kaken Pharmaceutical Co., Ltd.",NCT07285005,PHASE3,NOT_YET_RECRUITING,"Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome, CLOVES Syndrome","KP-001, Placebo",S-KY,RANDOMIZED,2,KP-001 | placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a phase 3, double-blind, randomized, placebo-controlled, parallel group, adaptive, multicenter study planned to be conducted at multiple sites in North America, Canada, Taiwan and South Korea.

The purpose of this study is to measure the efficacy and safety of KP-001 compared with placebo in patients aged ≥2 years with common VM, common LM, or KTS/CLOVES syndrome.

An independent data monitoring committee (DMC) will be established to determine whether to discontinue or continue the study",,2028-02,ESTIMATED,2 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Parallel, Multicenter, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of KP 001 in Patients Aged ≥2 Years With Common Venous Malformations, Common Lymphatic Malformations, or KTS/CLOVES Syndrome",2028-02,ESTIMATED,The ratio of volume of target lesions based on MRI,TREATMENT,ALL,2026-02-26,ESTIMATED,INTERVENTIONAL
LBRX,LB Pharmaceuticals Inc,NCT07363577,PHASE3,NOT_YET_RECRUITING,Schizophrenia,"LB-102 (50 mg tablet), LB-102 (100 mg tablet)",NOVA2,RANDOMIZED,3,LB-102 (50 mg tablet) | LB-102 (100 mg tablet) | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.",,2027-10,ESTIMATED,18 Years - 65 Years,456,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia",2027-06,ESTIMATED,Change from baseline to Week 6 on the Positive and Negative Syndrome Scale,TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
LBRX,LB Pharmaceuticals Inc,NCT07369154,PHASE3,NOT_YET_RECRUITING,Schizophrenia,LB-102,NOVA3,,1,LB-102,OTHER,"Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia",,2029-04,ESTIMATED,18 Years - 65 Years,900,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia",2028-12,ESTIMATED,"Evaluate long term safety and tolerability of LB-102 by evaluating the number of adverse event, incidence of treatment emergent events.",TREATMENT,ALL,2026-04,ESTIMATED,INTERVENTIONAL
MANE,"Veradermics, Incorporated",NCT06724614,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Androgenetic Alopecia, AGA, Male Pattern Baldness","VDPHL01, Placebo",,RANDOMIZED,4,VDHPL01 BID | VDPHL01 QD and Placebo QD | Placebo BID with treatment extension to VDPHL01 BID | Placebo BID with treatment extension to VDPHL01 QD and Placebo QD,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA).

AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness.

This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont",,2026-09,ESTIMATED,18 Years - 65 Years,480,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia",2026-02,ESTIMATED,Changes in non-vellus Target Area Hair Counts (TAHC) | Subjects Evaluation of Treatment Benefit,TREATMENT,MALE,2024-11-06,ACTUAL,INTERVENTIONAL
MANE,"Veradermics, Incorporated",NCT07146022,PHASE3,RECRUITING,"Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss","VDPHL01 QD, Placebo, VDPHL01 BID, Placebo",,RANDOMIZED,4,VDPHL01 BID | VDPHL01 QD and Placebo QD | Placebo BID with treatment extension to VDPHL01 BID | Placebo BID with treatment extension to VDPHL01 QD and Placebo QD,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"This study will evaluate the safety and efficacy of VDPHL01 in female subjects with Androgenetic Alopecia (AGA).

AGA is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormones) that causes hair loss. VDPHL01 is an investigational oral drug to treat AGA.

This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, mont",,2028-01,ESTIMATED,18 Years - 65 Years,552,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects With Androgenetic Alopecia",2027-06,ESTIMATED,Changes in non-vellus Target Area Hair Counts (TAHC) | Subjects Evaluation of Treatment Benefit,TREATMENT,FEMALE,2025-07-25,ACTUAL,INTERVENTIONAL
MANE,"Veradermics, Incorporated",NCT06972264,PHASE3,ACTIVE_NOT_RECRUITING,"Androgenetic Alopecia, AGA, Male Pattern Baldness","VDPHL01, Placebo",,RANDOMIZED,4,VDHPL01 BID | VDPHL01 QD and Placebo QD | Placebo BID with treatment extension to VDPHL01 BID | Placebo BID with treatment extension to VDPHL01 QD and Placebo QD,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA).

AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness.

This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont",,2027-07,ESTIMATED,18 Years - 65 Years,480,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects With Androgenetic Alopecia",2026-12,ESTIMATED,Changes in non-vellus Target Area Hair Counts (TAHC) | Subjects Evaluation of Treatment Benefit,TREATMENT,MALE,2025-03-11,ACTUAL,INTERVENTIONAL
MANE,"Veradermics, Incorporated",NCT06527365,PHASE2,ACTIVE_NOT_RECRUITING,"Androgenetic Alopecia, AGA, Male Pattern Baldness",VDPHL01,,,1,VDPHL01 Tablet,EXPERIMENTAL,"This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA).

AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness.

This multiple center, open-label, study will last about 13 months and inc",,2026-08,ESTIMATED,18 Years - 65 Years,70,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Multi-Dose Study to Evaluate the Safety and Efficacy of VDPHL01 in Male and Female Subjects With Androgenetic Alopecia,2026-08,ESTIMATED,Changes in non-vellus Total Area Hair Count (TAHC) | Subjects Evaluation of Treatment Benefit,TREATMENT,ALL,2024-07-08,ACTUAL,INTERVENTIONAL
MMDCF,Mind Medicine (MindMed) Inc. WT EXP 010724,NCT07302984,,RECRUITING,Post Traumatic Stress Disorder PTSD,,,RANDOMIZED,2,Mind-Body Skills Groups | Wait List Control,EXPERIMENTAL | NO_INTERVENTION,"The goal of this clinical trial is to learn if mind-body skills groups can reduce posttraumatic stress disorder and emotional and behavioral problems in war-traumatized adolescents in Gaza.

The main questions it aims to answer are:

* Do mind-body skills groups reduce posttraumatic stress disorder symptoms in war-traumatized adolescents in Gaza?
* Do mind-body skills groups reduce emotional and behavioral problems in war-traumatized adolescents in Gaza?

Researchers will compare the results of ",Americares,2026-03,ESTIMATED,11 Years - 17 Years,120,ESTIMATED,PARALLEL,OTHER,NONE,Mind-body Skills Groups for the Treatment of War-Related Trauma in Adolescents in Gaza: A Randomized Controlled Study,2026-03,ESTIMATED,Child Post-Traumatic Stress Disorder Symptom Scale - 5,TREATMENT,ALL,2025-12-26,ACTUAL,INTERVENTIONAL
MPLT,"MapLight Therapeutics, Inc.",NCT06887192,PHASE2,RECRUITING,Psychosis Associated With Alzheimer's Disease,"ML-007C-MA, Placebo",,RANDOMIZED,2,ML-007C-MA | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).

The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucina",,2027-02,ESTIMATED,55 Years - 90 Years,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis",2027-02,ESTIMATED,Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) score,TREATMENT,ALL,2025-08-15,ACTUAL,INTERVENTIONAL
MPLT,"MapLight Therapeutics, Inc.",NCT07038876,PHASE2,RECRUITING,Schizophrenia,"Placebo, ML-007C-MA BID, ML-007C-MA QD",,RANDOMIZED,3,ML-007C-MA 330/6 mg QD | ML-007C-MA 210/3 mg BID | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis.

The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syn",,2027-01,ESTIMATED,18 Years - 64 Years,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Orally Administered ML-007C-MA in Inpatient Adult Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis",2027-01,ESTIMATED,Change From Baseline to End of Treatment in Positive and Negative Syndrome Scale (PANSS) Total Score,TREATMENT,ALL,2025-06-27,ACTUAL,INTERVENTIONAL
MPLT,"MapLight Therapeutics, Inc.",NCT05081245,PHASE2,ACTIVE_NOT_RECRUITING,Autism Spectrum Disorder,"ML-004 (IR)/(ER) tablet, ML-004 Placebo",,RANDOMIZED,2,ML-004 (IR)/(ER) tablet | ML-004 Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.",,2026-11,ESTIMATED,12 Years - 45 Years,150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).",2026-10,ESTIMATED,Change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain Score,TREATMENT,ALL,2022-09-13,ACTUAL,INTERVENTIONAL
NPPNY,"Nippon Shinyaku Co., Ltd.",NCT05135663,PHASE2,ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy (DMD),"NS-089/NCNP-02, NS-089/NCNP-02",,NON_RANDOMIZED,2,NS-089/NCNP-02 40 mg/kg | NS-089/NCNP-02 80 mg/kg,EXPERIMENTAL | EXPERIMENTAL,"This is the extension study of NS-089/NCNP-02 (Study NCNP/DMT02), which is designed to assess the safety, tolerability and efficacy of NS-089/NCNP-02 in patients with Duchenne muscular dystrophy (DMD).",,2027-04-30,ESTIMATED,N/A - N/A,6,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Phase II, Open-Label, Extension Study of NS-089/NCNP-02 in Patients With Duchenne Muscular Dystrophy",2027-04-30,ESTIMATED,Incidence of adverse events,TREATMENT,MALE,2021-06-23,ACTUAL,INTERVENTIONAL
NPPNY,"Nippon Shinyaku Co., Ltd.",NCT04768062,PHASE3,ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy,Viltolarsen,,,1,Viltolarsen,EXPERIMENTAL,"This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who have completed the 48-week treatment period of either viltolarsen or placebo in Study NS-065/NCNP-01-301.","Nippon Shinyaku Co., Ltd.",2025-11,ESTIMATED,N/A - N/A,74,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)",2025-10,ESTIMATED,Number of participants with treatment related Adverse Events as assessed by CTCAE v4.03,TREATMENT,MALE,2021-04-13,ACTUAL,INTERVENTIONAL
NPPNY,"Nippon Shinyaku Co., Ltd.",NCT06046222,PHASE2,RECRUITING,"Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome","NS-229, Placebo",,RANDOMIZED,2,NS-229 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.,"Nippon Shinyaku Co., Ltd.",2026-07,ESTIMATED,18 Years - N/A,45,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis",2026-06,ESTIMATED,The proportion of subjects in remission [OGC 4.0],TREATMENT,ALL,2023-12-20,ACTUAL,INTERVENTIONAL
NPPNY,"Nippon Shinyaku Co., Ltd.",NCT06053814,"PHASE1, PHASE2",RECRUITING,Duchenne Muscular Dystrophy,"NS-050/NCNP-03, Placebo",,RANDOMIZED,3,Part 1: NS-050/NCNP-03 | Part 1: Placebo | Part 2: NS-050/NCNP-03,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly to ambulant boys with DMD, who have a DMD exon deletion amenable to exon 50 skipping.","Nippon Shinyaku Co., Ltd.",2027-05,ESTIMATED,4 Years - 14 Years,20,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1/2, First in Human, Multiple-dose, 2-part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)",2027-05,ESTIMATED,Part 1: Overall Summary of Treatment-emergent Adverse Events (TEAEs) | Part 1: Area Under the Plasma Concentration Versus Time Curve (AUC) of NS-050/NCNP-03 | Part 1: Amount of Drug Excreted in Urine of NS-050/NCNP-03 | Part 2: Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot),TREATMENT,MALE,2024-09-18,ACTUAL,INTERVENTIONAL
NPPNY,"Nippon Shinyaku Co., Ltd.",NCT05996003,PHASE2,RECRUITING,"Duchenne Muscular Dystrophy, Exon 44, DMD",NS-089/NCNP-02,,,1,NS-089/NCNP-02,EXPERIMENTAL,"This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly.

The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.","Nippon Shinyaku Co., Ltd.",2026-09-11,ESTIMATED,4 Years - 14 Years,20,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NS-089/NCNP-02 in Boys With Duchenne Muscular Dystrophy (DMD)",2026-09-11,ESTIMATED,Adverse Event and Adverse Drug Reaction | Plasma pharmacokinetic (PK) parameters | Plasma pharmacokinetic (PK) parameters | Plasma pharmacokinetic (PK) parameters | Plasma pharmacokinetic (PK) parameters | Plasma pharmacokinetic (PK) parameters | Plasma pharmacokinetic (PK) parameters | Plasma pharmacokinetic (PK) parameters | Urine pharmacokinetic parameters | Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot).,TREATMENT,MALE,2024-02-22,ACTUAL,INTERVENTIONAL
NURPF,Neuren Pharmaceuticals Limited,NCT07281079,PHASE3,RECRUITING,Phelan-McDermid Syndrome,"NNZ-2591, Placebo",,RANDOMIZED,2,NNZ-2591 Arm | Placebo Arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.",,2027-11-15,ESTIMATED,3 Years - 12 Years,160,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Orally Administered NNZ-2591 Compared With Placebo in Pediatric Participants With Phelan-McDermid Syndrome",2027-10-31,ESTIMATED,"Efficacy of NNZ-2591 compared with placebo as measured by the Phelan-McDermid Syndrome Assessment of Change (PMSA-C) overall score. | Efficacy of NNZ-2591 compared with placebo as measured by the change from baseline in the Vineland Adaptive Behavior Scales-3, Interview version (Vineland-3) receptive communication subdomain raw score.",TREATMENT,ALL,2025-11-12,ACTUAL,INTERVENTIONAL
NWPHF,Newron Pharmaceuticals S.p.A.,NCT07184619,PHASE3,RECRUITING,Treatment-resistant Schizophrenia,"Evenamide 15 mg bid, Placebo",ENIGMA-TRS 2,RANDOMIZED,2,Evenamide 15 mg bid | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment ",,2026-09-01,ESTIMATED,18 Years - N/A,400,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)",2026-09-01,ESTIMATED,"Change from baseline to endpoint (Week 12) on the total score of the Positive and Negative Syndrome Scale (PANSS). | Incidence of treatment-emergent adverse events (TEAEs), AEs leading to discontinuation (ADOs), and serious AEs (SAEs).",TREATMENT,ALL,2026-01-23,ACTUAL,INTERVENTIONAL
OCUTF,Ocumension Therapeutics,NCT04770610,PHASE3,ACTIVE_NOT_RECRUITING,"Myopia, Progressive","OT-101 Ophthalmic Solution, Vehicle",,RANDOMIZED,3,OT-101 alone | OT-101 plus vehicle | Vehicle,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects","ORA, Inc., Statistics & Data Corporation",2027-04,ESTIMATED,3 Years - 15 Years,678,ESTIMATED,PARALLEL,OTHER,DOUBLE,"A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects",2027-03,ESTIMATED,Percentage of study eyes with a -0.75D of progressive myopia defined as an increase in spherical equivalent of -0.75D or greater as assessed by cycloplegic autorefraction.,TREATMENT,ALL,2021-04-01,ACTUAL,INTERVENTIONAL
OXBDF,Oxford Biomedica plc,NCT01678872,PHASE1,ACTIVE_NOT_RECRUITING,Age-Related Macular Degeneration,RetinoStat,,,1,Long Term Follow up,OTHER,"The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.",,2029-03,ESTIMATED,50 Years - N/A,18,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration,2029-03,ESTIMATED,The incidence of adverse events,OTHER,ALL,2012-08,,INTERVENTIONAL
PEXXF,PT Tempo Scan Pacific Tbk,NCT06600152,,ACTIVE_NOT_RECRUITING,Wound Heal,,MOSAIC,RANDOMIZED,2,Microporous Annealed Particle (MAP) Wound Matrix | Hydrocolloid dressing (DuoDerm),EXPERIMENTAL | ACTIVE_COMPARATOR,"A randomized, open-label, investigational safety evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) device as a volumetric biomaterial scaffold applied to clean wounds after skin cancer surgery with Mohs micrographic surgery (MMS) compared to control.",,2026-08-30,ESTIMATED,22 Years - N/A,40,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Randomized, Open-label, Investigational Safety Evaluation of the Microporous Annealed Particle (MAP) Wound Matrix (TT101) Device as a Volumetric Biomaterial Scaffold Applied to Clean Wounds After Skin Cancer Surgery With Mohs Micrographic Surgery (MMS) Compared to Control.",2026-08-30,ESTIMATED,Incidence of serious adverse device effects in the treatment group compared to the control group.,TREATMENT,ALL,2024-08-26,ACTUAL,INTERVENTIONAL
PGBIF,"PegBio Co., Ltd.",NCT07347080,EARLY_PHASE1,NOT_YET_RECRUITING,T2DM,Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））,CR059101,,1,Exenatide Circular RNA-Lipid Nanoparticle Injection（CR059）,EXPERIMENTAL,"Primary Objectives:

•To evaluate the safety and tolerability of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（CR059）in Chinese subjects with T2DM.

Secondary Objectives:

* To characterize the pharmacokinetic (PK) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（CR059） in Chinese subjects with T2DM;
* To characterize the pharmacodynamic (PD) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059） in Chinese su","PegBio Co., Ltd.",2026-08-31,ESTIMATED,18 Years - 65 Years,9,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"A Single-Center, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus",2026-08-31,ESTIMATED,Incidence of Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2026-01-13,ESTIMATED,INTERVENTIONAL
PRTC,PureTech Health plc,NCT05321420,PHASE2,ACTIVE_NOT_RECRUITING,Idiopathic Pulmonary Fibrosis,"Placebo, Pirfenidone, Deupirfenidone",ELEVATE,RANDOMIZED,4,Placebo | pirfenidone 801 mg TID | LYT-100 550 mg TID | LYT-100 825 mg TID,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.",,2025-12-31,ESTIMATED,40 Years - N/A,240,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)",2024-10-15,ACTUAL,Rate of decline in Forced Vital Capacity over 26 weeks (Part A),TREATMENT,ALL,2022-07-22,ACTUAL,INTERVENTIONAL
PRTC,PureTech Health plc,NCT05829226,PHASE1,RECRUITING,"AML, Adult Recurrent, MDS","LYT-200, Venetoclax, Azacitidine, Decitabine",,NON_RANDOMIZED,2,Single agent dose escalation | Combination agent dose escalation,EXPERIMENTAL | EXPERIMENTAL,"A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)",,2026-03,ESTIMATED,18 Years - N/A,90,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)",2025-12,ESTIMATED,Incidence of Treatment-Emergent Adverse Events [Safety and RP2D determination] | Incidence of Dose Limiting Toxicities [Tolerability and RP2D determination],TREATMENT,ALL,2022-12-12,ACTUAL,INTERVENTIONAL
PRTC,PureTech Health plc,NCT07284602,PHASE3,NOT_YET_RECRUITING,Idiopathic Pulmonary Fibrosis (IPF),"Deupirfenidone, Pirfenidone (PFD)",SURPASS-IPF,RANDOMIZED,2,Active | Active Comparator,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone. Participants may have been treated with an approved antifibrotic drug for up to a year in the past, but they cannot be on background antifibrotic treatment during this study. Participants will be randomly assigned (meani",,2029-07,ESTIMATED,40 Years - N/A,1100,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF)",2029-06,ESTIMATED,Absolute change in forced vital capacity (FVC) measured in mL,TREATMENT,ALL,2026-04,ESTIMATED,INTERVENTIONAL
SGP,"SpyGlass Pharma, Inc.",NCT07218796,PHASE3,RECRUITING,"Cataract, Glaucoma, Ocular Hypertension","Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5%",,RANDOMIZED,2,Bimatoprost Implant System / IOL Combination | Timolol Maleate Ophthalmic Solution 0.5%,EXPERIMENTAL | ACTIVE_COMPARATOR,This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.,,2031-05-31,ESTIMATED,22 Years - N/A,400,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,",2029-05-31,ESTIMATED,Mean IOP Reduction from Baseline (mmHg) | BCDVA 20/40 or better,TREATMENT,ALL,2025-10-28,ESTIMATED,INTERVENTIONAL
SGP,"SpyGlass Pharma, Inc.",NCT07154810,,ACTIVE_NOT_RECRUITING,"Glaucoma, Cataract, Ocular Hypertension",,,,3,Bimatoprost Implant System / IOL Combination Low Dose | Bimatoprost Implant System / IOL Combination Medium Dose | Bimatoprost Implant System / IOL Combination High Dose, |  | ,"The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma. It will also further observe and learn about the safety of the Bimatoprost Implant System / IOL Combination. The main questions it aims to answer are:

* Does the Bimatoprost Implant System / IOL Combination continue lower the pressure inside the eye to treat ocular hypertension or glaucoma long te",,2031-04-14,ESTIMATED,N/A - N/A,23,ACTUAL,,INDUSTRY,,Observational Study to Evaluate Long-term Follow-up of Subjects Implanted With Sustained-release Bimatoprost With the SpyGlass IOL in Subjects With Ocular Hypertension or Mild-to-moderate Open-angle Glaucoma,2031-04-14,ESTIMATED,Unmedicated eyes with an IOP Reduction from SGP-SPEC-001 Baseline,,ALL,2023-03-16,ACTUAL,OBSERVATIONAL
SGP,"SpyGlass Pharma, Inc.",NCT06120842,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Cataract, Glaucoma, Ocular Hypertension","Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%",Tigris,RANDOMIZED,3,Bimatoprost Implant System (High Dose) / IOL Combination | Bimatoprost Implant System (Low Dose) / IOL Combination | Timolol Maleate Ophthalmic Solution 0.5%,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.,,2027-11,ESTIMATED,22 Years - N/A,201,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy, and Dose-response of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%",2025-01-31,ACTUAL,Mean IOP Reduction from Baseline (mmHg),TREATMENT,ALL,2023-10-13,ACTUAL,INTERVENTIONAL
SGP,"SpyGlass Pharma, Inc.",NCT07218783,PHASE3,RECRUITING,"Cataract, Glaucoma, Ocular Hypertension","Bimatoprost Implant System, Timolol Maleate Ophthalmic Solution, 0.5%",,RANDOMIZED,2,Bimatoprost Implant System / IOL Combination | Timolol Maleate Ophthalmic Solution 0.5%,EXPERIMENTAL | ACTIVE_COMPARATOR,This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.,,2031-03-31,ESTIMATED,22 Years - N/A,400,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,",2029-03-31,ESTIMATED,Mean IOP Reduction from Baseline (mmHg) | BCDVA 20/40 or better,TREATMENT,ALL,2025-10-15,ACTUAL,INTERVENTIONAL
SIGA,"SIGA Technologies, Inc.",NCT04957485,PHASE2,ACTIVE_NOT_RECRUITING,Smallpox,"Tecovirimat, Smallpox and Mpox Vaccine",,RANDOMIZED,2,JYNNEOS + TPOXX | JYNNEOS + matching TPOXX placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,This study is designed to evaluate the immunogenicity profile of JYNNEOS® when 2 doses are administered subcutaneously (SC) 4 weeks apart; and potential immunological interference while concomitantly administering TPOXX or placebo orally twice daily (BID) for 28 days.,United States Department of Defense,2026-01-01,ESTIMATED,18 Years - 42 Years,100,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase 1, Open-Label (JYNNEOS®), Double-Blind (TPOXX® And Placebo), Multicenter, Randomized, Placebo-Controlled, Drug-Vaccine Interaction Study To Evaluate the Impact of TPOXX on JYNNEOS Immunogenicity",2026-01-01,ESTIMATED,Adverse Events | Immunogenicity,TREATMENT,ALL,2022-04-05,ACTUAL,INTERVENTIONAL
SNPHY,"Santen Pharmaceutical Co., Ltd.",NCT06683651,PHASE3,RECRUITING,Blepharoptosis,"STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800",,RANDOMIZED,2,"STN1013800 ophthalmic solution | STN1013800 ophthalmic solution Liquid Base, without STN1013800",EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase III Study to evaluate the efficacy and safety of STN1013800 Ophthalmic Solution in Chinese Patients with Acquired Blepharoptosis.

At present, there are no medicines for the treatment of acquired blepharoptosis in China.

Therefore, to evaluate the efficacy and safety of 0.1% STN1013800 ophthalmic solution, Vehicle (Placebo) are designed.

For the screening period, 3-7 days were set to confirm the subjects and judge their qualification. Dosage and administration were based on pri",,2026-06,ESTIMATED,18 Years - 75 Years,180,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Multicenter, Randomized, Double-Masked, Placebo-Controlled Parallel Group Phase III Study to Evaluate the Efficacy and Safety of STN1013800 Ophthalmic Solution in Chinese Patients With Acquired Blepharoptosis",2026-06,ESTIMATED,Mean change from Baseline in the STN1013800 group versus the Vehicle (Placebo) group,TREATMENT,ALL,2024-10-22,ACTUAL,INTERVENTIONAL
SNPHY,"Santen Pharmaceutical Co., Ltd.",NCT06666855,PHASE3,RECRUITING,"Open Angle Glaucoma, Ocular Hypertension","DE-117B Eye Drops, Latanoprost",,RANDOMIZED,2,DE-117B Eye Drops | Latanoprost Eye Drops,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.

Subjects diagnosed with POAG (Primary Open Angle Glaucoma) or OHT (Ocular Hypertension) who meet eligibility criteria will washout of their current IOP lowering medication(s), if any.

The study will investigate plasma pharmacokinetics of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in",,2026-03-31,ESTIMATED,18 Years - N/A,338,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Phase III Study Including a Single-Arm, Open-Label, Multi-Dose PK Study Cohort and a Randomized, Evaluator-Masked, Active Drug Controlled, Parallel Group, Multicenter, Bridging Study Cohort With a Long-term Follow-up Phase Assessing the Efficacy and Safety of DE-117B Eye Drops in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China",2026-03-31,ESTIMATED,Intraocular Pressure (IOP) at Week 4,TREATMENT,ALL,2024-11-28,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT04731155,PHASE4,RECRUITING,Early PCSK9 Inhibitor on Ventricular Remodling,"PCSK9 inhibitor （Alirocumab）plus standard medications, standard medications",PERFECT-AMI,RANDOMIZED,2,standard group | experiment group,ACTIVE_COMPARATOR | EXPERIMENTAL,"This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then tw",,2025-10,ESTIMATED,18 Years - 80 Years,20,ESTIMATED,PARALLEL,OTHER,SINGLE,Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium,2025-10,ESTIMATED,myocardial salvage index measured by MRI | myocardial salvage index measured by MRI | eject fraction measured by MRI | eject fraction measured by MRI,TREATMENT,ALL,2021-04-12,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT04307511,PHASE4,RECRUITING,Acute Coronary Syndrome Patients With Diabetes After PCI,"Ticagrelor, Aspirin",TIGER-diabetes,RANDOMIZED,2,low dose DAPT therapy | standard dose DAPT therapy,EXPERIMENTAL | ACTIVE_COMPARATOR,"In this study, the investigates try to confirm the hypothesis that low dose ticagrelor(60mg) had similar anti-platelets function compared with the standard dose ticagrelor in acute coronary syndrome patients with diabetes. Totally 40 ACS patients with diabetes will be divided into 2 groups randomly after PCI for one month. Group 1 will be treated with ticagrelor 90mg and aspirin 100mg after PCI for 12 months as the standard group; Group2 will be treated with ticagrelor 60mg plus aspirin 100 mg f",,2024-05-31,ESTIMATED,18 Years - 90 Years,40,ESTIMATED,PARALLEL,OTHER,SINGLE,A Randomized Controlled sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients,2024-04-30,ESTIMATED,changes of PRI detected by VASP | changes of Maximum Amplitude (MA) detected by TEG,TREATMENT,ALL,2020-04-20,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT06995027,,RECRUITING,"Pacing Therapy, Cardiac Pacing",,BBAP-ECG/echo,,1,Single Arm - BBAP and RAA pacing,EXPERIMENTAL,"This is a prospective, single-site, non-randomized, interventional study. The purpose is to collect electrocardiographic (ECG) and echocardiographic (echo) parameters and computed tomography (CT) images (optional) during Bachmann's bundle area pacing (BBAP) and conventional pacing in the right atrial appendage (RAA) to compare the differences between atrial pacing modalities and to further investigate the clinical outcomes of BBAP.",,2025-12,ESTIMATED,18 Years - N/A,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Electrocardiographic and Echocardiographic Characteristics of Bachmann's Bundle Area Pacing,2025-05,ESTIMATED,Atrial-paced ECG P-wave duration at implantation and during regular follow-ups | Atrial-paced ECG P-wave amplitude at implantation and during regular follow-ups | Atrial-paced P-onset to A-wave initiation time under Doppler at mitral and tricuspid valves at implantation,TREATMENT,ALL,2024-08-31,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT05736978,PHASE2,RECRUITING,"AML, MRD","Azacitidine, Venetoclax, Selinexor",AVS,,1,Treatment regimen based on C1D14 MRD,EXPERIMENTAL,"This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.",,2027-03-15,ESTIMATED,18 Years - N/A,58,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Clinical Efficacy and Safety of Adaptive Treatment of Acute Myeloid Leukemia (AML) Based on D14 MRD results-a Multicenter, Single-arm, Prospective Clinical Study",2025-03-01,ESTIMATED,Percentage of Participants With Composite Complete Remission,TREATMENT,ALL,2023-03-31,ESTIMATED,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT06739512,,NOT_YET_RECRUITING,Atrial Fibrillation (AF),,,RANDOMIZED,3,Anatomical Guided Ablation Group | Electrogram Guided Ablation Group | Extensive Electro-Anatomical Guided Ablation Group,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | EXPERIMENTAL,"This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of pulsed field ablation (PFA) in patients with persistent atrial fibrillation (PeAF). We will compare three distinct substrate ablation strategies: anatomical guided ablation (ANAT group), electrogram guided ablation (EGM group), and extensive electro-anatomical guided ablation (EXT group). The study seeks to identify which ablation strategy yields the highest efficacy and safety profiles to potentially guid","Albert Einstein College of Medicine and Montefiore Medical Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shandong University of Traditional Chinese Medicine, Yuhuan Second People's Hospital, Changshu Hospital of Traditional Chinese Medicine, Jinan People's Hospital, Xuzhou Central Hospital, The PLA Navy Anqing Hospital",2026-12-01,ESTIMATED,18 Years - 80 Years,600,ESTIMATED,PARALLEL,OTHER,DOUBLE,Efficacy and Safety of Pulsed Field Ablation in Three Different Substrate Ablation Strategies for Persistent Atrial Fibrillation: a Multicenter Randomized Controlled Trial,2025-12-01,ESTIMATED,Freedom from Atrial Arrhythmia Recurrence at 12 Months,TREATMENT,ALL,2024-12-25,ESTIMATED,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT05292404,PHASE4,RECRUITING,Acute Myocardial Infarction,alirocumab,,RANDOMIZED,2,Early PCSK9 inhibitor treatment group | conventional treatment group,EXPERIMENTAL | OTHER,"This is a multi-center, prospective, randomized, controlled study. The patients with STEMI who were to undergo PPCI were divided into PCSK9 inhibitor group (n=80) and conventional treatment group (n=80) using the interactive web response system (IWRS), at a 1:1 ratio. In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months; the control group received conventional treatment",China Cardiovascular Association,2026-12,ESTIMATED,18 Years - 75 Years,160,ESTIMATED,PARALLEL,OTHER,NONE,"Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction： a Muti-center, Open-label, Randomized Controlled Trial",2026-06,ESTIMATED,myocardial salvage index,TREATMENT,ALL,2022-10-01,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT06061627,,RECRUITING,"Heart Failure, Intraventricular Block",,BATTLE,RANDOMIZED,2,LOT-CRT group | BiVP group,EXPERIMENTAL | ACTIVE_COMPARATOR,"BATTLE study has been designed as a prospective, multi-center, randomized, controlled trial. This study will enroll 83 patients with chronic heart failure accompanied by intraventricular block (NICD) over an estimated recruitment period of 3 years. An LOT-CRT group will be compared with a group of conventional BiVP in the follow-up of at least 6 months. The study aimed to compare the curative effect of LOT-CRT in preserving LV systolic function with traditional BiVP in chronic heart failure pati","Shanghai Zhongshan Hospital, Sir Run Run Shaw Hospital, Fu Wai Hospital, Beijing, China, West China Hospital, The First Affiliated Hospital of Dalian Medical University, The First People's Hospital of Yunnan, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Guangdong Provincial People's Hospital, Shanghai Tong Ren Hospital, Fujian Provincial Hospital, Fujian Medical University Union Hospital",2027-03,ESTIMATED,18 Years - 80 Years,86,ESTIMATED,PARALLEL,OTHER,DOUBLE,A Randomized Controlled Trial of Left Bundle brAnch opTimized Cardiac Resynchronization Therapy Versus conventionaL Bi-vEntricular Pacing in Heart Failure Patients With Nonspecific Intraventricular Conduction Delay,2027-03,ESTIMATED,Left ventricular ejection fraction(LVEF),TREATMENT,ALL,2023-09-21,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT06331923,,RECRUITING,Comprehensive Complication Index,,,RANDOMIZED,2,CGM group | Control group,EXPERIMENTAL | NO_INTERVENTION,"The goal of this multi-center, pragmatic, randomized controlled trial is to assess the effectiveness of continuous glucose monitoring (CGM) compared with conventional monitoring in enhancing surgical outcomes for diabetic patients. The main questions it aims to answer are:

* To assess the effectiveness of CGM compared with conventional monitoring in reducing the comprehensive complication index (CCI) for patients with diabetes or impaired glucose tolerance (IGT) within 30 days after surgery.
* ","Peking University International Hospital, Wang Jing Hospital, ZhuHai Hospital, Beijing Hospital, Siyang County Hospital of Traditional Chinese Medicine, Second Hospital of Shanxi Medical University, Henan Provincial Chest Hospital, Fuzhou First Hospital, Pinggu Hospital of Beijing Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Anhui University of Chinese Medicine, The First Affiliated Hospital of Zhengzhou University, Mindong Hospital of Ningde, The Fifth Hospital of Xiamen, People's Hospital of Ningxia Hui Autonomous Region, The First People's Hospital of Changzhou, The Fifth hospital of Deyang, Suzhou Municipal Hospital, Tang-Du Hospital, Yiyang Central Hospital, First Affiliated Hospital of Xinjiang Medical University, Peng Ding Shan Shi Zhong Yi Yi Yuan, Yueyang Central Hospital, The First People's Hospital of Lianyungang, Haimen District Traditional Chinese Medicine Hospital, The 910th Hospital, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Beijing Tiantan Hospital, Affiliated Hospital of Jiangsu University, Liaocheng People's Hospital, Beijing Chao Yang Hospital, Jilin City Hospital of Chemical Industry, Creen Hospital-465, Wuhan Central Hospital, Air Force Military Medical University, China, Shanghai Tong Ren Hospital, Beijing Anzhen Hospital, Emergency General Hospital, Beijing Tongren Hospital, Civil Aviation General Hospital, Peking University Shougang Hospital, The First Affiliated Hospital of Anhui Medical University, Chinese PLA Central Hospital",2025-12-31,ESTIMATED,18 Years - N/A,10168,ESTIMATED,PARALLEL,OTHER,SINGLE,"Assessing the Effectiveness of Continuous Glucose Monitoring Compared with Conventional Monitoring in Enhancing Surgical Outcomes for Patients with Diabetes: a Multi-center, Parallel-arm, Randomized, Pragmatic Trial in China",2025-10-31,ESTIMATED,Comprehensive complication index,TREATMENT,ALL,2024-04-12,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT04967833,EARLY_PHASE1,RECRUITING,Advanced Solid Tumors,Tumor Infiltrating Lymphocytes (TIL),,,1,Tumor Infiltrating Lymphocytes,EXPERIMENTAL,"This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with Advanced malignant solid tumors.Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.",Shanghai Tong Ren Hospital,2026-04-22,ESTIMATED,18 Years - 75 Years,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Clinical Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection in Patients With Advanced Malignant Solid Tumors,2025-12-22,ESTIMATED,Adverse Events(AE) | Objective Response Rate (ORR),TREATMENT,ALL,2021-04-22,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT05494658,,RECRUITING,"Insulin Resistance, Colorectal Cancer",,,RANDOMIZED,2,research group | control group,EXPERIMENTAL | PLACEBO_COMPARATOR,"Postoperative insulin resistance refers to the phenomenon that the body's glucose uptake stimulated by insulin is reduced due to stress effects such as trauma or the inhibitory effect of insulin on liver glucose output is weakened after surgery.

There is a clear link between postoperative insulin resistance and poor perioperative prognosis. Therefore, exploring interventions to reduce postoperative stress insulin resistance, stabilize postoperative blood glucose, and reduce postoperative compli","Huashan Hospital, Yangpu District Central Hospital Affiliated to Tongji University",2024-12,ESTIMATED,50 Years - 80 Years,224,ESTIMATED,PARALLEL,OTHER,NONE,A Multicenter Randomized Controlled Study of Preoperative Oral Administration of Branched-chain Amino Acids in Reducing Postoperative Insulin Resistance in Colorectal Cancer Patients,2024-12,ESTIMATED,The proportion of postoperative blood glucose>8mmol/L,TREATMENT,ALL,2022-08-26,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT06745167,,NOT_YET_RECRUITING,Atrial Fibrillation (AF),,,RANDOMIZED,2,Pulsed field ablation | Radiofrequency Ablation,EXPERIMENTAL | ACTIVE_COMPARATOR,"This multicenter, randomized controlled trial aims to compare the efficacy and safety of extensive electro-anatomical guided pulsed field ablation (EXT-PFA) with traditional radiofrequency ablation (RF) in treating persistent atrial fibrillation (PeAF). The trial seeks to determine if EXT-PFA, which integrates anatomical and electrogram-guided strategies, can provide superior outcomes in terms of safety and effectiveness compared to the standard RF ablation approach.","Albert Einstein College of Medicine and Montefiore Medical Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shandong University of Traditional Chinese Medicine, Yuhuan Second People's Hospital, Changshu Hospital of Traditional Chinese Medicine, The PLA Navy Anqing Hospital, Jinan People's Hospital, Xuzhou Central Hospital",2026-12-31,ESTIMATED,18 Years - 80 Years,600,ESTIMATED,PARALLEL,OTHER,DOUBLE,Comparative Efficacy and Safety of Electro-Anatomical Guided Pulsed Field Ablation Versus Radiofrequency Ablation in the Treatment of Persistent Atrial Fibrillation: A Randomized Controlled Trial,2026-12-31,ESTIMATED,Freedom from Atrial Arrhythmia Recurrence at 12 Months,TREATMENT,ALL,2025-01-01,ESTIMATED,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT05736965,PHASE2,RECRUITING,"AML, Adult","Selinexor, Azacitidine, Venetoclax",SAV,,1,SAV arm,EXPERIMENTAL,"This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.",,2027-04-30,ESTIMATED,18 Years - N/A,58,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Clinical Efficacy and Safety of Selinexol Combined With Azacitidine and Venetoclax (SAV Regimen) in the Treatment of Acute Myeloid Leukemia (AML)-a Multi-center, Single-arm, Prospective Clinical Study",2025-03-30,ESTIMATED,Percentage of Participants With Composite Complete Remission,TREATMENT,ALL,2023-02-20,ACTUAL,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT06583564,,NOT_YET_RECRUITING,Colorectal Cancer Stage III,,,RANDOMIZED,2,ICG group | Non-ICG group,EXPERIMENTAL | NO_INTERVENTION,"Previous studies of Indocyanine green (ICG) in colorectal surgery have focused on lymphatic mapping, lymph node detection, and the number of harvested lymph nodes. However, relatively few studies have evaluated the outcomes of this imaging technology, especially the prognosis following of colorectal cancer resection. The present study assessed the prognosis of stage III colorectal cancer patients following ICG fluorescence-guided surgery as compared to conventional surgery without the use of ICG",,2025-03-31,ESTIMATED,18 Years - N/A,192,ESTIMATED,PARALLEL,OTHER,NONE,A Single Center Randomized Controlled Study of the Prognosis After Indocyanine Green Fluorescence-guided Radical Surgery in Colorectal Cancer Patients of Stage III,2025-03-31,ESTIMATED,Disease-free survival (DFS) rate,TREATMENT,ALL,2024-09-27,ESTIMATED,INTERVENTIONAL
TGRNF,Tong Ren Tang Technologies Co. Ltd.,NCT06064669,,RECRUITING,"Metformin, Prediabetes, In-Vitro Fertilization","Metformin pretreatment before ovarian stimulation, Placebo pretreatment before ovarian stimulation, Metformin pretreatment before endometrial preparation for frozen embryo transfer, Placebo pretreatment before endometrial preparation for frozen embryo transfer",MELT-PreDM,RANDOMIZED,4,Metformin-Metformin Group | Metformin-Placebo Group | Placebo-Metformin Group | Placebo-Placebo Group,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,To evaluate the efficacy and safety of metformin pretreatment on reproductive outcomes in infertile women with prediabetes.,"Ren Ji Hospital of Shanghai Jiao Tong University, Women's Hospital of Zhejiang University, Shengjing Hospital, Nanjing Medical University, General Hospital of Ningxia Medical University, West China Second University Hospital, Maternal and Child Health Hospital of Henan Province, Qingdao women's and children's Hospital",2027-12-31,ESTIMATED,20 Years - 40 Years,988,ESTIMATED,FACTORIAL,OTHER,TRIPLE,Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial,2026-12-31,ESTIMATED,healthy live birth,TREATMENT,FEMALE,2024-02-22,ACTUAL,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT07082842,PHASE3,NOT_YET_RECRUITING,Idiopathic Pulmonary Fibrosis (IPF),"HEC585, Placebo, Pirfenidone",,RANDOMIZED,3,HEC585 | Placebo | pirfenidone,EXPERIMENTAL | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)",,2032-02-15,ESTIMATED,40 Years - 80 Years,472,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Parallel, Randomized, Placebo (Double-blind) and Pirfenidone (Open-label) Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HEC585 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)",2031-01-15,ESTIMATED,Change in FVC from baseline at 52 weeks (mL),TREATMENT,ALL,2025-10-09,ESTIMATED,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT04415853,PHASE3,RECRUITING,Esophageal Cancer,"Lerotinib, Irinotecan/Tegafur",,RANDOMIZED,2,Lerotinib Arm | Active Comparator Arm,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled and randomly assigned to the experimental group and control group at a 1: 1 ratio.,who received Larotinib and the chemotherapy regimen chosen by the investigator (Irinotecan Hydrochloride Injection or Tegafur Gimeracil Oteracil Potassium Capsule),respecitively.

Subjects ",,2026-12-30,ESTIMATED,18 Years - 80 Years,416,ESTIMATED,PARALLEL,INDUSTRY,NONE,Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study,2026-08,ESTIMATED,Overall survival,TREATMENT,ALL,2021-01-21,ACTUAL,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT05048368,PHASE1,NOT_YET_RECRUITING,"Esophageal Cancer, Advanced Solid Tumor",Larotinib,,NON_RANDOMIZED,4,Cohort A-Larotinib | Cohort B-Larotinib | Cohort C-Larotinib | Cohort D-Larotinib,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration",,2026-12-30,ESTIMATED,18 Years - 70 Years,32,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Pharmacokinetic Study of Larotinib in Subjects With Mild/Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function,2026-12-30,ESTIMATED,Cmax | Area Under Curve From 0 to Infinity (AUC0-infinity),TREATMENT,ALL,2026-10-30,ESTIMATED,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT05586074,PHASE3,RECRUITING,"Leukemia, Acute Myeloid (AML)","Clifutinib, LoDAC, Azacitidine, Decitabine, Ara-C±IDA, FLAG-IDA",,RANDOMIZED,2,Clifutinib | Salvage Chemotherapy,EXPERIMENTAL | ACTIVE_COMPARATOR,"A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.",,2027-06-14,ESTIMATED,18 Years - N/A,324,ESTIMATED,PARALLEL,INDUSTRY,NONE,"HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial",2026-03-10,ESTIMATED,OS | CR/CRh rate,TREATMENT,ALL,2023-03-03,ACTUAL,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT07102251,PHASE1,NOT_YET_RECRUITING,Healthy Subjects,"HEC-007 injection, Placebo, HEC-007 injection, Placebo",,RANDOMIZED,4,SAD Stage: HEC-007 Injection | SAD Stage: Placebo | MAD Stage: HEC-007 injection | MAD Stage: Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose administration in healthy subjects and multiple-dose administration in overweight or obese subjects.

The trial consists of two parts: Part A is a single ascending dose (SAD) study, planning to enroll 54 Chinese healthy subjects; Part B is a multiple ascending dose (MAD) study, p",,2026-12-31,ESTIMATED,18 Years - 65 Years,126,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HEC-007 Injection After Single-Dose Administration in Healthy Subjects and Multiple-Dose Administration in Overweight or Obese Subjects",2026-12-31,ESTIMATED,Adverse events (AEs) | The maximum plasma concentration (Cmax) | Time to maximum plasma concentration (Tmax) | Terminal half-life (t1/2) | Apparent clearance (CL/F) | Apparent volume of distribution (Vz/F) | Area Under the PlasmaConcentration-TimeCurve (AUC) of HEC-007 | Changes from baseline in Body Weight | Changes from baseline in waist circumference | Changes from baseline in Fasting Plasma Glucose | Changes from baseline in Fasting Insulin | Changes from baseline in fasting blood lipids,TREATMENT,ALL,2025-08-31,ESTIMATED,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT07376200,PHASE1,NOT_YET_RECRUITING,Healthy Adult Male,"HEC-151 Injection and placebo, Degludec insulin",,RANDOMIZED,2,HEC-151 Injection and placebo | Insulin Degludec,EXPERIMENTAL | ACTIVE_COMPARATOR,"Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants",,2026-09-27,ESTIMATED,18 Years - 45 Years,81,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"An I-phase Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics of a Single Dose of HEC-151 Injection in Healthy Chinese Participants in a Single-center, Randomized, Placebo (Single-blind) and Positive Control (Open-label) Study",2026-09-05,ESTIMATED,Adverse event | Electrocardiogram parameter（Heart rate） | Electrocardiogram parameter（PR interval） | Electrocardiogram parameter（QTcF interval） | Electrocardiogram parameter(QRS interval) | Vital signs parameter（Body temperature） | Vital signs parameter（Blood pressure） | Vital signs parameter（Pulse） | Vital signs parameter（Respiration）,TREATMENT,MALE,2026-03-11,ESTIMATED,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT05139719,PHASE2,RECRUITING,Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF),"HEC585 dose A, HEC585 dose B, Placebo",,RANDOMIZED,3,HEC585 tables does A | HEC585 tables does B | placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing interstitial lung diseases. This study is divided into two stages, i.e. main study stage with 24 weeks treatment duration followed by up to 96 weeks treatment extended study stage.",,2026-12,ESTIMATED,18 Years - N/A,110,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase IIb, Multi-center, Randomized, Double Blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With Progressive Fibrosing Interstitial Lung Disease",2024-12,ESTIMATED,Change from Baseline to Week 24 in FVC (mL) compared with placebo,TREATMENT,ALL,2023-02-15,ACTUAL,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT07341672,PHASE1,NOT_YET_RECRUITING,Healthy Adult Subject,"Clifutinib, Itraconazole, fluconazole, efavirenz",,RANDOMIZED,4,Clifutinib | Clifutinib and Itraconazole | Clifutinib and Fluconazole | Clifutinib and Efavirenz,EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"Evaluate the pharmacokinetic effects of itraconazole, fluconazole, or efavirenz on a single - dose of Clifutinib and the safety of the combination therapy in healthy participants.",,2026-05-08,ESTIMATED,18 Years - 50 Years,80,ESTIMATED,PARALLEL,INDUSTRY,NONE,The Drug-Drug Interaction Study of Clifutinib,2026-04-23,ESTIMATED,Cmax | AUC0-t | AUC0-∞ | %AUCex | Tmax | t1/2,TREATMENT,ALL,2026-03-04,ESTIMATED,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT07099118,PHASE1,NOT_YET_RECRUITING,Non - Alcoholic Steatohepatitis,"HEC169584 capsule, placebo",,RANDOMIZED,11,Dose group-1 | Dose group-2 | Dose group-3 | Dose group-4 | Dose group-5 | Dose group-6 | Dose group-7 | Dose group-8 | Dose group-9 | Dose group-10 | Dose group-11,EXPERIMENTAL | SHAM_COMPARATOR | SHAM_COMPARATOR | SHAM_COMPARATOR | SHAM_COMPARATOR | SHAM_COMPARATOR | SHAM_COMPARATOR | SHAM_COMPARATOR | SHAM_COMPARATOR | SHAM_COMPARATOR | SHAM_COMPARATOR,"The safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics study of HEC169584 capsules in healthy subjects .",,2027-03-06,ESTIMATED,18 Years - 45 Years,96,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of Single and Multiple Doses of HEC169584 Capsules and the Effect of Food on Its Pharmacokinetics in Healthy Subjects",2026-12-30,ESTIMATED,Adverse event,TREATMENT,ALL,2025-08-14,ESTIMATED,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT05451602,"PHASE1, PHASE2",RECRUITING,Advanced Solid Tumor,HEC169096,,,1,HEC169096,EXPERIMENTAL,"An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors.",,2027-08-30,ESTIMATED,18 Years - N/A,456,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Phase 1/2 Study of the Highly-selective RET Inhibitor,HEC169096 in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",2025-07-30,ESTIMATED,Phase 1: MTD and RP2D of HEC169096 | Phase 2: Overall Response Rate,TREATMENT,ALL,2022-10-21,ACTUAL,INTERVENTIONAL
YIHCF,"Sunshine Lake Pharma Co., Ltd.",NCT05133882,"PHASE1, PHASE2",RECRUITING,"Acute Myeloid Leukemia, Adult",Clifutinib Besylate,,NON_RANDOMIZED,3,Arm 1 | Arm 2 | Arm 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML,,2026-08-15,ESTIMATED,18 Years - N/A,133,ESTIMATED,SEQUENTIAL,INDUSTRY,SINGLE,"A Phase Ib/II, Multi-center, Open Clinical Trial of Crifortinib Besylate Combined With Chemotherapy in Newly-treated Adult Subjects With Acute Myeloid Leukemia",2026-05-15,ESTIMATED,Maximum tolerated dose(MTD) | Composite CR rate,TREATMENT,ALL,2022-10-31,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT04419402,PHASE2,ACTIVE_NOT_RECRUITING,Metastatic Castration-Resistant Prostate Cancer,"Lu-PSMA, Enzalutamide",ENZA-p,RANDOMIZED,2,Lu-PSMA + Enzalutamide | Enzalutamide,EXPERIMENTAL | ACTIVE_COMPARATOR,This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.,"National Health and Medical Research Council, Clinical Trials Centre, Prostate Cancer Research Alliance, Endocyte, Astellas Pharma Inc",2025-01-01,ESTIMATED,18 Years - N/A,162,ACTUAL,PARALLEL,OTHER,NONE,ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide (ANZUP 1901),2024-07-31,ESTIMATED,Prostate Specific Antigen (PSA) Progression-Free Survival,TREATMENT,MALE,2020-08-17,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT06926842,PHASE2,ACTIVE_NOT_RECRUITING,"Overweight, Type 2 Diabetes, Obesity",Petrelintide,,RANDOMIZED,6,Treatment A: Petrelintide Dose 1 | Treatment B: Petrelintide Placebo Dose 1 | Treatment C: Petrelintide Dose 2 | Treatment D: Petrelintide Placebo Dose 2 | Treatment E: Petrelintide Dose 3 | Treatment F: Petrelintide Placebo Dose 3,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.,Parexel,2026-08-13,ESTIMATED,18 Years - N/A,221,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes",2026-08-13,ESTIMATED,Percentage Change in Body Weight,TREATMENT,ALL,2025-04-22,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT07338214,PHASE1,ACTIVE_NOT_RECRUITING,Obesity & Overweight,Petrelintide,,RANDOMIZED,4,Arm A | Arm B | Arm C | Arm D,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with co-morbidities or related diseases.

The goal is to learn how the same single dose of petrelintide, given using different concentrations, works in the body when given to participants with a BMI at, or above, 27kg/m2.

The main questions it aims to answer are:

1. Are there differences in how the body absorbs, distributes, metabolises ",ICON Clinical Research,2026-03,ESTIMATED,18 Years - 64 Years,48,ACTUAL,PARALLEL,INDUSTRY,NONE,Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations in Participants With a BMI ≥27.0 kg/m²,2026-03,ESTIMATED,To investigate the Pharmacokinetics of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity | To investigate the Pharmacokinetics of a single dose administration of petrelintide administered subcutaneously using 4 different drug product concentrations in participants with overweight or obesity,BASIC_SCIENCE,ALL,2025-12-17,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT03905707,PHASE3,ACTIVE_NOT_RECRUITING,Short Bowel Syndrome,glepaglutide,EASE SBS 2,RANDOMIZED,2,Glepaglutide SC injections twice weekly | Glepaglutide SC injections once weekly and placebo once weekly,EXPERIMENTAL | EXPERIMENTAL,"The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS).

Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.",,2026-04,ESTIMATED,18 Years - 90 Years,145,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS),2026-04,ESTIMATED,Safety - Adverse Events,TREATMENT,ALL,2019-05-07,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT04881825,PHASE3,ACTIVE_NOT_RECRUITING,Short Bowel Syndrome,Glepaglutide,EASE SBS 3,,1,once-weekly glepaglutide,EXPERIMENTAL,"This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.",,2026-04,ESTIMATED,18 Years - 90 Years,129,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial",2026-04,ESTIMATED,Incidence and type of Adverse Events (AEs),TREATMENT,ALL,2021-06-16,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT07197944,PHASE3,RECRUITING,Short Bowel Syndrome,Glepaglutide,EASE SBS 5,RANDOMIZED,2,Glepaglutide Group | Placebo Group,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data.

Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.",,2032-02-28,ESTIMATED,18 Years - 90 Years,90,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Double-blind, Randomized, Parallel Group, Placebo-controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice Weekly, Followed by a Long-term, Open-label Safety Evaluation in Patients With Short Bowel Syndrome-intestinal Failure (SBS-IF)",2028-10-23,ESTIMATED,Change in weekly Parenteral Support (PS) volume,TREATMENT,ALL,2026-02-11,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT06662539,PHASE2,ACTIVE_NOT_RECRUITING,Obesity,"Petrelintide, Placebo",ZUPREME,RANDOMIZED,6,Petrelintide Dose 1 | Petrelintide Dose 2 | Petrelintide Dose 3 | Petrelintide Dose 4 | Petrelintide Dose 5 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.",Parexel,2026-03-16,ESTIMATED,18 Years - N/A,493,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-blind, Phase 2, Dose-finding Trial of Once Weekly Petrelintide Compared With Placebo in Participants With Obesity or Overweight With Weight Related Comorbidities",2025-09-30,ACTUAL,Percent change from baseline in body weight to Week 28,TREATMENT,ALL,2024-12-09,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT03941236,PHASE3,ACTIVE_NOT_RECRUITING,Congenital Hyperinsulinism,dasiglucagon,,,1,Dasiglucagon open-label,EXPERIMENTAL,"This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 or ZP4207-17109 (defined as lead-in trials).

The primary objective is to evaluate the long-term safety of dasiglucagon administered as a subcutaneous (SC) infusion in children with CHI.",,2026-12-31,ESTIMATED,5 Weeks - 13 Years,42,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism,2025-01-28,ACTUAL,Adverse Events,TREATMENT,ALL,2019-05-02,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT06682975,PHASE1,RECRUITING,Healthy Volunteers,"ZP9830, Placebo",,RANDOMIZED,2,ZP9830 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The primary object in this research study is to investigate the safety and tolerability of ZP9830 in healthy study participants, and in addition, the study will investigate how ZP9830 works in the body (pharmacokinetics, PK and pharmacodynamics, PD) compared to placebo.",,2026-08,ESTIMATED,18 Years - 45 Years,124,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A First-in-human, Randomized and Double-blind Within Cohorts, Placebo-controlled, Single and Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP9830 Administered to Healthy Participants.",2026-08,ESTIMATED,Incident of Treatment Emergent Adverse Events (TEAEs),TREATMENT,ALL,2024-11-12,ACTUAL,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT02446405,PHASE3,ACTIVE_NOT_RECRUITING,Prostatic Neoplasms,"Enzalutamide, NSAA, LHRHA or Surgical Castration",ENZAMET,RANDOMIZED,2,Enzalutamide | Conventional NSAA,EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.","Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Trials Ireland, Canadian Cancer Trials Group, Astellas Pharma Inc",2027-06-30,ESTIMATED,18 Years - N/A,1125,ACTUAL,PARALLEL,OTHER,NONE,Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET,2026-12-31,ESTIMATED,Overall Survival Time,TREATMENT,MALE,2014-03,,INTERVENTIONAL
ZLDPF,Zealand Pharma A/S,NCT05788601,PHASE2,ACTIVE_NOT_RECRUITING,"Obesity, Inflammation","Dapiglutide, Placebo",DREAM,RANDOMIZED,3,Placebo (4 mg and 6 mg) | 4 mg dapiglutide | 6 mg dapiglutide,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered subcutaneously once weekly. The study will investigate the efficacy of once-weekly subcutaneously administered of 4 mg and 6 mg dapiglutide versus placebo in 54 obese individuals (BMI \>30 kg/m2) during a 12-week treatment period.",Zealand Pharma,2025-08-15,ESTIMATED,18 Years - 75 Years,54,ESTIMATED,PARALLEL,OTHER,DOUBLE,"Dapiglutide for the Treatment of Obesity (DREAM): a Randomised, Double-blind, Placebo-controlled, Investigator-initiated Trial",2024-04-24,ACTUAL,Percentage change in body weight (kg),TREATMENT,ALL,2023-04-27,ACTUAL,INTERVENTIONAL
ORMP,Oramed Pharmaceuticals Inc.,NCT06731075,PHASE3,NOT_YET_RECRUITING,Type 2 Diabetes Mellitus,"ORMD-0801 8 mg, ORMD-0801 16 mg",,RANDOMIZED,4,ORMD-0801 8 mg once-daily at night - QD | ORMD-0801 8 mg twice daily - BID | ORMD-0801 16 mg once-daily at night - QD | Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"ORA-013-3 is a randomized, controlled study to test the efficacy and safety of an oral capsule of ORMD-0801 at several doses in patients with Type 2 Diabetes Mellitus (T2DM) who have not responded well to other glucose-lowering medications. A total of three hundred subjects will be enrolled in this study and will be required to complete this thirty-four-week clinical trial.","InClin, Inc.",2027-05-22,ESTIMATED,50 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on One to Three Glucose-lowering Agents",2027-04-25,ESTIMATED,Change from baseline in A1C at 26 weeks,TREATMENT,ALL,2025-12-15,ESTIMATED,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT05813678,,RECRUITING,Phenylketonuria (PKU),Pegvaliase,PALace,,0,,,"This is a 10-year multi-center, global, observational study to further characterize the safety profile of pegvaliase, including hypersensitivity reactions, long-term safety and tolerability, and the effectiveness of the additional risk minimization measures (aRMMs) (European Union (EU) only) in subjects receiving pegvaliase for the treatment of PKU. Subjects for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enroll",,2033-11-01,ESTIMATED,N/A - N/A,450,ESTIMATED,,INDUSTRY,,"A Multi-Center, Observational Study to Evaluate the Long-Term Safety of Subcutaneous Injections of Palynziq® (Pegvaliase) in Subjects With Phenylketonuria",2033-11-01,ESTIMATED,To quantify and characterize the risk of protocol-defined safety events in incident-users receiving pegvaliase for the treatment of PKU in a real¬ world setting.,,ALL,2022-06-06,ACTUAL,OBSERVATIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT03424018,PHASE3,ACTIVE_NOT_RECRUITING,Achondroplasia,BMN 111,,,1,BMN 111,EXPERIMENTAL,The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia,,2031-06,ESTIMATED,6 Years - N/A,119,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia",2031-06,ESTIMATED,Change from baselines in mean annualized growth velocity,TREATMENT,ALL,2017-12-12,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06668805,PHASE2,RECRUITING,"Short Stature Homeobox- Containing Gene SHOX Deficiency, Noonan Syndrome, Turner Syndrome","Vosoritide Injection, Human Growth Hormone",,RANDOMIZED,4,Vosoritide Dose 1 - Low Dose | Vosoritide Dose 2 - Medium Dose | Vosoritide Dose 3- High Dose | Human Growth Hormone,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this basket study in children with Turner syndrome, SHOX deficiency, and Noonan syndrome is to evaluate the effect of 3 doses of vosoritide versus hGH on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up to FAH.",,2041-09,ESTIMATED,3 Years - 11 Years,72,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Randomized, Human Growth Hormone-Controlled, Multicenter, Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With an Inadequate Response to Human Growth Hormone. (CANOPY NS, TS, SHOX-D-2)",2027-03,ESTIMATED,Change from baseline in Annualized Growth Velocity (AGV),TREATMENT,ALL,2024-11-22,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06738017,PHASE1,RECRUITING,Alpha 1-Antitrypsin Deficiency,"BMN 349, Placebo",,RANDOMIZED,2,Group A (PiZZ) | Group B (PiMZ),OTHER | OTHER,"The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH.

Primary outcome measures include incidence of any adverse events (including serious adverse events, dose limit toxicities, and adverse events of special interest), incidence of any laboratory test abnormalities, incidence of lung function test abnormalities and 12-lead ECG parameters.

Participants will receive a single dose of either BMN 349 or place",,2025-09,ESTIMATED,18 Years - 75 Years,12,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study Evaluating the Safety and Pharmacokinetics of BMN 349 in Homozygous for the Z Mutation of Alpha 1 Antitrypsin Gene (PiZZ) and Heterozygous for the Z Mutation (PiMZ/MASH)",2025-09,ESTIMATED,"Participant Adverse Events, Serious Adverse Events, Dose Limit Toxicities, Adverse Event of Special Interests, abnormal laboratory tests, abnormal pulmonary function tests, and 12-lead ECG parameters",TREATMENT,ALL,2025-02-21,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT04800692,PHASE1,RECRUITING,"Claudication, Intermittent, Peripheral Artery Disease, Peripheral Vascular Diseases","Tetrahydrobiopterin 10 mg/kg, Tetrahydrobiopterin 20 mg/kg, L-Ascorbate, L-Arginine",ATLAS,NON_RANDOMIZED,2,Tetrahydrobiopterin Dose 1 (Day 0 to 44) | Tetrahydrobiopterin Dose 2 (Day 45 to 90),EXPERIMENTAL | EXPERIMENTAL,This study will focus on people with claudication from peripheral arterial disease. The investigators are researching whether a multicomponent therapeutic can increase the production of Nitric Oxide in the blood and whether that leads to an improvement in pain free walking distance and overall physical activity.,BioMarin Pharmaceutical,2027-12,ESTIMATED,18 Years - N/A,10,ESTIMATED,PARALLEL,OTHER,NONE,The Effects of ATLAS (Arginine Tetrahydrobiopterin L-Ascorbate) Therapy on Nitric Oxide Bioavailability and Pain-free Walking in Patients With Intermittent Claudication,2027-07,ESTIMATED,Nitric Oxide bioavailability,OTHER,ALL,2021-06-15,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06382155,PHASE2,RECRUITING,Idiopathic Short Stature,"Vosoritide Injection, Human Growth Hormone, Placebo",,RANDOMIZED,5,Vosoritide Dose 1 - Low Dose | Vosoritide Dose 2 - Medium Dose | Vosoritide Dose 3 - High Dose | Placebo | Human Growth Hormone,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH), in children with idiopathic short stature (ISS).",,2036-12,ESTIMATED,3 Years - 10 Years,100,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children with Idiopathic Short Stature",2026-06,ESTIMATED,Change from baseline in Annualized Growth Velocity (AGV) | Change from baseline in height | Change from baseline in height Z-score,TREATMENT,ALL,2024-10-21,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT05270837,PHASE3,ACTIVE_NOT_RECRUITING,Phenylketonuria (PKU),Pegvaliase,PEGASUS,RANDOMIZED,2,Pegvaliase | Diet Only,EXPERIMENTAL | OTHER,This is a Phase 3 open-label randomized controlled study enrolling approximately 54 adolescents with PKU. The study is designed to assess the safety and efficacy of pegvaliase injections.,,2027-10,ESTIMATED,12 Years - 17 Years,55,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) With Phenylketonuria Featuring an Open-Label Randomized Two-Arm (Active vs Diet-Only Control) Design,2025-01-14,ACTUAL,Change in blood Phe concentration | Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0,TREATMENT,ALL,2022-06-17,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06224907,PHASE3,ACTIVE_NOT_RECRUITING,Hemophilia A,Valoctocogene roxaparvovec,GENEr8-JPN,,1,Valoctocogene roxaparvovec,EXPERIMENTAL,This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in Japanese patients with severe hemophilia A.,,2029-03,ESTIMATED,18 Years - N/A,6,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"GENEr8-JPN: A Phase 3 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Japanese Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions",2025-03,ESTIMATED,"Change in the human coagulation factor VIII (hFVIII) activity, as measured by chromogenic substrate assay, during Weeks 49 to 52 post BMN 270 infusion from Baseline.",TREATMENT,MALE,2023-12-25,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT04684940,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII",Valoctocogene roxaparvovec,GENEr8-INH,,1,Valoctocogene roxaparvovec Open Label,EXPERIMENTAL,"This Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII. Part A of the study will involve subjects who have active inhibitors to FVIII, and Part B involving subjects with a prior history of inhibitors.",,2029-04,ESTIMATED,18 Years - N/A,10,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Active or Prior Inhibitors",2029-04,ESTIMATED,"Number of participants with treatment-related adverse events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 after administration of BMN 270.",TREATMENT,MALE,2020-12-10,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06212947,,RECRUITING,Hypochondroplasia,,,,1,Children with Hypochondroplasia,,This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.,,2043-12-31,ESTIMATED,N/A - 15 Years,400,ESTIMATED,,INDUSTRY,,A Multicenter Multinational Observational Study of Children With Hypochondroplasia,2043-12-31,ESTIMATED,Change in annualized growth velocity (AGV) | Change in Height Z-score | Change in Height | Change in BMI | Change in BMI Z-score | Change in ratios of upper to lower body segments | Change in ratios of upper and lower leg length ratio | Change in ratio of arms span to standing height ratio,,ALL,2023-11-27,ACTUAL,OBSERVATIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT04554940,PHASE2,ACTIVE_NOT_RECRUITING,Achondroplasia,vosoritide,,RANDOMIZED,2,Vosoritide + Standard of Care | Standard of Care Alone,EXPERIMENTAL | NO_INTERVENTION,"Study 111-209 is a Phase 2 randomized, open-label clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia at a heightened risk of requiring cervicomedullary decompression surgery",,2027-12,ESTIMATED,0 Months - 12 Months,20,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery",2027-12,ESTIMATED,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],TREATMENT,ALL,2020-10-10,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06280209,"PHASE1, PHASE2",RECRUITING,Duchenne Muscular Dystrophy,BMN 351,,NON_RANDOMIZED,4,Cohort 1A | Cohort 1B | Cohort 2 | Cohort 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.,,2026-09-30,ESTIMATED,4 Years - 10 Years,18,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intravenous Doses of BMN 351 in Participants With Duchenne Muscular Dystrophy",2026-09-30,ESTIMATED,"To evaluate and safety and tolerability of single and multiple doses of BMN 351 (incidence, severity, and dose-relationship of adverse effects and changes in laboratory parameters).",TREATMENT,MALE,2024-01-03,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT02724228,PHASE2,ACTIVE_NOT_RECRUITING,Achondroplasia,BMN 111,ACH,,1,BMN 111 - Subcutaneous Injection,EXPERIMENTAL,"This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.",,2028-02,ESTIMATED,7 Years - N/A,30,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia",2027-12,ESTIMATED,Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability],TREATMENT,ALL,2016-01-26,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT04476862,,ACTIVE_NOT_RECRUITING,Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2,Cerliponase Alfa,,,1,Cerliponase alfa patients,,"This is a multicenter, observational study for patients with a confirmed diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as TPP1 deficiency, who intend to be or are currently being treated with cerliponase alfa. Patients receiving or expected to receive cerliponase alfa within 60 days of signing the informed consent form (ICF) may be eligible to enroll in the study, assuming all regulatory requirements for sites that have agreed to participate and protocol inclusion",,2030-08-31,ESTIMATED,N/A - N/A,35,ESTIMATED,,INDUSTRY,,Cerliponase Alfa Observational Study,2030-08-31,ESTIMATED,Safety surveillance of cerliponase alfa,,ALL,2020-08-19,ACTUAL,OBSERVATIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06780332,PHASE4,RECRUITING,"Phenylketonuria, PKU",RDD to Palynziq,PALLADIUM,,1,RDD,EXPERIMENTAL,"The purpose of this study is to determine if rapid drug desensitization (RDD) to Palynziq will improve drug tolerability and treatment persistence in adult patients on commercial Palynziq experiencing hypersensitivity reactions (HSRs) leading to treatment interruption or reduction of dose or dosing frequency. See Section 10.8 for full list of HSR preferred terms. Study details include:

* Study duration: Up to 30 weeks (up to 6 weeks for Screening, then RDD, and 24 weeks of follow-up)
* RDD dura",,2025-11,ESTIMATED,18 Years - N/A,10,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 4 Study to Evaluate the Impact of a Rapid Drug Desensitization (RDD) Protocol for Adults with Phenylketonuria and Experiencing Hypersensitivity Reactions to Palynziq,2025-11,ESTIMATED,To determine if RDD to Palynziq improves drug tolerability and treatment persistence in adults with PKU experiencing HSRs leading to treatment interruption or reduction of dose or dosing frequency (reactive HSR).,TREATMENT,ALL,2025-01,ESTIMATED,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06455059,PHASE3,ACTIVE_NOT_RECRUITING,Hypochondroplasia,"Vosoritide, Placebo",CANOPY-HCH-3,RANDOMIZED,2,vosoritide injection with vial and syringe | Placebo injection with vial and syringe,EXPERIMENTAL | PLACEBO_COMPARATOR,The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).,,2026-08-01,ESTIMATED,3 Years - 17 Years,80,ESTIMATED,SINGLE_GROUP,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children With Hypochondroplasia",2026-08-01,ESTIMATED,Change from baseline in annualized growth velocity (AGV) at Week 52 versus placebo,TREATMENT,ALL,2024-06-17,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT03989947,PHASE2,ACTIVE_NOT_RECRUITING,Achondroplasia,Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.,,,1,Active BMN 111,EXPERIMENTAL,"This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206.",,2038-05,ESTIMATED,15 Months - N/A,73,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia,2038-05,ESTIMATED,Evaluate the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Evaluate change in height/length z-score in children with ACH treated with BMN 111,TREATMENT,ALL,2019-06-12,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT07126262,PHASE2,RECRUITING,Hypochondroplasia,"Vosoritide, Placebo",,RANDOMIZED,2,Vosoritide injection with vial and syringe | Placebo injection with vial and syringe,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52-week period.,ICON Clinical Research,2028-06-30,ESTIMATED,0 Months - 36 Months,60,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 Months",2028-06-30,ESTIMATED,"Incidence of treatment-emergent adverse events | Incidence of serious adverse events versus placebo over the course of the study | Changes from baseline in standard clinical laboratory values (hematology, urinalysis, and chemistry) | Changes from baseline in heart rate | Change from baseline in height Z-score | Changes from baseline in respiratory rate | Changes from baseline in temperature | Changes from baseline in blood pressure",TREATMENT,ALL,2025-07-30,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06168201,,RECRUITING,Achondroplasia,,VISTA,,2,Primary Pediatric Cohort | Secondary Adolescent and Adult Cohort, | ,"This is an observational study of individuals with achondroplasia in the United States. The primary study population consists of pediatric individuals treated and untreated with VOXZOGO™. Study enrollment started in February 2023. The projected total duration of the study is approximately 5 years at minimum from start of study recruitment in February 2023, with the duration of individual prospective follow-up differing depending on the time of enrollment. The study duration may be extended based",PicnicHealth,2028-02,ESTIMATED,0 Months - 18 Years,170,ESTIMATED,,INDUSTRY,,VIrtual STudy in Achondroplasia for the US (VISTA),2028-02,ESTIMATED,"Height | Weight | Body Mass Index | Head Circumference | Annualized growth velocity (AGV) | Medical diagnoses by age | Surgical procedures and/or medical interventions by age | Changes in physical functioning | Changes in health-related quality of life (HRQoL) | Adherence to treatment with VOXZOGO™ (vosoritide), if prescribed",,ALL,2023-02-21,ACTUAL,OBSERVATIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT05121376,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Hereditary Angioedema, HAE",,HAErmony-1,,1,BMN 331,EXPERIMENTAL,"This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficienc",,2028-11,ESTIMATED,18 Years - N/A,44,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability & Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency",2028-11,ESTIMATED,Number of participants with treatment-emergent adverse events following a single IV administration of BMN 331,TREATMENT,ALL,2022-02-15,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06309979,,RECRUITING,Idiopathic Short Stature,,,,0,,,Study 111-903 will generate baseline growth data in children with ISS by collecting growth measurements and other variables of interest.,,2040-12-31,ESTIMATED,2 Years - 16 Years,300,ESTIMATED,,INDUSTRY,,"A Multicenter, Observational Study to Characterize Growth in Children With Idiopathic Short Stature",2040-12-31,ESTIMATED,Change in annualized growth velocity (AGV) | Change in Height Z-score | Change in Standing Height | Change in BMI | Change in BMI Z-score,,ALL,2024-08-08,ACTUAL,OBSERVATIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT04480567,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Phenylketonuria (PKU),BMN 307,,NON_RANDOMIZED,3,Dose 1 of BMN 307 | Dose 2 of BMN 307 | Dose 3 of BMN 307,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 1/2, open-label, dose escalation study to evaluate the safety, efficacy and tolerability of BMN 307 in adult PKU subjects with PAH deficiency. Participants will receive a single administration of BMN 307 and will be followed for safety and efficacy.",,2027-12,ESTIMATED,15 Years - N/A,100,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects with Phenylketonuria",2027-12,ESTIMATED,Change from baseline in mean Plasma Phe levels,TREATMENT,ALL,2020-09-24,ACTUAL,INTERVENTIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT06305234,,RECRUITING,Phenylketonuria (PKU),Pegvaliase,,,0,,,"This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvali",,2033-11-18,ESTIMATED,N/A - N/A,200,ESTIMATED,,INDUSTRY,,"A Multi-Center, Prospective, Longitudinal, Study Evaluating Immunologic, Inflammatory, and Laboratory Parameters Associated With Long-Term Palynziq® (Pegvaliase) Treatment in Subjects With Phenylketonuria (PKU) in the United States",2033-11-18,ESTIMATED,To evaluate immunologic and inflammatory responses associated with occurrences of,,ALL,2024-01-20,ACTUAL,OBSERVATIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT05579548,,RECRUITING,"Phenylketonuria, Maternal",Pegvaliase,PALomino,,1,Pregnant Women with PKU,,This is a Phase 4 observational study designed to assess the impact of Palynziq ® (pegvaliase) treatment in pregnant women with PKU and on their offspring who were exposed to pegvaliase at any time during pregnancy and breastfeeding.,Syneos Health,2032-10-04,ESTIMATED,N/A - N/A,50,ESTIMATED,,INDUSTRY,,"A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding",2032-10-04,ESTIMATED,Pregnancy outcome and infant development for women who have been treated with Palynziq (pegvaliase) within 2 weeks of their last menstrual period,,FEMALE,2022-11-22,ACTUAL,OBSERVATIONAL
BMRN,BioMarin Pharmaceutical Inc.,NCT04404530,,RECRUITING,Phenylketonurias,Palynziq,,,1,Palynziq Therapy for PKU,,"Phenylketonuria (PKU) is an inherited metabolic disorder that impairs the metabolism of the essential amino acid phenylalanine (Phe). Without stringent dietary control, Phe accumulates in the blood and brain of PKU patients, leading to severe cognitive deficits. Achieving metabolic control, defined as blood Phe levels within the range of 120-360 μmol/L, has been a significant challenge for PKU patients using traditional diet therapy. The new FDA approved pharmacologic treatment, Palynziq, offers",BioMarin Pharmaceutical,2028-12,ESTIMATED,16 Years - N/A,45,ESTIMATED,,OTHER,,"Palynziq and PKU: Treatment Impacts on Diet Quality, Neurological Health, Nutritional Status, and the Metabolome",2028-12,ESTIMATED,Intra-subject Change in Intact Protein Intake | Intra-subject Change in Medical Food Protein Intake | Sub study: Intra-subject change in intact protein and medical food protein intake.,,ALL,2019-10-08,ACTUAL,OBSERVATIONAL
QTTB,Q32 Bio Inc.,NCT05509023,PHASE2,ACTIVE_NOT_RECRUITING,Atopic Dermatitis,"ADX-914, Placebo",,RANDOMIZED,2,ADX-914 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.",,2024-12,ESTIMATED,18 Years - N/A,102,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis",2024-12,ESTIMATED,Part A only: Safety parameters including incidence of serious adverse events and adverse events of special interest | Part A and B: Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 14 for ADX-914 vs placebo,TREATMENT,ALL,2022-09-30,ACTUAL,INTERVENTIONAL
QTTB,Q32 Bio Inc.,NCT06018428,PHASE2,ACTIVE_NOT_RECRUITING,Alopecia Areata,bempikibart (ADX-914),SIGNAL-AA,,1,Experimental: bempikibart (ADX-914),EXPERIMENTAL,"Part A is a randomized, double-blind, placebo-controlled, multi-center Proof-of-Concept (POC) Trial in subjects with severe Alopecia Areata. All participants in Part A have completed participation.

Part B is a multicenter, open-label study to assess the efficacy, safety, and tolerability of bempikibart (ADX-914) in participants with severe Alopecia Areata.",,2026-09,ESTIMATED,18 Years - 75 Years,75,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial With Part B and Open-label Extension of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)",2026-06,ESTIMATED,Part A: Mean relative percent change in SALT score | Part B: Mean percent change from baseline in SALT score,TREATMENT,ALL,2023-09-12,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06506916,PHASE3,RECRUITING,"Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis",bimekizumab,BE UNIQUE,RANDOMIZED,3,Cohort A | Cohort B | Control Cohort,EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).,,2028-03-14,ESTIMATED,18 Years - N/A,90,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis,2027-03-09,ESTIMATED,Change from Baseline in composite gene expression score using reverse transcription-polymerase chain reaction (RT-PCR) in lesional skin at Week 48,TREATMENT,ALL,2024-07-29,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT04724941,,RECRUITING,Parkinson Disease,,PASS-PD,,2,REM behavior disorder + | REM behavior disorder -, | ,The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.,"UCB Biopharma SRL, University of Kiel",2027-12,ESTIMATED,50 Years - 99 Years,2000,ESTIMATED,,OTHER,,Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study,2027-12,ESTIMATED,Risk marker profile,,ALL,2021-06-01,ACTUAL,OBSERVATIONAL
UCBJY,UCB SA,NCT06617325,PHASE3,RECRUITING,Systemic Lupus Erythematosus,DZP,PHOENYCS FLY,RANDOMIZED,2,Dapirolizumab pegol | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.,,2028-05-31,ESTIMATED,16 Years - N/A,450,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus",2028-05-31,ESTIMATED,Achievement of British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-based Composite Lupus Assessment (BICLA) response at Week 48,TREATMENT,ALL,2024-11-21,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06336343,PHASE4,RECRUITING,Plaque Psoriasis,Bimekizumab,,,1,Individuals with moderate-to-severe psoriasis,EXPERIMENTAL,"The purpose of this research study is to evaluate the effectiveness and safety of bimekizumab in individuals with moderate-to-severe psoriasis who have failed similar therapies. Bimekizumab improves psoriasis by suppressing a type of substance found in bodies called interleukins (specifically, interleukins 17a and 17F), which are known to increase inflammation. This study will look at the effectiveness of bimekizumab in psoriasis patients that have failed previous therapies that target interleuk","UCB Pharma, Psoriasis Treatment Center of Central New Jersey",2026-03-13,ESTIMATED,18 Years - N/A,60,ESTIMATED,SINGLE_GROUP,OTHER,NONE,A Study to Evaluate the Safety and Efficacy of Bimekizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17 or IL-23 Therapies,2026-03-13,ESTIMATED,Body Surface Area (BSA) of < 1,TREATMENT,ALL,2024-06-03,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06055959,"PHASE2, PHASE3",RECRUITING,Generalized Myasthenia Gravis,Zilucoplan,ziMyG,,1,Zilucoplan Arm,EXPERIMENTAL,"The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).",,2026-12-25,ESTIMATED,12 Years - 17 Years,8,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter Open-Label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Activity of Zilucoplan in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis",2026-11-16,ESTIMATED,Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29) | Change from Baseline in sheep red blood cell (sRBC) lysis at Week 4 (Day 29) | Change from Baseline in complement component 5 (C5) levels at Week 4 (Day 29),TREATMENT,ALL,2024-10-16,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06149559,"PHASE2, PHASE3",RECRUITING,Generalized Myasthenia Gravis,rozanolixizumab,roMyG,,1,rozanolixizumab,EXPERIMENTAL,The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).,,2026-08-17,ESTIMATED,2 Years - 17 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis",2026-06-08,ESTIMATED,Occurrence of serious Treatment-Emergent Adverse Events (TEAEs) up to the End of Study (EOS) Visit | Occurrence of TEAEs leading to permanent withdrawal of Investigational Medicinal Product (IMP) up to the EOS Visit | Occurrence of Adverse Event(s) of Special Monitoring (AESM) up to the EOS Visit (up to 18 weeks),TREATMENT,ALL,2024-06-14,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06668181,PHASE3,RECRUITING,"Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis",Bimekizumab,,,1,Bimekizumab,EXPERIMENTAL,The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.,,2030-07-31,ESTIMATED,2 Years - 18 Years,40,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis",2028-04-12,ESTIMATED,Plasma bimekizumab concentrations over the Initial Treatment Period,TREATMENT,ALL,2025-03-11,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06921850,PHASE3,RECRUITING,Hidradenitis Suppurativa,Bimekizumab,,,1,Bimekizumab,EXPERIMENTAL,The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS),,2029-05-30,ESTIMATED,9 Years - 17 Years,40,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter, Open-Label Study to Assess The Pharmacokinetics And Safety of Bimekizumab in Pubertal Children And Adolescents With Moderate to Severe Hidradenitis Suppurativa",2027-03-19,ESTIMATED,Geometric Mean Plasma bimekizumab concentrations at Week 16,TREATMENT,ALL,2025-04-07,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06866483,,RECRUITING,"Myasthenia Gravis, Neuromuscular Disease, Neuromuscular Manifestations",,,,1,Participants with undiagnosed neuromuscular symptoms,,"This study expands and validates the pilot study NCT06381284. It is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The primary objective is to determine the validity of a self-assessment tool in encouraging undiagnosed participants, recruited through a social media campaign, to seek medical evaluation for suspected myasthenia gravis (MG).","UCB Pharma, University of California, San Francisco",2025-12-31,ESTIMATED,18 Years - N/A,1000,ESTIMATED,,INDUSTRY,,Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment,2025-12-31,ESTIMATED,Self-Assessment tool validity,,ALL,2025-02-26,ACTUAL,OBSERVATIONAL
UCBJY,UCB SA,NCT07225231,,NOT_YET_RECRUITING,"Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)",,TETRIS,,1,Patient treated with standard-of-care fenfluramine and wearing remote patient monitoring solution,EXPERIMENTAL,"The goal of this real world data study is to evaluate the clinical utility of remote patient monitoring solution (using Byteflies' EpiCare@Home with reduced EEG montage and other vital signs) with Dravet and LGS patients (ages 3 and up with the exclusion of adults above weight allowing variable titration) to identify an optimal Fenfluramine treatment.

Patients will wear one or more small portable and medically certified measuring devices. Through these devices, electroencephalography (EEG) sign",UCB Pharma,2026-12-31,ESTIMATED,3 Years - N/A,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Byteflies Real-world Data Study: Assessing the Clinical Utility of Reduced EEG Montage Home Monitoring for Clinician-driven Fenfluramine Titration in Dravet Syndrome and Lennox-Gastaut Syndrome,2026-12-31,ESTIMATED,Physician confidence in treatment decision-making using RPM data,SUPPORTIVE_CARE,ALL,2025-12-15,ESTIMATED,INTERVENTIONAL
UCBJY,UCB SA,NCT06380816,"PHASE1, PHASE2",RECRUITING,"Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms, Carcinoma, Renal Cell (Clear Cell Only), Esophageal Neoplasms, Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors), Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms",UCB4594,,NON_RANDOMIZED,2,Module A (UCB4594 monotherapy dose escalation) | Module B (UCB4594 monotherapy expansion),EXPERIMENTAL | EXPERIMENTAL,"This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells.

The four main aims of the clinical trial are to find out:

1. The best dose of UCB4594 that ca",UCB Biopharma SRL,2029-11,ESTIMATED,18 Years - N/A,167,ESTIMATED,SEQUENTIAL,OTHER,NONE,"A Cancer Research UK Phase I/II Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies",2029-11,ESTIMATED,Recommended Phase 2 dose (RP2D) of UCB4594 | Frequency of adverse events (AEs) considered at least possibly related to UCB4594 (up to 18 cycles).,TREATMENT,ALL,2024-07-09,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT05077904,PHASE3,RECRUITING,Stereotypical Prolonged Seizures,Staccato alprazolam,,RANDOMIZED,2,Staccato alprazolam Arm | Placebo Arm,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.,,2026-04-06,ESTIMATED,12 Years - N/A,350,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures",2026-04-06,ESTIMATED,Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administration | Treatment success for the treated seizure with no recurrence up to 2 hours,TREATMENT,ALL,2021-12-07,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT04901195,PHASE3,ACTIVE_NOT_RECRUITING,Hidradenitis Suppurativa,Bimekizumab,BE HEARD EXT,NON_RANDOMIZED,2,Bimekizumab dosing regimen 1 | Bimekizumab dosing regimen 2,EXPERIMENTAL | EXPERIMENTAL,The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS),,2026-07-28,ESTIMATED,18 Years - N/A,658,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa",2026-07-28,ESTIMATED,Percentage of participants with treatment-emergent adverse events (TEAEs) during the study,TREATMENT,ALL,2021-05-27,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT01277419,,RECRUITING,"Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Axial Psoriatic Arthritis (axPsA), Acute Anterior Uveitis (AAU), Crohn Disease (CD), Ulcerative Colitis (UC)",,GESPIC,,6,Ankylosing spondylitis | Non-radiographic axial spondyloarthritis | Juvenile spondyloarthritis | Crohn's disease | Acute anterior uveitis | Axial psoriatic arthritis, |  |  |  |  | ,"The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several yea","German Federal Ministry of Education and Research, AbbVie, Amgen, Centocor, Inc., Schering-Plough, Wyeth is now a wholly owned subsidiary of Pfizer, Berlin Institute of Health, Novartis, UCB Pharma",2030-07,ESTIMATED,N/A - N/A,1000,ESTIMATED,,OTHER,,German Spondyloarthritis Inception Cohort,2030-07,ESTIMATED,,,ALL,2000-07,,OBSERVATIONAL
UCBJY,UCB SA,NCT04225871,PHASE3,ACTIVE_NOT_RECRUITING,Generalized Myasthenia Gravis,zilucoplan (RA101495),RAISE-XT,,1,0.3 mg/kg zilucoplan (RA101495),EXPERIMENTAL,"The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.",,2026-06-02,ESTIMATED,18 Years - N/A,200,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis",2026-06-02,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs),TREATMENT,ALL,2019-12-23,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT07286682,PHASE1,RECRUITING,Healthy Participants,UCB5285,,RANDOMIZED,8,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 | Cohort 7 | Cohort 8,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the safety and tolerability of single ascending doses of UCB5285 in healthy study participants, including healthy Japanese study participants",,2026-12-13,ESTIMATED,18 Years - 55 Years,96,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1, Randomized, Placebo-Controlled Single Ascending Dose Participant- and Investigator-Blind Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants",2026-12-13,ESTIMATED,Incidence of Treatment-Emergent Adverse Events (TEAEs) | Incidence of Treatment-Emergent Serious Adverse Events (SAEs),BASIC_SCIENCE,ALL,2025-12-08,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06315322,PHASE3,RECRUITING,"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","Brivaracetam Film-coated tablet, Brivaracetam oral solution",,,1,Brivaracetam arm,EXPERIMENTAL,The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.,,2030-03-01,ESTIMATED,2 Years - N/A,120,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY",2030-03-01,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs) during the study | Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of investigational medicinal product (IMP) during the study,TREATMENT,ALL,2024-07-10,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06754098,PHASE2,RECRUITING,"Thymidine Kinase 2 (TK2 ) Deficiency, Mitochondrial Myopathies",Doxecitine and Doxribtimine,,,1,doxecitin and doxribthymine (dT+dC),EXPERIMENTAL,"The purpose of this clinical trial is to evaluate the efficacy and safety of Doxecitin and Doxribtimine (dC+dT) in adult participants with thymidine kinase 2 (TK2) deficiency attended in the Neuromuscular Unit of '12 de Octubre' Hospital.

The main questions it aims to answer are:

* Is dT+dC effective in the treatment of the adult participants with TK2 deficiency?
* Is dT+dC safe in the treatment of adult participants with TK2 deficiency?

Researchers will evaluate the effectiveness of the trea",UCB Pharma,2027-12-31,ESTIMATED,18 Years - N/A,15,ESTIMATED,SINGLE_GROUP,OTHER,NONE,An Off-Label Single Arm Clinical Study to Evaluate the Efficacy and Safety of Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency.,2027-01-31,ESTIMATED,Efficacy - Motor Function Assessments: Neurological Exam using Medical Research Council (MRC Scale) Scale for Muscle Strength | Efficacy - Motor Function Assessments: 6-minute walk test | Efficacy - Motor Function Assessments: North Star Ambulatory Assessment (NSAA) | Efficacy - Motor Function Assessments: 100 meter-time velocity test | Efficacy - Motor Function Assessments: Fatigue Scale test | Efficacy - Respiratory Assessments measured by spirometry | Efficacy - Respiratory Assessments: Use of ventilatory support (Use and Type ) | Efficacy - Respiratory Assessments: Time of use of ventilatory support | Serum Biomarkers: lactate levels | Serum Biomarkers: Growth/differentiation factor-15 (GDF15 ),TREATMENT,ALL,2025-01-01,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT07219420,PHASE3,RECRUITING,Palmoplantar Pustulosis,"Bimekizumab, Placebo",BeSeen,RANDOMIZED,2,Bimekizumab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).,,2029-10-29,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis",2027-12-27,ESTIMATED,Palmoplantar pustulosis-Investigator Global Assessment 0/1 (PPP-IGA 0/1) response at Week 16,TREATMENT,ALL,2025-11-14,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06961747,PHASE1,RECRUITING,Healthy Participants,Zilucoplan,,,1,Zilucoplan,EXPERIMENTAL,The purpose of this study is to assess the steady state (SS) concentrations of zilucoplan (ZLP) and its major metabolites in mature breast milk of healthy study participants following injection of repeated once-daily doses of ZLP.,,2026-07-22,ESTIMATED,18 Years - N/A,15,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label, Repeated-Dose Assessment of Zilucoplan Concentration in Breast Milk of Healthy Lactating Women",2026-07-22,ESTIMATED,Concentrations of zilucoplan and its major metabolites (RA103488 and RA102758) in breast milk during 24 hour steady state (SS) Sampling Period,BASIC_SCIENCE,FEMALE,2025-07-09,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT04436640,PHASE3,ACTIVE_NOT_RECRUITING,"Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa, Nr-axSpa",Bimekizumab,BE MOVING,,1,Bimekizumab,EXPERIMENTAL,"The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).",,2026-08-07,ESTIMATED,18 Years - N/A,508,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis",2026-08-07,ESTIMATED,Percentage of participants with treatment-emergent adverse events (TEAEs) during the study | Percentage of participants with serious adverse events (SAEs) during the study | Percentage of participants with with treatment-emergent adverse Events (TEAEs) leading to withdrawal from the study,TREATMENT,ALL,2020-06-16,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT05064878,PHASE3,ACTIVE_NOT_RECRUITING,"CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures","ZX008 (Fenfluramine Hydrochloride), Matching ZX008 Placebo",,RANDOMIZED,3,ZX008 0.8 mg/kg/day | Placebo | ZX008,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).",,2027-11-08,ESTIMATED,1 Year - 35 Years,87,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension",2027-11-08,ESTIMATED,"The median percentage change from the Baseline Period (Baseline) in ""monthly (28 days) countable motor seizure frequency",TREATMENT,ALL,2022-03-08,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT04009499,PHASE3,ACTIVE_NOT_RECRUITING,Psoriatic Arthritis,Bimekizumab,BE VITAL,,1,Bimekzumab dosage regimen,EXPERIMENTAL,"This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).",,2026-05-25,ESTIMATED,18 Years - N/A,1131,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis",2026-05-25,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs) during the study | Incidence of treatment-emergent serious adverse events (SAEs) during the study,TREATMENT,ALL,2019-08-13,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06598449,PHASE4,RECRUITING,"Dravet Syndrome (DS), Children Under 2 Years",fenfluramine,,,1,Fenfluramine,EXPERIMENTAL,"Dravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children with Dravet syndrome classically present in the first year of life with prolonged seizures, often hemiclonic and in the setting of fever or temperature changes such as getting in or out of bath water. Many anti-seizure medications are sodium channel blockers and exacerbate seizures in this patient population. This creates some limitations in ",UCB Pharma,2027-07,ESTIMATED,12 Months - 24 Months,12,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under the Age of 24 Months,2026-12,ESTIMATED,Percentage of participants that have at least one adverse event,TREATMENT,ALL,2024-10-22,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT07290036,PHASE1,RECRUITING,"Psoriatic Arthritis, Axial Spondyloarthritis","Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc",,RANDOMIZED,2,Bimekizumab arm 1 | Bimekizumab arm 2,EXPERIMENTAL | EXPERIMENTAL,To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.,,2028-07-04,ESTIMATED,18 Years - N/A,392,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis",2028-04-04,ESTIMATED,"Steady-state Trough Concentration (Ctrough,ss) at Week 16",TREATMENT,ALL,2025-12-10,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT04658199,PHASE1,ACTIVE_NOT_RECRUITING,Progressive Supranuclear Palsy,UCB0107 (bepranemab),,,1,UCB0107 (bepranemab),EXPERIMENTAL,The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).,,2027-12-13,ESTIMATED,40 Years - N/A,19,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy,2027-12-13,ESTIMATED,Incidence of treatment emergent adverse events from Baseline of the open-label extension to the end of the study,TREATMENT,ALL,2020-11-16,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06425549,PHASE3,RECRUITING,Moderate to Severe Plaque Psoriasis,"bimekizumab, ustekinumab, placebo",BE TOGETHER,RANDOMIZED,2,bimekizumab | ustekinumab,EXPERIMENTAL | ACTIVE_COMPARATOR,The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).,,2030-11-08,ESTIMATED,6 Years - 17 Years,168,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis",2028-08-21,ESTIMATED,Psoriasis Area Severity Index 90 (PASI90) response at Week 16 | Investigator´s Global Assessment (IGA) 0/1 response at Week 16,TREATMENT,ALL,2024-06-25,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06624228,PHASE3,ACTIVE_NOT_RECRUITING,Psoriatic Arthritis,"Bimekizumab, Risankizumab, Placebo",,RANDOMIZED,2,Bimekizumab | Risankizumab,EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).,,2026-05-26,ESTIMATED,18 Years - N/A,684,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis",2026-02-03,ESTIMATED,American College of Rheumatology 50 (ACR50) at Week 16,TREATMENT,ALL,2024-10-21,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT05063162,PHASE3,RECRUITING,Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD),Rozanolixizumab,cosMOG,RANDOMIZED,2,Rozanolixizumab Arm | Placebo Arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).",,2027-07-01,ESTIMATED,18 Years - 89 Years,104,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)",2027-05-06,ESTIMATED,For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment Period | For Part B: Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment Period | For Part B: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment Period,TREATMENT,ALL,2022-02-02,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT07033559,,NOT_YET_RECRUITING,Myasthenia Gravis Generalised,,,,0,,,"The goal of this observational study is to learn if computer analysis of voice recordings can detect a type of exhaustion called ""central fatigue"" in adults with generalised myasthenia gravis.

The main questions it aims to answer are:

1. Can advanced voice analysis accurately tell when participants are experiencing deep exhaustion based on how they speak?
2. How easy and acceptable is voice-based fatigue monitoring for people with myasthenia gravis?

Participants will:

1. Record themselves re",UCB Pharma,2026-12,ESTIMATED,18 Years - N/A,240,ESTIMATED,,INDUSTRY,,Remote Digital Voice Biomarkers for Central Fatigue Detection in Generalised Myasthenia Gravis: An Online Single-Cohort Observational Study,2026-06,ESTIMATED,Accuracy of AI Model for Binary Central Fatigue Classification as Assessed by Voice Biomarker Analysis,,ALL,2026-02,ESTIMATED,OBSERVATIONAL
UCBJY,UCB SA,NCT04985539,,ACTIVE_NOT_RECRUITING,"Parkinson Disease, Parkinsonian Disorders, Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases",,PPP-novo,,1,PD de novo,,"Currently, the Movement Disorders Society (MDS)-UPDRS scale remains the gold standard to document the outcomes in clinical trials for Parkinson's disease (PD). The MDS-UPDRS is far from infallible, as it is based on subjective scoring (using a rather crude ordinal score), while execution of the tests depends on clinical experience. Not surprisingly, the scale is subject to both significant intra- and inter-rater variability that are sufficiently large to mask an underlying true difference betwee","UCB Pharma, Verily Life Sciences LLC",2025-12,ESTIMATED,18 Years - N/A,103,ACTUAL,,OTHER,,The Personalized Parkinson Project De Novo Cohort,2025-11,ESTIMATED,Annual change in digital biomarkers for gait | Annual change in digital biomarkers for tremor | Annual change in digital biomarkers for bradykinesia | Annual change in digital biomarkers for postural sway | Annual change in digital biomarkers for time active vs inactive during the day | Annual change in digital biomarkers for heart rate variability | Annual change in digital biomarkers for skin impedance,,ALL,2020-08-29,ACTUAL,OBSERVATIONAL
UCBJY,UCB SA,NCT04715646,PHASE3,RECRUITING,Epilepsy,Brivaracetam,,,1,Brivaracetam,EXPERIMENTAL,The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.,,2030-07-08,ESTIMATED,1 Month - N/A,70,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy",2030-07-08,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs) during the study | Incidence of treatment-emergent serious adverse events (SAEs) during the study | Incidence of treatment-emergent adverse events (TEAEs) leading to discontinuation of study drug during the study,TREATMENT,ALL,2021-03-11,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT04179695,,RECRUITING,Parkinson's Disease,,PARKINSUN,RANDOMIZED,2,consultation with Parkinsun | consultation as usual without Parkinsun,EXPERIMENTAL | ACTIVE_COMPARATOR,"PARKINSUN is a new communication aid tool, expected to favor global patient centered care for PD patients during consultation with GPs and neurologists. Two groups of patients will be randomized to use or not PARKINSUN when they consult their physicians every 3 months during 7 months.","Expert center of Parkinson's Disease (CHU Lille), College of teaching general practitioners (CEMG Lille), Regional Health Agency (ARS), UCB Pharma, Orkyn'",2026-12,ESTIMATED,18 Years - 90 Years,120,ESTIMATED,PARALLEL,OTHER,NONE,"Optimizing PD Patient's Health Pathways: Favoring Global, Patient Centered Care by a New Communication Aid Tool PARKINSUN",2026-12,ESTIMATED,variation of the delta of G-MISS Questionnaire,HEALTH_SERVICES_RESEARCH,ALL,2020-07-21,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT01793103,,ACTIVE_NOT_RECRUITING,Rheumatoid Arthritis,,BRASS,,0,,,"The goal of the present study is to establish a prospective observational cohort of Rheumatoid Arthritis patients in order to

1. Determine and validate biomarkers that predict drug response and toxicity in RA.
2. Determine and validate biomarkers that predict disease activity and prognosis in RA.
3. Evaluate the natural history of treated RA in terms of its clinical, functional and economic outcomes.","Crescendo Bioscience, Bristol-Myers Squibb, UCB Pharma, Sanofi, Janssen, LP, Aqtual, Inc.",2028-03,ESTIMATED,18 Years - N/A,1598,ACTUAL,,OTHER,,Brigham and Women's Rheumatoid Arthritis Sequential Study,2028-03,ESTIMATED,Determine and validate biomarkers that predict drug response and toxicity in RA.,,ALL,2003-03,,OBSERVATIONAL
UCBJY,UCB SA,NCT04084145,,ACTIVE_NOT_RECRUITING,Chronic Kidney Diseases,,NURTuRE-CKD,,1,CKD,,"Chronic Kidney Disease (CKD) affects around 10% of the adult population and is associated with an increased risk of heart attack, stroke and end stage kidney disease (ESKD). This study aims to better predict who is most likely to progress to ESKD using previously identified risk factors and novel biomarkers in blood and urine samples, along with kidney biopsy tissue. Resources can then be directed to those most at risk of disease progression and other associated conditions such as heart attack a","Kidney Cancer UK, UK Renal Registry, University of Bristol, University of Birmingham, University of Southampton, University of Geneva, Switzerland, National Institute for Health Research, United Kingdom, UCB Pharma Ltd, Evotec International GmbH, AbbVie",2032-12-31,ESTIMATED,18 Years - N/A,3004,ACTUAL,,OTHER,,National Unified Renal Translation Research Enterprise - Chronic Kidney Disease,2032-12-31,ESTIMATED,Number of participants with CKD progression | Number of participants who experience a major acute cardiovascular event,,ALL,2016-07-27,ACTUAL,OBSERVATIONAL
UCBJY,UCB SA,NCT03845712,PHASE2,ACTIVE_NOT_RECRUITING,Thymidine Kinase 2 Deficiency,doxecitine and doxribtimine,Continuation,,1,doxecitine and doxribtimine,EXPERIMENTAL,This is a Phase 2 prospective open-label treatment study of the safety and efficacy of doxecitine and doxribtimine in study participants with thymidine kinase 2 (TK2) deficiency who participated in the retrospective study MT-1621-101 \[NCT03701568\] or who were receiving nucleos(t)ide treatment and were approved by the Sponsor.,,2026-02-19,ESTIMATED,N/A - N/A,47,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2 Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With Thymidine Kinase 2 Deficiency (TK2),2026-02-19,ESTIMATED,Safety as adverse events (AEs): number of participants who experience adverse events | Safety as determined by laboratory measurements | Safety as determined by electrocardiograms (ECGs),TREATMENT,ALL,2019-07-05,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06970301,PHASE1,RECRUITING,Healthy Study Participants,glovadalen,,RANDOMIZED,3,Cohort 1 (Caucasian) | Cohort 2 (Japanese) | Cohort 3 (Chinese),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.",,2026-05-29,ESTIMATED,18 Years - 55 Years,32,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Single-center, Placebo-controlled, Participant-blind, Investigator-blind, Randomized, Multiple Ascending Dose in Titration Study to Assess The Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants",2026-05-29,ESTIMATED,Occurrence of TEAEs (Part A) | Occurrence of TEAEs (Part B),BASIC_SCIENCE,ALL,2025-04-28,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06888193,PHASE1,RECRUITING,"Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa",Bimekizumab,BE CARING,,1,Bimekizumab,EXPERIMENTAL,Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.,,2027-05-03,ESTIMATED,18 Years - N/A,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)",2027-05-03,ESTIMATED,Concentration of bimekizumab in the breast milk on Day 1 | Concentration of bimekizumab in the breast milk on Day 2 | Concentration of bimekizumab in the breast milk on Day 3 | Concentration of bimekizumab in the breast milk on Day 5 | Concentration of bimekizumab in the breast milk on Day 7 | Concentration of bimekizumab in the breast milk on Day 9 | Concentration of bimekizumab in the breast milk on Day 11 | Concentration of bimekizumab in the breast milk on Day 13 | Concentration of bimekizumab in the breast milk on Day 15 | Concentration of bimekizumab in the breast milk on Day 29 | Concentration of bimekizumab in the breast milk on Day 57,OTHER,FEMALE,2025-11-05,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT07246564,PHASE4,RECRUITING,Myasthenia Gravis,Rozanolixizumab,,,1,Rozanolixizumab,EXPERIMENTAL,The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.,,2027-10-15,ESTIMATED,18 Years - N/A,40,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis",2027-10-15,ESTIMATED,Change from Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score in the first Treatment Cycle,TREATMENT,ALL,2025-12-01,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT01797224,,ACTIVE_NOT_RECRUITING,"Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis",,,,4,"Cohort 1 - Exposed Cohort | Cohort 2 - Diseased Comparison Cohort | Cohort 3 - Non-Diseased Comparison Cohort | Group 4 -Cimzia Registry, Not Qualified for the Cohort Study", |  |  | ,"The purpose of the OTIS Autoimmune Diseases in Pregnancy Study is to monitor planned and unplanned pregnancies exposed to certain medications, to evaluate the possible teratogenic effect of these medications and to follow live born infants for five years after birth. With respect to fetal outcome, it is important to evaluate the spectrum of outcomes that may be relevant to a medication exposure during pregnancy, and these include both easily recognizable defects which are visible at birth, as we","The Organization of Teratology Information Specialists, UCB Pharma",2026-03,ESTIMATED,N/A - N/A,925,ESTIMATED,,OTHER,,Cimzia (Certolizumab Pegol) Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project,2026-01,ESTIMATED,Major malformations,,FEMALE,2012-03,ACTUAL,OBSERVATIONAL
UCBJY,UCB SA,NCT04123795,PHASE3,ACTIVE_NOT_RECRUITING,"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis","Certolizumab pegol, Placebo",CIMcare,RANDOMIZED,3,Cohort A - certolizumab pegol | Cohort A - placebo | Cohort B - certolizumab pegol - Open-label,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.,,2034-08-15,ESTIMATED,6 Years - 17 Years,49,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis",2029-09-19,ESTIMATED,Plasma concentrations of Certolizumab pegol (CZP) at Week 16 | Plasma anti-CZP antibody titers at Week 16 | Plasma concentrations of CZP at Week 52 | Plasma anti-CZP antibody titers at Week 52,TREATMENT,ALL,2020-01-21,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT04666610,PHASE3,RECRUITING,"Childhood Absence Epilepsy, Juvenile Absence Epilepsy",Brivaracetam,EXPAND,RANDOMIZED,8,Brivaracetam 200 mg | Placebo to 200 mg brivaracetam | Brivaracetam 100 mg | Placebo to 100 mg brivaracetam | Optimal dose of BRV (defined following Stage 1) | Placebo to BRV optimal dose (defined following Stage 1) | Brivaracetam received during RDW | Placebo received during RDW,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).",,2026-08-24,ESTIMATED,2 Years - 25 Years,160,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Dose-Finding and Confirmatory, Double-Blind, Placebo-Controlled, Parallel-Group Multicenter Study With a 2 Stage Adaptive Design and Randomized Withdrawal to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy",2026-08-24,ESTIMATED,Percentage of participants who met the criteria for absence seizure freedom within 4 days prior to or during the 24-hour ambulatory electroencephalogram (EEG) at Day 14,TREATMENT,ALL,2021-07-29,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT07215949,PHASE3,RECRUITING,Generalized Myasthenia Gravis (gMG),Zilucoplan®,,,1,Zilucoplan,EXPERIMENTAL,"This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.",UCB Pharma,2028-04-01,ESTIMATED,18 Years - N/A,15,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Zilucoplan Treatment of Severe MG Exacerbations Leading to Hospitalization of Participants With Acetylcholine Receptor Antibody Positive gMG,2027-12-01,ESTIMATED,Change from baseline to Week 2 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) score,TREATMENT,ALL,2026-01-20,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT01848028,,RECRUITING,"Psoriasis, Psoriatic-arthritis",,,,25,Fumaric acid esters | Methotrexate | Cyclosporine A | Efalizumab (withdrawn) | Etanercept | Infliximab | Adalimumab | Ustekinumab | Golimumab | Secukinumab | Apremilast | Certolizumab | Retinoids | Leflunomids | systemic PUVA | Guselkumab | Brodalumab | Tildrakizumab | Risankizumab | Bimekizumab | Tofacitinib | Upadacitinib | Deucravacitinib | Ixekizumab | No treatment, |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ,"Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment an","Berufsverband der Deutschen Dermatologen e.V. (www.bvdd.de), Deutsche Dermatologische Gesellschaft e.V. (https://derma.de), AbbVie, Biogen, Janssen-Cilag G.m.b.H, medac GmbH, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer Pharmaceuticals Ltd., Merck Serono GmbH, Germany, PsoNet.eu (http://www.psonet.eu/), Celgene, Eli Lilly and Company, Amgen, Almirall Hermal GmbH, UCB Pharma, Bristol-Myers Squibb, Viatris Inc., LEO Pharma",2032-12,ESTIMATED,18 Years - N/A,3500,ESTIMATED,,OTHER,,Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics,2032-12,ESTIMATED,Psoriasis Area Severity Index (PASI),,ALL,2008-01,,OBSERVATIONAL
UCBJY,UCB SA,NCT07277660,PHASE2,RECRUITING,Atopic Dermatitis,"Galvokimig, Placebo",,RANDOMIZED,4,Galvokimig Arm 1 | Galvokimig Arm 2 | Galvokimig Arm 3 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).,,2028-03-06,ESTIMATED,18 Years - N/A,160,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis",2027-05-17,ESTIMATED,Percentage of participants with Eczema Area and Severity Index (EASI)75 response at Week 16,TREATMENT,ALL,2025-12-29,ACTUAL,INTERVENTIONAL
UCBJY,UCB SA,NCT06118255,PHASE3,ACTIVE_NOT_RECRUITING,Dravet Syndrome,fenfluramine,ORCHID,,1,Fenfluramine Open-label,EXPERIMENTAL,The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.,,2026-12-16,ESTIMATED,1 Year - 23 Months,25,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome",2026-09-03,ESTIMATED,"Change from Baseline in QT interval corrected by Fridericia (QTcF) at Visit 13 (End of Treatment/Early Termination (EOT/ET)) | Occurrence of a treatment-emergent (ie, post-Baseline through Visit 13 [EOT/ET]) result which meets the FDA case definition of drug associated valvulopathy | Occurrence of treatment-emergent (ie, post-Baseline through Visit 13 [EOT/ET]) clinically confirmed valvular heart disease (VHD) | Change from Baseline in body weight (Z-score) at each visit | Change from Baseline in recumbent length (Z-score) at each visit | Occurrence of a clinically significant abnormality on the neurological examination at each visit",TREATMENT,ALL,2024-05-21,ACTUAL,INTERVENTIONAL
GRCE,"Grace Therapeutics, Inc.",NCT05995405,PHASE3,ACTIVE_NOT_RECRUITING,Aneurysmal Subarachnoid Hemorrhage (aSAH),"GTX-104, Nimotop 30 MG Oral Capsule",STRIVE-ON,RANDOMIZED,2,GTX-104 | Oral nimodipine,EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules.,,2024-12,ESTIMATED,18 Years - N/A,100,ESTIMATED,PARALLEL,INDUSTRY,NONE,"Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial",2024-12,ESTIMATED,"Incidence (% or proportion) of subjects with at least one episode of clinically significant hypotension with a reasonable possibility that GTX-104/oral nimodipine caused the event, according to the Endpoint Adjudication Committee.",TREATMENT,ALL,2023-10-20,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07297732,,RECRUITING,Dentin Hypersensitivity,"Test Toothpaste 1, Test Toothpaste 2, Reference Toothpaste",,RANDOMIZED,3,Test Toothpaste 1 | Test Toothpaste 2 | Reference Toothpaste,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"The aim of this exploratory clinical study is to investigate the tooth whitening potential, Dentin Hypersensitivity (DH) efficacy, and oral tolerability of two experimental toothpastes in a DH population with appropriate tooth shade and dental stain levels for the evaluation of whitening performance.",,2026-03,ESTIMATED,18 Years - 65 Years,105,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,Exploratory Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Efficacy of Two Experimental Toothpastes,2026-03,ESTIMATED,"Mean VITA Shade Score at Baseline, Weeks 1, 2, 4 and 8 | Mean Total Modified Lobene Stain Index (MLSI) Score at Baseline, Weeks 1, 2, 4 and 8",TREATMENT,ALL,2025-12-15,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07255040,,RECRUITING,"Dental Plaque, Gingivitis","Test Dentifrice, Parodontax Complete Protection, Colgate Cavity Protection",,RANDOMIZED,3,Test Dentifrice | Reference Dentifrice (Positive Control) | Reference Dentifrice (Negative Control),EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The aim of this 24-week clinical study is to evaluate the ability of an experimental dentifrice containing 0.454 percent (%) weight by weight (w/w) Stannous fluoride (SnF2); to improve gingival health, plaque reduction and prevention of plaque accumulation compared with a regular fluoride dentifrice (negative control) in participants with mild to moderate gingivitis.",,2026-07,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A 24-Week, Randomised, Controlled, Examiner-blind, Clinical Study to Evaluate the Efficacy of an Experimental Stannous Fluoride Dentifrice in Improving Gingival Health and Reducing Plaque Accumulation",2026-07,ESTIMATED,Number of Bleeding Sites (Overall) at Week 24,TREATMENT,ALL,2025-11-19,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT06666660,,RECRUITING,Relatively Healthy Volunteers,,CEDIRA,RANDOMIZED,2,Multivitamin/Mineral Supplement (MVM) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Micronutrients, such as vitamins and minerals, are required to sustain fundamental physiological processes in individuals. As individuals age, the risk of having suboptimal levels of micronutrients increases due to several age-related changes affecting their digestion and assimilation processes. Suboptimal levels of micronutrients have been associated with increased risk of chronic diseases and accelerated ageing. Three years intake of a multivitamin and mineral supplement (MVM) improved global ",HALEON,2025-06-30,ESTIMATED,40 Years - 60 Years,400,ESTIMATED,PARALLEL,OTHER,DOUBLE,"Centrum; the Effect of Daily Intake of Multivitamin & Mineral Supplementation, on Biological Age in Relatively Healthy Middle-aged Individuals (CEDIRA)",2025-04-30,ESTIMATED,"Change in blood DNA methylation status, years",HEALTH_SERVICES_RESEARCH,ALL,2024-09-23,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07300540,,NOT_YET_RECRUITING,Dentin Sensitivity,,,,1,Test Toothpaste,OTHER,The aim of this study is to evaluate the impact of a commercially available desensitizing dentifrice containing 5 percent (%) Calcium sodium phosphosilicate (CSPS) on oral health related quality of life (OHrQoL) in a DH (Dentin Hypersensitivity) population in a real-world setting.,,2026-11,ESTIMATED,18 Years - 65 Years,500,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Real-World Evidence Study Evaluating Oral Health Related Quality of Life With Use of a Calcium Sodium Phosphosilicate Anti-Sensitivity Dentifrice for Dentin Hypersensitivity Management,2026-11,ESTIMATED,Change From Baseline in DHEQ Total Score at Week 24,OTHER,ALL,2026-02,ESTIMATED,INTERVENTIONAL
HLN,Haleon plc,NCT07274189,,RECRUITING,Periodontal Diseases,,,RANDOMIZED,2,Sodium bicarbonate toothpaste (67%) | Fluoride toothpaste (1450ppm),ACTIVE_COMPARATOR | SHAM_COMPARATOR,"The goal of this clinical trial is to determine whether sodium bicarbonate fluoride toothpaste can help maintain periodontal health in adults who have undergone non-surgical periodontal treatment. The main question it aims to answer is:

Does daily use of toothpaste affect the following outcomes: clinical oral health (plaque scores, gingival bleeding scores and periodontal pocket depths), salivary biochemical markers and the oral microbiome.

Outcomes measures will be recorded at 0,3, and 6 mont",HALEON,2027-01-30,ESTIMATED,18 Years - N/A,100,ESTIMATED,PARALLEL,OTHER,DOUBLE,Maintenance of Periodontal Health With Daily Use of Sodium Bicarbonate Toothpaste,2026-10-20,ESTIMATED,Maintenance of periodontal health,PREVENTION,ALL,2024-12-04,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT06633627,,RECRUITING,Dentine Hypersensitivity,,,,2,Experimental | Control, | ,"Dentine hypersensitivity (also known as sensitive teeth) is a common dental condition in which the dentine, a layer of sensitive hard tissue under the enamel of the teeth, becomes exposed making the teeth sensitive to stimuli, such as hot and cold. It poses a significant challenge for clinicians and affects patients' quality of life.

The overall aim of the study is to understand if a way of measuring brain activity (electroencephalography \[EEG\]) shows a response to tooth stimulation, and see ","University of Sheffield, HALEON",2025-09-30,ESTIMATED,18 Years - N/A,60,ESTIMATED,,OTHER,,Identification and Quantification of Neurological Responses in Patients with Dentine Hypersensitivity,2025-07-31,ESTIMATED,Electroencephalography (EEG) responses to tooth stimulation,,ALL,2024-10-11,ESTIMATED,OBSERVATIONAL
HLN,Haleon plc,NCT07273149,,RECRUITING,Denture Retention,,,,1,No Adhesive Use Followed by Adhesive Use,EXPERIMENTAL,The purpose of this decentralised study in a real-world setting is to assess the effectiveness of a marketed denture adhesive (Poligrip Power Max Hold + Seal) in preventing food entrapment under dentures (self-assessed). The study will evaluate participants perceived food occlusion of a marketed denture adhesive over three weeks compared to no adhesive use over three weeks in a real-world setting.,,2026-04,ESTIMATED,18 Years - N/A,375,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Decentralised, Open-labelled, Clinical Study to Assess the Effectiveness of a Marketed Denture Adhesive in Food Occlusion in Denture Wearers in a Real-world Setting",2026-04,ESTIMATED,Mean Score of the Food Occlusion Question Assessed Using the Numerical Rating Scale (NRS),OTHER,ALL,2025-12-05,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07273539,,RECRUITING,Gingivitis,"Sodium Bicarbonate Toothpaste, Sodium Fluoride Toothpaste",,RANDOMIZED,2,Test Toothpaste | Reference Toothpaste,EXPERIMENTAL | ACTIVE_COMPARATOR,The aim of this 12-week clinical study is to evaluate the effect of a toothpaste containing sodium bicarbonate over time on the oral microbiome and to explore its effect in comparison to a regular fluoride toothpaste in participants with localized gingivitis.,,2026-02,ESTIMATED,18 Years - 65 Years,55,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Randomised, Controlled, Examiner Blind Study to Evaluate the Effect of a Sodium Bicarbonate Toothpaste on the Oral Microbiome",2026-02,ESTIMATED,Change From Baseline in Bacterial Composition at Week 12 by Treatment Groups,BASIC_SCIENCE,ALL,2025-10-27,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07345130,PHASE1,RECRUITING,"Bioequivalence, Bioavailability","Advil Tablet (Mini) (Test Product), Advil Tablet (Reference Product)",,RANDOMIZED,6,Sequence 1: Treatment A/ Treatment B/ Treatment C | Sequence 2: Treatment B/ Treatment C/ Treatment A | Sequence 3: Treatment C/ Treatment A/ Treatment B | Sequence 4: Treatment A/ Treatment C/ Treatment B | Sequence 5: Treatment B/ Treatment A/ Treatment C | Sequence 6: Treatment C/ Treatment B/ Treatment A,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to assess the bioequivalence of Advil Tablet (Mini) (Test Product) to Advil Tablet (Reference Product) under fasted conditions and to characterize the impact of food on the bioavailability of the Test Product under fed conditions.,,2026-02,ESTIMATED,18 Years - 55 Years,75,ESTIMATED,CROSSOVER,INDUSTRY,NONE,"A Randomized, Open-label, Single-Center, Single-Dose, Three-Treatment, Three-Period, Six-Sequence Crossover Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) to Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions",2026-02,ESTIMATED,"Maximum Observed Post-dose Concentration (Cmax) Under Fasted Conditions (Test Versus (vs) Reference Product) | Area Under the Plasma Concentration Versus Time Curve Calculated from Time 0 to the Last Measurable Sampling Time Point, t (AUC[0-t]) Under Fasted Conditions (Test Vs Reference Product) | Cmax for Test Product Under Fed Conditions Compared to Fasted Conditions | AUC(0-t) for Test Product Under Fed Conditions Compared to Fasted Conditions | Area Under the Plasma Concentration Versus Time Curve Calculated From Time 0 to Infinity (AUC[0-inf]) for Test Product Under Fed Conditions Compared to Fasted Conditions",OTHER,ALL,2025-12-17,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07337109,,RECRUITING,Dentin Hypersensitivity,,,,1,New sufferers of self-reported Dentin Hypersensitivity aged 18+ years,,"The primary purpose of this study is to characterize changes in Oral-Health-Related Quality of Life (OHrQoL), as measured by the Dentin Hypersensitivity Experience Questionnaire (DHEQ) over a 12-month period.",,2027-04,ESTIMATED,18 Years - N/A,375,ESTIMATED,,INDUSTRY,,A Longitudinal Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers in the Real World,2027-04,ESTIMATED,Change From Baseline in Total DHEQ Score Over 12 Months,,ALL,2025-12-16,ACTUAL,OBSERVATIONAL
HLN,Haleon plc,NCT07352956,,RECRUITING,Dentin Sensitivity,"Test toothpaste, Sodium fluoride toothpaste",,RANDOMIZED,2,Test Toothpaste | Control Toothpaste,EXPERIMENTAL | OTHER,The purpose of this study is to evaluate the clinical efficacy of a 0.454 percent (%) weight/weight (w/w) stannous fluoride (SnF2) toothpaste in reducing dentin hypersensitivity (DH) to an evaporative (air) stimulus and tactile stimulus after 28 and 56 days twice daily brushing.,,2026-04,ESTIMATED,18 Years - 70 Years,100,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"An 8-Week, Randomised, Controlled, Examiner-blind Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste for the Relief of Dentin Hypersensitivity in a Chinese Population",2026-04,ESTIMATED,Change From Baseline in Schiff Sensitivity Score at Day 56 | Change From Baseline in Tactile Threshold (grams [g]) at Day 56,TREATMENT,ALL,2026-01-16,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07215767,PHASE3,RECRUITING,Dentin Hypersensitivity,"Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassium nitrate Dentifrice, Vehicle Dentifrice",,RANDOMIZED,4,Test Dentifrice | Reference Dentifrice 1 | Reference Dentifrice 2 | Reference Dentifrice 3,EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The aim of this clinical study is to demonstrate the superior antihypersensitivity efficacy of a novel stannous fluoride (SnF2) and potassium nitrate (KNO3) dentifrice (Investigational Product), compared to SnF2 only, KNO3 only and Vehicle dentifrices, after 8 weeks twice daily use.",,2026-08,ESTIMATED,12 Years - 65 Years,850,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice,2026-08,ESTIMATED,"Change from Baseline in Schiff sensitivity score at Week 8 (Test Dentifrice Versus [Vs] Reference Dentifrices 1, 2 and 3) | Change from Baseline in tactile threshold (grams [g]) at Week 8 (Test Dentifrice Vs Reference Dentifrices 1, 2 and 3)",TREATMENT,ALL,2025-09-16,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07433049,,RECRUITING,"Glucose Control, Mental Health, Musculoskeletal Health, Body Composition",,,RANDOMIZED,2,Multivitamin/mineral (MVM) study product | Placebo study product,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study investigates the role of multivitamin and multimineral (MVM) supplementation in improving metabolic, musculoskeletal, and mental health among midlife Asian women aged 40-60 years, a critical period marked by hormonal and physiological transitions from pre- to post-menopause. Evidence from the GUSTO cohort in Singapore has shown that higher plasma levels of vitamins B6, B9, B12, and D are associated with better metabolic profiles, insulin sensitivity, and mental wellbeing, while defici",HALEON,2028-01,ESTIMATED,40 Years - 60 Years,400,ESTIMATED,PARALLEL,OTHER,DOUBLE,Impact of Supplementation in Improving Metabolic Health Outcomes (ISMOS) Study,2028-01,ESTIMATED,Changes in MetaboAge,PREVENTION,FEMALE,2026-01-20,ACTUAL,INTERVENTIONAL
HLN,Haleon plc,NCT07195357,,NOT_YET_RECRUITING,"Dentin Hypersensitivity, Erosive Tooth Wear",,,,1,Adults age 18 living in five different areas of the United States,,"The goal of this observational study is to learn about tooth wear and tooth sensistivity and reasons for these conditions in five locations throughout the United States. The main question it aims to answer is:

The main objective of this study is to determine tooth wear and tooth sensitivity in adults in the U.S., and to investigate their association with risk factors",HALEON,2027-10,ESTIMATED,18 Years - N/A,2500,ESTIMATED,,OTHER,,"Erosive Tooth Wear, Dentin Hypersensitivity and Associated Risk Factors: An Observational, Cross-Sectional, Multi-Site, Epidemiological Study in the U.S."" IU IRB# 28041",2027-10,ESTIMATED,"Prevalence and severity of erosive tooth wear (ETW), assessed using the basic erosive wear examination (BEWE) index. | Prevalence and severity of dentin hypersensitivity (DH) using the Schiff Sensitivity Index. | Risk factors potentially associated to erosive tooth wear (ETW) and dentin hypersensitivity (DH), collected by questionnaires.",,ALL,2026-02,ESTIMATED,OBSERVATIONAL
ROIV,Roivant Sciences Ltd.,NCT05403541,PHASE3,ACTIVE_NOT_RECRUITING,Generalized Myasthenia Gravis,"Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly",,RANDOMIZED,6,Batoclimab Induction Dose 1 (Period 1) | Batoclimab Induction Dose 2 (Period 1) | Placebo Induction Dose (Period 1) | Batoclimab Maintenance Dose 1 (Period 2) | Batoclimab Maintenance Dose 2 (Period 2) | Placebo Maintenance Dose (Period 2),EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previo",,2025-04,ESTIMATED,18 Years - N/A,240,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)",2025-03,ESTIMATED,Change from Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor (AChR) Ab seropositive (AChRAb+) participants,TREATMENT,ALL,2022-06-27,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT05581199,PHASE2,ACTIVE_NOT_RECRUITING,Chronic Inflammatory Demyelinating Polyneuropathy,"Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo",,RANDOMIZED,18,"Treatment Period 1: Cohort A, Dose 1 | Treatment Period 1: Cohort A, Dose 2 | Treatment Period 1: Cohort B, Dose 1 | Treatment Period 1: Cohort B, Dose 2 | Treatment Period 1: Cohort C, Dose 1 | Treatment Period 1: Cohort C, Dose 2 | Treatment Period 1: Cohort D, Dose 1 | Treatment Period 1: Cohort D, Dose 2 | Withdrawal Period 2: Cohort A, Dose 2 | Withdrawal Period 2: Cohort A, Placebo | Withdrawal Period 2: Cohort B, Dose 2 | Withdrawal Period 2: Cohort B, Placebo | Withdrawal Period 2: Cohort C, Dose 2 | Withdrawal Period 2: Cohort C, Placebo | Withdrawal Period 2: Cohort D, Dose 2 | Withdrawal Period 2: Cohort D, Placebo | LTE Period: With Relapse in Period 2: Dose 1 and Dose 2 | LTE Period: Without Relapse in Period 2: Dose 2",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP. The study includes an up to 4-week Screening Period, an up to 12-week Washout Period, a 12-week Randomized Treatment Period (Period 1), an up to 24-week Randomized Withdrawal Period (Period 2), an up to 52-week Long-term Extension (LTE) Period (optional), and Safety Follow-up 4 weeks after the last dose of study treatment. The tot",,2027-01,ESTIMATED,18 Years - N/A,277,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",2026-01,ESTIMATED,"Period 2, Cohort A: Proportion of participants who remain relapse-free at Week 36",TREATMENT,ALL,2022-12-15,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT06980805,PHASE2,RECRUITING,"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","IMVT-1402, Placebo",,RANDOMIZED,2,Period 1: Placebo | IMVT-1402 Subcutaneous (SC) Once weekly (QW),PLACEBO_COMPARATOR | EXPERIMENTAL,"The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.

The study will consist of 3 periods:

Period 1: eligible participants will be randomized 1:1 to IMVT-1402 Dose 1 or placebo SC QW for 12 weeks.

Period 2: participants who completed Period 1 will receive IMVT-1402 Dose 1 SC QW for 14 weeks.

Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 Dose",,2027-04,ESTIMATED,18 Years - N/A,56,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations",2027-04,ESTIMATED,Percent change from Period 1 Baseline in Cutaneous Lupus Erythematosus Disease area and Severity Index activity (CLASI-A) score at Week 12,TREATMENT,ALL,2025-02-19,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT07286006,PHASE2,NOT_YET_RECRUITING,Graves' Disease,IMVT-1402,,NON_RANDOMIZED,3,Group A | Group B | Group C,EXPERIMENTAL | NO_INTERVENTION | NO_INTERVENTION,"This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.",,2030-03,ESTIMATED,18 Years - N/A,372,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease",2030-03,ESTIMATED,"Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402",TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT07018323,PHASE2,RECRUITING,Graves' Disease,"IMVT-1402, IMVT-1402, Placebo",,RANDOMIZED,3,IMVT-1402 Dose 1 | IMVT-1402 Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.",,2027-05,ESTIMATED,18 Years - 75 Years,210,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease",2027-05,ESTIMATED,Percentage of participants who are euthyroid and off ATD at Week 26 (Dose 1),TREATMENT,ALL,2025-06-19,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT07032662,PHASE2,RECRUITING,Chronic Inflammatory Demyelinating Polyneuropathy,"IMVT-1402, Placebo",,RANDOMIZED,2,IMVT-1402 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.,,2030-05,ESTIMATED,18 Years - N/A,162,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",2028-08,ESTIMATED,Proportion of participants remaining Relapse-free by Week 24,TREATMENT,ALL,2025-03-18,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT06727604,PHASE2,RECRUITING,Graves' Disease,"IMVT-1402, IMVT-1402, Placebo",,RANDOMIZED,4,Group 1 Period 1 and 2: IMVT-1402 | Group 2 Period 1 and 2: IMVT-1402 | Group 2 Period 1: IMVT-1402 and Period 2: Placebo | Group 3 Period 1 and 2: Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.",,2028-06,ESTIMATED,18 Years - 75 Years,240,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease",2028-06,ESTIMATED,"Percentage of participants who are euthyroid (local laboratory T3 [Total T3 or FT3], FT4, and TSH values within normal limits) and off ATD at Week 26",TREATMENT,ALL,2024-12-17,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT07039916,PHASE3,RECRUITING,Generalized Myasthenia Gravis,"IMVT-1402, IMVT-1402, Placebo, IMVT-1402",,RANDOMIZED,3,Group 1: IMVT-1402 Dose 1 | Group 2: IMVT-1402 Dose 2 | Placebo/ IMVT-1402,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.",,2028-12,ESTIMATED,18 Years - 80 Years,231,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis",2027-12,ESTIMATED,Change from Baseline in MG-ADL Score for Antibody-positive Participants,TREATMENT,ALL,2025-05-27,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT06754462,PHASE2,ACTIVE_NOT_RECRUITING,Rheumatoid Arthritis,"IMVT-1402, Placebo",,RANDOMIZED,3,IMVT-1402 Dose 1 | IMVT-1402 Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).",,2027-09,ESTIMATED,18 Years - N/A,120,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2b, Multicenter, Double-blind, Placebo-controlled Randomized Withdrawal Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat, ACPA-Positive Rheumatoid Arthritis",2027-09,ESTIMATED,Proportion of participants who maintain ACR20 response at Week 28,TREATMENT,ALL,2025-01-10,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT05524571,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,"Batoclimab, Placebo",,RANDOMIZED,2,Batoclimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.,,2026-03,ESTIMATED,18 Years - N/A,100,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)",2026-03,ESTIMATED,Percentage of proptosis responders,TREATMENT,ALL,2023-01-05,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT05517447,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,Batoclimab,,NON_RANDOMIZED,2,Observational cohort | Treatment Cohort,OTHER | EXPERIMENTAL,This is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.,,2026-08,ESTIMATED,18 Years - N/A,180,ESTIMATED,PARALLEL,INDUSTRY,NONE,An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED),2026-08,ESTIMATED,Duration of proptosis response off treatment in study eye in batoclimab responder participants in the feeder studies,TREATMENT,ALL,2022-11-06,ACTUAL,INTERVENTIONAL
ROIV,Roivant Sciences Ltd.,NCT06979531,PHASE2,RECRUITING,Primary Sjögren's Syndrome,"IMVT-1402, Placebo",,RANDOMIZED,3,Group 1: IMVT-1402 Dose 1 | Group 2: IMVT-1402 Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).",,2028-07,ESTIMATED,18 Years - 74 Years,180,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity",2028-07,ESTIMATED,Change from Baseline in clinESSDAI Score at Week 24 for IMVT-1402 Dose 1 compared to Placebo,TREATMENT,ALL,2025-06-30,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07047638,,RECRUITING,Skin Quality Improvement,,,RANDOMIZED,2,Restylane Skinboosters Vital Lidocaine | No treatment,EXPERIMENTAL | NO_INTERVENTION,"This is a randomized, evaluator-blinded, no-treatment controlled, study to evaluate the effectiveness and safety of Restylane Skinboosters Vital Lidocaine treatment to improve skin quality of the face in China. Subjects of Chinese origin, age 18 years, who are eligible for treatment to improve skin quality of the face. Study center is up to 8.

A total of approximately 171 subjects will be randomized (2:1) to either treatment with Restylane Skinboosters Vital Lidocaine Treatment Group (approxima",,2027-05-31,ESTIMATED,18 Years - N/A,171,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Randomized, Evaluator-blinded, No-treatment Controlled, Multicenter Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine for Improvement in Skin Quality of the Face",2026-03-31,ESTIMATED,Responder rate based on the Blinded Evaluators' live assessment using the Galderma Skin Quality - Fine Lines Scale (GSQ-FLS).,TREATMENT,ALL,2025-07-09,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT04162496,,ACTIVE_NOT_RECRUITING,"Aging, Wrinkle, Rhytides",,,RANDOMIZED,2,Treatment with Restylane Refyne Group 1 | Treatment with Restylane Refyne Group 2,EXPERIMENTAL | EXPERIMENTAL,"Subjects with grades ranging from 1---3 on the Transverse Neck Line Scale, will be randomized to receive up to 1cc of Restylane Refyne on one side of their neck utilizing a cannula and up to 1cc of Restylane Refyne on the other side utilizing a 30--gauge needle. On Day 30, this treatment with the same left---right assignment can be repeated if optimal correction on either side has not been achieved according to the treating investigator. Subjects will return 24--48 hours after their first treatm",Galderma R&D,2021-09-30,ESTIMATED,18 Years - N/A,24,ACTUAL,SINGLE_GROUP,OTHER,SINGLE,"An Evaluator -Blinded, Split-Neck, Randomized Clinical Study Investigating the Efficacy and Safety of Restylane Refyne for Correction of Static Horizontal Neck Rhytides Utilizing Either a Cannula or Needle",2021-01-22,ACTUAL,Change in transverse neck rhytides,TREATMENT,ALL,2020-08-11,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT03713203,,RECRUITING,"Paget Disease of the Vulva, Paget Disease, Extramammary",,PAGETEX,,1,Pagetex PDT,EXPERIMENTAL,"Vulvar Paget's disease is a rare skin tumour which affect Caucasian post-menopausal women. The disease is revealed by erythematous, eczematous, pruritus and vulvar burns. The diagnosis is often late (from a few months to several years) because the symptoms are neglected by patients or misinterpreted by doctors. The reference treatment is based on surgical excision but unfortunately local recurrences are very frequent (17 to 38% of cases).

Photodynamic therapy (PDT) is already used in some derma","Galderma R&D, Institut National de la Santé Et de la Recherche Médicale, France",2026-08-27,ESTIMATED,18 Years - N/A,24,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"An Interventional, Phase II, Non Randomized, Mono-centric Study on the Clinical Efficacy and Safety of the Medical Device PAGETEX® as a Photodynamic Therapy Device in the Treatment of Extra-Mammary Paget's Disease of the Vulva (EMPV)",2026-08-27,ESTIMATED,disease control rate in 30% of patients included,TREATMENT,FEMALE,2019-08-27,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07399028,,RECRUITING,"Volume Deficiency in the Mid-Face, Skin Laxity, Photo-aged Skin",,,,1,Treatment Group,EXPERIMENTAL,Adult subjects with moderate-to-severe cheek wrinkles will be treated with Sculptra for correction of fine lines and wrinkles in the cheek area.,,2026-09,ESTIMATED,45 Years - 65 Years,25,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Single-center, Open-label Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging",2026-09,ESTIMATED,Structural change in midface post-treatment with a biostimulator compared to pre-treatment assessed by standardized VISIA imaging and optical biopsy imaging,TREATMENT,FEMALE,2025-10-21,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07186413,PHASE3,RECRUITING,Acne Vulgaris,"Trifarotene, Vehicle Cream",AKLIEF,RANDOMIZED,2,Trifarotene Cream | Vehicle Cream,EXPERIMENTAL | ACTIVE_COMPARATOR,The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.,,2026-12-31,ESTIMATED,9 Years - N/A,561,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Multicenter, Randomized, Double-blinded, Parallel-group, Vehicle-controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris",2026-12-31,ESTIMATED,Percentage of Participants with Investigator Global Assessment (IGA) Success (Face only) at Week 12 | Change from Baseline to Week 12 in Facial Non-inflammatory Lesion Count | Change from Baseline to Week 12 in Facial Inflammatory Lesion Count,TREATMENT,ALL,2025-09-23,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT06351358,,ACTIVE_NOT_RECRUITING,"Photoaging, Weight Loss, Skin Laxity, Photodamaged Skin, Volume Deficiency of the Midface",,,,1,Sculptra and Restylane Treatment Group,EXPERIMENTAL,Adult subjects with a history of or currently taking glucagon-like peptide-1 (GLP-1) receptor agonist medication and moderate-to-severe cheek wrinkles and midface contour deficiencies will be treated with Sculptra correction of fine lines and wrinkles in the cheek area and Restylane Lyft or Restylane Contour for cheek augmentation and correction of midface contour deficiencies.,,2025-05-31,ESTIMATED,22 Years - 65 Years,40,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multi-center, Open-label Study to Evaluate the Synergistic Effects of Biostimulator and Dermal Fillers for Cheek Augmentation and Correction of Contour Deficiencies",2025-05-31,ESTIMATED,Change in skin hydration from baseline | Change in skin radiance from baseline | Change in skin elasticity from baseline | Change in skin thickness from baseline,TREATMENT,ALL,2024-02-19,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07074977,PHASE2,RECRUITING,Chronic Pruritus of Unknown Origin,"nemolizumab, Placebo",CPUO,RANDOMIZED,2,nemolizumab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective of this study is to assess the PK/PD relationship of nemolizumab in adult participants aged 18 years or above with chronic pruritus of unknown origin (CPUO) during a 16-week treatment period.,,2027-01,ESTIMATED,18 Years - N/A,50,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,An Exploratory Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics (PK/PD) of Nemolizumab in Adult Participants With Chronic Pruritus of Unknown Origin (CPUO),2026-09,ESTIMATED,Population Pharmacokinetics (PopPK) Model of the Elimination of nemolizumab During the 16-week Treatment Period Point | Population Pharmacokinetics (PopPK) Model of the Distribution of nemolizumab During the 16-week Treatment Period Point | Population Pharmacokinetics (PopPK) Model of the Absorption of nemolizumab During the 16-week Treatment Period Point | Pharmacokinetic (PK)/Pharmacodynamic (PD) Model of the Effect of nemolizumab Systemic Exposure on Pruritus during 16-week Treatment Period,TREATMENT,ALL,2025-10-20,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07342400,,RECRUITING,"Cheek Wrinkles, Menopausal Women",,,,1,Treatment Group,EXPERIMENTAL,To assess protein expression stimulated by poly L-lactic acid (PLLA) via punch biopsy at each follow-up visits compared to Baseline.,,2026-11,ESTIMATED,22 Years - N/A,40,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multi-center, Prospective Clinical Study to Assess Histological Changes From Treatment of Poly L-lactic Acid Biostimulator on Women at Various Menopausal Stages",2026-11,ESTIMATED,Protein Expression,TREATMENT,FEMALE,2025-08-12,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT06195605,,RECRUITING,Photoaging,,,,1,Photodamaged skin,EXPERIMENTAL,The purpose of the study is to investigate the impact of the injection of dermal filler on the quality of the skin dermal extracellular matrix in persons between the ages of 30-50 years. The quality of the dermal extracellular matrix will be assessed following injection of dermal filler compared to injection of saline vehicle.,Galderma R&D,2026-11,ESTIMATED,30 Years - 50 Years,15,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin,2026-11,ESTIMATED,Extracellular Matrix (ECM) deposition as measured using histological stain(s) of skin,TREATMENT,ALL,2024-05-09,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07047690,PHASE2,NOT_YET_RECRUITING,Systemic Sclerosis,"Nemolizumab, Placebo",,RANDOMIZED,3,Nemolizumab Dose 1 | Nemolizumab Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this target population.,,2028-07-23,ESTIMATED,18 Years - N/A,162,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Nemolizumab in Adult Patients With Systemic Sclerosis",2028-05-28,ESTIMATED,Change From Baseline (BL) in Modified Rodnan Skin Score (mRSS) at Week 52,TREATMENT,ALL,2025-12-15,ESTIMATED,INTERVENTIONAL
GALDY,Galderma Group AG,NCT06656923,,ACTIVE_NOT_RECRUITING,Lateral Gluteal Depression,,,,0,,,Primary Objective: use immunofluorescence (IF) on previously obtained biopsies to analyze and quantify changes in adipose tissue of subjects injected with poly-L-lactic acid (PLLA) or saline.,Galderma R&D,2025-08-30,ESTIMATED,N/A - N/A,14,ACTUAL,,OTHER,,PLLA-ADIPOGENESIS-IFA: Immunofluorescence Analysis to Quantify Changes Induced by Poly-L-Lactic Acid in Adipose Tissue,2025-02-28,ACTUAL,Change in cell count per area between PLLA and saline-treated specimens.,,FEMALE,2024-11-01,ACTUAL,OBSERVATIONAL
GALDY,Galderma Group AG,NCT06988618,,RECRUITING,Prurigo Nodularis,,RE-UNITE PN,,1,Nemolizumab,,The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.,,2027-11-30,ESTIMATED,18 Years - N/A,600,ESTIMATED,,INDUSTRY,,Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults,2027-11-30,ESTIMATED,Investigator Global Assessment-chronic Prurigo (IGA-CPG stage) at Month 6 | Peak Pruritus Numerical Rating Scale (PP NRS) at Month 6,,ALL,2025-08-11,ACTUAL,OBSERVATIONAL
GALDY,Galderma Group AG,NCT07225348,PHASE4,RECRUITING,Perioral Wrinkles,Poly-L-Lactic Acid,,RANDOMIZED,2,Arm A | Arm B,EXPERIMENTAL | EXPERIMENTAL,"The first goal of this clinical trial is to learn if topical application of PLLA in conjunction with a microneedling treatment works to treat perioral wrinkles in adults. The second goal is to see whether the application of topical PLLA is more effective before or after a microneedling treatment. The main questions it aims to answer are:

* Is PLLA present within the MN channels from in vivo biopsy samples?
* Is it safe to combine topical PLLA and MN in the treatment of perioral wrinkles, as det",Galderma R&D,2026-10-01,ESTIMATED,40 Years - 70 Years,26,ESTIMATED,PARALLEL,OTHER,SINGLE,Treatment of Perioral Wrinkles Using Topical Poly-L-lactic Acid and Microneedling Device,2026-06-01,ESTIMATED,Global Aesthetic Improvement Scale (GAIS),TREATMENT,ALL,2025-11-07,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT04204616,PHASE3,ACTIVE_NOT_RECRUITING,Prurigo Nodularis,Nemolizumab,,,1,Nemolizumab,EXPERIMENTAL,The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).,,2026-10-26,ESTIMATED,18 Years - N/A,500,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis",2026-10-26,ESTIMATED,Incidence of Adverse Events (AEs) by Severity,TREATMENT,ALL,2021-01-11,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT04341623,,ACTIVE_NOT_RECRUITING,Xerosis Due to Atopic Dermatitis,,,RANDOMIZED,3,Control Group | Digital Interaction Group | GPSkin group,OTHER | OTHER | OTHER,"The primary hypothesis is that routine measurement of trans epidermal water loss (TEWL) rates and stratum corneum (SC) hydration levels will promote patient adherence to maintenance moisturizer therapy and prevent disease relapse. The project will consist of a trial in which thirty subjects with xerosis receive moisturizer therapy and are randomized to receive either no intervention, a weekly electronic survey to assess patient's response to daily moisturizer, or daily monitoring of the effectiv",Galderma R&D,2026-08,ESTIMATED,18 Years - 85 Years,35,ACTUAL,SEQUENTIAL,OTHER,NONE,Epidermal Permeability Barrier Function and Stratum Corneum Hydration of Xerosis Following Application of a Topical Moisturizer,2026-03,ESTIMATED,Xerosis Severity | Xerosis Severity | Adherence - Moisturizer | Adherence - Moisturizer | Adherence - Moisturizer | Transepidermal water loss (TEWL) rates | Transepidermal water loss (TEWL) rates,OTHER,ALL,2021-01-21,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07398989,PHASE4,RECRUITING,"Crepey Skin, Aging Skin, Photo-aged Skin",Cetaphil,,,1,Skincare Product Treatment,EXPERIMENTAL,"Subjects having mild-to-moderate crepiness, photodamage, and loss of firmness will apply a topical skincare regimen to the knees, thighs, hands, and all over the body. Evaluations of the regimen's efficacy will be conducted at 4 weeks, 8 weeks, and 12 weeks post-baseline.",,2026-03,ESTIMATED,40 Years - 60 Years,30,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin",2026-03,ESTIMATED,Change of clinical grading compared to baseline | Change in skin hydration as measured by Corneometer | Change in tolerability grading compared to baseline | Change in skin quality measured by macroscopic imaging (Visioscan) | Measured pH values consistent with baseline,TREATMENT,ALL,2025-08-12,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07324564,,RECRUITING,Gluteal Skin Irregularities,,,RANDOMIZED,2,Treatment Group | Control Group,EXPERIMENTAL | NO_INTERVENTION,The main purpose of the study is to investigate the safety and effectiveness of Sculptra 011611 for improvement in appearance of gluteal skin irregularities.,,2027-04,ESTIMATED,18 Years - N/A,125,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Randomized, Evaluator-blinded, No-treatment Controlled, Multicenter Study to Evaluate the Effectiveness and Safety of Sculptra 011611 for Improvement in Appearance of Gluteal Skin Irregularities",2026-04,ESTIMATED,"Percentage of Responders Having At Least ""Improved"" in Both Buttocks at Maximal Contraction According to the Global Aesthetic Improvement Scale (GAIS), as Assessed Live by Blinded Evaluator, at Month 9",TREATMENT,FEMALE,2025-11-24,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT05987163,,ACTIVE_NOT_RECRUITING,Skin Manifestations,,NLF,RANDOMIZED,2,GP0116 | FDA Approved Device,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a prospective, randomized, evaluator-blinded, comparator-controlled, parallel group, multicenter study in the U.S. for correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds (NLFs).",,2026-03-31,ESTIMATED,22 Years - N/A,186,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Randomized, Evaluator-blinded, Parallel Group, Comparator-controlled, Multicenter Study to Evaluate the Safety and Effectiveness of GP0116 for Correction of Moderate to Severe Dynamic Facial Wrinkles and Folds, Such as Nasolabial Folds.",2024-10-29,ACTUAL,To demonstrate non-inferiority of GP0116 versus a comparator control,TREATMENT,ALL,2023-04-12,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT06988605,,RECRUITING,Atopic Dermatitis,,RE-UNITE AD,,1,Nemolizumab,,The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.,,2027-11-30,ESTIMATED,12 Years - N/A,1000,ESTIMATED,,INDUSTRY,,Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults,2026-11-06,ESTIMATED,Investigator Global Assessment (IGA) at Month 6 | Peak Pruritus Numerical Rating Scale (PP NRS) at Month 6,,ALL,2025-07-14,ACTUAL,OBSERVATIONAL
GALDY,Galderma Group AG,NCT03989206,PHASE3,ACTIVE_NOT_RECRUITING,Moderate-to-Severe Atopic Dermatitis,Nemolizumab,,,1,Nemolizumab,EXPERIMENTAL,Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description,,2026-08-31,ESTIMATED,12 Years - N/A,1700,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis",2026-08-31,ESTIMATED,Incidence and Severity of TEAEs | Incidence of Serious TEAEs | Incidence and Severity of Adverse Events of Special Interest (AESIs) Throughout the Study,TREATMENT,ALL,2019-12-30,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT06665477,,RECRUITING,Temple Hollowing,,,RANDOMIZED,2,Subject treated with Restylane Volyme | Subject non-treated with Restylane Volyme,EXPERIMENTAL | NO_INTERVENTION,"A randomized, no-treatment-controlled, evaluator-blinded, multi-center study to evaluate the effectiveness and safety of Restylane Volyme in the treatment of temple hollowing",,2026-07,ESTIMATED,18 Years - N/A,162,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Randomized, No-treatment-controlled, Evaluator-blinded, Multi-center Study to Evaluate the Effectiveness and Safety of Restylane Volyme in the Treatment of Temple Hollowing",2025-12,ESTIMATED,Responder Rate on a Temple Hollowing Scale,TREATMENT,ALL,2024-11-18,ACTUAL,INTERVENTIONAL
GALDY,Galderma Group AG,NCT07344584,,NOT_YET_RECRUITING,Wrinkle Reduction,,,RANDOMIZED,2,GP0122 | GP0124,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,The primary objective of the study is to evaluate the safety of GP0122 and GP0124 for the correction of lines and wrinkles in the cheek area.,,2027-06-30,ESTIMATED,18 Years - N/A,60,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles in the Cheek Area,2027-04-30,ESTIMATED,Number of Participants With all Adverse Events (AEs) | Number of Participants With Post-Treatment Responses as Assessed Using Subject Diary Data | Participant's Pain Assessment Using Numeric Pain Scale (NPS) Immediately Post Treatment and 30 Minutes Post Treatment,TREATMENT,ALL,2026-01-16,ESTIMATED,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05422222,PHASE3,RECRUITING,Cystic Fibrosis,VX-121/TEZ/D-IVA,,NON_RANDOMIZED,2,Part A: VX-121/TEZ/D-IVA | Part B: VX-121/TEZ/D-IVA,EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",,2030-06-30,ESTIMATED,1 Year - 11 Years,210,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age",2030-06-30,ESTIMATED,"Part A: Observed Pre-dose Plasma Concentration (Ctrough) of VX-121, TEZ, D-IVA, and Relevant Metabolites | Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",TREATMENT,ALL,2022-06-21,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT07349394,PHASE1,RECRUITING,Cystic Fibrosis,"VNZ/TEZ/D-IVA, Rosuvastatin",,,1,VNZ/TEZ/D-IVA and Rosuvastatin,EXPERIMENTAL,The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.,,2026-04-04,ESTIMATED,18 Years - 55 Years,18,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1, Open-label, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Vanzacaftor/Tezacaftor/Deutivacaftor on the Pharmacokinetics of Rosuvastatin in Healthy Subjects",2026-04-04,ESTIMATED,Maximum Observed Concentration (Cmax) of Rosuvastatin in the Absence and Presence of VNZ/TEZ/D-IVA | Area Under the Concentration Time-curve (AUC) of Rosuvastatin in the Absence and Presence of VNZ/TEZ/D-IVA,TREATMENT,ALL,2026-01-12,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06832410,PHASE3,RECRUITING,"Type 1 Diabetes, Kidney Transplant",Biological/Vaccine,,,1,VX-880,EXPERIMENTAL,"This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.",,2027-09-17,ESTIMATED,18 Years - 65 Years,10,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant",2026-09-17,ESTIMATED,Proportion of Participants who are Insulin Independent,TREATMENT,ALL,2025-03-31,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT07161037,PHASE2,RECRUITING,Autosomal Dominant Polycystic Kidney Disease (ADPKD),VX-407,AGLOW,,1,VX-407,EXPERIMENTAL,"The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.",,2027-12-31,ESTIMATED,18 Years - 65 Years,24,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants",2027-07-22,ESTIMATED,htTKV on MRI Over Time,TREATMENT,ALL,2025-11-19,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06619860,PHASE2,RECRUITING,Diabetic Peripheral Neuropathic Pain,"VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993)",,RANDOMIZED,2,VX-993 | Pregabalin,EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)",,2026-05-30,ESTIMATED,18 Years - 80 Years,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy",2026-04-30,ESTIMATED,Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12,TREATMENT,ALL,2024-10-18,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06794996,PHASE2,RECRUITING,Proteinuric Kidney Disease,Inaxaplin,AMPLIFIED,,1,IXP (Inaxaplin),EXPERIMENTAL,"The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).",,2026-12-30,ESTIMATED,18 Years - 67 Years,45,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease",2026-12-30,ESTIMATED,Percent Change in Urine Albumin-Creatinine Ratio (UACR),TREATMENT,ALL,2025-02-04,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT07074327,PHASE1,RECRUITING,Autosomal Dominant Polycystic Kidney Disease (ADPKD),"VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE",,NON_RANDOMIZED,4,Part A: VX-407 With Levonorgestrel/Ethinyl Estradiol (LNG/EE) | Part B (Optional): VX-407 With Norgestimate/Ethinyl Estradiol (NGM/EE) | Part C (Optional): VX-407 With Norethindrone/Ethinyl Estradiol (NET/EE) | Part D (Optional): VX-407 With Drospirenone/Ethinyl Estradiol (DRSP/EE),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE, norethindrone (NET) and EE and drospirenone (DRSP) and EE. Also, to evaluate the safety and tolerability of co-administration of VX-407 with LNG/EE, NGM/EE, NET/EE and DRSP/EE.",,2026-07-04,ESTIMATED,18 Years - 50 Years,148,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"Phase 1, Open-label Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Subjects",2026-06-29,ESTIMATED,Part A: Maximum Observed Plasma Concentration (Cmax) of LNG and EE in the Absence and Presence of VX-407 | Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG and EE in the Absence and Presence of VX-407 | Part B (Optional): Cmax of Norelgestromin (NGMN) and Norgestrel (NG) (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407 | Part B (Optional): AUC0-inf of NGMN and NG (Active Metabolites of NGM) and EE in the Absence and Presence of VX-407 | Part C (Optional): Cmax of NET and EE in the Absence and Presence of VX-407 | Part C (Optional): AUC0-inf of NET and EE in the Absence and Presence of VX-407 | Part D (Optional): Cmax of DRSP and EE in the Absence and Presence of VX-407 | Part D (Optional): AUC0-inf of DRSP and EE in the Absence and Presence of VX-407,TREATMENT,FEMALE,2025-07-11,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT07204275,"PHASE2, PHASE3",RECRUITING,Primary Membranous Nephropathy,"Povetacicept, Tacrolimus",OLYMPUS,RANDOMIZED,3,Phase 2b: Povetacicept | Phase 3: Povetacicept | Phase 3: Calcineurin Inhibitor (CNI),EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).","Zai Lab (Shanghai) Co., Ltd. (for China only)",2028-12-29,ESTIMATED,18 Years - 75 Years,176,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy",2028-12-29,ESTIMATED,Proportion of Participants with Complete Clinical Remission Definition 1 (CR1),TREATMENT,ALL,2025-09-30,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05951205,PHASE3,NOT_YET_RECRUITING,Sickle Cell Disease,Exa-cel,,,1,Exa-cel,EXPERIMENTAL,"The purpose of the study is to evaluate the efficacy and safety of CTX001 (exa-cel) in adolescent and adult participants with severe sickle cell disease (SCD), βS/βC genotype (HbSC).",,2033-12-31,ESTIMATED,12 Years - 35 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects With Severe Sickle Cell Disease, βS/βC Genotype",2033-12-31,ESTIMATED,Proportion of Participants with an Average Fetal Hemoglobin (HbF) Greater Than or Equal To (>=) 20 percent (%) on or After 6 Months,TREATMENT,ALL,2027-07-31,ESTIMATED,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06154447,PHASE1,RECRUITING,Cystic Fibrosis,"VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Placebo, Deutivacaftor, VX-828",,RANDOMIZED,8,"Part A: Single Ascending Dose (SAD) | Part A: Placebo | Part B: Multiple Ascending Dose (MAD) | Part B: Placebo | Part C: Drug Drug Interaction | Part D: VX-828 in combination with TEZ/VX-118 ,TEZ/D-IVA or D-IVA | Part D: Placebo | Part E: VX-828 in Combination with D-IVA with or without TEZ in CF",EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).",,2026-04-23,ESTIMATED,18 Years - N/A,255,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With Cystic Fibrosis",2026-04-23,ESTIMATED,Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Part E: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Part C: Maximum Observed Concentration (Cmax) of VX-828 in Plasma in the Absence and Presence of Itraconazole | Part C: Area Under the Concentration Versus Time Curve (AUC) of VX-828 in Plasma in the Absence and Presence of Itraconazole | Part C: Maximum Observed Concentration (Cmax) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA | Part C: Area Under the Concentration Versus Time Curve (AUC) of Midazolam in Plasma in the Absence and Presence of VX-828/TEZ/D-IVA,TREATMENT,ALL,2023-12-12,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05444257,PHASE3,ACTIVE_NOT_RECRUITING,Cystic Fibrosis,VX-121/TEZ/D-IVA,,,1,VX-121/TEZ/D-IVA,EXPERIMENTAL,"The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.",,2026-10-30,ESTIMATED,12 Years - N/A,822,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combination Therapy in Subjects With Cystic Fibrosis",2026-10-30,ESTIMATED,Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2022-11-08,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06628908,PHASE3,RECRUITING,Diabetic Peripheral Neuropathic Pain,"Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)",,RANDOMIZED,3,Suzetrigine (SUZ) | Pregabalin | Placebo,EXPERIMENTAL | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).",,2027-05-31,ESTIMATED,18 Years - 80 Years,1100,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy",2027-05-31,ESTIMATED,Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo,TREATMENT,ALL,2024-10-01,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05329649,PHASE3,RECRUITING,"Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies, Hematological Diseases",CTX001,,,1,CTX001,EXPERIMENTAL,"This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).",CRISPR Therapeutics,2026-05-31,ESTIMATED,2 Years - 11 Years,15,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease,2026-05-31,ESTIMATED,Proportion of Participants who do not Have any Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months (VF12),TREATMENT,ALL,2022-05-02,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06696443,PHASE3,ACTIVE_NOT_RECRUITING,Diabetic Peripheral Neuropathic Pain,Suzetrigine,,,1,Suzetrigine (SUZ),EXPERIMENTAL,The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.,,2027-01-25,ESTIMATED,18 Years - 80 Years,455,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy",2027-01-25,ESTIMATED,Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2024-12-18,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT07283770,PHASE1,RECRUITING,Cystic Fibrosis,"VX-581, Placebo",,RANDOMIZED,4,Part A: Single Ascending Dose | Placebo: Part A | Part B: Multiple Ascending Dose | Placebo: Part B,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.",,2026-11-19,ESTIMATED,18 Years - 55 Years,128,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects",2026-11-19,ESTIMATED,Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2025-12-09,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05791201,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Type 1 Diabetes,VX-264,,,1,VX-264,EXPERIMENTAL,"The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).",,2026-05-29,ESTIMATED,18 Years - 65 Years,7,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus",2026-05-29,ESTIMATED,Part A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Part B and Part C: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT),TREATMENT,ALL,2023-05-16,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT04786262,PHASE3,RECRUITING,"Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia",VX-880,,,1,VX-880,EXPERIMENTAL,"This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.",,2030-06-30,ESTIMATED,18 Years - 65 Years,52,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia",2027-06-30,ESTIMATED,Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) | Parts B and C: Proportion of Participants who are Insulin Independent with Absence of Severe Hypoglycemic Events (SHEs),TREATMENT,ALL,2021-03-29,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT07378865,PHASE1,NOT_YET_RECRUITING,Pain,Suzetrigine,,,1,SUZ,EXPERIMENTAL,"The purpose of the study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ) and its active metabolite in breast milk of lactating female participants. In addition, the purpose is also to evaluate the relative infant dose (RID), safety and tolerability of SUZ and its active metabolite in lactating female participants.",,2027-02-26,ESTIMATED,18 Years - N/A,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1, Open-label, Single-dose Study Evaluating the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Subjects",2027-02-26,ESTIMATED,Total Amount of SUZ in Breast Milk of Lactating Female Participants | Total Amount of SUZ Metabolite in Breast Milk of Lactating Female Participants | Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of SUZ and its Metabolite in Breast Milk | Maximum Observed Concentration (Cmax) of SUZ and its Metabolite in Breast Milk,TREATMENT,FEMALE,2026-02-03,ESTIMATED,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05356195,PHASE3,RECRUITING,"Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies",CTX001,,,1,CTX001,EXPERIMENTAL,"This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).",CRISPR Therapeutics,2026-05-31,ESTIMATED,2 Years - 11 Years,15,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia,2026-05-31,ESTIMATED,Proportion of Participants who Achieve Transfusion Independence for at Least 12 Consecutive Months (TI12),TREATMENT,ALL,2022-05-03,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06185764,"PHASE1, PHASE2",RECRUITING,Myotonic Dystrophy Type 1 (DM1),"VX-670, Placebo",Galileo,RANDOMIZED,4,Part A: Single Ascending Dose | Part A: Placebo | Part B: Single and Multiple Ascending Dose | Part B: Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.",,2026-12-22,ESTIMATED,18 Years - 64 Years,44,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1",2026-12-22,ESTIMATED,Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs),TREATMENT,ALL,2024-02-20,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05477563,PHASE3,RECRUITING,"Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia",CTX001,,,1,CTX001,EXPERIMENTAL,"This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.",,2027-06-09,ESTIMATED,12 Years - 35 Years,26,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease,2027-06-09,ESTIMATED,Fetal Hemoglobin (HbF) Concentration Over Time | Total Hemoglobin (Hb) Concentration Over Time,TREATMENT,ALL,2022-08-02,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05312879,"PHASE2, PHASE3",RECRUITING,Proteinuric Kidney Disease,"VX-147, Placebo",AMPLITUDE,RANDOMIZED,4,Phase 2: VX-147 | Phase 2: Placebo | Phase 3: VX-147 | Phase 3: Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.",,2026-06-30,ESTIMATED,10 Years - 65 Years,466,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease",2026-05-31,ESTIMATED,Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis) | Estimated Glomerular Filtration Rate (eGFR) Slope Assessed at the Week 48 Interim Analysis | eGFR Slope Assessed at Study Completion,TREATMENT,ALL,2022-03-30,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05331183,PHASE3,ACTIVE_NOT_RECRUITING,Cystic Fibrosis,"ELX/TEZ/IVA, IVA",,,1,ELX/TEZ/IVA,EXPERIMENTAL,"This study will evaluate the long-term safety, efficacy and pharmacodynamics of ELX/TEZ/IVA in participants with cystic fibrosis (CF) with at least 1 non-F508del ELX/TEZ/IVA-responsive CF transmembrane conductance regulator (CFTR) gene mutation.",,2027-04-06,ESTIMATED,6 Years - N/A,297,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes,2027-04-06,ESTIMATED,Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2022-11-23,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06460506,PHASE3,ACTIVE_NOT_RECRUITING,Cystic Fibrosis,"ELX/TEZ/IVA, IVA",,,1,ELX/TEZ/IVA,EXPERIMENTAL,"The purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (PD) of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA).",,2027-09-30,ESTIMATED,12 Months - N/A,50,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 Months of Age and Older",2027-09-30,ESTIMATED,Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2024-11-21,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT06747572,,ACTIVE_NOT_RECRUITING,Autosomal Dominant Polycystic Kidney Disease (ADPKD),,,,2,Part A | Part B, | ,"The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.",,2026-12-31,ESTIMATED,12 Years - 65 Years,401,ACTUAL,,INDUSTRY,,A Study to Determine the Prevalence and Clinical Characteristics Associated With PKD1 Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease (ADPKD),2026-12-31,ESTIMATED,Part A: Percentage of PKD1 Gene Variant Groups in the ADPKD Population | Part A: Weight of Participants Within Each PKD1 Gene Variant Group | Part A: Height of Participants Within Each PKD1 Gene Variant Group | Part A: Body Mass Index (BMI) of Participants Within Each PKD1 Gene Variant Group | Part A: Age of Participants at ADPKD Diagnosis Within Each PKD1 Gene Variant Group,,ALL,2024-12-19,ACTUAL,OBSERVATIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT07022119,PHASE1,RECRUITING,Autosomal Dominant Polycystic Kidney Disease (ADPKD),"VX-407, Placebo",,RANDOMIZED,4,Part A: Single Ascending Dose | Placebo Part A | Part B: Multiple Ascending Dose | Placebo Part B,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of VX-407 in healthy participants.",,2026-03-03,ESTIMATED,18 Years - 55 Years,32,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Extension Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of VX-407 in Healthy Subjects",2026-03-03,ESTIMATED,Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2025-06-12,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05668741,"PHASE1, PHASE2",RECRUITING,Cystic Fibrosis,"VX-522 mRNA therapy, IVA",,,4,Single Ascending Dose (SAD) | Multiple Ascending Dose (MAD) Cohort 1: VX-522 | MAD Cohort 1: VX-522+ IVA | MAD Cohort 2: VX-522+ IVA,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.","Moderna, Inc",2027-05-12,ESTIMATED,18 Years - 65 Years,39,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1/2 Dose Escalation Study Evaluating the Safety, and Tolerability and Efficacy of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy",2026-12-23,ESTIMATED,Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2023-02-27,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT07231419,PHASE3,RECRUITING,Diabetic Peripheral Neuropathic Pain,"Suzetrigine, Placebo (matched to SUZ)",,RANDOMIZED,2,Suzetrigine (SUZ) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).",,2027-04-06,ESTIMATED,18 Years - 80 Years,734,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy",2027-04-06,ESTIMATED,Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo,TREATMENT,ALL,2025-11-21,ACTUAL,INTERVENTIONAL
VRTX,Vertex Pharmaceuticals Incorporated,NCT05153317,PHASE3,ACTIVE_NOT_RECRUITING,Cystic Fibrosis,"ELX/TEZ/IVA, IVA",,,1,ELX/TEZ/IVA,EXPERIMENTAL,"The purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in CF participants 2 years of age and older.",,2026-04-30,ESTIMATED,2 Years - N/A,71,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3 Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older,2026-04-30,ESTIMATED,Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs),TREATMENT,ALL,2022-01-17,ACTUAL,INTERVENTIONAL
RNA,"Avidity Biosciences, Inc.",NCT05747924,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"FSHD, FSHD1, FSHD2, FMD, FMD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FSH","AOC 1020, Placebo",FORTITUDE,RANDOMIZED,5,AOC 1020 Regimen 1 | AOC 1020 Regimen 2 | AOC 1020 Regimen 3 | Placebo (Saline) Regimen 1 | Placebo (Saline) Regimen 2,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)",,2027-04,ESTIMATED,16 Years - 70 Years,90,ACTUAL,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)",2026-10,ESTIMATED,Incidence of treatment-emergent adverse events (Cohorts A & B) | Change in DUX4-regulated gene expression in muscle biopsies (Cohort C) | Change in a circulating biomarker of FSHD disease biology (Cohort C),TREATMENT,ALL,2023-04-04,ACTUAL,INTERVENTIONAL
RNA,"Avidity Biosciences, Inc.",NCT04635891,,RECRUITING,FSHD,,MOVE FSHD,,1,MOVE FSHD Study Visits,,"The primary goal of this proposal is to collect motor and functional outcomes specific to FSHD over time. By collecting measures specific to FSHD, this will help ensure the best level of clinical care is being provided. Also, the hope is to speed up drug development by gaining a better understanding of how having FSHD impacts motor function and other health outcomes (i.e. breathing, wheelchair use, etc.) and how big a change in motor function would be clinically meaningful to those with FSHD.

M","FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche, Springbok Analytics",2028-01,ESTIMATED,N/A - N/A,450,ESTIMATED,,OTHER,,Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD),2027-12,ESTIMATED,"10m walk/run | Shoulder and Arm Range of Motion | Shoulder and Arm Function | Spirometry (FVC, FEV1, PCF)",,ALL,2020-12-15,ACTUAL,OBSERVATIONAL
RNA,"Avidity Biosciences, Inc.",NCT06244082,PHASE2,ACTIVE_NOT_RECRUITING,"DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44",AOC 1044,EXPLORE44OLE,,1,AOC 1044 Multiple Dose Levels,EXPERIMENTAL,AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.,,2027-07-31,ESTIMATED,7 Years - 27 Years,39,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2 Open-label Study to Evaluate the Pharmacodynamics and Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants With Mutations Amenable to Exon 44 Skipping,2027-04-30,ESTIMATED,Incidence of Treatment Emergent Adverse Events (TEAEs),TREATMENT,MALE,2024-01-22,ACTUAL,INTERVENTIONAL
RNA,"Avidity Biosciences, Inc.",NCT07038200,PHASE3,RECRUITING,"Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome","AOC-1020, Placebo",FORTITUDE-3,RANDOMIZED,2,del-brax | placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)",,2028-07,ESTIMATED,16 Years - 70 Years,200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)",2028-05,ESTIMATED,Quantitative Muscle Testing (QMT) composite score,TREATMENT,ALL,2025-06-10,ACTUAL,INTERVENTIONAL
RNA,"Avidity Biosciences, Inc.",NCT06411288,PHASE3,ACTIVE_NOT_RECRUITING,"DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy","AOC 1001 (del-desiran), Placebo",HARBOR,RANDOMIZED,2,Del-desiran | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1",,2026-09,ESTIMATED,16 Years - 65 Years,159,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1",2026-08,ESTIMATED,Hand function,TREATMENT,ALL,2024-05-30,ACTUAL,INTERVENTIONAL
RLYB,Rallybio Corporation,NCT06797375,PHASE1,ACTIVE_NOT_RECRUITING,"Hematologic Diseases, Autoimmune Diseases",RLYB116 for Injection,,RANDOMIZED,3,RLYB116 Dose 1 | RLYB116 Dose 2 | Placebo for Injection,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RLYB116 (with an improved impurity profile) following repeated administration of RLYB116 in healthy participants.",,2026-06,ESTIMATED,18 Years - 55 Years,16,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RLYB116 in Healthy Participants",2026-03,ESTIMATED,Number of participants with treatment related adverse events as defined by CTCAE 5.0.,TREATMENT,ALL,2025-04-14,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT07294170,,RECRUITING,"Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis","Efgartigimod IV, Empasiprubart IV",,,1,ISA1 participants,,ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.,,2028-03-07,ESTIMATED,18 Years - N/A,70,ESTIMATED,,INDUSTRY,,"A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis",2028-03-07,ESTIMATED,To determine the safety and tolerability of multiple regimens (monotherapy or add-on therapy to backbone therapy) in MG subtypes,,ALL,2025-12-19,ACTUAL,OBSERVATIONAL
ARGX,argenx SE,NCT06909214,PHASE4,RECRUITING,New Onset Generalized Myasthenia Gravis (gMG),Efgartigimod PH20 SC,ADAPT-EARLY,,1,Efgartigimod PH20 SC,EXPERIMENTAL,The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.,,2027-05,ESTIMATED,18 Years - N/A,30,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 4, Open-Label, Prospective, Single-Group, Multicenter Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants With New-Onset Generalized Myasthenia Gravis",2026-08,ESTIMATED,Proportion of participants who achieve MSE of MG at any time within the first 16 weeks of treatment with efgartigimod PH20 SC,TREATMENT,ALL,2025-04-17,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT05523167,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome",EFG PH20 SC,ALKIVIA,RANDOMIZED,2,EFG PH20 SC | PBO PH20 SC,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome \[ASyS\]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found ",,2027-02-01,ESTIMATED,18 Years - N/A,265,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy",2026-12-01,ESTIMATED,"Total improvement score (TIS); measured on a [0,100] scale. Higher scores represent improvement; zero indicates no improvement or worsening (from baseline).",TREATMENT,ALL,2022-10-12,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT07011589,"PHASE1, PHASE2",NOT_YET_RECRUITING,"Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa",Efgartigimod,,,1,Efgartigimod,EXPERIMENTAL,"The study objective is to see if IV Efgartigimod and Vyjuvek treatment in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and IV Efgartigimod treatment in Epidermolysis Bullosa Acquisita (EBA) improves wound healing and affects the levels of C7 antibody levels in serum.

Fewer wounds, more rapidly healing wounds, and decreased C7 antibodies could improve quality of life.",argenx,2026-10,ESTIMATED,12 Years - N/A,18,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART),2026-07,ESTIMATED,Reduction in serum C7 antibody levels | Adverse Events and Effects | EBDASI improvement,TREATMENT,ALL,2025-07,ESTIMATED,INTERVENTIONAL
ARGX,argenx SE,NCT06920004,PHASE3,RECRUITING,"Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy","empasiprubart, IVIg",emvigorate,RANDOMIZED,3,Part A - empasiprubart + IVIg-placebo | Part A - IVIg + empasiprubart-placebo | Part B - empasiprubart,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL,"The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).",,2030-09,ESTIMATED,18 Years - N/A,218,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy",2027-09,ESTIMATED,Reduction of ≥1 point compared with baseline in aINCAT score at week 24,TREATMENT,ALL,2025-08-22,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT05988073,,ACTIVE_NOT_RECRUITING,Multifocal Motor Neuropathy,,iMMersioN,,0,,,"This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.",,2026-12-31,ESTIMATED,18 Years - N/A,413,ACTUAL,,INDUSTRY,,"A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy",2026-12-31,ESTIMATED,To characterize MMN patient profiles for participants | To assess the MMN disease management and disease course | To assess outcome measures specific to MMN disease and their evolution over time | To estimate the burden of MMN on participants' quality of life | To estimate the economic burden for participants with MMN | To collect data on relevant disease biomarkers,,ALL,2023-11-29,ACTUAL,OBSERVATIONAL
ARGX,argenx SE,NCT07284420,PHASE2,RECRUITING,"AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)","Efgartigimod IV, Empasiprubart IV",,,2,Efgartigimod IV + Empasiprubart IV | Efgartigimod IV (part A + C),EXPERIMENTAL | EXPERIMENTAL,"This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive ",,2028-03-07,ESTIMATED,18 Years - N/A,70,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod",2028-03-07,ESTIMATED,Incidence of adverse events and serious adverse events in parts A and B,TREATMENT,ALL,2025-12-19,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06655155,PHASE2,RECRUITING,Systemic Sclerosis (SSc),,eSScape,RANDOMIZED,2,Efgartigimod PH20 SC | Placebo PH20 SC,EXPERIMENTAL | PLACEBO_COMPARATOR,"The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months.",,2027-06-14,ESTIMATED,18 Years - N/A,81,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis",2026-08-17,ESTIMATED,Change from baseline in mRSS at week 24,TREATMENT,ALL,2024-11-11,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT05701189,PHASE2,RECRUITING,Guillain-Barre Syndrome,"Efgartigimod Alfa-Fcab, Intravenous Immunoglobulin (IVIg)",,RANDOMIZED,2,Efgartigimod Alfa-Fcab | Intravenous Immunoglobulin (IVIg),EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this clinical trial is to evaluate the safety and effectiveness of Efgartigimod in patients with Guillain-Barre syndrome (GBS). The main questions it aims to answer are:

* Is Efgartigimod a safe treatment option for GBS patients?
* Does treatment with Efgartigimod improve patient outcomes?

In addition to standard-of-care procedures and assessments, participants will:

* Undergo seven blood draws during hospitalization and in four follow-up study visits to evaluate the concentration",argenx,2027-05,ESTIMATED,18 Years - N/A,30,ESTIMATED,PARALLEL,OTHER,DOUBLE,"Phase 2, Randomized, Patient- and Rater-blinded Single-site Trial Evaluating Safety and Efficacy of Efgartigimod in Patients With Guillain-Barré Syndrome.",2026-08,ESTIMATED,Guillain-Barre Syndrome Disability Scale (GBS-DS) | Number and seriousness in adverse events in the studied population,TREATMENT,ALL,2024-09-10,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06684847,PHASE3,RECRUITING,Primary Sjogrens Disease,Efgartigimod PH20 SC,Unity,RANDOMIZED,3,Double-blinded treatment period: Efgartigimod PH20 SC | Double-blinded treatment period: Placebo PH20 SC | Open-label treatment period,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.,,2028-07,ESTIMATED,18 Years - N/A,580,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial With Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients With Primary Sjögren's Disease",2027-07,ESTIMATED,Change from baseline in clinESSDAI score at week 48,TREATMENT,ALL,2025-01-15,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06860633,PHASE4,RECRUITING,"Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis",Efgartigimod,,,1,Efgartigimod,EXPERIMENTAL,"This study plans to learn more about if the drug efgartigimod can be used in the hospital to treat exacerbations in participants with myasthenia gravis (MG). Efgartigimod has been approved by the FDA for ongoing (chronic) treatment of generalized MG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive but has not been studied in the treatment of worsening weakness requiring hospital admission (known as ""exacerbation""). This investigation aims to see if using efgartigimo",argenx,2026-12-31,ESTIMATED,18 Years - N/A,20,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod: A Single Arm, Open Label Prospective Cohort Study",2026-12-31,ESTIMATED,Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 11,TREATMENT,ALL,2025-03-06,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT04150887,PHASE1,ACTIVE_NOT_RECRUITING,"Leukemia, Myeloid, Acute","Cusatuzumab, Azacitidine, Venetoclax",ELEVATE,NON_RANDOMIZED,2,Experimental: Cohort 2: Cusatuzumab + Venetoclax | Cohort 3: Cusatuzumab + Venetoclax + Azacitidine (CVA),EXPERIMENTAL | EXPERIMENTAL,The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).,"argenx, Janssen Research & Development, LLC",2026-05-15,ESTIMATED,18 Years - N/A,61,ACTUAL,PARALLEL,INDUSTRY,NONE,"An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia",2026-05-15,ESTIMATED,"Frequency and Severity of Adverse Events (AEs), Laboratory Abnormalities, and Physical Exam Findings as a Measure of Safety",TREATMENT,ALL,2019-12-23,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06688253,PHASE4,NOT_YET_RECRUITING,Myasthenia Gravis Crisis,IV efgartigimod,,NON_RANDOMIZED,2,Interventional group with Efgartigimod | Historical PLEX group,EXPERIMENTAL | NO_INTERVENTION,"Efgartigimod in Myasthenic Crisis Background Myasthenia gravis (MG) is a prevalent autoimmune disorder affecting neuromuscular junctions, characterized by weakness in skeletal muscles. It is associated with the production of autoantibodies, primarily targeting acetylcholine receptors (AchR), and is often complicated by myasthenic crisis, which can lead to severe respiratory failure. Current treatments primarily involve non-specific immunosuppression, which may not provide rapid relief.

Aim This",argenx,2025-03-30,ESTIMATED,18 Years - 99 Years,16,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis,2025-01-15,ESTIMATED,MG-ADL scores observed before and after treatment initiation,TREATMENT,ALL,2024-11-15,ESTIMATED,INTERVENTIONAL
ARGX,argenx SE,NCT07377396,PHASE1,NOT_YET_RECRUITING,Healthy Volunteers,ARGX-124,,RANDOMIZED,2,ARGX-124 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study aims to assess the safety of ARGX-124 in healthy adults. Another aim is to measure the amount of ARGX-124 in the blood over time to learn how it acts and moves in the body and how the immune system responds to it. Participants will remain in the study for up to approximately 23 weeks.,,2026-12-31,ESTIMATED,18 Years - 65 Years,104,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-124 in Healthy Adult Participants",2026-12-31,ESTIMATED,"Incidence of AEs, SAEs and AEs leading to ARGX-124 discontinuation",TREATMENT,ALL,2026-01-23,ESTIMATED,INTERVENTIONAL
ARGX,argenx SE,NCT06307626,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,,UplighTED,RANDOMIZED,2,Efgartigimod arm | Placebo arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC.

After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up ",,2026-03-31,ESTIMATED,18 Years - N/A,105,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease",2025-12-15,ACTUAL,Percentage of participants who were proptosis responders,TREATMENT,ALL,2024-03-28,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06299748,,RECRUITING,"Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy",Efgartigimod,,,2,Retrospective Pregnancy | Prospective Pregnancy, | ,"This is a multi-country, prospective safety study of pregnant women exposed to efgartigimod or efgartigimod PH20 SC any time within 25 days prior to conception or any time during pregnancy. Women exposed to efgartigimod or efgartigimod PH20 SC only during breastfeeding will also be eligible to enroll. Background rates of major congenital malformations (MCMs) will be obtained from populations within the same countries/regions as the countries/regions in which the efgartigimod or efgartigimod PH20",,2033-12,ESTIMATED,N/A - N/A,279,ESTIMATED,,INDUSTRY,,"A Worldwide Pregnancy Safety Study To Assess Maternal, Fetal, And Infant Outcomes Following Exposure To Efgartigimod During Pregnancy And/Or Breastfeeding",2033-01,ESTIMATED,Pregnancy outcomes,,FEMALE,2023-11-30,ACTUAL,OBSERVATIONAL
ARGX,argenx SE,NCT04023526,PHASE2,ACTIVE_NOT_RECRUITING,"Leukemia, Myeloid, Acute","Azacitidine, Cusatuzumab",CULMINATE,RANDOMIZED,2,Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg | Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg,EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.,"argenx, Janssen Research & Development, LLC",2026-05-15,ESTIMATED,18 Years - N/A,103,ACTUAL,PARALLEL,INDUSTRY,NONE,A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy,2023-08-15,ACTUAL,Percentage of Participants With Complete Remission (CR),TREATMENT,ALL,2019-07-29,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06968338,PHASE1,RECRUITING,Healthy Volunteers,ARGX-213,,RANDOMIZED,2,ARGX-213 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study aims to assess the safety of ARGX-213 in healthy adults. Another aim is to measure the amount of ARGX-213 in the blood over time to learn how it moves through the body and acts in the body. The participants will remain in the study for approximately up to 21 weeks.,,2026-06-30,ESTIMATED,18 Years - 65 Years,80,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-213 in Healthy Adult Participants",2026-06-30,ESTIMATED,"Incidence of adverse events, serious adverse events, and adverse events leading to the discontinuation",TREATMENT,ALL,2025-04-11,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT04812925,PHASE3,ACTIVE_NOT_RECRUITING,Primary Immune Thrombocytopenia,efgartigimod PH20 SC,ADVANCE SC+,,1,efgartigimod PH20 SC,EXPERIMENTAL,A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia,,2026-10-01,ESTIMATED,18 Years - N/A,173,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia",2026-10-01,ESTIMATED,"Incidence, frequency, and severity of adverse events (AEs), AEs of special interest (AESIs), and serious AEs (SAEs) | Vital sign measurement: blood pressure in the overall population | ECG: PR, QT and QRS interval in the overall population | Laboratory safety evaluations: CRP analysis in the overall population",TREATMENT,ALL,2021-11-17,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT07091630,PHASE3,RECRUITING,"Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy",Empasiprubart IV,emnergize,RANDOMIZED,3,Part A - Empasiprubart | Part A - Placebo | Part B - Empasiprubart,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).",,2031-01-23,ESTIMATED,18 Years - N/A,160,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy",2027-10-07,ESTIMATED,Reduction of ≥1 point compared with baseline in aINCAT score at week 24,TREATMENT,ALL,2025-09-16,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06637072,PHASE4,ACTIVE_NOT_RECRUITING,Chronic Inflammatory Demyelinating Polyneuropathy,Efgartigimod PH20 SC,,,1,Efgartigimod PH20 SC,EXPERIMENTAL,This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.,,2026-02-23,ESTIMATED,18 Years - N/A,23,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 4, Open-Label, Single-Group, Multicenter Study in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy Who Transition From Treatment With Intravenous Immunoglobulin to Efgartigimod PH20 SC",2026-02-23,ESTIMATED,Proportion of participants who begin treatment with efgartigimod PH20 SC within 1 week after stopping IVIg therapy and are still receiving efgartigimod PH20 SC at the end of the 12-week treatment period,TREATMENT,ALL,2024-12-10,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06078553,,RECRUITING,Congenital Myasthenic Syndrome,,,,0,,,"Participants will attend up to 4 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with CMS due to mutations in DOK7, MUSK, AGRN, or LRP4.",,2027-06,ESTIMATED,2 Years - N/A,100,ESTIMATED,,INDUSTRY,,"Multicenter, Multinational, Natural History Study in Participants With Congenital Myasthenic Syndromes Due to Mutations in DOK7, MUSK, AGRN, or LRP4",2027-06,ESTIMATED,Summary statistics of retrospective and prospective collection of data on diagnosis. | Summary statistics of retrospective and prospective collection of data on health care utilization. | Summary statistics of retrospective and prospective collection of data on medications. | Summary statistics of retrospective and prospective collection of data on change in health status related to CMS,,ALL,2024-02-13,ACTUAL,OBSERVATIONAL
ARGX,argenx SE,NCT06544499,PHASE3,RECRUITING,Primary Immune Thrombocytopenia (ITP),Efgartigimod IV,advance NEXT,RANDOMIZED,2,Efgartigimod IV | Placebo IV,EXPERIMENTAL | EXPERIMENTAL,"The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-labe",,2028-06,ESTIMATED,18 Years - N/A,69,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia",2028-06,ESTIMATED,"Extent of disease control, defined as the number of cumulative weeks during the 24-week Double-Blinded Treatment Period with platelet counts of at least 50 × 10^9/L",TREATMENT,ALL,2024-10-18,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06284954,PHASE2,ACTIVE_NOT_RECRUITING,"Dermatomyositis, Myositis",Empasiprubart IV,empacific,RANDOMIZED,2,Empasiprubart | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM).

The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (d",,2026-11,ESTIMATED,18 Years - N/A,3,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis",2026-11,ESTIMATED,Incidence of adverse events (AEs) | Percentage of participants discontinuing investigational medicinal product (IMP) due to an adverse event (AE),TREATMENT,ALL,2024-08-20,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT07264426,,RECRUITING,"Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)",Efgartigimod PH20 SC,,,0,,,"The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the ""treatment journey"" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.

As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to",,2029-10,ESTIMATED,18 Years - N/A,200,ESTIMATED,,INDUSTRY,,Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study,2029-10,ESTIMATED,Change in aINCAT score over time | Change in I-RODS score over time | Change in grip strength over time | Change in EQ-5D value from index date over time,,ALL,2025-08-11,ACTUAL,OBSERVATIONAL
ARGX,argenx SE,NCT06765161,PHASE3,RECRUITING,Myasthaenia Gravis,efgartigimod administration,,,1,treatment,EXPERIMENTAL,"This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.",argenx,2027-01-06,ESTIMATED,18 Years - 80 Years,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Efgartigimod in IVIG Dependent Myasthenia Gravis Patients,2027-01-06,ESTIMATED,MG-ADL,TREATMENT,ALL,2025-02-06,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06453694,PHASE2,RECRUITING,Optic Neuritis,"Efgartigimod Alfa, Placebo",PET-AON,RANDOMIZED,2,Efgartigmod alfa | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The goal of this pilot clinical trial is to test efgartigimod alfa against placebo in adults with first-time optic neuritis (optic nerve inflammation). The main questions it aims to answer are:

* Is it feasible to use efgartigimod alfa for optic neuritis?
* Is it feasible to run a larger trial testing efgartigimod alfa in optic neuritis?
* Does efgartigimod alfa work better than placebo in improving how quickly and how much vision returns?

Participants will:

* have their vision and blood test",argenx,2027-07,ESTIMATED,18 Years - N/A,20,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,A Pilot Randomized Trial of Efgartigimod Alfa for the Treatment of Incident Moderate to Severe Acute Optic Neuritis,2026-12,ESTIMATED,Recruitment Rate | Study Adherence Rate | Change in high contrast visual acuity for effect size and standard deviation estimation | Change in low contrast visual acuity for effect size and standard deviation estimation,TREATMENT,ALL,2025-08-12,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06392386,"PHASE2, PHASE3",RECRUITING,Generalized Myasthenia Gravis,Efgartigimod PH20 SC,ADAPT Jr SC,,1,Efgartigimod PH20 SC,EXPERIMENTAL,"The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to \<18 years. The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this study. Participants will receive injections of efgartigimod PH20 SC and will be monitored for safety until the end of the study. At the end of the follow-up",,2026-09-30,ESTIMATED,2 Years - 17 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod PH20 SC in Participants From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis",2026-09-30,ESTIMATED,"Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Clearance (CL) | Efgartigimod serum concentrations as input for compartmental, model-driven analysis to determine age and size dependency of Volume Distribution (Vd) | Total G immunoglobulins (IgG) levels as input for pharmacokinetics (PK)/pharmacodynamics (PD) modelling analysis | Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK)/ pharmacodynamics (PD) modelling analysis",TREATMENT,ALL,2024-06-28,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06558279,PHASE3,ACTIVE_NOT_RECRUITING,"Myasthenia Gravis, Ocular",,ADAPT oculus,RANDOMIZED,2,Efgartigimod PH20 SC in part A+B | Placebo PH20 SC in Part A + Efgartigimod PH20 SC in Part B,EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receive efgartigimod PH20 SC and the other half will receive placebo. In part B, all participants will receive efgartigimod PH20 SC. The participants will be in the study for about up to 2 years and 12 week",,2027-12,ESTIMATED,18 Years - N/A,141,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis",2026-01,ESTIMATED,MGII (PRO) ocular score change from baseline to day 29 in part A,TREATMENT,ALL,2024-09-18,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT05405361,PHASE2,ACTIVE_NOT_RECRUITING,Multifocal Motor Neuropathy (MMN),ARGX-117,ARDA+,RANDOMIZED,2,ARGX-117 | Placebo,EXPERIMENTAL | EXPERIMENTAL,"This trial is an extension of the antecedent trial ARGX-117-2002. It is a multicenter trial that has been designed to evaluate the long-term safety and tolerability, efficacy, immunogenicity, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ARGX-117 Intravenously (IV) in adults with Multifocal Motor Neuropathy (MMN). The trial will include a double-blinded rollover treatment period (DTP), an open-label treatment period (OTP), and a safety follow-up period.",,2029-09-30,ESTIMATED,18 Years - N/A,51,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Long-term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy",2029-09-30,ESTIMATED,Safety outcomes based on adverse event (AE) monitoring.,TREATMENT,ALL,2023-01-18,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT04833894,"PHASE2, PHASE3",RECRUITING,Generalized Myasthenia Gravis,Efgartigimod IV,ADAPT Jr,,1,Efgartigimod,EXPERIMENTAL,"The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG.

Trial details include:

* The maximum trial duration for each individual participant will be approximately 28 weeks
* The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)",,2027-03,ESTIMATED,2 Years - 18 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis",2027-03,ESTIMATED,"Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL) | Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Volume of Distribution (Vd) | Total Immunoglobulin G (IgG) levels as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis | Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis",TREATMENT,ALL,2021-10-26,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06742190,PHASE3,RECRUITING,"Multifocal Motor Neuropathy (MMN), MMN","Empasiprubart, IVIG (Intravenous Immunoglobulin)",Empassion,RANDOMIZED,3,Part A - empasiprubart + IVIg-placebo | Part A - IVIg + empasiprubart-placebo | Part B - empasiprubart,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL,"The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.",,2029-12,ESTIMATED,18 Years - N/A,115,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy",2026-09,ESTIMATED,Change from baseline in grip strength (3-day moving average) in the most affected hand at week 24,TREATMENT,ALL,2024-12-18,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06298552,PHASE3,ACTIVE_NOT_RECRUITING,"Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis",Efgartigimod IV,ADAPT SERON,RANDOMIZED,2,Efgartigimod IV | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary purpose of this study is to measure the efficacy and safety of efgartigimod IV compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). The study consists of a Part A where participants will be randomized to receive either efgartigimod IV or placebo IV and a Part B where participants completing part A will receive open-label efgartigimod IV. Participants will be in the study for up to (approximately) ,,2027-06,ESTIMATED,18 Years - N/A,119,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis",2025-06-30,ACTUAL,MG-ADL total score change from baseline,TREATMENT,ALL,2024-04-16,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT07194850,"PHASE2, PHASE3",RECRUITING,"Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura ( ITP ), Idiopathic Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura (ITP)",Efgartigimod IV,,RANDOMIZED,2,Efgartigimod IV | Placebo IV,EXPERIMENTAL | PLACEBO_COMPARATOR,"The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).

The study consists of a double-blinded treatment period (DBTP) in which the participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV. At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first year open-label treatment perio",,2030-10,ESTIMATED,12 Years - 17 Years,24,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP",2028-10,ESTIMATED,Efgartigimod serum concentrations in the DBTP | Total IgG levels in the DBTP,TREATMENT,ALL,2025-10-20,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06503731,PHASE2,RECRUITING,Antibody-mediated Rejection,,Shamrock,RANDOMIZED,3,Treatment arm 1 | Treatment arm 2 | Treatment arm 3,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney transplantation.

After a screening period of up to 6 weeks, eligible participants will be randomized in a 1:1:1 ratio. The study drug will be administered subcutaneously while patients remain on their standard background immunosuppression therapy (tacrolimus, mycophenolate mofetil, steroids) during ",,2027-09,ESTIMATED,18 Years - 80 Years,30,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection",2027-09,ESTIMATED,Incidence of Adverse Events (AEs) | Percentage of participants with permanent treatment discontinuation due to adverse events (AEs),TREATMENT,ALL,2024-08-30,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06298565,,RECRUITING,Myasthenia Gravis,efgartigimod,,,2,efgartigimod cohort | non-efgartigimod cohort, | ,"This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.",,2034-06,ESTIMATED,18 Years - N/A,680,ESTIMATED,,INDUSTRY,,"A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa",2034-06,ESTIMATED,The overall long-term safety of efgartigimod including the occurrence of serious infections in generalized myasthenia gravis (gMG) patients treated with efgartigimod compared to gMG patients not exposed to efgartigimod,,ALL,2024-11-04,ACTUAL,OBSERVATIONAL
ARGX,argenx SE,NCT06436742,PHASE1,RECRUITING,"Congenital Myasthenic Syndrome, CMS",ARGX-119,,RANDOMIZED,3,Double-blinded treatment period - ARGX-119 IV | Double-blinded treatment period - Placebo IV | Active-treatment period - ARGX-119 IV,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenital Myasthenic Syndromes. The study will also assess how ARGX-119 is processed by the body (pharmacokinetics), how the immune system reacts to it (immunogenicity), and how it may improve the way patients feel and function.

After the screening period, eligible participants will be randomized in a 4:1 ratio to receive intravenous infusions of ARGX-119 or placebo during the double",,2028-01-24,ESTIMATED,18 Years - N/A,16,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes",2027-08-24,ESTIMATED,Assessment of adverse events (AEs) | Change from active-treatment baseline over time for 6MWT distance,TREATMENT,ALL,2024-09-24,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT05152238,,RECRUITING,Immune Thrombocytopenia,,ITP-Registry,,0,,,"The objective of this ITP registry is to collect clinical information, including biosampling, from consenting patients with a variety of ITPs at different points in the course of their disease.","University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx",2027-04,ESTIMATED,18 Years - N/A,1100,ESTIMATED,,OTHER,,Multicenter National ITP Registry and Accompanying Biospecimen Collection,2026-09,ESTIMATED,epidemiological data on ITP - Incidence | epidemiological data on ITP - Age | epidemiological data on ITP - Sex distribution | Description of the causes of ITP | ITP treatment type received | Remission,,ALL,2021-11-29,ACTUAL,OBSERVATIONAL
ARGX,argenx SE,NCT06307613,PHASE3,ACTIVE_NOT_RECRUITING,Thyroid Eye Disease,,UplighTED,RANDOMIZED,2,Efgartigimod arm | Placebo arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod PH20 SC in participants with active, moderate-to-severe TED, compared with placebo PH20 SC.

After the screening period, eligible participants will be randomized in a 2:1 ratio to receive efgartigimod PH20 SC or placebo PH20 SC, respectively during the double-blinded treatment period (DBTP). At the end of the DBTP, participants may enter a follow-up ",,2026-03-31,ESTIMATED,18 Years - N/A,102,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease",2025-12-15,ACTUAL,Percentage of participants who were proptosis responders,TREATMENT,ALL,2024-03-27,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT05907096,PHASE2,ACTIVE_NOT_RECRUITING,Delayed Graft Function,ARGX-117,VARVARA,RANDOMIZED,2,ARGX-117 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The main purpose of this study is to evaluate the safety, efficacy and tolerability of ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function.

The study consists of 2 parts: part A comprises the main study period, and part B comprises the long-term observational follow-up period. During part A, after the screening period, eligible participants will be randomized to receive either ARGX-117 or placebo, entering the treatment and evaluation period (duration of u",,2026-07-31,ESTIMATED,18 Years - 70 Years,103,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of ARGX-117 in Improving Allograft Function in Recipients of a Deceased Donor Renal Allograft at Risk for Delayed Graft Function",2025-11,ESTIMATED,eGFR at 24 weeks posttransplant,TREATMENT,ALL,2024-02-17,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT06441682,PHASE2,ACTIVE_NOT_RECRUITING,Amyotrophic Lateral Sclerosis,ARGX-119,ReALiSe,RANDOMIZED,4,ARGX-119 - Dose 1 | ARGX-119 - Dose 2 | ARGX-119 - Dose 3 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study aims to evaluate the safety of ARGX-119 in adults with ALS. The study will also assess the impact of ARGX-119 on ALS disease outcomes, including muscle function. The study consists of 2 periods: a treatment period when participants will receive one of three ARGX-119 doses or placebo and an extension period when all participants will receive the same dose of ARGX-119. Participation in the study will last up to approximately 100 weeks.",,2027-07,ESTIMATED,18 Years - 80 Years,60,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis",2027-07,ESTIMATED,Assessment of adverse events (AEs),TREATMENT,ALL,2024-10-23,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT07287982,PHASE2,RECRUITING,Spinal Muscular Atrophy (SMA),ARGX-119 IV,Sparkle,RANDOMIZED,3,DBTP - ARGX-119 IV | DBTP - Placebo IV | ATEP - ARGX-119 IV,EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"This study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune system responds to it. The study consists of a double-blinded treatment period (DBTP) where participants will either receive ARGX-119 IV or placebo IV, in addition to disease-modifying therapy (DMT) for 24 weeks. Participants who complete the DBTP will enter the open-label active-treatment extensio",,2029-05-28,ESTIMATED,5 Years - 17 Years,60,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy",2029-05-28,ESTIMATED,Incidence of AEs | Incidence of SAEs | Change in RHS total score from baseline to week 24 of the double blinded treatment period (DBTP),TREATMENT,ALL,2025-12-19,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT04280718,PHASE2,ACTIVE_NOT_RECRUITING,Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),Efgartigimod PH20 SC,ADHERE+,,1,efgartigimod PH20 SC,EXPERIMENTAL,"This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.

Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.",,2027-04-30,ESTIMATED,18 Years - N/A,229,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",2027-04-30,ESTIMATED,Incidence of treatment-emergent adverse events and serious adverse events,TREATMENT,ALL,2020-09-18,ACTUAL,INTERVENTIONAL
ARGX,argenx SE,NCT04225156,PHASE3,ACTIVE_NOT_RECRUITING,Primary Immune Thrombocytopenia,efgartigimod,ADVANCE+,,1,efgartigimod,EXPERIMENTAL,This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.,,2026-03-11,ESTIMATED,18 Years - N/A,101,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia.",2026-03-11,ESTIMATED,Frequency and severity of Adverse Events | Frequency and severity of vital signs | Frequency and severity of laboratory assessments,TREATMENT,ALL,2020-06-02,ACTUAL,INTERVENTIONAL
PTN,"Palatin Technologies, Inc.",NCT06565611,PHASE2,ACTIVE_NOT_RECRUITING,Obesity,"bremelanotide, tirzepatide",BMT-801,RANDOMIZED,4,tirzepatide and bremelanotide Combination Therapy | tirzepatide Monotherapy | bremelanotide Monotherapy | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR | NO_INTERVENTION,"This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).",,2025-03-31,ESTIMATED,18 Years - 65 Years,108,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity",2025-02-05,ACTUAL,Percent change in body weight between treatment arms,TREATMENT,ALL,2024-08-05,ACTUAL,INTERVENTIONAL
PTN,"Palatin Technologies, Inc.",NCT05466890,PHASE2,ACTIVE_NOT_RECRUITING,"Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare","PL8177 Placebo, PL8177",PL8177-205,RANDOMIZED,2,PL8177 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).",,2025-03-31,ESTIMATED,18 Years - 75 Years,16,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers with Oral Colon Delivery PL8177 in Adult Subjects with Active Ulcerative Colitis",2025-02-10,ACTUAL,To evaluate the safety and tolerability of PL8177 compared to placebo in patients with active UC. | To compare the proportion of subjects achieving Mayo Endoscopic Subscore of ≤ 1 point (0 or 1) between PL8177 and placebo after 8 weeks of treatment.,TREATMENT,ALL,2022-09-15,ACTUAL,INTERVENTIONAL
ASRT,"Assertio Holdings, Inc.",NCT06158620,"PHASE1, PHASE2",RECRUITING,"Post Operative Pain, Urolithiasis, Ureter Calculi, Stent Complication","intra-nasal ketorolac, oral diclofenac",,RANDOMIZED,2,Sprix | Diclofenac,EXPERIMENTAL | ACTIVE_COMPARATOR,"Objective: To improve quality-of-life and health care delivery to patients receiving ureteral stents.

Specific Aims: Evaluate the feasibility, practicality, and qualitative outcomes of utilizing intra-nasal ketorolac in patients with indwelling ureteral stents (Phase I), followed by a randomized trial comparing two non-steroidal anti-inflammatory drugs, intra-nasal Ketorolac versus oral Diclofenac.

Hypotheses: Due to its favorable pharmacokinetics in relieving acute pain, investigators expect ","assertio Therapeutics, Inc",2026-12-01,ESTIMATED,18 Years - N/A,80,ESTIMATED,PARALLEL,OTHER,NONE,Intra-nasal Ketorolac Versus Oral Diclofenac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease,2026-04-01,ESTIMATED,Change in pain scores as measured by USSQ Pain Survey | Change in pain scores as measured by PROMIS questionnaire | Change in pain scores as measured by Likert Scale Questionnaire,TREATMENT,ALL,2025-03-01,ACTUAL,INTERVENTIONAL
INSM,Insmed Incorporated,NCT06685835,PHASE2,ACTIVE_NOT_RECRUITING,Hidradenitis Suppurativa,"Brensocatib, Placebo",CEDAR,RANDOMIZED,4,Brensocatib 10 mg | Brensocatib 40 mg | Placebo Followed by Brensocatib 10 mg | Placebo Followed by Brensocatib 40 mg,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.,,2027-01-28,ESTIMATED,18 Years - 80 Years,214,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa - The CEDAR Study",2026-05-22,ESTIMATED,Percent Change From Baseline in Total Abscess and Inflammatory Nodule (AN) Count at Week 16,TREATMENT,ALL,2024-12-16,ACTUAL,INTERVENTIONAL
INSM,Insmed Incorporated,NCT05649722,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Pulmonary Hypertension, Interstitial Lung Disease","Treprostinil Palmitil Inhalation Powder, Placebo",,,1,Treprostinil Palmitil Inhalation Powder,EXPERIMENTAL,The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.,,2026-03-14,ESTIMATED,18 Years - N/A,31,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease",2026-03-14,ESTIMATED,Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE),TREATMENT,ALL,2023-05-11,ACTUAL,INTERVENTIONAL
INSM,Insmed Incorporated,NCT06817382,PHASE1,RECRUITING,Duchenne Muscular Dystrophy,,ASCEND,NON_RANDOMIZED,4,Part 1: Cohort 1 | Part 1: Cohort 2 | Part 2: Cohort 3 | Part 2: Cohort 4,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The primary objective of this study is to evaluate the safety and tolerability of a single dose of INS1201 via IT administration in ambulatory male participants with DMD.,,2028-03-31,ESTIMATED,2 Years - 4 Years,12,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Multicenter, Open-label Study to Investigate the Safety and Biodistribution of a Single Intrathecal Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (The ASCEND Study)",2028-01-31,ESTIMATED,Parts 1 and 2: Incidence and Severity of Treatment Emergent Adverse Events (TEAEs),TREATMENT,MALE,2025-07-22,ACTUAL,INTERVENTIONAL
INSM,Insmed Incorporated,NCT05649748,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,Pulmonary Arterial Hypertension,"Treprostinil Palmitil, Placebo",,,1,Treprostinil Palmitil Inhalation Powder (TPIP),EXPERIMENTAL,"The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.",,2026-12-31,ESTIMATED,18 Years - N/A,91,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension",2026-12-31,ESTIMATED,Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity,TREATMENT,ALL,2023-03-07,ACTUAL,INTERVENTIONAL
INSM,Insmed Incorporated,NCT07290062,PHASE1,RECRUITING,Amyotrophic Lateral Sclerosis,,ARMOR,NON_RANDOMIZED,3,Cohort 1 | Cohort 2 | Cohort 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.",,2030-03-31,ESTIMATED,18 Years - 79 Years,23,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Multicenter, Open-label, Dose-Finding Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection of INS1202 in Patients With Amyotrophic Lateral Sclerosis",2030-03-31,ESTIMATED,Incidence and Severity of Treatment Emergent Adverse Events (TEAEs),TREATMENT,ALL,2026-01-09,ACTUAL,INTERVENTIONAL
INSM,Insmed Incorporated,NCT06144996,,RECRUITING,"Bronchiectasis, Non-Tuberculous Mycobacterial Pneumonia",,,,2,Non-CF Bronchiectasis Patients with or without NTM | Nontuberculosis Mycobacteria (NTM), | ,The investigators aim to develop a comprehensive patient registry of patients with non-CF bronchiectasis and/or Nontuberculosis Mycobacteria (NTM),"Insmed Incorporated, Trudell Medical International",2050-01,ESTIMATED,18 Years - 120 Years,2000,ESTIMATED,,OTHER,,Development of a Canadian Bronchiectasis and NTM Database,2050-01,ESTIMATED,Patient Recruitment and Data analysis for NTM and Bronchiectasis,,ALL,2023-01-01,ACTUAL,OBSERVATIONAL
INSM,Insmed Incorporated,NCT07179380,PHASE3,RECRUITING,"Pulmonary Hypertension, Interstitial Lung Disease","Treprostinil Palmitil Inhalation Powder, Placebo",PALM-ILD,RANDOMIZED,2,Treprostinil Palmitil Inhalation Powder | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.,,2028-12-30,ESTIMATED,18 Years - N/A,344,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease",2028-12-30,ESTIMATED,Change in 6MWD Measured at Peak Exposure From Baseline to Week 24,TREATMENT,ALL,2026-01-07,ACTUAL,INTERVENTIONAL
INSM,Insmed Incorporated,NCT07234032,PHASE3,NOT_YET_RECRUITING,"Pulmonary Hypertension, Interstitial Lung Disease","Treprostinil Palmitil Inhalation Powder, Placebo",,,1,Treprostinil Palmitil Inhalation Powder (TPIP),EXPERIMENTAL,The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).,,2031-01-22,ESTIMATED,18 Years - N/A,344,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease,2031-01-22,ESTIMATED,Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2026-04-01,ESTIMATED,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06878560,"PHASE1, PHASE2",RECRUITING,"ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation",10 GE Xenokidney,EXPAND,,1,10 GE Xenokidney,EXPERIMENTAL,"The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2).

The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (",,2075-10,ESTIMATED,40 Years - 70 Years,50,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,EXPAND: A Prospective Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With End-stage Renal Disease (ESRD),2028-10,ESTIMATED,Survival Rate of Patients with ESRD Receiving the 10 GE Xenokidney at 24 Weeks Post Transplant | Survival Rate of the 10 GE Xenokidney at 24 Weeks Post Transplant | Survival Time of Participants Receiving the 10 GE Xenokidney | Survival Time of the 10 GE Xenokidney (Overall Survival) | Survival Time of the 10 GE Xenokidney (Death-censored Survival) | 10 GE Xenokidney Function Post Transplant (Endogenous GFR) | 10 GE Xenokidney Function Post Transplant (Exogenous GFR) | Quality of Life in Participants Receiving the 10 GE Xenokidney by EuroQol 5-Dimension 5-Level (EQ-5D-5L) | Quality of Life in Participants Receiving the 10 GE Xenokidney by Standardized Outcomes in Nephrology Life Participant (SONG-LP) | Quality of Life in Participants Receiving the 10 GE Xenokidney by Kidney Transplant Questionnaire (KTQ) | Quality of Life in Participants Receiving the 10 GE Xenokidney by Patient Global Impression of Change (PGI-C) | Incidence of Treatment-Emergent Adverse Events (Safety of the 10 GE Xenokidney) | Incidence of Proteinuria | Incidence of Zoonotic Infection | Incidence of Opportunistic Infection,TREATMENT,ALL,2025-10-29,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06964009,PHASE1,RECRUITING,"Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma","DT2216, Paclitaxel",,,1,DT2216 + Paclitaxel,EXPERIMENTAL,"The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer.

The names of the study drugs involved in this study are:

* DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein)
* Paclitaxel (a type of antimicrotubule agent)","United States Department of Defense, Dialectic Therapeutics, Inc, American Society of Clinical Oncology",2027-12-30,ESTIMATED,18 Years - N/A,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer,2026-12-30,ESTIMATED,DT2216 Maximum Tolerated Dose (MTD) | Number of Participants Experiencing a Dose-Limiting Toxicity (DLT),TREATMENT,FEMALE,2025-09-22,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06374459,"PHASE1, PHASE2",RECRUITING,Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer,"Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab",,RANDOMIZED,4,Phase Ib: Zunsemetinib + Capecitabine | Phase II Arm 1: Standard of care anti-resorptive + Capecitabine | Phase II Arm 2: Zunsemetinib (RP2D-L1) + Capecitabine | Phase II Arm 3: Zunsemetinib (RP2D-L2) + Capecitabine,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).,"United States Department of Defense, Aclaris Therapeutics, Inc.",2032-05-31,ESTIMATED,18 Years - N/A,152,ESTIMATED,SEQUENTIAL,OTHER,NONE,A Phase Ib/II Trial of Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis,2032-05-31,ESTIMATED,Number of participants with adverse events (Phase Ib only) | Recommended phase II dose of zunsemetinib (Phase Ib only) | Number of participants with dose-limiting toxicities (Phase Ib only) | Percent change in serum CTX (Phase II only) | Progression-free survival (PFS) (Phase II only),TREATMENT,ALL,2025-01-30,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT07261241,PHASE2,NOT_YET_RECRUITING,Neuroblastoma,"Radiation: 131I-MIBG, Dinutuximab, Vorinostat",,RANDOMIZED,3,Arm A: 131I-MIBG + vorinostat | Arm B: 131I-MIBG + dinutuximab | Arm C: 131I-MIBG + vorinostat + dinutuximab,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat. Patients on Arm B will receive a single treatment course with 131I-MIBG and dinutuximab. Patients on Arm C will receive a single treatment course with 131I-MIBG with dinutuximab + vorinostat. After this course of treatment, we will check to see your response and then check to see how you are doing over time. All patients may choo","United Therapeutics, Jubilant DraxImage Inc.",2031-07-31,ESTIMATED,1 Year - 30 Years,118,ESTIMATED,PARALLEL,OTHER,NONE,NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma,2030-07-31,ESTIMATED,Objective Tumor Response After One Course of Therapy,TREATMENT,ALL,2026-07-31,ESTIMATED,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06477640,,RECRUITING,Pulmonary Arterial Hypertension PAH,,,RANDOMIZED,2,Exercise Intervention Group | Standard of Care,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk test/walk distance) and improve quality of life. Ultimately, this information could help improve the management of patients with PAH.","United Therapeutics, Mayo Clinic, University of Vermont Medical Center",2026-12-31,ESTIMATED,18 Years - N/A,55,ESTIMATED,PARALLEL,OTHER,TRIPLE,Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension,2026-12-31,ESTIMATED,Mean change in cardiac effort,TREATMENT,ALL,2024-07-29,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06388421,,RECRUITING,"Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease",,,,3,Cohort 1 | Cohort 2 | Cohort 3, |  | ,"This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).",,2030-11-30,ESTIMATED,18 Years - N/A,1000,ESTIMATED,,INDUSTRY,,DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD),2030-09-01,ESTIMATED,"Baseline characteristics as described by demographics, medical history, ILD history, PH history, family history (comorbidities), and diagnostic right heart catheterization values",,ALL,2025-01-23,ACTUAL,OBSERVATIONAL
UTHR,United Therapeutics Corporation,NCT05848687,"PHASE1, PHASE2",RECRUITING,Lymphoblastic Leukemia,"Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib",,,1,Treatment,EXPERIMENTAL,The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.,"Pediatric Oncology Experimental Therapeutics Investigators' Consortium, Amgen, Lucile Packard Foundation for Children's Health, Kura Oncology, Inc., United States Department of Defense, Cannonball Kid's Cancer",2033-12,ESTIMATED,N/A - 1 Year,90,ESTIMATED,SINGLE_GROUP,OTHER,NONE,TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II,2028-12,ESTIMATED,Minimal Residual Disease,TREATMENT,ALL,2023-11-03,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT02573896,PHASE1,ACTIVE_NOT_RECRUITING,Neuroblastoma,"Dinutuximab, NK Cells, Lenalidomide",,,1,NK cells with Dinutuximab & Lenalidomide,EXPERIMENTAL,"This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for treatment of children with refractory or recurrent neuroblastoma.","Nationwide Children's Hospital, United Therapeutics",2025-09,ESTIMATED,N/A - 30 Years,13,ACTUAL,SINGLE_GROUP,OTHER,NONE,A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide,2025-09,ESTIMATED,NK cell production feasibility (lowest dose level) | NK cell production feasibility | MTD/RP2D determination,TREATMENT,ALL,2019-01-14,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT07391215,"PHASE1, PHASE2",RECRUITING,"Malignant Primary Gliomas, Glioblastoma Multiforme (GBM)","Paxalisib, Temozolomide capsule",5G-PEARL,NON_RANDOMIZED,2,Phase 1b | Phase 2,EXPERIMENTAL | EXPERIMENTAL,"The purpose of this clinical trial is to evaluate the safety and tolerability of paxalisib in combination with temozolomide and to determine the preliminary antitumour activity of the combination therapy. In the Phase 1b of this study parallel biomarker defined arms will be opened in the front-line unmethylated MGMT setting, enrolling 10 patients onto each arm. These patients will be treated with paxalisib in combination with temozolomide (TMZ). The starting dose of paxalisib will be 45mg once a","Minderoo Foundation, Kazia Therapeutics Limited, Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK",2029-06-30,ESTIMATED,16 Years - N/A,64,ESTIMATED,PARALLEL,OTHER,NONE,5G-PEARL: Paxalisib in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform,2029-01-19,ESTIMATED,Phase 1b - Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) in patients with malignant brain tumours | Phase 1b - To determine the preliminary antitumour activity of the investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumours | Phase 2 - To determine the antitumour activity of investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumours | Phase 2 - To determine the antitumour activity of investigational agent administered at the RP2D in patients with molecularly defined malignant brain tumours,HEALTH_SERVICES_RESEARCH,ALL,2026-01-19,ESTIMATED,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT04850105,,RECRUITING,Hereditary Transthyretin Amyloidosis With Polyneuropthy,,,,2,TEGSEDI-exposed cohort | TEGSEDI-unexposed cohort, | ,"This is a prospective, non-interventional, Long-term, multinational cohort safety study of patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN). The overarching goal of this study is to further characterize the long-term safety of TEGSEDI (inotersen) in patients with hATTR-PN under real-world conditions.","United BioSource, LLC",2036-03-31,ESTIMATED,18 Years - N/A,240,ESTIMATED,,INDUSTRY,,"A Prospective, Non-interventional, Long-term, Multinational Cohort Safety Study of Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (hATTR-PN)",2036-03-31,ESTIMATED,Further characterization of the long-term safety of TEGSEDI in patients with hATTR-PN under real-world conditions.,,ALL,2021-09-21,ACTUAL,OBSERVATIONAL
UTHR,United Therapeutics Corporation,NCT05245006,PHASE1,ACTIVE_NOT_RECRUITING,"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","89Zr-DFO-YS5, YS5 antibody",,NON_RANDOMIZED,3,"Cohort A: 89Zr-DFO-YS5 | Cohort B: 89Zr-DFO-YS5, YS5 antibody | Cohort C: 89Zr-DFO-YS5, Optimal dose YS5 antibody",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is that CD46 expression, measured via our novel imaging biomarker, is a characteristic feature of mCRPC, and particularly common in the most lethal forms of the disease including adenocarcinoma and Small-cell neuroendocrine carcinoma (SCNC). These data will provide crucial information about the feasibility of targeting c","United States Department of Defense, Fortis Therapeutics, Inc.",2025-12-31,ESTIMATED,18 Years - N/A,30,ACTUAL,SEQUENTIAL,OTHER,NONE,"A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer",2025-12-31,ESTIMATED,Optimal time point for imaging using 89Zr-DFO-YS5 PET post-injection (Cohort A) | Optimal antibody dose for imaging using 89Zr-DFO-YS5 PET (Cohort B) | Proportion of participants with metastatic lesions accurately detected in mCRPC using 89Zr-DFO-YS5 PET (sensitivity) (Cohort C) | Median SUVmax (Cohort C) | Average SUVmax (SUVmax-ave) (Cohort C),DIAGNOSTIC,ALL,2022-03-18,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT03045029,,ACTIVE_NOT_RECRUITING,Pulmonary Arterial Hypertension,Oral treprostinil,ADAPT,,1,Oral treprostinil,,"This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation",,2025-12,ESTIMATED,18 Years - N/A,300,ESTIMATED,,INDUSTRY,,ADAPT - A Patient Registry of the Real-world Use of Orenitram®,2025-12,ESTIMATED,Real-world use and tolerability of Orenitram in new starts and prostacyclin transition patients,,ALL,2017-07-18,ACTUAL,OBSERVATIONAL
UTHR,United Therapeutics Corporation,NCT05943535,PHASE3,RECRUITING,"Progressive Pulmonary Fibrosis, Interstitial Lung Disease","Placebo, Inhaled Treprostinil",,RANDOMIZED,2,Placebo | Inhaled Treprostinil,PLACEBO_COMPARATOR | EXPERIMENTAL,Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.,,2027-11,ESTIMATED,18 Years - N/A,698,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)",2027-11,ESTIMATED,Change in Absolute FVC from Baseline to Week 52,TREATMENT,ALL,2023-10-30,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT03804944,PHASE2,RECRUITING,Breast Cancer,"Pembrolizumab (200mg IV for 30 minutes, CDX-301",CBCV,RANDOMIZED,4,ARM 1 | ARM 2 | ARM 3 | ARM 4,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are eligible to a randomized trial, concurrently open at five US academic institutions. Patients receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with immunotherapy combinations.","United States Department of Defense, Merck Sharp & Dohme LLC, Celldex Therapeutics",2027-12-31,ESTIMATED,18 Years - 90 Years,100,ESTIMATED,PARALLEL,OTHER,NONE,Converting HR+ Breast Cancer Into an Individualized Vaccine,2026-12-31,ESTIMATED,"Tolerability will be demonstrated if no grade 3 or higher toxicities are observed in the first 8 patients, of each arm. | Clinical response rate to tumor radiation +/-immunotherapy during standard endocrine therapy for HR+ breast cancer will be measured. | Pathological response rate to tumor radiation +/-immunotherapy during standard endocrine therapy for HR+ breast cancer will be measured.",TREATMENT,FEMALE,2020-03-17,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT07224763,"PHASE1, PHASE2",RECRUITING,"ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation",GGTA1 KO Thymokidney,EXTEND,,1,GGTA1 KO Thymokidney,EXPERIMENTAL,"The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2).

The study consists of xenotransplantation followed by a 24-week Post",,2076-03,ESTIMATED,40 Years - 70 Years,50,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD),2029-03,ESTIMATED,Survival Rate of Patients with ESRD Receiving the GGTA1 KO Thymokidney at 24 Weeks Post Transplant | Survival Rate of the GGTA1 KO Thymokidney at 24 Weeks Post Transplant | Survival Time of Participants Receiving the GGTA1 KO Thymokidney | Survival Time of the GGTA1 KO Thymokidney (Overall Survival) | Survival Time of the GGTA1 KO Thymokidney (Death-censored Survival) | GGTA1 KO Thymokidney Function Post Transplant (Endogenous GFR) | GGTA1 KO Thymokidney Function Post Transplant (Exogenous GFR) | GGTA1 KO Thymokidney Function Post Transplant (Proliferative Responsiveness) | Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by EuroQol 5-Dimension 5-Level (EQ-5D-5L) | Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Standardized Outcomes in Nephrology Life Participant (SONG-LP) | Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Kidney Transplant Questionnaire (KTQ) | Quality of Life in Participants Receiving the GGTA1 KO Thymokidney by Patient Global Impression of Change (PGI-C) | Incidence of Treatment-Emergent Adverse Events (Safety of the GGTA1 KO Thymokidney) | Incidence of Proteinuria | Incidence of Zoonotic Infection | Incidence of Opportunistic Infection,TREATMENT,ALL,2026-03,ESTIMATED,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06814717,PHASE2,RECRUITING,Thermal Burns,cP12,,,1,Open-label,EXPERIMENTAL,"This is a Phase 2a, open-label, single-dose study to evaluate the safety, tolerability, and PK profile of cP12 in 6 male and female subjects with thermal burns of up to and including 10% TBSA. Enrolled subjects must have at least 1% superficial (epidermal), superficial partial-thickness, or deep partial-thickness burns.

Eligible subjects will receive a single administration of 0.01 mg/kg cP12. Vital signs, ECGs, and blood samples and urine samples will be obtained at screening and at several ti",United States Department of Defense,2026-11-01,ESTIMATED,18 Years - 65 Years,6,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"A Phase 2a, Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of a Single Dose of cP12 in Otherwise Healthy Adults With Up To and Including 10% Total Body Surface Area Thermal Burns",2026-07-01,ESTIMATED,Incidence and severity of adverse events from dosing through follow-up | Incidence and severity of adverse events from dosing through follow-up | Incidence and severity of adverse events from dosing through follow-up,OTHER,ALL,2025-05-12,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06425796,,RECRUITING,Iron Deficiency Anemia of Pregnancy,,ADIPREG,RANDOMIZED,2,Iron 25 | IRON 50,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This study aims to explore how body fat influences the response to either 25 or 50 mg of daily iron supplements during pregnancy. We will conduct a double-blind randomized controlled intervention study involving 312 pregnant women recruited from antenatal clinics in the Northern Trust Area. Participants will be randomly assigned to receive either 25 or 50 mg of iron per day from 12 weeks of pregnancy until delivery, using the Active Iron supplement brand. Blood samples will be collected at 12, 2","Solvotrin Therapeutics - Active Iron, National Health Service, United Kingdom",2026-01-19,ESTIMATED,18 Years - N/A,312,ESTIMATED,PARALLEL,OTHER,DOUBLE,Impact of Maternal Adiposity on Maternal Iron Status and Requirements: a Randomised Intervention Study,2026-01-19,ESTIMATED,* - Adjusted maternal ferritin concentrations in response to iron supplementation (ng/mL),PREVENTION,FEMALE,2024-05-20,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06450041,PHASE2,RECRUITING,Neuroblastoma,"Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan, Dinutuximab, GM-CSF",,,1,Treatment,EXPERIMENTAL,"This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.","Nationwide Children's Hospital, United Therapeutics, Children's Neuroblastoma Cancer Fund",2038-12,ESTIMATED,1 Year - 31 Years,62,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial",2028-12,ESTIMATED,Best Overall Response Rate of Evaluable Patients,TREATMENT,ALL,2024-12-16,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT05231122,PHASE2,RECRUITING,"Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma","Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab",,RANDOMIZED,2,"Arm I (pembrolizumab, bevacizumab) | Arm II (pembrolizumab, bevacizumab, CDX-1140)",ACTIVE_COMPARATOR | EXPERIMENTAL,"This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, an","Merck Sharp & Dohme LLC, Celldex Therapeutics, United States Department of Defense",2026-12-30,ESTIMATED,18 Years - N/A,80,ESTIMATED,PARALLEL,OTHER,SINGLE,Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer,2026-12-30,ESTIMATED,Incidence of adverse events | Objective response rate (ORR),TREATMENT,FEMALE,2024-03-12,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT05421897,PHASE1,ACTIVE_NOT_RECRUITING,Neuroblastoma,Dinutuximab with Chemotherapy,RAPID,,1,Rapid infusion of dinutuximab with chemotherapy,EXPERIMENTAL,Studies have shown that the anti-GD2 human-mouse chimeric monoclonal antibody dinutuximab has contributed significantly to the improvement of treatment for children with high-risk neuroblastoma and has become a mainstay in treating high risk neuroblastoma in children as part of up-front therapy and relapsed/refractory therapy. The administration of dinutuximab requires a significant amount of time and resources to complete the 10-20 hour standard infusion time for 4 days in the inpatient setting,United Therapeutics,2026-01,ESTIMATED,1 Year - N/A,11,ESTIMATED,SINGLE_GROUP,OTHER,NONE,RAPID Feasibility Study: A Pilot Study for the Rapid Infusion of Dinutuximab,2026-01,ESTIMATED,Determine feasibility of administering dinutuximab in Cycle 1 | Determine average dinutuximab infusion time in Cycle 1,TREATMENT,ALL,2022-11-29,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT05203510,PHASE4,ACTIVE_NOT_RECRUITING,Pulmonary Arterial Hypertension,"Parenteral Treprostinil, Oral Treprostinil",ARTISAN,,1,Treprostinil,EXPERIMENTAL,The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).,Lung Biotechnology PBC,2028-04-30,ESTIMATED,18 Years - N/A,52,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction)",2026-04-30,ESTIMATED,"Change From Baseline in Right Ventricular Ejection Fraction (RVEF), as Measured by Cardiac Magnetic Resonance Imaging (cMRI) at Month 12",TREATMENT,ALL,2022-10-20,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT01321073,,ACTIVE_NOT_RECRUITING,Pulmonary Arterial Hypertension,,DelIVery,,1,DelIVery for Pulmonary Arterial Hypertension Single Arm,EXPERIMENTAL,"The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when used with the Medtronic SynchroMed® II Implantable Infusion System to deliver Remodulin® (treprostinil) Injection.

As of June 2021, PMA approval of the Implantable System for Remodulin (ISR) is no longer being pursued and development and commercialization efforts have been halted. The approximately 30 subjects still implanted with the PIVoT system req",United Therapeutics,2032-12,ESTIMATED,18 Years - N/A,64,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,DelIVery for Pulmonary Arterial Hypertension (PAH) Clinical Study,2013-06,ACTUAL,Rate of Catheter-related Complications Per 1000 Patient Days,SUPPORTIVE_CARE,ALL,2011-06,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT03047369,,RECRUITING,"Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome",,MDBP,,0,,,"The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.

Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, ","National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), Biogen, Eli Lilly and Company, Myrtelle Inc., Orchard Therapeutics Ltd., Passage Bio, Inc., Synaptix Biotherapeutics Ltd., Takeda, Boehringer Ingelheim, Ionis Pharmaceuticals, Inc., Sanofi Winthrop Industrie, Sana Biotechnology, Yaya Foundation for 4H Leukodystrophy, University of Pennsylvania, United MSD Foundation, Foundation to Fight H-ABC, Calliope Joy Foundation, Don't Forget Me Foundation",2030-12-08,ESTIMATED,N/A - N/A,12000,ESTIMATED,,OTHER,,The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network,2030-12-08,ESTIMATED,Define Novel Homogeneous Groups of Patients with Unclassified Leukodystrophy,,ALL,2016-12-08,ACTUAL,OBSERVATIONAL
UTHR,United Therapeutics Corporation,NCT07116681,EARLY_PHASE1,NOT_YET_RECRUITING,Pulmonary Hypertension,Inhaled treprostinil,,,1,Treatment group,EXPERIMENTAL,"This study aims to investigate therapies for exercise induced pulmonary hypertension (EiPH). This is a condition that effects the blood vessels in the lungs and causes shortness of breath with activity. Currently, there are very limited treatment options for this condition. Inhaled treprostinil, also known as Tyvaso, is a medication used to treat other forms of lung disease and is safe and well tolerated. This study will measure the ability of Tyvaso to improve symptoms related to EiPH and impro",United Therapeutics,2027-07-01,ESTIMATED,18 Years - N/A,8,ESTIMATED,SINGLE_GROUP,OTHER,NONE,The Acute Effects of Dry Powder Inhaled Treprostinil on Stroke Volume Augmentation and Dead Space Ventilation in Patients With Exercise-induced Pulmonary Hypertension,2027-07-01,ESTIMATED,Stroke volume augmentation before and after inhaled treprostinil,TREATMENT,ALL,2025-10-01,ESTIMATED,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06911632,,ACTIVE_NOT_RECRUITING,"Pulmonary Hypertension, Interstitial Lung Disease (ILD)",,MOMENTOUS,RANDOMIZED,4,High Risk Device | Not High Risk Device | High Risk Control Arm | Not High Risk Control Arm,EXPERIMENTAL | EXPERIMENTAL | OTHER | OTHER,"MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.",United Therapeutics,2028-07,ESTIMATED,18 Years - N/A,1000,ESTIMATED,PARALLEL,INDUSTRY,NONE,MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion),2028-05,ESTIMATED,Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the High risk Control group.,DIAGNOSTIC,ALL,2025-07-23,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06580444,PHASE2,NOT_YET_RECRUITING,"Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)",Brexanolone,,RANDOMIZED,4,Placebo | 90mcg/kg/h dose of Brexanolone | 60mcg/kg/h dose of Brexanolone | 30mcg/kg/h dose of Brexanolone,NO_INTERVENTION | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,The purpose of this research study is to find out how Zulresso®/brexanolone influences Posttraumatic Stress Disorder (PTSD) symptoms and alcohol use.,"United States Department of Defense, Congressionally Directed Medical Research Programs, VA Connecticut Healthcare System, Sage Therapeutics, RTI International, Yale University",2027-03-19,ESTIMATED,21 Years - 70 Years,40,ESTIMATED,PARALLEL,OTHER,TRIPLE,Brexanolone to Target Concurrent Posttraumatic Stress Disorder (PTSD) and Stress Induced Alcohol Use in Veterans: A Dose Finding Study,2027-02-26,ESTIMATED,Severity and numbers of treatment-emergent AEs | Change in Heart Rate from onset of Brexanolone administration until discharge from the drug administration session. | Change in Blood Pressure from onset of Brexanolone administration until discharge from the drug administration session. | Change in Cortisol from onset of Brexanolone administration until discharge from the drug administration session. | Change in percentage of milliliters of alcohol consumed during the 2-hour ad-libitum drinking paradigm between laboratory sessions (stress vs. neutral). | Change in Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) score from intake until 30-day follow-up | Change in Change in Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) score from intake until end of dosing.,OTHER,ALL,2025-07-28,ESTIMATED,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT04246281,,ACTIVE_NOT_RECRUITING,"Low Back Pain, Back Pain",,,RANDOMIZED,2,Group 1: Peripheral Nerve Stimulation (PNS) | Group 2: Standard Interventional Management (Standard of Care),ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,The purpose of this study is to compare standard of care treatments for back pain to electrical stimulation. Stimulation is delivering small amounts of electricity to the nerves in your low back. This study will use a device called the SPRINT Peripheral Nerve Stimulation (PNS) System. The device is cleared by the FDA for up to 60 days of use for the relief of chronic or acute pain (including back pain),United States Department of Defense,2027-04,ESTIMATED,21 Years - 75 Years,230,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain",2026-04,ESTIMATED,Reduction in average pain intensity | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs) | Study-Related Adverse Events (AEs),TREATMENT,ALL,2020-06-17,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT04005469,"PHASE1, PHASE2",RECRUITING,"Ischemia Reperfusion Injury, Delayed Graft Function",Treprostinil,,,1,Trepostinil,EXPERIMENTAL,"The objectives of this study are to test the preliminary safety and efficacy of a two-day peri-operative course of treprostinil in reducing ischemia-reperfusion injury in adult patients receiving a deceased donor kidney transplantation. Treprostinil, a prostacyclin analog, is expected to facilitate the restoration of blood supply to the revascularized kidney graft via its vasodilatory actions, well characterized protective effects, and longer elimination half-life. These properties and actions o","University of Rhode Island, United Therapeutics",2026-06-30,ESTIMATED,18 Years - 65 Years,20,ESTIMATED,SINGLE_GROUP,OTHER,NONE,A Phase I/II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation,2025-07-01,ESTIMATED,Serum creatinine (SCr),PREVENTION,ALL,2020-11-13,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT06059118,PHASE2,RECRUITING,Prostate Cancer,"DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide",,,1,Repeat Sequential DFMO and High dose Testosterone in Sequence with Enzalutamide,EXPERIMENTAL,Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose testosterone in sequence with enzalutamide to improve primary and secondary outcomes.,"Panbela Therapeutics, Prostate Cancer Foundation, United States Department of Defense",2029-11-30,ESTIMATED,18 Years - N/A,50,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Repeat Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Asymptomatic Patients With Metastatic Castration-Resistant Prostate Cancer: The APEX (Androgen and Polyamine Elimination Alternating With Xtandi) Trial,2027-01-04,ESTIMATED,PSA response rate at Cycle 1 Day 64,TREATMENT,MALE,2023-10-04,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT05776225,,RECRUITING,"Interstitial Lung Disease, Pulmonary Hypertension",,PHINDER,,1,Experimental study arm,,"Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).",,2026-04,ESTIMATED,18 Years - N/A,300,ESTIMATED,,INDUSTRY,,Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER),2026-03,ESTIMATED,Percentage of patients with PH as indicated by RHC,,ALL,2023-08-11,ACTUAL,OBSERVATIONAL
UTHR,United Therapeutics Corporation,NCT06335407,PHASE1,RECRUITING,"Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)","Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg",,,1,BXCL501 Dose Range 40µg to 160µg,OTHER,The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.,"United States Department of Defense, Congressionally Directed Medical Research Programs, VA Connecticut Healthcare System, BioXcel Therapeutics Inc, Yale University, RTI International",2026-05-31,ESTIMATED,21 Years - 65 Years,10,ESTIMATED,SEQUENTIAL,OTHER,NONE,Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Outpatient Study,2026-03-30,ESTIMATED,Change in Blood Pressure (Systolic and Diastolic) from baseline (pre-treatment) through day 28. | Change in anxiety (measured via the State Trait Anxiety Inventory - STAI-6) from baseline (pre-treatment) through day 28. | Number and Proportion of Adverse Events,OTHER,ALL,2025-07-28,ACTUAL,INTERVENTIONAL
UTHR,United Therapeutics Corporation,NCT07037836,PHASE2,RECRUITING,"COPD (Chronic Obstructive Pulmonary Disease), Hypoxemia",Inhaled Treprostinil (Tyvaso Nebulizer),Tyvaso,,1,Inhaled Treprostinil in COPD Patients With Hypoxemia and Preserved DLCO,EXPERIMENTAL,"The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%).

The main questions it aims to answer are:

1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured",United Therapeutics,2027-07-01,ESTIMATED,40 Years - N/A,10,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia,2027-07-01,ESTIMATED,Ventilation Defect Percentage (VDP) on HP129XeMRI | Membrane Defect Percentage on HP129XeMRI | Low Membrane Region Percentage on HP129XeMRI | RBC Transfer Defect Percentage on HP129XeMRI | Low RBC Transfer Region Percentage on HP129XeMRI | RBC Oscillation Amplitude Normalized for RBC Transfer Defect | RBC Chemical Shift on HP129XeMRI Spectroscopy,TREATMENT,ALL,2025-09-29,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06221969,PHASE3,ACTIVE_NOT_RECRUITING,Type 2 Diabetes,"Cagrilintide, Semaglutide, Tirzepatide",,RANDOMIZED,2,CagriSema | Tirzepatide,EXPERIMENTAL | ACTIVE_COMPARATOR,This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr,,2026-04-03,ESTIMATED,18 Years - N/A,1000,ESTIMATED,PARALLEL,INDUSTRY,NONE,Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor,2026-02-20,ESTIMATED,Change in glycated haemoglobin (HbA1c) | Relative change in body weight,TREATMENT,ALL,2024-01-16,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04775082,PHASE3,ACTIVE_NOT_RECRUITING,Obesity,"Liraglutide, Placebo",,RANDOMIZED,2,Liraglutide 3.0 mg | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects.

Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The parti",,2027-01-15,ESTIMATED,6 Years - 12 Years,78,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial",2023-08-01,ACTUAL,Relative change in BMI (Body mass index),TREATMENT,ALL,2021-03-04,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07087795,PHASE1,RECRUITING,"Diabetes Mellitus, Type 1","NNC0194-0499, Placebo, Semaglutide",,RANDOMIZED,2,Part A: NNC0194-0499/Placebo | Part B: NNC0194-0499/Placebo + Semaglutide,EXPERIMENTAL | EXPERIMENTAL,This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.,,2026-09-25,ESTIMATED,18 Years - 64 Years,96,ESTIMATED,CROSSOVER,INDUSTRY,QUADRUPLE,"A Study to Investigate Efficacy and Safety of NNC0194-0499 Versus Placebo, Both Administered Alone or in Combination With Semaglutide in People With Type 1 Diabetes",2026-09-12,ESTIMATED,Part A: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL) | Part B: Change in time in range (TIR) 3.9-10.0 mmol/L (70-80 mg/dL),TREATMENT,ALL,2025-07-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04916132,,RECRUITING,"Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies, Diabetes type2, Molecular Sequence Variation, Kidney Biopsy",,PRIMETIME2,,1,Peolpe with T2DM and albuminuria,,"a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit fr","Rigshospitalet, Denmark, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center",2043-12-31,ESTIMATED,18 Years - 120 Years,300,ESTIMATED,,OTHER,,Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors,2043-12-31,ESTIMATED,Prevalence,,ALL,2021-08-10,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06504368,PHASE1,RECRUITING,"Solid Tumors, Adult",DCR-PDL1,,,1,DCR-PDL1,EXPERIMENTAL,"The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.",,2027-12-31,ESTIMATED,18 Years - N/A,32,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-PDL1 in Adults With Solid Tumors",2026-06-01,ESTIMATED,"Incidence and Nature of Adverse Events (AEs) | Incidence of Dose-limiting Toxicities (DLTs) | Change From Baseline in Vital Signs: Oral, Tympanic, Temporal Artery Temperature | Change From Baseline in Vital Signs: Systolic and Diastolic Blood Pressure | Change From Baseline in Vital Signs: Pulse and Respiratory Rate | Change from Baseline in 12-lead Electrocardiogram (ECG): Heart Rate and Pulse Rate | Change from Baseline in 12-lead Electrocardiogram (ECG): QRS intervals | Change from Baseline in 12-lead Electrocardiogram (ECG): QT intervals | Change from Baseline in 12-lead Electrocardiogram (ECG): QTcF intervals (QT Interval Corrected by the Fridericia Formula) | Change from Baseline in Hematology Parameter: Red blood cells, White blood cells, Lymphocytes, Monocytes, Eosinophils, Neutrophils, Basophils and Platelets, Reticulocytes | Change from Baseline in Hematology Parameter: Mean corpuscular volume (MCV) | Change from Baseline in Hematology Parameter: Mean corpuscular hemoglobin (MCH) | Change from Baseline in Hematology Parameter: Hemoglobin | Change from Baseline in Hematology Parameter: Hematocrit and Mean corpuscular hemoglobin concentration (MCHC) | Change from Baseline in Coagulation Parameter: International normalized ratio (INR) | Change from Baseline in Coagulation Parameter: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) | Change from Baseline in Coagulation Parameter: Fibrinogen | Change from Baseline in Clinical Chemistry Parameter: Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyl transferase (GGT), Alkaline phosphatase (ALP), Lactate dehydrogenase (LDH) and Creatine kinase (CK) | Change from Baseline in Clinical Chemistry Parameter: Total protein and Albumin | Change from Baseline in Clinical Chemistry Parameter: Total bilirubin, Direct bilirubin, Fasting blood glucose, Creatinine and Blood urea nitrogen (BUN) | Change from Baseline in Clinical Chemistry Parameter: Sodium, Chloride and Potassium | Change from Baseline in Urinalysis Parameter: Glucose, Protein, Bilirubin and Urobilinogen | Change from Baseline in Urinalysis Parameter: Specific Gravity | Change from Baseline in Urinalysis Parameter: Potential of Hydrogen (pH) of Urine | Change from Baseline in Urinalysis Parameter: Blood | Change from Baseline in Urinalysis Parameter: Ketones and Nitrite | Change from Baseline in Urinalysis Parameter: Leukocyte esterase | Number of Participants with Change from Baseline in Physical Examination Findings: Cardiovascular, Respiratory, Gastrointestinal, and Neurological systems",TREATMENT,ALL,2024-05-29,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06740318,,RECRUITING,Alcoholic Hepatitis (AH),,A-HEP,,1,Treatment,EXPERIMENTAL,"Genetic activity and metabolic changes may be part of the pathogenesis in alcohol related hepatitis. We do not know exactly how alcohol cessation affects liver functions and metabolism.

The aim of this study is to assess the impact of alcohol cessation in patients with alcohol related hepatitis and gain knowledge of the metabolic and genetic functions of the liver during remission and recompensation from alcohol related hepatitis.

The study will assess

1. The effect of alcohol cessation on th","Copenhagen University Hospital, Hvidovre, The Novo Nordisk Foundation Center for Basic Metabolic Research",2029-12-31,ESTIMATED,18 Years - N/A,160,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Recompensation in Alcohol Related Hepatitis- A Prospective Cohort With Alcohol Cessation,2028-12-31,ESTIMATED,Change from baseline in the proteomic profile | Change from baseline in the lipidomic profile | Number of participants in recompensation,TREATMENT,ALL,2024-11-25,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05424003,PHASE2,RECRUITING,NAFLD,"Semaglutide Pen Injector, Placebo",,RANDOMIZED,2,Semaglutide | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a ""sugar pill"") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.",Novo Nordisk A/S,2026-02,ESTIMATED,18 Years - 75 Years,50,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,A Randomized Double Blinded Placebo-Controlled Trial of Semaglutide to Prevent Weight Gain Following Liver Transplantation,2026-02,ESTIMATED,Change in weight,PREVENTION,ALL,2024-02-22,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06442644,,NOT_YET_RECRUITING,"Stress, Pain",,,,1,Adult intensive care patients,OTHER,"The goal of this quasi-experimental pre- post test study is to test a patient-tailored live music intervention's effect on stress and pain reduction in adult, critically ill patients admitted to the intensive care unit.

The main question it aims to answer is:

• Does live music reduce stress and pain in adult intensive care patients?

In the pre-post test design, the patients will be their own control. There will be no randomisation. Researchers will compare measurements of heartrate, respirati","Region MidtJylland Denmark, Novo Nordisk A/S, The Royal Conservatory of Music",2026-12,ESTIMATED,18 Years - N/A,202,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Live Music in the Intensive Care Unit,2025-12,ESTIMATED,Heartrate variability,SUPPORTIVE_CARE,ALL,2024-09,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07246421,,RECRUITING,"Metabolic Associated Fatty Liver Disease, Type 2 Diabetes (T2DM)",,,NON_RANDOMIZED,2,Subjects with T2DM and MR spectroscopy verified NO steatosis | Subjects with T2DM and MR spectroscopy verified steatosis,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The goal of this clinical trial is to investigate the sensitivity to glucagon in patients with type 2 diabetes mellitus (T2DM), with and without metabolic associated fatty liver disease (MASLD).

The main questions it aims to answer are:

1. Is the sensitivity to glucagon with respect to hepatic FA oxidation and suppression of VLDL-TG secretion impaired in humans with T2DM and MASLD?
2. Is glucagon resistance and MASLD reflected in an aberrated lipidomic/metabolomic profile in blood and adipose ",Novo Nordisk A/S,2028-07-31,ESTIMATED,30 Years - 70 Years,24,ESTIMATED,PARALLEL,OTHER,NONE,Mechanisms for Glucagon Resistance as Driver of Metabolic Associated Steatotic Liver Disease and Cardiovascular Disease in Humans With Type 2 Diabetes,2027-07-31,ESTIMATED,Hepatic FFA oxidation rate (µmol/100Ml/min) | Blood and adipose tissue proteomic and lipidomic profiles,BASIC_SCIENCE,ALL,2026-01-29,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06118281,PHASE3,RECRUITING,"Cardiovascular Risk, Acute Myocardial Infarction (AMI)","Ziltivekimab, Placebo",ARTEMIS,RANDOMIZED,2,Ziltivekimab | Placebo ziltivekimab,EXPERIMENTAL | EXPERIMENTAL,"The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant w",Duke Clinical Research Institute,2026-09-03,ESTIMATED,18 Years - N/A,10000,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction,2026-09-03,ESTIMATED,"Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal stroke",TREATMENT,ALL,2024-06-25,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05135559,PHASE3,ACTIVE_NOT_RECRUITING,Haemophilia A and B With and Without Inhibitors,Concizumab,Explorer10,NON_RANDOMIZED,2,Concizumab-naïve patients | Patients coming from compassionate use,EXPERIMENTAL | EXPERIMENTAL,"This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.

Participants will have to inject the study medicine every day under the skin with a pen-injector.

The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for pur",,2029-11-02,ESTIMATED,N/A - N/A,153,ESTIMATED,PARALLEL,INDUSTRY,NONE,"Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors",2026-04-21,ESTIMATED,For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes | For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes,TREATMENT,ALL,2022-03-24,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07253285,PHASE3,RECRUITING,"Overweight, Obesity","Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide",,RANDOMIZED,4,CagriSema | Semaglutide | Cagrilintide | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment partic",,2033-09-20,ESTIMATED,8 Years - 18 Years,460,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or Obesity",2030-03-20,ESTIMATED,Relative change in body mass index (BMI),TREATMENT,ALL,2026-01-08,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT02986984,,RECRUITING,"Diabetic Nephropathies, Diabetic Glomerulosclerosis",,TRIDENT,,2,Confirmed Diabetic Nephropathy | Confirmed Non-diabetic Nephropathy, | ,"This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (\> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of ","MOUNT SINAI HOSPITAL, University of North Carolina, Northwestern University, University of New Mexico, Stanford University, The University of Texas Health Science Center at San Antonio, Ohio State University, Yale University, Albert Einstein College of Medicine, Oregon Health and Science University, Lehigh Valley Health Network, University of Arkansas, University of Southern California, University of Virginia, Regeneron Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Juvenile Diabetes Research Foundation, Novo Nordisk A/S",2027-06,ESTIMATED,18 Years - 100 Years,400,ESTIMATED,,OTHER,,Transformative Research In DiabEtic NephropaThy,2027-06,ESTIMATED,Rapid progression of kidney function loss,,ALL,2016-12,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06977438,PHASE4,NOT_YET_RECRUITING,"Obesity, Childhood",Semaglutide,,RANDOMIZED,3,High Dose HBLT | Medium Dose HBLT | Low Dose HBLT,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is","Patient-Centered Outcomes Research Institute, Novo Nordisk A/S",2032-01-31,ESTIMATED,12 Years - 18 Years,1020,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Promoting Healthy Children and Youth,2031-01-31,ESTIMATED,Body Mass Index (BMI) Reduction,TREATMENT,ALL,2027-01-01,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06685185,PHASE1,RECRUITING,"Diabetes Mellitus, Type 1","NNC0363-1063, Placebo, Insulin degludec, Insulin detemir",,RANDOMIZED,7,Part 1A: SAD: NNC0363-1063 | Part 1A: SAD: Placebo | Part 1B: SAD: NNC0363-1063 | Part 1B: SAD: Insulin degludec | Part 2: PoP: NNC0363-1063 | Part 3 Meal test: NNC0363-1063 | Part 3 Meal test: Insulin detemir,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,This study will look into testing a new medicine called NNC0363-1063 which may be used to treat people with diabetes. The study consists of three parts: Part 1 is a single ascending dose (SAD) study that comprises two subtypes: Part 1A conducted in healthy participants and Part 1B conducted in participants with type 1 diabetes (T1D). This study part will last for about 1½ to 5½ weeks. Part 2 is a proof-of-principle (PoP) study part conducted in participants with T1D and will last for about 3½ to,,2026-05-15,ESTIMATED,18 Years - 64 Years,154,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Study Investigating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes",2026-05-15,ESTIMATED,"Part 1 SAD: Number of adverse events | Part 2 PoP: CL/F,I1063,SD- Apparent serum clearance of NNC0363-1063 after a single dose | Part 3 Meal test: AUC,PG,meal: Area under the plasma glucose concentration-time curve at steady state",TREATMENT,ALL,2024-11-12,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07112339,PHASE4,RECRUITING,"Diabetes Mellitus, Type 2","Insulin icodec, Basal insulin analogues",,RANDOMIZED,2,Insulin icodec | Basal insulin analogues,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec)",,2028-08-31,ESTIMATED,18 Years - N/A,586,ESTIMATED,PARALLEL,INDUSTRY,NONE,EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice,2026-08-04,ESTIMATED,Change in glycated haemoglobin (HbA1c),TREATMENT,ALL,2025-08-15,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07357766,PHASE3,NOT_YET_RECRUITING,"Overweight, Obesity","Cagrisema, Placebo CagriSema",,RANDOMIZED,3,CagriSema B in device 2 + Placebo in device 1 | CagriSema in device 1 + Placebo in device 2 | Placebo in device 1 + Placebo in device 2,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The s",,2028-01-17,ESTIMATED,18 Years - N/A,1400,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity,2027-11-29,ESTIMATED,Relative change in body weight,TREATMENT,ALL,2026-06-22,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06979375,PHASE2,RECRUITING,Heart Failure,"CDR132L, Placebo",8282-Reduced,RANDOMIZED,2,CDR132L + SoC | Placebo + SoC,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.",,2028-01-23,ESTIMATED,40 Years - 84 Years,200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy",2027-05-16,ESTIMATED,Main Phase: Change in normalised microRNA-132-3p (miR-132),TREATMENT,ALL,2025-06-30,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06198712,PHASE2,RECRUITING,Sickle Cell Disease,Etavopivat,HIBISCUS KIDS,,1,Etavopivat,EXPERIMENTAL,"This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat. Eligible participants who enter the study will start a 96-week treatment period. At the end of the 96 weeks, participants will have an end of study visit that occurs 4 weeks later. The participants will receive etavopiv",Novo Nordisk A/S,2029-08-08,ESTIMATED,12 Years - 18 Years,50,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease",2028-02-23,ESTIMATED,"Single-dose: maximum plasma concentration (Cmax) | Single-dose: area under the plasma concentration time curve from dosing (time 0) to time t ((AUC)0-t) | Single-dose: area under the plasma concentration time curve from zero to time infinity (AUC0-inf) | Steady-state maximum plasma concentration (Cmax,ss) | Steady-state area under the concentration time curve over the dosing interval (AUCtau,ss) | Steady-state average plasma concentration (Cavg,ss) | Steady-state minimum plasma concentration (Cmin,ss) | Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs related to etavopivat | Number of premature discontinuations | Number of dose interruptions | Number of dose reductions",TREATMENT,ALL,2023-01-12,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04121780,PHASE2,RECRUITING,"TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency",Growth Hormone,,RANDOMIZED,2,Growth Hormone | Saline,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).",Novo Nordisk A/S,2026-09,ESTIMATED,18 Years - 76 Years,42,ESTIMATED,PARALLEL,OTHER,TRIPLE,Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency,2025-03,ESTIMATED,Cognitive functions- Working Memory | Cognitive functions- Processing Speed | Cognitive functions- Executive Function. | Cognitive functions- Verbal learning and memory | Cognitive functions- ANAM ( Automated Psychological Assessment Metrics),TREATMENT,MALE,2019-10-08,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07405229,PHASE4,RECRUITING,"Idiopathic Ventricular Fibrillation, Cardiac Arrest, Out-Of-Hospital",Beta-blocker treatment group,RIME-IVF,RANDOMIZED,2,Beta-blocker | No medication,ACTIVE_COMPARATOR | NO_INTERVENTION,"A person who has experienced a cardiac arrest with no apparent cause is at risk of having recurrent cardiac arrest. Hence an implantable cardioverter-defibrillator (ICD) is recommended on empirical grounds. Today, there is no uniform way of approaching prevention of recurrence in idiopathic ventricular fibrillation (IVF) patients, beside ICD implantation. Better reatment and risk stratification tools are needed Medical treatment in these patients has never been assessed systematically, but at le","The Novo Nordisk Foundation, Per Henriksen Foundation, Danish Heart Foundation, RH research funds",2035-12-31,ESTIMATED,18 Years - N/A,218,ESTIMATED,PARALLEL,OTHER,SINGLE,"Investigation of RIsk Factors in Out-of-hospital-cardiac-arrest Patients, and MEdical Treatment in Idiopathic Ventricular Fibrillation Patients",2032-12-31,ESTIMATED,First appropriate therapy by ICD or 3 years after discharge,TREATMENT,ALL,2018-05-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05685238,PHASE3,ACTIVE_NOT_RECRUITING,"Haemophilia A, Haemophilia A With Inhibitors",Mim8,FRONTIER4,NON_RANDOMIZED,3,Arm 1 | Arm 2 | Arm 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study is looking at how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used to avoid bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study. The study will end if Mim8 is approved and marketed in participant's country during the study, or the ",,2028-06-30,ESTIMATED,N/A - N/A,451,ESTIMATED,PARALLEL,INDUSTRY,NONE,"Open-label, Long-term Safety and Efficacy Study of Mim8 in Participants With Haemophilia A With or Without Inhibitors",2028-06-30,ESTIMATED,Arm 1 and 2: Number of treatment emergent adverse events | Arm 3: Number of treatment emergent adverse events,TREATMENT,ALL,2023-02-13,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05669755,PHASE3,ACTIVE_NOT_RECRUITING,Cardiovascular Disease,"Cagrilintide, Semaglutide, Placebo",REDEFINE 3,RANDOMIZED,2,CagriSema | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called ""placebo"") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected br",,2027-10-13,ESTIMATED,55 Years - N/A,7101,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease,2027-09-01,ESTIMATED,"Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke",TREATMENT,ALL,2023-03-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07262788,,RECRUITING,Type 2 Diabetes,,ON LiMiT,RANDOMIZED,2,CH-rich diet with exercise | CH-reduced diet with exercise,EXPERIMENTAL | EXPERIMENTAL,"The overall aim of this study is to examine the feasibility of a 12-month, two-arm lifestyle intervention to induce and maintain remission of type 2 diabetes (T2D). The findings from the feasibility study will inform the recruitment, design and delivery of the interventions in a 5-arm, 24-month randomised controlled trial.","Steno Diabetes Center Aarhus (SDCA), Aarhus University Hospital, Steno Diabetes Center Odense, University of Copenhagen, The Novo Nordisk Foundation Center for Basic Metabolic Research, Bispebjerg Hospital",2027-03,ESTIMATED,18 Years - 75 Years,24,ESTIMATED,PARALLEL,OTHER,NONE,A Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes (ON LiMiT),2027-03,ESTIMATED,Feasibility testing of diet adherence | Feasibility testing of exercise adherence | Feasibility testing of GP recruitment & safety procedures - quantitative assessment | Feasibility testing of GP experiences and study procedures - qualitative assessment | Feasibility testing of participant recruitment & retention | Feasibility testing of intervention participation - quantitative assessment | Feasibility testing of intervention participation - qualitative assessment | Feasibility testing of protocol adherence - number of days with deviations | Feasibility testing of acceptability and experiences,TREATMENT,ALL,2025-09-30,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06609226,PHASE3,RECRUITING,"Sickle Cell Disease, Thalassemia","Etavopivat A, Etavopivat B, Etavopivat C",FLORAL,NON_RANDOMIZED,5,Participants greater than or equal to (≥) 12 years old with sickle cell disease | Participants ≥ 12 years old with sickle cell disease transfusion dependent | Participants ≥ 12 years old with transfusion-dependent thalassaemia | Participants ≥ 12 years old with non-transfusion dependent thalassaemia | Participants ≥ 2 years to less than (<) 12 years old with sickle cell disease,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant",,2030-12-30,ESTIMATED,2 Years - N/A,480,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study",2030-12-30,ESTIMATED,"Number of treatment emergent adverse events (TEAEs), reported for each indication and age group separately | Number of adverse reactions, reported for each indication and age group separately",TREATMENT,ALL,2025-01-10,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04777396,PHASE3,ACTIVE_NOT_RECRUITING,Early Alzheimer's Disease,"Semagludtide, Placebo (semaglutide)",EVOKE,RANDOMIZED,2,Oral Semaglutide | Placebo (semagludtide),EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.

Participants will either get semaglutide or placebo (a ""dummy"" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.

The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10",,2026-01-23,ESTIMATED,55 Years - 85 Years,1840,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE),2025-09-16,ACTUAL,Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score,TREATMENT,ALL,2021-05-18,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07227246,PHASE3,RECRUITING,Intracerebral Hemorrhage,"Recombinant Factor VIIa, Biological/Vaccine: Placebo",FASTEST Part 2,RANDOMIZED,2,Recombinant Factor VIIa | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 90 days as measured by the Modified Rankin Score (mR","National Institute of Neurological Disorders and Stroke (NINDS), Japan Agency for Medical Research and Development, Novo Nordisk A/S",2029-06,ESTIMATED,18 Years - 80 Years,350,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial - Part 2,2029-01,ESTIMATED,Modified Rankin Scale,TREATMENT,ALL,2025-05-06,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07191925,,ACTIVE_NOT_RECRUITING,"Quality of Life (QOL), Physical Activity, Diet Quality, Obesity &Amp; Overweight, Body Esteem, Community",,,RANDOMIZED,2,Intervention Group | Control Group,EXPERIMENTAL | NO_INTERVENTION,"The goal of this intervention study is to learn if community co-designed activities to improve diet and physical activity can impact the health of children ages 6-13 in Mississauga, Canada. The main questions it aims to answer are:

1. Do the community co-designed interventions improve health-related quality of life of children after one year and two years?
2. Do the community co-designed interventions improve the physical activity and eating behaviors of children after one year and two years?

","Novo Nordisk A/S, Delivery Associates, Ophea, 8 80 Cities, The Behavioural Insights Team",2027-11,ESTIMATED,6 Years - 13 Years,4900,ESTIMATED,PARALLEL,OTHER,SINGLE,"An Evaluation of ""Growing Healthy Places: Mississauga""",2027-11,ESTIMATED,Health-related Quality of Life as assessed by KIDSCREEN-10 index,PREVENTION,ALL,2025-10-16,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06719011,PHASE1,RECRUITING,"Obesity, Overweight","NNC0174-1213 A, Cagrilintide B, Placebo A (NNC0174 1213 A)",,RANDOMIZED,6,Part A: NNC0174-1213 (SD1-SD5) | Part A: Cagrilintide (SDA and SDB) | Part A: Placebo | Part B: NNC0174-1213 (MD1-MD5) | Part B: Cagrilintide (MDA) | Part B: Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called ""cagrilintide"" or a placebo (a ""dummy medicine"" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided ",,2026-05-17,ESTIMATED,18 Years - 55 Years,177,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Randomized, Placebo Controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0174 1213 in Male Participants With Overweight or Obesity.",2026-03-26,ESTIMATED,Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213 | Part B: Number of treatment emergent adverse events (TEAE),TREATMENT,MALE,2024-12-03,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07238816,PHASE1,RECRUITING,Haemophilia A,NNC0442-0344 A,,RANDOMIZED,4,Group A | Group B | Group C | Reference dose,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this study is to test a new medicine called Inno8. The study will test how eating and drinking before and after taking Inno8 affects how well it is absorbed in the stomach. The study consists of four arms. Participants will take the study medicine after an overnight fast. How long participants will need to fast depends on which group participants are in. After taking the study medicine, participants will need to fast again. The study will last for up to 9.5 weeks.",,2026-04-29,ESTIMATED,18 Years - 45 Years,80,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Single-centre, Open-label, Randomised, Single-dose Study to Evaluate the Effect of Pre- and Post-dose Meal Timings on the Pharmacokinetic Properties of Inno8 in Healthy Participants",2026-04-29,ESTIMATED,AUC0-∞: the area under the plasma Inno8 concentration-time curve from time 0 to infinity after a single oral dose,TREATMENT,MALE,2025-11-18,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06807190,,RECRUITING,"Diabetes Mellitus, Type 1",Insulin Icodec,,,1,Awiqli,,The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.,,2028-01-31,ESTIMATED,N/A - N/A,630,ESTIMATED,,INDUSTRY,,"A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan",2027-07-31,ESTIMATED,Number of Adverse Reactions (ARs),,ALL,2025-04-15,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT07237685,,RECRUITING,"Type 2 Diabetes, Coronary Artery Disease (CAD), Atherosclerosis Cardiovascular Disease",,EVOLVE,,0,,,"People with type 2 diabetes have a much higher risk of heart disease. One common problem is when the blood vessels that supply the heart become narrowed or blocked by fatty deposits, called plaque. This makes it harder for blood to reach the heart and can lead to serious problems such as chest pain, heart attacks, or even death.

This study will follow people with type 2 diabetes who have already had a special heart scan called a coronary CT angiography. This scan takes detailed pictures of the ","Horizon Innovative Health Initiative, Novo Nordisk A/S, INSTITUTO DE INVESTIGACION BIOMEDICA DE SALAMANCA (IBSAL), Cardiology Centers of the Netherlands",2036-10-01,ESTIMATED,18 Years - N/A,1000,ESTIMATED,,OTHER,,Evaluating Atherosclerotic Disease Progression in High-Risk Patients With Diabetes Mellitus,2026-10-01,ESTIMATED,progression of total coronary plaque volume (mm3),,ALL,2025-06-06,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06388187,PHASE3,ACTIVE_NOT_RECRUITING,Obesity,"Cagrilintide, Semaglutide, Placebo",,RANDOMIZED,4,CagriSema Dose 1 | Placebo Dose 1 | CagriSema Dose 2 | Placebo Dose 2,EXPERIMENTAL | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.",,2026-04-21,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity,2026-04-21,ESTIMATED,Relative change in body weight | Achievement of ≥5% weight reduction,TREATMENT,ALL,2024-06-24,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07400107,PHASE3,NOT_YET_RECRUITING,"Obesity, Overweight, Diabetes Mellitus, Type 2","NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111), Placebo (matched to semaglutide)",AMAZE 8,RANDOMIZED,2,NNC0487-0111 | Semaglutide,EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin once a week. The placebo is a treatment with no active medicine in it and will be given to all participants. In addition to placebo, participants will receive either of the active medicine NNC0487-0111 (the treatment be",,2029-01-26,ESTIMATED,18 Years - N/A,1000,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)",2028-12-12,ESTIMATED,Relative change in body weight,TREATMENT,ALL,2026-05-20,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07011667,PHASE3,ACTIVE_NOT_RECRUITING,Obesity,"CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)",,RANDOMIZED,2,CagriSema | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more li,,2028-10-17,ESTIMATED,18 Years - N/A,609,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity,2027-03-01,ESTIMATED,Relative change in body weight,TREATMENT,ALL,2025-06-03,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07415954,PHASE2,NOT_YET_RECRUITING,"Diabetes Mellitus, Type 2","NNC0662-0419, Semaglutide, Placebo",,RANDOMIZED,3,NNC0662-0419 | Semaglutide | Placebo,EXPERIMENTAL | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors ",,2027-09-03,ESTIMATED,18 Years - 75 Years,270,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study,2027-09-03,ESTIMATED,Change in glycated haemoglobin (HbA1c) (week 16) | Change in HbA1c (week 28) | Change in HbA1c (week 40),TREATMENT,ALL,2026-04-17,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04657783,,RECRUITING,"Diabetes Mellitus, Type 1, Cardiovascular Diseases, Hypoglycemia, Patient Participation",,SFDT1,,0,,,"Cardiovascular (CV) diseases are the most frequent type 1 diabetes (T1D) complications. A recent epidemiological study showed that patients with T1D have a two-fold CV mortality risk, even in case of good glycemic control. In addition, it has been shown that patients with T1D with no traditional CV risk factors had about a 80% higher risk of cardiovascular event compared to non-diabetic individuals. This indicates that further modifiable risk factors in relation to CV mortality remain to be iden","Société Francophone du Diabète, Sanoia, Institut National de la Santé Et de la Recherche Médicale, France, Eli Lilly and Company, Abbott Diabetes Care, Air Liquide Santé International, Novo Nordisk A/S, Sanofi, Insulet Corporation, DexCom, Inc., Luxembourg Institute of Health, Creapharm, Medtronic, mylife Diabetes Care AG, LifeScan",2035-06-10,ESTIMATED,6 Years - 100 Years,15000,ESTIMATED,,OTHER,,French National Cohort of People With Type 1 Diabètes: the SFDT1 Study,2025-06-10,ESTIMATED,Major adverse cardiovascular events (MACE),,ALL,2020-06-10,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06979362,PHASE2,RECRUITING,Heart Failure,"CDR132L, Placebo",8212-Preserved,RANDOMIZED,4,CDR132L: Dose 1 | CDR132L: Dose 2 | CDR132L: Dose 3 | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.",,2028-01-23,ESTIMATED,40 Years - 84 Years,200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy",2027-05-16,ESTIMATED,Main phase: Change in normalised microRNA-132-3p (miR-132),TREATMENT,ALL,2025-06-27,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05283512,,RECRUITING,"Contrast-induced Nephropathy, Kidney Injury, Kidney Failure, Chronic, Risk Reduction",,ENRICH,RANDOMIZED,2,IV-hydration group (standard of care according to international guidelines) | Oral hydration group,OTHER | ACTIVE_COMPARATOR,"The use of contrast media (CM) poses a risk of post-contrast acute kidney injury (PC-AKI), especially among patients chronic kidney disease (CKD). International guidelines recommend intravenous (IV) hydration with isotonic 0.9% NaCl for three-four hours pre-contrast and four-six hours post-contrast. Recent studies have proven that oral hydration or no hydration is non-inferior to IV hydration in patients with mild to moderate CKD (eGFR 30-60 mL/min/1.73 m2). However, no randomized controlled tri","Department of Nephrology, Odense University Hospital, Department of Clinical Genetics, Odense University Hospital, The A.P. Moller Foundation, The Research Counsil of Odense University Hospital, Copenhagen University's Research Foundation for Medical Students, Helen and Ejnar Bjørnow's Foundation, Novo Nordisk A/S, Sophus Jacobsen and Astrid Jacobsen's Foundation, Region of Southern Denmark",2027-12-31,ESTIMATED,18 Years - N/A,254,ESTIMATED,PARALLEL,OTHER,SINGLE,Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease (ENRICH): A Randomized Controlled Trial,2026-12-31,ESTIMATED,Incidence of PC-AKI,PREVENTION,ALL,2022-04-20,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06717698,PHASE2,RECRUITING,Chronic Kidney Disease,"NNC0519-0130, Placebo, Semaglutide",,RANDOMIZED,9,Dosing scheme a: NNC0519-0130 | Dosing scheme a: Placebo | Dosing scheme b: NNC0519-0130 | Dosing scheme b: Placebo | Dosing scheme c: NNC0519-0130 | Dosing scheme c: Placebo | Dosing scheme d: NNC0519-0130 | Dosing scheme d: Placebo | Dosing scheme e: Semaglutide,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a ""dummy"" substance). Which treatment the participant will get is decided by chance. The study wil",,2026-09-17,ESTIMATED,18 Years - N/A,465,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study",2026-09-01,ESTIMATED,Change in urinary albumin-to-creatinine ratio (UACR) at week 12 | Change in urinary albumin-to-creatinine ratio (UACR) at week 24 | Change in urinary albumin-to-creatinine ratio (UACR) at week 36,TREATMENT,ALL,2024-12-02,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07357740,PHASE2,NOT_YET_RECRUITING,"Diabetes Mellitus, Type 2","CagriSema, Placebo CagriSema",,RANDOMIZED,2,CagriSema in device 1 + Placebo CagriSema B in device 2 | CagriSema B in device 2 + Placebo CagriSema in device 1,EXPERIMENTAL | EXPERIMENTAL,This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.,,2027-10-13,ESTIMATED,18 Years - 64 Years,400,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes,2027-08-25,ESTIMATED,Change in glycated haemoglobin (HbA1c),TREATMENT,ALL,2026-08-27,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07214870,PHASE1,RECRUITING,Fatty Liver Disease,"NNC4005-001, Placebo",,RANDOMIZED,2,NNC4005-0001 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine. The study will last for about for about 7 to 8 months.",,2027-05-14,ESTIMATED,18 Years - 69 Years,60,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NNC4005-0001 in Adults",2027-05-14,ESTIMATED,Number of Treatment-emergent adverse event (TEAEs),TREATMENT,ALL,2025-10-08,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04042402,PHASE3,ACTIVE_NOT_RECRUITING,"Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3)",DCR-PHXC,PHYOX3,,1,Open Label,EXPERIMENTAL,"The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.",,2030-04-01,ESTIMATED,N/A - N/A,75,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria,2030-04-01,ESTIMATED,The annual rate of decline in eGFR in participants with PH1,TREATMENT,ALL,2019-07-09,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06449625,PHASE2,NOT_YET_RECRUITING,"Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity","Semaglutide Pen Injector [Ozempic], Placebo",PROTECT,RANDOMIZED,2,Semaglutide | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The primary objective of this clinical trial is to ievaluate the effect of semaglutide (GLP-1 receptor agonist) in reducing intensity of gastrointestinal (GI) mucositis in patients undergoing high-dosage chemotherapy followed by autologous (auto) haematopoietic stem cell transplantation (HSCT). The secondary objective is to evaluate the effect and safety of semaglutide in reducing gut barrier injury and systemic inflammation in patients undergoing auto-HSCT.

Study design:

The study is designed","Novo Nordisk A/S, Independent Research Fund Denmark",2027-02-01,ESTIMATED,18 Years - N/A,40,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Semaglutide Treatment for PRevention Of Toxicity in High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation,2026-12-31,ESTIMATED,gastrointestinal mucositis severity,PREVENTION,ALL,2024-08-12,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07411560,PHASE1,NOT_YET_RECRUITING,"Overweight, Obese","Glucose-dependent Insulinotropic Polypeptide (GIP), Cagrilintide, Placebo GIP",,RANDOMIZED,4,Arm 1:Glucose dependent Insulinotropic Polypeptide(GIP)+Cagrilintide then Placebo GIP+Cagrilintide | Arm 2: Placebo GIP + Cagrilintide then GIP + Cagrilintide | Arm 3: GIP + Cagrilintide then Placebo GIP + Cagrilintide | Arm 4: Placebo GIP + Cagrilintide then GIP + Cagrilintide,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period participants will get two medicines: cagrilintide and NNC0480-0389. In the other period, participants will get cagrilintide together with a placebo version of NNC0480-0389.The placebo looks like the real treatment but does not have any active medicine in it. Cagrilintide and NNC0480-0389 is a new med",,2027-01-26,ESTIMATED,18 Years - 64 Years,100,ESTIMATED,CROSSOVER,INDUSTRY,QUADRUPLE,Single-centre Study Investigating the Role of Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA) in Combination With Long-acting Subcutaneous Amylin Receptor Agonist on Gastrointestinal Tolerability in Participants With Overweight or Obesity,2027-01-26,ESTIMATED,"Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea",TREATMENT,FEMALE,2026-02-09,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07189676,,RECRUITING,Cardiometabolic Diseases,,PlanetDiet,RANDOMIZED,3,Planetary health diet (PHD) | Ovo-lacto-vegetarian diet | Control group (habitual diet),EXPERIMENTAL | EXPERIMENTAL | OTHER,"This study aims to investigate the effects of sustainable diets on traditional and novel cardiometabolic risk factors.

The primary objective is:

• To test the effects of a sustainable diet on traditional cardiometabolic risk factors, specifically, a metabolic health score.

The secondary objectives are:

* To test the effects of sustainable diets on blood lipids, inflammatory markers, glucose markers, and anthropometric and body composition markers.
* To test the effect of sustainable diets on","Novo Nordisk Foundation (NNF), Danish Heart Foundation",2027-04,ESTIMATED,45 Years - 70 Years,180,ESTIMATED,PARALLEL,OTHER,SINGLE,PLANETDIET: Sustainable Diets and Cardiometabolic Health: a Multi-omics Approach in a Randomized Controlled Trial (RCT),2027-04,ESTIMATED,Changes in metabolic health score,PREVENTION,ALL,2025-11-24,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05021835,PHASE3,ACTIVE_NOT_RECRUITING,"Cardiovascular Risk, Chronic Kidney Disease, Inflammation","Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C)",ZEUS,RANDOMIZED,2,Ziltivekimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.

Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same.

Z",,2026-06-26,ESTIMATED,18 Years - N/A,6200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation",2026-06-26,ESTIMATED,"Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal stroke",TREATMENT,ALL,2021-08-30,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07423481,,NOT_YET_RECRUITING,Obesity & Overweight,,SEMAFOLLOW,,1,SEMAFOLLOW study population,,"SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.",Novo Nordisk A/S,2027-03-01,ESTIMATED,18 Years - N/A,3000,ESTIMATED,,OTHER,,"SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France",2027-03-01,ESTIMATED,Describe weight changes during the follow-up period according to patient characteristics.,,ALL,2026-06-01,ESTIMATED,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT05725902,PHASE2,ACTIVE_NOT_RECRUITING,Sickle Cell Disease,Etavopivat,,,1,Etavopivat,EXPERIMENTAL,"An open-label, single arm study in patients 12 to 21 years of age with SCD to evaluate the effects of etavopivat on cerebral and muscle hemodynamics.",,2026-02-26,ESTIMATED,12 Years - 21 Years,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Pilot Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease,2025-12-08,ESTIMATED,Effect of etavopivat on cerebral blood flow (CBF) | Effect of etavopivat on oxygen ejection fraction (OEF) | Effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2),TREATMENT,ALL,2024-03-25,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07035769,PHASE1,RECRUITING,Healthy Participants,"Debio 1453P, Placebo",,RANDOMIZED,2,Part 1: Single ascending dose (SAD) | Part 2: Multiple ascending dose (MAD),EXPERIMENTAL | EXPERIMENTAL,"The main purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of Debio 1453P compared to placebo across different dose levels in healthy adults after single and repeated oral dosing.","Biomedical Advanced Research and Development Authority, Wellcome Trust, Germany's Federal Ministry of Research, Technology and Space (BMFTR), Global Antimicrobial Resistance Innovation Fund-(GAMRIF), Novo Nordisk Foundation (NNF)",2026-05,ESTIMATED,18 Years - 55 Years,88,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Debio 1453P in Healthy Adults",2026-04,ESTIMATED,Number of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-06-18,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06411210,PHASE2,RECRUITING,"Diabetes type1, Obesity","Semaglutide Pen Injector, Placebo",,RANDOMIZED,2,Semaglutide | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and ","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S",2028-06-30,ESTIMATED,18 Years - 30 Years,54,ESTIMATED,PARALLEL,OTHER,DOUBLE,Obesity Complicating Type 1 Diabetes in Young Adults: Physiology and Impact of GLP-1 Analogue Anti-obesity Treatment on Cardiometabolic Risk Factors,2028-04-30,ESTIMATED,Change in VAT/(VAT+SAT) from baseline to 12 months | Change in hepatic insulin resistance from baseline to 12 months | Change in triglycerides from baseline to 12 months,BASIC_SCIENCE,ALL,2024-07-16,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07255807,,NOT_YET_RECRUITING,"Metabolic Health, Insulin Sensitivity/Resistance",,SIGNATURE,RANDOMIZED,2,Baseline Characterization | Lifestyle Interventions,NO_INTERVENTION | EXPERIMENTAL,"The goal of this intervention study is to learn more about what causes insulin resistance in otherwise healthy adults, and how short-term changes in physical activity or diet may influence it. The study includes healthy male and female participants aged 25 to 55 years, who meet specific health criteria.

The main questions it aims to answer are:

Does the cause of insulin resistance vary between individuals due to their genes and lifestyle?

Can the investigators identify different types (sub-ph","University of Sydney, Queen Mary University of London, Novo Nordisk A/S",2038-06-30,ESTIMATED,25 Years - 55 Years,80,ESTIMATED,PARALLEL,OTHER,NONE,sIgnatuRe: Defining the Human Insulin Resistance Molecular Network,2028-06-30,ESTIMATED,Whole-body insulin action,BASIC_SCIENCE,ALL,2025-12-01,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06805539,,ACTIVE_NOT_RECRUITING,"Overweight, Obesity",,,,2,Consent video | Video call, | ,"The purpose of this study is to collect health data related from participants living with an overweight condition in a decentralised clinical study set-up. All data will be collected remotely using an app downloaded on your personal smartphone and devices (watch and scale).

Participants will participate in this study for 24 weeks. The study does not include any study medicine.",,2026-04-30,ESTIMATED,18 Years - N/A,200,ESTIMATED,,INDUSTRY,,Decentralised Observational Disease Area Study Exploring Remote Collection of Data in Adult Participants With Overweight Condition or Obesity Undergoing Weight Management Program,2026-04-30,ESTIMATED,Completion of the electronic informed consent process (e-consent) | Body weight measurements recorded,,ALL,2025-04-14,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT03308916,,RECRUITING,"Liver Diseases, Alcoholic, Fibrosis",,SIPHON,,1,Liver stiffness measurement,EXPERIMENTAL,"Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver disease, alcoholic fatty liver disease, with a control group of participants recruited from the general population.","Horizon 2020 - European Commission, Novo Nordisk A/S, University of Southern Denmark, Esbjerg University Hospital of South-West Jutland, Odense Municipality Alcohol Rehabilitation Unit, Svendborg Municipality Alcohol Rehabilitation Unit, University of Copenhagen, University of Oslo, Nordic Bioscience A/S, VLV Bio, Peviva AB, Manatee APS, Siemens Healthcare A/S, Steno Diabetes Center Copenhagen, Biomedical Research Foundation, Academy of Athens, European Molecular Biology Laboratory, EMBL, University of Heidelberg",2035-10-30,ESTIMATED,30 Years - 75 Years,6500,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers,2025-12-30,ESTIMATED,Biopsy-verified advanced fibrosis | Liver-related outcomes,DIAGNOSTIC,ALL,2017-10-06,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06240208,,RECRUITING,Overweight,,,RANDOMIZED,2,Inactivity | Control,EXPERIMENTAL | NO_INTERVENTION,"The goal of this parallel-group, two-arm, assessor-blinded, randomised clinical trial is to investigate the effects of reducing physical activity on food intake and satiety in physically active and healthy males, 40-55 years of age.

The main questions it aims to answer are:

* Does physical inactivity affect GLP-1 stimulated food intake?
* Does physical inactivity affect food preferences, satiety and other mechanisms supporting appetite regulation?

Participants will be randomised (1:1) to two ","Novo Nordisk A/S, TrygFonden, Denmark",2026-03,ESTIMATED,40 Years - 55 Years,40,ESTIMATED,PARALLEL,OTHER,SINGLE,"The Effects of Inactivity on GLP-1 Stimulated Appetite Regulation in Healthy Normal Weight Males: A Randomised, Parallel Group Study",2026-02-01,ESTIMATED,The change in food intake at an ad libitum meal during GLP-1 infusion,PREVENTION,MALE,2024-03-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05689372,,NOT_YET_RECRUITING,"Diabetes Mellitus, Type 2",Semaglutide,,,1,Participants with type 2 diabetes,,The aim of this study is to assess the safety and effectiveness of Ozempic initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Ozempic as prescribed by study doctor. The study will last for about 26 weeks.,,2027-05-31,ESTIMATED,19 Years - N/A,600,ESTIMATED,,INDUSTRY,,"A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic Solution for Injection 1.34mg/ml (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea",2026-11-30,ESTIMATED,Number (incidence) of adverse events (AEs),,ALL,2026-02-28,ESTIMATED,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06752967,,RECRUITING,"Obesity, Normal Weight, Overweight",,MEMORY,RANDOMIZED,2,Protein liquid test meal | Carbohydrate liquid test meal,EXPERIMENTAL | EXPERIMENTAL,"The overall aim of the MEMORY study is to examine the concept of 'food memory' - how specific macronutrient compositions influence subsequent food preference and intake, and whether this differs across the BMI range from normal weight to obesity.","Novo Nordisk A/S, University of Leeds, University of Copenhagen",2026-12-31,ESTIMATED,18 Years - 45 Years,45,ESTIMATED,CROSSOVER,OTHER,NONE,Hormonal Control of Energy and Macronutrient Intake in Obesity,2025-12-31,ESTIMATED,Difference in energy intake from sweet tasting carbohydrates.,TREATMENT,ALL,2024-12-12,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07282613,PHASE3,NOT_YET_RECRUITING,"Diabetes Mellitus, Type 2","CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)",REIMAGINEYOUNG,RANDOMIZED,3,Part 1: CagriSema | Part 1: Placebo | Part 2: CagriSema,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight. The study has 2 parts: in the first part participant will get either CagriSema or placebo, and in the second part participant will get CagriSema. In the first part, which treatment participant gets is decided by chance and second part is open label and all participants will get CagriSema during this part. The st",,2030-03-30,ESTIMATED,10 Years - 18 Years,80,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes,2029-09-07,ESTIMATED,Change in glycated haemoglobin (HbA1c),TREATMENT,ALL,2026-08-04,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07220759,PHASE3,RECRUITING,"Overweight, Obesity, Type 2 Diabetes","Cagrilintide, Placebo (matched to Cagrilintide)",RENEW 2,RANDOMIZED,2,Cagrilintide | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study wil",,2027-07-28,ESTIMATED,18 Years - N/A,330,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes,2027-06-09,ESTIMATED,Relative change in body weight | Number of participants with achievement of greater than or equals (>=) 5% body weight reduction,TREATMENT,ALL,2025-11-05,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT01239550,,ACTIVE_NOT_RECRUITING,"Diabetes, Obesity",Detemir,IDIOM,RANDOMIZED,2,Insulin Detemir Treatment | Comparator: No insulin,EXPERIMENTAL | NO_INTERVENTION,"The purpose of this study is to evaluate the effects of the medication insulin detemir on weight, brain function and mood, and on blood vessel and other risk factors for heart disease. The study will compare how diet and insulin detemir affect areas of the brain that are involved in food intake and the sense of pleasure people get from eating.

Participants will be randomized into one of 2 groups. Group 1 will follow a low calorie diet only. Group 2 will follow a low calorie diet and take insuli",Novo Nordisk A/S,2028-12,ESTIMATED,31 Years - 60 Years,240,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Making an ""Obese""Brain(and Body)Lean: Insulin Detemir,Monoamines,and Reward",2028-12,ESTIMATED,Low dose basal insulin detemir will potentiate weight loss in obese patients with type 2 diabetes mellitus undergoing a hypocaloric diet intervention by improving dopamine signaling,BASIC_SCIENCE,ALL,2011-04,,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04580420,PHASE2,RECRUITING,"Primary Hyperoxaluria Type 1, End Stage Renal Disease",DCR-PHXC,PHYOX7,,1,Open-Label DCR-PHXC,EXPERIMENTAL,"The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.",,2032-01-30,ESTIMATED,N/A - N/A,28,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis",2031-12-30,ESTIMATED,Safety: Incidence of Events | Safety: Incidence of Events,TREATMENT,ALL,2021-04-15,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06312410,,RECRUITING,"Child, Parents, Mental Disorder, Child of Impaired Parents, Preventive Health Services",,,RANDOMIZED,2,VIA Family 2.0 | Treatment as usual (TAU),EXPERIMENTAL | ACTIVE_COMPARATOR,"VIA Family 2.0 - a Family Based Intervention for families with parental mental illness

Background: Children born to parents with mental illness have consistently been shown to have increased risks for a range of negative life outcomes including increased frequencies of mental disorders, somatic disorders, poorer cognitive functioning, social, emotional and behavioral problems and lower quality of life. Further these children are often overlooked by both society and mental health services, altho","Aalborg Psychiatric Hospital, TrygFonden, Denmark, Novo Nordisk A/S, Lundbeck Foundation, Liljeborgfonden, Ebbefos Fonden, KV Fonden",2028-12-31,ESTIMATED,0 Years - 17 Years,1452,ESTIMATED,PARALLEL,OTHER,DOUBLE,The VIA Family 2.0 Study: a Randomized Clinical Trial Evaluating Family-based Interventions for Children Born to Parents with Mental Disorders,2027-12-31,ESTIMATED,Change in Strengths and Difficulties Questionnaire (SDQ) | Change in Bayley-4 Bayley Scales Test for Infant and Toddler Development | Change in Family Assessment Device - General Function Scale (FAD-GF) | Change in Parental Stress Scale (PSS),PREVENTION,ALL,2024-03-18,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT03811561,PHASE3,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 2","Semaglutide, Placebo (semaglutide)",FOCUS,RANDOMIZED,2,Semaglutide | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper",,2027-11-07,ESTIMATED,18 Years - N/A,1500,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes,2026-12-25,ESTIMATED,Presence of at least 3 steps Early Treatment Diabetic Retinopathy Study (ETDRS) subject level progression.,TREATMENT,ALL,2019-05-08,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07302802,,RECRUITING,Monogenic Obesity,Semaglutide (administered by PDS290 pen-injector),,,6,"Patients with biallelic variants in the LEPR, PCSK1, POMC, and MC4R gene | Patients with monoallelic variants in the LEPR gene | Patients with monoallelic variants in the PCSK1 gene | Patients with monoallelic variants in the POMC gene | Patients with monoallelic variants in the MC4R gene | Patients with monoallelic variants in the SH2B1 gene or with 16p11.2 deletions", |  |  |  |  | ,"This observational study aims to assess the effect of once-weekly s.c. semaglutide 2.4 mg as an adjunct to a calorie-reduced diet and increased physical activity on weight loss, change in hunger, body composition, depression, and quality of life after 68 weeks of treatment in adolescents diagnosed with monogenic obesity in routine clinical care.",Novo Nordisk A/S,2028-12,ESTIMATED,12 Years - 21 Years,70,ESTIMATED,,OTHER,,Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice,2028-06,ESTIMATED,Proportion of participants achieving ≥10% BMI reduction from baseline (week 0) to week 68.,,ALL,2025-12-01,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT07220564,PHASE1,RECRUITING,Haemophilia A,NNC0442-0344 A,VOYAGER2,NON_RANDOMIZED,2,Cohort 1 | Cohort 2,EXPERIMENTAL | EXPERIMENTAL,This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.,,2026-12-21,ESTIMATED,18 Years - 64 Years,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Peroral Doses of Inno8 in People With Haemophilia A",2026-12-21,ESTIMATED,Number of treatment emergent adverse events,TREATMENT,MALE,2025-10-23,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04083781,PHASE3,ACTIVE_NOT_RECRUITING,"Haemophilia A With Inhibitors, Haemophilia B With Inhibitors",Concizumab,explorer7,RANDOMIZED,4,Arm 1: No prophylaxis | Arm 2: Concizumab prophylaxis | Arm 3: Concizumab prophylaxis | Arm 4: Concizumab prophylaxis,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B with inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group, participants will get study medicine from the start of the study. In the other group, participants will continue with their normal medicine and get study m",,2027-02-21,ESTIMATED,N/A - N/A,134,ACTUAL,PARALLEL,INDUSTRY,NONE,Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors,2021-12-27,ACTUAL,Rate of Treated Spontaneous and Traumatic Bleeding Episodes,TREATMENT,MALE,2019-10-21,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07010432,PHASE1,RECRUITING,Obesity,"Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide",RAMBO,RANDOMIZED,4,Cagrilintide | Semaglutide | CagriSema | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semaglutide, CagriSema (cagrilintide combined with semaglutide), or placebo. Which treatment participants ",,2028-05-03,ESTIMATED,50 Years - 70 Years,144,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With Obesity,2028-05-03,ESTIMATED,Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT),TREATMENT,FEMALE,2025-06-12,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05441267,PHASE4,RECRUITING,"Diabetes Mellitus, Type 2","Semaglutide Oral Tablet, Placebo oral tablet",ASCEND PLUS,RANDOMIZED,2,Oral semaglutide | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.",Novo Nordisk A/S,2048-08-17,ESTIMATED,55 Years - N/A,20000,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,A Study of Cardiovascular Events iN Diabetes Plus,2028-08-17,ESTIMATED,Time to the first occurrence of a Major Adverse Cardiovascular Events (MACE+),PREVENTION,ALL,2023-03-13,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07004322,PHASE1,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 2, Obesity","NNC0519-0130, Placebo",,RANDOMIZED,2,NNC0519-0130 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and excess body weight. In this study, the concentration of NNC0519-0130 in the blood will be measured and its safety will be evaluated. The participants will either get NNC0519-0130 or placebo (a ""dummy"" substance), which treatment the participants get is decided by chance. This study will test up to 7 different doses of NNC0519-0130 and will last for about 28 wee",,2026-04-07,ESTIMATED,18 Years - 55 Years,20,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Investigation of Pharmacokinetics, Safety and Tolerability of Multiple Subcutaneous Doses of NNC0519-0130 in Male Chinese Participants With Overweight or Obesity",2026-04-07,ESTIMATED,"AUC, NNC0519-0130, SS: Area under the NNC0519-0130 plasma concentration-time curve after the last dose in each treatment period",TREATMENT,MALE,2025-05-26,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06718998,PHASE1,RECRUITING,Obesity,NNC0519-0130,,RANDOMIZED,4,Arm 1: NNC0519-0130 | Arm 2: NNC0519-0130 | Arm 3: NNC0519-0130 | Arm 4: NNC0519-0130,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and people with excess body weight. This study will look at the safety and tolerability of NNC0519-0130. The purpose of this study is to investigate if different ways of increasing the dose of NNC0519-0130 in the main and extension phase can lessen the side effects that may occur when people take NNC0519-0130. There will be four different ways of increasing the dos,,2026-01-08,ESTIMATED,18 Years - 64 Years,114,ESTIMATED,PARALLEL,INDUSTRY,NONE,Evaluation of Different Dose Escalation Regimens for NNC0519-0130 in Participants With Overweight and Obesity,2026-01-08,ESTIMATED,Number of Adverse Events (AEs),TREATMENT,ALL,2024-11-20,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06789900,PHASE2,RECRUITING,Postmenopausal Women,Everolimus (Afinitor®),RapaLoad,RANDOMIZED,4,Control group | Football fitness group | Everolimus group | Everolimus and Football fitness group,NO_INTERVENTION | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"It is estimated that women lose around 20-25% of bone mass during the 5-10 years period of postmenopausal transition, and menopause is considered a major risk factor for osteoporotic fragility fracture. Currently, there is no preventive strategy to counteract these changes, and hormone replacement therapy is not considered an attractive option for many women, because of concerns related to side effects. Rapamycin, through inhibition of mTOR (the mechanistic target of Rapamycin) has been demonstr","Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark., OPEN - Odense Patient data Explorative Network, The University of Southern Denmark, Odense, Denmark, Novo Nordisk A/S",2025-07,ESTIMATED,45 Years - 60 Years,136,ESTIMATED,PARALLEL,OTHER,NONE,Targeting mTOR With Everolimus and/or Physical Training for Preventing Postmenopausal Bone Loss and Accelerated Skeletal Aging: The RapaLoad Study,2025-07,ESTIMATED,Procollagen type 1 N-terminal propeptide (P1NP),PREVENTION,FEMALE,2024-10-14,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06341179,,RECRUITING,"Sleep Duration, Child Obesity, Child Development, Child Behavior",,More2Sleep,RANDOMIZED,2,Sleep extension | Control,EXPERIMENTAL | NO_INTERVENTION,"More2Sleep is a randomized, controlled, parallel trial with two groups (sleep extension vs control) including 142 school-aged children (6-12 years) who have a BMI above average, defined as age- and sex-specific BMI Z-score above zero using WHO reference standards, and habitually sleep for ≤ 9 h/night. Data will be collected before and after a 3-month sleep extension intervention, and after a 6-month follow-up (at months 0, 3, and 9). The collection of data is mainly related to the main study. Ho","Novo Nordisk Foundation (NNF), Faculty of Health, Medicine and Life Sciences, Maastricht University, Center for Obesity Research & Education, Temple University, Danish Research Centre for Magnetic Resonance, University of Southern Denmark",2028-12-31,ESTIMATED,6 Years - 12 Years,142,ESTIMATED,PARALLEL,OTHER,NONE,A Randomized Controlled Trial of Sleep Extension to Regulate Body Weight and Improve Learning in School-aged Children,2027-12-31,ESTIMATED,BMI Z-score | Learning ability: skill learning | Learning ability: Explicit memory,TREATMENT,ALL,2024-08-13,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06122441,,ACTIVE_NOT_RECRUITING,"Lifestyle, Healthy, Muscle Weakness, Abdominal Obesity, Cardiometabolic Syndrome, Self Efficacy, Diet, Healthy",,RESTART,RANDOMIZED,2,Complex lifestyle intervention | Active control,EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of the RESTART RCT is to examine whether a complex lifestyle intervention, coordinated with municipal and non-government organizations (NGO), can establish and preserve improvements in risk factors and functional capacity among older adults at high risk of cardiometabolic disease. The main objectives to investigate are whether a complex lifestyle intervention, compared to an active control group, will at 24 months have:

1. Produced a clinically relevant increase in cardiorespiratory fi","The Research Council of Norway, Novo Nordisk A/S, Tromso Municipality, University Hospital of North Norway, University of Oslo, Molde University College, National Association for Heart and Lung Diseases, Tromso, Norway, Norwegian Trekking Association, KRAFT Sports Center",2027-06-30,ESTIMATED,60 Years - 75 Years,119,ACTUAL,PARALLEL,OTHER,SINGLE,RE-inventing Strategies for Healthy Ageing; Recommendations and Tools (RESTART) - a Randomized Controlled Trial Testing a Complex Lifestyle Intervention in Older Adults at Increased Risk for Cardiometabolic Disease,2026-06-30,ESTIMATED,Change from baseline in VO2max at month 24 | Change from baseline in VO2max at month 12 | Change from baseline in VO2max at month 6,PREVENTION,ALL,2024-01-15,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05723835,PHASE3,ACTIVE_NOT_RECRUITING,"SGA, Turner Syndrome, Noonan Syndrome, ISS",Somapacitan,REAL 9,,1,Somapacitan,EXPERIMENTAL,"The purpose of this study is to find out if somapacitan is safe and how well somapacitan works in children either born small for gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature. Somapacitan is a new growth hormone medicine for treatment of low level of growth hormone. The study will last for about 3 years. During the study, the participants will be treated with somapacitan once a week. Somapacitan can be injected anytime during the day. The study doctor or nu",,2027-10-29,ESTIMATED,10 Years - 18 Years,47,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Study Evaluating the Safety and Efficacy of Once-weekly Dosing of Somapacitan in a Basket Study Design in Paediatric Participants With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome or Idiopathic Short Stature",2024-06-07,ACTUAL,Number of Adverse Events (AEs) Reported in Children Born Small for Gestational Age- Weeks 0 to 26 | Number of Adverse Events Reported for Turner Syndrome (TS)- Weeks 0 to 26 | Number of Adverse Events Reported for Noonan Syndrome- Weeks 0 to 26 | Number of Adverse Events Reported for Idiopathic Short Stature (ISS)- Weeks 0 to 26,TREATMENT,ALL,2023-02-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06534411,PHASE3,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 2","Cagrilintide, Semaglutide, Tirzepatide",REIMAGINE 5,RANDOMIZED,2,CagriSema | Tirzepatide,EXPERIMENTAL | EXPERIMENTAL,"This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 ",,2026-07-14,ESTIMATED,18 Years - N/A,1023,ACTUAL,PARALLEL,INDUSTRY,NONE,"Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both",2026-06-02,ESTIMATED,Change in Glycated Haemoglobin (HbA1c) | Relative Change in Body Weight,TREATMENT,ALL,2024-11-05,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06137261,,ACTIVE_NOT_RECRUITING,"Obesity, Heart Failure",,SCOR(hf)E,RANDOMIZED,2,Participants randomized to HF screening | Participants randomized to standard care,EXPERIMENTAL | NO_INTERVENTION,"Rationale:

Obesity prevalence in Dutch adults increased to 14.2% in 2020. Obesity is strongly associated with cardiovascular disease, especially heart failure (HF). HF is a serious condition with significant morbidity and mortality. HF in people with obesity often remains undetected for a relatively long time, because symptoms are attributed to the obesity and not to possible HF. As a result, individuals seek help late for already advanced HF. Screening may reveal HF risk factors or a HF diagno","Erasmus Medical Center, Star-shl, De Leefstijlkliniek, Leefstijl Centrum Rotterdam, Voedingsadvies Broer, Biotronik SE & Co. KG, Boehringer Ingelheim, Sanofi, Novo Nordisk A/S",2026-07-08,ESTIMATED,45 Years - N/A,420,ESTIMATED,PARALLEL,OTHER,NONE,Screening Adults With Obesity to Reduce Heart Failure Events,2026-07-08,ESTIMATED,Number of participants with a combined endpoint of left ventricular dysfunction and/or heart failure,DIAGNOSTIC,ALL,2024-02-26,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06797869,PHASE2,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy","CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)",,RANDOMIZED,2,CagriSema | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a ""dummy"" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.",,2026-08-21,ESTIMATED,18 Years - N/A,142,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy,2026-08-21,ESTIMATED,Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS),TREATMENT,ALL,2025-01-29,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04398628,,RECRUITING,"Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease",,,,7,Hemophilia | Congenital Platelet Disorders | Von Willebrand Disease | Rare Disorders | Bleeding NOS | Thrombosis/Thrombophilia | Non-Neoplastic Hematologic Conditions, |  |  |  |  |  | ,"In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5

In 2019 a","Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., CSL Behring, Sanofi, Novo Nordisk A/S, Hemab ApS",2035-12,ESTIMATED,N/A - N/A,3000,ESTIMATED,,NETWORK,,"ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders",2035-06,ESTIMATED,"To determine the safety of therapies used in the treatment of participants with congenital or acquired non-neoplastic, bleeding and clotting disorders and connective tissue disorders with bleeding tendency (blood disorders).",,ALL,2020-09-30,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT05780905,PHASE4,RECRUITING,"Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack",Semaglutide Auto-Injector,,RANDOMIZED,2,Placebo | Active,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication.

Given th",Novo Nordisk A/S,2026-12-31,ESTIMATED,40 Years - 65 Years,50,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes,2026-03-31,ESTIMATED,Intracranial blood flow (IBF) | bloodbrain barrier Ktrans,SCREENING,ALL,2024-01-11,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07301034,PHASE3,RECRUITING,Myocardial Infarction,"Ziltivekimab, Ziltivekimab Placebo",ZEPHYR,RANDOMIZED,2,Ziltivekimab dose level 1 + standard of care (SOC) | Placebo + SOC,EXPERIMENTAL | PLACEBO_COMPARATOR,"The study is testing the effect of ziltivekimab on reducing plaque in the blood vessels of the heart, specifically aiming to manage or reduce atherosclerotic plaque. The purpose of the study is to determine whether ziltivekimab can effectively reduce this plaque. Participants will either receive ziltivekimab (the active medicine) or a placebo (a dummy medicine with no effect on the body), with the treatment assignment decided by chance. It is important to note that ziltivekimab is not yet approv",,2029-02-24,ESTIMATED,18 Years - N/A,332,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomography Imaging Study",2028-11-14,ESTIMATED,Change in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interest,TREATMENT,ALL,2025-12-18,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04639414,PHASE4,ACTIVE_NOT_RECRUITING,"Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)","Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Placebo matching empagliflozin and placebo pen injector matching semaglutide",COMBAT_T2_NASH,RANDOMIZED,3,Combined treatment with Empagliflozin and Semaglutide | Empagliflozin monotherapy | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm parallel group, interventional study is to assess for the first time the effects of either a combined therapy with the antihyperglycemic drugs semaglutide and empagliflozin or empagliflozin monotherapy compared to placebo as potential treatments for non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes.","Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S",2025-12,ESTIMATED,25 Years - 75 Years,192,ESTIMATED,PARALLEL,OTHER,TRIPLE,Combined Active Treatment in Type 2 Diabetes with NASH,2025-01-31,ESTIMATED,Histological resolution of NASH without worsening of fibrosis,TREATMENT,ALL,2021-03-26,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06577766,PHASE1,ACTIVE_NOT_RECRUITING,"Obesity, Overweight","NNC0638-0355, Placebo (NNC0638-0355)",,RANDOMIZED,2,NNC0638-0355 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in your body, and what your body does to the study medicine. Participants will either get the study medicine or placebo (a ""dummy medicine"" similar to the study medicine but without active ingredients) given as an injection under your skin. Which treatment the participants get is decided by chance. The study medicine is a potential new",,2026-09-24,ESTIMATED,18 Years - 55 Years,88,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Randomised, Placebo Controlled, Double Blinded Study Assessing the Safety, Tolerability and Pharmacokinetics of Single and Multiple Subcutaneous Doses of NNC0638-0355 in Participants With Overweight or Obesity",2026-03-23,ESTIMATED,"Part A: Number of treatment emergent adverse events (TEAE) | Part B,C,D : Number of treatment emergent adverse events (TEAE)",TREATMENT,ALL,2024-09-03,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05726227,PHASE3,ACTIVE_NOT_RECRUITING,Obesity,"Semaglutide, Placebo",STEP Young,RANDOMIZED,2,Group Kids | Group Teens,EXPERIMENTAL | EXPERIMENTAL,"This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a ""dummy"" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a ""dumm",,2026-12-07,ESTIMATED,6 Years - 18 Years,210,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight,2025-10-15,ACTUAL,Group Kids: Change in body mass index (BMI),TREATMENT,ALL,2023-07-07,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04822181,PHASE3,ACTIVE_NOT_RECRUITING,Non-alcoholic Steatohepatitis,"Semaglutide, Placebo",ESSENCE,RANDOMIZED,2,Semaglutide OW (once weekly ) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.

Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.

Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.

The study will last for about 5 years. Participants will have up to 21 clinic visits a",,2029-04-25,ESTIMATED,18 Years - N/A,1205,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis,2029-04-25,ESTIMATED,Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No) | Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis (Yes/No) | Part 2: Cirrhosis-free survival (Yes/No),TREATMENT,ALL,2021-04-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07276282,PHASE3,NOT_YET_RECRUITING,"Coronary Artery Disease, Acute Myocardial Infarction (AMI), Coronary Atherosclerosis of Native Coronary Artery","Ziltivekimab, Placebo",ZEPHYR,RANDOMIZED,2,Ziltivekimab Arm | Placebo Arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"Despite improvements in the treatment, coronary artery disease (CAD) remains one of the leading causes of death worldwide. Around 20% of people who have suffered a heart attack (myocardial infarction) need to be hospitalized again within a year, and 10% experience another heart attack. Despite currently available medication, patients remain at risk of further episodes after a heart attack. Scientists have discovered that inflammation in the body plays a decisive role in the development and narro","Novo Nordisk A/S, Insel Gruppe AG, University Hospital Bern, Cardialysis B.V.",2028-12-01,ESTIMATED,18 Years - N/A,332,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomography Imaging Study",2028-09-01,ESTIMATED,Change in percent atheroma volume,TREATMENT,ALL,2025-12-11,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05953584,PHASE2,RECRUITING,Sickle Cell Disease,"Etavopivat, Hydroxyurea",HIBISCUS 3,NON_RANDOMIZED,2,Etavopivat | Etavopivat with HU,EXPERIMENTAL | EXPERIMENTAL,"The study will test a new medicine, etavopivat, for sickle cell disease and see if it is safe and help-ful for participants with sickle cell disease who are at an increased risk of stroke. Participants will be divided into two cohorts depending on their transcranial doppler (TCD) ultrasound results and whether or not they receive hydroxyurea (medication that they may already be taking). In one cohort, participants with conditional transcranial doppler (TCD) or participants with abnormal TCD who ",,2027-09-20,ESTIMATED,12 Years - 16 Years,27,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke,2027-09-20,ESTIMATED,"Change in the highest TAMMV in any of the L/R internal carotid artery [ICA] and L/R middle cerebral artery [MCA], whichever is highest, as measured by TCD",TREATMENT,ALL,2023-06-20,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04873050,PHASE4,RECRUITING,"Pre Diabetes, Postpartum Disorder","Semaglutide Pen Injector [Ozempic], Placebo semaglutide pen injector",SWEET,RANDOMIZED,2,Semaglutide Pen Injector (Ozempic) | Placebo,EXPERIMENTAL | SHAM_COMPARATOR,The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.,Novo Nordisk A/S,2026-03-01,ESTIMATED,18 Years - 45 Years,102,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn with a Recent History of Gestational DiabETes Mellitus: the SWEET Study",2026-01-01,ESTIMATED,Regression to normoglycemia,TREATMENT,FEMALE,2022-01-13,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04624659,PHASE3,ACTIVE_NOT_RECRUITING,Sickle Cell Disease,"Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets",HIBISCUS,RANDOMIZED,4,Double blind etavopivat Low Dose | Double blind etavopivat High Dose | Double blind placebo | Open label etavopivat,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).,This study is currently undergoing a sponsor transition from Forma to Novo Nordisk. Sponsor field will be updated once the transition is complete.,2027-03-19,ESTIMATED,12 Years - 65 Years,450,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)",2026-02-20,ESTIMATED,Hemoglobin response rate | Annualized vaso-occlusive crisis,TREATMENT,ALL,2021-01-29,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04082429,PHASE3,ACTIVE_NOT_RECRUITING,"Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors",Concizumab,explorer8,RANDOMIZED,4,Arm 1: No prophylaxis (PPX) | Arm 2: Concizumab prophylaxis | Arm 3: Concizumab prophylaxis | Arm 4: Concizumab prophylaxis,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use. Participants who usually only take medicine to treat bleeds (on-demand) will be placed in one of two groups. In one group participants will get study medicine from the start of the study. In the other group participants will continue with their normal medicine and get study ,,2028-02-21,ESTIMATED,12 Years - N/A,156,ACTUAL,PARALLEL,INDUSTRY,NONE,Efficacy and Safety of Concizumab Prophylaxis in Patients With Haemophilia A or B Without Inhibitors,2022-07-12,ACTUAL,Haemophilia A Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding Episodes | Haemophilia B Participants Without Inhibitors: Rate of Treated Spontaneous and Traumatic Bleeding Episodes,TREATMENT,MALE,2019-11-13,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07184632,PHASE2,RECRUITING,"Overweight, Obesity","NNC0662-0419, Placebo",,RANDOMIZED,2,NNC0662-0419 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but ha",,2026-12-01,ESTIMATED,18 Years - 65 Years,220,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Study Investigating Safety, Tolerability and Efficacy of Once-weekly NNC0662-0419 in Participants Living With Overweight or Obesity",2026-12-01,ESTIMATED,Part A: Number of treatment-emergent adverse events (TEAE) | Part B: Relative change in body weight | Part C: Occurrence of premature treatment discontinuation (Yes/No),TREATMENT,ALL,2025-10-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07207811,PHASE3,RECRUITING,Transthyretin Amyloid Cardiomyopathy (ATTR CM),"NNC6019-0001, Placebo (NNC6019-0001)",CLEOPATTRA,RANDOMIZED,2,NNC6019-0001 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.",,2029-06-29,ESTIMATED,18 Years - N/A,1280,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM),2029-06-29,ESTIMATED,Number of occurrences of composite endpoint of cardiovascular (CV) deaths and recurrent CV events (CV hospitalisations and urgent heart failure [HF] visits),TREATMENT,ALL,2025-10-02,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05768958,,ACTIVE_NOT_RECRUITING,"Overweight and Obesity, Type 2 Diabetes",,TIMEX,RANDOMIZED,4,Morning exercise | Morning control | Evening exercise | Evening control,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The overall aim is to investigate effects of acute exercise on ad libitum energy intake and study whether this differs between morning and evening in individuals with overweight/obesity with or without type 2 diabetes (T2D). Furthermore, the aim is to examine the role of hedonic and homeostatic drivers of appetite control in obesity and T2D in the context of meal and exercise timing.","University of Leeds, Novo Nordisk A/S",2026-07-31,ESTIMATED,18 Years - 75 Years,58,ESTIMATED,CROSSOVER,OTHER,NONE,Hedonic and Homeostatic Appetite Control in Obesity and Type 2 Diabetes in the Context of Meal and Exercise Timing,2024-08-21,ACTUAL,Ad libitum energy intake (KJ) after exercise compared with rest,TREATMENT,ALL,2023-03-22,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06200207,PHASE3,RECRUITING,"Heart Failure, Systemic Inflammation","Ziltivekimab, Placebo",ATHENA,RANDOMIZED,2,Ziltivekimab | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicin,,2027-01-10,ESTIMATED,18 Years - N/A,680,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation,2026-10-05,ESTIMATED,Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS),TREATMENT,ALL,2024-04-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06780449,PHASE3,ACTIVE_NOT_RECRUITING,Obesity,"Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide",,RANDOMIZED,2,CagriSema | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look at how well CagriSema helps people with obesity lose weight compared to a ""dummy medicine"". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or ""dummy medicine"". Which treatment participants get is decided by ",,2028-10-31,ESTIMATED,18 Years - N/A,400,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity,2028-08-28,ESTIMATED,Relative change in body weight,TREATMENT,ALL,2025-02-10,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07395687,PHASE2,RECRUITING,"Overweight, Obesity","UBT251, Placebo",,RANDOMIZED,11,Part A - UBT251 | Part A - placebo | Part B - Arm A (UBT251) | Part B - Arm B (UBT251) | Part B - Arm C (UBT251) | Part B - Arm D (UBT251) | Part B - Arm E (UBT251) | Part B - placebo | Part C - UBT251 dose 1 | Part C - UBT251 dose 2 | Part C - UBT251 dose 3,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.",,2027-02-18,ESTIMATED,18 Years - 65 Years,333,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity",2027-01-14,ESTIMATED,Part A - Number of treatment emergent adverse events (TEAEs) | Part B - Relative change in body weight | Part C- AUC; the area under the UBT251 plasma concentration time curve,TREATMENT,ALL,2026-02-02,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06291805,,RECRUITING,"Transthyretin Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Quality of Life",,,,2,wtATTR-CM patients (n = 100) | Control (n = 20), | ,Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.,Novo Nordisk A/S,2025-12,ESTIMATED,18 Years - N/A,120,ESTIMATED,,OTHER,,Phenotyping and Characterization of Danish Wild-type Transthyretin Amyloidosis Cardiomyopathy Patients: A Cross-sectional Study,2025-12,ESTIMATED,Investigation of cardiac amyloidosis severity in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy. | Investigation of the relations between cardiac amyloid severity and patient quality of life in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy. | Assessment of transthyretin and pathogenic fragments and relation to cardiac amyloid severity in patients with Wild-type Transthyretin Amyloidosis Cardiomyopathy,,ALL,2024-02-20,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06222151,,RECRUITING,"Postoperative Pain, Acute, Postoperative Pain, Chronic, Bariatric Surgery, Mobilization, Physical Activity",,,RANDOMIZED,4,A | B | C | D,EXPERIMENTAL | OTHER | OTHER | ACTIVE_COMPARATOR,"The aim is to investigate the effect of early initiated and supervised mobilization continued after discharge as management of postoperative pain and recovery following obesity surgery, including patient experiences, pain coping, physical functionality and quality of life.",Novo Nordisk A/S,2027-02-01,ESTIMATED,18 Years - 70 Years,112,ESTIMATED,PARALLEL,OTHER,NONE,Recovering From Bariatric Surgery: the Effects of Early Initiated and Supervised Mobilization,2027-02-01,ESTIMATED,Abdominal pain | Physical function,TREATMENT,ALL,2024-04-22,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06185296,,RECRUITING,Type 2 Diabetes Treated With Insulin,,DiaTRUST,RANDOMIZED,3,Intelligent telemonitoring | Telemonitoring | Usual care,EXPERIMENTAL | ACTIVE_COMPARATOR | NO_INTERVENTION,"The trial is an open-label, randomized controlled trial. Patients with T2D on insulin therapy will be randomized to an intelligent telemonitoring group (intervention), a telemonitoring group (control), and a usual care group (control). Both the intelligent telemonitoring group and the telemonitoring group will use various devices at home. Hospital staff will monitor their data for three months. In the intelligent telemonitoring group, hospital staff and participants will be supported by decision","Novo Nordisk A/S, DexCom, Inc.",2026-09,ESTIMATED,18 Years - N/A,51,ESTIMATED,PARALLEL,OTHER,NONE,The Intelligent Diabetes TelemonitoRing Using Decision Support to Treat Patients on Insulin Trial: Study Protocol for a Randomized Controlled Trial,2026-09,ESTIMATED,CGM time in range,TREATMENT,ALL,2025-11-15,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07184086,PHASE1,RECRUITING,Obesity,CagriSema (Cagrilintide B + semaglutide I),,RANDOMIZED,2,CagriSema (Cagrilintide + Semaglutide) / CagriSema | Low Energy Diet (LED) / CagriSema,EXPERIMENTAL | EXPERIMENTAL,"In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been tested in humans. The study is split into 2 parts. In the first part of the study, participants will either get CagriSema or a weight loss diet (calorie reduced). In the second part of the study,all participants will get Cagr",,2027-10-12,ESTIMATED,18 Years - 65 Years,80,ESTIMATED,PARALLEL,INDUSTRY,NONE,The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study,2027-10-12,ESTIMATED,Change in sleeping metabolic rate (SMR),TREATMENT,ALL,2025-09-26,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06269120,,RECRUITING,Type 2 Diabetes,Oral Semaglutide,,,1,Patients with type 2 diabetes,,Participant will get oral semaglutde as prescribed by the study doctor. The study will last for about 26 ± 4 weeks (5 to 7 months). Participant will be asked to complete a questionnaire about how they take oral semaglutide tablets during normal scheduled visit with doctor. Participant will also be asked questions about health and their diabetes treatment and lab tests as part of normal doctor's appointment.,,2026-03-31,ESTIMATED,18 Years - N/A,470,ESTIMATED,,INDUSTRY,,"SEMA-CardioDiab HUNGARY: A Multicentre, Prospective, Non-interventional Study to Evaluate Glycemic Control and Weight Changes in Patients With Type 2 Diabetes Initiating Treatment With Oral Semaglutide by Cardiologists or Diabetologists as Part of Local Clinical Practice in Hungary",2026-03-31,ESTIMATED,Glycated haemoglobin (HbA1c ) reduction greater than or equal to (≥) 0.5%-point and body weight reduction ≥ 5%,,ALL,2024-09-30,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT07270731,PHASE1,RECRUITING,"Healthy Volunteer, Type 2 Diabetes","NNC9733-0001, Placebo",,RANDOMIZED,2,NNC9733-0001 | Placebo,EXPERIMENTAL | EXPERIMENTAL,This study is testing a new medicine that might help treat people with type 2 diabetes. The study is conducted to see if the new medicine can lower high sugar levels in the blood. The purpose of the study is to see if the new study medicine is safe and how well is tolerated by the body. There will be two groups of partici-pants in this study: healthy participants and participants with type 2 diabetes. Participant will either get study medicine (NNC9733-0001) or placebo (a treatment that has no a,,2027-11-12,ESTIMATED,18 Years - 64 Years,72,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"Investigation of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics of Single Administrations of NNC9733-0001 in Healthy Participants and in Participants With Type 2 Diabetes",2027-08-30,ESTIMATED,Number of treatment emergent adverse events (TEAEs) | Number of hypoglycaemic events,TREATMENT,ALL,2025-11-25,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07339423,PHASE3,NOT_YET_RECRUITING,Obesity,"NNC0487-0111, Placebo (matched to NNC0487-0111)",AMAZE 1,RANDOMIZED,2,NNC0487-0111 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.,,2029-08-21,ESTIMATED,18 Years - N/A,1150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity (AMAZE 1),2029-06-26,ESTIMATED,Relative change in body weight,TREATMENT,ALL,2026-02-24,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05567796,PHASE3,ACTIVE_NOT_RECRUITING,Obesity,"Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide",REDEFINE 1,RANDOMIZED,4,Cagrisema | Cagrilintide | Semaglutide | Placebo s.c.,EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a ""dummy"" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSem",,2026-10-19,ESTIMATED,N/A - N/A,3400,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity,2024-10-30,ACTUAL,CagriSema versus placebo: Relative change in body weight | CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction,TREATMENT,ALL,2022-11-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05350592,PHASE2,ACTIVE_NOT_RECRUITING,"Acute Myocardial Infarction, Cardiogenic Shock","Tocilizumab, Dobutamine, NaCl 0.9%",DOBERMANN,RANDOMIZED,4,Tocilizumab + Dobutamine | Tocilizumab + Placebo | Placebo + Dobutamine | Placebo + Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"In the present study, we aim to investigate the effects of dobutamine infusion and/or a single intravenous (IV) dose of the IL-6 antagonist Tocilizumab administered after percutaneous coronary intervention (PCI) to patients with acute myocardial infarction (AMI) presenting \< 24 hours from onset of chest pain and an intermediate to high risk of cardiogenic shock (CS) by assessment with the ORBI risk score (≥10 - not in overt shock at hospital admission).

Plasma concentrations of pro-B-type natr","Novo Nordisk A/S, Simon Spies Fonden, Helge Peetz og Verner Peetz og hustru Vilma Peetz Legat",2025-09-30,ESTIMATED,18 Years - N/A,100,ACTUAL,FACTORIAL,OTHER,QUADRUPLE,"Low-dose Dobutamine Infusion and Single-dose Tocilizumab in Acute Myocardial Infarction Patients With High Risk of Cardiogenic Shock Development - a 2x2 Multifactorial, Double-blinded, Randomized, Placebo Controlled Trial",2025-06-30,ACTUAL,ProBNP,TREATMENT,ALL,2022-03-13,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07187830,,NOT_YET_RECRUITING,"Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight",,ADIPOLIVE,,2,No semaglutide | Semaglutide, | ,"Obesity is considered a global pandemic and is associated with various diseases and metabolic complications, such as type 2 diabetes mellitus, high blood pressure, cholesterol disorders, cancer, cardiovascular disease, and kidney disease. Obesity can affect the kidneys in two main ways: indirectly, through mechanisms related to diabetes mellitus and/or high blood pressure, and directly, through complex proteins called ""adipokines,"" which are produced by adipocytes.

Many of these adipokines are ",Novo Nordisk Canada Inc.,2028-01-15,ESTIMATED,18 Years - N/A,52,ESTIMATED,,OTHER,,Region-specific Adipose Tissues and Liver Changes Associated With Semaglutide Treatment in Chronic Kidney Disease Patients,2027-12-15,ESTIMATED,Correlation between kidney disease progression and cardiometabolic changes,,ALL,2026-02-15,ESTIMATED,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06612268,PHASE3,RECRUITING,Sickle Cell Disease,"Etavopivat, Placebo",Hibiscus 2,RANDOMIZED,2,Etavopivat | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the par",,2029-03-12,ESTIMATED,12 Years - N/A,408,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease",2027-08-27,ESTIMATED,Number of adjudicated Vaso-occlusive crisis (VOC) events with a medical contact,TREATMENT,ALL,2025-02-17,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07160816,,RECRUITING,"Diabetes Mellitus, Type 1",Insulin icodec,,,1,Insulin icodec,,"The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 1 diabetes (T1D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.",,2027-01-20,ESTIMATED,18 Years - N/A,245,ESTIMATED,,INDUSTRY,,"A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Use of Insulin Icodec in People Living With Type 1 Diabetes",2027-01-20,ESTIMATED,Change in glycated haemoglobin (HbA1c),,ALL,2025-08-28,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT05330325,PHASE3,ACTIVE_NOT_RECRUITING,"SGA, Turner Syndrome, Noonan Syndrome, ISS","Somapacitan, Norditropin®",REAL 8,RANDOMIZED,2,Somapacitan | Norditropin®,EXPERIMENTAL | ACTIVE_COMPARATOR,"The study compares two medicines for treatment of children born small and who stay small, or with Turner Syndrome, Noonan Syndrome, or idiopathic short stature. The purpose of the study is to see how well treatment with somapacitan works compared to treatment with Norditropin®. Somapacitan is a new medicine, and Norditropin® is a medicine doctors can already prescribe in some countries. The study will last for upto 5.5 years. The participants will either get somapacitan once a week up to 5.5 yea",,2027-10-29,ESTIMATED,2 Years - 10 Years,399,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Study Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® as Well as Evaluating Long-term Safety of Somapacitan in a Basket Study Design in Children With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature",2024-08-05,ACTUAL,"Height velocity reported separately for small for gestational age (SGA), Turner syndrome (TS), Noonan syndrome (NS) and idiopathic short stature (ISS)",TREATMENT,ALL,2022-08-10,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07153172,PHASE1,RECRUITING,Obesity,INV-347,,,1,Participants from the study INV-CL-108,EXPERIMENTAL,The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last for about 2 years.,,2027-09-15,ESTIMATED,18 Years - N/A,91,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Safety Follow-up Study of Participants Previously Dosed With INV-347 in the First-in-Human Study INV-CL-108,2027-09-15,ESTIMATED,Number of adverse events,OTHER,ALL,2025-08-06,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07225816,PHASE1,RECRUITING,Obesity,"Liraglutide, Oral Semaglutide, Semaglutide",,NON_RANDOMIZED,3,Liraglutide | Oral semaglutide | Semaglutide,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.",,2026-07-17,ESTIMATED,18 Years - N/A,75,ESTIMATED,PARALLEL,INDUSTRY,NONE,"Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide",2026-06-19,ESTIMATED,"Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No) | Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of oral semaglutide once daily (Yes/No) | Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of s.c. semaglutide once weekly (Yes/No)",TREATMENT,ALL,2025-11-07,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT04777409,PHASE3,ACTIVE_NOT_RECRUITING,Early Alzheimer´s Disease,"Semaglutide, Placebo (semaglutide)",EVOKE Plus,RANDOMIZED,2,Oral semaglutide | Placebo (semaglutide),EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.

Participants will either get semaglutide or placebo (a ""dummy"" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.

The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10",,2026-01-23,ESTIMATED,55 Years - 85 Years,1840,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus),2025-09-15,ACTUAL,Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score,TREATMENT,ALL,2021-05-18,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06571383,PHASE4,ACTIVE_NOT_RECRUITING,Obesity,Semaglutide,,,1,Semaglutide,EXPERIMENTAL,"The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.",,2031-11-15,ESTIMATED,12 Years - 15 Years,500,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c.2.4 mg Once-weekly,2028-11-15,ESTIMATED,Maintenance of Body Mass Index (BMI) below obesity threshold,TREATMENT,ALL,2024-09-17,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07379684,PHASE1,RECRUITING,"Surgical Wound Infection, Traumatic Wound Infection","Amicidin-β topical solution - 15 mL, Amicidin-β topical solution - 50 mL, Standard of Care (SOC)",,RANDOMIZED,4,SOC + Amicidin-β topical solution - 15 mL | SOC + Amicidin-β topical solution - 50 mL - Scheme 1 | SOC + Amicidin-β topical solution - 50 mL - Scheme 2 | SOC,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this Phase 1 clinical trial is to learn about the safety profile of Amicidin-β topical solution applied directly into infected surgical or traumatic wounds during a surgical procedure. The main questions it aims to answer are:

1. Is Amicidin-β topical solution safe to test in larger clinical trials?
2. Is Amicidin-β topical solution absorbed into the bloodstream from local wound application?
3. Is Amicidin-β topical solution easy for the surgeon to use? Participants will receive eit","Biomedical Advanced Research and Development Authority, Novo Nordisk Foundation (NNF23SA0088536), Global Antimicrobial Resistance Innovation Fund-(GAMRIF), US NIH Grant/Contract Award Number: HHS/BARDA OTA No. 75A50122C00028, Wellcome Trust 224842/Z/21/Z, Germany's Federal Ministry of Education and Research (BMBF) Agreement Dated 1/30/23, UK Secretary of State for Health and Social Care (""DHSC""), Agreement dated 02/28/2023",2026-10-28,ESTIMATED,18 Years - 75 Years,44,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,A Phase 1 Study to Assess Safety and Tolerability of Amicidin-β Topical Solution in Adult Patients Undergoing Interventional Management of a Surgical or Traumatic Wound Infection,2026-10-28,ESTIMATED,Overall comparison of treatment emergent adverse events (TEAES) of combined SOC + Amicidin-β topical solution recipients to SOC only recipients across 3 cohorts.,TREATMENT,ALL,2026-02-02,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07220642,PHASE3,ACTIVE_NOT_RECRUITING,"Obesity, Overweight","Cagrilintide, Placebo",RENEW 1,RANDOMIZED,2,Cagrilintide | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look at how much cagrilintide helps people with overweight or obesity lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participants will either get cagrilintide or placebo. Which treatment participants get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. Possible side effects will be followed carefully duri",,2027-06-29,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity,2027-05-11,ESTIMATED,Relative change in body weight | Number of participants with achievement of greater than or equals (>=) 5 percent (%) body weight reduction,TREATMENT,ALL,2025-11-05,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07052292,,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2",,,,1,DuraTouch® (Insulin injection),,"This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.",,2026-01-02,ESTIMATED,N/A - N/A,125,ESTIMATED,,INDUSTRY,,DuraTouch® - Post-Market Clinical Follow-up (PMCF) Study in a Real-world Setting,2026-01-02,ESTIMATED,"Participant rating the ease of use, convenience and satisfaction with the device",,ALL,2025-07-01,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06421467,,NOT_YET_RECRUITING,Diabetes,,,,0,,,"In this era of pharmaceutical and technological advancements, gaining insights into prevalent insulin administration practices under real-life conditions becomes pivotal for healthcare professionals. The investigators aim to explore insulin injection habits through an online survey among a broad, unselected group of participants with type 1 and type 2 diabetes undergoing daily prandial and/or basal insulin treatment. Eligible participants will access and complete the survey at their convenience ",Novo Nordisk A/S,2024-10,ESTIMATED,18 Years - N/A,400,ESTIMATED,,OTHER,,Insulin Injection Practices in People With Diabetes in Spain,2024-10,ESTIMATED,Number of total insulin injections | Number of prandial insulin injections | Number of basal insulin injections | Timing of prandial insulin injection | Time interval before prandial insulin injection | Time interval after prandial insulin injection | Insulin overdosing | Insulin underdosing | Insulin administration site | Site rotation | Change of the insulin needle | Use of smart pens | Type of prandial insulin | Daily dose of prandial insulin | Type of basal insulin | Daily dose of basal insulin | Last HbA1c | Date of last HbA1c | Diabetic ketoacidosis | Hypoglycemic episodes | Hyperglycemic episodes | Age of diabetes onset | Self-monitoring of capillary glucose | Glucose monitoring in real-time or intermittently scanned | Lack of daily glucose monitoring | Lack of correction based on glucose values | Time in Range (%TIR) | Time Below Range (%TbR) | Time Above Range (%TaR) | Mean glucose (mg/dL) | Coefficient of variation of continuous glucose sensor values (CV),,ALL,2024-07,ESTIMATED,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT05636176,PHASE3,RECRUITING,Heart Failure,"Ziltivekimab, Placebo",HERMES,RANDOMIZED,2,Ziltivekimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to u,,2027-07-02,ESTIMATED,18 Years - N/A,5600,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation,2027-07-02,ESTIMATED,"Time to First Occurrence of a Composite Heart Failure Endpoint Consisting of: Cardiovascular (CV) Death, Heart Failure (HF) Hospitalisation or Urgent HF Visit",TREATMENT,ALL,2023-05-08,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07271251,PHASE3,RECRUITING,Type 2 Diabetes,Oral semaglutide,,RANDOMIZED,2,Oral semaglutide D | Oral semaglutide,EXPERIMENTAL | EXPERIMENTAL,"The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the n",,2026-08-21,ESTIMATED,18 Years - N/A,264,ESTIMATED,PARALLEL,INDUSTRY,NONE,A Study Investigating Clinical Comparability of Two Formulations of Oral Semaglutide in Japanese Participants With Type 2 Diabetes,2026-08-21,ESTIMATED,Change in glycated haemoglobin (HbA1c).,TREATMENT,ALL,2025-12-01,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06574984,,RECRUITING,"Congenital Bleeding Disorder, Haemophilia A",Turoctocog alfa,,,1,Turoctocog alfa,,"The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement thera",,2026-04-30,ESTIMATED,N/A - N/A,900,ESTIMATED,,INDUSTRY,,Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study,2026-02-27,ESTIMATED,Annual bleeding Rate (ABRs) among patients treated with different regimen of turoctocog alfa after previous FVIII replacement therapy,,MALE,2024-11-10,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT07305805,PHASE1,RECRUITING,"Diabetes Mellitus, Type 1",NNC0363-1063,,RANDOMIZED,4,Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The purpose of this clinical study is to find out how the novel insulin NNC0363-1063 and a non-glucose carbohydrate used in food and beverage might interact in participants with type 1 diabetes and if co-administration of these substances is safe and tolerable. All participants will get a fixed dose of NNC0363-1063 and an oral administration of different amounts of the non-glucose carbohydrate in a random order during 4 interaction tests. The participants will be in this clinical study for about,,2026-05-21,ESTIMATED,18 Years - 64 Years,36,ESTIMATED,CROSSOVER,INDUSTRY,NONE,A Multiple Dose Study Investigating Pharmacodynamics and Pharmacokinetics of Subcutaneous NNC0363-1063 in Participants With Type 1 Diabetes,2026-05-17,ESTIMATED,"AUC, GIR,SS: Area under the glucose infusion rate-time curve at steady state",TREATMENT,ALL,2025-12-15,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05714683,,NOT_YET_RECRUITING,"Diabetes Mellitus, Type 2",Semaglutide,,,1,Participants with T2DM,,The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.,,2026-10-30,ESTIMATED,19 Years - N/A,600,ESTIMATED,,INDUSTRY,,"A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea",2026-10-30,ESTIMATED,Number (Incidence) of adverse events (AEs),,FEMALE,2025-12-31,ESTIMATED,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT07157423,PHASE4,RECRUITING,Severe Postpartum Haemorrhage,Eptacog alfa (NovoSeven),,NON_RANDOMIZED,1,Eptacog alfa (NovoSeven),EXPERIMENTAL,"This study will look at how safe is the medicine eptacog alfa when used in women in India for stopping heavy bleeding after giving birth. If participants have heavy bleeding after giving birth then they will get the medicine eptacog alfa. This study will be conducted to get more knowledge on the safety of the medicine eptacog alfa use in these women. At first participants will receive one dose of medicine eptacog alfa. If the given dose is not helpful to stop the bleeding, participants will get ",,2027-03-26,ESTIMATED,18 Years - N/A,64,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Safety of Eptacog Alfa in Severe Postpartum Haemorrhage in India: A Phase IV Interventional Study,2027-03-26,ESTIMATED,Number of thromboembolic events,TREATMENT,FEMALE,2025-08-26,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05621746,,RECRUITING,Haemophilia A,Esperoct,,,1,Participants with Haemophilia A,,This study will collect information on the long term health of joints in people with haemophilia A who have started treatment with Esperoct within twelve months prior to participation to the study. This study is conducted to look at how joint health of people with haemophilia changes over time when they are receiving the medicine Esperoct. The participants will get Esperoct as prescribed to the participants by the study doctor. The participant's treatment will not be affected by their involvemen,,2026-06-30,ESTIMATED,18 Years - N/A,100,ESTIMATED,,INDUSTRY,,Non-Interventional Study of the Change in Joint Health in Adult Patients With Haemophilia A After Switching to Prophylaxis With Turoctocog Alfa Pegol (N8-GP),2026-06-30,ESTIMATED,Change in haemophilia joint health score (HJHS),,MALE,2022-11-23,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT03878446,PHASE2,ACTIVE_NOT_RECRUITING,Short Stature Children Born Small for Gestational Age (SGA),"Somapacitan, Norditropin®",,RANDOMIZED,5,Somapacitan 0.24 mg/kg/week | Somapacitan 0.20 mg/kg/week | Somapacitan 0.16 mg/kg/week | Norditropin® 0.035 mg/kg/day | Norditropin® 0.067 mg/kg/day,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).

Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once ",,2026-12-23,ESTIMATED,2 Years - 11 Years,62,ACTUAL,PARALLEL,INDUSTRY,NONE,A Dose-finding Trial Evaluating the Effect and Safety of Once-weekly Treatment of Somapacitan Compared to Daily Norditropin® in Children With Short Stature Born Small for Gestational Age With no Catch-up Growth by 2 Years of Age or Older,2021-05-05,ACTUAL,Height Velocity,TREATMENT,ALL,2019-07-04,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06403761,PHASE1,ACTIVE_NOT_RECRUITING,"Diabetes Mellitus, Type 2","Semaglutide, Cagrilintide, Placebo semaglutide, Placebo cagrilintide",,RANDOMIZED,4,CagriSema | Semaglutide | Cagrilintide | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors may not yet prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a ''dummy'' medicine. Which treatment the participants will get is decided by chance. Participants will get the study medicine together w",,2026-02-13,ESTIMATED,18 Years - 75 Years,150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Effect of CagriSema, Semaglutide and Cagrilintide on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes",2026-01-05,ESTIMATED,To compare the effect of CagriSema versus placebo: Change in M-value in hyperinsulinaemic euglycaemic clamp (HEC),TREATMENT,ALL,2024-05-06,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT03496883,PHASE3,ACTIVE_NOT_RECRUITING,Intracerebral Hemorrhage,"Recombinant Activated Factor VII (rFVIIa), Placebo",FASTEST,RANDOMIZED,2,Recombinant Activated Factor VII (rFVIIa) | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m","Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS)",2028-01-01,ESTIMATED,18 Years - 80 Years,860,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial,2028-01-01,ESTIMATED,Modified Rankin Scale (mRS),TREATMENT,ALL,2021-12-03,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05651724,,RECRUITING,"MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver, Steatosis of Liver, Type 2 Diabetes, Obesity, Metabolic Syndrome, Arterial Hypertension",,GRIPonMASH,,0,,,"GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepati","UMC Utrecht, Echosens, MIMETAS BV, Nordic Bioscience A/S, Elevate BV, Leiden University, Amsterdam University Medical Center, Andaluz Health Service, National Research Council, Institute of Clinical Physiology, Italy, Leiden University Medical Center, Université Libre de Bruxelles, University Hospital, Antwerp, Catholic University of the Sacred Heart, Medical Education Research And Innovation Center S.R.L., EUROPEAN LIVER PATIENTS ASSOCIATION, Harokopio University, General University Hospital, Prague, Novo Nordisk A/S, Maastricht University, Mercodia Aktiebolag, EXIT071 BV, European Atherosclerosis Society, MetaDeq Limited, Associação para Investigação e Desenvolvimento da Faculdade de Medicina, Institute of Cardiometabolism and Nutrition, France, University Hospital, Saarland, Roche Pharma AG, Inventiva Pharma, Biocellvia, Franciscus Gasthuis & Vlietland (Hospital)",2031-03-31,ESTIMATED,18 Years - 75 Years,10000,ESTIMATED,,INDUSTRY,,Global Research Initiative for Patients Screening on MASH - Implementation of an International Transmural Patient Care Pathway,2031-03-31,ESTIMATED,"Prevalence of liver steatosis and MASLD estimated by FibroScan CAP in patients at risk | Prevalence of liver fibrosis estimated by FibroScan LSM in patients at risk | Prevalence of at-risk MASH estimated by FAST score in patients at risk | *Subset of patients: prevalence of MASH in patients at risk | Comparison of the prevalence of MASLD, liver fibrosis and (at-risk) MASH between the participating countries | Evaluate added value of a 2-step pathway as compared to FibroScan only for detection of high-risk patients",,ALL,2023-06-30,ACTUAL,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06891365,PHASE1,RECRUITING,"Healthy Volunteers, Hepatic Steatosis","NNC0581-0001, Placebo (NNC0581-0001)",,RANDOMIZED,2,Cohort 1: NNC0581-0001 (Dose 1) | Cohort 2: NNC0581-0001 (Dose 2),EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis (increased liver fat and suspected inflammation). NNC0581-0001 will be given in 2 different dose levels as injection under the skin (once per month for 3 months). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance. NNC0581-0001 is a new medicine which ca",,2027-01-25,ESTIMATED,18 Years - 64 Years,48,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Investigation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of NNC0581-0001 in Participants With Hepatic Steatosis and Suspected Steatohepatitis",2027-01-25,ESTIMATED,Number of treatment emergent adverse events (TEAEs),TREATMENT,ALL,2025-03-12,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT05857319,,NOT_YET_RECRUITING,"Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2, Sleep Apnea, Obstructive, NAFLD, NASH",,SCOOP-RNPC,,4,General Cohort | Connected Objects Group | Obstructive Sleep Apnea Syndrome (OSAS) Group | Neuropathies Group, |  |  | ,"The investigators hypothesize that weight loss obtained with the French RNPC weight reduction program is beneficial for the general health of overweight/obese patients in the medium term.

The objective of this cohort study is to demonstrate the effectiveness of the RNPC program on the reduction of drug or instrumental treatments (for example, continuous positive pressure ventilation for the treatment of sleep apnea syndrome) and the improvement of overweight/obesity-associated comorbidities in ","University Grenoble Alps, Novo Nordisk A/S, Lyon Est University",2030-07-15,ESTIMATED,18 Years - 85 Years,10000,ESTIMATED,,INDUSTRY,,"Assessment of the Impact of Short, Medium and Long-term Weight Loss, Obtained by a Standardized Nutritional and Psycho-Behavioral Rehabilitation Program (RNPC Program) and in Real Life Conditions, in Obese or Overweight Patients",2030-07-15,ESTIMATED,Effectiveness of the national RNPC weight reduction program on the change of treatments (drug or instrumental treatments) or in the comorbidities of overweight/obesity.,,ALL,2023-07-15,ESTIMATED,OBSERVATIONAL
NVO,Novo Nordisk A/S,NCT06260709,PHASE2,ACTIVE_NOT_RECRUITING,Transthyretin Amyloid Cardiomyopathy (ATTR CM),NNC6019-0001,,,1,NNC6019-0001,EXPERIMENTAL,"This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called ""A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis"". Only participants who have completed that study",,2028-08-15,ESTIMATED,18 Years - 85 Years,80,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Open-label Extension Study of Long-term Safety and Efficacy of NNC6019-0001 in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM),2028-02-29,ESTIMATED,Number of Treatment Emergent Adverse Events,TREATMENT,ALL,2024-02-20,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07068295,PHASE1,RECRUITING,"Diabetes Mellitus, Type 2","NNC0471-0119 H, Insulin Aspart",,RANDOMIZED,2,NNC0471-0119 H then Insulin Aspart | Insulin Aspart then NNC0471-0119 H,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump. The study tests how fast insulin NNC0471-0119 enters bloodstream, how long it stays there and how much it lowers blood sugar. The new insulin NNC0471-0119 will be compared to insulin aspart. The study will last for about 13-67 days (or a half to 2 months).",,2026-01-12,ESTIMATED,18 Years - 69 Years,65,ESTIMATED,CROSSOVER,INDUSTRY,QUADRUPLE,A Study Investigating the Pharmacokinetic and Pharmacodynamic Properties and Safety and Tolerability of NNC0471-0119 H When Administered as Bolus in a Continuous Subcutaneous Insulin Infusion Regimen in Participants With Type 2 Diabetes,2026-01-12,ESTIMATED,"AUC(GIR,0-1h,basal-corrected): Area under the basal-corrected glucose infusion rate (GIR)-time curve from 0 to 1 hour",TREATMENT,ALL,2025-07-11,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07218627,PHASE1,RECRUITING,Heart Failure,"NNC0537-1482, Placebo",,RANDOMIZED,7,Cohort 1A | Cohort 2A | Cohort 3A | Cohort 4A | Cohort 5A | Cohort B | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The study is testing a new drug (NNC0537-1482) to potentially treat people with heart failure. The purpose of the study is to see if NNC0537-1482 is safe and how it works in the body. Participants will either get NNC0537-1482 or placebo (a ""dummy drug"" without any active ingredients) and which treatment they get is decided by chance. This study will last up to 64 days with an additional screening period up to 28 days.",,2027-01-15,ESTIMATED,40 Years - 75 Years,36,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Randomised, Placebo-controlled, Double-blinded Phase 1b Study Investigating Safety, Tolerability, Pharmacokinetics and Effects on Biomarkers From Multiple Ascending Doses of NNC0537-1482 in Participants With Heart Failure",2027-01-15,ESTIMATED,Number of treatment emergent adverse events (TEAE),TREATMENT,ALL,2025-10-23,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06018467,PHASE2,ACTIVE_NOT_RECRUITING,"Osteopenia, Osteoporosis, Age-related Bone Loss",Dasatinib 100 Mg Oral Tablet,SENIOR,RANDOMIZED,3,Dasatinib plus Quercetin (DQ) | Nicotinamide Riboside (NR) | Control,EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,This randomised clinical trial aims to study osteoporosis as a disease of accelerated skeletal aging caused by the accumulation of senescent cells within the skeleton and investigate the effects and safety of senolytics and antioxidant therapy on bone.,"Odense Patient Data Explorative Network, The Novo Nordisk Foundation Center for Basic Metabolic Research",2026-04-30,ESTIMATED,60 Years - 90 Years,120,ESTIMATED,PARALLEL,OTHER,SINGLE,SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial,2026-04-30,ESTIMATED,Bone resorption marker CTX,TREATMENT,ALL,2023-09-06,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07061665,,NOT_YET_RECRUITING,"Quality of Life (QOL), Nutrition, Physical Activity, Obesity, Childhood Obesity",,CBH COPI JAPAN,RANDOMIZED,2,Intervention Group | Control Group,EXPERIMENTAL | NO_INTERVENTION,"The goal of this interventional study is to prevent childhood obesity in children aged 6-12 years in Chiba City, Japan. The main questions it aims to answer are:

* Does the multi-component intervention for environments around children reduce the BMI z-score of children aged 6-12 years after one and two years?
* Does the multi-component intervention for environments around children improve the health-related quality of life (assessed by KIDSCREEN-10) of children aged 6-12 years after one and two","Novo Nordisk A/S, The Behavioural Insights Team, Delivery Associates",2027-09,ESTIMATED,6 Years - 12 Years,2200,ESTIMATED,PARALLEL,OTHER,NONE,Cities for Better Health Childhood Obesity Prevention Initiative in JAPAN,2027-09,ESTIMATED,Body mass index z-score (BMI-z) adjusted for age and sex,PREVENTION,ALL,2025-07,ESTIMATED,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06649630,PHASE1,RECRUITING,Haemophilia A,"NNC0442-0344 A, Placebo",VOYAGER1,RANDOMIZED,14,Cohort 1 (SAD): NNC0442-0344 A | Cohort 2 (SAD): NNC0442-0344 A | Cohort 3 (SAD): NNC0442-0344 A | Cohort 4 (SAD): NNC0442-0344 A | Cohort 5 (SAD): NNC0442-0344 A | Cohort 1 (MAD): NNC0442-0344 A | Cohort 2 (MAD): NNC0442-0344 A | Cohort 3 (MAD): NNC0442-0344 A | Cohort 4 (MAD): NNC0442-0344 A | Cohort 1 (SSD): NNC0442-0344 A | Cohort 2 (SSD): NNC0442-0344 A | SAD: Placebo | MAD: Placebo | SSD: Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"This study will test how different doses of study medicine (Inno8) work in the healthy men. The purpose of this study is to prove safety of Inno8 in healthy men, which will support further development of Inno8 in people with Haemophilia A. The study consists of three parts: single ascending dose (SAD), multiple ascending dose (MAD) and single subcutaneous dose (SSD). Each part will have more than one cohort (like sub-parts). No matter which part the participants will be enrolled in, they will ei",,2026-05-04,ESTIMATED,18 Years - 45 Years,108,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous, Oral and Subcutaneous Doses of Inno8 in Healthy Male Participants",2026-05-04,ESTIMATED,SAD: Number of treatment emergent adverse events | MAD: Number of treatment emergent adverse events | SSD: Number of treatment emergent adverse events,TREATMENT,MALE,2024-09-23,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT06859073,PHASE1,RECRUITING,"Healthy Volunteers, Hyperuricemia","NNC4004-0002, Placebo",,RANDOMIZED,2,NNC4004-0002 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will evaluate an investigational drug called NNC4004-0002. ""Investigational"" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and",,2026-06-01,ESTIMATED,35 Years - 75 Years,60,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1, Double-blinded, Placebo-controlled Study of Single Ascending Doses of NNC4004-0002 in Adults With Asymptomatic Hyperuricemia",2026-06-01,ESTIMATED,Number of Treatment-emergent adverse event (TEAEs),TREATMENT,ALL,2024-11-13,ACTUAL,INTERVENTIONAL
NVO,Novo Nordisk A/S,NCT07076199,PHASE3,RECRUITING,"Diabetes Mellitus, Type 1","Insulin icodec, Insulin glargine, Insulin aspart",ONWARDS 11,RANDOMIZED,2,Insulin icodec + insulin aspart | Insulin glargine+ insulin aspart,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.",,2026-12-28,ESTIMATED,18 Years - N/A,877,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes",2026-11-23,ESTIMATED,Change in glycosylated haemoglobin (HbA1c),TREATMENT,ALL,2025-08-11,ACTUAL,INTERVENTIONAL
BSEM,"BioStem Technologies, Inc.",NCT06811909,,RECRUITING,"Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis, Venous Reflux",,,RANDOMIZED,2,BR-AC plus Standard Care | Standard Care,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study examines a patient population with a non-healing, non-infected venous leg ulcer (VLU) having adequate arterial perfusion with confirmed venous reflux. It is hypothesized that weekly applications of the human placental allograft BioREtain® Amnion Chorion (BR-AC) applied to a non-healing VLU will result in a higher proportion of wounds showing complete healing within 12 weeks of initiating therapy, compared to standard care alone.

This study has a crossover period, where subjects on st",,2026-10,ESTIMATED,18 Years - N/A,60,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC",2026-08,ESTIMATED,"To determine whether non-ischemic, non-infected VLUs treated with standard care plus BR-AC results in a higher probability of achieving complete wound closure compared to standard care alone.",TREATMENT,ALL,2025-02-14,ACTUAL,INTERVENTIONAL
BSEM,"BioStem Technologies, Inc.",NCT06565156,,ACTIVE_NOT_RECRUITING,"Non-infected Diabetic Foot Ulcer, Diabetic Foot, Diabetic Wound, Diabetic Foot Ulcer, Non-ischemic Diabetic Foot Ulcer",,,RANDOMIZED,2,BR-AM plus Standard Care | Standard Care,EXPERIMENTAL | ACTIVE_COMPARATOR,"This trial is a multicenter, randomized, controlled study designed to evaluate the safety and efficacy of BioREtain® Amniotic Membrane (BR-AM) plus standard of care versus standard of care only in the treatment of diabetic foot ulcers. The trial design will control potential variables that may affect the outcome between the treatment group and the control group by standardizing the requirements for debridement, wound dressings, and offloading. Weekly subject visits will help monitor compliance i",,2026-06,ESTIMATED,18 Years - N/A,72,ACTUAL,PARALLEL,INDUSTRY,SINGLE,"A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM",2026-04,ESTIMATED,To determine whether DFUs treated with standard care plus BR-AM results in a higher probability of achieving complete wound closure compared to standard care alone.,TREATMENT,ALL,2024-10-28,ACTUAL,INTERVENTIONAL
BTMD,biote Corp.,NCT06348264,PHASE2,RECRUITING,Salivary Gland Neoplasm Duct,"Rezvilutamide, Leuprolide Acetate",,,1,Rezvilutamide plus LHRHa,EXPERIMENTAL,"The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma (SDC).

The procedures include screening, treatment and follow-up period. The treatment includes rezvilutamide plus Luteinizing Hormone Releasing Hormone agonist (LHRHa) for up to 2 years.","Jiangsu Hengrui Pharmaceutical Co., Ltd., Beijing Biote Pharmaceutical Co.,Ltd",2031-03-30,ESTIMATED,18 Years - N/A,37,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma: a Single-arm Phase 2 Trial",2029-03-30,ESTIMATED,3-year disease-free survival (DFS),TREATMENT,ALL,2024-10-10,ACTUAL,INTERVENTIONAL
TLPH,"Talphera, Inc.",NCT06150742,,RECRUITING,Acute Kidney Injury,,NEPHRO,RANDOMIZED,2,Niyad | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.",,2025-12,ESTIMATED,18 Years - 80 Years,70,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Placebo-controlled, Double-blind, Multi-center Study of the Safety and Efficacy of Niyad in Patients Undergoing Continuous Renal Replacement Therapy (CRRT) Who Cannot Tolerate Heparin or Are at a Higher Risk for Bleeding",2025-12,ESTIMATED,mean post-filter activated clotting time (ACT),TREATMENT,ALL,2024-08-15,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07111988,PHASE2,NOT_YET_RECRUITING,Obsessive-Compulsive Disorder,"Valbenazine, Placebo",,RANDOMIZED,2,Valbenazine followed by placebo | Placebo followed by valbenazine,OTHER | OTHER,The primary aim of the study is to examine the efficacy and safety of valbenazine in adults with moderate to severe obsessive-compulsive disorder (OCD).,Neurocrine Biosciences,2027-12,ESTIMATED,18 Years - 65 Years,30,ESTIMATED,CROSSOVER,OTHER,QUADRUPLE,Valbenazine in Obsessive-compulsive Disorder: A Randomized Double-blind Placebo-controlled Crossover Trial,2027-12,ESTIMATED,Yale-Brown Obsessive-Compulsive Scale (Y-BOCS),TREATMENT,ALL,2026-02,ESTIMATED,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT04490915,PHASE3,ACTIVE_NOT_RECRUITING,Congenital Adrenal Hyperplasia,"Crinecerfont, Placebo",CAHtalyst,RANDOMIZED,2,Placebo | Crinecerfont,PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the stu",,2027-08,ESTIMATED,18 Years - N/A,182,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment",2023-07-19,ACTUAL,Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24,TREATMENT,ALL,2020-12-16,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT06963034,PHASE3,RECRUITING,Schizophrenia,"NBI-1117568, Placebo",,RANDOMIZED,2,NBI-1117568 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.,,2027-10,ESTIMATED,18 Years - 65 Years,284,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization",2027-10,ESTIMATED,Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5,TREATMENT,ALL,2025-05-08,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07105111,PHASE4,RECRUITING,"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia",Valbenazine,,,1,Valbenazine,EXPERIMENTAL,This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.,,2027-04,ESTIMATED,18 Years - N/A,50,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor",2027-04,ESTIMATED,Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24,TREATMENT,ALL,2025-08-29,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07288333,PHASE2,NOT_YET_RECRUITING,Schizophrenia,"NBI-1117570, Placebo",,RANDOMIZED,3,NBI-1117570: Lower-dose | NBI-1117570: Higher-dose | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.,,2027-08,ESTIMATED,18 Years - 55 Years,120,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization",2027-08,ESTIMATED,Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 35,TREATMENT,ALL,2025-12,ESTIMATED,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07365462,PHASE2,NOT_YET_RECRUITING,Tardive Dyskinesia,"NBI-1065890, Placebo",,RANDOMIZED,2,NBI-1065890 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.,,2027-03,ESTIMATED,18 Years - 75 Years,100,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia",2027-02,ESTIMATED,Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 8 Based on the Blinded Central AIMS Video Raters' Assessment,TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT05206513,PHASE3,ACTIVE_NOT_RECRUITING,"Dyskinesia, Cerebral Palsy","Placebo, Valbenazine",,RANDOMIZED,2,Placebo | Valbenazine,PLACEBO_COMPARATOR | EXPERIMENTAL,The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.,,2026-06,ESTIMATED,6 Years - 70 Years,86,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy",2025-12,ESTIMATED,Change in the Total Maximal Chorea (TMC) Score of the Unified Huntington Disease Rating Scale (UHDRS) from Baseline to the Average of the Week 12 and Week 14 assessments,TREATMENT,ALL,2022-04-15,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT06966401,PHASE3,RECRUITING,Major Depressive Disorder,NBI-1065845,,,1,NBI-1065845,EXPERIMENTAL,This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.,,2030-05,ESTIMATED,18 Years - N/A,600,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)",2029-05,ESTIMATED,Number of Participants with Treatment-emergent Adverse Events (TEAEs),TREATMENT,ALL,2025-04-16,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT05226780,PHASE2,ACTIVE_NOT_RECRUITING,SCN8A Developmental and Epileptic Encephalopathy Syndrome,NBI-921352,,,1,NBI-921352,EXPERIMENTAL,Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).,,2026-03,ESTIMATED,2 Years - 22 Years,8,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)",2026-03,ESTIMATED,"The participant incidence of serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation of study treatment, and fatal TEAEs",TREATMENT,ALL,2022-07-12,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT06786624,PHASE3,RECRUITING,Major Depressive Disorder,"NBI-1065845, Placebo",,RANDOMIZED,2,NBI-1065845 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.,,2027-07,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)",2027-07,ESTIMATED,Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56,TREATMENT,ALL,2025-01-22,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07288320,PHASE2,NOT_YET_RECRUITING,"Bipolar I Disorder, Mania","NBI-1117568, Placebo",,RANDOMIZED,2,NBI-1117568 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.,,2028-02,ESTIMATED,18 Years - 65 Years,150,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization",2028-02,ESTIMATED,Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Day 21,TREATMENT,ALL,2025-12,ESTIMATED,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT05207085,PHASE2,RECRUITING,Trichotillomania (Hair-Pulling Disorder),Valbenazine Oral Capsule,,RANDOMIZED,2,Valbenazine | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This trial aims to evaluate the efficacy, safety and tolerability of valbenazine, titrated to the subject's optimal dose of 40mg or 80mg, administered once daily, for 12 weeks, for the treatment of trichotillomania (TTM) in a double blind placebo controlled design study. After week 12, subjects will begin a 12-week, open-label portion of the study. During the open-label portion of the study, all subjects will receive the study drug at their optimal dose. The primary endpoint of these studies wil",Neurocrine Biosciences,2027-02-15,ESTIMATED,18 Years - 65 Years,20,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Titration Study to Assess the Safety, Tolerability, and Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults",2027-02-15,ESTIMATED,Change in Massachusetts General Hospital Hairpulling Scale (MGH-HPS) from baseline to Week 12,TREATMENT,ALL,2024-02-02,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07187375,PHASE2,RECRUITING,Congenital Adrenal Hyperplasia,Crinecerfont,,,1,Crinecerfont,EXPERIMENTAL,The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).,,2029-10-04,ESTIMATED,0 Years - 23 Months,6,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia",2029-09-06,ESTIMATED,Plasma Concentration of Crinecerfont,TREATMENT,ALL,2025-09-30,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07227818,PHASE3,NOT_YET_RECRUITING,Schizophrenia,"NBI-1117568, Placebo",,RANDOMIZED,2,NBI-1117568 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.,,2029-07,ESTIMATED,18 Years - 65 Years,560,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia",2029-07,ESTIMATED,Time From Randomization to Relapse,TREATMENT,ALL,2025-12,ESTIMATED,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07105098,PHASE3,RECRUITING,Schizophrenia,"NBI-1117568, Placebo",,RANDOMIZED,2,NBI-1117568 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.,,2027-11,ESTIMATED,18 Years - 65 Years,284,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization",2027-11,ESTIMATED,Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5,TREATMENT,ALL,2025-08-11,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT04400331,PHASE3,ACTIVE_NOT_RECRUITING,"Chorea, Huntington",Valbenazine,,,1,Valbenazine,EXPERIMENTAL,"This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.",Huntington Study Group,2026-03,ESTIMATED,18 Years - 75 Years,154,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease,2026-03,ESTIMATED,Number of Participants with Treatment-Emergent Adverse Events (TEAEs),TREATMENT,ALL,2020-09-18,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07114874,PHASE3,RECRUITING,Schizophrenia,NBI-1117568,,,1,NBI-1117568,EXPERIMENTAL,This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.,,2031-12,ESTIMATED,18 Years - 65 Years,800,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia",2031-12,ESTIMATED,Number of Participants with Treatment-emergent Adverse Events,TREATMENT,ALL,2025-07-11,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT04806451,PHASE3,ACTIVE_NOT_RECRUITING,Congenital Adrenal Hyperplasia,"Crinecerfont, Placebo",,RANDOMIZED,2,Crinecerfont | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric participants with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of open-label treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The durati",,2027-08,ESTIMATED,2 Years - 17 Years,103,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment",2023-03-10,ACTUAL,Change From Baseline in Serum Androstenedione at Week 4,TREATMENT,ALL,2021-06-25,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT06911112,PHASE3,RECRUITING,Major Depressive Disorder,"NBI-1065845, Placebo",,RANDOMIZED,2,NBI-1065845 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.,,2027-07,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)",2027-07,ESTIMATED,Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56,TREATMENT,ALL,2025-03-31,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT06963021,PHASE3,RECRUITING,Major Depressive Disorder,"NBI-1065845, Placebo",,RANDOMIZED,2,NBI-1065845 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.,,2027-07,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)",2027-07,ESTIMATED,Change from Baseline in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Day 56,TREATMENT,ALL,2025-05-30,ACTUAL,INTERVENTIONAL
NBIX,"Neurocrine Biosciences, Inc.",NCT07196501,PHASE3,RECRUITING,Major Depressive Disorder,"NBI-1065845, Placebo",,RANDOMIZED,3,Open-label Treatment Period: NBI-1065845 | Randomized Double-blind Maintenance Period: NBI-1065845 | Randomized Double-blind Maintenance Period: Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.,,2028-07,ESTIMATED,18 Years - N/A,550,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)",2028-07,ESTIMATED,Time from Randomization to Relapse,TREATMENT,ALL,2025-08-18,ACTUAL,INTERVENTIONAL
KRRO,"Korro Bio, Inc.",NCT06677307,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Alpha-1 Anti-trypsin Deficiency, AATD",KRRO-110,REWRITE,RANDOMIZED,2,Arm 1: KRRO-110 (Part A and Part B) | Arm 2: Placebo (Part A only),EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).",,2026-12,ESTIMATED,18 Years - 70 Years,64,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)",2026-12,ESTIMATED,Safety and Tolerability,TREATMENT,ALL,2025-01-13,ACTUAL,INTERVENTIONAL
SCYX,"SCYNEXIS, Inc.",NCT05908682,,RECRUITING,"Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis",,,,1,Study Cohort,,This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.,AWINSA,2029-10-31,ESTIMATED,0 Years - N/A,100,ESTIMATED,,INDUSTRY,,"A Single-arm Safety Study of Subjects Exposed to Ibrexafungerp Whilst Pregnant, Including Infant Outcomes Up to One Year",2029-10-31,ESTIMATED,Major Structural Defects,,FEMALE,2022-07-28,ACTUAL,OBSERVATIONAL
CGTX,"Cognition Therapeutics, Inc.",NCT05531656,PHASE2,ACTIVE_NOT_RECRUITING,Early Alzheimer's Disease,"CT1812, Placebo",,RANDOMIZED,3,CT1812 100 mg | CT1812 200 mg | Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.","National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium",2027-04,ESTIMATED,50 Years - 85 Years,540,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.",2027-04,ESTIMATED,Change from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale.,TREATMENT,ALL,2023-06-28,ACTUAL,INTERVENTIONAL
PASG,"Passage Bio, Inc.",NCT03047369,,RECRUITING,"Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome",,MDBP,,0,,,"The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.

Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, ","National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), Biogen, Eli Lilly and Company, Myrtelle Inc., Orchard Therapeutics Ltd., Passage Bio, Inc., Synaptix Biotherapeutics Ltd., Takeda, Boehringer Ingelheim, Ionis Pharmaceuticals, Inc., Sanofi Winthrop Industrie, Sana Biotechnology, Yaya Foundation for 4H Leukodystrophy, University of Pennsylvania, United MSD Foundation, Foundation to Fight H-ABC, Calliope Joy Foundation, Don't Forget Me Foundation",2030-12-08,ESTIMATED,N/A - N/A,12000,ESTIMATED,,OTHER,,The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network,2030-12-08,ESTIMATED,Define Novel Homogeneous Groups of Patients with Unclassified Leukodystrophy,,ALL,2016-12-08,ACTUAL,OBSERVATIONAL
PASG,"Passage Bio, Inc.",NCT04747431,"PHASE1, PHASE2",RECRUITING,"Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72",PBFT02,upliFT-D,NON_RANDOMIZED,2,"Cohort 1 | Cohort 2, 3, 4 and 5",EXPERIMENTAL | EXPERIMENTAL,"PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with frontotemporal dementia and mutations in the granulin precursor (GRN) or chromosome 9 open reading frame 72 (C9ORF72) genes",,2031-08,ESTIMATED,35 Years - 75 Years,30,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the ICM of Adults With FTD and Mutations in the GRN or C9ORF72 Genes",2028-08,ESTIMATED,Number of Participants with Treatment-Related AEs and SAEs | Change in Nerve Conduction Velocity and Amplitude from Baseline on Nerve Conduction Studies | Change in Cellular and Humoral Response Against the Vector and Transgene in Serum,TREATMENT,ALL,2021-09-14,ACTUAL,INTERVENTIONAL
TNYA,"Tenaya Therapeutics, Inc.",NCT06311708,,RECRUITING,Arrhythmogenic Right Ventricular Cardiomyopathy,,RIDGE,,1,Retrospective and Prospective,,"This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC. Participation from all patients is encouraged regardless of interest in or eligibility for gene therapy.","University of California, San Francisco, Brigham and Women's Hospital, New York University, University of Colorado, Denver, Johns Hopkins University, The Cleveland Clinic, Mayo Clinic, Medical University of South Carolina, Hopital Louis Pradel, Istituti Clinici Scientifici Maugeri SpA, The Queen Elizabeth Hospital, St George's University Hospitals NHS Foundation Trust, Royal Brompton & Harefield NHS Foundation Trust, Barts & The London NHS Trust, Skane University Hospital, Centro Cardiologico Monzino, Hôpital Haut-Lévêque, Nantes University Hospital, Pitié-Salpêtrière Hospital, Wuerzburg University Hospital, University Hospital Muenster",2030-07-11,ESTIMATED,14 Years - 65 Years,200,ESTIMATED,,INDUSTRY,,Seroprevalence Study of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC),2030-03-29,ESTIMATED,Investigate the seroprevalence of pre-existing antibodies to AAV9 in patients with PKP2-associated ARVC,,ALL,2023-01-31,ACTUAL,OBSERVATIONAL
TNYA,"Tenaya Therapeutics, Inc.",NCT05836259,"PHASE1, PHASE2",RECRUITING,Hypertrophic Cardiomyopathy,,MyPEAK-1,NON_RANDOMIZED,2,Cohort 1 | Cohort 2,EXPERIMENTAL | EXPERIMENTAL,"This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.",,2032-08,ESTIMATED,18 Years - 75 Years,30,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)",2027-08,ESTIMATED,Number and severity of Adverse Events over the course of the study. | Number of Serious Adverse Events related to study drug.,TREATMENT,ALL,2023-08-10,ACTUAL,INTERVENTIONAL
TNYA,"Tenaya Therapeutics, Inc.",NCT06228924,PHASE1,RECRUITING,Arrhythmogenic Right Ventricular Cardiomyopathy,,RIDGE-1,NON_RANDOMIZED,2,Cohort 1 | Cohort 2,EXPERIMENTAL | EXPERIMENTAL,"This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.",,2029-10-01,ESTIMATED,18 Years - 65 Years,15,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-401, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Plakophilin-2 (PKP2) Transgene, in Adults With PKP2 Mutation-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)",2026-05-01,ESTIMATED,Number and severity of Adverse Events over the course of the study. | Number of Serious Adverse Events related to study drug.,TREATMENT,ALL,2024-03-26,ACTUAL,INTERVENTIONAL
TNYA,"Tenaya Therapeutics, Inc.",NCT05112237,,RECRUITING,Cardiomyopathy,,MyCLIMB,,2,Retrospective | Prospective, | ,"The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.",,2028-06,ESTIMATED,0 Years - 18 Years,200,ESTIMATED,,INDUSTRY,,A Prospective and Retrospective Registry and Biomarker Study to Evaluate the Natural History of Pediatric Patients With Cardiomyopathy Due to MYBPC3 Mutations,2028-06,ESTIMATED,To characterize the disease course and natural history in participants with pathogenic or likely pathogenic MYBPC3 mutations with a specific focus on cardiac events and measurement,,ALL,2021-11-01,ACTUAL,OBSERVATIONAL
GANX,"Gain Therapeutics, Inc.",NCT07280299,PHASE2,NOT_YET_RECRUITING,Parkinson Disease,"Low Dose GT-02287, High Dose GT-02287, Placebo",,RANDOMIZED,3,Low Dose GT-02287 | High Dose GT-02287 | Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.",,2028-06-30,ESTIMATED,30 Years - 85 Years,111,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Placebo-controlled, Double-blind, Phase 2a Study to Evaluate the Clinical Efficacy, Safety, Tolerability, and Biomarker Effects of 2 Dose Levels of GT-02287 in Participants With Early Parkinson's Disease",2028-06-30,ESTIMATED,Change from Baseline to Week 48 in the sum of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score and Part III score [Efficacy],TREATMENT,ALL,2026-05-30,ESTIMATED,INTERVENTIONAL
GANX,"Gain Therapeutics, Inc.",NCT06732180,PHASE1,RECRUITING,Parkinson Disease,GT-02287,,,1,single-arm. All participants receive the active molecule (once daily GT-02287 administration),EXPERIMENTAL,"The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are:

* What medical problems do participants have when taking GT-02287?
* How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)?
* Are there any biological effects of GT-02287 in blood and in cerebrospinal fluid that could be beneficial for people with Parkinson's disease?

Participants will:

* visit the clinic t",,2025-11-30,ESTIMATED,30 Years - 85 Years,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants With Parkinson's Disease With or Without a Pathogenic GBA1 Mutation",2025-11-30,ESTIMATED,"Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs) | Incidence of clinically significant findings for clinical laboratory evaluations, physical and neurological examinations, body weight , vital signs measurements, 12-lead o 12-lead electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale (C-SSRS)",TREATMENT,ALL,2025-02-21,ACTUAL,INTERVENTIONAL
MDGL,"Madrigal Pharmaceuticals, Inc.",NCT07335601,PHASE2,ACTIVE_NOT_RECRUITING,MASH - Metabolic Dysfunction-Associated Steatohepatitis,"Resmetirom, Placebo",,RANDOMIZED,4,Arm 1: Resmetirom 80 or 100 mg daily - Cohort 1 | Arm 2: Resmetirom 80 or 100 mg daily - Cohort 2 | Arm 3: Placebo - Cohort 1 | Arm 4: Placebo - Cohort 2,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.",,2027-12,ESTIMATED,18 Years - 75 Years,120,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate MGL-3196 (Resmetirom) in Patients With MASH Who Have Undergone Liver Transplant for MASH Cirrhosis or Other Etiologies",2027-07,ESTIMATED,Percent change from baseline in liver fat content (LFC) as assessed by MRI-PDFF at Week 28,TREATMENT,ALL,2025-12-29,ACTUAL,INTERVENTIONAL
MDGL,"Madrigal Pharmaceuticals, Inc.",NCT04951219,PHASE3,ACTIVE_NOT_RECRUITING,Non-Alcoholic Fatty Liver Disease,Resmetirom,,RANDOMIZED,6,Double-blind 80 mg Daily | Double-blind 100 mg Daily | Open-label | Open-Label 80 mg | Open Label 100 mg | Open-Label 40 mg,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)",,2026-04,ESTIMATED,18 Years - N/A,1000,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)",2026-03,ESTIMATED,"The effect of once daily, oral administration of resmetirom on the incidence of adverse events.",TREATMENT,ALL,2021-07-09,ACTUAL,INTERVENTIONAL
MDGL,"Madrigal Pharmaceuticals, Inc.",NCT03900429,PHASE3,ACTIVE_NOT_RECRUITING,NASH - Nonalcoholic Steatohepatitis,"MGL-3196, Placebo",MAESTRO-NASH,RANDOMIZED,3,Matching Placebo | 80 mg MGL-3196 | 100 mg MGL-3196,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease,,2028-01,ESTIMATED,18 Years - N/A,1759,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation",2028-01,ESTIMATED,"Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with Baseline | Month 54 Primary Objective: Time to experiencing an adjudicated Composite Clinical Outcome event (Final Primary Endpoint, at 54 months)",TREATMENT,ALL,2019-03-28,ACTUAL,INTERVENTIONAL
MDGL,"Madrigal Pharmaceuticals, Inc.",NCT05500222,PHASE3,ACTIVE_NOT_RECRUITING,"NASH, Cirrhosis, Liver","Resmetirom, Placebo",,RANDOMIZED,2,Resmetirom | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.,,2027-01,ESTIMATED,18 Years - N/A,700,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients With Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH-OUTCOMES),2026-12,ESTIMATED,Incidence Of adjudicated Composite Clinical Outcome event,TREATMENT,ALL,2022-08-26,ACTUAL,INTERVENTIONAL
IMUX,"Immunic, Inc.",NCT05201638,PHASE3,ACTIVE_NOT_RECRUITING,"Multiple Sclerosis, Relapsing-Remitting","IMU-838 tablets, Placebo matching IMU-838 tablets",ENSURE-2,RANDOMIZED,2,IMU-838 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)",,2033-10,ESTIMATED,18 Years - 55 Years,1100,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)",2026-11,ESTIMATED,To evaluate efficacy of IMU-838 versus placebo based on time to first relapse,TREATMENT,ALL,2022-01-12,ACTUAL,INTERVENTIONAL
IMUX,"Immunic, Inc.",NCT05134441,PHASE3,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,"IMU-838 tablets, Placebo matching IMU-838 tablets",ENSURE-1,RANDOMIZED,2,IMU-838 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)",,2033-09,ESTIMATED,18 Years - 55 Years,1121,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)",2026-11,ESTIMATED,To evaluate efficacy of IMU-838 versus placebo regarding time to first relapse,TREATMENT,ALL,2021-11-18,ACTUAL,INTERVENTIONAL
IMUX,"Immunic, Inc.",NCT05054140,PHASE2,ACTIVE_NOT_RECRUITING,Multiple Sclerosis,"IMU-838, Placebo matching IMU-838",CALLIPER,RANDOMIZED,2,IMU-838 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER",,2025-01-07,ESTIMATED,18 Years - 65 Years,450,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis",2025-01-07,ESTIMATED,Efficacy of IMU-838 versus placebo,TREATMENT,ALL,2021-09-30,ACTUAL,INTERVENTIONAL
IMUX,"Immunic, Inc.",NCT03846219,PHASE2,ACTIVE_NOT_RECRUITING,Relapsing-Remitting Multiple Sclerosis (RRMS),"IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo, IMU-838 (10 mg/day)",EMPhASIS,RANDOMIZED,4,IMU-838 (30 mg/day) | IMU-838 (45 mg/day) | Placebo | IMU-838 (10 mg/day) - Cohort 2,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), 30 mg/day and 45 mg/day in the main study, cohort 1 (and 10 mg/day for the patients in the cohort 2 substudy), in patients with RRMS and evidence of active disease.

The trial consists of a screening period, a blinded 24-week main treatme",,2029-12,ESTIMATED,18 Years - 55 Years,210,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)",2020-04-24,ACTUAL,Difference Between 45 mg/Day IMU-838 and Placebo in the Cumulative Number of Combined Unique Active (CUA) MRI Lesions,TREATMENT,ALL,2019-01-28,ACTUAL,INTERVENTIONAL
COYA,"Coya Therapeutics, Inc.",NCT07161999,PHASE2,RECRUITING,Amyotrophic Lateral Sclerosis (ALS),"COYA 302, Placebo",ALSTARS,RANDOMIZED,5,DB: COYA 302 Regimen 1 | DB: COYA 302 Regimen 2 | DB: Placebo | EXT: Regimen 1 | EXT: Regimen 2,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS).

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macroph",,2027-07,ESTIMATED,18 Years - 80 Years,120,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)",2027-01,ESTIMATED,The change in disease progression as measured by the Revised ALS Functional Rating Scale (ALSFRS-R),TREATMENT,ALL,2025-10-01,ACTUAL,INTERVENTIONAL
CLNN,Clene Inc.,NCT05299658,PHASE2,ACTIVE_NOT_RECRUITING,Amyotrophic Lateral Sclerosis,CNMAu8,,,1,Open label extension,EXPERIMENTAL,This is an optional open-label extension to participants that have completed the clinical trial CNMAu8.205.,,2026-08,ESTIMATED,30 Years - 80 Years,40,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-Label Extension for the Phase 2, Randomised, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS",2026-06,ESTIMATED,Safety measures | Electromyography measures,TREATMENT,ALL,2021-11-13,ACTUAL,INTERVENTIONAL
ANVS,"Annovis Bio, Inc.",NCT07284784,"PHASE2, PHASE3",RECRUITING,"Parkinson's Disease (PD), Deep Brain Stimulation",buntanetap/posiphen,,NON_RANDOMIZED,2,Cohort 1 - buntanetap | Cohort 2 - buntanetap,EXPERIMENTAL | EXPERIMENTAL,This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.,Duke Clinical Research Institute,2029-11,ESTIMATED,40 Years - 85 Years,500,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Parkinson's Disease,2029-09,ESTIMATED,Safety of buntanetap | Adverse Events (AE) | Treatment Emergent Adverse Events (TEAE) | Serious Adverse Events (SAE),TREATMENT,ALL,2026-01-09,ACTUAL,INTERVENTIONAL
ANVS,"Annovis Bio, Inc.",NCT06709014,PHASE3,RECRUITING,Early Alzheimers Disease,"buntanetap/posiphen, Placebo",,RANDOMIZED,2,buntanetap | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

* Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
* Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
* What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Pos",Prevail Infoworks,2028-06,ESTIMATED,55 Years - 85 Years,760,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer's Disease",2027-12,ESTIMATED,Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13) | Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL),TREATMENT,ALL,2025-02-04,ACTUAL,INTERVENTIONAL
IGC,"IGC Pharma, Inc.",NCT05543681,PHASE2,RECRUITING,"Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression","IGC-AD1-Active, IGC-AD1-Placebo",CALMA,RANDOMIZED,2,Active Comparator: IGC-AD1Active | Placebo Comparator: IGC-AD1 Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.",,2026-03-30,ESTIMATED,60 Years - N/A,164,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease",2026-03-30,ESTIMATED,Agitation,TREATMENT,ALL,2022-10-11,ACTUAL,INTERVENTIONAL
ALGS,"Aligos Therapeutics, Inc.",NCT07342881,PHASE1,NOT_YET_RECRUITING,Chronic Hepatitis B Infection,Pevifoscorvir Sodium (ALG-000184),,NON_RANDOMIZED,2,Subjects with renal Impairment | Subjects without renal impairment,EXPERIMENTAL | EXPERIMENTAL,"This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.",,2026-07-01,ESTIMATED,18 Years - 75 Years,30,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1 Non-Randomized, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function",2026-06-15,ESTIMATED,Area under the concentration time curve [AUC] | Maximum plasma concentration [Cmax] | Minimum plasma concentration [Cmin] | C0 [predose] | Half-life [t1/2] | Time to maximum plasma concentration [Tmax] | Apparent Clearance (CL/F) | Apparent Volume of Distribution (V/F) | Total Amount of Drug Excreted in Urine (Ae) | Renal Clearance (CLr),TREATMENT,ALL,2026-02-02,ESTIMATED,INTERVENTIONAL
ALGS,"Aligos Therapeutics, Inc.",NCT06963710,PHASE2,RECRUITING,Chronic Hepatitis B Infection,"ALG-000184, TDF",B-SUPREME,RANDOMIZED,2,ALG-000184 | TDF,EXPERIMENTAL | ACTIVE_COMPARATOR,This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.,,2028-08,ESTIMATED,18 Years - 65 Years,200,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)",2027-03,ESTIMATED,"HBeAg positive: HBV DNA <Lower Limit of Quantification [LLOQ] (10 IU/mL, target detected or target not detected) | HBeAg negative: HBV DNA <Lower Limit of Quantification [LLOQ] (10 IU/mL, target not detected)",TREATMENT,ALL,2025-07-15,ACTUAL,INTERVENTIONAL
ALGS,"Aligos Therapeutics, Inc.",NCT07342868,PHASE1,RECRUITING,Chronic Hepaititis B Infections,Pevifoscorvir Sodium (ALG-000184),,NON_RANDOMIZED,2,Subjects with Hepatic Impairment | Subjects without Hepatic impairment,EXPERIMENTAL | EXPERIMENTAL,"This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).",,2026-05-05,ESTIMATED,18 Years - 75 Years,16,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1 Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety- and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function",2026-04-20,ESTIMATED,Area under the concentration time curve [AUC] | Time to maximum plasma concentration [Tmax] | Maximum plasma concentration [Cmax] | Minimum plasma concentration [Cmin] | C0 (predose) | Half-life [t1/2],TREATMENT,ALL,2026-01-30,ACTUAL,INTERVENTIONAL
ALGS,"Aligos Therapeutics, Inc.",NCT06672900,PHASE1,ACTIVE_NOT_RECRUITING,Healthy Volunteer,"Carbamazepine, Itraconazole (Sporanox), ALG-000184",,NON_RANDOMIZED,3,ALG-000184 | Carbamazepine | Itraconazole,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs).

In Part 1, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Itraconazole; participants will be assigned to receive multiple doses of ALG-000184 and Itraconazole over a two week period.

In Part 2, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Carbamazepine; participants will be assigned to receive multiple doses of ALG-000184 and ascending doses of Ca",,2025-07-07,ESTIMATED,18 Years - 55 Years,24,ACTUAL,PARALLEL,INDUSTRY,NONE,A Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of Multiple Doses of ALG-000184.,2025-07-07,ESTIMATED,Area under the concentration time curve [AUC] | Area under the concentration time curve [AUC] | Time to maximum plasma concentration [Tmax] | Time to maximum plasma concentration [Tmax] | Maximum plasma concentration [Cmax] | Maximum plasma concentration [Cmax] | Minimum plasma concentration [Cmin] | Minimum plasma concentration [Cmin] | C0 [predose] | C0 [predose] | Half-life [t1/2] | Half-life [t1/2],OTHER,ALL,2025-01-09,ACTUAL,INTERVENTIONAL
RNTX,Rein Therapeutics Inc.,NCT06968845,PHASE2,RECRUITING,Idiopathic Pulmonary Fibrosis (IPF),"LTI-03, Placebo",,RANDOMIZED,4,(1) 2.5 mg LTI-03 capsule BID | (2) 2.5 mg LTI-03 capsules BID | (1) Placebo capsule BID | (2) Placebo capsules BID,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by progressive fibrosis (scarring) of the lungs. As the disease progresses, patients experience loss of lung function and increased breathing problems. LTI-03 is hypothesized to treat IPF by protecting and restoring the functio",,2027-12-31,ESTIMATED,40 Years - N/A,120,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients With Idiopathic Pulmonary Fibrosis",2027-09-30,ESTIMATED,Safety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs),TREATMENT,ALL,2026-02-02,ACTUAL,INTERVENTIONAL
CRDL,Cardiol Therapeutics Inc.,NCT06708299,PHASE3,RECRUITING,Recurrent Pericarditis,CardiolRx,MAVERIC,RANDOMIZED,2,CardiolRx | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation.

Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks.

The objective is to assess whether patients who discontinue therapy with an IL-1 blocke",,2026-10-21,ESTIMATED,18 Years - N/A,110,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"IMpAct of CardiolRxTM oVer 6 Months Following IL-1 Blocker Cessation in pERICarditis Patients - MAVERIC A Randomized, Double-blind, Placebo-controlled Trial",2026-09-21,ESTIMATED,Recurrence of pericarditis,PREVENTION,ALL,2025-04-07,ACTUAL,INTERVENTIONAL
ETST,"Earth Science Tech, Inc.",NCT05722925,PHASE4,ACTIVE_NOT_RECRUITING,Prostate Cancer,Fluciclovine PET/CT,,,1,Fluciclovine PET/CT,EXPERIMENTAL,"The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help detect local recurrence and whether the results of Fluciclovine PET can change management.","Blue Earth Diagnostics, Oregon Health and Science University",2026-12-01,ESTIMATED,18 Years - N/A,50,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Prospective Study Evaluating the Role of Axumin® (Fluciclovine or 18F-FACBC) PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET,2026-12-01,ESTIMATED,Number of participants with BCR and a positive Fluciclovine PET performed within 30 days after a negative or equivocal PSMA PET,DIAGNOSTIC,MALE,2023-10-04,ACTUAL,INTERVENTIONAL
JSPR,"Jasper Therapeutics, Inc.",NCT06162728,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Chronic Spontaneous Urticaria,Briquilimab,BEACON,RANDOMIZED,2,Briquilimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled.

The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a",,2026-10-31,ESTIMATED,18 Years - N/A,88,ACTUAL,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines and/or Omalizumab, or Who Cannot Tolerate Omalizumab",2026-10-31,ESTIMATED,Evaluate the safety and tolerability of briquilimab,TREATMENT,ALL,2023-11-29,ACTUAL,INTERVENTIONAL
JSPR,"Jasper Therapeutics, Inc.",NCT06736262,PHASE2,ACTIVE_NOT_RECRUITING,Urticaria Chronic,Briquilimab,,,1,Briquilimab,EXPERIMENTAL,"Phase 2, open-label, extension study to evaluate the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants previously enrolled in a Jasper sponsored CU clinical trial.",,2026-09-30,ESTIMATED,18 Years - N/A,67,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,Open-Label Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Chronic Urticaria,2026-08-13,ESTIMATED,To evaluate the safety and tolerability of briquilimab,TREATMENT,ALL,2024-11-26,ACTUAL,INTERVENTIONAL
RVPH,"Reviva Pharmaceuticals Holdings, Inc.",NCT05184335,PHASE3,RECRUITING,Schizophrenia,Brilaroxazine,RECOVER,RANDOMIZED,3,RP5063 15 mg once daily | RP5063 (brilaroxazine) 50 mg once daily | Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.",,2025-02,ESTIMATED,18 Years - 65 Years,690,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects With Schizophrenia, Followed by a 52-Week Open-label Extension",2025-02,ESTIMATED,Double Blind Safety and Efficacy of Brilaroxazine (RP5063) | Open label Safety and Efficacy of Brilaroxazine (RP5063),TREATMENT,ALL,2022-01-24,ACTUAL,INTERVENTIONAL
OTLK,"Outlook Therapeutics, Inc.",NCT05112861,PHASE3,ACTIVE_NOT_RECRUITING,"Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema",bevacizumab,NORSE SEVEN,,1,Biological: bevacizumab,EXPERIMENTAL,"The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.",,2025-03,ESTIMATED,18 Years - N/A,120,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVEN",2025-03,ESTIMATED,Frequency and incidence of treatment-emergent adverse events following intravitreal injections of ONS-5010 in vials or PFS,TREATMENT,ALL,2021-11-15,ACTUAL,INTERVENTIONAL
PLNH,Planet 13 Holdings Inc.,NCT05642715,,RECRUITING,"Hiv, Tobacco Use",Varenicline,,RANDOMIZED,2,EX+/HR | EX+/TAU,EXPERIMENTAL | ACTIVE_COMPARATOR,"Cigarette smoking is now the leading killer of people with HIV (PWH) in the US, and most cessation strategies tried to date have failed to increase long-term quit rates. An ""all or none"" approach to smoking cessation in PWH offers little benefit to the large majority of PWH who are unable or unwilling to quit. In this proposal we argue that a harm reduction approach (i.e., cut down, get screened for lung cancer, control your blood pressure and cholesterol) has the potential to yield significant ","Westat, Massachusetts General Hospital, Truth Initiative, National Cancer Institute (NCI), Red Planet Testing",2027-03,ESTIMATED,40 Years - 79 Years,400,ESTIMATED,PARALLEL,OTHER,SINGLE,Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes,2027-03,ESTIMATED,Change in cigarettes smoked per day (CPD) | Occurrence of low-dose CT (LDCT) screening for lung cancer | Change in systolic blood pressure (SBP) | Change in total cholesterol | Change in American College of Cardiology/American Heart Association Pooled Cohort Equation score (ACC/PCEs) | Biochemically-confirmed 7-day point-prevalence abstinence (PPA),TREATMENT,ALL,2024-04-04,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT02863250,,RECRUITING,"Massive Transfusion, Trauma, Cardiothoracic Surgery, Gastrointestinal Bleeding, Vascular Surgery, Obstetric Bleeding, Liver Transplant",,ANZ-MTR,,1,Massively transfused patients,,"Severe and un-stopped blood loss can occur for a number of different reasons including after a serious injury, delivery of a baby and following other medical and surgical emergencies. The investigators understanding of how to best treat people with serious bleeding is still incomplete, with many questions remaining. These include questions regarding how many people have serious bleeding events, what happens to them and the best way to treat them.

The Massive Transfusion Registry (MTR) is a regi","CSL Behring, Department of Health and Human Services Victoria, National Blood Authority, New Zealand Blood Service",2028-12-31,ESTIMATED,18 Years - N/A,50000,ESTIMATED,,OTHER,,Improving Outcomes for Patients With Critical Bleeding Requiring Massive Transfusion,2028-12-31,ESTIMATED,Mortality,,ALL,2011-03,,OBSERVATIONAL
CSLLY,CSL Limited,NCT06878105,,RECRUITING,"Anemia, Coagulopathy",,CEEPBM,,2,Hospital self audit data baseline before PBM training | Hospital self audit data after 6 month after PBM training, | ,"The goal of the study is data collection on available fixed and personal assets required for Patient Blood Management (elements of the 3 pillars of PBM) in Central Eastern Europe countries hospitals, status before and after PBM training.",CSL Behring,2025-12-31,ESTIMATED,18 Years - N/A,2000,ESTIMATED,,OTHER,,Evaluation of Fixed and Personal Assets for Patient Blood Management Implementation in CEE Countries in Practice,2025-09-30,ESTIMATED,Was the PBM training able to significantly reduce the use of blood products in the audited periods?,,ALL,2024-05-27,ACTUAL,OBSERVATIONAL
CSLLY,CSL Limited,NCT07080905,PHASE3,RECRUITING,Hemophilia B,,IX-TEND 3004,,1,CSL222,EXPERIMENTAL,"This is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.",,2033-10-24,ESTIMATED,138 Months - 206 Months,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to &lt; 18 Years of Age) With Severe or Moderately Severe Hemophilia B",2033-10-24,ESTIMATED,Annualized Bleeding Rate (ABR),TREATMENT,MALE,2025-07-28,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT07224360,PHASE2,RECRUITING,Sickle Cell Disease,"Anumigilimab, Placebo",,RANDOMIZED,2,Anumigilimab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD.

The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 w",,2028-06-29,ESTIMATED,18 Years - N/A,63,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease",2028-06-29,ESTIMATED,"Number of participants with Treatment Emergent Adverse Events (TEAEs), Overall and by severity, seriousness and relationship to Investigational Product (IP) | Percentage of participants with TEAEs Overall and by severity, seriousness and relationship to IP | Number of participants with Adverse Events of Special Interest (AESI) | Percentage of participants with AESI | Number of participants with clinically relevant changes from baseline in laboratory assessments and vital signs | Percentage of participants with clinically relevant changes from baseline in laboratory assessments and vital signs",TREATMENT,ALL,2026-02-02,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT07001280,,RECRUITING,Hereditary Angioedemas,,GREAT,,1,Garadacimab,,"This is a multinational, multicenter, prospective, observational cohort study of patients with HAE in the real-world setting. The study will include patients newly initiating garadacimab in routine clinical practice. Each participant will be followed for 48 months after index date (date of the first administration of garadacimab).

Patient data will be collected from the HAE eDiary, patient medical records (MRs) and/or during a routine clinical visit and will be entered into the electronic case ",,2030-08-31,ESTIMATED,12 Years - N/A,200,ESTIMATED,,INDUSTRY,,"Garadacimab Real-world Treatment Outcomes of Effectiveness, Safety, and Quality-of-Life in Patients With HAE (GREAT Study)",2028-08-31,ESTIMATED,Incidence Rate Ratio (IRR) of HAE Attacks,,ALL,2025-07-21,ACTUAL,OBSERVATIONAL
CSLLY,CSL Limited,NCT07332091,PHASE2,RECRUITING,Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis,"Vamifeport, Placebo",,RANDOMIZED,3,Vamifeport Low Dose | Vamifeport High Dose | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH.",,2028-04-06,ESTIMATED,18 Years - N/A,84,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)",2028-03-06,ESTIMATED,Change from baseline in magnetic resonance imaging (MRI)-based liver iron concentration (LIC),TREATMENT,ALL,2026-02-08,ESTIMATED,INTERVENTIONAL
CSLLY,CSL Limited,NCT03805789,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,Acute-graft-versus-host Disease,"AAT, Placebo",MODULAATE,RANDOMIZED,5,AAT (low dose) | AAT (medium dose) | AAT (high dose) | AAT (selected dose from open-label) | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is a phase 2 / 3 prospective, double-blind, randomized, multicenter, placebo-controlled study for prevention of acute GVHD (aGVHD) in participants undergoing an unrelated (matched or single allele mismatched) or matched related allogeneic hematopoietic cell transplantation (HCT).",,2026-03-31,ESTIMATED,12 Years - N/A,222,ACTUAL,SEQUENTIAL,INDUSTRY,QUADRUPLE,"A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft-versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)",2026-03-31,ESTIMATED,The time to Grade II-IV aGVHD or death,PREVENTION,ALL,2019-03-27,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT06738485,PHASE3,RECRUITING,Congenital Hemophilia A,Recombinant single-chain factor VIII (rVIII-SingleChain),,,1,rVIII-SingleChain,EXPERIMENTAL,"For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than \[\<\] 1%).",,2026-06-26,ESTIMATED,0 Days - 65 Years,60,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) With Hemophilia A",2026-06-26,ESTIMATED,Incremental Recovery (IR) of rVIII-SingleChain | Maximum Concentration (Cmax) of rVIII-SingleChain | Area Under the Plasma Concentration Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of rVIII-SingleChain | Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUC0-inf) of rVIII-SingleChain | Half-life (t1/2) of rVIII-SingleChain | Clearance (Cl) of rVIII-SingleChain | Annualized Spontaneous Bleeding Rate (AsBR) | Number of participants who develop FVIII inhibitors,PREVENTION,MALE,2025-01-09,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT05727384,PHASE2,ACTIVE_NOT_RECRUITING,"Inflammation, Frailty","Clazakizumab, Placebo",RIGHT,RANDOMIZED,2,Clazakizumab | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to learn about the effects of inflammation-lowering therapy on mobility and disability in older adults. The main questions it aims to answer are:

* Will therapy improve walking speed/pace?
* Will therapy improve levels of blood inflammation markers and other indicators of physical, cognitive and immune function?

Participants will be asked to receive injections of drug or placebo every 4 weeks for 24 weeks. They will also be asked to undergo testing that asses",CSL Behring,2026-07,ESTIMATED,70 Years - N/A,29,ACTUAL,PARALLEL,OTHER,QUADRUPLE,Reducing Inflammation for Greater Health Trial: The RIGHT Study,2026-02,ESTIMATED,Mean Change in Speed of Walking 400 Meters from Baseline to 24 Weeks,TREATMENT,ALL,2023-08-01,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT03684018,PHASE4,RECRUITING,Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),IgPro10,,RANDOMIZED,2,IgPro10 (dose level 1) | IgPro10 (dose level 2),EXPERIMENTAL | EXPERIMENTAL,"A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment",,2029-12-20,ESTIMATED,2 Years - 17 Years,30,ESTIMATED,PARALLEL,INDUSTRY,NONE,Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP,2029-12-20,ESTIMATED,Percentage (%) of subjects with CIDP relapse in the Randomized Phase by dose level,TREATMENT,ALL,2019-02-28,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT05086575,,ACTIVE_NOT_RECRUITING,Haemophilia B,,OrPHEe,,0,,,"OrPHEe is a non-interventional, prospective and national study which aim is to record real life data in haemophilia B French patients treated with Idelvion® to confirm the efficacy and safety of this product established in clinical development studies.",,2027-12,ESTIMATED,N/A - N/A,222,ACTUAL,,INDUSTRY,,Observatory of Patients With Haemophilia B Treated by IdElvion®,2027-12,ESTIMATED,"Annual bleeding rates (overall, spontaneous and traumatic) under the scope of long-term prophylaxis or on-demand treatment of non-surgical bleeding events | Number of spontaneous bleeding events per patient | Number of Idelvion® infusions and doses injected by infusion required to prevent and resolve non-surgical bleeding episodes | Incidence of non-surgical bleeding episodes",,ALL,2021-12-03,ACTUAL,OBSERVATIONAL
CSLLY,CSL Limited,NCT07048262,PHASE2,RECRUITING,Non-cystic Fibrosis Bronchiectasis,"CSL787, Placebo",,RANDOMIZED,3,CSL787 High Dose | CSL787 Low Dose | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is a phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose range finding study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (immunoglobulin G \[IgG\] inhalation solution) compared with placebo over a period of 6 to 12 months independent of the occurrence of pulmonary exacerbations.

The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 act",,2028-03-28,ESTIMATED,18 Years - 85 Years,450,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis",2028-02-28,ESTIMATED,Time to first (TTF) Exacerbation,TREATMENT,ALL,2025-09-03,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT06806657,PHASE4,RECRUITING,Hereditary Angioedema,Garadacimab,,,1,Garadacimab,EXPERIMENTAL,This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.,,2026-06-15,ESTIMATED,12 Years - N/A,30,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE ≥ 12 Years of Age,2026-06-15,ESTIMATED,Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Percentage of Participants With TEAEs | Number of TEAEs | Rate of TEAEs per injection | Rate of TEAEs per participant year,PREVENTION,ALL,2025-03-19,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT06699849,PHASE2,RECRUITING,Sickle Cell Disease Vaso-occlusive Crisis,"CSL889, Placebo",,RANDOMIZED,3,CSL889 Regimen 1 | CSL889 Regimen 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when given intravenously (IV) to adults and adolescents with sickle cell disease (SCD) experiencing vaso-occlusive crises (VOC). The main objectives of the study are to evaluate the safety and tolerability of CSL889 in study participants, and to assess how CSL889 affects the time it takes for VOC to resolve in participants with SC",,2027-08-07,ESTIMATED,12 Years - N/A,70,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis",2027-08-07,ESTIMATED,Number of participants with treatment-emergent adverse events (TEAEs) | Percentage of participants with TEAEs | Number of participants with detectable treatment emergent (TE) anti-CSL889 antibodies | Percentage of participants with detectable TE anti-CSL889 antibodies | Time to resolution of VOC (time to discontinuation of parenteral opioids),TREATMENT,ALL,2025-07-10,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT06003387,PHASE3,RECRUITING,Hemophilia B,,,,1,CSL222,EXPERIMENTAL,The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreatment AAV5 Nabs.,,2032-04-02,ESTIMATED,18 Years - N/A,35,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B With Detectable Pretreatment AAV5 Neutralizing Antibodies",2028-10-04,ESTIMATED,Annualized Bleeding Rate (ABR),TREATMENT,ALL,2024-01-30,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT04398628,,RECRUITING,"Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease",,,,7,Hemophilia | Congenital Platelet Disorders | Von Willebrand Disease | Rare Disorders | Bleeding NOS | Thrombosis/Thrombophilia | Non-Neoplastic Hematologic Conditions, |  |  |  |  |  | ,"In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from well controlled, pivotal studies often cannot be replicated once a therapy has been approved for general use.2,3,4,5

In 2019 a","Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., CSL Behring, Sanofi, Novo Nordisk A/S, Hemab ApS",2035-12,ESTIMATED,N/A - N/A,3000,ESTIMATED,,NETWORK,,"ATHN Transcends: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People With Non-Neoplastic Hematologic Disorders",2035-06,ESTIMATED,"To determine the safety of therapies used in the treatment of participants with congenital or acquired non-neoplastic, bleeding and clotting disorders and connective tissue disorders with bleeding tendency (blood disorders).",,ALL,2020-09-30,ACTUAL,OBSERVATIONAL
CSLLY,CSL Limited,NCT07326592,PHASE4,NOT_YET_RECRUITING,"Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema",CE1226,,RANDOMIZED,3,CE1226 low dose | CE1226 medium dose | CE1226 high dose,ACTIVE_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density decline in alpha-1 antitrypsin (AAT) deficient participants over 3 years as compared with the marketed dose 60 milligrams per kilogram (mg/kg).",,2033-09-15,ESTIMATED,18 Years - 65 Years,270,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 4, Multicenter, Double-blind, Study to Investigate the Efficacy, Safety, and Tolerability of 3 Active Doses of Respreeza® / Zemaira® Weekly Intravenous Infusions Administered Over 3 Years as Longterm Maintenance Therapy in Adult Subjects With Emphysema Related to Alpha1 Antitrypsin Deficiency",2033-09-15,ESTIMATED,Annual rate of change in adjusted lung density,TREATMENT,ALL,2026-01-15,ESTIMATED,INTERVENTIONAL
CSLLY,CSL Limited,NCT07076446,PHASE4,RECRUITING,Primary Immunodeficiency,IgPro,,,1,IgPro20,EXPERIMENTAL,"This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK, safety, and tolerability of IgPro20. The primary objective of this study is to characterize the PK of IgPro20 and to assess the safety and tolerability of IgPro20 in IG treatment-naïve participants with PID who are aged greater than or equal to (\>=) 18 years.",,2026-05-04,ESTIMATED,18 Years - N/A,8,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-naïve Subjects With Primary Immunodeficiency",2026-05-04,ESTIMATED,Trough concentration (Ctrough) Levels of IgPro20 | Number of Participants Experiencing Any Treatment-Emergent Adverse Event (TEAEs) or Serious TEAEs | Number of TEAEs and Serious TEAEs Events | TEAEs and Serious TEAEs Event Rates Per Days with Infusion,TREATMENT,ALL,2025-07-15,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT05485961,"PHASE2, PHASE3",RECRUITING,"Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD","CSL300, Placebo",POSIBIL6ESKD,RANDOMIZED,6,CSL300 (low dose)(Phase 2b) | CSL300 (medium dose)(Phase 2b) | CSL300 (high dose)(Phase 2b) | Placebo (Phase 2b) | CSL300 (Phase 3) | Placebo (Phase 3),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a dose-finding study for CSL300 vs placebo. Part 2 (phase 3) aims to assess the efficacy of CSL300 on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.",,2029-08-30,ESTIMATED,18 Years - N/A,2310,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis",2029-08-30,ESTIMATED,Change from Baseline on the log scale in high-sensitivity C-reactive protein (hs-CRP)(Phase 2b) | Time to first occurrence of CV death or myocardial infarction (MI) (Phase 3),SUPPORTIVE_CARE,ALL,2022-10-21,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT06399289,PHASE3,ACTIVE_NOT_RECRUITING,Hemophilia B,Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP),,,1,rIX-FP,EXPERIMENTAL,"This study will investigate the pharmacokinetics (PK), efficacy, and safety of rIX-FP for the routine prophylaxis of bleeding episodes in male Chinese previously treated patients (PTPs) with hemophilia B (FIX activity of ≤ 2%). In addition to the scheduled rIX-FP prophylaxis regimen, subjects may also receive rIX-FP episodic (on-demand) treatment for breakthrough bleeding episodes and rIX-FP for the prophylaxis and treatment of bleeding in emergency surgical procedures.",,2026-12-01,ESTIMATED,N/A - 70 Years,23,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Chinese Subjects With Hemophilia B",2026-12-01,ESTIMATED,Incremental recovery (IR) (plasma FIX activity) | Maximum plasma concentration (Cmax) | Terminal elimination half-life (t1/2) of rIX-FP | Area under the concentration-time curve (AUC) | Clearance (Cl) of rIX-FP | Annualized spontaneous bleeding rate (AsBR) | Number of subjects who develop an inhibitor to FIX,PREVENTION,MALE,2024-07-28,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT04672733,,RECRUITING,Chronic Inflammatory Demyelinating Polyneuropathy,Hizentra,pHeNIx,,0,,,"The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).",,2027-12,ESTIMATED,18 Years - N/A,100,ESTIMATED,,INDUSTRY,,Hizentra® in Inflammatory Neuropathies - pHeNIx Study,2027-12,ESTIMATED,Length of time of Continuation of treatment,,ALL,2022-06-10,ACTUAL,OBSERVATIONAL
CSLLY,CSL Limited,NCT05360706,,ACTIVE_NOT_RECRUITING,Hemophilia B,,,,1,CSL220,,"This is an open-label, extension study enrolling patients who have successfully completed all assessments in Study CT-AMT-060-01 (Years 1-5). Assessment phase will begin at Visit 36 (the first clinical visit in this extension study, approximately 5.5 years after the initial dosing visit Study CT-AMT-060-01) and go to Visit 45 (10-years post-dosing in Study CT-AMT-060-01).",,2026-05,ESTIMATED,18 Years - N/A,9,ACTUAL,,INDUSTRY,,A Phase I/IIb Extension Study Assessing the Long-term Safety and Efficacy of an Adeno-associated Viral Vector Containing a Codon-optimized Human Factor IX Gene (AAV5-hFIX) Previously Administered to Adult Patients With Severe or Moderately Severe Haemophilia B During the CT-AMT-060-01 Phase I/II Study,2026-05,ESTIMATED,Number of Adverse events Possibly or probably related to previous AAV5-hFIX administration | Neutralizing FIX antibodies (FIX inhibitors) | ALT/AST levels | Liver pathology score Assessed by ultrasound every 6 months | Alfa fetoprotein levels,,MALE,2021-03-18,ACTUAL,OBSERVATIONAL
CSLLY,CSL Limited,NCT06617897,PHASE3,RECRUITING,Acquired Fibrinogen Deficiency,"CSL511 Fibrinogen concentrate (human), Cryoprecipitate",,RANDOMIZED,2,CSL511 | Cryoprecipitate,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (\>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CS",,2026-10-30,ESTIMATED,18 Years - N/A,90,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 3, Single-center, Randomized, Controlled Clinical Study to Investigate the Efficacy of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery",2026-09-01,ESTIMATED,Percentage of participants with overall hemostatic success,TREATMENT,ALL,2024-10-01,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT06471621,,RECRUITING,"Acute Kidney Injury, Surgery-Complications, Frailty",,PEAK,,0,,,"The goal of this prospective observational study is to define a risk profile for cardiovascular surgery associated acute kidney injury (AKI), using clinical patient characteristics, operation parameters as well as blood and urine laboratory values.

The main question it aims to answer is:

• Does a combination of the factors mentioned above better predict patient outcome than classical factors used to date in clinical practice?

Participants of this study are adults aged 18 and above who are sch",CSL Behring,2026-10-31,ESTIMATED,18 Years - N/A,100,ESTIMATED,,OTHER,,PrEcision Medicine in the Management of Cardiovascular Surgery Associated AKI - PEAK: a Prospective Observational Cohort Study,2026-01-31,ESTIMATED,Change from baseline of serum Fetuin-A values,,ALL,2024-06-16,ACTUAL,OBSERVATIONAL
CSLLY,CSL Limited,NCT05485155,PHASE2,RECRUITING,Eosinophilic Esophagitis,Alpha-proteinase inhibitor,ZEEPS,,1,Active Drug,EXPERIMENTAL,"This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.","CSL Behring, National Institutes of Health (NIH)",2027-01,ESTIMATED,18 Years - 70 Years,15,ESTIMATED,SINGLE_GROUP,OTHER,NONE,An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects With Eosinophilic Esophagitis,2026-10,ESTIMATED,Change in esophageal alpha1 anti-trypsin (A1AT) concentration | Adverse events,TREATMENT,ALL,2025-05-15,ACTUAL,INTERVENTIONAL
CSLLY,CSL Limited,NCT06008938,,RECRUITING,Hemophilia B,Factor IX (FIX),IX-TEND 4001,,2,HEMGENIX | FIX Prophylaxis, | ,"This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX.",,2043-08-01,ESTIMATED,18 Years - N/A,500,ESTIMATED,,INDUSTRY,,An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients With Hemophilia B,2043-08-01,ESTIMATED,Bleeding Rate (all bleeds) - HEMGENIX Cohort,,ALL,2023-06-15,ACTUAL,OBSERVATIONAL
CSLLY,CSL Limited,NCT07094087,PHASE3,RECRUITING,Complex Cardiovascular Surgery With Cardiopulmonary Bypass,"BE1116, FFP",,RANDOMIZED,2,BE1116 | Fresh frozen plasma,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is a phase 3, multicenter, randomized, open-label, parallel-group, controlled study to assess the efficacy and safety of BE1116 compared with fresh frozen plasma (FFP) in adult participants undergoing complex cardiovascular surgery with CPB. The primary purpose of the study is to compare the efficacy of BE1116 and FFP in correcting coagulation factor deficiencies in bleeding participants undergoing complex cardiovascular surgery with CPB.",,2026-12-17,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 3, Multicenter, Randomized, Open-label, Controlled Study to Investigate the Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass",2026-11-18,ESTIMATED,Number of Participants With and Without a Successful Correction of Coagulation Factor Deficiency,TREATMENT,ALL,2025-09-15,ACTUAL,INTERVENTIONAL
ATYR,"aTyr Pharma, Inc.",NCT05892614,PHASE2,RECRUITING,Interstitial Lung Disease,"efzofitimod 450 mg, efzofitimod 270 mg, Placebo",,RANDOMIZED,3,efzofitimod 450 mg | efzofitimod 270 mg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1 ",,2026-04,ESTIMATED,18 Years - N/A,25,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"Randomized, Double-blind, Placebo-controlled Proof-of-Concept (PoC) Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)",2026-04,ESTIMATED,Absolute change from baseline in forced vital capacity (FVC) in mL | Annual rate of decline in FVC in mL | Annual rate of decline in FVC in percent predicted | Change in HRCT fibrosis score,TREATMENT,ALL,2023-10-26,ACTUAL,INTERVENTIONAL
ATYR,"aTyr Pharma, Inc.",NCT05415137,PHASE3,ACTIVE_NOT_RECRUITING,Pulmonary Sarcoidosis,"Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo",,RANDOMIZED,3,Efzofitimod 3 mg/kg | Efzofitimod 5 mg/kg | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.","Kyorin Pharmaceutical Co.,Ltd",2025-08-31,ESTIMATED,18 Years - N/A,268,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis",2025-07-31,ESTIMATED,Change from baseline in mean daily oral corticosteroid (OCS) dose at Week 48,TREATMENT,ALL,2022-09-15,ACTUAL,INTERVENTIONAL
CRVO,CervoMed Inc.,NCT06987643,PHASE2,RECRUITING,"Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke","Neflamapimod, Placebo",RESTORE,RANDOMIZED,4,Cohort 1 neflamapimod | Cohort 1 placebo | Cohort 2 placebo | Cohort 2 neflamapimod,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.,"CervoMed, Inc",2026-06-28,ESTIMATED,45 Years - N/A,90,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke",2026-05-31,ESTIMATED,Change from baseline to Week 12 in Fugl-Meyer Assessment of Motor Recovery after Stroke (FMMS) motor score (upper and lower) and total score | Change from baseline to Week 12 in the Timed Up and Go Test (TUG) | Change from baseline to Week 12 in National Institutes of Health Stroke Scale (NIHSS) motor score,TREATMENT,ALL,2025-06-20,ACTUAL,INTERVENTIONAL
CRVO,CervoMed Inc.,NCT06815965,PHASE2,ACTIVE_NOT_RECRUITING,Dementia With Lewy Bodies (DLB),neflamapimod,,,1,"Neflamapimod, Open-label",EXPERIMENTAL,The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.,"CervoMed, Inc",2026-04,ESTIMATED,55 Years - N/A,25,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB),2026-03,ESTIMATED,Evaluate the safety and tolerability 80 mg neflamapimod given twice daily in patients with dementia with Lewy bodies. | Evaluate the safety and tolerability of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies. | Evaluate the maximum plasma concentration (Cmax) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies. | Evaluate the trough plasma concentration (Ctrough) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.,OTHER,ALL,2024-10-16,ACTUAL,INTERVENTIONAL
CRVO,CervoMed Inc.,NCT07033481,PHASE2,RECRUITING,Nonfluent Variant Primary Progressive Aphasia (nfvPPA),"Neflamapimod, Placebo",,RANDOMIZED,2,Neflamapimod | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.","CervoMed, Inc",2026-10,ESTIMATED,40 Years - 85 Years,20,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA),2026-09,ESTIMATED,Incidence of Adverse Events and Serious Adverse Events.,TREATMENT,ALL,2025-08,ESTIMATED,INTERVENTIONAL
GOSS,"Gossamer Bio, Inc.",NCT04816604,PHASE2,ACTIVE_NOT_RECRUITING,Pulmonary Arterial Hypertension,GB002 (seralutinib),,,1,GB002 (seralutinib),EXPERIMENTAL,This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.,,2027-12,ESTIMATED,18 Years - 80 Years,74,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH),2027-12,ESTIMATED,Number of Participants With Treatment Emergent Adverse Events,TREATMENT,ALL,2021-04-05,ACTUAL,INTERVENTIONAL
GOSS,"Gossamer Bio, Inc.",NCT07181382,PHASE3,RECRUITING,Pulmonary Hypertension Associated With Interstitial Lung Disease,"Placebo, Seralutinib",SERANATA,RANDOMIZED,3,Placebo | Seralutinib 90 mg | Seralutinib 120 mg,PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,"This Phase 3 study is designed as a 24-week randomized, double-blind, placebo-controlled period (PCP) followed by a 144-week long-term extension (LTE) period. The primary objective of the PCP is to evaluate the effect of seralutinib on improving exercise capacity in subjects with World Health Organization (WHO) Group 3 pulmonary hypertension associated with interstitial lung disease. The primary objective of the LTE is to evaluate the long-term safety and tolerability of seralutinib.",Chiesi Farmaceutici S.p.A.,2028-12,ESTIMATED,18 Years - 80 Years,480,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Followed by a Long-Term Extension Evaluating Safety and Efficacy",2028-12,ESTIMATED,"Change in distance achieved on the six-minute walk test (6MWT), from baseline to PCP Week 24 | Incidence of treatment-emergent adverse events",TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
GOSS,"Gossamer Bio, Inc.",NCT06274801,PHASE3,ACTIVE_NOT_RECRUITING,Pulmonary Arterial Hypertension,Seralutinib,,,1,Seralutinib 90 mg,EXPERIMENTAL,"This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study",,2026-12,ESTIMATED,18 Years - 75 Years,316,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH),2026-12,ESTIMATED,Incidence of treatment-emergent adverse events (TEAEs),TREATMENT,ALL,2024-09-03,ACTUAL,INTERVENTIONAL
ATGGF,Actinogen Medical Limited,NCT06125951,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Dementia Moderate, Dementia, Mild, Alzheimer Disease","Xanamem, Placebo",XanaMIA,RANDOMIZED,3,10 mg Xanamem | Placebo | Open label phase,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).

This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be el",,2028-02,ESTIMATED,50 Years - N/A,247,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2b/3, Double-Blind, Placebo-Controlled, Parallel-Group, 36-Week, 2-Arm Trial With an Open-Label Extension Phase to Assess the Safety, Tolerability, and Efficacy of Xanamem® 10 mg Daily in Patients With Mild or Moderate Dementia Due to Alzheimer's Disease",2026-10,ESTIMATED,Effects of 10 mg Xanamem on integrated cognitive and functional abilities | Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem],TREATMENT,ALL,2024-04-12,ACTUAL,INTERVENTIONAL
BRIBF,Brii Biosciences Limited,NCT06650852,PHASE2,RECRUITING,Chronic Hepatitis B Virus (HBV) Infection,"BRII-179, BRII-835 (VIR-2218), PEG-IFNα, Placebo of BRII-179, Placebo of BRII-835",,RANDOMIZED,3,Regimen 1: BRII-179 + BRII-835 + PEG-IFNα | Placebo of BRII-179 + Placebo of BRII-835 + PEG-IFNα | Regimen 2: BRII-179 + BRII-835 + PEG-IFNα,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL,"This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection without cirrhosis receiving neucloes(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.",,2027-07,ESTIMATED,18 Years - 60 Years,250,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2 Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and Pegylated Interferon Alpha (PEG-IFNα) in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)",2026-07,ESTIMATED,The percentage of participants achieving HBsAg seroclearance. | Percentage of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).,TREATMENT,ALL,2024-10-31,ACTUAL,INTERVENTIONAL
BRIBF,Brii Biosciences Limited,NCT05970289,PHASE2,ACTIVE_NOT_RECRUITING,Chronic Hepatitis B Virus Infection,"PEG-IFNα, BRII-835",,RANDOMIZED,4,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.,"Vir Biotechnology, Inc.",2026-02,ESTIMATED,18 Years - 60 Years,86,ACTUAL,PARALLEL,INDUSTRY,NONE,"A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection",2025-07-16,ACTUAL,Proportion of participants with HBsAg loss at end of treatment | Proportion of participants with HBsAg loss at 24 weeks post-end of treatment | Proportion of participants with treatment-emergent adverse events (TEAEs) | Proportion of participants with serious adverse events (SAEs),TREATMENT,ALL,2023-08-22,ACTUAL,INTERVENTIONAL
BRIBF,Brii Biosciences Limited,NCT06491563,PHASE2,ACTIVE_NOT_RECRUITING,For Treatment of Chronic Hepatitis B Virus Infection,"BRII-179, BRII-835 (VIR-2218), PEG-IFNα",,NON_RANDOMIZED,2,BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα | BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα,EXPERIMENTAL | EXPERIMENTAL,"This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase inhibitors (NRTIs) as background therapy.","Vir Biotechnology, Inc.",2027-06,ESTIMATED,18 Years - 60 Years,150,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 2 Multicenter, Open-label Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and Pegylated Interferon Alpha (PEG-IFNα) for the Treatment of Chronic Hepatitis B Virus (HBV) Infection (ENRICH)",2026-12,ESTIMATED,Percentage of participants achieving HBsAg seroclearance at 24 weeks post end of study treatment in anti-HBs responders compared with non-responders defined at protocol-specific timepoint,TREATMENT,ALL,2024-08-06,ACTUAL,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT06555835,,RECRUITING,Healthy,,,,0,,,"Postural stability has an important role for functional movements, injury prevention and the performance of many athletic skills. Therefore, it is very important to understand the factors that affect postural stability. The aim of this study is to investigate the effect of lower extremity flexibility on postural stability in healthy individuals.",Atlas University,2024-11-15,ESTIMATED,18 Years - 25 Years,64,ESTIMATED,,OTHER,,Effect of Lower Extremity Flexibility on Postural Stability,2024-10-25,ESTIMATED,Passive straight leg raise test | Passive ankle dorsiflexion range of motion | Postural stability,,ALL,2024-08-05,ACTUAL,OBSERVATIONAL
CANSF,Atlas Energy Corp.,NCT07338760,,RECRUITING,"Archery, Core Stability, Balance",,,RANDOMIZED,2,Core training group | Control Group,EXPERIMENTAL | NO_INTERVENTION,"This randomized controlled study aims to investigate the acute effects of a single session of core stabilization exercises on balance and upper extremity functional performance in competitive archers. Core stability is essential for postural control, neuromuscular coordination, and efficient force transfer during archery shooting. Understanding the immediate effects of core stabilization exercises may support their use as an effective warm-up and performance-enhancing strategy in archery athlete",,2026-02-01,ESTIMATED,N/A - N/A,30,ESTIMATED,PARALLEL,OTHER,NONE,Acute Effect of Core Stabilization Exercises Among Archers,2025-08-09,ACTUAL,Lower extremity Balance Performance,OTHER,ALL,2025-06-03,ACTUAL,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07289282,,NOT_YET_RECRUITING,"Breast Cancer, Neoadjuvant Therapy, Pathological Response, Invasive Breast Carcinoma, MicroRNAs",,miRNA-NAC,,1,Breast Cancer Cohort,,"This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating ",,2026-12,ESTIMATED,18 Years - N/A,80,ESTIMATED,,OTHER,,The Relationship Between microRNAs in Breast Cancer Subtypes and Response to Neoadjuvant Chemotherapy and Pathological Response,2026-08,ESTIMATED,Change in circulating microRNA expression levels before and after neoadjuvant chemotherapy,,FEMALE,2025-12-15,ESTIMATED,OBSERVATIONAL
CANSF,Atlas Energy Corp.,NCT07342946,,NOT_YET_RECRUITING,PCOS (Polycystic Ovary Syndrome),,,RANDOMIZED,2,Placebo | Synbiotics,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"This study will look at whether a reduced-calorie Mediterranean-style eating plan, together with a synbiotic supplement, can improve health measures and quality of life in women who have polycystic ovary syndrome (PCOS) and are overweight or have obesity. Participants will be assigned by chance (like flipping a coin) to receive either the synbiotic supplement or a placebo (a look-alike product with no active ingredients). All participants will follow the same reduced-calorie Mediterranean diet f",,2027-08-01,ESTIMATED,18 Years - 45 Years,32,ESTIMATED,PARALLEL,OTHER,SINGLE,Effects of a Mediterranean Diet and Synbiotic Supplementation on Anthropometric and Biochemical Parameters and Quality of Life in Obese Women With Polycystic Ovary Syndrome,2027-04-01,ESTIMATED,Change in body weight | Change in body mass index (BMI) | Change in body composition | Change in waist circumference | Change in hip circumference,TREATMENT,FEMALE,2025-12-20,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07404215,,NOT_YET_RECRUITING,"Ankle Stability, Balance Performance, Vertical Jump Performance, Reaction Time, Basketball Players",,KT-DT-BB,NON_RANDOMIZED,2,Kinesio Taping - Dorsiflexion Technique | Dynamic Taping - Plantarflexion Technique,EXPERIMENTAL | EXPERIMENTAL,"This study aims to compare the effects of two different ankle taping methods-kinesio taping and dynamic taping-on balance, vertical jump performance, and reaction time in basketball players.

Basketball involves frequent jumping, rapid changes in direction, and single-leg balance tasks that place substantial demands on ankle stability. Reduced ankle stability may negatively affect athletic performance and increase injury risk. Taping methods are commonly used in sports settings to support the an",,2026-03-15,ESTIMATED,18 Years - 30 Years,20,ESTIMATED,CROSSOVER,OTHER,NONE,"Comparison of the Effects of Kinesio Taping and Dynamic Taping Applied to the Ankle on Vertical Jump, Balance, and Reaction Time in Basketball Players",2026-03-15,ESTIMATED,Dynamic Balance Performance,PREVENTION,ALL,2026-02-15,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT06964984,,NOT_YET_RECRUITING,"Pain, Anxiety, Inguinal Hernia",,,RANDOMIZED,4,music group | stress ball | virtual reality glasses | control group,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,"Although it changes with age, due to its high incidence and prevalence, inguinal hernia is one of the most commonly performed surgeries by general surgeons. Pain, anxiety and changes in comfort levels in patients after inguinal hernia repair surgery negatively affect the patient's recovery after surgery. One of the goals of nursing care practices in the perioperative period, especially in patients undergoing surgery, is to provide and maintain patient comfort. Today, the concept of comfort is a ",,2025-08-01,ESTIMATED,18 Years - 70 Years,120,ESTIMATED,PARALLEL,OTHER,NONE,"Effects of Virtual Glasses, Stress Ball and Music Intervention on Pain, Anxiety and Comfort in Patients Undergoing Inguinal Hernia Surgery: A Randomized Controlled Trial",2025-08-01,ESTIMATED,comfort | pain assessment | anxiety | comfort | pain assesment | anxiety,PREVENTION,ALL,2025-06-05,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT06980558,,RECRUITING,"Surgery, Sleep Quality, Sleep",,,RANDOMIZED,2,Exercise group | Control group,EXPERIMENTAL | NO_INTERVENTION,"Patients undergoing urological surgery are usually elderly individuals and may experience sleep problems due to factors such as fear of death, anesthesia, and uncertainty. Insomnia can also cause problems such as delayed wound healing, increased pain, tension, and difficulty complying with treatment. This study aimed to improve sleep quality by performing gradual muscle exercises on patients undergoing urological surgery.",,2025-06-30,ESTIMATED,18 Years - 70 Years,2,ESTIMATED,PARALLEL,OTHER,SINGLE,Effect of Progressive Relaxation Exercises on Sleep Quality in Patients Undergoing Urological Surgery,2025-06-15,ESTIMATED,Richard's Campbell sleep scale,TREATMENT,ALL,2025-05-01,ACTUAL,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07048301,,NOT_YET_RECRUITING,"Infectious Diseases, Attitude, Behavior, Knowledge",,,RANDOMIZED,2,BUHOS app | Control Group,EXPERIMENTAL | ACTIVE_COMPARATOR,"Background: Infectious diseases remain significant public health concerns due to several factors such as climate and environmental changes and natural disasters. Mobile health applications (mHealth apps) can be an appropriate way for fostering community participation, disseminating knowledge, and promoting behavior change toward infectious disease prevention. This study aims to describe a protocol for a pilot randomized controlled study to evaluate the impact of the Omaha System-Based mHealth ap","Atlas University, Istanbul Medeniyet University, Istanbul University - Cerrahpasa, Hatay Devlet Hastanesi, Health Institutes of Turkey",2026-06,ESTIMATED,18 Years - 64 Years,112,ESTIMATED,PARALLEL,OTHER,DOUBLE,"Developing an Omaha System-Based Health Application on Improving Knowledge, Attitude, and Behaviors Regarding Infectious Disease Prevention in the Community",2025-12,ESTIMATED,Omaha System- Problem Rating Scale for Outcomes Knowledge parameter | Omaha System- Problem Rating Scale for Outcomes Behavior parameter | Communicable Diseases Risk Awareness and Protection Scale (CDRAPS) | Community Communicable Diseases Knowledge Survey,PREVENTION,ALL,2025-09,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT06954935,,RECRUITING,"Nausea, Vomiting, Laparoscopic Cholecystectomy",,,RANDOMIZED,2,periorbital massage | control,EXPERIMENTAL | NO_INTERVENTION,"Laparoscopic cholecystectomy is one of the commonly used surgical treatment methods for gallbladder diseases. However, many patients experience significant nausea and vomiting after laparoscopic cholecystectomy. It is observed that approximately 20% to 30% of patients experience postoperative nausea and vomiting as the most common complaint after laparoscopic cholecystectomy. This study aims to investigate the effectiveness of periorbital massage in postoperative nausea and vomiting in patients ",,2025-09-10,ESTIMATED,18 Years - 70 Years,2,ESTIMATED,PARALLEL,OTHER,NONE,Effectiveness of Periorbital Massage in the Management of Nausea and Vomiting After Laparoscopic Cholecystectomy,2025-08-25,ESTIMATED,Apfel risk score | Numerical Scale of Nausea | Postoperative Nausea and Vomiting Impact Scale,PREVENTION,ALL,2025-04-23,ACTUAL,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT06673914,,ACTIVE_NOT_RECRUITING,"Metabolic Syndrome, Insulin Resistance, Obesity, Abdominal, Obesity",,,RANDOMIZED,2,Control Group: Diet Group | Experimental: Oleuropein and Diet Group,ACTIVE_COMPARATOR | EXPERIMENTAL,The aim of this study is to determine the effect of 6 weeks supplementation of oleuropein on individuals diagnosed with metabolic syndrome. The baseline and end biochemical parameters and anthropometric measurements will be compared with control subjects.,,2025-01-15,ESTIMATED,18 Years - 49 Years,34,ACTUAL,PARALLEL,OTHER,NONE,EFFECTS OF OLEUROPEIN ON BLOOD PARAMETERS AND INFLAMMATORY MARKERS IN ADULTS WITH METABOLIC SYNDROME,2024-12-30,ESTIMATED,"Change from Baseline in the Fasting Blood Glucose (mg/dl) at 6 weeks | Change from Baseline in the Insulin (uU/mL) at 6 weeks | Change from Baseline in the Triglyceride (TG) (mg/dl), high density lipoprotein (HDL-C) (mg/dl), low density lipoprotein (LDL-C) (mg/dl), Total Cholesterol (mg/dl) at 6 weeks | Change from Baseline in the HOMA-IR at 6 weeks | Change from Baseline in the BMI (kg/m2) | Change from Baseline in the Anthropometric Measurements",TREATMENT,ALL,2024-11-01,ACTUAL,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT06226857,PHASE3,RECRUITING,"Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation",Cetuximab,CRC01,RANDOMIZED,2,A | BC,ACTIVE_COMPARATOR | EXPERIMENTAL,"Patients meeting the inclusion criteria will be randomized 1:1 into Cohort A (n ≈ 177) or Cohort BC (n ≈ 177). Cohort A is the control: patients receive combination chemotherapy with FOLFOX plus anti-EGFR therapy (panitumumab or cetuximab) based on RAS/BRAF wild-type data, according to clinical guidelines.

The BC cohort begins FOLFOX chemotherapy and simultaneously undergoes extensive molecular genetic profiling. Further, the BC cohort, depending on the profile, is divided into cohort B - patie","Atlas Biomed, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka",2027-12-31,ESTIMATED,18 Years - 99 Years,355,ESTIMATED,PARALLEL,OTHER_GOV,NONE,Predictive Value of Other Oncogene Mutations for Anti-EGFR Monoclonal Antibodies Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer: Multicenter Randomized Phase III Trial,2026-12-31,ESTIMATED,progression-free survival,TREATMENT,ALL,2024-01-17,ACTUAL,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07123623,,RECRUITING,"The Effect of Couples' Participation in Childbirth Preparation Education on Pregnant Women's Perceived Spousal Support, Fear of Childbirth, and Self-Efficacy",,,,3,Mothers who have not received prenatal education | Expectant mothers undergoing childbirth preparation training | Expectant parents undergoing childbirth preparation training, |  | ,Fear of childbirth can be defined as approaching the process of giving birth with fear and anxiety. The aim of prenatal education is to help expectant mothers develop positive feelings towards childbirth and to foster a sense of security.,,2025-09-25,ESTIMATED,18 Years - 50 Years,102,ESTIMATED,,OTHER,,"The Effect of Couples' Participation in Childbirth Preparation Education on Pregnant Women's Perceived Spousal Support, Fear of Childbirth, and Self-Efficacy",2025-08-30,ESTIMATED,"Spousal Support Scale(SSS), | Wijma Delivery Expectancy/Experience Questionnaire Version A | Birth Self-Efficacy Scale Short Form (BSES-SF32) | Spousal Support Scale(SSS), The Wijma Delivery Expectancy/Experience Questionnaire Version A (W-DEQ), Birth Self-Efficacy Scale Short Form (BSES-SF32)",,FEMALE,2024-09-09,ACTUAL,OBSERVATIONAL
CANSF,Atlas Energy Corp.,NCT07024316,"PHASE1, PHASE2",RECRUITING,Congenital Erythropoietic Porphyria (CEP),ATL-001 (Ciclopirox oral solution),ATL001-PII-CEP,,1,ATL-001,EXPERIMENTAL,"This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD",,2027-11-01,ESTIMATED,18 Years - N/A,6,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase I-II, N-of-1, Open-Label, Prospective Study to Evaluate the Efficacy and Safety of ATL-001 in Adult Patients With Congenital Erythropoietic Porphyria (CEP)",2027-10-01,ESTIMATED,To evaluate the efficacy of ATL-001 in patients with CEP in terms of change in lesions associated with photosensitivity.,TREATMENT,ALL,2026-01-15,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT06997224,,RECRUITING,"Mitral Valve Failure, Surgery",,,RANDOMIZED,2,triflow group | control group,EXPERIMENTAL | NO_INTERVENTION,"The purpose of breathing exercises or the use of assistive devices is to provide deep breathing after surgery and to obtain a normal breathing pattern. The purpose of choosing the method to be applied is to obtain the best result. The results of the few studies conducted on this subject are contradictory and insufficient. In this context, the purpose of this study is to compare the effects of using only triflow and using triflow together with deep breathing and cough exercises on postoperative r",,2025-08-01,ESTIMATED,18 Years - 80 Years,60,ESTIMATED,PARALLEL,OTHER,SINGLE,Comparison of the Effects of Triflow and Deep Breathing and Cough Exercises on Postoperative Respiratory Functions in Patients Undergoing Mitral Valve Replacement: A Randomized Controlled Trial,2025-07-01,ESTIMATED,The Visual Analog Scale (VAS) | The Visual Analog Scale (VAS) | Postoperative Patient Follow-Up and Evaluation Form,OTHER,ALL,2025-05-15,ACTUAL,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07430176,,NOT_YET_RECRUITING,"Lobectomy, Lobectomy Patient, Sleep",,,RANDOMIZED,3,Benson Relaxation Group | Progressive muscle relaxation group | Control Group,EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,"During lobectomy surgical treatment, thoracotomy is performed on patients, and post-thoracotomy pain is observed. Pain is one of the most common problems in patients and causes serious morbidity. As a result of the pain experienced, changes in sympathetic activity and the release of catecholamines as a result of the stress response lead to many complications, primarily in the cardiovascular, urinary, gastrointestinal, and nervous systems. In addition, pain can cause sleep problems in the patient",,2026-06-15,ESTIMATED,18 Years - N/A,160,ESTIMATED,PARALLEL,OTHER,SINGLE,THE EFFECT OF BENSON AND PROGRESSİVE RELAXATİON TECHNİQUES ON PAİN AND SLEEP QUALİTY İN LOBECTOMY PATİENS,2026-04-23,ESTIMATED,THE VİSUAL ANALOG SCALA,OTHER,ALL,2026-02-20,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07279857,,NOT_YET_RECRUITING,Preconception Period,,,RANDOMIZED,2,Intervention Group | Control Group,EXPERIMENTAL | ACTIVE_COMPARATOR,This randomized controlled trial aims to evaluate the effect of a mobile application-based support and counseling program on women in the preconception period. The study includes women aged 18 to 49 who plan to conceive within two years and meet the eligibility criteria. Participants are randomly assigned to an intervention group receiving structured preconception counseling through a mobile application or a control group receiving standard information via a booklet. The intervention consists of,,2026-12-30,ESTIMATED,18 Years - 49 Years,110,ESTIMATED,PARALLEL,OTHER,SINGLE,"The Impact of a Mobile Application-based Support and Counseling Program on Women's Knowledge, Attitudes and Self-efficacy in the Preconceptional Period",2026-09-01,ESTIMATED,Change in Preconception Knowledge Score,HEALTH_SERVICES_RESEARCH,FEMALE,2026-01-01,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07328672,,NOT_YET_RECRUITING,"Chronic Pelvic Pain Syndrome, Female",,,RANDOMIZED,3,Pain Neuroscience Education + Standard Physiotherapy and Rehabilitation | Basic Body Awareness Therapy + Standard Physiotherapy Group | Standard Physiotherapy and Rehabilitation Group,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"This randomized controlled trial aims to investigate the effects of Pain Neuroscience Education and Basic Body Awareness Therapy, when added to standard physiotherapy and rehabilitation, on pain, autonomic nervous system responses, and pelvic floor muscle activity in women with chronic pelvic pain. A total of 45 women diagnosed with chronic pelvic pain will be randomly allocated into three groups: (1) standard physiotherapy and rehabilitation, (2) standard physiotherapy plus Pain Neuroscience Ed",Istinye University,2026-12-15,ESTIMATED,20 Years - 65 Years,45,ESTIMATED,PARALLEL,OTHER,SINGLE,"Investigation of the Effects of Pain Neuroscience Education and Basic Body Awareness Therapy on Pain, Autonomic Nervous System Responses, and Pelvic Floor Muscle Activity in Women With Chronic Pelvic Pain",2026-10-15,ESTIMATED,Pressure Pain Threshold and Pain Tolerance | Pain Intensity and Characteristics (Short Form McGill Pain Questionnaire) | Pain Catastrophizing (Pain Catastrophizing Scale) | Autonomic Nervous System Responses - Tonic Skin Conductance Level (SCL) | Autonomic Nervous System Responses- Phasic Skin Conductance Response (SCR) Amplitude | Autonomic Nervous System Responses- Skin Conductance Response Frequency | Autonomic Nervous System Responses- Skin Conductance Response Latency | Resting Pelvic Floor Muscle Activity (Resting sEMG) (Surface Electromyography) | Minimum Pelvic Floor Muscle Activation (Minimum sEMG) (Surface Electromyography) | Maximum Voluntary Contraction of Pelvic Floor Muscles (MVC) (Surface Electromyography) | Pelvic Floor Muscle Relaxation Time (Surface Electromyography),TREATMENT,FEMALE,2026-01-15,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT06608043,,RECRUITING,"Breast Cancer, Quality of Life",,,,2,Intervention Group | Control Group, | ,"The aim of this study is to investigate the effects of the reborn lifestyle regulation program on physical activity, fatigue level, pain, mental health burden and quality of life in breast cancer patients.",,2025-08-01,ESTIMATED,18 Years - N/A,60,ESTIMATED,,OTHER,,Reborn Lifestyle Adjustment Program for Breast Cancer Patients,2025-02-01,ESTIMATED,Breast Cancer Specific Quality of Life Scale | Modified Borg Scale | Sit up Test | Cancer Fatigue Scale | McGill-Melzack Pain Questionnaire | Depression Anxiety Stress Scale (DASS-21) | Pittsburgh Sleep Quality Index (PSQI),,FEMALE,2024-08-01,ACTUAL,OBSERVATIONAL
CANSF,Atlas Energy Corp.,NCT07297134,,RECRUITING,"Breast Cancer, Metastatic Breast Cancer, miRNAs, PTEN",,PTEN-miR-MBC,,3,Metastatic Breast Cancer | Non-Metastatic Early-Stage Breast Cancer | Healthy Controls, |  | ,"This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Three groups will be included: patients with metastatic breast cancer (n=80), patients with non-metastat",,2026-12,ESTIMATED,18 Years - N/A,160,ESTIMATED,,OTHER,,Serum PTEN Levels and Organ-Specific microRNA Signatures as Predictors of Metastatic Patterns in Breast Cancer: A Prospective Observational Study,2026-10,ESTIMATED,Serum PTEN Level | Serum microRNA (miRNA) Expression Levels,,FEMALE,2025-12-01,ACTUAL,OBSERVATIONAL
CANSF,Atlas Energy Corp.,NCT06897761,,RECRUITING,Bronchiectasis,,,RANDOMIZED,2,Breathing Game Group | Control Group,EXPERIMENTAL | ACTIVE_COMPARATOR,Our study aims to develop a personalized interactive digital breathing game and device that can be produced in our country and to provide daily airway cleaning treatment at home via mobile phone or computer without the need for a physiotherapist or healthcare professional with the use of an interactive digital breathing game.,,2026-01-15,ESTIMATED,7 Years - 18 Years,40,ESTIMATED,PARALLEL,OTHER,SINGLE,Development of an Interactive Digital Respiratory Game and Device and Investigation of Its Effectiveness in Children With Bronchiectasis,2025-12-07,ACTUAL,6 Minute Walk Test | Evaluation of Expiratory Muscle Strength | Evaluation of Inspiratory Muscle Strength,TREATMENT,ALL,2025-10-07,ACTUAL,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07348731,,NOT_YET_RECRUITING,Heel Lance Procedures,,,RANDOMIZED,2,Buzzy | Shotblocker,EXPERIMENTAL | EXPERIMENTAL,"This randomized controlled study was designed to compare the effects of Warm Foot Bath, ShotBlocker®, and Buzzy®-applied prior to heel lance-on the vital signs of newborns. Heel lance is one of the most frequently performed invasive procedures during the neonatal period, and the pain and stress experienced during the procedure may lead to alterations in vital parameters such as heart rate, respiratory rate, and oxygen saturation. Therefore, identifying non-pharmacological, safe, and feasible pai",,2026-05-15,ESTIMATED,4 Days - 1 Month,90,ESTIMATED,PARALLEL,OTHER,SINGLE,"Comparison of the Effects of Foot Bath, ShotBlocker®, and Buzzy® on Neonatal Vital Signs During Heel Lance",2026-02-25,ESTIMATED,Neonatal Infant Pain Scale | Neonatal Infant Pain Scale | Neonatal Infant Pain Scale | Heart Rate | Heart Rate | Heart Rate | Respiratory rate | Respiratory rate | Respiratory rate | Saturation level | Saturation level | Saturation level,SUPPORTIVE_CARE,ALL,2026-02-25,ESTIMATED,INTERVENTIONAL
CANSF,Atlas Energy Corp.,NCT07045675,,ACTIVE_NOT_RECRUITING,"Massage, Labor Pain, Foot Massage, Refleksoloji",,,,2,experimental group | control group, | ,"To evaluate the effect of reflexology massage, which is a non-pharmacological tool based on the effect of reflexology massage applied to the foot, on the perception of labor pain, on the perception of labor pain.",,2025-10-28,ESTIMATED,18 Years - 49 Years,94,ESTIMATED,,OTHER,,The Effect of Foot Reflexology Massage on the Perception of Labor Pain in Nulliparous Pregnant Women,2025-10-28,ESTIMATED,Vizüel Analog Skala (VAS) | Pregnant Introduction Form | Labor Follow-up Form | Birth Comfort Scale | Postpartum Evaluation Form | Birth Satisfaction Scale Short Form,,FEMALE,2024-01-30,ACTUAL,OBSERVATIONAL
CELG.RT,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,NCT07335562,PHASE3,NOT_YET_RECRUITING,Systemic Sclerosis,"BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib",Breakfree-SSc,RANDOMIZED,2,Arm A: BMS-986353 | Arm B: Standard of Care,EXPERIMENTAL | EXPERIMENTAL,The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis,Celgene Corporation,2030-11-11,ESTIMATED,16 Years - N/A,92,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)",2028-11-14,ESTIMATED,The absolute change from baseline in Forced Vital Capacity (FVC) in mL,TREATMENT,ALL,2026-04-30,ESTIMATED,INTERVENTIONAL
CELG.RT,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,NCT06313996,PHASE3,NOT_YET_RECRUITING,Relapsed or Refractory Follicular Lymphoma,"Cyclophosphamide, Doxorubicin, Vincristine, Rituximab, Prednisone, Bendamustine, Lenalidomide, Fludarabine, Liso-cel",,RANDOMIZED,2,Arm A | Arm B,ACTIVE_COMPARATOR | EXPERIMENTAL,The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma.,Celgene Corporation,2031-10-16,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of Lisocabtagene Maraleucel (JCAR017/BMS-986387) to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (TRANSFORM FL),2031-10-16,ESTIMATED,Progression-free survival (PFS),TREATMENT,ALL,2024-03-29,ESTIMATED,INTERVENTIONAL
CELG.RT,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,NCT02622581,,RECRUITING,"Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage II, Non Small Cell Lung Cancer Stage III, Small-cell Lung Cancer, Non-small Cell Lung Cancer Stage I",,CRISP,,5,"NSCLC, Non-squamous cell carcinoma | NSCLC, Squamous cell carcinoma | NSCLC, Non-squamous cell carcinoma (not tested) | NSCLC, Stage I/II/III | Small cell lung cancer (SCLC)", |  |  |  | ,"Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany","AstraZeneca, Celgene Corporation, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, iOMEDICO AG, Eli Lilly and Company, Roche Pharma AG, Takeda, Amgen, Janssen-Cilag G.m.b.H, GlaxoSmithKline, Daiichi Sankyo, Regeneron Pharmaceuticals, Gilead Sciences",2027-12,ESTIMATED,18 Years - N/A,12400,ESTIMATED,,OTHER,,"Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients",2026-09,ESTIMATED,biomarker | treatment | Response rate | progression free survival | overall survival | physician-reported factors | supportive therapies | changes during the project | general health-related and individual quality of life (QoL) patient-reported outcomes | physical and psychological well-being patient-reported outcomes | anxiety patient-reported outcomes,,ALL,2015-12,ACTUAL,OBSERVATIONAL
CELG.RT,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,NCT06615479,PHASE3,RECRUITING,Relapsed or Refractory Multiple Myeloma (RRMM),"BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib",,RANDOMIZED,2,Arm A | Arm B,EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.,Celgene Corporation,2032-06-22,ESTIMATED,18 Years - N/A,440,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma",2027-12-30,ESTIMATED,Progression Free Survival (PFS) | Minimal residual disease (MRD)-negativity in complete response (CR),TREATMENT,ALL,2025-03-12,ACTUAL,INTERVENTIONAL
CELG.RT,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,NCT01848028,,RECRUITING,"Psoriasis, Psoriatic-arthritis",,,,25,Fumaric acid esters | Methotrexate | Cyclosporine A | Efalizumab (withdrawn) | Etanercept | Infliximab | Adalimumab | Ustekinumab | Golimumab | Secukinumab | Apremilast | Certolizumab | Retinoids | Leflunomids | systemic PUVA | Guselkumab | Brodalumab | Tildrakizumab | Risankizumab | Bimekizumab | Tofacitinib | Upadacitinib | Deucravacitinib | Ixekizumab | No treatment, |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ,"Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment an","Berufsverband der Deutschen Dermatologen e.V. (www.bvdd.de), Deutsche Dermatologische Gesellschaft e.V. (https://derma.de), AbbVie, Biogen, Janssen-Cilag G.m.b.H, medac GmbH, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, Pfizer Pharmaceuticals Ltd., Merck Serono GmbH, Germany, PsoNet.eu (http://www.psonet.eu/), Celgene, Eli Lilly and Company, Amgen, Almirall Hermal GmbH, UCB Pharma, Bristol-Myers Squibb, Viatris Inc., LEO Pharma",2032-12,ESTIMATED,18 Years - N/A,3500,ESTIMATED,,OTHER,,Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics,2032-12,ESTIMATED,Psoriasis Area Severity Index (PASI),,ALL,2008-01,,OBSERVATIONAL
CELG.RT,Bristol-Myers Squibb Company CELGENE CONTINGENT VAL RIGHTS 12/31/2030,NCT06220201,PHASE1,RECRUITING,"Multiple Sclerosis, Myasthenia Gravis","CC-97540, Fludarabine, Cyclophosphamide",,NON_RANDOMIZED,3,Administration of CC-97540 (RMS arm) | Administration of CC-97540 (PMS arm) | Administration of CC-97540 (MG arm),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).",Celgene Corporation,2027-07-15,ESTIMATED,18 Years - 60 Years,120,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG).",2027-07-15,ESTIMATED,Number of participants with adverse events (AEs) | Number of participants with serious adverse events (SAEs) | Number of participants with adverse events of special interest (AESIs) | Number of participants with laboratory test result abnormalities | Number of participants with imaging abnormalities | Number of participants with dose-limiting toxicities (DLTs) | Recommended Phase 2 dose (RP2D) based on the incidence of DLTs that occur during the DLT evaluation period,TREATMENT,ALL,2024-03-28,ACTUAL,INTERVENTIONAL
CLDGF,Cleo Diagnostics Ltd,NCT06566716,,RECRUITING,Ovarian Neoplasms,,,,2,Malignant | Non-Malignant, | ,"Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery.

Cleo Diagnostics have developed a new test that uses five biomarkers in the blood to better differentiate between benign and malignant ovarian conditions. In initial studies, this test outperformed the cu",Lindus Health,2026-08,ESTIMATED,18 Years - N/A,1000,ESTIMATED,,INDUSTRY,,Validation of Ovarian Adnexal Mass Assessment Score Test System,2025-08,ESTIMATED,Calculation of the CleoDX adnexal mass score,,FEMALE,2024-09-06,ACTUAL,OBSERVATIONAL
CNTB,Connect Biopharma Holdings Limited,NCT06733480,,RECRUITING,"Rotator Cuff Tears, Anatomic Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty",,,NON_RANDOMIZED,2,Group 1 Band Connect | Group 2 Standard Care,EXPERIMENTAL | NO_INTERVENTION,"Participants are being invited to take part in this research study because you will be undergoing total shoulder replacement or rotator cuff repair and will be participating in physical therapy rehabilitation following the procedure. The purpose of this research is to investigate the effectiveness of Band Connect, a connected health platform, in enhancing compliance with home exercise programs among patients undergoing physical therapy. This study aims to evaluate the implications of increased c",Band Connect,2026-06-01,ESTIMATED,18 Years - 89 Years,499,ESTIMATED,PARALLEL,OTHER,NONE,"Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue",2026-06-01,ESTIMATED,Number of physical therapy visits as measured by medical record review. | Number of home exercise programs completed as measured by medical record review. | Number of in clinic visits as measured by medical record review. | Number of patients who were able to return to work | Time to return to work measured in weeks | Number of patients who returned to sports | Change in pain as measured by the Visual Analog Scale | Active range of motion measured in degrees | Passive range of motion measured in degrees | Strength will be measured on a scale of 0-5 | Patient satisfaction as measured by American Shoulder and Elbow Surgeons (ASES) Score | Number of adverse events as measured by medical record review.,TREATMENT,ALL,2025-02-04,ACTUAL,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT04937062,EARLY_PHASE1,ACTIVE_NOT_RECRUITING,"STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder, Developmental and Epileptic Encephalopathy",Glycerol Phenylbutyrate 1100 MG/ML [Ravicti],,NON_RANDOMIZED,2,SLC6A1 and STXBP1 | Monogenetic Epileptic Encephalopathy,EXPERIMENTAL | EXPERIMENTAL,"This study is to evaluate the use of glycerol phenylbutyrate for monogenetic developmental epileptic encephalopathies (DEEs). DEEs are characterized by epilepsy and developmental delay in early life.

Two examples of DEEs are STXBP1 and SLC6A1, though there are dozens of others.

STXBP1 Encephalopathy is a severe disease that can cause seizures and developmental delays in infants and children. SLC6A1 neurodevelopmental disorder is characterized by developmental delay and often epilepsy. Both STX","Children's Hospital Colorado, SLC6A1 Connect, STXBP1 Foundation, Clara Inspired, University of Pennsylvania Orphan Disease Center, Horizon Therapeutics",2026-12-31,ESTIMATED,0 Months - 17 Years,50,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy,2026-12-01,ESTIMATED,"Short Term Adverse events (i.e., safety) | Long Term Adverse events (i.e., safety) | Percentage of doses taken by participants (i.e., tolerability)",TREATMENT,ALL,2021-03-01,ACTUAL,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT06607341,,RECRUITING,"Diabetes, Pre-diabetes, Hypertension, Overweight and Obesity",,CEAL-DMV,RANDOMIZED,2,"Multi-level, community-digital health promotion intervention | Delayed control intervention group",EXPERIMENTAL | ACTIVE_COMPARATOR,"The Community Engagement Alliance against Disparities - Washington District of Columbia, Maryland, Virginia (CEAL DMV), is a multi-community and multi-university consortium. Through collaboration and shared leadership, the CEAL-DMV the consortium- comprising five institutions: George Washington University, Howard University, Johns Hopkins University, Morgan State University, and the University of Maryland, Baltimore-has established a regional structure for bi-directional community involvement to","Baltimore CONNECT, Coaching Salud Holistica, La Clinica del Pueblo, Rivera Group, The Medi Inc., Westat",2027-09-30,ESTIMATED,18 Years - N/A,664,ESTIMATED,SEQUENTIAL,OTHER,NONE,"Community Engagement ALliance Against Disparities - Washington District of Columbia (DC), Maryland, and Virginia (CEAL-DMV)",2027-09,ESTIMATED,Service utilization as assessed by the number of participants who use referral services,PREVENTION,ALL,2024-12-20,ACTUAL,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT07213986,,RECRUITING,"Neurogenic Bowel Dysfunction, Spinal Cord Injury",,,,1,Vibrant Capsule,EXPERIMENTAL,The goal of this study is to test the safety and effectiveness of Vibrant capsules in spinal cord injury patients with neurogenic bowel.,Mission Connect,2026-03-01,ESTIMATED,21 Years - N/A,12,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Pilot Trial of the Vibrant Capsule for Spinal Cord Injury Neurogenic Bowel Dysfunction,2026-03-01,ESTIMATED,Safety of Vibrant capsule as indicated by number of participants who had an adverse event | Safety of Vibrant capsule as indicated by number of participants who had an adverse event | Safety of Vibrant capsule as assessed by the Penn Spasm Frequency Scale (PSFS) | Safety of Vibrant capsule as assessed by the Penn Spasm Frequency Scale (PSFS) | Safety as assessed by average weekly Numerical Pain Score | Safety as assessed by average weekly Numerical Pain Score | Safety as assessed by the Neurogenic Bladder Symptom Score (NBSS) | Safety as assessed by the Neurogenic Bladder Symptom Score (NBSS),TREATMENT,ALL,2026-01-06,ACTUAL,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT06239818,,RECRUITING,Sports-related Concussion,,,RANDOMIZED,2,Treatment: Photobiomodulation therapy (PBMt) | Control,EXPERIMENTAL | ACTIVE_COMPARATOR,"The purpose of this study is to compare effects of Photobiomodulation therapy (PBMt) to standard of care in adolescent athletes at risk for delayed recovery from subacute sports concussion, to substantiate the impact of subacute PBMt over time on functional and structural connectivity of the brain using advanced MRI sequences and to correlate the psychological and behavioral outcomes to neuroimaging findings",TIRR/Mission Connect,2026-04-01,ESTIMATED,13 Years - 18 Years,30,ESTIMATED,PARALLEL,OTHER,SINGLE,Assessing the Effects of Photobiomodulation on Clinical Recovery From Concussion in Adolescents,2026-04-01,ESTIMATED,Change in depression as assessed by the Neuro-QoL Short Form v1.1 - Pediatric Depression scale | Change in anxiety as assessed by the Neuro-QoL Short Form v1.0 - Pediatric Anxiety scale | Change in intensity of post-concussion symptoms as assessed by Total Symptom Score on the Post-Concussion Symptoms Scale (PCSS) of the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) Concussion Test | Change in quality of sleep as assessed by the Adolescent Sleep-Wake Scale-S (ASWS-Short Version) | Change in brain volume as assessed by Magnetic Resonance Imaging (MRI) of the brain | Change in Diffusion Tensor Image Analysis Along the Perivascular Space (DTI-ALPS) as assessed by MRI of the brain | Change in Fractional Anisotropy (FA) of compact white matter as assessed by MRI of the brain | Change in Radial Diffusivity (RD) of compact white matter as assessed by MRI of the brain,TREATMENT,ALL,2024-04-17,ACTUAL,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT07315867,,RECRUITING,Autism,,,,1,Leadership training for autistic adult and autism accommodation training for learning partner,EXPERIMENTAL,"Subjects are enrolled in pairs. Pairs consist of an autistic adult age 18-36 and a non-autistic learning partner who has a relationship with the autistic adult, such as a parent. The autistic adult in each pair receives the first stage of Kairon's online leadership training consisting of emotional literacy and healthy relationship topics. The learning partner in each pair receives Kairon's autism accommodation training while encouraging and providing feedback to their paired autistic adult. Afte",,2026-02-28,ESTIMATED,18 Years - N/A,20,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"Better Social, Emotional Communication, Healthy Relationship and ASD Accommodation Skills: Emotional Intelligence (""EQ"") Training for Autistic People and ASD Accommodation Training for People Who Care",2026-02-28,ESTIMATED,Training effectiveness,HEALTH_SERVICES_RESEARCH,ALL,2025-12-30,ESTIMATED,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT06940154,PHASE2,RECRUITING,COPD Acute Exacerbation,Matching placebo in prefilled syringe,,RANDOMIZED,2,Rademikibart | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation",,2026-05,ESTIMATED,40 Years - 80 Years,160,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation",2026-04,ESTIMATED,Treatment failure rate,TREATMENT,ALL,2025-08-12,ACTUAL,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT00178659,,ACTIVE_NOT_RECRUITING,"Brain Injuries, Traumatic, Traumatic Brain Injury",,Proteomics,,4,1 healthy volunteers | 2 head trauma | 3 orthopedic injury | 4 Mild TBI, |  |  | ,The specific aim of this research is to determine if the blood from brain-injured patients contains reproducible protein markers that appear prior to elevations in intracranial pressure (ICP).,"TIRR/Mission Connect, The Center for Clinical and Translational Sciences (CCTS) Clinical Research Unit at The University of Texas Health Science Center at Houston",2030-12,ESTIMATED,14 Years - 65 Years,260,ACTUAL,,OTHER,,Proteomics of Brain Trauma-associated Elevated Intracranial Pressure (ICP),2030-12,ESTIMATED,Elevated intracranial pressure,,ALL,2004-07,ACTUAL,OBSERVATIONAL
CNTB,Connect Biopharma Holdings Limited,NCT05437536,,RECRUITING,VWD - Von Willebrand's Disease,,,,0,,,"A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD). Data will be self-reported by patients and/or collected by registry personnel, as appropriate. The purpose of the sVWD Patient Registry is to create a database of well-characterized (with respect to demographics, medical history, symptoms, laboratory and genetic data, etc.) patients with sVWD for participation in retrospective and prospective r",,2027-01,ESTIMATED,N/A - N/A,400,ESTIMATED,,OTHER,,The Severe Von Willebrand Disease Patient Registry: a Longitudinal Natural History and Patient Outcomes Study,2027-01,ESTIMATED,Outcomes are not applicable; this study is a patient registry.,,ALL,2021-12-10,ACTUAL,OBSERVATIONAL
CNTB,Connect Biopharma Holdings Limited,NCT06016257,,RECRUITING,"Shoulder Disease, Shoulder Injuries",,VirtuaCare,NON_RANDOMIZED,2,VirtuaCare Group | Usual and Customary Group,EXPERIMENTAL | NO_INTERVENTION,"This study will be performed to determine if Band Connect's VirtuaCare™ platform increases patient compliance and provides an effective alternative to current physical therapy treatment while reducing the frequency of visits compared with standard orthopedic physical therapy treatment performed in the outpatient clinic.

Participants are being asked to take part in this research study if 18 years and older and have been prescribed physical therapy rehabilitation for an acute or chronic shoulder ","Band Connect, Inc",2025-12-31,ESTIMATED,18 Years - N/A,20,ESTIMATED,PARALLEL,OTHER,NONE,Using VirtuaCareTM Platform for Home Programs in Acute and Chronic Shoulder Conditions: A Pilot Study,2025-12-31,ESTIMATED,Reduced Number of Visits,TREATMENT,ALL,2024-02-01,ACTUAL,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT06940141,PHASE2,RECRUITING,Asthma Acute,Matching placebo in prefilled syringe,,RANDOMIZED,2,Rademikibart | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 2, randomized, multicenter study in adult and adolescent participants with asthma and type 2 inflammation",,2026-05,ESTIMATED,12 Years - 75 Years,160,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Rademikibart as an Add-on Treatment for Acute Exacerbation in Adult and Adolescent Participants With Asthma and Type 2 Inflammation",2026-04,ESTIMATED,Treatment failure rate within 28 days after randomization,TREATMENT,ALL,2025-08-08,ACTUAL,INTERVENTIONAL
CNTB,Connect Biopharma Holdings Limited,NCT06543277,,RECRUITING,Chronic Incomplete Cervical Spinal Cord Injury (SCI),,,,1,Transcutaneous Auricular Vagus Nerve Stimulation (taVNS),EXPERIMENTAL,The purpose of this study is to evaluate the safety and feasibility of transcutaneous auricular Vagus Nerve Stimulation (taVNS) paired with upper-limb rehabilitation in adults with tetraplegia caused by cervical spinal cord injury.,Mission Connect,2027-12-30,ESTIMATED,18 Years - N/A,12,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Safety and Feasibility of Paired taVNS With Upper Limb Rehabilitation in Incomplete Spinal Cord Injury,2027-06-30,ESTIMATED,Safety as assessed by number of subjects with change in systolic blood pressure | Safety as assessed by number of subjects with change in diastolic blood pressure | Safety as assessed by number of subjects with change in heart rate | Safety as assessed by number of subjects with change in respiratory rate | Safety as assessed by number of subjects with change in autonomic dysreflexia | Safety as assessed by number of subjects with worsening spasticity | Safety as assessed by number of subjects with change in pain at stimulation site | Safety as assessed by number of adverse events that occurred during the study period | Feasibility as assessed by the number of treatment sessions attended by each participant . The intervention is considered feasible if at least 80% adherence rate is achieved and no serious adverse events occurred. | Feasibility as assessed by the participants' perceptions of the study procedures | Feasibility as assessed by the participants' perceptions of the usefulness of the intervention,OTHER,ALL,2025-08-15,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06627322,,RECRUITING,Type 2 Diabetes,"Dual-combination therapy, Triple-combination therapy",REMATCH,RANDOMIZED,2,Standard treatment arm (HbA1c 7.0% target) | Intensive treatment arm (HbA1c 6.0% target): plus real-time CGM,ACTIVE_COMPARATOR | EXPERIMENTAL,"Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D). However, intensive control to near-normal glycated hemoglobin (HbA1c) yielded complex results in previous landmark trials. Potential risks of intensive glycemic control, such as hypoglycemia and weight gain, may partly contributed to the possible harms associated with this approach. Recent advances in diabetes management with de","Boryung Pharmaceutical Co., Ltd, Dong-A ST Co., Ltd., HK inno.N Corporation, Daewoong Pharmaceutical Co. LTD., Chong Kun Dang Pharmaceutical Corp., Celltrion, Kakao Healthcare Corp., Handok Inc.",2029-09-30,ESTIMATED,19 Years - N/A,5950,ESTIMATED,PARALLEL,OTHER,NONE,Registry Based Randomized Controlled Trial of Multiple Combination Strategies of Intensive Glycemic Control to Reduce a Composite of Macrovascular and Microvascular Events in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH Study),2029-09-30,ESTIMATED,A composite of major adverse cardiovascular events (MACE) or diabetic microvascular events,PREVENTION,ALL,2024-11-21,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06630559,PHASE3,ACTIVE_NOT_RECRUITING,Plaque Psoriasis,"CT-P55, EU-approved Cosentyx",,RANDOMIZED,2,CT-P55 | EU-approved Cosentyx,EXPERIMENTAL | ACTIVE_COMPARATOR,The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P55 with Cosentyx in patients with moderate to severe plaque psoriasis,,2026-10,ESTIMATED,18 Years - 75 Years,153,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P55 With Cosentyx in Patients With Moderate to Severe Plaque Psoriasis",2026-02-18,ACTUAL,Percent change from baseline in Psoriasis Area and Severity Index (PASI) score,TREATMENT,ALL,2025-05-26,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT05866614,,RECRUITING,"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis","Remsima IV, Remsima SC",,,3,"CT-P13 SC for RA patients | CT-P13 SC for As, PsA and Ps patients | CT-P13 IV for As, PsA and Ps patients", |  | ,"This is an observational, prospective cohort study to evaluate the safety of Remsima® SC in the treatment of RA, AS, PsA and Ps.",,2027-03,ESTIMATED,18 Years - N/A,864,ESTIMATED,,INDUSTRY,,"An Observational, Prospective Cohort Study to Evaluate Safety of Remsima® Subcutaneous in Patients With Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis",2027-03,ESTIMATED,evaluation of adverse events of special interest (AESI),,ALL,2023-01-13,ACTUAL,OBSERVATIONAL
CONI.F,"Celltrion, Inc.",NCT07200986,PHASE1,ACTIVE_NOT_RECRUITING,Healthy Participants,Ixekizumab,,RANDOMIZED,2,CT-P52 | United States (US)-licensed Taltz,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study is designed to demonstrate PK similarity of the proposed biosimilar test product CT-P52 and the reference product, US-licensed Taltz.",,2026-03-31,ESTIMATED,19 Years - 55 Years,218,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1, Randomized, Double-blind, Two-arm, Parallel-Group, Single-dose Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects",2026-03-31,ESTIMATED,AUC0-inf | Cmax,TREATMENT,ALL,2025-09-17,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06687928,PHASE1,ACTIVE_NOT_RECRUITING,Healthy,"CT-P6 SC, EU-Approved Herceptin SC",,RANDOMIZED,2,Subcutaneous CT-P6 | Subcutaneous EU-approved Herceptin,EXPERIMENTAL | ACTIVE_COMPARATOR,"A Randomized, Double-blind, Two-arm, Parallel-group, Single-dose, Phase 1 Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects",,2025-08-05,ESTIMATED,19 Years - 55 Years,200,ESTIMATED,PARALLEL,INDUSTRY,TRIPLE,"A Randomized, Double-blind, Two-arm, Parallel-group, Single-dose, Phase 1 Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects",2025-08-05,ESTIMATED,Demonstrate PK similarity | Demonstrate PK similarity,TREATMENT,MALE,2025-03-25,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06059989,PHASE3,RECRUITING,"Inflammatory Disease, Disease Crohn, Bowel Disease","Infliximab subcutaneous, Immunosuppressive Agents",DIRECTCD,RANDOMIZED,2,Monotherapy | Combination therapy,EXPERIMENTAL | EXPERIMENTAL,"Study Design:

A Prospective Multicenter Randomized Controlled, Open-label Non-inferiority Study to Investigate the Efficacy of Subcutaneous (SC) Infliximab (IFX) with and without Immunomodulators during Induction treatment in Moderate to Severe Crohn's Disease.

Primary endpoint:

The proportion of patients in corticosteroid-free clinical remission (as defined by a Crohn's disease activity index (CDAI)\<150) and endoscopic response (as defined by a simple endoscopic score for Crohn's disease (S",Celltrion,2025-12,ESTIMATED,18 Years - 80 Years,158,ESTIMATED,PARALLEL,OTHER,NONE,"A Multicenter Randomized, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn's Disease",2025-06,ESTIMATED,"Crohn's disease activity index <150 (-10 to 480) AND endoscopic response , where the higher score means worse outcome .",TREATMENT,ALL,2021-11-25,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT07367958,PHASE1,NOT_YET_RECRUITING,Healthy Male Subjects,CT-P52,,RANDOMIZED,2,CT-P52 Auto-injector | CT-P52 Pre-filled syringe,EXPERIMENTAL | ACTIVE_COMPARATOR,"This is phase 1 study to Compare the Pharmacokinetics, Safety and Immunogenicity of the Auto-injector and Pre-filled syringe of CT-P52 in Healthy Male Subjects.",,2027-01,ESTIMATED,19 Years - 55 Years,218,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Phase 1, Randomized, Open-label, Two-arm, Parallel-Group, Single-dose Study to Compare Pharmacokinetics and Safety of CT-P52 AI and CT-P52 PFS in Healthy Male Subjects",2026-08,ESTIMATED,PK similarity demonstration by AUC 0-inf | PK similarity demonstration by Cmax,OTHER,MALE,2026-01,ESTIMATED,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT07093476,PHASE3,RECRUITING,"T2DM, Diabete Type 2, DM","Metformin, Alogliptin, empagliflozin",,RANDOMIZED,3,Study group 1 | Study group 2 | Control Group,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,Phase 3 study to assess the Efficacy and Safety of CT-L02-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Alogliptin Combination Therapy.,,2027-04,ESTIMATED,19 Years - N/A,171,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Trial and Open-Label Extension Study to Evaluate the Efficacy and Safety of Add-On Therapy With Empagliflozin for Patients With Inadequately Controlled Type 2 DiabetesMellitus in the Combination Treatment With Metformin and Alogliptin",2026-12,ESTIMATED,HbA1c,TREATMENT,ALL,2025-07-18,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06113913,PHASE4,RECRUITING,"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","Infliximab, Infliximab, Infliximab",AMARETTO,RANDOMIZED,3,"Interventional (SC infliximab, weekly) | Interventional comparator (SC infliximab, bi-weekly) | Intravenous comparator (IV infliximab, optimized dosing schedule)",EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this clinical trial is to learn about the treatment with subcutaneous infliximab in patients with inflammatory bowel disease (IBD) that were previously treated with an optimized dose of intravenous infliximab.

The main question it aims to answer is:

\- Is switching to a weekly dose of subcutaneous infliximab (120 mg) associated with a better outcome compared to the standard fortnightly administration of 120 mg subcutaneous infliximab in patients who received an optimized intravenou",Celltrion,2026-11,ESTIMATED,18 Years - N/A,275,ESTIMATED,PARALLEL,OTHER,NONE,Subcutaneous Infliximab After A Previous Intravenous Dose Optimization,2026-05,ESTIMATED,• The proportion of patients that maintain steroid-free clinical and biological remission by week 52 without treatment optimization after switch to SC infliximab (composite endpoint),TREATMENT,ALL,2024-04-09,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06939595,PHASE3,RECRUITING,Non Squamous Non Small Cell Lung Cancer,"CT-P51, EU-approved Keytruda",,RANDOMIZED,2,CT-P51 | EU-approved Keytruda,EXPERIMENTAL | ACTIVE_COMPARATOR,The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.,,2028-07,ESTIMATED,18 Years - N/A,606,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination With Platinum-Pemetrexed Chemotherapy in Patients With Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer",2027-02,ESTIMATED,ORR based on the confirmed best overall response (BOR) by the end of Cycle 11 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1,TREATMENT,ALL,2025-01-30,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06571591,PHASE3,ACTIVE_NOT_RECRUITING,T2DM,"CT-L03 Group 1, CT-L03 Group 2, Placebo, Empagliflozin, Metformin",CT-L03,RANDOMIZED,3,Group 1 | Group 2 | Placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.,,2026-05,ESTIMATED,19 Years - N/A,582,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone Co-administration in Patients With Type II Diabetes With Insufficient Glycemic Control With Metformin and Empagliflozin Combination Therapy",2026-05,ESTIMATED,HbA1c,TREATMENT,ALL,2024-08-27,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT07013578,,RECRUITING,"Crohn Disease (CD), Ulcerative Colitis (UC), Inflammatory Bowel Disease (IBD)",,,RANDOMIZED,2,Sessions with a social worker based on Healing Circuits™ Methodology | Online modules of a self-directed Healing Circuits™ curriculum,EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the onl","Amgen, Celltrion",2027-07-01,ESTIMATED,18 Years - 75 Years,100,ESTIMATED,PARALLEL,OTHER,NONE,A Randomized Evaluation of Changes in Anxiety and Depression in Inflammatory Bowel Disease Patients Comparing Structured Mental Health Support to App Based Mental Health Support in Addition to Standard of Care Medical Treatment,2026-12-31,ESTIMATED,Change in Generalized Anxiety Disorder 7-item Scale (GAD-7) Score | Time to Improvement in Generalized Anxiety Disorder 7-item Scale (GAD-7) Score | Change in Patient Health Questionnaire-9 (PHQ-9) Score | Time to Improvement in Patient Health Questionnaire-9 (PHQ-9) Score,TREATMENT,ALL,2025-07-22,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06738719,PHASE3,ACTIVE_NOT_RECRUITING,Moderately to Severely Active Rheumatoid Arthritis,"CT-P13 SC Auto-Injector, Placebo Auto-Injector",,RANDOMIZED,2,CT-P13 Auto-Injector | Placebo Auto-Injector,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis",,2026-04-15,ESTIMATED,18 Years - 75 Years,192,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients With Moderately to Severely Active Rheumatoid Arthritis",2025-06-25,ACTUAL,Proportion of patients achieving clinical response according to the ACR20 criteria at Week 12,TREATMENT,ALL,2025-01-03,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT05906992,PHASE3,RECRUITING,Relapsing-remitting Multiple Sclerosis,"CT-P53, US-Ocrevus, EU-Ocrevus",,RANDOMIZED,3,CT-P53 | US-Ocrevus | EU-Ocrevus,EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.",,2029-01,ESTIMATED,18 Years - 55 Years,512,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1/3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis",2027-02,ESTIMATED,Area under the concentration-time curve in PK group | Total number of new GdE lesions on T1-weighted brain MRI in Main study group,TREATMENT,ALL,2024-01-11,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT07237516,,RECRUITING,"Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)",,ZEST,,0,,,The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb as part of their regular medical care for CD or UC will answer online survey questions about their bowel habits for 1 year.,Celltrion,2028-11-03,ESTIMATED,18 Years - N/A,200,ESTIMATED,,OTHER,,Zymfentra (Infliximab-dyyb) REal World Cohort STudy,2028-11-03,ESTIMATED,Clinical remission as evaluated by the Simple Clinical Colitis Activity Index (SCCAI) for the patient-reported outcomes. | Clinical remission as evaluated by the Simple Crohn's Disease Activity Index (sCDAI for the patient-reported outcomes.,,ALL,2025-11-20,ACTUAL,OBSERVATIONAL
CONI.F,"Celltrion, Inc.",NCT03474744,PHASE2,ACTIVE_NOT_RECRUITING,Marginal Zone Lymphoma,"Copanlisib, Rituximab",,,1,Experimental Arm,EXPERIMENTAL,"For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such. Depending on the MZL subtype Rituximab/chemotherapy is able to induce in part long remissions, but do not prevent relapse later on. In addition, chemotherapy associated toxicity is often problematic in MZL patients, who are mostly of advanced age. Thus, chemotherapy - free approaches are highly attractive for this patient gr","University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer",2027-12-31,ESTIMATED,18 Years - N/A,36,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (COUP-1),2027-12-30,ESTIMATED,Complete Response,TREATMENT,ALL,2019-12-15,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06997055,,RECRUITING,"Crohn Disease, Plaque Psoriasis","Ustekinumab 45 mg, Ustekinumab 90 mg",ROLL'YN-UST,,2,CD group | Psoriasis Group, | ,"ROLL'YN-UST is a real-life study, which includes patients in clinical remission for at least 3 months and who have been treated with a reference biotherapy for at least 6 months, and for whom the physician has decided, independently of the study and as part of a shared medical decision, to switch them to STEQEYMA®. The main aim of this study is to the maintenance of clinical remission 12 months after initiation of a biosimilar as well as patient satisfaction 6 and 12 months after initiation of a",Sanoia,2027-12-31,ESTIMATED,18 Years - N/A,225,ESTIMATED,,INDUSTRY,,"ROLL'YN-UST: Etude Observationnelle de Cohorte Pour la Prise en Charge Des Patients Atteints de Pathologies Inflammatoires Chroniques traités Par Steqeyma®, un Biosimilaire de l'ustékinumab",2027-09-30,ESTIMATED,"Maintenance of remission, 12 months after initiation of biosimilar treatment",,ALL,2025-03-17,ACTUAL,OBSERVATIONAL
CONI.F,"Celltrion, Inc.",NCT06274294,PHASE3,RECRUITING,Inflammatory Bowel Diseases,CT-P13,PASSPORT,RANDOMIZED,2,SC CT-P13 induction | IV CT-P13 induction,EXPERIMENTAL | OTHER,"The goal of this clinical trial is to compare induction treatment with CT-P13 SC to induction treatment with CT-P13 IV in terms of pharmacokinetics in adult patients with inflammatory bowel disease (IBD) who have been diagnosed for at least 3 months and for whom the physician has decided to initiate treatment with infliximab CT-P13 as part of the standard of care.

The main aim of this study is to demonstrate that induction treatment with CT-P13 SC is non-inferior to CT-P13 IV in terms of pharma","Paris IBD Center, Celltrion HealthCare France",2025-01,ESTIMATED,18 Years - N/A,130,ESTIMATED,PARALLEL,OTHER,SINGLE,"The ""PASSPORT Trial"": Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active Crohn's Disease or Ulcerative Colitis.",2025-01,ESTIMATED,Ratio SC/IV,TREATMENT,ALL,2024-07-10,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT07425639,,RECRUITING,"Chronic Spontaneous Urticaria (CSU), Allergic Asthma",Omalizumab,ROLL'YN-OMA,,2,CSU group | Allergic asthma group, | ,"ROLL'YN-OMA is a real-world study in patients receiving standard biologic therapies who have been in control and/or remission of their disease for at least 3 months and whose physician has independently decided, within the framework of a shared medical decision, to switch them to OMLYCLO®. The primary objective of this study is to evaluate the maintenance of this control and/or clinical remission 12 months after initiation of the biosimilar, and subsequently, patient satisfaction at 6 and 12 mon",,2028-09,ESTIMATED,18 Years - N/A,225,ESTIMATED,,INDUSTRY,,"ROLL'YN-OMA : Etude Observationnelle de Cohorte Pour la Prise en Charge Des Patients Atteints de Pathologies Inflammatoires Chroniques traités Par Omlyclo®, un Omalizumab Biosimilaire",2028-03,ESTIMATED,Maintenance of disease control and/or remission 12 months after initiation of biosimilar treatment.,,ALL,2025-10-02,ACTUAL,OBSERVATIONAL
CONI.F,"Celltrion, Inc.",NCT06952478,PHASE3,RECRUITING,Refractory or Relapsed Multiple Myeloma,"CT-P44(Daratumumab), Darzalex Faspro(Daratumumab)",,RANDOMIZED,2,CT-P44 | Darzalex Faspro,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma",,2029-06-25,ESTIMATED,18 Years - N/A,486,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blind, Randomized, Active-Controlled, Parallel-group, Phase 1/3 Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma",2027-11-15,ESTIMATED,PK equivalence of CT-P44 and Darzalex Faspro | Therapeutic equivalence of CT-P44 and Darzalex Faspro,TREATMENT,ALL,2025-08-12,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT04627753,PHASE2,RECRUITING,Primary CNS Lymphoma,"Rituximab, lenalidomide",Lemon-C,,1,Lenalidomide and Rituximab therapy,EXPERIMENTAL,"* After standard treatment of primary central nervous system lymphoma (PCNSL), high-dose methotrexate induction therapy, and consolidation therapy, most patients reach complete remission, but within the first 6 months, 35-60% of patients refractory to treatment or experience relapse during the first treatment.
* The progression-free survival (PFS) period of relapsed patients is 2.2 months (0-29.6 months), and the survival period is reported as 3.5 months (0-29.6 months). After relapse, the major","Celltrion, Samyang Biopharmaceuticals Corporation",2026-11-02,ESTIMATED,19 Years - N/A,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Phase II Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With Primary CNS Diffuse Large B-cell Lymphoma (Nickname: Lemon-C Study),2025-11-02,ESTIMATED,1 year progression free survival,TREATMENT,ALL,2020-11-02,ACTUAL,INTERVENTIONAL
CONI.F,"Celltrion, Inc.",NCT06989723,PHASE4,RECRUITING,"Type 2 Diabetes, Fatty Liver","Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]",,RANDOMIZED,3,Pioglitazone | Empagliflozin | Pioglitazone & Empagliflozin,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation",Celltrion,2027-06-30,ESTIMATED,20 Years - N/A,120,ESTIMATED,PARALLEL,OTHER,DOUBLE,Evaluation of Pioglitazone and Empagliflozin Combination Therapy in Type 2 Diabetes Patients With Metabolic Dysfunction-Associated Fatty Liver Disease,2026-12-31,ESTIMATED,Proportion of Participants Achieving HbA1c Treatment Targets | Change in Fibroscan Controlled Attenuation Parameter (CAP) Score,TREATMENT,ALL,2025-01-01,ACTUAL,INTERVENTIONAL
CWBHF,"Charlotte's Web Holdings, Inc.",NCT05015439,PHASE1,RECRUITING,Autism Spectrum Disorder,"Cannabidiol, Placebo",,RANDOMIZED,2,Cannabidiol | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"There are no FDA approved treatments for use in adults with autism spectrum disorder (ASD), many of whom have distressing anxiety, mood disturbances, sleep problems, and agitation. Some researchers and individuals with ASD have noted that cannabidiol (CBD) is beneficial for those psychiatric problems. This study is to learn more about the effectiveness and safety of CBD in the treatment of psychiatric problems in adults with ASD. The study will last 14 weeks total, during which six weeks partici","Charlotte's Web, Inc",2026-12,ESTIMATED,18 Years - N/A,40,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Crossover Trial of Cannabidiol (CBD) Versus Placebo for Psychiatric Presentations in Adults With Autism Spectrum Disorder,2026-12,ESTIMATED,Change in Aberrant Behaviors as assessed by the Aberrant Behavior Checklist,TREATMENT,ALL,2023-04-20,ACTUAL,INTERVENTIONAL
CYYNF,Cynata Therapeutics Limited,NCT05643638,PHASE2,RECRUITING,"Graft Versus Host Disease, Acute","CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Placebo, Corticosteroids",,RANDOMIZED,2,CYP-001 plus corticosteroids | Placebo plus corticosteroids,EXPERIMENTAL | PLACEBO_COMPARATOR,This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD. Severity of GvHD will be assessed at screening and throughout the study using Mount Sinai Acute GvHD International Consortium (MAGIC) guidelines. Eligible subjects will be randomized to receive either CYP-001 IV infusion on Days 0 and 4 or placebo on the same days. All subjects will receive,,2027-12,ESTIMATED,18 Years - N/A,60,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease",2026-03,ESTIMATED,Overall response rate (ORR),TREATMENT,ALL,2024-03-04,ACTUAL,INTERVENTIONAL
EAHGF,ECO Animal Health Group plc,NCT06386133,,NOT_YET_RECRUITING,"Multiple Sclerosis, Fatigue Syndrome, Chronic",,MSBoost,RANDOMIZED,2,Boost Group | Control Group,EXPERIMENTAL | ACTIVE_COMPARATOR,"The main objective of the MS Boost study is to demonstrate the superiority of MSCopilot Boost over standard practice in reducing the impact of fatigue on Patients with Multiple Sclerosis (MS).

The secondary objectives include validating MSCopilot Boost clinical performance in reducing fatigue and its impact as well as evaluating its functional tests performance and its safety of use. The investigation team will also investigate the effects of MSCopilot Boost on patient symptoms, functional para","URC-ECO Clinical trial unit on health Economics, Hotel-Dieu Hospital",2027-08-01,ESTIMATED,18 Years - N/A,208,ESTIMATED,PARALLEL,OTHER,NONE,"Chronic Fatigue in Multiple Sclerosis: Validating Clinical Performance, Economic, and Organizational Benefits of MSCopilot Boost Compared to Standard Care",2027-08-01,ESTIMATED,To demonstrate that MSCopilot Boost is superior to standard practice in reducing the impact of fatigue on Patients with Multiple Sclerosis,SUPPORTIVE_CARE,ALL,2026-12-01,ESTIMATED,INTERVENTIONAL
EZYMF,Enzymatica AB (publ),NCT07041671,,NOT_YET_RECRUITING,URTI - Viral Upper Respiratory Tract Infection,,,RANDOMIZED,2,ColdZyme treatment | No intervention,ACTIVE_COMPARATOR | NO_INTERVENTION,Many respiratory diseases spread through aerosols. ColdZyme is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The objective of this study is assessing if ColdZyme could also contribute to decreased airborne transmission by decreasing the amount of (infectious) virus that is exhaled by an infected subject.,Enzymatica AB,2028-12,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,OTHER,SINGLE,"Evaluation of Number of Particles Containing Viral RNA and Their Virus Infectivity in Exhaled Air From Participants With Upper Respiratory Tract Infection Symptoms, Before and After Use of One Dose With ColdZyme Mouth Spray",2027-12,ESTIMATED,Number of virus genome copies in exhaled aerosol,PREVENTION,ALL,2025-09-30,ESTIMATED,INTERVENTIONAL
FPHAF,Faron Pharmaceuticals Oy,NCT05428969,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML","Bexmarilimab, Azacitidine, Venetoclax",BEXMAB,NON_RANDOMIZED,3,"Phase 1 - Intermediate/high risk MDS, CMML 10-19%, MDS/CMML failure to HMA, r/r AML | Phase 1 - Newly diagnosed AML patients non-fit for induction therapy | Phase 2 - Intermediate/high risk MDS, CMML, MDS/CMML failure to HMA, r/r AML & newly diagnosed AML",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.",,2026-04,ESTIMATED,18 Years - N/A,181,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia",2026-04,ESTIMATED,Reporting of incidence and frequency of dose limiting toxicities (DLTs). | Frequency and severity based on NCI-CTCAE grading of treatment emergent AEs and serious adverse events (SAE). | Complete response (CR) rate for MDS and CMML-2. | Overall response rate (ORR) for MDS and CMML failure to prior HMA. | Complete remission with incomplete blood recovery (CRi) for r/r AML. | Minimal residual disease (MRD) status for newly diagnosed AML.,TREATMENT,ALL,2022-06-02,ACTUAL,INTERVENTIONAL
HOFBF,Hofseth BioCare ASA,NCT07119645,,NOT_YET_RECRUITING,"Activity-Related Knee Discomfort, Joint Discomfort, Functional Joint Pain, Functional Knee Pain, Knee Acute and Chronic Pain",,NTII-JOINT,RANDOMIZED,3,NT-II™ 240 mg | NT-II™ 480 mg | Glucosamine/Chondroitin,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this clinical trial is to learn whether a natural marine supplement called NT-II™ (Salmon Undenatured Type II Collagen) can help lower knee discomfort caused by physical activity in otherwise healthy adults. Many active people experience knee pain when performing daily movements like climbing stairs, walking long distances, or squatting, even if they do not have a medical diagnosis such as arthritis. This discomfort can limit mobility, impact exercise routines, and reduce overall qua",,2026-03-15,ESTIMATED,20 Years - 65 Years,120,ESTIMATED,PARALLEL,INDUSTRY,NONE,"A Decentralized, Randomized, Active-Controlled Clinical Trial Investigating the Effects of NT-II™ (Salmon Undenatured Type II Collagen) on Activity-Related Knee Discomfort and Functional Performance in Healthy Adults",2026-03-15,ESTIMATED,Change in participant-nominated activity-related knee discomfort (VASNA for pain) from baseline to week 12,TREATMENT,ALL,2025-10-19,ESTIMATED,INTERVENTIONAL
IXHL,Incannex Healthcare Inc.,NCT06146101,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,Obstructive Sleep Apnea,"IHL-42X Low Dose, IHL-42X High Dose, Placebo, IHL-42X (Optimal Dose), Dronabinol, Acetazolamide, Placebo",REPOSA,RANDOMIZED,7,Phase 2 Investigational Product - IHL-42X Low dose | Phase 2 Investigational Product - IHL-42X High dose | Phase 2 Placebo | Phase 3 Investigational Product - IHL-42X | Phase 3 Comparator - Reference Listed Drug/Dronabinol | Phase 3 Comparator - Reference Listed Drug/Acetazolamide | Phase 3 Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The goal of this randomised, double-blind phase II/III clinical trial is to determine the safety and efficacy of IHL-42X in subjects with obstructive sleep apnoea who are intolerant, non-compliant, or naïve to positive airway pressure.

Phase II study will be a 4-week dose-finding study comparing two dose strengths of IHL-42X to placebo. The optimal dose strength will be selected based on comparing the safety and efficacy of the two IHL-42X dose strengths to placebo over a 4-week treatment perio",,2026-12,ESTIMATED,18 Years - N/A,560,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL-42X in Subjects With Obstructive Sleep Apnoea Who Are Intolerant, Non-Compliant, or Naïve to Positive Airway Pressure",2026-12,ESTIMATED,Change in apnea-hypopnea index (AHI) | Change in apnea-hypopnea index (AHI),TREATMENT,ALL,2024-05-02,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05011331,,RECRUITING,Rotator Cuff Injuries,,,RANDOMIZED,2,MedCline Shoulder Relief System | Control,EXPERIMENTAL | ACTIVE_COMPARATOR,The objective of this study is to determine if a pillow sleep aid improves sleep quality in the short term for patients who have shoulder pain from a rotator cuff injury and are being managed non-operatively.,"Amenity Health, Inc.",2027-12,ESTIMATED,18 Years - N/A,80,ESTIMATED,PARALLEL,OTHER,NONE,The Effect of a Custom Pillow on Sleep Quality in Patients With Nonoperative Rotator Cuff Syndrome: a Prospective Randomized Study,2026-12,ESTIMATED,Change in Sleep Difficulty as Assessed as Assessed Using the Insomnia Severity Index (ISI) | Change from Baseline in Pain Scores on the Visual Analog Scale (VAS) | Change in Quality of Life as Assessed Using the Euroqol (EQ-5D) | Change in Shoulder Function as Assessed Using the American Shoulder and Elbow Surgeons Shoulder Score (ASES) | Change in Shoulder Function as Assessed Using the Single Assessment Numeric Evaluation (SANE) | Change in Shoulder Function as Assessed Using the Western Ontario Rotator Cuff Index (WORC),TREATMENT,ALL,2020-10-13,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05990881,PHASE3,RECRUITING,"Carpometacarpal Sprain, Thumb Sprain, Clostridium; Botulinum","Botulinum toxin, Standard-of-care corticosteroid injections",,RANDOMIZED,2,Control | Botulinum Toxin,ACTIVE_COMPARATOR | EXPERIMENTAL,"The purpose of this clinical trial is to gather information on the safety and effectiveness of botulinum toxin injection (or Botox) in the treatment of thumb joint pain/arthritis. People with thumb joint pain or arthritis usually receive steroid injections to help with the pain. However, this medicine does not always work well and also carries known important side effects. There is currently no alternative to this injection medicine.

This clinical trial seeks to investigate botulinum toxin as a",,2026-07,ESTIMATED,18 Years - N/A,50,ESTIMATED,PARALLEL,OTHER,SINGLE,Botulinum Toxin Injection in the Management of Thumb Carpometacarpal Arthritis: a Randomized Controlled Trial,2025-12,ESTIMATED,Thumb Pain,TREATMENT,ALL,2023-08-27,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06579209,,RECRUITING,"Cognitive Change, Inflammation, Neurodegenerative Diseases",,,RANDOMIZED,3,Pre-testing prior to intervention | Post-testing after intervention | Intervention,NO_INTERVENTION | NO_INTERVENTION | EXPERIMENTAL,"The goal of this clinical trial is to learn if Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women who identify as Latina and are between the ages of 40-80. The main questions it aims to answer are:

Will executive function change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving the NAD+ to see if the results differ fr",National Institute of General Medical Sciences (NIGMS),2025-09-01,ESTIMATED,40 Years - 80 Years,50,ESTIMATED,PARALLEL,OTHER,DOUBLE,NAD+ Oral Supplement Pilot Intervention in Adult Females,2025-09-01,ESTIMATED,Neurocognition | Neurodegenerative disease panel | Markers of systemic inflammation,TREATMENT,FEMALE,2024-12-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07404800,,ACTIVE_NOT_RECRUITING,"Dating Violence, Firearm Injury and Violence",,,,1,Cohort consists of adult participants with an average age of 28 - 30 years old.,,"This sub-study aims to identify key individual (e.g., demographic, socioeconomic, attitudes), relationship, behavioral and situational, trauma related, and neighborhood/community risk and protective factors for gun access, carriage, and use.","Rhode Island Hospital, Georgia State University, Sam Houston State University, Centers for Disease Control and Prevention",2027-12,ESTIMATED,18 Years - N/A,1500,ESTIMATED,,OTHER,,Longitudinal Investigation of the Risk and Protective Factors of Dating Violence (Dating it Safe) - Firearms,2027-12,ESTIMATED,"Identify key individual (e.g., demographic, socioeconomic, attitudes), relationship, behavioral and situational, trauma related, and neighborhood/community risk and protective factors for gun access, carriage, and use. | Qualitative interviews with known gun-carriers",,ALL,2024-06-16,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07197476,,NOT_YET_RECRUITING,"PTSD, Substance Use Disorder (SUD), Acute Stress Disorder",,ASSIST,,1,Develop and Pilot Test ASSIST Video Intervention,EXPERIMENTAL,"The long-term goal of this study is to address the adoption of the new trauma center requirement to establish best practices of screening for acute stress with an intervention to prevent both adolescent PTSD and substance use. The investigators will develop, refine, and pilot test the Adolescent Stress and Substance Intervention Subsequent to Trauma (ASSIST) video interventions that build upon the American College of Surgeons Committee on Trauma guidelines to improve mental health care during an",National Institute on Drug Abuse (NIDA),2027-04,ESTIMATED,12 Years - 17 Years,62,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Adolescent Injury: Intervening to Prevent Posttraumatic Stress and Substance Use Outcomes,2027-04,ESTIMATED,"To develop and refine two ASSIST video interventions for adolescents and parents admitted to a level 1 pediatric trauma center. | To evaluate the feasibility, acceptability, and implementation potential of the ASSIST video interventions. | Develop the ASSIST implementation protocol",TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06974604,PHASE2,RECRUITING,"Breast Neoplasms, Lung Neoplasms",Dexamethasone oral,,,1,Dexamethasone 10mL,EXPERIMENTAL,"TROPION-DM/BrUOG-431 is a prospective, , phase 2 trial with two non-comparative cohorts analyzed jointly for primary endpoint in adult patients with either (Cohort 1:) advanced/metastatic hormone-receptor positive (\[HR+\], estrogen receptor and/or progesterone receptor positive) breast cancer (BC), or advanced/metastatic triple negative breast cancer (TNBC) or (Cohort 2:) advanced/metastatic non-squamous non-small cell lung cancer (NSCLC).

All patients will be treated with Datopotumab deruxtec","Rhode Island Hospital, The Miriam Hospital",2029-05-31,ESTIMATED,18 Years - N/A,60,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Prevention of Datopotamab Deruxtecan (TROP-2 Directed ADC) Associated Stomatitis in Patients With HER2-negative Metastatic Breast Cancer or Non-small Cell Lung Cancer Using Dexamethasone Mouthwash: a Single-arm, Phase 2 Trial (TROPION- DM, 2023-ESR-000087)",2027-05-31,ESTIMATED,Lower the incidence of all stomatitis,TREATMENT,ALL,2025-10-22,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06931158,,RECRUITING,"Chronic Low-back Pain, Chronic Pain",Open-label Placebo,HOPE,RANDOMIZED,4,OLP + Standard Rationale | OLP + Mindfulness Rationale | OLP + Control Rationale | No Treatment + Control Rationale,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | SHAM_COMPARATOR,The goal of this clinical trial is to examine the effect of rationale condition when taking open-label placebos on pain by 1) comparing each rationale to the no rationale control condition and the no treatment control condition; and 2) comparing the rationale conditions to each other. We also aim to examine the effect of rationale condition on prescription opioid use by 1) comparing each rationale to the no rationale control condition and the no treatment control condition; and 2) comparing the ,,2027-03,ESTIMATED,18 Years - 89 Years,340,ESTIMATED,PARALLEL,OTHER,NONE,Optimizing Open Placebos for Chronic Pain Patients,2027-01,ESTIMATED,Pain intensity,TREATMENT,ALL,2025-03-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06411158,,RECRUITING,"Urinary Incontinence, Delivery Complication",,TULIP,RANDOMIZED,3,Interventionist-guided training | Home pelvic floor exercises guided by the leva® device | Education,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | OTHER,"This is a multi-center, randomized single-blind nonsurgical trial conducted in approximately 216 primiparous postpartum women at high risk for prolonged/sustained pelvic floor disorders with symptomatic, bothersome urinary incontinence (UI) amenable to nonsurgical treatment.

TULIP is a 3-Arm trial with two active interventions (Arms 1 and 2) and a Patient Education control arm (Arm 3). Arm 1 consists of pelvic floor muscle training (PFMT). Arm 2 uses a home biofeedback device (leva®).

The prim","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Duke University, Kaiser Permanente, University of California, San Diego, University of Chicago, University of Pennsylvania, University of Texas Southwestern Medical Center, Women and Infants Hospital of Rhode Island, RTI International",2027-11-12,ESTIMATED,18 Years - N/A,216,ESTIMATED,PARALLEL,NETWORK,SINGLE,Training for Urinary Leakage Improvement After Pregnancy,2027-05-12,ESTIMATED,Change in urinary incontinence measure by the ICIQ-SF,TREATMENT,FEMALE,2024-11-12,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06896656,,RECRUITING,"Loneliness, Opioid Use Disorder",,STAR,RANDOMIZED,2,MPS App | Enhanced Treatment as Usual,EXPERIMENTAL | ACTIVE_COMPARATOR,"People with a history of Opioid Use Disorder and criminal justice involvement are more likely to experience loneliness following release from jail/prison leading to negative outcomes such as treatment dropout and increased substance use. Providing peer recovery support, particularly through a highly accessible, digital health platform, is a potential way to decrease loneliness in this population. The current study seeks to test whether a mobile peer recovery support app, delivered to individuals",,2026-04-30,ESTIMATED,18 Years - N/A,90,ESTIMATED,PARALLEL,OTHER,SINGLE,Improving Social Connectedness Through Digital Health to Enhance Recovery from OUD Among the Justice Involved Population,2026-01-31,ESTIMATED,Social Support | Loneliness,TREATMENT,ALL,2025-03-17,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05380765,,RECRUITING,"Alcohol Drinking, Tobacco Use, Drug Use",,,RANDOMIZED,2,Native PATHS Condition | Wait-List Control,EXPERIMENTAL | NO_INTERVENTION,"The overall objective of this project is to develop and obtain preliminary data on acceptability, feasibility, and initial efficacy of Native PATHS. This work is guided by the stage model guidelines for treatment development and adaptation 25. Stage 1a will occur in two sequential steps. First, the investigators will recruit youth who are in 5th - 8th grade and their family members (N=24, 12 youth, 12 adults 18+) to participate in three talking circle sessions to obtain feedback on the cultural ",,2025-05-31,ESTIMATED,10 Years - 14 Years,60,ESTIMATED,PARALLEL,OTHER,NONE,Developing a Positive Approach to Substance Use Prevention in North American Indian Adolescents,2025-05-31,ESTIMATED,Past month alcohol use | Past month alcohol use | Past month alcohol use | Past three-month alcohol use | Past three-month alcohol use | Past three-month alcohol use | Past month marijuana use | Past month marijuana use | Past month marijuana use | Past three-month marijuana use | Past three-month marijuana use | Past three-month marijuana use | Past month cigarette smoking | Past month cigarette smoking | Past month cigarette smoking | Past three-month cigarette smoking | Past three-month cigarette smoking | Past three-month cigarette smoking | Alcohol use intentions | Alcohol use intentions | Alcohol use intentions | Cigarette smoking susceptibility | Cigarette smoking susceptibility | Cigarette smoking susceptibility | Marijuana use intentions | Marijuana use intentions | Marijuana use intentions,PREVENTION,ALL,2024-06-17,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT02412696,,ACTIVE_NOT_RECRUITING,"Obstructive Sleep Apnea, Pregnancy, Obesity, Preeclampsia, Sleep",,PAP-SAP,RANDOMIZED,2,Positive Airway Pressure | Nasal Dilator Strips,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"This study is testing the hypothesis of whether continuous positive airway pressure (CPAP) therapy improves placental histopathology and secretory function. The main aims of the study are to identify shared mechanisms between obstructive sleep apnea and preeclampsia, both common highly morbid conditions.","Brown University, Rhode Island Hospital, Women and Infants Hospital of Rhode Island, Brigham and Women's Hospital",2025-05-01,ESTIMATED,18 Years - N/A,262,ESTIMATED,PARALLEL,OTHER,SINGLE,Placental Role in Mediating Adverse Outcomes in Obstructive Sleep Apnea,2020-08-01,ACTUAL,Alterations in circulating placenta-secreted markers. | Changes in placental histopathology for markers of malperfusion and placental expression of markers,OTHER,FEMALE,2015-06-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06474741,,NOT_YET_RECRUITING,Torticollis,,,RANDOMIZED,2,intervention | control,EXPERIMENTAL | NO_INTERVENTION,"The goal of this clinical trial is to test whether an app-based intervention can reduce the likelihood of a torticollis diagnosis in infants. The main question\[s\] it aims to answer are:

* whether an app can successfully deliver an intervention to parents of young infants
* whether parents who learn about torticollis will increase behaviors intended to prevent torticollis compared to parents who learn about general infant development

Participants will complete a monthly survey for 6 months as",Duquesne University,2027-12,ESTIMATED,1 Day - 1 Month,56,ESTIMATED,PARALLEL,OTHER,SINGLE,Both Sides Now: Using Computer Vision and App-based Intervention for Prediction and Prevention of Infant Torticollis and Plagiocephaly,2027-05,ESTIMATED,symmetry score,PREVENTION,ALL,2025-06,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05491941,,RECRUITING,"Sepsis Severe, Septic Shock",,AIMS,RANDOMIZED,2,Hour-1 Bundle | 3-Hour Bundle,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"Since the introduction of sepsis bundles, there have been multiple published trials that have demonstrated a consistent, strong association between implementation of sepsis ""bundles"" (3-hour bundle) and improved survival. The current proposal is a Hybrid 2, pragmatic, cluster randomized clinical effectiveness/implementation trial evaluating mortality and respiratory failure-based outcomes, in patients admitted to the emergency department with sepsis, comparing the effectiveness of implementation",,2027-07-15,ESTIMATED,18 Years - N/A,10000,ESTIMATED,PARALLEL,OTHER,NONE,Assessment for Implementation Methods in Sepsis,2027-07-15,ESTIMATED,Mortality,TREATMENT,ALL,2022-07-15,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07303946,,NOT_YET_RECRUITING,Obsessive-Compulsive Disorder,,,RANDOMIZED,2,ACB | vALIC arms,EXPERIMENTAL | EXPERIMENTAL,"This is a double blind pilot feasibility study, with a within subject crossover design of DBS of the anterior cingulate bundle(ACB) and the ventral anterior limb of the internal capsule(vALIC) in four patients with intractable OCD. Patients will be screened according to inclusion exclusion criteria listed above, approved by an independent Neuropsychiatric review board and informed consent obtained.","Brown University, Baylor College of Medicine, Butler Hospital",2031-01,ESTIMATED,21 Years - 65 Years,4,ESTIMATED,CROSSOVER,OTHER,QUADRUPLE,"Double-Blind, Crossover, Feasibility Study of Deep Brain Stimulation of the Anterior Cingulate Bundle (ACB) and the Ventral Anterior Limb of the Internal Capsule (vALIC) in Patients With Intractable Obsessive Compulsive Disorder (OCD)",2030-01,ESTIMATED,Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) | Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) | Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) | Clinical Global Impression (CGI) | Clinical Global Impression (CGI) | Clinical Global Impression (CGI),TREATMENT,ALL,2026-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04253262,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Metastatic Castration-resistant Prostate Cancer,"Rucaparib, Copanlisib",,NON_RANDOMIZED,6,Dose Level -2 | Dose Level -1 | Dose Level 1 | Dose Level 2 | Dose Level 3 | Dose Level 4,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a single arm Phase Ib/II, open label, safety, pharmacokinetic and efficacy clinical study in adult patients with metastatic castration-resistant prostate cancer (mCRPC). Patients will be treated with the combination of copanlisib and rucaparib for as long as the patient does not have clinically significant progressive disease and/or unacceptable toxicity and/or as long as the investigator deems that the patient is benefiting from treatment. Treatment may also be stopped if the patient wi","Rhode Island Hospital, The Miriam Hospital, Bayer, Clovis Oncology, Inc.",2027-01,ESTIMATED,18 Years - N/A,13,ACTUAL,SEQUENTIAL,OTHER,NONE,A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer,2027-01,ESTIMATED,Maximum Tolerated Dose | Response,TREATMENT,MALE,2020-04-03,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06861868,,RECRUITING,Obesity and Overweight,,RESONATE,,0,,,"The investigators project, RESONATE, aims to investigate why some children develop obesity. To do this it uses data on eating and eating-related behaviors, genetic and environmental factors, and brain structure and function. This data is collected in a sub-sample of RESONANCE, a large study of families of children from infancy through childhood. The results will lay foundations for the development of early interventions to prevent or treat obesity.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Rhode Island Hospital, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of Washington",2029-03-31,ESTIMATED,7 Years - 12 Years,210,ESTIMATED,,OTHER,,Early Brain Development and Child Nutrition and Obesity,2029-03-31,ESTIMATED,Meal test intake as assessed by total kilocalories consumed | Weight/adiposity as assessed by BMI | Food-related reward as assessed by food-related delay discounting task | Food-related cognitive control as assessed by food-related go/no-go task | Functioning in brain appetite circuits as assessed by cue reactivity task | Functioning in brain appetite circuits as assessed by cognitive control task,,ALL,2024-12-02,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06849869,,RECRUITING,Perinatal Mental Health,,COMPASS+,RANDOMIZED,2,COMPASS+ | Usual care,EXPERIMENTAL | NO_INTERVENTION,"The collaborative care model (CCM) is a health services intervention that integrates mental health care in primary care settings. The goal of this study is to adapt the CCM to the perinatal care context, including community co-designed adaptations to enhance health equity (COMPASS+). The main objectives of the study are to:

1. Evaluate the effect of COMPASS+ on depression symptom outcomes. Specifically we will evaluate population-level depression symptom trajectories and the prevalence of suici","Brown University, National Institute of Nursing Research (NINR)",2028-06,ESTIMATED,18 Years - N/A,14820,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Collaborative Care Model for Perinatal Depression Support Services -- Population-Level Equity-Centered Systems Change (COMPASS-PLUS): a Hybrid Type 2 Cluster Randomized Trial,2028-06,ESTIMATED,Patient Health Questionnaire-9 (PHQ9) trajectories,HEALTH_SERVICES_RESEARCH,FEMALE,2025-02-24,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06316830,"PHASE2, PHASE3",RECRUITING,Opioid Use Disorder,Buprenorphine,Optimal Bup,RANDOMIZED,2,High Maintenance Daily Dose (24mg) | Standard Maintenance Daily Dose (16mg),EXPERIMENTAL | ACTIVE_COMPARATOR,"The investigators aim to test the effectiveness of a high maintenance daily dose of buprenorphine (24 mg) for improving outcomes among patients who used fentanyl compared to the standard daily dose (16 mg).

The main question it aims to answer is: will patients who are randomly assigned to the high 24 mg maintenance dose, as compared to patients randomly assigned to the standard 16 mg maintenance dose, have improved retention in buprenorphine treatment (primary outcome), improved treatment respo",Brown University,2027-11-01,ESTIMATED,18 Years - N/A,250,ESTIMATED,PARALLEL,OTHER,NONE,Randomized Clinical Trial of a 16 mg vs. 24 mg Maintenance Daily Dose of Buprenorphine to Increase Retention in Treatment Among People With Opioid Use Disorder,2027-08-01,ESTIMATED,Treatment Engagement,TREATMENT,ALL,2025-01-06,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04680377,,RECRUITING,"NSCLC, Stage III, Locally Advanced Lung Carcinoma",,Microdurva,,1,Participants receiving standard of care durvalumab,,This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.,Rhode Island Hospital,2026-12,ESTIMATED,18 Years - N/A,44,ESTIMATED,,OTHER,,Using Microbiome to Predict Durvalumab Toxicity in Post-CCRT NSCLC Patients (Microdurva),2025-12,ESTIMATED,Grade 3 or higher adverse events (AE's) | Longitudinal changes in Microbiome | Longitudinal changes in bacterial metabolic pathway,,ALL,2021-04-12,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06135636,PHASE4,RECRUITING,"Non-birthing Partner Vaccination in Pregnancy, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Vaccine Exposure During Pregnancy",Vaccine administration,ITAPP,RANDOMIZED,3,Usual Care | Upfront Education Only | Upfront Education and Vaccination Administration:,NO_INTERVENTION | EXPERIMENTAL | EXPERIMENTAL,"The goal of this randomized control trial is to assess if prenatal vaccine education and in-office vaccination administration for non-birthing partners of pregnant patients increases Tdap vaccination rates compared to usual care.

The main question\[s\] it aims to answer are:

* To assess whether compared to standard prenatal care, targeted prenatal education regarding Tdap vaccination recommendations with and without in office vaccination opportunities improves Tdap uptake among non-birthing pa",,2025-06-30,ESTIMATED,19 Years - 50 Years,150,ESTIMATED,PARALLEL,OTHER,NONE,Assessing Interventions to Increase Tdap Acceptance for Non-birthing Partners in Pregnancy,2025-06-30,ESTIMATED,Tdap vaccination rate for non-birthing partners,HEALTH_SERVICES_RESEARCH,ALL,2024-05-28,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06894277,,RECRUITING,"Risky Sexual Behavior, Emotion Regulation, Adolescent Behavior",,iTRAC-HERO,RANDOMIZED,2,Waitlist Control | iTRAC-HERO,NO_INTERVENTION | EXPERIMENTAL,"Using the efficacious iTRAC intervention to enhance emotion regulation competencies as a foundation, this study will create and test iTRAC-HERO to teach emotion regulation skills in the context of sexual health education.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Rhode Island Hospital, University of Oregon",2025-12-08,ESTIMATED,12 Years - 14 Years,120,ESTIMATED,PARALLEL,INDUSTRY,NONE,Interactive Emotion Regulation Skills Training to Improve Adolescent Health Ph II,2025-12-08,ESTIMATED,Change in Sexual Self-Efficacy (SSE) from baseline to 6 months. | Change in Self Efficacy for HIV Prevention from baseline to 6 month.,PREVENTION,ALL,2025-04-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04302259,,ACTIVE_NOT_RECRUITING,Spinal Cord Injury,,ISI-C,,1,SCI Patient,EXPERIMENTAL,"This research study is being done to test a new device developed for spinal cord injury (SCI) patients. The purpose of this study is to collect data on how the nervous system signals travel within the spinal cord of SCI patients. Once the investigators understand that, they hope to develop a device that may help rehabilitation of SCI patients so that they can regain function in their lower limbs.

This study involves some imaging studies (e.g. X-rays etc.), surgical implantation of a portion of ","US Department of Veterans Affairs, Brown University, Intel Corporation",2025-06-30,ESTIMATED,18 Years - 65 Years,3,ACTUAL,SINGLE_GROUP,OTHER,NONE,An Early Feasibility Study to Evaluate ISI-C in SCI Patients,2025-06-30,ESTIMATED,Evaluate safety issues,DEVICE_FEASIBILITY,ALL,2021-09-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT03626103,,ACTIVE_NOT_RECRUITING,"Depressive Disorder, Violence",,iDOVE2,RANDOMIZED,4,"+ Brief ED Intervention (BI), + Text | + Brief ED Intervention (BI), no Text | No Brief ED Intervention (BI), + Text | No Brief ED Intervention (BI), no Text",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,"The purpose of this investigation is to test the efficacy of ""iDOVE2"" (a brief emergency department introductory session and longitudinal automated text-message depression prevention program for high-risk teens), and to determine the most potent and parsimonious combination of intervention components for preventing peer violence and depressive symptoms among at-risk youth.",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),2025-02,ESTIMATED,13 Years - 17 Years,800,ESTIMATED,FACTORIAL,OTHER,SINGLE,A Technology-Augmented Intervention to Prevent Peer Violence & Depressive Symptoms Among At-Risk Emergency Department Adolescents,2025-02,ESTIMATED,"Conflict Tactics Scale-2, physical subset (CTS-2) | Center for Epidemiologic Studies Depression Scale Revised (CESD-R)",PREVENTION,ALL,2018-08-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT03936361,PHASE3,RECRUITING,Intracerebral Hemorrhage,Statins,SATURN,RANDOMIZED,2,Statin | No-statin,ACTIVE_COMPARATOR | NO_INTERVENTION,"The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype.

An MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cere","NINDS Stroke Trials Network (StrokeNet), Canadian Stroke Consortium (CSC), University of Cincinnati, Medical University of South Carolina, Yale University, MetroHealth Medical Center, UH, Cleveland Medical Center, Corewell Health West, West Virginia University, Columbia University, Weill Medical College of Cornell University, New York Presbyterian Brooklyn Methodist Hospital, Buffalo General Medical Center, State University of New York - Upstate Medical University, St. Joseph's Regional Medical Center, New Jersey, Tufts Medical Center, Massachusetts General Hospital, UMass Memorial Health, Brigham and Women's Hospital, Baystate Medical Center, University of Vermont Medical Center, Lahey Hospital & Medical Center, Augusta University Medical Center, Prisma Health-Upstate, The Moses H. Cone Memorial Hospital, University of Virginia, George Washington University, University of Maryland, Baltimore, Mount Sinai Hospital, New York, NYU Langone Medical Center - Tisch Hospital, Montefiore Medical Center, NYU Langone Hospital - Brooklyn, Froedtert Hospital, Central DuPage Hospital, Rush University Medical Center, Loyola University, Stanford University, Mercy San Juan Medical Center, Oregon Health and Science University, Kaiser Permanente, University of Southern California, Cedars-Sinai Medical Center, University of New Mexico, Long Beach Memorial Medical Center, University of California, Irvine, Arrowhead Regional Medical Center, Huntington Memorial Hospital, Scripps Health, University of California, San Diego, Ochsner Health System, St. Joseph's Hospital and Medical Center, Phoenix, Desert Care Network, Eden Medical Center, San Francisco General Hospital, University of California, San Francisco, University of Louisville, Ohio State University, University of Iowa, Sanford Medical Center Fargo, University of Nebraska, Tampa General Hospital, University of Florida, Jackson Health System, Mayo Clinic, Baptist Medical Center Jacksonville, Wayne State University, University of Michigan, Mercy Health Saint Mary Grand Rapids, Metro Health, Michigan, University of Kentucky, McLaren Health Care, Regions Hospital, Allina Health System, University of Kansas, University of Minnesota, St. Cloud Hospital, Milton S. Hershey Medical Center, Abington Memorial Hospital, Temple University, University of Pennsylvania, Lehigh Valley Hospital, York Hospital, York, PA, Thomas Jefferson University, University of Pittsburgh, St. David's HealthCare, Baylor College of Medicine, Tulane Medical Center, The University of Texas Health Science Center at San Antonio, OU Medical Center, University of Utah, Swedish Medical Center, St. Mary's Medical Center, Banner University Medical Center, Intermountain Medical Center, Legacy Emanuel Medical Center, Sacred Heart Medical Center Springfield, Harborview Injury Prevention and Research Center, University of Wisconsin, Madison, Aurora BayCare Medical Center, Wake Forest University Health Sciences, University of Alabama at Birmingham, University of South Alabama, Carolinas Medical Center, Barnes-Jewish Hospital, St. Luke's Hospital, Kansas City, Missouri, University of Arkansas, OSF Healthcare System, Cox Medical Center South, North Shore University Hospital, Rhode Island Hospital, Hartford Hospital, Staten Island University Hospital, Johns Hopkins University, University of North Carolina, Chapel Hill, University of Alberta, The Ottawa Hospital, London Health Sciences Centre, Hamilton General Hospital, Hopital de l'Enfant-Jesus, Montreal Neurological Institute and Hospital, Foothills Medical Centre, University Health Network, Toronto, Health Sciences Centre, Winnipeg, Manitoba, Thunder Bay Regional Health Sciences Centre, Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Fraser Health, Hopital de Chicoutimi, Université de Sherbrooke",2028-12-31,ESTIMATED,50 Years - N/A,1456,ESTIMATED,PARALLEL,OTHER,SINGLE,STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS,2027-06-30,ESTIMATED,Recurrent symptomatic ICH,PREVENTION,ALL,2020-06-10,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06480227,,RECRUITING,"Stress Urinary Incontinence, Urinary Incontinence, Mixed Urinary Incontinence",,BASIS,RANDOMIZED,2,Solyx Single-incision Sling | Bulkamid Transurethral Bulking Agent,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.

The Primary Aim is to determine the comparative effectiveness (as defined by ""much"" or ""very much"" better on PGI-I) of transurethral bulking agent (TBA) \[for 1 or 2 injections in 12 months\] vs. single-incision sling (SIS) 12 months after treatment interventio","Duke University, Kaiser Permanente, University of Chicago, University of Pennsylvania, University of Texas Southwestern Medical Center, Women and Infants Hospital of Rhode Island, RTI International, University of California, San Diego, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",2030-01-01,ESTIMATED,21 Years - N/A,358,ESTIMATED,PARALLEL,NETWORK,DOUBLE,A Randomized Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence,2028-01-01,ESTIMATED,Subjective success measured by Patient Global Impression-Improvement [PGI-I] (>2) for TBA vs. SIS at 12 months.,TREATMENT,FEMALE,2024-08-28,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06376006,,ACTIVE_NOT_RECRUITING,"Competence, Assessment, Self",,EMR-STAT,,0,,,Quality improvement project with the aim to use a standardized assessment tool (EMR-STAT) to establish learning curves and competence thresholds for key cognitive and technical colorectal EMR core skills among advanced endoscopy trainees (AETs).,"Duke University, University of South Florida, Stony Brook University, Atrium Medical Center, Hofstra University, Long Island Jewish Medical Center, Vanderbilt University, Yale University, Columbia University, Geisinger Clinic, Unity Health Toronto, University of Virginia, Baylor University, University of Kentucky, Cedars-Sinai Medical Center, University of Chicago, University of California, Irvine, University of Alabama at Birmingham, Beth Israel Deaconess Medical Center",2024-12-01,ESTIMATED,18 Years - N/A,42,ESTIMATED,,OTHER,,Prospective Multicenter Study Evaluating Learning Curves and Competence in Colorectal Endoscopic Mucosal Resection Among Advanced Endoscopy Trainees Using A Standardized Assessment Tool: A Quality Improvement Initiative,2024-04-01,ACTUAL,Primary Endpoint,,ALL,2022-05-11,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05795114,,RECRUITING,Perinatal Depression,,PPD-ACE,RANDOMIZED,2,Enhanced treatment as usual | ROSE intervention,NO_INTERVENTION | EXPERIMENTAL,"The goal of this clinical trial is to evaluate the impact of ROSE in individuals with adverse childhood experiences. The main question it aims to answer is, compared to enhanced treatment as usual, does the delivery of ROSE within a collaborative care model improve depressive symptom trajectories and prevent the development of perinatal depression.

Participants will be randomized to either enhanced treatment as usual or the ROSE intervention, delivered by a care manager within a perinatal colla",Women and Infants Hospital of Rhode Island,2026-01-31,ESTIMATED,18 Years - N/A,76,ESTIMATED,PARALLEL,OTHER,SINGLE,Prevention of Perinatal Depression in Birthing People With a History of Adverse Childhood Experiences: A Type 2 Effectiveness Implementation Trial,2025-09-01,ESTIMATED,Depression symptoms | Perinatal depression,PREVENTION,FEMALE,2023-07-20,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06747221,,NOT_YET_RECRUITING,HIV,,HEATED-SAIA,RANDOMIZED,1,Standard care,ACTIVE_COMPARATOR,"There are \~38 million people living with HIV (PLH), with the majority in low-and middle-income countries (LMICs), where the UNAIDS 95-95-95 HIV targets are at risk of not being achieved. Data show that incident infections are concentrated in sub-Saharan Africa and focused in difficult to reach populations. These harder to reach persons frequently also have higher-risk profiles for HIV, making them essential target populations to receive HIV Testing Services (HTS). Among target populations, men,","University of Washington, Brown University",2030-03-31,ESTIMATED,18 Years - N/A,184,ESTIMATED,PARALLEL,OTHER,NONE,HIV Enhanced Access Testing in Emergency Department Program Using a Systems Analysis and Improvement Approach (HEATED-SAIA) Cluster Randomized Trial,2028-06-30,ESTIMATED,Reach: Staff Engagement | Reach: Patient Participation | Effectiveness: HIV Testing Delivery | Effectiveness: Linkage to Care for People Living with HIV | Effectiveness: PrEP Screening & Referral | Adoption: Uptake Determinants | Adoption: Staff Intentions | Implementation: Feasibility | Implementation: Fidelity | Implementation: Facilitators & Barriers | Maintenance: Sustainability | Maintenance: Penetration | Economic evaluation: ED-HTS and implementation of the HEATED-SAIA program,HEALTH_SERVICES_RESEARCH,ALL,2026-06-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07011563,,RECRUITING,"HIV Prevention, Sexual Health",,,RANDOMIZED,2,Intervention | Treatment as usual +,EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this study is to help young people talk to trusted adults (including their parents, but also other adults) about sexual health more openly and honestly- including how to prevent sexually transmitted diseases like HIV - while also respecting a young person's right to privacy. If youth don't have a parent they can talk to about sexual health, we want to help them find a trusted adult to talk to. We also want to help youth take control of their own health by learning about different way",National Institute of Mental Health (NIMH),2025-11-01,ESTIMATED,14 Years - 17 Years,40,ESTIMATED,PARALLEL,OTHER,SINGLE,Prepping for The Talk: Helping Trusted Adults and Youth Talk About Sexual Health,2025-11-01,ESTIMATED,Sexual health communication scale score - youth | Sexual health communication scale score - parent,PREVENTION,MALE,2025-05-16,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06737055,,RECRUITING,"Sleep, Postpartum Depression, Pregnancy Related, Insomnia, Sleep Deprivation, Sleep Hygiene, Sleep Disturbance",,,NON_RANDOMIZED,2,Home Visitors | Expectant and New Parents,EXPERIMENTAL | EXPERIMENTAL,"Insufficient and disrupted sleep are rarely addressed in expectant and new mothers, despite evidence that disturbed sleep is a modifiable risk factor for negative health outcomes for mothers and their children. In this study the investigators will adapt, refine, and pilot test the implementation of a behavioral sleep intervention consisting of short videos designed to accompany a free behavioral sleep app. In Phase 1, the investigators will develop and refine the intervention with input from dir",Bradley Hospital,2025-06-30,ESTIMATED,18 Years - 99 Years,55,ESTIMATED,SINGLE_GROUP,OTHER,NONE,The Dream Team: Testing Implementation of a Sleep Intervention for Perinatal Women Delivered by Direct Care Workers,2025-05-31,ESTIMATED,Phase 1 Reach | Phase 1 Effectiveness | Phase 1 Acceptability | Phase 2 Reach | Phase 2 Effectiveness | Phase 2 Effectiveness - Insomnia Severity Index | Phase 2 Effectiveness - Implementation,HEALTH_SERVICES_RESEARCH,ALL,2023-08-08,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT03543098,,ACTIVE_NOT_RECRUITING,"Knee Dislocations, Multiple Ligament Knee Injuries",,,RANDOMIZED,6,Early Surgery & Early Rehab | Early Surgery & Delayed Rehab | Delayed Surgery & Early Rehab | Delayed Surgery & Delayed Rehab | Early Rehab Only | Delayed Rehab Only,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to investigate effects of timing of surgery (early vs. delayed) and timing of post-operative rehabilitation (early vs. delayed) for the treatment of military personnel and civilians that sustain a multiple ligament knee injury. To achieve this overall objective of this project, we will conduct two parallel randomized clinical trials. For the first study we will randomize individuals to timing of surgery and timing of post-operative rehabilitation. We hypothesize that","Rhode Island Hospital, Hospital for Special Surgery, New York, Mayo Clinic, New York University, University of Cincinnati, University of Kentucky, University of Maryland, University of Michigan, University of Minnesota, University of Missouri-Columbia, University of New Mexico, University of Washington, Washington University School of Medicine, San Antonio Military Medical Center, Walter Reed National Military Medical Center, William Beaumont Army Medical Center, TRIA Orthopaedic Center, Wake Forest University, Unity Health Toronto, Western University, Canada, Ochsner Health System, Yale University, OrthoCarolina Research Institute, Inc., Louisiana State University Health Sciences Center Shreveport, Duke University, University of Calgary, Oregon Health and Science University, Wake Forest University Health Sciences, Orlando Health, Inc., Fraser Orthopaedic Institute",2027-06,ESTIMATED,16 Years - 55 Years,690,ESTIMATED,PARALLEL,OTHER,NONE,STaR (Surgical Timing and Rehabilitation) Trial for Multiple Ligament Knee Injuries,2027-06,ESTIMATED,Time to Return to Pre-Injury Level of Activity | Patient-Reported Physical Function - Activity Limitation Scale of the Multiple Ligament Quality of Life (MLQoL) Questionnaire,TREATMENT,ALL,2018-07-31,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05674604,,RECRUITING,"Shoulder Pain, Knee Pain, Spasticity, Pain, Acute Stroke",,,,1,Participants,,"The purpose of the study is to measure the outcomes of a standard care, an ultrasound guided mini-invasive percutaneous procedure, performed on recent stroke patients on reduces pain, increases function \& quality of life

The primary objective of the project is to reduce shoulder and/or knee pain in patients who have had a stroke so that they can more readily engage in rehabilitation.

Secondary objectives are to reduce analgesic medications, increase independence and improve range of motion, t",,2024-12,ESTIMATED,18 Years - 80 Years,25,ESTIMATED,,OTHER,,Cryoneurolysis as a Drug Free Novel Treatment for Knee and Shoulder Pain Impairing Inpatient Neurological Rehabilitation,2024-10,ESTIMATED,"to determine any changes in shoulder pain, after the cryoneurolysis. | to determine any changes in shoulder pain, based on physician's assessment, after the cryoneurolysis. | to determine any changes in knee pain, after the cryoneurolysis | the degree of range of motion changes after the cryoneurolysis. | The degree of changes in targeted muscles tone.",,ALL,2022-10-10,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04629599,,RECRUITING,Major Depressive Disorder,,HeAL,RANDOMIZED,2,Interpersonal psychotherapy for major depression following perinatal loss | Coping with Depression,EXPERIMENTAL | ACTIVE_COMPARATOR,"This study tests the efficacy of interpersonal psychotherapy (IPT) for major depression following perinatal loss (early and late fetal death and early neonatal death) in a sample of 274 women in Flint and Detroit, Michigan. The trial will be the first fully powered randomized trial of treatment for any psychiatric disorder following perinatal loss.",Women and Infants Hospital of Rhode Island,2025-11-01,ESTIMATED,18 Years - 50 Years,200,ESTIMATED,PARALLEL,OTHER,SINGLE,IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL),2025-11-01,ESTIMATED,Time to Major Depressive Disorder recovery,TREATMENT,FEMALE,2021-08-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05420766,,RECRUITING,"Asthma in Children, Sleep Hygiene, Sleep, Inadequate",,AIMS,RANDOMIZED,2,Shortened Sleep | Usual Sleep Schedule,EXPERIMENTAL | ACTIVE_COMPARATOR,"Urban children with asthma are at high risk for short sleep, due to an environment that jeopardizes both sleep and asthma management. Further, urban children with asthma suffer from altered immune balance, a key biological process contributing to individual differences in asthma morbidity and sleep health. In the proposed research, the researchers will examine the effects of shortened and recovery sleep on immune balance and associated changes in lung function in urban children with allergic ast","Brown University, University of Mississippi Medical Center",2026-07-31,ESTIMATED,7 Years - 11 Years,204,ESTIMATED,PARALLEL,OTHER,NONE,Impact of Sleep Duration on Immune Balance in Urban Children With Asthma,2026-07-01,ESTIMATED,10mL of heparinized blood,OTHER,ALL,2022-05-15,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06537622,,NOT_YET_RECRUITING,"Cerebral Palsy, Prematurity",,CP,RANDOMIZED,2,Intervention aim | Implementation aim,OTHER | OTHER,"In this research, the investigators are using an implementation science approach to enhance the uptake of a clinical practice guideline for earlier diagnosis of cerebral palsy (i.e. what is being implemented) in neonatal follow-up clinics across Canada. This clinical practice guideline should be part of what neonatal follow-up specialists do in their routine clinical work with children born preterm. However, there is a wide variability in practice. The goal of this project is to harmonize practi","IWK Health Centre, St. Boniface Hospital, Sunnybrook Health Sciences Centre, Montreal Children's Hospital of the MUHC, Harvard University, University of British Columbia, Queen Alexandra Centre for Children's Health, Victoria, Jewish General Hospital, CHU de Quebec-Universite Laval, BC Women's Hospital & Health Centre, Dr. Everett Chalmers Hospital, Janeway Children's Health and Rehabilitation Centre, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Horizon Health Network, Moncton hospital, Windsor Regional Hospital, Maisonneuve-Rosemont Hospital, The Hospital for Sick Children, MOUNT SINAI HOSPITAL, Health Sciences Centre, Winnipeg, Manitoba, Glenrose Foundation, Hamilton Health Sciences Centre, London Health Sciences Centre, Children's Hospital of Eastern Ontario, Kingston Health Sciences Centre, Foothills Medical Centre, Island Health, Victoria, BC, Canadian Premature babies Foundation",2028-11-01,ESTIMATED,2 Months - 30 Months,2000,ESTIMATED,PARALLEL,OTHER,NONE,Implementation of Best Practices for Early Diagnosis of Cerebral Palsy (CP) in Very Preterm Infants: a Stepped-wedge Cluster Randomized Controlled Trial (RCT),2026-11-01,ESTIMATED,Intervention : corrected age at detection of early signs of CP. | Intervention : Developmental functioning at 18-24 month CA,SCREENING,ALL,2025-02-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06654427,,NOT_YET_RECRUITING,"Trauma, Obstetrics Trauma, Pregnancy Related",,OBTIC,,1,Implementation of OBTIC,EXPERIMENTAL,"Many pregnant women have experienced trauma, which can make perinatal care stressful and increase the risk of pregnancy-related health conditions. However, obstetric providers can modify procedures to reduce distress and enhance patients' sense of control and safety. Although obstetric providers frequently care for trauma survivors, most are not trained in trauma-informed care (TIC). Additionally, there are no data on feasibility, appropriateness, or acceptability of TIC tools and interventions ",Women and Infants Hospital of Rhode Island,2026-06-30,ESTIMATED,18 Years - 99 Years,165,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Trauma-Informed Obstetric Care: Development and Implementation of a Stakeholder- Informed Toolkit for Obstetric Providers and Patients,2026-06-01,ESTIMATED,Change in Adoption of trauma-screening protocols | Evaluation of intervention components for adaptation and scale-up implementation | Evaluation of intervention components for adaptation and scale-up implementation | Change in Acceptability of Intervention Measure | Change in Intervention Appropriateness Measure | Change in Feasibility of Intervention Measure,HEALTH_SERVICES_RESEARCH,ALL,2025-01-02,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04478851,,RECRUITING,"Cancer, Head and Neck Cancer, Colon Cancer, Breast Cancer, Prostate Cancer, Cancer Caregivers",,EXCEL,,1,Intervention,EXPERIMENTAL,"Project EXCEL will provide community or online exercise programs to rural and remote and under-served cancer survivors, as well as encourage participants to become life-long exercisers. Exercise is an evidence-based self-management strategy that benefits all cancer survivors. However, most cancer survivors who live in remote or rural places don't have adequate opportunities to be involved in exercise programs that are tailored to their needs.","University of Alberta, Dalhousie University, Alberta Health services, University Health Network, Toronto, Memorial University of Newfoundland, University of British Columbia, University of Prince Edward Island",2027-12-31,ESTIMATED,18 Years - 100 Years,1500,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"Project EXCEL: Dissemination, Implementation, and Effectiveness of the Exercise Oncology Survivorship Partnership Model - Reaching Rural Cancer Survivors to Enhance Quality of Life",2027-12-31,ESTIMATED,Physical Activity Minutes Per Week,SUPPORTIVE_CARE,ALL,2020-09-02,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT03374332,PHASE2,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia,Gemtuzumab Ozogamicin (GO),,NON_RANDOMIZED,2,Treatment 1: Gemtuzumab Ozogamicin and DLI Dose Level 1 | Treatment 2: Gemtuzumab Ozogamicin and DLI Dose Level 2,EXPERIMENTAL | EXPERIMENTAL,"This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available. Researchers are studying whether the drug Gemtuzumab Ozogamicin, followed by an infusion of blood cells called leukocytes from a donor, can stimulate the immune system to potentially fight the leukemia. Gemtuzmab ozogamicin is a class of drugs known as an antibody drug conjugate. The drug is given on days 1,4","Rhode Island Hospital, The Miriam Hospital, Pfizer",2024-09,ESTIMATED,18 Years - N/A,11,ACTUAL,SINGLE_GROUP,OTHER,NONE,Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia,2023-09-26,ACTUAL,Response Rate,TREATMENT,ALL,2019-12-31,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07222852,PHASE3,NOT_YET_RECRUITING,"Preeclampsia, Hypertensive Disorder of Pregnancy, Hypertension, Gestational Hypertension, Gestational Hypertension After Childbirth",Enalapril,CAPP-E,RANDOMIZED,2,Enalapril | Standard treatment,EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of this study is to learn if postpartum women are willing to be randomized to different blood pressure medicines after delivery and how that affects blood pressure in women with hypertensive disorders of pregnancy.,,2027-10-15,ESTIMATED,18 Years - N/A,60,ESTIMATED,PARALLEL,OTHER,SINGLE,Cardiovascular Protection After Preeclampsia With Enalapril,2027-10-15,ESTIMATED,Feasibility of enrollment | Feasibility of retention,TREATMENT,FEMALE,2025-11-15,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06353438,,NOT_YET_RECRUITING,"Aging, Fall, Old Age; Debility, Muscle Weakness",,,,1,Intervention,EXPERIMENTAL,"The goal of this quasi-experimental study using a pre and post test design is to learn about the effect of participating in an exercise program with hydraulic exercise equipment on fall risk in the older adult population. The main questions it aims to answer are:

* Does the use of hydraulic exercise equipment decrease fall risk in older adults?
* Does the use of hydraulic exercise equipment improve function in older adults?

Participants will be evaluated pre and post intervention for strength,",Bay Ridge Center,2024-12-31,ESTIMATED,60 Years - N/A,20,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Implementation of a Community Based Exercise Program for Older Adults Using Hydraulic Resistance Equipment,2024-07-31,ESTIMATED,Berg Balance Scale | Timed Up and Go | Tinetti Balance and Gait Assessment Tool | Lower Extremity Functional Scale,PREVENTION,ALL,2024-05-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06960291,,RECRUITING,"Cancer, Prostate Cancers, Breast Cancers, Colon Cancer, Lung Cancers",,EXCEL,,1,Intervention,EXPERIMENTAL,"EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC). Research has shown that targeted programs that include tailored exercise prescriptions are more successful in helping individuals with chronic disease to incorporate physical activity and exercise into their daily routines. While ILWBC are advised by healthcare professionals (HCPs) to engage in exercise, there is a lack of cancer-specific exercise programs and cancer-t","University of Alberta, Dalhousie University, Nova Scotia Health Authority, University of Toronto, Centre hospitalier de l'Université de Montréal (CHUM), University of British Columbia, Memorial University of Newfoundland, University of Prince Edward Island, Alberta Health services",2026-11-30,ESTIMATED,18 Years - N/A,740,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada,2026-10-30,ESTIMATED,Physical Activity Level,SUPPORTIVE_CARE,ALL,2025-03-11,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT02676973,,ACTIVE_NOT_RECRUITING,Visceral Prolapse,,ASPIRe,RANDOMIZED,3,Sacral Colpopexy | Transvaginal Native Tissue Repair | Apical Transvaginal Mesh Repair,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The study is a multi-center, randomized, surgical trial of women with symptomatic post-hysterectomy apical (cuff) prolapse desiring surgical treatment. This study will compare the three available surgical treatments performed in usual practice. The purpose of this study is to compare two commonly performed mesh apical repair (sacral colpopexy vs. Apical Transvaginal Mesh) and vaginal native tissue apical repairs with mesh reinforced repairs. The primary outcome is measured over time (up to 60 mo","The Cleveland Clinic, University of Alabama at Birmingham, University of California, San Diego, Duke University, University of New Mexico, Women and Infants Hospital of Rhode Island, RTI International, University of Pennsylvania, University of Pittsburgh, Kaiser Permanente, University of Texas Southwestern Medical Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",2026-12-31,ESTIMATED,21 Years - N/A,360,ACTUAL,PARALLEL,NETWORK,SINGLE,"Three Arm Apical Suspension Trial for Post-Hysterectomy Vault Prolapse: Prospective Randomized Trial Involving Sacral Colpopexy, Transvaginal Mesh and Native Tissue Apical Repair",2022-07-28,ACTUAL,Number of Participants Considered Failures,TREATMENT,FEMALE,2016-02-29,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06517628,,RECRUITING,"Pregnancy Complications, Cardiovascular",,HOPE,,1,Pregnant people with cardiovascular disease,,"This is a prospective, observational study which is evaluating the obstetrical, neonatal, and cardiovascular outcomes of 1000 pregnant people with known heart disease to define how best to structure cardio-obstetrics care to optimize outcomes.","Albert Einstein College of Medicine, Baylor College of Medicine, Beth Israel Deaconess Medical Center, Inc., The Children's Hospital Corporation, The Brigham and Women's Hospital, Inc., The Trustees of Columbia University in the City of New York, Henry Ford Hospital, The Johns Hopkins University, The Miriam Hospital/Lifespan, The General Hospital Corporation d/b/a Massachusetts General Hospital, Northwell Health, Northwestern University, Oregon Health and Science University, Saint Luke's Health System Inc., Board of Trustees of the Leland Stanford Junior University, The Research Foundation for the State University of New York, The Regents of the University of California, Irvine, The Regents of the University of California, Los Angeles, University of North Carolina, Chapel Hill, The Board of Trustees of the University of Illinois, Trustees of Indiana University, University of Kansas Medical Center, University of Massachusetts Chan Medical School, Regents of the University of Michigan, University of Mississippi Medical Center, The Curators of the University of Missouri, The Trustees of the University of Pennsylvania, University of Pittsburgh, The University of South Florida Board of Trustees for University of South Florida, University of Washington, University of Texas Southwestern Medical Center, Weil Medical Colleqe of Cornell University, Women and Infants Hospital of Rhode Island, Tennessee Maternal Fetal Medicine PLC",2028-06-30,ESTIMATED,18 Years - N/A,1000,ESTIMATED,,OTHER,,The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study,2028-06-30,ESTIMATED,Rate of Adverse pregnancy outcomes,,FEMALE,2025-01-14,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT02656706,PHASE2,ACTIVE_NOT_RECRUITING,Melanoma,"Ipilumumab, Nivolumab",,,1,Adjuvant treatment,EXPERIMENTAL,Effective adjuvant treatment can increase cure in patients with high-risk resected melanoma. High dose interferon is a standard of care in the adjuvant setting but is highly toxic and marginally effective. The combination of ipilimumab and nivolumab is the most active regimen in patients with advanced melanoma so there is clear rationale to test this regimen in the adjuvant setting. Investigators are testing if nivolumab 3mg/kg every 2 weeks with 1mg/kg ipilimumab every 6 weeks in the high risk ,"Rhode Island Hospital, The Miriam Hospital",2026-01,ESTIMATED,18 Years - N/A,22,ACTUAL,SINGLE_GROUP,OTHER,NONE,Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,2019-03,ACTUAL,Number of Participants With Treatment Related Toxicities | Number of Participants With Progression-free and Survival Overall,TREATMENT,ALL,2016-07,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05780918,,ACTIVE_NOT_RECRUITING,"Serious Injury, Communication",,,RANDOMIZED,2,Best Case/Worst Case-ICU Communication Tool | Usual Care,EXPERIMENTAL | NO_INTERVENTION,"The purpose of this study is to test the effectiveness of the Best Case/Worst Case-ICU communication tool on quality of communication, clinician moral distress, and ICU length of stay for older adults with serious traumatic injury. Investigators will follow an estimated 4500 patients aged 50 years and older who are in the ICU for 3 or more days and survey 1500 family members and up to 1600 clinicians from 8 sites nationwide.","National Institute on Aging (NIA), University of Maryland, Baltimore, University of California, Davis, Harborview Injury Prevention and Research Center, Lehigh Valley Health Network, Grady Memorial Hospital, Froedtert Hospital, University of Alabama at Birmingham, Rhode Island Hospital, American College of Surgeons, Coalition for National Trauma Research",2026-12-31,ESTIMATED,18 Years - N/A,7600,ESTIMATED,CROSSOVER,OTHER,NONE,A Randomized Clinical Trial of Scenario Planning for Older Adults With Serious Injury,2025-08-31,ACTUAL,Family-reported Quality of Communication (QOC) within 5-7 days of ICU admission,HEALTH_SERVICES_RESEARCH,ALL,2023-07-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07133906,,NOT_YET_RECRUITING,"Neonatal Hypoglycemia, Gestational Diabetes, Maternal Obesity Complicating Pregnancy, Small-for-gestational Age, Large-for-gestational Age",,,,1,Pregnant women >24 weeks gestation and their infants,,"Low blood sugar in newborns is common and if prolonged or untreated may place them at increased risk for later learning and behavior challenges. Currently, we measure newborn glucose with at least four painful heel sticks, missing one in four episodes of low blood sugar. The goal of this observational study is to develop a less invasive approach to glucose monitoring, developed for newborns, that provides more frequent glucose measurements. We will also measure how a pregnant woman's health impa",,2027-06,ESTIMATED,N/A - N/A,114,ESTIMATED,,OTHER,,Accuracy of Interstitial Continuous Glucose Sensors in Neonates,2026-12,ESTIMATED,Point Accuracy: System agreement analysis,,ALL,2025-09,ESTIMATED,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05287646,,RECRUITING,"Amputation, Lower Limb",,,RANDOMIZED,2,Suction Suspension First | Elevated Vacuum Suspension First,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"Individuals with lower extremity amputation are often challenged by complications that arise from poor prosthetic fit, including movement of the residual limb in the socket, known as pistoning. Pistoning can lead to gait instability, skin problems, and pain. Different prosthetic suspension systems have been developed to decrease this motion, including elevated vacuum suspension, which utilizes a pump to draw air from the socket. However, scientific analyses to understand the movement between the","Rutgers University, University of Rhode Island",2026-03-31,ESTIMATED,18 Years - N/A,21,ESTIMATED,CROSSOVER,FED,NONE,Quantifying Bone and Skin Movement in the Residual Limb-Socket Interface of Individuals With Transtibial Amputation Using Dynamic Stereo X-Ray,2026-02-28,ESTIMATED,Changes in dynamic residual tibia kinematics between suspension techniques | Changes in dynamic skin deformation of the residual limb between suspension techniques,BASIC_SCIENCE,ALL,2024-01-05,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06034678,,RECRUITING,Food Allergy in Children,,,RANDOMIZED,2,Food Allergy Mastery Program | Usual Care,EXPERIMENTAL | NO_INTERVENTION,"The proposed research project will evaluate a novel behavioral intervention that promotes early adolescent food allergy self-management and adjustment through 1) food allergy education, 2) problem-solving, communication, assertiveness, and anxiety management skill building, and 3) peer support.","National Institute of Allergy and Infectious Diseases (NIAID), Northwestern University, Rhode Island Hospital",2027-11-30,ESTIMATED,10 Years - 14 Years,240,ESTIMATED,PARALLEL,OTHER,SINGLE,Evaluation of a Behavioral Intervention to Promote Food Allergy Self-Management Among Early Adolescents: The Food Allergy Mastery Program,2026-11-30,ESTIMATED,Food Allergy Knowledge | Food Allergy Knowledge | Food Allergy Knowledge | Food Allergy Management Skills- Label Reading | Food Allergy Management Skills- Label Reading | Food Allergy Management Skills- Label Reading | Food Allergy Management Skills- Epinephrine Auto-Injector Use | Food Allergy Management Skills- Epinephrine Auto-Injector Use | Food Allergy Management Skills- Epinephrine Auto-Injector Use | Food Allergy Management Behaviors | Food Allergy Management Behaviors | Food Allergy Management Behaviors | Food Allergy Quality of Life- Child Self Report | Food Allergy Quality of Life- Child Self-Report | Food Allergy Quality of Life- Child Self-Report | Food Allergy Quality of Life- Parent Proxy | Food Allergy Quality of Life- Parent Proxy | Food Allergy Quality of Life- Parent Proxy | Food Allergy Impact | Food Allergy Impact | Food Allergy Impact | Frequency of Treatment for Allergic Reactions | Frequency of Treatment for Allergic Reactions | Frequency of Treatment for Allergic Reactions | Frequency of Allergy Appointments | Frequency of Allergy Appointments | Frequency of Emergency Room/Urgent Care Visits for Allergic Reactions | Frequency of Allergy Appointments | Frequency of Emergency Room/Urgent Care Visits for Allergic Reactions | Frequency of Emergency Room/Urgent Care Visits for Allergic Reactions,TREATMENT,ALL,2023-06-26,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05681624,,RECRUITING,"Fetal Distress, Fetal Hypoxia, Labor and Delivery Complication",,MOXY,RANDOMIZED,2,Oxygen | Room air,OTHER | ACTIVE_COMPARATOR,"More than 80% of the 3 million women who labor and deliver each year in the United States undergo continuous electronic fetal monitoring (EFM) during labor in order to fetal hypoxia and prevent the transition to acidemia, expedited operative delivery, and/or neonatal morbidity. Category II EFM is the most commonly observed group of fetal heart rate features in labor. One common response to Category II EFM is maternal oxygen (O2) supplementation. The theoretic rationale for O2 administration is t","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Michigan, University of Texas at Austin, Women and Infants Hospital of Rhode Island, Dell Children's Medical Center of Central Texas, Brown University",2028-08-01,ESTIMATED,N/A - N/A,2124,ESTIMATED,CROSSOVER,OTHER,SINGLE,Maternal Oxygen Supplementation for Intrauterine Resuscitation: a Multicenter Randomized Trial,2027-12-31,ESTIMATED,Percentage of neonates meeting criteria for composite neonatal morbidity,PREVENTION,FEMALE,2023-05-22,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05979272,,ACTIVE_NOT_RECRUITING,"Cannabis Use, Adolescent",,TECH,RANDOMIZED,2,TAU-only | TAU + TECH,ACTIVE_COMPARATOR | EXPERIMENTAL,"The study is about helping teens who are involved in the court system to cut down or quit using marijuana. Teens may be asked to test out an experimental smartphone app, called TECH, that will be used only by teens in this study. This app is a private online community where teens can work towards changing their substance use and other behavior with the help of other anonymous teens. We will use this information to learn how the app may help teens make a change and to improve the TECH app.","Brown University, Rhode Island Hospital, National Institute on Drug Abuse (NIDA)",2026-01,ESTIMATED,14 Years - 18 Years,60,ESTIMATED,PARALLEL,OTHER,NONE,"Development and Preliminary Testing of an Adjunct Smartphone App to Reduce Marijuana Use in Court-Involved, Non-Incarcerated Adolescents",2026-01,ESTIMATED,Change in days of cannabis use (Preliminary Efficacy),TREATMENT,ALL,2023-06-21,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05124808,,RECRUITING,"Gestational Diabetes, Pregnancy, High Risk, Overweight and Obesity",,iGDM,RANDOMIZED,2,Intensive glycemic targets | Standard glycemic targets,EXPERIMENTAL | ACTIVE_COMPARATOR,This is a multicenter randomized clinical trial of 828 overweight and obese individuals with gestational diabetes designed to compare standard to intensive glycemic targets.,"University of Pittsburgh, University of Alabama at Birmingham, University of Oklahoma, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Women and Infants Hospital of Rhode Island",2026-04-08,ESTIMATED,18 Years - 45 Years,828,ESTIMATED,PARALLEL,OTHER,NONE,Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes Mellitus: A Multicenter Randomized Trial,2026-04-01,ESTIMATED,Number of participants with composite neonatal morbidity,TREATMENT,FEMALE,2022-03-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05363878,,RECRUITING,"Alcohol Drinking, Trauma, Psychological, Historical Trauma",,NativeHEALTH,RANDOMIZED,2,Native HEALTH Condition | Wait-List Control,EXPERIMENTAL | NO_INTERVENTION,"The objective of this project is to develop and obtain preliminary data on a culturally grounded, trauma-informed alcohol intervention. The specific aims are to (1) use Community-Based Participatory Research methods to deepen partnerships with First Nation through capacity-building and knowledge sharing; (2) collect and apply qualitative data to develop a culturally grounded, trauma-informed alcohol intervention that is focused on historical trauma for use with a First Nation sample; and (3) con",National Institute on Alcohol Abuse and Alcoholism (NIAAA),2025-09-29,ESTIMATED,18 Years - 90 Years,60,ESTIMATED,PARALLEL,OTHER,NONE,"Development of a Culturally Grounded, Trauma-Informed Alcohol Intervention With a Reserve-Dwelling First Nation Group",2025-03-26,ACTUAL,Time Line Follow-Back (TLFB) | Time Line Follow-Back (TLFB) | Time Line Follow-Back (TLFB) | Historical Loss and Associated Symptoms Scale | Historical Loss and Associated Symptoms Scale | Historical Loss and Associated Symptoms Scale,TREATMENT,ALL,2025-01-13,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05599425,,RECRUITING,Alzheimer Disease,,,RANDOMIZED,2,Healthy Living Education | Enhanced Healthy Living Education,ACTIVE_COMPARATOR | EXPERIMENTAL,"Modifying health behaviors like physical activity level, diet, stress, and mental activity level can lower risk for Alzheimer's disease, but many middle-aged and older adults find it difficult to sustain health behavior changes over the long term. This project will develop a new intervention that educates people about Alzheimer's disease risk factors and helps them understand how their personal health beliefs may prevent them from making long-lasting lifestyle changes. The goal is to help people",,2025-02-01,ESTIMATED,45 Years - 69 Years,40,ESTIMATED,PARALLEL,OTHER,NONE,Development of a Personalized Intervention to Motivate Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease,2024-12-30,ESTIMATED,Perceived Threat of Alzheimer's Disease Scale | Perceived Threat of Alzheimer's Disease Scale | Perceived Threat of Alzheimer's Disease Scale | Perceived Threat of Alzheimer's Disease Scale | Dementia Awareness Questionnaire | Dementia Awareness Questionnaire | Dementia Awareness Questionnaire | Dementia Awareness Questionnaire | Generalized Self-Efficacy Scale | Generalized Self-Efficacy Scale | Generalized Self-Efficacy Scale | Generalized Self-Efficacy Scale,PREVENTION,ALL,2024-03-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06769282,,RECRUITING,"Aggression Childhood, Teen Dating Violence",,SPARE,RANDOMIZED,2,Intervention (SPARE) plus Treatment as Usual | Treatment As Usual,EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this clinical trial is to learn if this intervention (Social Skills, Problem Solving, emotion Regulation, and psycho-Education on Trauma: A Trauma-Informed Peer Aggression and Teen Dating Violence Prevention Program; SPARE) can treat peer aggression and prevent teen dating violence in preteens receiving intensive mental health services. The main questions it aims to answer are:

* Does receiving SPARE reduce proactive and reactive aggression at post-intervention and 3- and 9-month fo",Centers for Disease Control and Prevention,2027-03-30,ESTIMATED,11 Years - 13 Years,88,ESTIMATED,PARALLEL,OTHER,NONE,Cross-Cutting Trauma-Informed Peer Aggression and Dating Violence Prevention for Preteens Receiving Intensive Mental Health Services,2026-06-30,ESTIMATED,Proactive and Reactive Aggression Questionnaire (PRA),PREVENTION,ALL,2024-10-25,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07092345,,RECRUITING,"Suicidal and Self-injurious Behavior, Linkage to Care",,ED_SMART,RANDOMIZED,3,Psychosocial | Psychosocial with text messages | Psychosocial with text messages and family navigator,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The goal of this study is to develop a feasible brief, family-based adaptive intervention, via SMART design, for youth with suicidal and non-suicidal self-injurious behavior (SSIB) to increase community-based mental health (MH) care attendance and reduce SSIB risk post emergency department (ED) admission. The intervention will focus to increase understanding on youth MH literacy, MH communication, and MH engagement. Integrating an adaptive intervention via a SMART design in the ED could address ",National Institute of Mental Health (NIMH),2029-03,ESTIMATED,8 Years - 17 Years,186,ESTIMATED,FACTORIAL,OTHER,SINGLE,An Adaptive Intervention to Increase Engagement to Community-based Care After an ED Admission: For Youth at Risk for Suicide and Self-injurious Behavior,2029-01,ESTIMATED,Intervention Feasibility | Child and Adolescent Service Assessment (CASA) | Intervention Acceptability,HEALTH_SERVICES_RESEARCH,ALL,2025-03-17,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06365645,,ACTIVE_NOT_RECRUITING,"Postpartum Depression, Postpartum Anxiety, Stress",,,RANDOMIZED,2,App-based digital parenting education | M.Bapp,ACTIVE_COMPARATOR | EXPERIMENTAL,"Postpartum depression (PPD) affects up 10-15% of mothers overall, but the rate of PPD can be as high as 25% among mothers with personal or obstetric risk factors. The Mothers \& Babies Program (MB) is a cognitive behavioral therapy (CBT)-based program that has been shown to prevent PPD among high-risk mothers without a prior history of depression. MB has been so consistently effective that the United States Preventive Services Task Force recommends this program be given to high-risk pregnant pat",,2025-09,ESTIMATED,18 Years - 60 Years,90,ESTIMATED,SINGLE_GROUP,OTHER,QUADRUPLE,Examining the Feasibility and Acceptability of a Novel App-based Cognitive Behavioral Therapy Intervention for Preventing Postpartum Depression,2025-09,ESTIMATED,Feasibility | Acceptability,PREVENTION,FEMALE,2024-06-07,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05147441,,RECRUITING,"Spasticity, Muscle",,,,0,,,"The purpose of the study is to measure the effects of obturator nerve cryoneurotomy, on clinical measures in adult (ages 19+) and paediatric (ages 12-18) patients with hip adductor spasticity, who will receive this procedure as a part of their treatment based on the spasticity treatment available guidelines. The results will provide us valuable information like how long cryoneurotomy is effective, before regeneration happens",,2024-12,ESTIMATED,12 Years - N/A,20,ESTIMATED,,OTHER,,Evaluating the Efficacy of Obturator Cryoneurotomy for Hip Adductor Spasticity,2024-10,ESTIMATED,The degree of changes in hip abductors' active range of motion. | The degree of changes in hip abductors' maximum passive range of motion. | The degree of changes in hip abductors' spasticity | The degree of changes in inter knees distance at maximum passive hip abduction range of motion,,ALL,2021-08-10,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05625373,"PHASE2, PHASE3",RECRUITING,Postoperative Complications,Vancomycin,,RANDOMIZED,2,Vancomycin powder | No vancomycin powder,EXPERIMENTAL | NO_INTERVENTION,The study will be a pilot randomized control trial with a 1:1 patient randomization of vancomycin powder placement at the time of surgery (compared to no vancomycin placement) with the goal of reducing postoperative complications in patients undergoing an inguinal lymph node dissection for vulvar cancer. The primary objective is to measure the composite rate of postoperative complications within 30 days of inguinal lymph node dissection in patients with vulvar cancer.,,2024-08-30,ESTIMATED,18 Years - N/A,30,ESTIMATED,PARALLEL,OTHER,NONE,The Effect of Intrawound Vancomycin Powder on Surgical Site Infection in Inguinal Lymph Node Dissection,2024-04-25,ESTIMATED,Composite rate of postoperative complications,PREVENTION,FEMALE,2022-10-25,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06316089,,NOT_YET_RECRUITING,"Hiv, Substance Use Disorders",,,RANDOMIZED,2,PrEPared For Release | Standard of Care,EXPERIMENTAL | NO_INTERVENTION,"Pre-exposure prophylaxis (PrEP) is effective in preventing HIV infection among people who inject drugs (PWID) yet studies suggest that its use is low among this population which is particularly vulnerable to HIV infection. The criminal justice (CJ) system, at the intersection of increased risk of HIV infection and substance use, presents a unique opportunity to engage PWID in HIV prevention care that incudes PrEP. The study will characterize the facilitators and barriers to PrEP initiation, adhe",,2027-06,ESTIMATED,18 Years - N/A,100,ESTIMATED,PARALLEL,OTHER,NONE,"An Intervention to Improve HIV Pre-exposure Prophylaxis Initiation, Adherence and Linkage to Care for Recently Incarcerated Men Who Inject Drugs.",2027-01,ESTIMATED,PrEP initiation,PREVENTION,MALE,2025-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05347238,,RECRUITING,"Late-Onset Neonatal Sepsis, Extreme Prematurity, Neonatal Hypotension","Dopamine, Norepinephrine",,,2,Dopamine Units | Norepinephrine Units, | ,"Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring \>48 hours of age). In Canada, \~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \~35-40% die. Unlike for adult patients, there is little evidence to inform practice. Wh","Sunnybrook Health Sciences Centre, The Hospital for Sick Children, London Health Sciences Centre, Windsor Regional Hospital, Foothills Medical Centre, Health Sciences Centre, Winnipeg, Manitoba, St. Boniface Hospital, Jewish General Hospital, St. Justine's Hospital, IWK Health Centre, University College Cork, Coombe Women and Infants University Hospital, Island Health, Victoria, BC, Assaf-Harofeh Medical Center, Dayton Children's Hospital, Banner University Medical Center, Methodist Healthcare, Hospital Universitario La Paz, McMaster Children's Hospital, Children's Hospital of Eastern Ontario, BC Women's Hospital & Health Centre, Stony Brook University, The Children's Hospital at Montefiore, Golisano Children's Hospital",2027-03-31,ESTIMATED,21 Weeks - 32 Weeks,550,ESTIMATED,,OTHER,,Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis: An International Comparative Effectiveness Research Project,2026-06-30,ESTIMATED,All cause in-hospital mortality,,ALL,2023-02-06,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07077707,,NOT_YET_RECRUITING,Genetic Counseling,,,RANDOMIZED,2,In-person genetic counseling | Prenatal Genetics Chatbot- Prenatal GENEie,ACTIVE_COMPARATOR | EXPERIMENTAL,"During pregnancy, all pregnant people are offered tests to look for genetic conditions in the baby. However, there isn't a standard way of giving this information to patients. Doctors have a lot of things to discuss during the first prenatal visit and don't always have time to explain genetics in detail. Also, not everyone has access to genetic counselors. Prenatal genetics can be confusing, especially for people who haven't had a lot of formal education or who speak languages other than English",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),2029-03-31,ESTIMATED,18 Years - 55 Years,1470,ESTIMATED,PARALLEL,OTHER,NONE,A Randomized Trial of Chatbot for Prenatal Genetic Counseling,2029-03-31,ESTIMATED,Change in Prenatal Knowledge Score | Rate of Prenatal Screening,HEALTH_SERVICES_RESEARCH,FEMALE,2026-01-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04860336,,ACTIVE_NOT_RECRUITING,"Gestational Diabetes, Pregnancy Related",,GO MOMs,,1,Pregnant women less than or equal to 14w0d gestation,,"The overarching goal of Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMs) is to perform a comprehensive, longitudinal description of maternal glycemia over the course of pregnancy and to evaluate how glucose levels throughout pregnancy relate to traditional third trimester gestational diabetes mellitus (GDM) screening and perinatal outcomes.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Yale University, Women and Infants Hospital of Rhode Island, University of Pittsburgh, Massachusetts General Hospital, Tufts Medical Center, Columbia University, Kaiser Permanente",2025-10-01,ESTIMATED,18 Years - N/A,2179,ACTUAL,,OTHER,,Glycemic Observation and Metabolic Outcomes in Mothers and Offspring / Glycemic Profile of Pregnancy Consortium,2025-06-09,ACTUAL,Gestational diabetes (GDM) | Large for gestational age (LGA),,FEMALE,2021-04-01,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05462704,PHASE3,RECRUITING,"Iron Deficiency Anemia, Pregnancy","Ferric derisomaltose, Ferrous sulfate",IVIDA2,RANDOMIZED,2,IV Iron | Oral Iron,EXPERIMENTAL | ACTIVE_COMPARATOR,"Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<30 ng/mL) at 13 - 30 weeks will be effective, safe and cost-effective in reducing severe maternal morbidity-as measured by maternal anemia at delivery-and will also improve offspring neurodevelopment.","Hasbro Children's Hospital, University of Michigan, Washington University School of Medicine, University of Utah, University of Alabama at Birmingham, Oregon Health and Science University, GNP Research at Heme-on-Call",2027-03-31,ESTIMATED,18 Years - 45 Years,300,ESTIMATED,PARALLEL,OTHER,TRIPLE,Double-blind Placebo-controlled Multicenter Randomized Trial of Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy,2027-03-30,ESTIMATED,Rate of maternal anemia (hgb<11mg/dL) at delivery,TREATMENT,FEMALE,2023-01-17,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07217795,,RECRUITING,"Alcohol Use Disorder (AUD), PTSD",,RISE,RANDOMIZED,2,RISE | Control: Wait-List Control,EXPERIMENTAL | OTHER,"This is a two-part study to develop and test a brief, virtual therapy program for lesbian, gay, bisexual, transgender, and queer (LGBTQ+) people who have experienced trauma and use alcohol.

Phase 1: You'll be invited to share your perspective to help make the program relevant, inclusive, and affirming.

Phase 2: You may have the opportunity to try the adapted program by receiving free virtual therapy with LGBTQ+-affirming therapists.",Rhode Island Foundation,2028-09,ESTIMATED,18 Years - N/A,80,ESTIMATED,PARALLEL,OTHER,SINGLE,Developing a Telehealth Intervention for Alcohol and Trauma Among LGBTQ+ People,2026-11,ESTIMATED,Posttraumatic Stress Disorder Diagnosis and Severity using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | Posttraumatic Stress Disorder Symptom Severity using the PTSD Checklist for DSM-5 (PCL-5) | Hazardous drinking levels | Change in average weekly drinking quantity | Change in heavy drinking frequency,TREATMENT,ALL,2025-11-30,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05861531,,RECRUITING,"Language Delay, Language Development, Feeding; Difficult, Newborn, Mother-Infant Interaction, Maternal Behavior",,,RANDOMIZED,3,Oral motor stimulation with language | Oral motor stimulation | Standard Care,EXPERIMENTAL | ACTIVE_COMPARATOR | NO_INTERVENTION,"This is a randomized controlled trial to study an oromotor stimulation in combination with a reading curriculum in the NICU among preterm infants using oral muscle exercises, Language Environment Analysis (LENA) recordings, linguistic feedback, and a language curriculum to improve the neonatal inpatient oral feeding and language outcomes for preterm infants.",,2030-07-01,ESTIMATED,23 Weeks - 30 Weeks,124,ESTIMATED,PARALLEL,OTHER,SINGLE,The Combined Association of an Oral Motor Stimulation and Language Intervention on Preterm Infant Feeding,2028-07-01,ESTIMATED,Oral feeding measures,PREVENTION,ALL,2025-07-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05762705,,RECRUITING,"Medication Adherence, HIV/AIDS",,,RANDOMIZED,2,Multilevel Gaming Adherence | Treatment as Usual +,EXPERIMENTAL | ACTIVE_COMPARATOR,"In this study, the investigators will test the mobile game, Viral Combat, for efficacy and acceptability among diverse participants, ages 15-34 years, receiving PrEP care in clinical settings in New England and Mississippi. Formative evaluation interviews will be conducted with stakeholders (healthcare workers, clinic administrators, and patients taking PrEP) to inform intervention delivery. Data from the formative interviews will also be used to make necessary adaptations to the game and assess",,2027-03-03,ESTIMATED,15 Years - 34 Years,200,ESTIMATED,PARALLEL,OTHER,SINGLE,A Multisite Randomized Trial of Viral Combat: A Mobile Gaming App to Improve Adherence to PrEP,2027-03-03,ESTIMATED,Tenofovir (TFV) blood concentration at 24 weeks,PREVENTION,ALL,2024-06-21,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06332781,PHASE4,RECRUITING,Recurrent Uti,"Gentamicin, Nitrofurantoin",,RANDOMIZED,2,Standard of Care | Experimental,ACTIVE_COMPARATOR | EXPERIMENTAL,Feasibility assessment of intravesical gentamicin instillation (putting antibiotics directly into the bladder) versus the current standard of care of oral nitrofurantoin prophylaxis (taking a low dose of antibiotics by mouth every day) to prevent recurrent urinary tract infections (UTI),,2026-05-31,ESTIMATED,40 Years - N/A,30,ESTIMATED,PARALLEL,OTHER,NONE,Intravesical Gentamicin to Prevent Recurrent UTI,2025-09-30,ACTUAL,Assess feasibility of trial recruitment | Examine treatment compliance | Examine trial retention,PREVENTION,FEMALE,2025-04-28,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06359587,,RECRUITING,Hospital Acquired Condition,,RePORT-BC,RANDOMIZED,2,Intervention Arm (Intervention Bundle Implementation) | Control Arm (No LTO Bundle Implementation),EXPERIMENTAL | NO_INTERVENTION,"The goal of this stepped-wedge cluster randomized trial is to assess the impact of a laboratory test overuse intervention bundle on laboratory test utilization in 6 health authorities (16 hospitals) in British Columbia. The main question it aims to answer is if the intervention bundle, inclusive of healthcare provider and patient engagement tools, can be effectively implemented for hospitalized medical inpatients in 16 hospitals across BC and reduce laboratory test over-use. Researchers will com","Providence Health & Services, Vancouver Coastal Health, Fraser Health, Interior Health, Northern Hospital, Australia, Canadian Institutes of Health Research (CIHR), Island Health",2026-11-16,ESTIMATED,18 Years - N/A,700000,ESTIMATED,SEQUENTIAL,OTHER,NONE,Re-Purposing the Ordering of Routine Laboratory Testing in Hospitalized Medical Patients in British Columbia,2026-11-16,ESTIMATED,Change in number of target laboratory tests ordered per patient-day with LTO bundle compared to control period without LTO bundle,HEALTH_SERVICES_RESEARCH,ALL,2024-05-06,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06117683,,RECRUITING,"Airway Management, Respiration, Artificial",,,NON_RANDOMIZED,2,Bag mask ventilation with Adult Sotair device | Mechanical Ventilation,ACTIVE_COMPARATOR | NO_INTERVENTION,"Effective respiratory ventilation is achieved by moving the right amount of air in and out of the lungs while keeping the pressures at a safe level. A disposable safety device, Adult Sotair®, was created to improve manual ventilation delivery. In this non-inferiority study, we will perform a pre-post study design (single group, within-group comparison) to test the non-inferiority of the Adult Sotair® device compared to mechanical ventilation.",,2025-07,ESTIMATED,18 Years - 80 Years,310,ESTIMATED,SINGLE_GROUP,OTHER,SINGLE,Non-inferiority Comparative Trial Between Sotair® Device Attached to Manual Resuscitator Versus Mechanical Ventilation in Patients Undergoing Non-emergent Surgery With General Anesthesia,2025-06-30,ESTIMATED,Peak airway pressure,SUPPORTIVE_CARE,ALL,2023-12-20,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07218016,,RECRUITING,"Pelvic Organ Prolapse, Pelvic Organ Prolapse (POP), Pelvic Organ Prolapse Vaginal Surgery, Pelvic Organ Prolapse, Patient Education",,AccelERate,RANDOMIZED,2,Standard of Care | Postoperative Exercise regimen,NO_INTERVENTION | ACTIVE_COMPARATOR,"The AccelERate study will evaluate the physical recovery of patients who have undergone Pelvic Organ Prolapse (POP) surgery. This will be evaluated via a self-reported recovery questionnaire completed daily. Participants will wear an accelerometer device on their non-dominant wrist and be given either routine or exercise-focused postoperative instructions. The primary outcome will be a comparison of the number of days needed to reach self-reported ""mostly recovered"" status between randomly assig","RTI International, University of California, San Diego, University of Chicago, Duke University, Women and Infants Hospital of Rhode Island, University of Pennsylvania, Kaiser Permanente, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",2028-12-31,ESTIMATED,18 Years - 99 Years,288,ESTIMATED,PARALLEL,NETWORK,SINGLE,Accelerometer Measured Early Recovery After Prolapse Surgery,2028-03-31,ESTIMATED,Recovery Status,TREATMENT,FEMALE,2025-10-02,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT01888198,,ACTIVE_NOT_RECRUITING,Renal Cancer,,,,1,renal mass ablation candidates,,"The purpose of this study is to better understand how effective ablation is for destroying tumor cells in the kidney and whether quality of life is improved for patients. Participation in ARMOR may involve retrospective data collection only, combined retrospective and prospective data collection, or prospective data collection","Rhode Island Hospital, M.D. Anderson Cancer Center, University of California, San Francisco, Thomas Jefferson University, Barbara Ann Karmanos Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Maryland, Baltimore County, Dartmouth-Hitchcock Medical Center, San Diego Imaging Medical Group, Hospital Sirio-Libanes, University Hospital, Bordeaux, University of California, Los Angeles",2026-06,ESTIMATED,18 Years - N/A,294,ESTIMATED,,OTHER,,Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment,2026-06,ESTIMATED,assess renal ablation outcomes,,ALL,2013-06,,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05881629,,RECRUITING,"Cesarean Delivery Affecting Fetus, Labor Dystocia, Labor Complication",,,RANDOMIZED,2,Side-lying peanut ball group | Control group,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this randomized trial is to test if changing a person's position in labor can increase the chances of delivering their baby vaginally.

Specifically, it aims to answer the questions:

* In fetuses who are facing upwards (occiput posterior, OP) or sideways (occiput transverse, OT) during labor, does changing the patient's position during active labor to a side-lying posture with a peanut ball increase the chances of them having a successful, spontaneous vaginal delivery?
* Does changi",,2026-09-01,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,OTHER,NONE,Early Diagnosis and Intervention for Fetal Malposition in Active Labor and Its Impact on Mode of Delivery: A Randomized Controlled Trial,2026-09-01,ESTIMATED,Operative Delivery Rate,TREATMENT,FEMALE,2024-05-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05458037,,RECRUITING,"Pain, Acute, Pain, Procedural",,,RANDOMIZED,2,Fast tenaculum application | Slow tenaculum application,EXPERIMENTAL | EXPERIMENTAL,"This project will be a randomized controlled trial (RCT) measuring pain perception with two different tenaculum placement techniques on the uterine cervix. A tenaculum is an instrument used to hold the cervix (the opening to the uterus or womb) in place. The trial will measure pain perception with a Visual Analog Scale (VAS) from 0 to 100 mm for two different tenaculum placement techniques, fast and slow closure on the uterine cervix. The main objective of this study is to determine if there is ",,2026-12,ESTIMATED,18 Years - N/A,150,ESTIMATED,PARALLEL,OTHER,SINGLE,A Randomized Controlled Trial of Pain Perception With Fast and Slow Tenaculum Application to the Uterine Cervix,2026-12,ESTIMATED,Pain perception with tenaculum application,TREATMENT,FEMALE,2020-09-29,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04978168,,RECRUITING,Opioid-use Disorder,,JCOIN,RANDOMIZED,3,Implementation Core | Randomized Trial of Peer Support Specialist Model | Randomized to Treatment as Usual,EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR,Determine whether a facilitated local change team intervention improves a probation organization's client-level medication for opioid use disorder (MOUD) outcomes and implementation outcomes relative to baseline across multiple sites. Determine whether client-level outcomes are further enhanced by the introduction of Peer Support Services.,"University of North Carolina, Chapel Hill, Temple University, University of Rhode Island, The Miriam Hospital, National Institute on Drug Abuse (NIDA), CODAC Behavioral Healthcare, Duke University",2026-04-30,ESTIMATED,18 Years - N/A,450,ESTIMATED,PARALLEL,OTHER,NONE,Using Implementation Interventions and Peer Recovery Support to Improve Opioid Treatment Outcomes in Community Supervision,2025-12-30,ESTIMATED,Individual-Level Experimental (Period 2) Outcome: Engagement in MOUD | Program-Level Implementation Outcome: Engagement in MOUD,HEALTH_SERVICES_RESEARCH,ALL,2021-03-02,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06409975,,RECRUITING,Healthy,,,,1,Mindful Self-Compassion Intervention,EXPERIMENTAL,"The goal of this single-arm feasibility study is to evaluate the feasibility and acceptability of an 8-week mindful self-compassion intervention and associated data-collection plan among transgender and nonbinary young adults. Participants will be asked to:

* Complete weekly 2.5-hour virtual classes for 8 weeks and a 4-hour virtual retreat
* Practice specific activities in between classes for 20-30 minutes a day
* Answer survey questions before starting the intervention, half-way through the in",National Center for Complementary and Integrative Health (NCCIH),2028-08-30,ESTIMATED,18 Years - 25 Years,50,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Evaluating the Feasibility and Acceptability of Mindful Self-Compassion Among Transgender and Nonbinary Young Adults,2028-03-31,ESTIMATED,Recruitment of participants into study | Percent of Sample Completing the Intervention | Percent of participants who report satisfaction with MSC as Excellent or Good | Likelihood of recommending to others | Intent to use specific intervention activities in the future | Percent of completed data at each data-collection point,BASIC_SCIENCE,ALL,2025-06-12,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07144631,,RECRUITING,"Restless Leg Disorder, Restless Leg Syndrome (RLS), Pregnancy, Sleep Disorder (Disorder)",,PENS-P,,1,TOMAC™ Peroneal Nerve Stimulation,EXPERIMENTAL,"The goal of this study is to evaluate whether peroneal electrical nerve stimulation (PNS) using the TOMAC™ device is a feasible, acceptable, and safe non-pharmacologic intervention for managing Restless Legs Syndrome (RLS) during pregnancy. This pilot study will also collect preliminary information on symptom relief, sleep quality, and maternal-fetal safety associated with device use.

The main questions the study aims to answer are:

Is TOMAC™ PNS a feasible and acceptable intervention for RLS ",American College of Chest Physicians,2026-10-31,ESTIMATED,18 Years - N/A,15,ESTIMATED,SINGLE_GROUP,OTHER,NONE,PENS-P: Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome (RLS),2026-09-30,ESTIMATED,Acceptability of Intervention Measure (AIM) Score | Intervention Appropriateness Measure (IAM) Score | Feasibility of Intervention Measure (FIM) Score,TREATMENT,FEMALE,2025-10-15,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06873698,,RECRUITING,Functional Neurological Disorder,,NBT for mFND,RANDOMIZED,2,Neuro-Behavioral Therapy | Standard Medical Care,EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this pilot randomized clinical trial is to learn if Neurobehavioral Therapy (NBT) works to treat motor functional neurological disorder (mFND) (also referred to as functional motor disorder).

The main questions it aims to answer are:

* Does NBT lower mFND symptoms?
* Does NBT lower common co-occurring symptoms and improve functioning?

Researchers will compare NBT to standard medical care (SMC).

Participants will be randomized to receive either:

* 12 weekly sessions of NBT, along",,2028-06,ESTIMATED,18 Years - 70 Years,40,ESTIMATED,PARALLEL,OTHER,SINGLE,A Pilot Randomized Controlled Trial (RCT) of Neurobehavioral Therapy (NBT) Vs Standard Medical Care (SMC) for Functional Neurological Disorder (FND),2028-01,ESTIMATED,SF-36 Health Survey (SF-36) | Psychogenic Movement Disorders Rating Scale (PMDRS) | Simplified Functional Movement Disorders Rating Scale (S-FMDRS),TREATMENT,ALL,2024-09-25,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05999032,,RECRUITING,Pediatric Asthma,,PR-AIR,RANDOMIZED,2,Low-Intensity (Virtual) Intervention Implementation | High Intensity (in-Person) Intervention Implementation,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The purpose of this study is to adapt and deliver an evidence-based multi-level intervention to reduce asthma disparities, and that promote and improve population health in the high-burden communities of San Juan, Puerto Rico.

The Puerto Rico-Asthma Integrated Response Program (PR-AIR) will be implemented and evaluated to address pediatric asthma disparities in San Juan, PR, an area of high asthma burden. This study unfolds in two phases: In Phase 1, the researchers will collaborate with commun",University of Puerto Rico,2027-07-31,ESTIMATED,2 Years - 12 Years,480,ESTIMATED,PARALLEL,OTHER,NONE,"The Puerto Rico Asthma Integrated Response Program (""PR-AIR"")",2026-11-30,ESTIMATED,"Change in Child Asthma Control (Individual Level, ages 2-4 years) | Change in Child Asthma Control (Individual Level, ages 5-11 years) | Change in Child Asthma Control (Individual Level; ages 12 and up) | Health Care Utilization-ED visits (Community Level) | Health Care Utilization-Hospitalizations (Community Level) | Health Care Utilization-Urgent Care Visits (Community Level)",TREATMENT,ALL,2024-12-16,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05211206,,RECRUITING,ERCP,,,,2,Aggressive hydration | Conservative hydration, | ,"Aggressive intravenous hydration has been shown in randomized trials to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP), though studied regimens are often impractical. To date, no studies have prospectively assessed short-term (60-90 minute) aggressive hydration regimens that are feasible for outpatients undergoing ERCP and subsequent discharge. Furthermore, little is known with regard to fluid type, volume, and timing with respect to ERCP. In this study, we","McGill University, University of Ottawa, Queen's University, Halton Health (Oakville), Island Health, Victoria, BC",2026-02-28,ESTIMATED,18 Years - N/A,13000,ESTIMATED,,OTHER,,Association Between Peri-procedural Intravenous Hydration and Post- Endoscopic Retrograde Cholangiopancreatography Pancreatitis,2025-12-31,ESTIMATED,post-ERCP pancreatitis,,ALL,2022-01-10,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06942455,,RECRUITING,"Sleep, Sleep Quality, Intervention Study, Ethnic Minority",,SIESTA,RANDOMIZED,2,SIESTA | Sleep Education plus Child Health attention control,EXPERIMENTAL | OTHER,"The main goal of this study is to evaluate the ""SIESTA"" intervention, a culturally and contextually tailored sleep hygiene intervention that has the potential to exert greater improvements in sleep hygiene and sleep outcomes for group that may be more vulnerable to poor sleep health.

The main question is: do SIESTA participants have improved sleep outcomes, sleep hygiene behaviors and less sleep-related impairment compared to Control Group participants?

Participants randomized to the SIESTA in","National Institute on Minority Health and Health Disparities (NIMHD), University of Puerto Rico",2029-03-31,ESTIMATED,11 Years - 13 Years,300,ESTIMATED,PARALLEL,OTHER,NONE,"A Sleep Hygiene Intervention to Improve Sleep Health in Urban, Latino Middle School Children",2029-03-31,ESTIMATED,Sleep Duration | Sleep Efficiency/Quality,TREATMENT,ALL,2025-06-25,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06754527,,NOT_YET_RECRUITING,"Substance Use (Drugs, Alcohol), Substance Use Risk, Substance Use, Emotion Regulation, Risk Reduction Behavior, Risk Reduction",,ON-TRAC,RANDOMIZED,2,ON-TRAC Intervention | Waitlist Control,EXPERIMENTAL | NO_INTERVENTION,"This study will examine the effectiveness of ON-TRAC (Options for Navigating Talking about Risk and Adolescent Choices), which is an online substance use prevention program that also teaches emotion regulation skills. 200 adolescents, 12-15 years of age, will be randomized to ON-TRAC or a wait list comparison group (who will be offered the intervention at the end of their study participation) to determine impact on substance use, emotion regulation abilities, mental health symptoms, and other ri",,2029-02-01,ESTIMATED,12 Years - 15 Years,200,ESTIMATED,PARALLEL,OTHER,NONE,Emotion Regulation Intervention to Prevent Substance Use Among Youth in the Child Welfare System,2028-09-01,ESTIMATED,Timeline Follow Back,PREVENTION,ALL,2026-03-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05141942,,RECRUITING,Bile Leak,,,,0,,,"Post-surgical biliary leaks are relatively common after surgeries associated with hepatobiliary health. Left untreated, biliary leaks can lead to significant morbidity. Biliary leaks are most often successfully managed endoscopically, by way of performing an ERCP (endoscopic retrograde cholangio-pancreatography) procedure. These procedures help manage the bile leak by decreasing pressure at the opening of the common bile duct and promoting bile flow into the small bowel (rather than out the leak","McGill University, Queen's University, Island Health, Victoria, BC, University of Ottawa, Halton Healthcare Oakville",2026-03-31,ESTIMATED,18 Years - N/A,200,ESTIMATED,,OTHER,,Validation of a Clinical Prediction Rule to Determine the Need for Repeat ERCP After Endoscopic Treatment of Postsurgical Biliary Leaks,2025-12-31,ESTIMATED,Absence of persistent bile leak,,ALL,2019-11-19,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04907201,,ACTIVE_NOT_RECRUITING,Muscle Spasticity,,,,2,Patients | Healthy participants, | ,"Spasticity is a common complication after many upper motor neurone disorders. Many surgical techniques have been introduced for patients with refractory spasticity though they are not without peri-operative risks. Cryoneurotomy is another procedure which is cheaper, faster and less invasive in comparison to other surgical interventions. While many studies support the use of cryoneurotomy for pain relief, there are not much studies on use of cryoneurotomy to manage spasticity. The purpose of this",,2024-11,ESTIMATED,18 Years - 70 Years,60,ESTIMATED,,OTHER,,Electrophysiological Assessment of Cryoneurotomy in Spastic Lower Limbs.,2024-09,ESTIMATED,Any changes in H max to M max amplitude ratio (H/ M ratio) | Changes in maximum H reflex amplitude,,ALL,2020-12-15,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06885996,PHASE2,NOT_YET_RECRUITING,"Post Traumatic Stress Disorder PTSD, Intimate Partner Violence (IPV)",Psilocybin,PsiPTSD,RANDOMIZED,2,High Dose | Low Dose,EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this randomized controlled trial is to evaluate the efficacy of psilocybin administered with Acceptance and Commitment Therapy (ACT) as an intervention to reduce post-traumatic stress disorder (PTSD) symptom burden in adult (aged 18-65) survivors of intimate partner violence (IPV).

This trail will test the following 2 aims:

AIM 1 : To compare the efficacy of a therapeutic psilocybin dose at improving outcomes on the PCL-5 and CAPS-5 as compared to an active control psilocybin dose ","Vancouver Island University, University of British Columbia",2029-08-01,ESTIMATED,18 Years - 65 Years,76,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence,2028-08-01,ESTIMATED,Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | PTSD Checklist for DSM-5 (PCL-5),TREATMENT,ALL,2026-08-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06842875,,RECRUITING,"Hypertension in Pregnancy, Postpartum Preeclampsia, Postpartum Complication",,RI-SPHERES,RANDOMIZED,2,RI-SPHERES | Standard self-measured blood pressure program,EXPERIMENTAL | ACTIVE_COMPARATOR,This is a hybrid type 1 non-inferiority implementation effectiveness trial among postpartum patients with hypertension (N=1536) that will test the hypothesis that RI-SPHERES (a technologically enabled collaborative care model) is non-inferior to a standard self-measured blood pressure program in terms of persistent hypertension at six weeks postpartum and preventive care receipt within one year of delivery.,"Brown University, Kent Hospital, Rhode Island",2029-03-01,ESTIMATED,18 Years - 60 Years,1536,ESTIMATED,PARALLEL,OTHER,TRIPLE,Effect of a Technology-based Collaborative Model on Persistent Hypertension and Preventive Care Attendance Among Postpartum People With Hypertensive Disorders of Pregnancy,2029-03-01,ESTIMATED,Persistent hypertension,HEALTH_SERVICES_RESEARCH,FEMALE,2025-04-15,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT02917876,,ACTIVE_NOT_RECRUITING,"Obstructive Sleep Apnea, Pregnancy, Obesity, Sleep",,Predictors,,0,,,"This study seeks to understand the physical, physiologic and biologic features that predispose a woman to the development of obstructive sleep apnea once they are exposed to the cardiopulmonary and metabolic physiological changes of pregnancy. Knowing these specific predictive factors can help identify a population at risk and guide clinicians to develop suitable targeting screening strategies.","Brown University, Rhode Island Hospital, Women and Infants Hospital of Rhode Island",2025-05-01,ESTIMATED,18 Years - N/A,450,ESTIMATED,,OTHER,,Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy,2023-12-30,ACTUAL,Characteristics of participants who develop obstructive sleep apnea defined as an apnea hypopnea index >5 events per hour,,FEMALE,2016-11,,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05840900,,RECRUITING,Postpartum Psychiatric Disorders,,MORPHE,RANDOMIZED,2,App-based mindfulness training | Usual Care,EXPERIMENTAL | NO_INTERVENTION,"Dispositional optimism (the general assumption that more good things than bad will occur across various life domains) has been tied to improved somatic and mental health outcomes. Dispositional optimism is malleable, although prior interventions have been time and resource intensive and thus are not well-tailored to the peripartum period. The purpose of this pilot study is to evaluate the feasibility and acceptability of a pregnancy-oriented mindfulness phone application (Expectful) versus stand",The Miriam Hospital,2026-10-01,ESTIMATED,18 Years - N/A,100,ESTIMATED,PARALLEL,OTHER,SINGLE,"Mindfulness, Optimism, and Resilience for Perinatal Health and Equity Study",2026-04-01,ESTIMATED,Percentage of participants completing the assigned mindfulness exercises | Intervention acceptability,TREATMENT,FEMALE,2024-02-20,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05806164,PHASE4,RECRUITING,Urgency Urinary Incontinence,"Beta3-Agonists, Adrenergic [Mirabegron/Vibegron], OnabotulinumtoxinA 100 UNT [Botox]",BEST,RANDOMIZED,2,Beta-3 receptor agonist oral medication | Intradetrusor onabotulinumtoxinA,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI).

Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months.

Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity.

The study ","University of New Mexico, University of Alabama at Birmingham, University of California, San Diego, Howard University, Brown University, Patient-Centered Outcomes Research Institute",2030-08-01,ESTIMATED,18 Years - N/A,432,ESTIMATED,PARALLEL,OTHER,SINGLE,Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence,2026-07-15,ESTIMATED,Change in score Overactive Bladder Questionnaire-Symptom Bother Scale (OAB-q-SS) at 3 months | Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General Questionnaire (FACIT-TS-G) at 3 months,TREATMENT,FEMALE,2023-06-06,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07211087,,NOT_YET_RECRUITING,"Depression Disorders, HIV (Human Immunodeficiency Virus)",,,RANDOMIZED,2,COMBEX | COMB,EXPERIMENTAL | ACTIVE_COMPARATOR,"Depression is a common psychiatric condition among Youth with HIV (YWH), with prevalence as high as 25% in the United States. The treatment of depression is essential for improving both psychiatric and medical outcomes for YWH (e.g., adherence to antiretroviral treatment). Practice guidelines for the treatment of depression and substantial research (including for those with and without HIV), indicate that measured-care treatment (care decisions guided by systematic symptom measurement) and using",National Institute of Mental Health (NIMH),2030-03-31,ESTIMATED,15 Years - 24 Years,130,ESTIMATED,PARALLEL,OTHER,SINGLE,Improving the Treatment of Depression Among Youth With HIV,2030-03-31,ESTIMATED,Patient Health Questionnaire-9 (PHQ-9),TREATMENT,ALL,2026-04-15,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06930508,,NOT_YET_RECRUITING,"HIV, PrEP",,,NON_RANDOMIZED,2,Patient Participant | Physician Participant,EXPERIMENTAL | EXPERIMENTAL,"The goal of this clinical trial is to understand what patients and physicians think about providing medications to prevent HIV transmission to patients in a family planning clinic. These medications are known as pre-exposure prophylaxis, or PrEP. The main questions to answer are:

1. Do patients find it acceptable to be asked about, and offered, PrEP during their visit to a family planning clinic?
2. What things make it easier or harder to ask about PrEP in a family planning clinic setting?
3. W",Advance RI CTR,2026-06-30,ESTIMATED,16 Years - N/A,83,ESTIMATED,PARALLEL,OTHER,NONE,Implementing HIV Pre-Exposure Prophylaxis in a Family Planning Clinic: A Study of Feasibility and Acceptability (Aka The Pilot Fish Study),2026-02-28,ESTIMATED,Post-visit questionnaire | Pre- and post-study questionnaires,SCREENING,ALL,2025-07-01,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04205916,PHASE4,RECRUITING,Patient Preference,Dexamethasone,CIMPLIFY,RANDOMIZED,2,Experimental Group | Control Group,EXPERIMENTAL | ACTIVE_COMPARATOR,To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.,"Ocular Therapeutix, Inc.",2020-12-01,ESTIMATED,22 Years - 100 Years,50,ESTIMATED,SINGLE_GROUP,OTHER,NONE,A Prospective Trial Evaluating a Intracanalicular Insert Delivery System Compared to Traditional Topical Drops in Controlling Post-operative Pain and inFlammation in Subjects Undergoing Sequential Bilateral Cataract Surgery,2020-06-30,ESTIMATED,Patient Preference,OTHER,ALL,2019-11-04,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06969326,PHASE3,RECRUITING,"Postoperative Bleeding, Gender Dysphoria, Hysterectomy",Use of topical estradiol,,RANDOMIZED,2,Placebo | Estradiol,PLACEBO_COMPARATOR | EXPERIMENTAL,The purpose of this study is to determine if applying a single dose of topical estrogen cream in the operating room at the end of your hysterectomy (removal of uterus and cervix) improves the postoperative experience with bleeding and potential symptoms of dysphoria (a feeling of discomfort or distress). Topical estrogen cream is sometimes used if patients have increased risk of bleeding with surgery but is not currently utilized in a consistent way. This study aims to answer the question of whe,,2026-12-01,ESTIMATED,18 Years - N/A,48,ESTIMATED,PARALLEL,OTHER,NONE,Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy,2026-09-01,ESTIMATED,Evaluate the efficacy of one-time topical estrogen application for reducing postoperative health system contacts for vaginal bleeding in the first two weeks post hysterectomy. | Examine the impact of topical estrogen application on postoperative healing as defined by number of days of bleeding and patient Quality of Life Measures.,TREATMENT,FEMALE,2025-05-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07094308,,NOT_YET_RECRUITING,Intestinal Failure,,,RANDOMIZED,2,Physicians with No Tele-Mentoring then with Tele-Mentoring | Physicians with Tele-Mentoring after No Tele-Mentoring,ACTIVE_COMPARATOR | EXPERIMENTAL,"This is a multi-site research study to evaluate the efficacy and effectiveness of the LIFT-ECHO program to improve clinical outcomes in patients and improve patient reported quality of life (PRQOL). LIFT-ECHO (Learn Intestinal Failure Tele-ECHO) is a tele-health learning program whereby non-specialist clinicians meet with and learn from CIF specialist teams with the goal of improving the knowledge of CIF. LIFT-ECHO sessions consist of group discussion of anonymized real-world patient cases, foll","Rhode Island Hospital, The New York Academy of Medicine, University of Utah, London School of Economics and Political Science",2030-06-30,ESTIMATED,5 Years - N/A,150,ESTIMATED,CROSSOVER,OTHER,NONE,Improving Outcomes in Chronic Intestinal Failure Using the ECHO Model: The LIFT-ECHO Last Mile Project,2030-06-30,ESTIMATED,Patient-Reported Quality of Life (PRQOL) Score,HEALTH_SERVICES_RESEARCH,ALL,2026-01-02,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04828083,PHASE4,RECRUITING,"Arthroplasty, Replacement, Knee, Total Knee Arthroplasty","Lidocaine IV, Saline IV",ACBSL,RANDOMIZED,2,Ultrasound-guided adductor canal block with local anesthetic | Ultrasound-guided adductor canal block with saline,ACTIVE_COMPARATOR | SHAM_COMPARATOR,The investigators are evaluating the postoperative outcomes in patients undergoing total knee arthroplasty that receive either systemic lidocaine or ultrasound-guided adductor canal block as part of their anesthetic plan.,,2024-11-30,ESTIMATED,18 Years - 80 Years,120,ESTIMATED,PARALLEL,OTHER,TRIPLE,"The Efficacy of Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty: a Randomized, Double-blinded, Non-inferiority Study",2024-10-31,ESTIMATED,Postoperative opioid consumption,SUPPORTIVE_CARE,ALL,2021-03-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05382403,,RECRUITING,"Postpartum Hemorrhage, Maternal Death",,NOVIC,RANDOMIZED,2,Jada® System | Standard care,EXPERIMENTAL | ACTIVE_COMPARATOR,"This will be the first, definitive, randomized control trial (N=424) to test the hypothesis that the Jada® System is effective, safe and cost-effective in treating PPH, compared to standard care.","Washington University School of Medicine, University of Ghana, Kwame Nkrumah University of Science and Technology",2027-04-30,ESTIMATED,18 Years - 44 Years,424,ESTIMATED,PARALLEL,OTHER,NONE,Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage: a Multicenter Randomized Trial,2026-08-31,ESTIMATED,Maternal survival without surgical intervention,TREATMENT,FEMALE,2023-10-23,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05723445,,RECRUITING,"Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis With Intestinal Manifestations",,DINE,,1,Low Glycemic Load Diet,EXPERIMENTAL,"This study will evalute the effect of a low glycemic load (LGL diet on dysglycemia, insulin requirements, DXA-derived body composition, gastrointestinal symptoms and quality of life measures in adults with cystic fibrosis-related diabetes (CFRD). We will use continuous glucose monitors (CGM) to assess the LGL diet both in a controlled setting (via a meal delivery company) and in free-living conditions.",Cystic Fibrosis Foundation,2026-07-01,ESTIMATED,18 Years - 70 Years,15,ESTIMATED,SEQUENTIAL,OTHER,NONE,The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes,2026-07-01,ESTIMATED,Change in percent time in target range 70-180 mg/dL,TREATMENT,ALL,2023-09-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06320015,,RECRUITING,"Substance Use Disorders, Overdose, Opioid Use Disorder, Alcohol Use Disorder",,EMPOWER,,2,SMART Participant | Usual Care, | ,"This is an observational, prospective case-control study evaluating the effects of an emergency department community health worker-peer recovery specialist program (PCHW), the Substance Misuse Assistance Response Team (SMART). Aims of this study are to 1) understand participant experiences working with a SMART PCHW and identify possible mechanisms for successful recovery linkage; 2) Evaluate SMART effectiveness on patient-centered outcomes, building recovery capital, and recovery linkage; 3) Eva","Rhode Island Hospital, The Miriam Hospital, Brown University",2026-10,ESTIMATED,18 Years - N/A,400,ESTIMATED,,OTHER,,Emergency Department Community Health Worker-Peer Recovery Navigation for Linkage to Recovery: A Mixed Methods Evaluation,2026-09,ESTIMATED,Treatment engagement | Recovery Capital,,ALL,2024-07-01,ACTUAL,OBSERVATIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05087680,,RECRUITING,HIV Prevention,,,RANDOMIZED,2,Control Group | ACTPrEP,ACTIVE_COMPARATOR | EXPERIMENTAL,"Investigators will use a generalized framework for the adaptation of EBIs to inform the development of a brief Acceptance and Commitment Therapy (ACT)-based culturally appropriate pre-exposure prophylaxis (PrEP) intervention tailored to young Black men who have sex with men (YBMSM), named ACTPrEP.",University of Mississippi Medical Center,2025-12-01,ESTIMATED,18 Years - 34 Years,66,ESTIMATED,PARALLEL,OTHER,SINGLE,An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South,2025-12-01,ESTIMATED,ACTPrEP Feasibility | ACTPrEP Acceptability,PREVENTION,MALE,2023-09-14,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06750107,PHASE3,ACTIVE_NOT_RECRUITING,"Intervention, Control",,,RANDOMIZED,2,Behavioral Intervention Safe South Africa | Control of Standard Care,EXPERIMENTAL | NO_INTERVENTION,"In this study, investigators will examine the efficacy of Safe South Africa, a behavioral intervention that is developmentally- and gender-tailored to prevent human immunodeficiency virus (HIV) and intimate partner violence (IPV) among adolescent boys. South Africa faces some of the highest global rates of HIV and IPV with sustained high incidence of HIV and alarming rates of IPV among adolescents and thus, is an ideal site to advance prevention science to tackle these urgent public health prior","American University, Medical Research Council, South Africa, Rhode Island Hospital",2028-12-30,ESTIMATED,15 Years - 17 Years,836,ACTUAL,PARALLEL,OTHER,DOUBLE,Testing the Efficacy of Safe South Africa: An Intervention to Prevent HIV Risk and Interpersonal Violence Among Adolescent Boys,2028-04-30,ESTIMATED,Reduction in incidence of HIV and or Chlamydia and or Gonorrhoeae | Reduction in acts of intimate partner violence | Lower proportion of those who have reduced endorsement of intimate partner violence supportive attitudes,PREVENTION,MALE,2025-01-22,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06953271,PHASE4,NOT_YET_RECRUITING,"Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)","Methenamine Hippurate, Typically prescribed oral antibiotic prophylaxis",META,RANDOMIZED,2,Typically prescribed oral antibiotic prophylaxis | Methenamine hippurate prophylaxis,ACTIVE_COMPARATOR | EXPERIMENTAL,The goal of this clinical trial is to compare methenamine hippurate prophylaxis to routine antibiotic prophylaxis following onabotulinumtoxinA (BOTOX-A) injections in women with overactive bladder (OAB). Participants will be randomly selected to receive one of the two post-procedural prophylaxis medications. The primary outcome measure will be urinary tract infection (UTI) rates within 30 days from the BOTOX-A procedure. Secondary outcomes will assess patient satisfaction with the two post-proce,,2027-01-01,ESTIMATED,18 Years - N/A,164,ESTIMATED,PARALLEL,OTHER,NONE,Methenamine Hippurate Compared to Typical Antibiotic Prophylaxis in the Prevention of Urinary Tract Infection Following Intradetrusor OnabotulinumtoxinA Injection for Treatment of Overactive Bladder: a Randomized Controlled Non-Inferiority Trial,2026-05-01,ESTIMATED,Acute Urinary Tract Infection,PREVENTION,FEMALE,2025-05-15,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06872307,,RECRUITING,"HIV Prevention, HIV Infection Primary",,,RANDOMIZED,2,Standard of Care (Control Arm) | RAMP-It-Up intervention,NO_INTERVENTION | EXPERIMENTAL,"The investigators will conduct a fully powered randomized controlled trial (RCT) to test the effect of a patient navigation intervention for Black/African American (B/AA) men who have sex with men (MSM) on PrEP initiation, adherence and retention in care. B/AA men who have sex with men (MSM) are disproportionately impacted by the HIV/AIDS epidemic in the United States. Pre-exposure prophylaxis (PrEP), a once daily medication, can dramatically reduce HIV acquisition risk. However, social and stru","Whitman-Walker Institute, Rhode Island Public Health Institute, University of Mississippi Medical Center, National Institute of Mental Health (NIMH)",2028-07-31,ESTIMATED,18 Years - N/A,300,ESTIMATED,PARALLEL,OTHER,NONE,Intervention to Enhance Prep Persistence Among African American Men Who Have Sex with Men,2028-07-31,ESTIMATED,PrEP Adherence - Pharmacy Fill Data | PrEP Adherence - Drug Levels,PREVENTION,MALE,2024-10-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06909058,,ACTIVE_NOT_RECRUITING,"Postoperative Care, MIGS",,,RANDOMIZED,2,Control. Patients to receive standard postoperative instructions. | Study. Patients to receive liberalized postoperative instructions.,NO_INTERVENTION | EXPERIMENTAL,"The goal of this randomized controlled trial is to assess recovery in patients undergoing benign laparoscopic gynecologic surgery. The main question it aims to answer is: do liberalized postoperative restrictions improve patient recovery after laparoscopic gynecologic surgery?

Researchers will compare postoperative recovery surveys from the control group (patients given standard postoperative restrictions limiting activity for 2 weeks) to the research group (patients given liberalized postopera",,2026-02-01,ESTIMATED,18 Years - N/A,148,ESTIMATED,PARALLEL,OTHER,NONE,Postoperative Restrictions for Patients Undergoing Minimally Invasive Gynecologic Procedures,2026-01-16,ESTIMATED,Postoperative recovery,SUPPORTIVE_CARE,FEMALE,2025-04-07,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06943404,PHASE2,NOT_YET_RECRUITING,"Acute Stress Reaction, Acute Stress Disorder, Post-traumatic Stress Disorder","BXCL501 (dexmedetomidine HCl), Placebo",RISE,RANDOMIZED,2,BXCL501 (dexmedetomidine HCl) | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will examine the safety and efficacy of BXCL501 to reduce ASR symptoms and behavioral changes among patients presenting to the Emergency Department (ED) after Motor Vehicle Collision (MVC). Specifically, the investigators will perform the BXCL501 (BASIS) Trial, a double-blind placebo-controlled Randomized Controlled Trial (RCT) to determine if BXCL501 (dexmedetomidine hydrochloride sublingual film) initiated in the ED in the hours after MVC to high risk individuals, treats/reduces ASR","United States Department of Defense, Mclean Hospital, Washington University School of Medicine, University of Florida, Rhode Island Hospital, Vanderbilt University School of Medicine, Walter Reed Army Institute of Research (WRAIR)",2026-09-29,ESTIMATED,18 Years - 65 Years,100,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With a Sublingual Formulation of Dexmedetomidine (BXCL501),2026-09-29,ESTIMATED,Change in ASD Score,PREVENTION,ALL,2026-02-11,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT07316166,PHASE4,RECRUITING,Postoperative Pain Management,"Dexmedetomidine, Ropivacaine",,RANDOMIZED,2,Ropivacaine | Ropivacaine plus Dexmedetomidine,ACTIVE_COMPARATOR | EXPERIMENTAL,"The investigators are evaluating postoperative outcomes in patients undergoing hip replacement surgery performed with either spinal or general anesthesia, who also receive a suprainguinal fascia iliaca block using either perineural ropivacaine alone or ropivacaine combined with dexmedetomidine.",,2027-06,ESTIMATED,18 Years - 80 Years,120,ESTIMATED,PARALLEL,OTHER,TRIPLE,"Comparison of Suprainguinal Fascia Iliac Block With and Without Dexmedetomidine as an Adjunct to Ropivacaine for Postoperative Analgesia Following Hip Surgery: a Randomized, Double-blinded Study.",2027-06,ESTIMATED,Time of administration of first analgesic after the surgery,SUPPORTIVE_CARE,ALL,2025-12-08,ESTIMATED,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06998069,PHASE3,RECRUITING,Head and Neck Neoplasms,"Arm I Carboplatin, Paclitaxel, Pembrolizumab, Arm II Carboplatin, Paclitaxel, Cetuximab, Arm III Pembrolizumab",,NON_RANDOMIZED,3,Arm I PD-L1 CPS 1-19 % | Arm II PD-L1 CPS 0 | Arm III PD-L1 CPS > or = 20%,OTHER | OTHER | OTHER,"This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as frail, with a CGA score of 3-5, will then be treated with a novel reduced intensity regimen. The regimen will be tailored based on the programmed cell death ligand 1 combined positive score (PD-L1 CPS) and will involve 4 cycles of systemic chemotherapy and/or i","The Miriam Hospital, Rhode Island Hospital",2027-06-01,ESTIMATED,65 Years - N/A,20,ESTIMATED,PARALLEL,OTHER,NONE,Head and Neck Cancer Study Project in the Geriatric Population,2026-06-01,ESTIMATED,Treatment Completion,TREATMENT,ALL,2025-08-27,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04861636,,ACTIVE_NOT_RECRUITING,"Adolescent Obesity, Weight Loss",,HealthTRAC,RANDOMIZED,2,HealthTRAC | Standard Behavioral Weight Control (SBWC),EXPERIMENTAL | ACTIVE_COMPARATOR,"The prevalence of obesity in adolescents is remarkably high, with 38.7% of youth 12-15 years of age and 41.5% of 16-19 year olds meeting criteria for overweight or obesity. Behavioral weight control interventions for adolescents have had limited impact on this field and there is considerably more that needs to be done. Notably, adolescents who have difficulty managing their feelings have been found to consume higher caloric foods and report greater amounts of sedentary time. Poor emotion managem","Rhode Island Hospital, University of Oregon, Oregon Health and Science University",2026-01-31,ESTIMATED,13 Years - 17 Years,172,ACTUAL,PARALLEL,OTHER,SINGLE,Enhancing Emotion Regulation to Support Weight Control Efforts in Adolescents With Overweight and Obesity,2026-01-31,ESTIMATED,Change in BMI from baseline to 12 months post-intervention,TREATMENT,ALL,2021-05-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06439953,,RECRUITING,"Post-Op Complication, Spine Surgery, Site Infection, Surgical Site Infection, Spinal Instrumentation, Index Spinal Instrumentation, Layer-by-Layer Closure, Locoregional Flap-Based Closure",Vancomycin,,RANDOMIZED,2,Irrisept Irrigation | Vancomycin-saline Irrigation,EXPERIMENTAL | ACTIVE_COMPARATOR,"Various spine surgeons perform wound irrigation using saline mixed with vancomycin, relying on mechanical debridement of non-viable tissue, physical disruption of biofilm, and bacteriostatic effect against gram positive flora. When used as a powder, topical application of vancomycin has demonstrated increased risk of symptomatic seroma formation, which is an adverse outcome that often requires bedside or intra-operative aspiration. Broad-spectrum antiseptic agents, such as Irrisept, offer bacter",,2026-09-30,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,OTHER,SINGLE,Impact of Prophylactic Use of Irrisept Irrigation System for Spinal Instrumentation,2026-09-30,ESTIMATED,Occurrence of surgical site infection,PREVENTION,ALL,2024-10-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT06771453,,ACTIVE_NOT_RECRUITING,"Aneuploidy, Genetic Counseling, Informed Consent, Decisional Conflict",,GEM,RANDOMIZED,2,Usual Prenatal Care | Video Educational Tool Arm,NO_INTERVENTION | EXPERIMENTAL,"The goal of this randomized clinical trial is to assess the impact of a video educational tool on patient decisional conflict at the time when making a decision about prenatal genetic testing. The control group will receive standard prenatal care.

The secondary aims include assessing the impact of the video educational tool versus standard care on pregnant participants': perception of likelihood of having a baby affected by a genetic problem, intended plan for genetic testing, patient-provider ",,2026-02,ESTIMATED,18 Years - N/A,140,ESTIMATED,PARALLEL,OTHER,DOUBLE,The GEM Trial - Genetics Education and Equity in Maternal Fetal Medicine: A Pilot Feasibility Randomized Controlled Trial to Assess Impact of a Video Education Tool (VET) on Decisional Conflict Among Prenatal Patients,2025-10,ESTIMATED,Score on Decisional Conflict Scale (low health literacy version of the tool),OTHER,ALL,2025-01-16,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT04005469,"PHASE1, PHASE2",RECRUITING,"Ischemia Reperfusion Injury, Delayed Graft Function",Treprostinil,,,1,Trepostinil,EXPERIMENTAL,"The objectives of this study are to test the preliminary safety and efficacy of a two-day peri-operative course of treprostinil in reducing ischemia-reperfusion injury in adult patients receiving a deceased donor kidney transplantation. Treprostinil, a prostacyclin analog, is expected to facilitate the restoration of blood supply to the revascularized kidney graft via its vasodilatory actions, well characterized protective effects, and longer elimination half-life. These properties and actions o","University of Rhode Island, United Therapeutics",2026-06-30,ESTIMATED,18 Years - 65 Years,20,ESTIMATED,SINGLE_GROUP,OTHER,NONE,A Phase I/II Study Evaluating the Preliminary Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During De Novo Adult Kidney Transplantation,2025-07-01,ESTIMATED,Serum creatinine (SCr),PREVENTION,ALL,2020-11-13,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT05184556,,ACTIVE_NOT_RECRUITING,"Anorexia Nervosa, Eating Disorders",,,RANDOMIZED,2,Family-based treatment | Integrative family therapy,EXPERIMENTAL | ACTIVE_COMPARATOR,"This randomized, controlled effectiveness trial will assess outcomes, implementation, and mechanisms of two psychological treatments for adolescent anorexia nervosa (AN) delivered in the home setting, in the context of community-based mental health. Adolescents with AN-spectrum disorders (n=50) and their caregivers will be randomly assigned to either family-based treatment or integrated family therapy delivered in the home. Caregivers and adolescents will provide data on weight, eating, and puta","National Institute of Mental Health (NIMH), Lifespan, Rhode Island College",2026-04-30,ESTIMATED,12 Years - 18 Years,77,ACTUAL,PARALLEL,OTHER,SINGLE,Project HOME: Home-Based Treatment Options and Mechanisms for Eating Disorders,2026-03-30,ESTIMATED,Body mass index percentile | Eating Disorder Examination,TREATMENT,ALL,2022-08-01,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT03355976,PHASE2,ACTIVE_NOT_RECRUITING,"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Extra Renal Origin, Clear Cell Adenocarcinoma","Nivolumab, Ipilimumab",,RANDOMIZED,4,Arm 1 Nivolumab Ovarian | Arm 2 Nivolumab and Ipilimumab Ovarian | Arm 1 Nivolumab Extra-renal | Arm 2 Nivolumab and Ipilimumab Extra-renal,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Preclinical and early-phase clinical data suggest that immune modulation represents a treatment strategy that is worthy of further investigation in relapsed epithelial ovarian cancer. One method by which tumor cells may evade immune surveillance is by activation of the programmed cell death (PD-1) pathway, mediated by expression of PD-1 on the surface of T lymphocytes, which conveys an inhibitory signal after binding to its ligand PD-L1 on the surface of tumor cells. Nivolumab and Ipilimumab hav","Bristol-Myers Squibb, Rhode Island Hospital, The Miriam Hospital, Women and Infants Hospital of Rhode Island",2026-03,ESTIMATED,18 Years - N/A,46,ACTUAL,PARALLEL,OTHER,NONE,BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas,2026-01,ESTIMATED,Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab,TREATMENT,ALL,2018-04-30,ACTUAL,INTERVENTIONAL
ILPLF,Island Pharmaceuticals Limited,NCT03063372,,ACTIVE_NOT_RECRUITING,"Antioxidant, Burnout, Professional, Psychological Distress",,,RANDOMIZED,2,Pomegranate Supplement | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"Medical students and residents have high rates of mental distress and burnout related to the intellectual and time demands of their training. Research shows that physiological stress on the body can be a result of fatigue and high stress work, and is associated with experiences related to mental distress. Pomegranate is a fruit that is known to contain a variety of antioxidant substances that can reduce physiological stress. This study will look at the potential for pomegranate supplementation t",University of Rhode Island,2027-02-01,ESTIMATED,21 Years - 40 Years,50,ESTIMATED,PARALLEL,OTHER,DOUBLE,Pomegranate Supplementation and Well-Being Among Medical Students and Residents,2027-02-01,ESTIMATED,Changes in Scores on Maslach Burnout Inventory over time | Changes in health as measured by scores on the RAND Short-Form 12 over time | Changes in fatigue as measured by the Iowa Fatigue Scale over time | Changes in mental health symptoms measured by the Depression/Anxiety/Stress Scale (21) over time,OTHER,ALL,2017-02-28,ACTUAL,INTERVENTIONAL
MBGPF,Moberg Pharma AB (publ),NCT05279846,PHASE3,ACTIVE_NOT_RECRUITING,Onychomycosis,"MOB015B, Vehicle (Placebo Comparator)",,RANDOMIZED,2,MOB015B | Control Arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Distal Subungual Onychomycosis (DSO)",,2025-01,ESTIMATED,12 Years - 75 Years,350,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multi-center, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)",2025-01,ESTIMATED,Proportion of subjects with complete cure of the target toenail | Incidence of adverse events (Safety),TREATMENT,ALL,2022-05-09,ACTUAL,INTERVENTIONAL
OXNXF,Valerio Therapeutics Société anonyme,NCT07175350,,RECRUITING,Oncologic Diseases,,FIT-RT,,1,Oncologic patients undergoing radiotherapy,,"Non- profit, multicenter, prospective, observational study. The study aims to assess financial toxicity (FT) in patients undergoing radiotherapy for oncological diseases, assessed with a validated questionnaire (Patient Reported Outcome for Fighting FInancial Toxicity-PROFFIT- questionnaire).","National Cancer Institute (NCI), Naples",2026-06-01,ESTIMATED,18 Years - N/A,1000,ESTIMATED,,OTHER,,"Valutazione Della ""Financial Toxicity"" Nei Pazienti Sottoposti a Radioterapia: Uno Studio Multicentrico Italiano Promosso da yAIRO (Associazione Italiana Radioterapia e Ocologia Clinica)",2025-12-01,ESTIMATED,"Financial toxicity (PROFFIT financial score and ""determinants"")",,ALL,2024-09-06,ACTUAL,OBSERVATIONAL
PBIGF,Paradigm Biopharmaceuticals Limited,NCT06917404,PHASE3,RECRUITING,"Osteoarthritis, Knee","Pentosan Polysulfate Sodium twice weekly, Placebo",,RANDOMIZED,2,PPS | Placebo,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee OA pain.

Study details include:

* The study duration will be up to 64 weeks.
* The treatment duration will be 6 weeks.
* The visit frequency will be twice weekly during treatment.
* The visit/contact frequency will be every 4-6 weeks during the 52-week Follow-up period.
* Approximatel",,2027-07,ESTIMATED,18 Years - N/A,466,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomised, Double-Blind, Placebo-Controlled Multi-Centre Study to Evaluate the Treatment Effect of Pentosan Polysulfate Sodium Compared to Placebo in Participants With Knee Osteoarthritis Pain",2027-07,ESTIMATED,Change from baseline at Day 112 in knee pain as assessed by the weekly average of daily pain (ADP) score on the numerical rating scale (NRS) 11-point (0-10) scale.,TREATMENT,ALL,2025-05-29,ACTUAL,INTERVENTIONAL
PBIGF,Paradigm Biopharmaceuticals Limited,NCT04809376,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Osteoarthritis, Knee","Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly",,RANDOMIZED,4,PPS Twice Weekly | PPS Once Weekly | PPS Fixed Dose Once Weekly | Placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee osteoarthritis pain.

Study details include:

* The study duration will be up to 31 weeks per participant
* The treatment duration will be 6 weeks.
* The visit frequency will be twice weekly during treatment.
* The visit frequency will be every 4 weeks during the follow-up period.",,2025-01-06,ESTIMATED,18 Years - N/A,602,ACTUAL,PARALLEL,INDUSTRY,TRIPLE,"A 2-stage, Adaptive, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate Dose and Treatment Effect of Pentosan Polysulfate Sodium Compared With Placebo in Participants With Knee Osteoarthritis Pain",2024-10-15,ESTIMATED,Change from baseline at Day 56 in knee pain as assessed by the average pain sub-scale score of the WOMAC® NRS 3.1 Index.,TREATMENT,ALL,2021-10-19,ACTUAL,INTERVENTIONAL
PLYX,"Polaryx Therapeutics, Inc.",NCT04637282,PHASE3,NOT_YET_RECRUITING,Juvenile Neuronal Ceroid Lipofuscinosis,"PLX-200, Placebo",,RANDOMIZED,2,PLX-200 | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to evaluate the safety and efficacy of multiple doses of PLX-200 in patients with CLN3 disease.,,2026-03-31,ESTIMATED,6 Years - 18 Years,39,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Randomized. Multicenter, Double-Blind, Placebo-Controlled Safety, Tolerability, and Efficacy Study of PLX-200 in Participants With Mild-to-Moderate Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Disease",2026-03-31,ESTIMATED,"Efficacy of PLX-200 in CLN3 as assessed by the change in the motor score of the Hamburg Rating Scale compared with that of the Placebo group | Number of patients with treatment-related adverse events, as assessed by CTCAE v5.0, abnormal laboratory results, and abnormal cardiovascular and/or abdominal findings.",TREATMENT,ALL,2026-03-01,ESTIMATED,INTERVENTIONAL
RPGLF,Regent Pacific Group Limited,NCT01894139,,ACTIVE_NOT_RECRUITING,"Pregnancy, Obesity, Gestational Age and Weight Conditions, Maternal Care for Excessive Fetal Growth, Metabolic Disorders",,,RANDOMIZED,2,High-protein/Low-GI Diet | Low-protein/High-GI Diet,EXPERIMENTAL | ACTIVE_COMPARATOR,The Nutrition Research Unit at Copenhagen University Hospital Herlev will during the fall 2013 initiate a randomized and controlled intervention study engaging 390 obese pregnant women. The overall aim of APPROACH is to investigate how an optimal diet during pregnancy influences the programming of the offspring. The children will after birth be included in a prospective cohort according to maternal randomization and examined six times from delivery until the age of nine years.,"The Danish Dairy Research Foundation, Denmark, Nordea-Fonden, Denmark, LEGO Charity, Denmark, Pharma Nord, Danish Agriculture and Food Council, Danish Pork Levy Foundation, The Novo Nordic Foundation",2027-12-31,ESTIMATED,18 Years - 42 Years,280,ACTUAL,PARALLEL,OTHER,SINGLE,An Optimized Programming of Healthy Children (APPROACH) - The Most Favourable Dietary Protein:Carbohydrate Ratio During Pregnancy in the Context of New Nordic Diet,2018-01,ACTUAL,Gestational weight gain,PREVENTION,FEMALE,2014-01-04,ACTUAL,INTERVENTIONAL
RPGLF,Regent Pacific Group Limited,NCT04332822,PHASE3,RECRUITING,"DLBCL, Diffuse Large B Cell Lymphoma","R-pola-mini-CHP, R-mini-CHOP",POLAR BEAR,RANDOMIZED,2,Arm A - R-mini-CHOP | Arm B - R-pola-mini-CHP,ACTIVE_COMPARATOR | EXPERIMENTAL,"This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy, Australia and New Zealand, in elderly patients with untreated diffuse large B-cell lymphoma. Elderly is defined as either ≥80 years of age, or ≥75 years and frail, according to a simplified Comprehensive Geriatric Assessment. Patients will be randomized 1:1 to either the standard treatment for this population, R-miniCHOP, or an experimental regimen, R-pola-miniCHP, where vincrist",Roche Pharma AG,2028-12-28,ESTIMATED,75 Years - N/A,300,ESTIMATED,PARALLEL,NETWORK,NONE,"R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial",2025-12-28,ESTIMATED,Progression-free survival (PFS).,TREATMENT,ALL,2020-08-19,ACTUAL,INTERVENTIONAL
RPGLF,Regent Pacific Group Limited,NCT06908421,,RECRUITING,Asthma,,SiASMARTer,,1,Study population,,"The goal of this observational study is to determine if using the SiA® (Systematic Intervention Agent) system can improve inhaler technique and medication adherence in adults with asthma who are already using Trimbow pMDI inhalers. Furthermore, it will be addressed if the SiA® system can be used to discriminate between patients, where increased inflammatory markers are caused by incorrect inhaler technique/adherence to medication or patients that have ongoing inflammation requiring adjustment of",Briota ApS,2027-09,ESTIMATED,18 Years - N/A,60,ESTIMATED,,INDUSTRY,,"A 52-week, Multicentre, Observational, Prospective Study on the Use of a Smart Platform Connected to a Single-inhaler Triple Therapy (ICS/LABA/LAMA) to Evaluate Effectiveness on Treatment Adherence and Inhaler Technique in Patients With Poorly Controlled Asthma.",2027-09,ESTIMATED,To evaluate the impact of the SiA® platform on the level of the type 2 inflammation biomarker FeNO,,ALL,2025-09-15,ESTIMATED,OBSERVATIONAL
RPGLF,Regent Pacific Group Limited,NCT05683041,,RECRUITING,Myoma,,PALLM,RANDOMIZED,2,intrauterine gel application | no intra-uterine gel application,EXPERIMENTAL | NO_INTERVENTION,"Clinical study on the prevention of intrauterine adhesions after laparoscopic or laparotomic myomectomy.

Myomas are common in women of reproductive age and myomectomy can lead to intra-uterine adhesions, which can be detrimental to fertility. This study investigates whether the use of an intrauterine gel can prevent the development of these adhesions.",Nordic Pharma SAS,2028-01,ESTIMATED,18 Years - 45 Years,30,ESTIMATED,PARALLEL,OTHER,TRIPLE,Prevention of Intra-uterine Adhesions Following Laparoscopic and Laparotomic Myomectomy,2027-01,ESTIMATED,Adhesion formation postoperatief.,PREVENTION,FEMALE,2023-02-22,ACTUAL,INTERVENTIONAL
RPGLF,Regent Pacific Group Limited,NCT07417787,,RECRUITING,Abortion Early,,POCT VEMA,,2,VEMA Patients | Staff Members, | ,This study will investigate the use of a point of care test in patients who are having an abortion at a gestation of \<6 weeks (known as a very early medical abortion). These patients have their pregnancy hormone level checked at Day 0 and Day 7 to see if their treatment has worked. We plan to use a point of care test machine to see if we can check their pregnancy hormone level earlier than Day 7.,"NORDIC pharma (funding), NHS Lothian, Karolinska Institutet, Karolinska University Hospital, Göteborg University, Sahlgrenska University Hospital",2028-02,ESTIMATED,16 Years - 55 Years,130,ESTIMATED,,OTHER,,Point of Care Testing for HCG to Improve Access to Very Early Medical Abortion and Simplify the Follow up Process,2027-02,ESTIMATED,Sensitivity | Specificity,,FEMALE,2026-02-23,ESTIMATED,OBSERVATIONAL
RPGLF,Regent Pacific Group Limited,NCT03880435,,ACTIVE_NOT_RECRUITING,"Infertility, Polyp Uterus, Myoma;Uterus, Adhesion, Hysteroscopy, Uterine Septum, Retained Products of Conception",,AGNOHSTIC,RANDOMIZED,2,Hyalobarrier® gel endo | No Hyalobarrier® gel endo,EXPERIMENTAL | NO_INTERVENTION,"To compare the costs and effects of HYALOBARRIER® GEL ENDO versus no HYALOBARRIER® GEL ENDO for increasing the chance of conception leading to live birth measured at 30 weeks after randomization in women wishing to become pregnant after surgical removal of intrauterine pathology (endometrial polyps, fibroids with uterine cavity deformation, uterine septa, IUAs or RPOC after miscarriage) by hysteroscopy as an outpatient or in hospital treatment.","Belgium Health Care Knowledge Centre, Nordic Pharma SAS, Universitaire Ziekenhuizen KU Leuven, Universitair Ziekenhuis Brussel, Health, Innovation and Research Institute (HIRUZ) UZ Ghent, University of Liege, UCL Bruxelles, Jessa hospital, Hasselt",2025-05-31,ESTIMATED,18 Years - 47 Years,419,ACTUAL,PARALLEL,OTHER,TRIPLE,"The Cost-effectiveness of Anti-adhesion Treatment With HYALOBARRIER® GEL ENDO Versus no Gel Following the Removal by Hysteroscopy of Endometrial Polyps, Fibroids With Uterine Cavity Deformation, Uterine Septa, Intrauterine Adhesions or Retained Products of Conception for Improving Reproductive Outcome in Women Wishing to Become Pregnant: a Multi-centre, Parallel Group, Superiority, Double-blind, Randomized Controlled Trial",2024-06-30,ACTUAL,Conception leading to live birth,PREVENTION,FEMALE,2019-04-01,ACTUAL,INTERVENTIONAL
RPGLF,Regent Pacific Group Limited,NCT05651724,,RECRUITING,"MASH, MASLD, MASH With Fibrosis, Fibrosis, Liver, Steatosis of Liver, Type 2 Diabetes, Obesity, Metabolic Syndrome, Arterial Hypertension",,GRIPonMASH,,0,,,"GRIPonMASH will assist (primary) health care providers clinicians to implement the latest patient care pathway, as described by the European Association for the Study of the Liver (EASL), to identify patients at risk of severe metabolic dysfunction-associated steatotic liver disease (MASLD) and to raise awareness. The primary objective is to implement a transmural patient care pathway, in order to identify patients with MASLD and its progressive form metabolic dysfunction-associated steatohepati","UMC Utrecht, Echosens, MIMETAS BV, Nordic Bioscience A/S, Elevate BV, Leiden University, Amsterdam University Medical Center, Andaluz Health Service, National Research Council, Institute of Clinical Physiology, Italy, Leiden University Medical Center, Université Libre de Bruxelles, University Hospital, Antwerp, Catholic University of the Sacred Heart, Medical Education Research And Innovation Center S.R.L., EUROPEAN LIVER PATIENTS ASSOCIATION, Harokopio University, General University Hospital, Prague, Novo Nordisk A/S, Maastricht University, Mercodia Aktiebolag, EXIT071 BV, European Atherosclerosis Society, MetaDeq Limited, Associação para Investigação e Desenvolvimento da Faculdade de Medicina, Institute of Cardiometabolism and Nutrition, France, University Hospital, Saarland, Roche Pharma AG, Inventiva Pharma, Biocellvia, Franciscus Gasthuis & Vlietland (Hospital)",2031-03-31,ESTIMATED,18 Years - 75 Years,10000,ESTIMATED,,INDUSTRY,,Global Research Initiative for Patients Screening on MASH - Implementation of an International Transmural Patient Care Pathway,2031-03-31,ESTIMATED,"Prevalence of liver steatosis and MASLD estimated by FibroScan CAP in patients at risk | Prevalence of liver fibrosis estimated by FibroScan LSM in patients at risk | Prevalence of at-risk MASH estimated by FAST score in patients at risk | *Subset of patients: prevalence of MASH in patients at risk | Comparison of the prevalence of MASLD, liver fibrosis and (at-risk) MASH between the participating countries | Evaluate added value of a 2-step pathway as compared to FibroScan only for detection of high-risk patients",,ALL,2023-06-30,ACTUAL,OBSERVATIONAL
SYMQY,SymBio Pharmaceuticals Limited,NCT07387367,PHASE3,NOT_YET_RECRUITING,Adenovirus Infections,"cidofovir, Brincidofovir",ENOVIA,RANDOMIZED,2,IV BCV | IV CDV,EXPERIMENTAL | ACTIVE_COMPARATOR,"This randomized, open-label, parallel group, two-arm, multi-center assessment will compare IV BCV with IV CDV in adult and pediatric allogeneic HCT recipients with AdV viremia. A virologic response-driven approach to duration of treatment will be evaluated, in which randomized subjects are treated with either BCV or CDV until AdV viremia is confirmed as undetectable or until a maximum of 12 weeks of therapy, whichever occurs first. All subjects will be followed for a total of 24 weeks post-rando",,2028-06-30,ESTIMATED,2 Months - N/A,180,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,"A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir Versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)",2028-01-31,ESTIMATED,"To assess efficacy of intravenous (IV) brincidofovir (BCV), compared with IV cidofovir (CDV), in subjects after allo-HCT with adenovirus (AdV) viremia.",TREATMENT,ALL,2026-02-15,ESTIMATED,INTERVENTIONAL
SYMQY,SymBio Pharmaceuticals Limited,NCT04706923,PHASE2,RECRUITING,"Adenovirus Infections, Cytomegalovirus Infection",BCV,ATHENA,NON_RANDOMIZED,4,BCV 0.2mg/kg BIW | BCV 0.3mg/kg BIW | BCV 0.4 mg/kg BIW | BCV 0.4 mg/kg QW,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV",,2026-09-30,ESTIMATED,2 Months - N/A,52,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection",2026-09-30,ESTIMATED,"Safety will be evaluated based on incidence and severity of Adverse Events, Serious Adverse Events and laboratory assessments. | Antiviral Effects",TREATMENT,ALL,2021-08-16,ACTUAL,INTERVENTIONAL
SENOF,Sensorion SA,NCT05402813,,RECRUITING,"Sensorineural Hearing Loss, Bilateral, AUNB1, DFNB1A, Congenital Deafness, DFNB9, OTOF Gene Mutation, GJB2 Gene Mutation",,Otoconex,,3,Cohort 1a | Cohort 1b | Cohort 2, |  | ,The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 16 years of age.,,2028-11-18,ESTIMATED,N/A - 16 Years,180,ESTIMATED,,INDUSTRY,,Longitudinal Study of the Natural History of Two Autosomal Recessive Non Syndromic Deafness (DFNB1A and DFNB9) in Children Up to 16 Years of Age,2028-11-18,ESTIMATED,Audiological characteristics | Electrophysiological characteristics: ABR | Electrophysiological characteristics: OAE,,ALL,2022-11-18,ACTUAL,OBSERVATIONAL
SENOF,Sensorion SA,NCT06354010,,RECRUITING,"Sensorineural Hearing Loss, Bilateral",,SONG,,2,Patients with adulthood-onset bilateral sensorineural hearing loss (SNHL) | Patients that carry mutations in the gene GJB2 from patients with adulthood-onset bilateral SNHL, | ,The purpose of this study is to characterize and assess the evolution of hearing impairment of patients with adulthood-onset bilateral sensorineural hearing loss carrying mutations on GJB2 gene.,,2027-07,ESTIMATED,30 Years - 55 Years,100,ESTIMATED,,INDUSTRY,,Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis,2027-07,ESTIMATED,Evolution of hearing impairment of adult patients with early-onset presbycusis carrying mutations in GJB2 gene. | Evolution of hearing impairment of adult patients with early-onset presbycusis carrying mutations in GJB2 gene,,ALL,2024-06-14,ACTUAL,OBSERVATIONAL
SENOF,Sensorion SA,NCT06370351,"PHASE1, PHASE2",RECRUITING,"OTOF Gene Mutation, DFNB9, Congenital Deafness, Hearing Disorders, Ear Diseases, Otorhinolaryngologic Diseases, Deafness, Hearing Loss, Sensorineural",,AUDIOGENE,NON_RANDOMIZED,3,Dose escalation - Low dose group | Dose escalation - High dose group | Dose expansion group,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study intends to assess safety, tolerability, and efficacy of SENS-501 in children between the ages of 6-31 months with pre-lingual hearing loss due to a mutation in the Otoferlin gene.",,2031-07,ESTIMATED,6 Months - 31 Months,12,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase I/II, Open-ended, Adaptative, Open Label Dose Escalation and Expansion Clinical Trial to Evaluate the Efficacy and Safety of Unilateral Intracochlear Injection of SENS-501 Using an Injection System in Children with Severe to Profound Hearing Loss Due to Otoferlin Gene Mutations",2027-07,ESTIMATED,Safety and tolerability of SENS-501 | Efficacy of SENS-501 assessed by ABR,TREATMENT,ALL,2024-06-21,ACTUAL,INTERVENTIONAL
SEOVF,Sernova Biotherapeutics Inc,NCT03513939,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Type 1 Diabetes Mellitus,,,,1,T1D Cell Pouch Recipients,EXPERIMENTAL,"The Cell Pouch™ is a novel implantable device, that is transplanted with therapeutic cells such as insulin producing islets. This combination product is designed for the treatment of Type 1 Diabetes Mellitus (T1D) with hypoglycemia unawareness and a history of severe hypoglycemic episodes. Upon implantation, the Cell Pouch is designed to form a natural environment, rich in tissue and microvessels for the transplant and function of therapeutic cells. The Cell Pouch is designed as a scaffold made ","ICON plc, University of Chicago, Breakthrough T1D",2026-10,ESTIMATED,18 Years - 65 Years,17,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation",2026-10,ESTIMATED,"To assess the safety of the Cell Pouch following implantation, and islet transplantation, by evaluating the incidence and severity of adverse events (AEs) determined to be probable or highly probable to the Cell Pouch",TREATMENT,ALL,2019-02-07,ACTUAL,INTERVENTIONAL
SHIEF,Shield Therapeutics plc,NCT06203418,,ACTIVE_NOT_RECRUITING,Anorexia Nervosa,,,,1,Intervention,EXPERIMENTAL,The proposed project is an intensive multi family therapy (MFT) intervention involving patients with anorexia nervosa and their families. MFT interventions are informed from the principles of the family based treatment (FBT)/family therapy for Anorexia Nervosa (FT-AN) models. This program will offer families in vivo/virtual support while connecting with other families to increase knowledge of eating disorders and develop skills related to successfully supporting their adolescent during difficult,Blue Cross Blue Shield,2025-12-30,ESTIMATED,11 Years - 18 Years,200,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Investigation of Multi-Family Therapy for Anorexia Nervosa,2024-12-30,ACTUAL,Effect on Eating Disorder Symptomatology (multiple variables) - 1. weight | Effect on Eating Disorder Symptomatology (multiple variables) - 2. BMI | Effect on Eating Disorder Symptomatology (multiple variables) - 3. Heart rate | Effect on Eating Disorder Symptomatology (multiple variables) - 4. eating disorder thoughts and behaviors | Effect on Eating Disorder Symptomatology (multiple variables) - 5. co-morbid psychiatric disorders | Effect on Eating Disorder Symptomatology (multiple variables) - 6. co-morbid psychiatric disorders | Effect on Eating Disorder Symptomatology (multiple variables) - 7. co-morbid psychiatric disorders | Effect on Eating Disorder Symptomatology (multiple variables) 8. sleep quality | Effect on Eating Disorder Symptomatology (multiple variables) - 9. expressed emotion | Effect on Eating Disorder Symptomatology (multiple variables) - 10. expressed emotion | Effect on Eating Disorder Symptomatology (multiple variables) - 11. expressed emotion | Effect on Eating Disorder Symptomatology (multiple variables) - 12. Parenting styles,TREATMENT,ALL,2020-05-21,ACTUAL,INTERVENTIONAL
SHIEF,Shield Therapeutics plc,NCT05795439,,RECRUITING,"Type2diabetes, Type 2 Diabetes Treated With Insulin",,,RANDOMIZED,2,Intervention Group | Control Group,EXPERIMENTAL | NO_INTERVENTION,"The CARING study assesses the health benefits of nutrition education for Blue Cross Blue Shield subscribers, as well as potential healthcare cost savings to subscribers and the insurance company.",Blue Cross Blue Shield,2026-12,ESTIMATED,18 Years - N/A,700,ESTIMATED,PARALLEL,OTHER,SINGLE,The CARING Study: Creating and Restoring Health Through Nutrition Guidance,2026-12,ESTIMATED,Medical Utilization | Body Weight | Plasma Lipid Concentrations | HbA1C,TREATMENT,ALL,2023-07-11,ACTUAL,INTERVENTIONAL
SHIEF,Shield Therapeutics plc,NCT06934564,,RECRUITING,"Breast Lumpectomy, Laparoscopic Cholecystectomy, Inguinal Hernia Repair",,,RANDOMIZED,6,Wave 1 | Wave 2 | Wave 3 | Wave 4 | Wave 5 | Wave 6,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This trial aims to evaluate the effectiveness of a multi-level, multi-component de-implementation strategy to reduce unnecessary preoperative testing. Sixteen Michigan Value Collaborative (MVC)/Michigan Surgical Quality Collaborative (MSQC) sites in Michigan will implement several tools that have been proven to reduce unnecessary testing at a single site, including clinician education, a decision aid, audit and feedback on performance, and a pay-for-performance incentive. The researchers believe","Agency for Healthcare Research and Quality (AHRQ), Blue Cross Blue Shield of Michigan Foundation",2026-12,ESTIMATED,18 Years - N/A,16,ESTIMATED,SEQUENTIAL,OTHER,NONE,De-Implementation of Low-value Testing in Patients Undergoing Low-Risk Surgery,2026-12,ESTIMATED,Number of tests within 30 days of surgery not associated with an emergency department visit,HEALTH_SERVICES_RESEARCH,ALL,2025-04-01,ACTUAL,INTERVENTIONAL
SHIEF,Shield Therapeutics plc,NCT04018638,,ACTIVE_NOT_RECRUITING,"Knee Injuries, Knee Osteoarthritis, Knee Arthritis",,,NON_RANDOMIZED,2,Adults with TKR Perform Home Exercise Program | Healthy Controls Only,EXPERIMENTAL | NO_INTERVENTION,This study will determine the safety and efficacy of using blood-flow restriction exercise enhancement (B-FREE) to overcome persistent quadriceps muscle weakness that occurs following a total knee replacement (TKR).,Blue Cross Blue Shield of Michigan Foundation,2025-12-25,ESTIMATED,40 Years - 75 Years,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,B-FREE in the UP! Improving Recovery After a Knee Replacement With Blood-Flow Restriction Exercise Enhancement,2025-12-25,ESTIMATED,Change in Muscle size | Change in Muscle strength,TREATMENT,ALL,2019-06-25,ACTUAL,INTERVENTIONAL
SRNM.F,Sirnaomics Ltd.,NCT05037149,PHASE1,ACTIVE_NOT_RECRUITING,Solid Tumor,STP707,,NON_RANDOMIZED,6,Part 1: Arm A | Part 1: Arm B | Part 1: Arm C | Part 1: Arm D | Part 1: Arm E | Part 1: Arm F,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administration in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy.",,2024-03-30,ESTIMATED,18 Years - N/A,50,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"Ph.1, Open-Label, Dose Escalation & Expansion for Safety, Tolerability, PK, & Anti-Tumor Activity of STP707 Administered IV in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy.",2024-03-30,ESTIMATED,Maximum Tolerated Dose (MTD) | Limited Dose Toxicity (LDT),TREATMENT,ALL,2021-11-01,ACTUAL,INTERVENTIONAL
SRNM.F,Sirnaomics Ltd.,NCT05844293,PHASE1,RECRUITING,FXI,FXI-GalNAc-siRNA,,RANDOMIZED,5,Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5,OTHER | OTHER | OTHER | OTHER | OTHER,"The purpose of this study is to evaluate safety, tolerability, PK, and PD of SAD of FXI-GalNAc-siRNA administered SC to healthy subjects.",,2024-06,ESTIMATED,18 Years - 55 Years,40,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"Single-center, Randomized, Double-blind, Placebo-controlled, Sequential Cohort Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAD of FXI-GalNAc-siRNA When Administered Subcutaneously to Healthy Subjects.",2024-05,ESTIMATED,Maximum peak concentration | Time to maximum concentration. | Apparent terminal elimination rate constant. | Half life | Area under the curve | Area under the curve from 0-infinity,TREATMENT,ALL,2023-05-16,ACTUAL,INTERVENTIONAL
TRYPF,Tryp Therapeutics Inc.,NCT06206265,PHASE2,ACTIVE_NOT_RECRUITING,Irritable Bowel Syndrome,TRYP-0082,,RANDOMIZED,2,Open Label Oral Psilocybin | Waitlist Control,EXPERIMENTAL | OTHER,"Participants with IBS (all subtypes) and with no exclusionary comorbid psychiatric or medical disorders will be enrolled in the study.

This study will involve a randomized waitlist control design to investigate the rapid and sustained effects of TRP-8802 following two experimental sessions in which an oral dose of TRP-8802 is administered to participants with IBS. The study will include clinician and participant ratings of depression and anxiety pre- and post-drug-session, monitor and participa",,2026-03-01,ESTIMATED,21 Years - 64 Years,14,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design",2026-03-01,ESTIMATED,Incidence of Treatment-Emergent Adverse Events - Hypertension | Incidence of Treatment-Emergent Adverse Events - Abuse-Related Psychological Events | Incidence of Treatment-Emergent Adverse Events - EKG QT Prolongation,TREATMENT,ALL,2024-01-17,ACTUAL,INTERVENTIONAL
TTRX,Turn Therapeutics Inc.,NCT07355075,PHASE2,RECRUITING,"Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis",,GX-03 in AD,RANDOMIZED,2,GX-03 | Vehicle,EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a randomized, double-blind, vehicle-controlled clinical study designed to evaluate the efficacy and safety of GX-03, a topically applied emollient, in adult subjects with moderate to severe eczema. Approximately 120 adult participants will be enrolled and randomized in a 1:1 ratio to receive either GX-03 or a petrolatum-based vehicle control for 8 consecutive weeks. Efficacy will be assessed using validated clinical outcome measures, including the Eczema Area and Severity Index (EASI), t",,2026-06-30,ESTIMATED,18 Years - 70 Years,100,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-Blind, Vehicle-Controlled Study to Assess the Efficacy of GX-03 When Used in a Population of Adult Individuals With Moderate to Severe Eczema",2026-05-31,ESTIMATED,Change in Eczema Area and Severity (EASI),TREATMENT,ALL,2025-07-11,ACTUAL,INTERVENTIONAL
VXRT,"Vaxart, Inc.",NCT06944717,PHASE1,ACTIVE_NOT_RECRUITING,Norovirus Infections,"VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T",,NON_RANDOMIZED,3,Bivalent Low Dose Next Generation Vaccine | Bivalent High Dose Legacy Vaccine | Bivalent High Dose Next Generation Vaccine,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The primary objective of this study is to determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.,,2026-05-01,ESTIMATED,18 Years - 80 Years,60,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 1, Single Center, Open Label, Single Dose, Dose Escalation Study to Determine the Safety and Immunogenicity of a Novel Bivalent Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Volunteers Aged ≥ 18 Years and ≤ 80 Years Old",2026-05-01,ESTIMATED,Number of Participants Experiencing Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) for 1 Week Following Study Intervention Dose | Duration of Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) for 1 Week Following Study Intervention Dose | Severity of Solicited Symptoms of Reactogenicity (Gastrointestinal and Systemic) for 1 Week Following Study Intervention Dose | Number of Participants Experiencing Unsolicited Adverse Events (AE) for 28 Days Following the Study Intervention Dose | Number of Participants Experiencing Unsolicited New Onset of Chronic Illness (NOCI) for 28 Days Following the Study Intervention Dose | Duration of Unsolicited AEs for 28 Days Following the Study Intervention Dose | Duration of Unsolicited NOCIs for 28 Days Following the Study Intervention Dose | Severity of Unsolicited AEs for 28 Days Following the Study Intervention Dose | Severity of Unsolicited NOCIs for 28 Days Following the Study Intervention Dose | Geometric Mean Titer (GMT) at Day 0 of Serum Functional Antibody Against GI.1 Measured by Norovirus Blocking Antibody Assay (NBAA) | GMT at Day 28 of Serum Functional Antibody Against GI.1 Measured by NBAA | GMT at Day 0 of Serum Functional Antibody Against GII.4 Measured by NBAA | GMT at Day 28 of Serum Functional Antibody Against GII.4 Measured by NBAA | Geometric Mean Fold Rise (GMFR) from Day 0 to Day 28 of Serum Functional Antibody Against GI.1 Measured by NBAA | GMFR from Day 0 to Day 28 of Serum Functional Antibody Against GII.4 Measured by NBAA,PREVENTION,ALL,2025-03-03,ACTUAL,INTERVENTIONAL
VXRT,"Vaxart, Inc.",NCT06672055,PHASE2,ACTIVE_NOT_RECRUITING,"SARS-CoV2, COVID-19","VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3",,RANDOMIZED,4,VXA-CoV2-3.1 Safety Sentinel Cohort | COMIRNATY® Safety Sentinel Cohort | VXA-CoV2-3.3 | COMIRNATY®,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR,"The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).

In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) ",,2026-11,ESTIMATED,18 Years - N/A,10400,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 2b, Double-Blind, Multi-Center, Randomized, Comparator-Controlled Trial to Determine the Relative Efficacy, Safety, and Immunogenicity of the Investigational Oral SARS-CoV-2 Vaccine Tablet Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection",2026-11,ESTIMATED,KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic Polymerase Chain Reaction (PCR)-Positive COVID-19 at 14 Days Post-vaccination | KP.2 Cohorts: Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 at 12 Months Post-vaccination | XBB Sentinel Cohorts: Percentage of Participants who Experience any Solicited Local Reactogenicity Through 7 Days Post-vaccination | XBB Sentinel Cohorts: Percentage of Participants who Experience any Solicited Systemic Reactogenicity Through 7 Days Post-vaccination | XBB Sentinel Cohorts: Percentage of Participants who Experience Unsolicited Adverse Events (AEs) Through 30 Days Post-vaccination | XBB Sentinel Cohorts: Percentage of Participants who Experience Treatment-emergent Adverse Events (TEAEs) Through 12 Months Post-vaccination | XBB Sentinel Cohorts: Percentage of Participants With any Clinically Significant Abnormal Safety Laboratory Results Within 7 Days Pots-vaccination,PREVENTION,ALL,2024-10-08,ACTUAL,INTERVENTIONAL
CAMP,Camp4 Therapeutics Corporation,NCT06247670,PHASE1,RECRUITING,Healthy Volunteers,CMP-CPS-001,,RANDOMIZED,2,Single Ascending Dose Part | Multiple Ascending Dose Part,EXPERIMENTAL | EXPERIMENTAL,"The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of CMP-CPS-001 administered as a subcutaneous injection in adult healthy volunteers.",,2025-08,ESTIMATED,18 Years - 55 Years,96,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of CMP-CPS-001 in Healthy Volunteers",2025-08,ESTIMATED,Adverse events,TREATMENT,ALL,2024-02-05,ACTUAL,INTERVENTIONAL
AVTX,"Avalo Therapeutics, Inc.",NCT06603077,PHASE2,ACTIVE_NOT_RECRUITING,Hidradenitis Suppurativa,"AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo",LOTUS,RANDOMIZED,3,AVTX-009 Regimen 1 | AVTX-009 Regimen 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).,,2026-04,ESTIMATED,18 Years - N/A,250,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa (LOTUS)",2026-03,ESTIMATED,Proportion of patients achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75),TREATMENT,ALL,2024-09-16,ACTUAL,INTERVENTIONAL
NERV,"Minerva Neurosciences, Inc.",NCT04020575,PHASE1,RECRUITING,Metastatic Breast Cancer,"huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells, huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D",,NON_RANDOMIZED,4,Dose Escalation | Luminal | HER2+ | Triple Negative,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Phase I/II study of adoptive immunotherapy for advanced MUC1\* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1\*).",City of Hope Medical Center,2035-01-15,ESTIMATED,18 Years - N/A,69,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 or huMNC2-CAR22, Specific for a Cleaved Form of MUC1 (MUC1*)",2025-01,ESTIMATED,Incidence of Adverse Events,TREATMENT,ALL,2020-01-15,ACTUAL,INTERVENTIONAL
SLGL,Sol-Gel Technologies Ltd.,NCT06050122,PHASE3,ACTIVE_NOT_RECRUITING,Gorlin Syndrome,"Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib",,RANDOMIZED,2,Patidegib Gel 2% | Vehicle Gel,EXPERIMENTAL | PLACEBO_COMPARATOR,"The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.

People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.",,2026-08,ESTIMATED,18 Years - N/A,140,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double Blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Gorlin Syndrome",2026-08,ESTIMATED,Number of new BCCs on the face at Month 12,PREVENTION,ALL,2024-03-17,ACTUAL,INTERVENTIONAL
IRD,"Opus Genetics, Inc.",NCT05616793,"PHASE1, PHASE2",RECRUITING,LCA5,AAV8.hLCA5,,NON_RANDOMIZED,4,Dose Group 1 | Dose Group 2 | Dose Group 3 | Part B Observational,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | NO_INTERVENTION,The goals of this clinical trial are assess the natural course of LCA5-IRD over 6 months and to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration due to biallelic mutations in the LCA5 gene. Funding Source- FDA Office of Orphan Products Development (OOPD).,University of Pennsylvania,2028-06-15,ESTIMATED,4 Years - N/A,22,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Open Label, Dose Exploration, Safety and Tolerability Study of a Subretinal Injection of an OPGx-001 Gene Vector to Participants With LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) With OCncurrent Non-Interventional Follow-Up of Untreated Patients",2028-06-15,ESTIMATED,Incidence of Dose Limiting Toxicities | Number of adverse events related to OPGx-001 | Incidence of adverse events related to OPGx-001 | Severity of adverse events related to OPGx-001 | Number of procedure-related adverse events | Incidence of procedure-related adverse events | Severity of procedure-related adverse events | Assessment of cross-sectional spectral domain optical coherence tomography images | Assessment of Natural course of LCA5-IRD | Assessment of Natural course of LCA5-IRD | Assessment of Natural course of LCA5-IRD | Assessment of Natural course of LCA5-IRD | Assessment of Natural course of LCA5-IRD | Assessment of Natural course of LCA5-IRD | Assessment of Natural course of LCA5-IRD,OTHER,ALL,2023-06-15,ACTUAL,INTERVENTIONAL
IRD,"Opus Genetics, Inc.",NCT07185256,"PHASE1, PHASE2",RECRUITING,"ARB, BVMD, Autosomal-Dominant Bestrophinopathy, Best Vitelliform Macular Dystrophy",,BIRD-1,,1,OPGx-BEST1,EXPERIMENTAL,"The goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1. The main questions it aims to answer are:

Evaluate the safety and tolerability of drug OPGx-BEST1 in one eye (the treatment eye), for 5 years post-injection, in participants with BVMD or ARB.

A second question it aims to answer is identification of the most appropriate dose strength of OPGx-BEST1 for clinical development.

Evaluate",,2030-08,ESTIMATED,18 Years - N/A,10,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1b/2a, Open-Label, Dose-Exploration Basket Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-BEST1 Administered in Patients With Either Autosomal-Dominant BEST1 Disease (Best Vitelliform Macular Dystrophy [BVMD]) or Autosomal-Recessive Bestrophinopathy (ARB)",2030-08,ESTIMATED,Number of dose-limiting toxicity (DLT) events at the dose tested | Number and severity of procedure-related adverse events | Number and severity of adverse events related to OPGx-BEST1,TREATMENT,ALL,2025-09-25,ACTUAL,INTERVENTIONAL
MSLE,Satellos Bioscience Inc.,NCT07287189,PHASE2,RECRUITING,"Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies","SAT-3247, Placebo",BASECAMP,RANDOMIZED,3,SAT-3247 60 mg | SAT-3247 120 mg | placebo,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.",,2027-06-30,ESTIMATED,7 Years - 9 Years,51,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients",2027-03-31,ESTIMATED,Safety of SAT-3247 | Tolerability of SAT-3247 | SAT-3247 effects on muscle strength,TREATMENT,MALE,2025-12-08,ACTUAL,INTERVENTIONAL
ABOS,"Acumen Pharmaceuticals, Inc.",NCT06335173,PHASE2,ACTIVE_NOT_RECRUITING,Alzheimer Disease,"sabirnetug, Placebo",ALTITUDE-AD,RANDOMIZED,4,Double-blind Treatment (DBT) Period: sabirnetug 35 mg/kg | DBT Period: sabirnetug 50 mg/kg | DBT Period: Placebo | Open-Label Extension (OLE) Period: sabirnetug 35 mg/kg,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.,,2026-10,ESTIMATED,50 Years - 90 Years,542,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer's Disease",2026-10,ESTIMATED,Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score,TREATMENT,ALL,2024-02-29,ACTUAL,INTERVENTIONAL
PLX,"Protalix BioTherapeutics, Inc.",NCT07280156,PHASE2,RECRUITING,Gout,"PRX-115, Methotrexate (MTX)",RELEASE,RANDOMIZED,6,E4W with placebo-MTX | E4W with MTX | E6W with MTX | E8W with MTX | placebo E4W | placebo E6W,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR | PLACEBO_COMPARATOR,"This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the respective placebos in adult patients with gout.",,2028-06,ESTIMATED,18 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Efficacy, Safety, and Dosing Regimen Selection of Multiple Intravenous Infusions of PRX-115 With and Without Methotrexate Versus Placebo in Adult Patients With Gout (RELEASE)",2027-12,ESTIMATED,Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6,TREATMENT,ALL,2025-12-22,ACTUAL,INTERVENTIONAL
ENLV,Enlivex Ltd.,NCT06522035,PHASE1,RECRUITING,"Arthritis, Psoriatic",Allocetra,,NON_RANDOMIZED,2,Stage 1 | Stage 2,EXPERIMENTAL | EXPERIMENTAL,This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).,,2026-09,ESTIMATED,18 Years - N/A,6,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis,2026-03,ESTIMATED,Primary outcome,TREATMENT,ALL,2024-08-01,ACTUAL,INTERVENTIONAL
ENLV,Enlivex Ltd.,NCT06208241,EARLY_PHASE1,ACTIVE_NOT_RECRUITING,Knee Osteoarthritis,Allocetra-OTS,,,1,Allocetra-OTS,EXPERIMENTAL,This is a pilot study to assess safety and possible efficacy of Allocetra-OTS in end-stage knee osteoarthritis.,Enlivex Therapeutics Ltd.,2025-12-30,ESTIMATED,18 Years - N/A,18,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety,2025-09-25,ESTIMATED,Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection,TREATMENT,ALL,2023-07-12,ACTUAL,INTERVENTIONAL
ENLV,Enlivex Ltd.,NCT06233474,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Osteoarthritis, Knee",Allocetra,,RANDOMIZED,3,Safety run-in phase - Allocetra increasing dose | Randomization phase - Placebo. | Randomization phase - Allocetra,OTHER | PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a double blind, randomized,multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra compared to placebo in patients with symptomatic knee osteoarthritis.",Nordic Bioscience Clinical Development (NBCD),2026-05-15,ESTIMATED,45 Years - 80 Years,160,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,"A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis",2026-03-15,ESTIMATED,Treatment-emergent adverse events and Serious adverse events following Allocetra-OTS injection,TREATMENT,ALL,2024-01-26,ACTUAL,INTERVENTIONAL
CPHRF,Cipher Pharmaceuticals Inc.,NCT05310734,PHASE4,RECRUITING,Scabies,Spinosad Topical,,,1,PK and Safety,EXPERIMENTAL,"A population of approximately 50 pediatric subjects will be enrolled to assess the PK of spinosad and benzyl alcohol for 3 hours following a single, full-body topical application (open label) on a single in-clinic visit (Day 1, or Day 2 if screening only on Day 1). There will be approximately 50 subjects ages 1 month to 3 years 11 months of age enrolled with the goal of completing approximately 16 subjects. With assistance from a caregiver, Natroba will be applied over the entire body from the n","Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix",2026-03-31,ESTIMATED,1 Month - 4 Years,50,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Single Treatment Pharmacokinetic and Safety Study of Natroba (Spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age With an Active Scabies Infestation,2025-11-30,ESTIMATED,Cmax for Spinosyn A | Tmax for Spinosyn A | Area Under the Curve (AUC) 0-3 for Spinosyn A | Cmax for Spinosyn D | Tmax for Spinosyn D | Area Under the Curve (AUC) 0-3 for Spinosyn D | Cmax for Benzyl Alcohol | Tmax for Benzyl Alcohol | Area Under the Curve (AUC) 0-3 for Benzyl Alcohol | Treatment Emergent Adverse Events | Change in General Skin Irritation | Change in General Eye Irritation,BASIC_SCIENCE,ALL,2022-03-04,ACTUAL,INTERVENTIONAL
ABEO,Abeona Therapeutics Inc.,NCT05725018,PHASE3,ACTIVE_NOT_RECRUITING,"Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB",EB-101 Surgical application of RDEB wounds,,,1,EB-101 Surgical application of RDEB wounds,EXPERIMENTAL,"To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen \[C7\] expression) for the treatment of large, chronic DEB wounds in new and previously EB-101 treated patients 12 months and older.",,2025-09-30,ESTIMATED,12 Months - N/A,12,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients,2025-09-30,ESTIMATED,Safety Endpoint (number of treatment-related and treatment-emergent adverse events (AEs) and serious adverse events (SAEs) | Safety Endpoint (number of patients and wounds that have an infection or any related adverse event.) | Safety Endpoint (number of patients and wounds that result in hospitalization (serious adverse event ) | Safety Endpoint (Incidence of squamous cell carcinoma) | Safety Endpoint RCR status,TREATMENT,ALL,2023-04-02,ACTUAL,INTERVENTIONAL
ABEO,Abeona Therapeutics Inc.,NCT02716246,"PHASE2, PHASE3",RECRUITING,"MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III","UX111, Prophylactic Immunomodulatory (IM) Therapy, Optimized Prophylactic IM Therapy, Adjuvant IM Therapy",,NON_RANDOMIZED,4,Cohort 1 Low Dose | Cohort 2 Mid Dose | Cohort 3 High Dose | Cohort 4 High Dose (Spain Only),EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,The main objective of this study is to evaluate the efficacy and safety of UX111 for the treatment of MPS IIIA.,"Abeona Therapeutics, Inc",2027-07,ESTIMATED,N/A - N/A,36,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA,2027-07,ESTIMATED,Cerebrospinal Fluid (CSF) Heparan Sulfate (HS) (Disaccharide) Exposure,TREATMENT,ALL,2016-04-25,ACTUAL,INTERVENTIONAL
ALEC,"Alector, Inc.",NCT06079190,PHASE2,ACTIVE_NOT_RECRUITING,Alzheimer's Disease,GSK4527226,PROGRESS-AD,RANDOMIZED,3,GSK4527226 Dose 1 | GSK4527226 Dose 2 | Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment \[MCI\] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.,Alector Inc.,2026-11-23,ESTIMATED,50 Years - 85 Years,367,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease",2026-09-30,ESTIMATED,"Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76",TREATMENT,ALL,2023-10-20,ACTUAL,INTERVENTIONAL
ALEC,"Alector, Inc.",NCT07105709,PHASE2,RECRUITING,Alzheimer's Disease,GSK4527226,,,1,GSK4527226,EXPERIMENTAL,"The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD ",Alector Inc.,2028-12-08,ESTIMATED,50 Years - 85 Years,220,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease",2028-09-15,ESTIMATED,Number of Participants with Treatment Emergent Adverse Events (AEs) during the OLE | Number of Participants with Adverse Event of Special Interest (AESIs) during the OLE | Number of Participants with Serious Adverse Events (SAEs) during the OLE | Number of Participants with Amyloid related imaging abnormalities (ARIAs) Including Severity during the OLE,TREATMENT,ALL,2025-08-14,ACTUAL,INTERVENTIONAL
PMN,"ProMIS Neurosciences, Inc.",NCT06750432,PHASE1,ACTIVE_NOT_RECRUITING,"Alzheimer Disease, Early Onset","PMN310, Placebo",,RANDOMIZED,3,Cohort 1 PMN310 350 mg or placebo | Cohort 2 PMN310 700 mg or placebo | Cohort 3 PMN310 1400 mg or placebo,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.",,2026-12,ESTIMATED,50 Years - N/A,144,ESTIMATED,SEQUENTIAL,INDUSTRY,DOUBLE,"A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients With Early Alzheimer's Disease",2026-12,ESTIMATED,Safety and tolerability of PMN310 following repeat intravenous infusions of PMN310 | Biomarker response to PMN310 following repeat intravenous infusions of PMN310 | Safety and tolerability of PMN310 following repeat intravenous infusions of PMN310 | Biomarker response to PMN310 following repeat intravenous infusions of PMN310,TREATMENT,ALL,2024-12-13,ACTUAL,INTERVENTIONAL
PALI,"Palisade Bio, Inc.",NCT07428096,PHASE1,ACTIVE_NOT_RECRUITING,Fibrostenotic Crohn's Disease,PALI-2108,,,1,FSCD Arm,EXPERIMENTAL,"This is a Phase 1b, open-label, exploratory study designed to evaluate the pharmacodynamic effects of PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor, in patients with fibrostenotic Crohn's disease (FSCD). The study will assess molecular, cellular, and histologic changes in intestinal tissue and peripheral blood following short-term oral administration of PALI-2108.

Eligible participants with FSCD will undergo paired ileal pinch biopsies and peripheral blood collection at baseline and after 1",Altasciences Company Inc.,2026-03-15,ESTIMATED,18 Years - 60 Years,6,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of PALI-2108 in Healthy Volunteers, With an Open-Label Study of a Patient Cohort With Ulcerative Colitis and a Phase 1b, Open-Label, Cohort in Patients With Fibrostenosing Crohn's Disease",2026-01-30,ACTUAL,Safety and tolerability of PALI-2108 administered for 14 days. | Safety and tolerability of PALI-2108 | Safety and tolerability of PALI-2108 | Safety and tolerability of PALI-2108,TREATMENT,ALL,2025-10-17,ACTUAL,INTERVENTIONAL
DERM,Journey Medical Corporation,NCT07111429,,NOT_YET_RECRUITING,"Complication,Postoperative, Stoma",,COCG-SITI,,1,SITI-CD Classification of Stoma-related Complication in cancer patients,,"Colorectal cancer is an important cancer worldwide, and its incidence is increasing year by year. A large proportion of patients may require diverting stoma or even permanent stoma after surgery. Some of these patients will have a variety of stoma-related complications, which seriously affect the quality of life of patients. At present, the mainstream postoperative complication classification is the traditional CD classification, which is suitable for the classification of most postoperative com","Beijing Chao Yang Hospital, Peking University Third Hospital, Peking University First Hospital, Peking University People's Hospital, Peking Union Medical College Hospital, Beijing New Journey Cancer Hospital, Beijing Nanjiao Tumor Hospital, Xuanwu Hospital, Beijing, Beijing Hospital, Hebei medical college fourth hospital, China-Japan Union Hospital, Jilin University, Jiangsu Province people hospital, Jinzhou Medical University, Shanxi Province Cancer Hospital, Ruijin Hospital, Changhai Hospital, The Second Affiliated Hospital of Suzhou Medical University, Tianjin People's Hospital, Yantai Yuhuangding Hospital, First Affiliated Hospital of Zhejiang University, Zhejiang cancer University, China-Japan Friendship Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Affiliated Drum Tower Hospital, Nanjing University",2025-12-15,ESTIMATED,18 Years - 80 Years,5000,ESTIMATED,,OTHER,,"Evaluation of a Modified Clavien-Dindo Classification (COCG) of Stoma Complication in Cancer Patients: a Prospective, Registry-based, Non-randomized Trial (COCG-01 Trial) on Behalf of Chinese Ostomy Collaboration Group",2025-12-15,ESTIMATED,Incidence of stoma complications in different SITI grades,,ALL,2025-08-15,ESTIMATED,OBSERVATIONAL
ACHV,"Achieve Life Sciences, Inc.",NCT07392125,PHASE3,NOT_YET_RECRUITING,Vaping Cessation,"Cytisinicline, Placebo",ORCA-V2,RANDOMIZED,2,Arm A | Arm B,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR,"This will be a multi-center, double-blind, randomized, placebo-controlled, Phase 3 study conducted in male or female adults who are daily nicotine e-cigarette users only.

A total of approximately 800 subjects will be randomly assigned (1:1) to one of two Arms:

* Arm B, 12 weeks cytisinicline + behavior support: N=400 or
* Arm A, 12 weeks of placebo+ behavior support: N=400) The primary objective is to assess whether subjects randomized to Arm B (3 mg cytisinicline TID for 12 weeks plus behavio",,2027-09-30,ESTIMATED,18 Years - N/A,800,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes",2026-11-15,ESTIMATED,Primary Efficacy Objective,TREATMENT,ALL,2026-05-15,ESTIMATED,INTERVENTIONAL
AARD,"Aardvark Therapeutics, Inc.",NCT06828861,PHASE3,RECRUITING,"Hyperphagia, Prader-Willi Syndrome","Placebo, ARD-101",HERO,RANDOMIZED,2,Treatment Arm A | Treatment Arm B,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS). It will also teach us about the safety of ARD-101.

The main questions it aims to answer are:

* Does ARD-101 improve the total score of the HQCT-9 (hyperphagia questionnaire for clinical trials, 9 questions)?
* What medical problems do participants have when taking ARD-101?

Researchers will compare ARD-101 to a placebo (a look-alike substance that con",,2026-04,ESTIMATED,7 Years - N/A,90,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients With Prader-Willi Syndrome",2026-03,ESTIMATED,Change in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score,TREATMENT,ALL,2024-12-20,ACTUAL,INTERVENTIONAL
AARD,"Aardvark Therapeutics, Inc.",NCT07197034,PHASE3,RECRUITING,"Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome",ARD-101,,,1,ARD-101,EXPERIMENTAL,"The goal of this clinical trial is to learn if ARD-101 works to treat hyperphagia-related behavior in patients with Prader-Willi syndrome (PWS) when used in a long term setting. It will also teach us about the safety of ARD-101.

The main questions it aims to answer are:

What medical problems do participants have when taking ARD-101 in a long term setting

Does ARD-101 improve the total score of the HQCT-9 (hyperphagia questionnaire for clinical trials, 9 questions)?

Eligible participants will",,2027-04,ESTIMATED,13 Years - N/A,90,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 3, Multicenter, Open-Label Extension Study to Assess the Safety and Efficacy of ARD-101 in Patients With Prader-Willi Syndrome",2027-03,ESTIMATED,Change in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score,TREATMENT,ALL,2024-07-23,ACTUAL,INTERVENTIONAL
ELDN,"Eledon Pharmaceuticals, Inc.",NCT06972069,EARLY_PHASE1,RECRUITING,"Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation","Conditioning Regimen (Rituxan, Siplizumab, Cyclophosphamide, Tegoprubart)",,NON_RANDOMIZED,2,Recipient | Donor,EXPERIMENTAL | OTHER,"This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft. The investigators propose to treat 6 adult subjects in end-stage renal disease (ESRD) who do not demonstrate evidence of prior sensitization.","Eledon Pharmaceuticals, ITB-Med LLC",2030-12-31,ESTIMATED,18 Years - 65 Years,12,ESTIMATED,PARALLEL,OTHER,NONE,Tolerance Through Mixed Chimerism (Sip-Tego),2030-12-31,ESTIMATED,Induction of mixed chimerism without chimeric transition syndrome | Achievement of IS minimization (tacrolimus or Belatacept monotherapy) | Number of patients who complete full immunosuppression withdrawal,TREATMENT,ALL,2025-05-31,ACTUAL,INTERVENTIONAL
ELDN,"Eledon Pharmaceuticals, Inc.",NCT05027906,"PHASE1, PHASE2",RECRUITING,Prevention of Rejection in Kidney Transplant,AT-1501,,,1,AT-1501 Single Arm,EXPERIMENTAL,"This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.",,2027-01,ESTIMATED,18 Years - 100 Years,48,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant",2027-01,ESTIMATED,Safety Incidences | Pharmacokinetic- PK profile | Pharmacokinetic- Area under the plasma concentration | Pharmacokinetic- Cmax | Pharmacokinetic- Tmax | Pharmacokinetic- Ke | Pharmacokinetic- (t1/2) | Pharmacokinetic- CL | Pharmacokinetic- (Vdss),TREATMENT,ALL,2022-02-18,ACTUAL,INTERVENTIONAL
ANIK,"Anika Therapeutics, Inc.",NCT06353893,,ACTIVE_NOT_RECRUITING,Rotator Cuff Tears,,,,0,,,"The goal of this observational study is to evaluate the effectiveness and safety of the Integrity bio-inductive implant in treating partial and full thickness rotator cuff tears. The main questions it aims to answer are:

* How does the application of the Integrity implant affect patient-reported outcome measures (PROMs) such as ASES, SANE, and PROMIS?
* What are the imaging characteristics of the rotator cuff tears at 3 and 6 months postoperatively when using the Integrity implant?

Postoperati","Anika Therapeutics, Inc.",2026-05-01,ESTIMATED,N/A - N/A,20,ACTUAL,,OTHER,,Postoperative MRI Evaluation of the Integrity Bio-inductive Implant Augmentation of Rotator Cuff Tears of the Shoulder,2025-12-01,ESTIMATED,MRI Assessment of Adverse Events and Structural Integrity,,ALL,2024-04-01,ACTUAL,OBSERVATIONAL
ANIK,"Anika Therapeutics, Inc.",NCT02659215,,ACTIVE_NOT_RECRUITING,Defect of Articular Cartilage,,FastTRACK,RANDOMIZED,2,Hyalofast with BMAC | Microfracture,EXPERIMENTAL | ACTIVE_COMPARATOR,The purpose of this study is to evaluate the safety and efficacy of Hyalofast® scaffold with bone marrow aspirate concentrate (BMAC) compared to microfracture in the treatment of symptomatic cartilage defects of the knee.,,2026-06-30,ESTIMATED,18 Years - 60 Years,200,ACTUAL,PARALLEL,INDUSTRY,SINGLE,"A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast® With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control",2025-03-20,ACTUAL,Superiority of Hyalofast with Bone Marrow Aspirate Concentrate (BMAC) vs. Microfracture for % Change in Knee injury and Osteoarthritis Outcome Score (KOOS) Pain Score | Superiority of Hyalofast with Bone Marrow Aspirate Concentrate (BMAC) vs. Microfracture for % Change in International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score,TREATMENT,ALL,2015-12,ACTUAL,INTERVENTIONAL
ANIK,"Anika Therapeutics, Inc.",NCT06741527,,RECRUITING,Rotator Cuff Tears of the Shoulder,,,,1,Integrity Implant System,OTHER,"The study design is a prospective, multi-center, single-arm, non-randomized post market clinical follow-up study to confirm the performance, safety and clinical benefit of the Integrity Implant System when used for rotator cuff tear augmentation (with or without repair).",,2027-10,ESTIMATED,18 Years - N/A,150,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,Post Market Confirmatory Interventional Clinical Study of the Integrity Implant System Used for Rotator Cuff Tear Augmentation,2027-06,ESTIMATED,Re-tear rate after rotator cuff augmentation,TREATMENT,ALL,2025-02-01,ACTUAL,INTERVENTIONAL
NGNE,Neurogene Inc.,NCT05228145,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Neuronal Ceroid Lipofuscinosis CLN5,,CLN5-200,NON_RANDOMIZED,3,Cohort 1 | Cohort 2 | Cohort 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a prospective, non-randomized, open-label, dose escalation study of a single administration of gene therapy in children who are 3 to 9 years old with Neuronal Ceroid Lipofuscinosis (Batten) Subtype 5 (CLN5) disease.",,2028-11,ESTIMATED,3 Years - 9 Years,6,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,A Phase 1/2 Intracerebroventricular and Intravitreal Administration of NGN-101 for Treatment of Neuronal Ceroid Lipofuscinosis (NCL) Subtype 5 (CLN5) Disease,2028-11,ESTIMATED,Incidence of Treatment Emergent Adverse Events (TEAEs) | Incidence of Serious Adverse Events (SAEs) | Incidence of clinical laboratory abnormalities | Incidence of new nerve conduction study (NCS) abnormalities | Incidence of new physical and neurologic exam abnormalities,TREATMENT,ALL,2022-01-31,ACTUAL,INTERVENTIONAL
NGNE,Neurogene Inc.,NCT05898620,PHASE3,RECRUITING,Rett Syndrome,,,NON_RANDOMIZED,4,Pediatric 1e15 vg dose (fully enrolled) | Adolescent/Adult 1e15 vg Dose (fully enrolled) | Pediatric 3e15 vg dose (discontinued) | Pivotal Cohort,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study will evaluate the efficacy and safety profiles of the investigational gene therapy, NGN-401, in females with typical Rett syndrome.",,2029-12,ESTIMATED,3 Years - N/A,33,ESTIMATED,SEQUENTIAL,INDUSTRY,SINGLE,"A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of NGN-401 in Subjects With Rett Syndrome (Embolden)",2029-12,ESTIMATED,Efficacy of NGN-401,TREATMENT,FEMALE,2023-06-13,ACTUAL,INTERVENTIONAL
VYGR,"Voyager Therapeutics, Inc.",NCT06874621,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Alzheimer&#39;s Disease (AD),"VY7523, Placebo Comparator",,RANDOMIZED,6,Cohort 1 active | Cohort 1 placebo | Cohort 2 active | Cohort 2 placebo | Cohort 3 active | Cohort 3 placebo,EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR,"This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors an",,2027-05,ESTIMATED,50 Years - 90 Years,52,ESTIMATED,SEQUENTIAL,INDUSTRY,QUADRUPLE,"VY7523-102: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Ascending Intravenous Doses of VY7523 in Participants With Early Alzheimer's Disease",2027-05,ESTIMATED,Characterization of the safety and tolerability of VY7523 in participants with early AD,TREATMENT,ALL,2025-03-03,ACTUAL,INTERVENTIONAL
RANI,"Rani Therapeutics Holdings, Inc.",NCT06891287,PHASE1,NOT_YET_RECRUITING,Obesity,PG-102,,RANDOMIZED,4,Group A1 - Subcutaneous injection control | Group A2 - RT-114 | Group B1 - Placebo | Group B2 - RT-114,ACTIVE_COMPARATOR | EXPERIMENTAL | PLACEBO_COMPARATOR | EXPERIMENTAL,"The goal of this Phase 1 study is to evaluate the safety and tolerability of RT-114 in healthy volunteers. The main objectives are:

Primary: To evaluate safety and tolerability of RT-114 when administered as single and multiple doses by assessing treatment emergent adverse events (TEAEs) in healthy volunteers

Secondary:

* To determine the pharmacokinetics of RT-114 administered as single and multiple doses
* To determine the pharmacodynamic effects of RT-114 administered as multiple doses

In",,2026-04-01,ESTIMATED,18 Years - 65 Years,60,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RT-114 in Healthy Volunteers",2026-03-01,ESTIMATED,To evaluate safety and tolerability of RT-114 by assessing treatment emergent adverse events (TEAEs),TREATMENT,ALL,2025-06-01,ESTIMATED,INTERVENTIONAL
MIST,Milestone Pharmaceuticals Inc.,NCT06716021,PHASE3,NOT_YET_RECRUITING,Atrial Fibrillation,"Placebo, Etripamil",ReVeRA-301,RANDOMIZED,2,Placebo | Etripamil,PLACEBO_COMPARATOR | EXPERIMENTAL,"This is a multi-national, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil NS in patients with atrial fibrillation (AF). This study includes Screening Visit, Randomization Visit, a Treatment Period with scheduled Follow-up Visits (Monthly Follow-up and Post-treatment Follow-up Visits), a Final Study Visit, and an End of Study Telephone Follow up Visit.

Each patient will be randomized 1:1 to receive placebo or 70 mg Etripamil NS regimens. Pati",,2030-01,ESTIMATED,18 Years - N/A,750,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,"Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atrial Fibrillation and Rapid Ventricular Rate (RVR)",2029-01,ESTIMATED,Demonstrate the efficacy of etripamil NS over placebo in patients with AF.,TREATMENT,ALL,2027-01,ESTIMATED,INTERVENTIONAL
MIST,Milestone Pharmaceuticals Inc.,NCT05763953,PHASE2,RECRUITING,Paroxysmal Supraventricular Tachycardia,Etripamil NS,,,1,Etripamil NS 70mg,EXPERIMENTAL,"NODE-202 is a Phase 2, multicenter, multinational, single dose, open-label, 2-part, sequential design study in pediatric patients with an established diagnosis of paroxysmal supraventricular tachycardia (PSVT) presenting with a symptomatic episode of PSVT.

In Part 1, at least 30 patients aged 12 to \<18 years will be enrolled and treated with etripamil nasal spray (NS). Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of 70 mg etripamil NS (",,2027-06-30,ESTIMATED,6 Years - 17 Years,60,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular Tachycardia",2027-06-01,ESTIMATED,Efficacy: The percentage of patients converting to sinus rhythm (SR) in the first 15 minutes after administration of etripamil NS.,TREATMENT,ALL,2023-12-11,ACTUAL,INTERVENTIONAL
TNXP,Tonix Pharmaceuticals Holding Corp.,NCT04789148,PHASE1,RECRUITING,Vasopressin Deficiency,"Intranasal Oxytocin (IN-OXT), Intranasal Oxytocin (IN-OXT), Placebo, Intranasal Oxytocin (IN-OXT), Placebo",,RANDOMIZED,8,Part A Arm 1 | Part A Arm 2 | Part A Arm 3 | Part A Arm 4 | Part A Arm 5 | Part A Arm 6 | Part B Arm 1 | Part B Arm 2,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL,"This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depression, and socioemotional functioning (Part A), with an optional randomized, double-blind, placebo-controlled 2-week repeated dose substudy of intranasal oxytocin 6 IU or placebo (Part B).

Following a screening visit to ","Tonix Pharmaceuticals, Inc.",2026-06,ESTIMATED,18 Years - N/A,40,ESTIMATED,CROSSOVER,OTHER,QUADRUPLE,Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency - A Pilot Study,2026-06,ESTIMATED,Dot-probe task - anxious behavior between low dose oxytocin and placebo,BASIC_SCIENCE,ALL,2025-09-10,ACTUAL,INTERVENTIONAL
TNXP,Tonix Pharmaceuticals Holding Corp.,NCT06636786,PHASE2,RECRUITING,"Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress","Cyclobenzaprine HCl, Placebo",OASIS,RANDOMIZED,2,Cyclobenzaprine HCl | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study will examine the safety and efficacy of TNX-102 SL to reduce ASR symptoms and behavioral changes among patients presenting to the emergency department (ED) after motor vehicle collision (MVC). Specifically, the investigators will perform the Optimizing Acute Stress reaction Interventions with TNX-102 SL (OASIS) Trial, a double-blind placebo-controlled randomized clinical trial (RCT) to determine if TNX-102 SL initiated in the ED in the hours after MVC to high risk individuals, treats/","United States Department of Defense, Tonix Pharmaceuticals, Inc., Mclean Hospital, Cooper University Health Care",2025-09,ESTIMATED,18 Years - 55 Years,180,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS),2025-09,ESTIMATED,Change in ASD Score,PREVENTION,ALL,2025-03-25,ACTUAL,INTERVENTIONAL
TNXP,Tonix Pharmaceuticals Holding Corp.,NCT07413367,PHASE1,ACTIVE_NOT_RECRUITING,"Pharmakokinetic, Open Label, Phase 1",TNX-102 SL Tablet,,,1,TNX-102 SL,EXPERIMENTAL,"TNX-102 SL has recently been approved by the United States (US) Food and Drug Administration (FDA) under the brand name TONMYA for the treatment of fibromyalgia. Fibromyalgia is a long-lasting condition that causes pain all over the body, along with feeling tired and not sleeping well. TNX-102 SL is not approved for any conditions in Canada.

The study looks at the safety and blood levels of a study drug called TNX-102 SL \[cyclobenzaprine hydrochloride (HCl) sublingual (SL) tablets\], taken und",Syneos Health,2026-02-10,ESTIMATED,18 Years - N/A,50,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,"A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants",2026-02-10,ESTIMATED,AUC0-inf: Area Under the curve from time zero to infinity | AUC0-t: Area Under the Curve from time zero to the last measurable concentration | Cmax: Maximum Plasma Concentration,BASIC_SCIENCE,ALL,2025-12-09,ACTUAL,INTERVENTIONAL
TNXP,Tonix Pharmaceuticals Holding Corp.,NCT07204080,PHASE2,NOT_YET_RECRUITING,"Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation",TNX-1500,TONIX-1500,,1,Kidney Transplant Recipient,EXPERIMENTAL,"The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.","Tonix Pharmaceuticals, Inc.",2029-06-30,ESTIMATED,18 Years - 75 Years,5,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Phase II Clinical Trial Evaluating the Safety and Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients,2028-09-01,ESTIMATED,Number of Adverse Events in each subject | Number of Serious Adverse Events in each subject,TREATMENT,ALL,2026-07-01,ESTIMATED,INTERVENTIONAL
SLN,Silence Therapeutics plc,NCT05499013,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,Polycythemia Vera,"SLN124, Placebo",SLN,RANDOMIZED,3,Phase 1 open-label SLN124 | Phase 2 Blinded SLN124 | Phase 2 Blinded Placebo,EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.",,2030-03,ESTIMATED,18 Years - N/A,69,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera",2026-09,ESTIMATED,Phase 1: Incidence of treatment-emergent adverse events (AEs) | Phase 1: Assessment of the number of phlebotomies at intervals | Phase 2: Proportion of patients who achieve response between week 18 and week 36 (placebo controlled double blind phase),TREATMENT,ALL,2023-01-26,ACTUAL,INTERVENTIONAL
ACB,Aurora Cannabis Inc.,NCT05883436,,RECRUITING,Degenerative Disc Disease,,DEXA-C,,1,Single Arm Observational,OTHER,"FDA Cleared interbody product for the cervical spine, designed to match a patients DEXA scan for increase in fusion rate.",,2027-02-22,ESTIMATED,18 Years - N/A,80,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Prospective, Multi-Center Investigation of the DEXA- C Anterior Cervical Interbody System",2026-12-31,ESTIMATED,Fusion Assesment,TREATMENT,ALL,2023-02-22,ACTUAL,INTERVENTIONAL
ACB,Aurora Cannabis Inc.,NCT03936361,PHASE3,RECRUITING,Intracerebral Hemorrhage,Statins,SATURN,RANDOMIZED,2,Statin | No-statin,ACTIVE_COMPARATOR | NO_INTERVENTION,"The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype.

An MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cere","NINDS Stroke Trials Network (StrokeNet), Canadian Stroke Consortium (CSC), University of Cincinnati, Medical University of South Carolina, Yale University, MetroHealth Medical Center, UH, Cleveland Medical Center, Corewell Health West, West Virginia University, Columbia University, Weill Medical College of Cornell University, New York Presbyterian Brooklyn Methodist Hospital, Buffalo General Medical Center, State University of New York - Upstate Medical University, St. Joseph's Regional Medical Center, New Jersey, Tufts Medical Center, Massachusetts General Hospital, UMass Memorial Health, Brigham and Women's Hospital, Baystate Medical Center, University of Vermont Medical Center, Lahey Hospital & Medical Center, Augusta University Medical Center, Prisma Health-Upstate, The Moses H. Cone Memorial Hospital, University of Virginia, George Washington University, University of Maryland, Baltimore, Mount Sinai Hospital, New York, NYU Langone Medical Center - Tisch Hospital, Montefiore Medical Center, NYU Langone Hospital - Brooklyn, Froedtert Hospital, Central DuPage Hospital, Rush University Medical Center, Loyola University, Stanford University, Mercy San Juan Medical Center, Oregon Health and Science University, Kaiser Permanente, University of Southern California, Cedars-Sinai Medical Center, University of New Mexico, Long Beach Memorial Medical Center, University of California, Irvine, Arrowhead Regional Medical Center, Huntington Memorial Hospital, Scripps Health, University of California, San Diego, Ochsner Health System, St. Joseph's Hospital and Medical Center, Phoenix, Desert Care Network, Eden Medical Center, San Francisco General Hospital, University of California, San Francisco, University of Louisville, Ohio State University, University of Iowa, Sanford Medical Center Fargo, University of Nebraska, Tampa General Hospital, University of Florida, Jackson Health System, Mayo Clinic, Baptist Medical Center Jacksonville, Wayne State University, University of Michigan, Mercy Health Saint Mary Grand Rapids, Metro Health, Michigan, University of Kentucky, McLaren Health Care, Regions Hospital, Allina Health System, University of Kansas, University of Minnesota, St. Cloud Hospital, Milton S. Hershey Medical Center, Abington Memorial Hospital, Temple University, University of Pennsylvania, Lehigh Valley Hospital, York Hospital, York, PA, Thomas Jefferson University, University of Pittsburgh, St. David's HealthCare, Baylor College of Medicine, Tulane Medical Center, The University of Texas Health Science Center at San Antonio, OU Medical Center, University of Utah, Swedish Medical Center, St. Mary's Medical Center, Banner University Medical Center, Intermountain Medical Center, Legacy Emanuel Medical Center, Sacred Heart Medical Center Springfield, Harborview Injury Prevention and Research Center, University of Wisconsin, Madison, Aurora BayCare Medical Center, Wake Forest University Health Sciences, University of Alabama at Birmingham, University of South Alabama, Carolinas Medical Center, Barnes-Jewish Hospital, St. Luke's Hospital, Kansas City, Missouri, University of Arkansas, OSF Healthcare System, Cox Medical Center South, North Shore University Hospital, Rhode Island Hospital, Hartford Hospital, Staten Island University Hospital, Johns Hopkins University, University of North Carolina, Chapel Hill, University of Alberta, The Ottawa Hospital, London Health Sciences Centre, Hamilton General Hospital, Hopital de l'Enfant-Jesus, Montreal Neurological Institute and Hospital, Foothills Medical Centre, University Health Network, Toronto, Health Sciences Centre, Winnipeg, Manitoba, Thunder Bay Regional Health Sciences Centre, Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Fraser Health, Hopital de Chicoutimi, Université de Sherbrooke",2028-12-31,ESTIMATED,50 Years - N/A,1456,ESTIMATED,PARALLEL,OTHER,SINGLE,STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS,2027-06-30,ESTIMATED,Recurrent symptomatic ICH,PREVENTION,ALL,2020-06-10,ACTUAL,INTERVENTIONAL
ACB,Aurora Cannabis Inc.,NCT06513533,"PHASE2, PHASE3",RECRUITING,Adrenomyeloneuropathy Without Cerebral Involvement,Dimethyl fumarate,,RANDOMIZED,2,DMF arm | Placebo arm,EXPERIMENTAL | PLACEBO_COMPARATOR,"The goal of this clinical trial is to determine if dimethyl fumarate is effective in treating motor problems in adults with Adrenomyeloneuropathy. The trial will also assess the safety of dimethyl fumarate and explore the molecular mechanisms underlying the disease. The primary questions it aims to answer are:

* Does dimethyl fumarate improve motor problems in participants?
* What medical issues do participants experience while taking dimethyl fumarate? Researchers will compare the effects of d","Instituto de Salud Carlos III, Spanish Clinical Research Network - SCReN, Institut d'Investigació Biomèdica de Bellvitge",2028-06-30,ESTIMATED,18 Years - 65 Years,40,ESTIMATED,PARALLEL,INDIV,TRIPLE,"Effect of Dimethyl Fumarate Administered to Patients With Adrenomyeloneuropathy: a Multicenter, Placebo Controlled, Phase IIb/III Trial",2028-03-31,ESTIMATED,Postural sway test | Postural sway test | Postural sway test,TREATMENT,ALL,2024-04-23,ACTUAL,INTERVENTIONAL
ARCT,Arcturus Therapeutics Holdings Inc.,NCT06747858,PHASE2,RECRUITING,"Cystic Fibrosis, CFTR Gene Mutation",ARCT-032,LunairCF,NON_RANDOMIZED,3,Cohort 1 | Cohort 2 | Cohort 3,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.",,2025-12,ESTIMATED,18 Years - N/A,12,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis",2025-12,ESTIMATED,"Incidence, severity and dose relationship of adverse events",TREATMENT,ALL,2024-12-12,ACTUAL,INTERVENTIONAL
ARCT,Arcturus Therapeutics Holdings Inc.,NCT07390968,PHASE2,NOT_YET_RECRUITING,Hematopoietic and Lymphatic System Neoplasm,"SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran",,RANDOMIZED,2,Arm I (LUNAR-COV19) | Arm II (Comirnaty),EXPERIMENTAL | EXPERIMENTAL,"This phase IIb trial compares the effect of LUNAR-COV19 vaccine to Comirnaty vaccine in treating adult patients who have received a hematopoietic cell transplant (HCT). Guidelines recommend repeating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination of 3 messenger ribonucleic acid (mRNA) vaccines followed by a fourth booster 3-6 months after treatment. However, vaccination is less effective in HCT patients compared to healthy people due to impaired immune responses. LUNAR-","Arcturus Therapeutics, Inc., Seqirus",2029-01-01,ESTIMATED,18 Years - N/A,56,ESTIMATED,PARALLEL,OTHER,DOUBLE,"A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity of a Self-Amplifying mRNA COVID-19 Vaccine in Adult Hematopoietic Cell Transplant Recipients",2028-09-01,ESTIMATED,Geometric mean titer (GMT) of neutralizing antibody (nAb) against spike protein matching the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant,PREVENTION,ALL,2026-09-01,ESTIMATED,INTERVENTIONAL
ARCT,Arcturus Therapeutics Holdings Inc.,NCT07201818,,NOT_YET_RECRUITING,Fibromyalgia,,,RANDOMIZED,2,Active LET group | Sham LET group,EXPERIMENTAL | SHAM_COMPARATOR,"The study is a double blinded, randomized, sham-controlled, parallel group trial conducted at UT Southwestern (UTSW) Medical Center. The purpose of this research study is to determine the effectiveness of Lymphatic Enhancement Technology (LET) treatment in patients with fibromyalgia. Participants will complete assessments of heart rate and blood pressure, pain thresholds to mechanical stimuli, and completion of quality-of-life surveys. In addition, participants will receive four treatments, one ",Arcturus Star Products,2028-01,ESTIMATED,18 Years - 65 Years,40,ESTIMATED,PARALLEL,OTHER,SINGLE,A Randomized Sham-Controlled Trial of Lymphatic Enhancement Technology in the Treatment of Fibromyalgia,2027-10,ESTIMATED,Change in severity and functional impact of fibromyalgia symptoms as measured by FIQR at week 2 from baseline | Change in severity and functional impact of fibromyalgia symptoms as measured by FIQR at week 3 from baseline | Change in severity and functional impact of fibromyalgia symptoms as measured by FIQR at week 4 from baseline | Change in severity and functional impact of fibromyalgia symptoms as measured by FIQR at week 8 from baseline,TREATMENT,FEMALE,2026-06,ESTIMATED,INTERVENTIONAL
ARCT,Arcturus Therapeutics Holdings Inc.,NCT06488313,PHASE2,RECRUITING,"OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD",ARCT-810,,,1,ARCT-810,EXPERIMENTAL,Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.,,2026-09-01,ESTIMATED,12 Years - N/A,9,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase 2a, Open-label, Multiple Ascending Dose Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency",2026-06-01,ESTIMATED,"Incidence, severity and dose-relationship of adverse events (AEs)",TREATMENT,ALL,2024-11-04,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT06821074,,RECRUITING,Myopia,,,RANDOMIZED,2,Defocus-enhanced spectacles | Single vision spectacles,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to compare the effectiveness of vision function training using defocus-enhanced spectacles (DIMS) versus single vision spectacles combined with vision function training in controlling myopia progression in children aged 6-18 years.,"High Myopia Control Alliance (HIMALAYA), Beijing New Vision Eye Hospital",2027-02-28,ESTIMATED,6 Years - 18 Years,1000,ESTIMATED,PARALLEL,OTHER,QUADRUPLE,Comparative Study of Visual Function Training With Defocus-Enhanced Spectacles vs. Single Vision Spectacles on Myopia Control in Children,2026-12-31,ESTIMATED,Change in spherical equivalent 12 months after the commencement of training.,TREATMENT,ALL,2025-02-08,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT05745805,,RECRUITING,"COVID-19, Post-COVID-19 Syndrome, Acute COVID-19, Post-Acute COVID-19",,,,3,Mild COVID-19 group | Moderate COVID-19 group | Uninfected Healthy controls, |  | ,"Our main objective is to analyze the development of physical impact, mental health and blood profile over follow-up time during the 1st wave of the COVID-19. Besides, we aim to establish a database of post-COVID-19 based on simultaneous cortico-spinal magnetic resonance imaging data to identify high-risk patients with long COVID and prevent the neurological symptoms evolution, optimize the tactics of management in China.","Nuclear 215 Hospital of Shaanxi Province, Yanan Traditional Chinese Medicine Hospital, Shangluo Central Hospital, Xian QinHuang Hospital, Yulin No.2 Hospital, Hanzhong Central Hospital, Ankang Central Hospital, Baoji High-tech Hospital",2026-09-12,ESTIMATED,18 Years - 65 Years,600,ESTIMATED,,OTHER,,Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China,2026-06-12,ESTIMATED,Change in brain structure. | Change in brain function.,,ALL,2023-01-12,ACTUAL,OBSERVATIONAL
HITI,High Tide Inc.,NCT06600932,,NOT_YET_RECRUITING,Cataract Surgery Experience,,,RANDOMIZED,2,TMS | Control,EXPERIMENTAL | SHAM_COMPARATOR,"The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) can improve the visual outcomes in patients after cataract surgery. The main question it aims to answer is:

• Does TMS improve the visual outcome in patients after cataract surgery? Researchers will compare TMS to the sham-controlled treatment (exposure to recorded sounds of pulses without real magnetic stimulation) to see if TMS works to improve the visual outcomes of patients after cataract surgery.

Partic",,2026-10,ESTIMATED,30 Years - 80 Years,200,ESTIMATED,PARALLEL,OTHER,DOUBLE,Effects of Transcranial Magnetic Stimulation on Visual Outcome in Patients After Cataract Surgery,2025-10,ESTIMATED,Visual acuity,TREATMENT,ALL,2024-10,ESTIMATED,INTERVENTIONAL
HITI,High Tide Inc.,NCT06656676,,RECRUITING,HIV Prevention,,,RANDOMIZED,4,Intervention group: Transgender women | Control group: Transgender women | Intervention group: PrEP service providers | Control group: PrEP service providers,EXPERIMENTAL | ACTIVE_COMPARATOR | EXPERIMENTAL | ACTIVE_COMPARATOR,"HIV prevalence among transgender women (TW) in the United States is high (\~14%). The best way to reduce HIV incidence in this population is to link TW to HIV pre-exposure prophylaxis (PrEP), which can reduce HIV transmission by up to 86%, with optimal adherence. The FDA approved the first long-acting form of PrEP, injectable cabotegravir (CAB-LA), in late 2021, which has the potential to decrease HIV transmission and increase PrEP adherence among TW. The addition of CAB-LA to available PrEP opt","Mile High Behavioral Healthcare Transgender Center of the Rockies, The Gay Lesbian Bisexual & Transgender Community Center of Colorado",2027-02,ESTIMATED,18 Years - 65 Years,75,ESTIMATED,PARALLEL,OTHER,NONE,WePrEP: A Bilingual Shared Decision-making Tool to Facilitate Conversations Between Transgender Women and Their Providers as They Select an Ideal PrEP Method,2026-12,ESTIMATED,Feasibility | Acceptability,PREVENTION,MALE,2025-01-29,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT06570759,,ACTIVE_NOT_RECRUITING,"Myocardial Infarction, Myocardial Ischemia, Acute Coronary Syndrome, Diagnosis, Morality",,DIFOCCULT-3,RANDOMIZED,2,OMI/NOMI arm | STEMI/NSTEMI arm,EXPERIMENTAL | ACTIVE_COMPARATOR,"The investigators hypothesize that occlusion myocardial infarction(MI)/non-occlusion MI approach to MI treatment will better predict acute coronary occlusion on coronary angiography, better limit infarct size, better preserve left ventricular function and result in lower long-term adverse cardiac events (all cause mortality, all cause rehospitalization) compared to standard ST-elevation/non-ST-elevation MI paradigm.","Ankara Etlik City Hospital, Antalya City Hospital, Bağcılar Training and Research Hospital, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Ataturk University, Eskisehir City Hospital, Kartal Kosuyolu High Speciality Training and Research Hospital, Marmara University Pendik Training and Research Hospital, Istanbul Mehmet Akif Ersoy Educational and Training Hospital, Muğla Sıtkı Koçman University, Necmettin Erbakan University, Eskisehir Osmangazi University, Sirnak State Hospital, Tokat Gaziosmanpasa University, Van Training and Research Hospital, Yuzuncu Yil University, Kutahya Health Sciences University",2026-09-01,ESTIMATED,18 Years - 99 Years,6000,ACTUAL,PARALLEL,OTHER_GOV,NONE,Time for a DIagnostic Paradigm Shift From ST-elevation/Non-ST-elevation to OCClUsion/Non-occLusion Myocardial infarcTion,2025-09-01,ACTUAL,Primary end point: Major adverse events (Mortality and rehospitalization) | Primary end point: Major adverse events (Mortality and rehospitalization) in STEMI (-) OMI (+) subgroup,DIAGNOSTIC,ALL,2024-10-01,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT05546671,,RECRUITING,"Sarcopenia, Frailty",,,,2,Strong grippers | Weak grippers, | ,Hand grip strength has been shown to be a predictor of adverse cardiovascular outcomes in the elderly population. This study aims to investigate whether measurement of hand grip strength could be used as a predictor of prolonged hospital stay after cardiac surgery in elderly patients.,,2024-11-30,ESTIMATED,70 Years - N/A,240,ESTIMATED,,OTHER_GOV,,Usefulness of Hand Grip Strength as a Predictor of Prolonged Hospital Stay in Elderly Patients Undergoing Cardiac Surgery,2024-10-31,ESTIMATED,Prolonged hospital stay,,ALL,2022-11-01,ACTUAL,OBSERVATIONAL
HITI,High Tide Inc.,NCT05226117,PHASE2,RECRUITING,Urothelial Carcinoma,Sacituzumab govitecan,,,1,Treatment arm,EXPERIMENTAL,"SURE-01 is a neoadjuvant phase 2, open-label, non-randomized, singlecohort study in patients with urothelial carcinoma of the bladder. Patients will be consecutively enrolled and treated. The primary objective of the study is to assess whether sacituzumab govitecan results in pathological complete response (in patients with Muscle-invasive Bladder Cancer who cannot receive or refuse cisplatin-based chemotherapy). Secondary objectives were to evaluate the radiological response of those patients w",High Research,2025-06,ESTIMATED,18 Years - N/A,44,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"SURE-01_An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Sacituzumab Govitecan, Before Radical Cystectomy, for Patients With Muscleinvasive Bladder Cancer Who Cannot Receive or Refuse Cisplatin-based Chemotherapy",2025-06,ESTIMATED,Pathological complete response,TREATMENT,ALL,2022-03-23,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT07030153,,RECRUITING,Myopia,,,,2,Genetic and myopia onset | Genetic and myopia intervention, | ,"This study aims to identify genetic factors linked to myopia, including those that influence a person's risk of developing it and how quickly it progresses (like changes in eye length). It will also examine how different treatments-such as low-dose atropine drops, orthokeratology lenses, specialized glasses, and increased outdoor time-interact with these genes. Finally, the research will develop a genetic risk score to help tailor personalized myopia prevention and treatment plans.","Beijing New Vision Eye Hospital, High Myopia Control Alliance (HIMALAYA)",2028-12-31,ESTIMATED,6 Years - 18 Years,1000,ESTIMATED,,OTHER,,"Genetic Variants and Their Association With Myopia Risk, Progression, and Optimal Interventions in Children",2028-08-31,ESTIMATED,Polygenic Risk Score (PRS) for Myopia Progression,,ALL,2025-07-01,ESTIMATED,OBSERVATIONAL
HITI,High Tide Inc.,NCT07412522,,RECRUITING,"Postoperative Pain, Postoperative Analgesia",Bupivacaine,CABG,RANDOMIZED,2,SPSIPB Group | Control Group,EXPERIMENTAL | NO_INTERVENTION,"Postoperative pain after cardiac surgery is commonly moderate to severe due to sternotomy, thoracotomy, internal mammary artery harvesting, and chest tube placement, and may contribute to adverse systemic and pulmonary outcomes if inadequately managed. Enhanced Recovery After Surgery (ERAS) protocols emphasize opioid-sparing strategies to reduce opioid-related side effects and complications. Ultrasound-guided fascial plane blocks have increasingly been incorporated into perioperative analgesia p",,2026-09-01,ESTIMATED,18 Years - 75 Years,60,ESTIMATED,PARALLEL,OTHER_GOV,SINGLE,Off-pump Minimal Invaziv Koroner Arter Bypass Cerrahisi geçiren Hastalarda Serratus Posterior Superior Interkostal Plan Blokunun Analjezik etkinliği: Randomize kontrollü çalışma,2026-09-01,ESTIMATED,Quality of Recovery-15 (QoR-15) Score,PREVENTION,ALL,2025-09-01,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT06845306,PHASE3,NOT_YET_RECRUITING,"Colo-rectal Cancer, Colonic Neoplasms Malignant",ICG-guided bowel perfusion assessment,ICG-NIRF,RANDOMIZED,2,The ICG group | The control group,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,"Anastomotic leakage (AL) is a serious complication after surgery for colon cancer, leading to a significant increase in mortality.Intraoperative fluorescence imaging using indocyanine green has proven to be a feasible and reproducible technique for real-time perfusion assessment.

An increasing number of studies are being published on the use of indocyanine green (ICG) fluorescence imaging in colorectal cancer surgery, showing promising results.

Therefore, we propose conducting a multicenter, r",,2026-09-01,ESTIMATED,18 Years - N/A,1268,ESTIMATED,PARALLEL,NETWORK,SINGLE,"Indocyanine Green Near-infrared Fluorescence Bowel Perfusion Quantitative Assessment to Prevent Anastomotic Leakage in Colorectal Surgery: a Multicentre, Randomised, Controlled Study",2026-07-01,ESTIMATED,30-days Anastomotic Leakage (AL) rate,TREATMENT,ALL,2025-06-01,ESTIMATED,INTERVENTIONAL
HITI,High Tide Inc.,NCT03741374,,ACTIVE_NOT_RECRUITING,Chronic Periodontitis,,,,1,Minimally-invasive non-surgical therapy,EXPERIMENTAL,This investigation aims to assess the clinical and radiographic outcomes of intrabony defects treated with minimally-invasive non-surgical therapy.,"Ravenscourt Dental Practice, South Coast Dental Specialists, Claremonth Dental Practice, Pall Mall Dental, Rose Lane Dental Practice, Periosouth, Clinica de Periodoncia, Studio Dentistico Associato Montevecchi D' Alessandro, 11th floor 141 Queen St. Brisdane, The Dentist, High Barnet Dental Care",2025-12-31,ESTIMATED,18 Years - 70 Years,66,ACTUAL,SINGLE_GROUP,OTHER,NONE,Analysis of Intrabony Defects Treated With Minimally-invasive Non-surgical Therapy: A Prospective Cohort Multicentre Study,2025-12-31,ESTIMATED,Radiographic whole defect depth reduction,TREATMENT,ALL,2019-02-01,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT06788418,,RECRUITING,Myopia,,,RANDOMIZED,3,SMILE Group | ICL group | Wavelight Plus Alcon Group,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"Myopia is a prevalent refractive error with significant lifestyle impact. While traditional SMILE (Small Incision Lenticule Extraction) and ICL (Implantable Collamer Lens) surgeries are standard options, the advent of the Wavelight Plus Alcon system presents a promising new technique. This trial aims to evaluate the safety, efficacy, and patient satisfaction across these methods.","High Myopia Control Alliance (HIMALAYA), Beijing New Vision Eye Hospital, Shanghai Parkway Hospital",2025-12-31,ESTIMATED,18 Years - 40 Years,1000,ESTIMATED,PARALLEL,OTHER,SINGLE,"Comparative Study of SMILE, ICL, and Wavelight Plus Alcon Technologies in Myopia Correction",2025-12-31,ESTIMATED,Vision at 12 months post-surgery,TREATMENT,ALL,2025-01-20,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT03062085,,RECRUITING,"High Myopia, Cataract, Visual Outcome, Genetic Anticipation",,,,3,High myopic cataract group | Age-related cataract group | Ametropic cataract group, |  | ,The purpose of this study is to evaluate the long-term visual outcome of the cataract surgery using a large-scale and comprehensive database of high myopic cataract and age-related cataract patients. The investigators will further investigate into the various genetic and environmental factors that may contribute to the pathogenesis of high myopic cataract.,Eye & ENT Hospital of Fudan University,2040-12-31,ESTIMATED,20 Years - 100 Years,60000,ESTIMATED,,OTHER,,Visual Outcome Evaluation and Genetic Analysis: Shanghai High Myopia Study,2030-12-31,ESTIMATED,Differences in the clinical phenotypes and visual outcomes of high myopic cataract patients | Differences in the clinical phenotypes and visual outcomes of age-related cataract patients | Differences in the clinical phenotypes and visual outcomes of ametropic cataract patients,,ALL,2015-01-01,ACTUAL,OBSERVATIONAL
HITI,High Tide Inc.,NCT07420738,,NOT_YET_RECRUITING,Intracranial Hypertension,,,,2,Minimal Invasive Extracorporeal Circulation (MiECC) Group | Conventional Extracorporeal Circulation (cECC) Group, | ,"This prospective study aims to compare the effects of minimal invasive extracorporeal circulation (MiECC) and conventional reservoir-based extracorporeal circulation techniques on cerebral perfusion in patients undergoing elective coronary artery bypass graft (CABG) surgery. Although the adverse effects of cardiopulmonary bypass on cerebral perfusion and oxygenation are well recognized, the relationship between these effects and changes in intracranial pressure has not been fully elucidated. In ",,2027-05-01,ESTIMATED,18 Years - 75 Years,70,ESTIMATED,,OTHER_GOV,,The Effects of Different Extracorporeal Circulation Techniques on Cerebral Perfusion Markers and Postoperative Awakening in Coronary Artery Bypass Graft Surgery,2027-05-01,ESTIMATED,Perioperative Optic Nerve Sheath Diameter (ONSD),,ALL,2026-05-01,ESTIMATED,OBSERVATIONAL
HITI,High Tide Inc.,NCT07264348,,NOT_YET_RECRUITING,"Hormone, Cardiovascular, Obesity & Overweight",,,RANDOMIZED,4,Experimental Group 1:Pre-menopausal | Control Group 1 | Experimental Group 2:Post-menopausal | Control group 2,EXPERIMENTAL | NO_INTERVENTION | EXPERIMENTAL | NO_INTERVENTION,"This study aims to evaluate the effects of a 4 month Zumba training program on cardiometabolic, hormonal, inflammatory, hepatic, renal, and functional parameters in overweight and obese women. Participants will be classified according to menopausal status (pre- or post-menopausal) and randomly assigned to an exercise group or a non-exercise control group.",,2026-04-15,ESTIMATED,18 Years - 65 Years,73,ESTIMATED,PARALLEL,OTHER,NONE,"Effects of a 4-month Intervention on Cardiometabolic, Hormonal, Inflammatory, Liver, Renal, Electrolyte, and Muscle Enzyme Parameters in Pre- and Post-Menopausal Overweight and Obese Women: A Randomized Controlled Trial",2026-04-15,ESTIMATED,Body Mass Index (BMI) | Body Fat Percentage | Waist Circumference | Waist-Hip Ratio | Hip Circumference | Prolactin | Testosterone | Cortisol | Progesterone | Estradiol | Follicle-Stimulating Hormone (FSH) | Luteinizing Hormone (LH) | Thyroid Stimulating Hormone (TSH) | Free Thyroxine (FT4) | Parathyroid Hormone (PTH) | Total Cholesterol | High-Density Lipoprotein (HDL) Cholesterol | Low-Density Lipoprotein (LDL) Cholesterol | Triglycerides | C-Reactive Protein (CRP) | Erythrocyte Sedimentation Rate (ESR) | Complete Blood Count (CBC) | Alanine Aminotransferase (ALT) | Aspartate Aminotransferase (AST) | Alkaline Phosphatase (ALP) | Gamma-Glutamyl Transferase (GGT) | Lactate Dehydrogenase (LDH) | Gamma-Glutamyl Transferase (GGT) | Bilirubin Total | Bilirubin Direct | Creatinine | Urea | Uric Acid | Sodium (Na) | Potassium (K) | Calcium (Ca) | Magnesium (Mg) | Phosphate (PO₄) | Creatine Phosphokinase (CPK) | Lactate Dehydrogenase (LDH),PREVENTION,FEMALE,2025-12-01,ESTIMATED,INTERVENTIONAL
HITI,High Tide Inc.,NCT06222645,,RECRUITING,"Anastomosis, Perfusion, Postoperative Complications, Gastrointestinal Neoplasms, Gastric Cancer (GC), Colorectal Cancer",ICG fluorescence imaging technology,,RANDOMIZED,2,Indocyanine green (ICG) imaging system | imaging photoplethysmography (iPPG),ACTIVE_COMPARATOR | EXPERIMENTAL,"This randomized controlled trial compares a novel optical technique against the standard of care for assessing tissue perfusion in gastrointestinal surgery. Participants are randomized to receive either intraoperative imaging photoplethysmography (iPPG) or indocyanine green (ICG) fluorescence imaging. In the ICG group, the fluorescence data are comprehensively analyzed in two distinct ways: (1) Qualitative Assessment: real-time visual interpretation of the angiogram flow by the operating surgeon","Shandong Linglong Yingcheng Hospital, High-Tech Clinic Beloostrov",2026-05-31,ESTIMATED,18 Years - N/A,200,ESTIMATED,PARALLEL,OTHER,NONE,Comparison Between Fluorescenceimaging With Photoplethysmography （PPG） and Indocyaningreen (ICG) for Tissue Perfusion in Gastrointestinal Resections,2026-04-30,ESTIMATED,Incidence of Anastomotic Leak | Incidence of Anastomotic Leak: Qualitative vs Quantitative ICG Assessment,DIAGNOSTIC,ALL,2023-11-01,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT06616506,,RECRUITING,"Cataract, High Myopia, Myopia, Automatic Judgement, Risk Reduction, Diagnoses Disease",,AI-HMC,,4,Highly myopic cataract patients without fundus defects | Highly myopic cataract patients with fundus defects | Highly myopic cataract patients with lens grading of NC2-3 | Highly myopic cataract patients with lens grading of NC4-5, |  |  | ,"This study aims to establish a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract, so as to improve the accuracy of the prediction of postoperative diopter in highly myopic cataract patients.",Eye and ENT Hospital of Fudan University,2035-12-31,ESTIMATED,N/A - N/A,500000,ESTIMATED,,OTHER,,Artificial Intelligence for Highly Myopic Cataract,2030-12-31,ESTIMATED,a multi-center artificial intelligence model for the accurate calculation of intraocular lens and its clinical application in highly myopic cataract | a multi-center artificial intelligence model for the cataract grading and its clinical application in highly myopic cataract,,ALL,2016-01-01,ACTUAL,OBSERVATIONAL
HITI,High Tide Inc.,NCT07420712,,RECRUITING,Analgesia,Bupivacaine,,RANDOMIZED,2,SPSIPB Group | Control Group,EXPERIMENTAL | NO_INTERVENTION,This prospective randomized controlled trial aims to evaluate the effectiveness of the serratus posterior superior intercostal plane block (SPSIPB) as part of a multimodal analgesia strategy in patients undergoing minimally invasive cardiac surgery. Sixty adult ASA III patients scheduled for minimally invasive coronary artery bypass surgery will be randomly assigned to either an SPSIPB group or a control group receiving standard analgesic management without a plane block. The primary outcome is ,,2026-07-01,ESTIMATED,18 Years - 75 Years,60,ESTIMATED,PARALLEL,OTHER_GOV,SINGLE,Multimodal Analgesia in Minimally Invasive Cardiac Surgery: A Randomized Controlled Study on the Effectiveness of the Serratus Posterior Superior Intercostal Plane Block,2026-07-01,ESTIMATED,Postoperative Opioid Consumption,PREVENTION,ALL,2025-07-01,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT06622681,,RECRUITING,"Executive Dysfunction, Physical Stress, Mental Health Wellness 1",,IARP,,1,Participant of the study,,"This study aims to understand child health during adolescence. We will examine the role of lifestyle (e.g. physical activity), growth trajectories and other environmental factors that can influence the development of phenotypes in adolescence which confer risk for later physical and mental disorders. With this study, we will develop a deeper understanding of adolescent health and well-being and their main determinants in the local Singaporean context, identify levers for early interventions to m","National Institute of Education, Nanyang Technological University, Institute of High Performance Computing (IHPC), A*STAR Research Institutes",2026-12,ESTIMATED,13 Years - 15 Years,1200,ESTIMATED,,OTHER,,Integrative Adolescence Research Programme (IARP) - iAdoRe Study,2026-06,ESTIMATED,Child health and environmental factors | Social Science factors,,ALL,2024-05-21,ACTUAL,OBSERVATIONAL
HITI,High Tide Inc.,NCT04793932,PHASE3,ACTIVE_NOT_RECRUITING,Pancreas Ductal Adenocarcinoma,"PAXG, mFOLFIRINOX, short-course chemotherapy, long-course chemotherapy",CASSANDRA,RANDOMIZED,4,PAXG Arm A | mFOLFIRINOX Arm B | short-course chemotherapy | long-course chemotherapy,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,The main aim of this study is to compare the efficacy of short-course versus long-course pre-operative chemotherapy with PAXG or mFOLFIRINOX in patients who receive a diagnosis of pancreatic ductal adenocarcinoma (PDAC) resectable or borderline resectable.,"High Research srl, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente",2026-01-31,ESTIMATED,18 Years - 75 Years,261,ACTUAL,FACTORIAL,OTHER,NONE,A Randomized Phase III Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC),2025-03-15,ACTUAL,Event-free survival | Event-free survival,TREATMENT,ALL,2020-11-03,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT05588934,,RECRUITING,"Sleep Deprivation, Caffeine",,2B-2,RANDOMIZED,5,Placebo Dose Both Nights | Standard Caffeine Dose Both Nights | Optimized Caffeine Dose Both Nights | Placebo Dose 1st Night/Standard Caffeine Dose 2nd Night | Placebo Dose 1st Night/Optimized Caffeine Dose 2nd Night,PLACEBO_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This clinical trial will be a comparison between personalized recommended caffeine dosing regimen versus the standard recommended caffeine dosing regimen for sustaining performance during sleep deprivation and minimizing side effects and subsequent sleep disruption. The questions this study aims to answer are: Whether the personalized caffeine recommendations improve vigilance, sleepiness, and cognition after total sleep deprivation, compared to standard recommendations; Whether the personalized","U.S. Army Medical Research Acquisition Activity, Biotechnology High Performance Computing Software Applications Institute",2026-03,ESTIMATED,18 Years - 39 Years,180,ESTIMATED,FACTORIAL,OTHER,DOUBLE,A Head-to-Head Comparison of the 2B-Alert Caffeine Optimization Algorithm Versus Standard Caffeine Dosing on Performance During Sleep Deprivation (2B-2),2026-03,ESTIMATED,Mean psychomotor vigilance test reaction time,OTHER,ALL,2023-06-09,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT04301518,,ACTIVE_NOT_RECRUITING,"Preterm Labor, Preterm Birth",,PRIME,RANDOMIZED,2,PTB Prevention | Control,EXPERIMENTAL | NO_INTERVENTION,"This prospective, randomized, controlled study evaluates the safety and efficacy of a preterm birth (PTB) prevention strategy versus standard of care pregnancy management to reduce the incidence of adverse pregnancy outcomes.","High Risk Pregnancy Center, Las Vegas, Nevada",2026-12-30,ESTIMATED,18 Years - N/A,6500,ESTIMATED,PARALLEL,INDUSTRY,NONE,Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs,2024-12-06,ACTUAL,Neonatal morbidity/mortality | Length of neonatal hospital stay,PREVENTION,FEMALE,2020-11-06,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT07425717,,NOT_YET_RECRUITING,"Retinal Degeneration, Vision Impairment and Blindness",,,RANDOMIZED,2,TMS | Control,EXPERIMENTAL | SHAM_COMPARATOR,"The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) works to restore vision in adults with severe retinal degeneration. It will also learn about the safety of TMS treatment. The main questions it aims to answer are:

1. Does TMS treatment improve the visual function of participants?
2. What medical problems do participants have when receiving TMS treatment? Researchers will compare TMS treatment to a sham stimulation (identical procedures using a sham coil with",,2029-05-31,ESTIMATED,45 Years - 70 Years,136,ESTIMATED,PARALLEL,OTHER,TRIPLE,Effectiveness of TMS for Visual Restoration: a Multicenter Randomized Controlled Trial,2028-05-31,ESTIMATED,Best-corrected visual acuity (BCVA) change,TREATMENT,ALL,2026-06-01,ESTIMATED,INTERVENTIONAL
HITI,High Tide Inc.,NCT06877988,,RECRUITING,Visual Impairment,,,RANDOMIZED,2,AI-assisted | Traditional,EXPERIMENTAL | NO_INTERVENTION,"The goal of this observational study is to evaluate the performance, operational efficiency, acceptability, feasibility, and cost-effectiveness of an AI-assisted screening model for visual impairment in a community setting. The main questions it aims to answer are:

* Can the AI-assisted screening model improve screening and referral accuracy compared to the current traditional screening approach?
* Does the AI-assisted model enhance operational efficiency and reduce healthcare costs in a commun","Institute of High Performance Computing (IHPC), A*STAR Research Institutes, National University Polyclinics, Singapore",2026-03-31,ESTIMATED,50 Years - N/A,400,ESTIMATED,PARALLEL,OTHER,DOUBLE,"Artificial Intelligence (AI) - Assisted Visual Impairment Screening Model: Community-based Implementation and Evaluation of Performance, Feasibility and Costs.",2026-03-31,ESTIMATED,Performance of AVIRI on the detection of visual impairment,DIAGNOSTIC,ALL,2024-06-27,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT06938490,,NOT_YET_RECRUITING,"Colorectal Cancer (CRC), Surgery, Colorectal, Oncology",,COLAP-D3,RANDOMIZED,2,LCA preserved | First SA preserved,ACTIVE_COMPARATOR | ACTIVE_COMPARATOR,"This study is a randomized, controlled trial comparing the short- and long-term outcomes of left colonic artery or first sigmoid artery preservation for rectal surgery. Eligible patients will be randomized to D3-lymphodissection with preservation of the first sigmoid artery or left colonic artery in a 1:1 ratio according to a computer-generated randomization list created in advance (includes removal of 252, 253 l/u groups, 241 groups of distal sigmoid colon sites when the neoplasm is highly loca",,2029-05,ESTIMATED,N/A - N/A,778,ESTIMATED,FACTORIAL,NETWORK,NONE,A Randomized Multicenter Prospective Study of Colorectal Anastomosis Failures With First Sigmoid or Left Colonic Artery Preservation With D3 Lymphadenectomy (COLAP-D3 - Colorectal Anastomotic Leakage and Arterial Preservation With D3 Lymphadenectomy),2028-05,ESTIMATED,Failure of colorectal anastomoses within 30 days of surgery,PREVENTION,ALL,2025-04,ESTIMATED,INTERVENTIONAL
HITI,High Tide Inc.,NCT05487417,PHASE4,RECRUITING,"Ischemic Stroke, Acute",Minocycline,MIST-A,RANDOMIZED,2,Minocycline treatment group | Routine treatment group,EXPERIMENTAL | NO_INTERVENTION,"Minocycline is the second generation of tetracycline. Because of its lipophilicity, it has high penetrance of blood-brain barrier. Animal model studies have shown that minocycline can reduce cerebral damage after ischemic stroke, and its mechanism involves multiple molecular pathways, such as antioxidant, anti-inflammatory, anti apoptotic pathways, and protection of blood-brain barrier. Clinical studies have also shown that minocycline can significantly improve 3-month National Institute of Heal","Xi'an No.3 Hospital, Xi'an Gaoxin Hospital, First People's Hospital of Xianyang, Xi'an XD Group Hospital, Baoji High-tech Hospital, Weinan Central Hospital, Xi'An Daxing Hospital, Yan'an University Xianyang Hospital, The First Hospital of Yulin, Northwest University First Hospital, Jingyang County Hospital, Yulin No.2 Hospital, Yan'an people's Hospital, Yuncheng Central Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an No.9 Hospital, First Affiliated Hospital Xi'an Jiaotong University, Pucheng County Hospital",2025-09-10,ESTIMATED,18 Years - 85 Years,180,ESTIMATED,PARALLEL,OTHER,SINGLE,Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy,2025-06-10,ACTUAL,Change in infarct volume from baseline to day 5,TREATMENT,ALL,2022-11-01,ACTUAL,INTERVENTIONAL
HITI,High Tide Inc.,NCT07097051,PHASE2,RECRUITING,Mild Cognitive Impairment (MCI),,,RANDOMIZED,2,real tACS | sham tACS,EXPERIMENTAL | PLACEBO_COMPARATOR,"Older adults with Mild Cognitive Impairment (MCI) often show less brain activity in a specific range (8-13 Hz, known as alpha power) compared to healthy older adults. Those with lower alpha activity, especially in the front part of the brain, usually have problems with executive functions like planning and multitasking. Our research has shown that older adults with lower alpha power in these areas also struggle more with balance when they have to do two things at once (like standing and performi","Wake Forest University Health Sciences, Hebrew SeniorLife",2026-12-31,ESTIMATED,65 Years - 85 Years,20,ESTIMATED,PARALLEL,OTHER,DOUBLE,Multi-session Transcranial Alternating Current Stimulation to Improve Dual-task Standing and Brain Activity in Older Adults With Mild Cognitive Impairment,2026-12-31,ESTIMATED,EEG alpha-band power | Change of postural sway speed,TREATMENT,ALL,2025-05-13,ACTUAL,INTERVENTIONAL
HUMA,"Humacyte, Inc.",NCT03005418,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Trauma, Vascular System Injury",Human Acellular Vessel (HAV),,,1,Human Acellular Vessel (HAV),EXPERIMENTAL,This study evaluates the use of the Human Acellular Vessel (HAV) in adults with vascular trauma below the neck who are undergoing vascular reconstructive surgery. There will be a torso cohort and a limb cohort. All subjects will be implanted with a HAV as an interposition vessel or bypass using standard vascular surgical techniques. There is no control arm.,"Atlantic Research Group, U.S. Army Medical Research and Development Command",2027-09-01,ESTIMATED,18 Years - 85 Years,72,ACTUAL,SINGLE_GROUP,INDUSTRY,NONE,A Phase 2/3 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients With Life or Limb-threatening Vascular Trauma,2027-09-01,ESTIMATED,HAV primary patency | Frequency and Severity of Adverse Events,TREATMENT,ALL,2018-09-01,ACTUAL,INTERVENTIONAL
HUMA,"Humacyte, Inc.",NCT05908084,PHASE3,RECRUITING,End Stage Renal Disease (ESRD),Acellular Tissue Engineered Vessel (ATEV),,RANDOMIZED,2,ATEV treatment arm | AVF treatment arm,EXPERIMENTAL | ACTIVE_COMPARATOR,"The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD).

Participants will be stratified by location of the vascular access (forearm versus upper arm) and by type of AVF creation procedure planned by the surgeon at randomization (1-stage AVF versus 2-stage AVF). The comparator is ",IQVIA Biotech,2027-10,ESTIMATED,18 Years - N/A,150,ESTIMATED,PARALLEL,INDUSTRY,SINGLE,A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Acellular Tissue Engineered Vessel (ATEV) With That of an Autogenous Arteriovenous Fistula (AVF) in Female Patients With End-Stage Renal Disease Requiring Hemodialysis,2026-10,ESTIMATED,The number of catheter-free days since randomization to Month 12. | The rate of infections related to any HD access.,TREATMENT,FEMALE,2023-09-07,ACTUAL,INTERVENTIONAL
SGMO,"Sangamo Therapeutics, Inc.",NCT02500849,PHASE1,ACTIVE_NOT_RECRUITING,HIV,,,NON_RANDOMIZED,2,Cohort 1: | Cohort 2:,EXPERIMENTAL | EXPERIMENTAL,The purpose of the study is to evaluate the safety and feasibility of administering SB-728mR-HSPC after conditioning with busulfan.,"Sangamo Therapeutics, California Institute for Regenerative Medicine (CIRM)",2026-08-24,ESTIMATED,18 Years - 75 Years,12,ESTIMATED,SINGLE_GROUP,OTHER,NONE,"A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients",2026-08-24,ESTIMATED,Toxicity in subjects who received SB-728mR-HSPC after each busulfan dose level,TREATMENT,ALL,2016-03-10,ACTUAL,INTERVENTIONAL
SGMO,"Sangamo Therapeutics, Inc.",NCT05987527,,ACTIVE_NOT_RECRUITING,"Kidney Transplant Rejection, End Stage Renal Disease",,,,2,Treatment group | Control group, | ,This long-term follow-up study is being conducted to collect long-term (up to 15 years post-infusion) safety and tolerability data from subjects enrolled in studies evaluating TX200-TR101.,,2039-06-11,ESTIMATED,18 Years - 72 Years,11,ESTIMATED,,INDUSTRY,,"Long-Term Follow-Up of Patients Who Have Received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg Therapy, TX200-TR101) in a Prior Clinical Study",2039-06-11,ESTIMATED,Safety and Tolerability of TX200-TR101 infusion evaluated by overall survival | Safety and Tolerability TX200-TR101 infusion evaluated by and incidence of serious adverse events (SAEs) according to CTCAE V5.0.,,ALL,2023-08-15,ACTUAL,OBSERVATIONAL
SGMO,"Sangamo Therapeutics, Inc.",NCT04628871,,ACTIVE_NOT_RECRUITING,"Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II","SB-318, SB-913, SB-FIX",LTFU,,3,Subjects who received SB-318 | Subjects who received SB-913 | Subjects who received SB-FIX, |  | ,"Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.",,2030-01-01,ESTIMATED,18 Years - N/A,13,ESTIMATED,,INDUSTRY,,"Long-Term Follow-up of Subjects Who Were Treated With SB-318, SB-913, or SB-FIX, for Targeted Genome Editing Into the Albumin Gene in the Liver",2030-01-01,ESTIMATED,Long-term safety,,ALL,2020-11-03,ACTUAL,OBSERVATIONAL
SGMO,"Sangamo Therapeutics, Inc.",NCT04817774,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Kidney Transplant Rejection, End Stage Renal Disease",TX200-TR101,STEADFAST,NON_RANDOMIZED,2,Treatment group | Control group and Transplant donors,EXPERIMENTAL | NO_INTERVENTION,"The purpose of this study is to evaluate the safety and tolerability of TX200-TR101 and its effects on the donated kidney in living donor kidney transplant recipients. TX200-TR101 is a product made from a kidney transplant recipient's own immune cells, which are genetically modified and designed to help the transplant recipient's body accept their donated kidney and prevent their immune system from rejecting it.",,2025-10-29,ESTIMATED,18 Years - 70 Years,26,ACTUAL,SEQUENTIAL,INDUSTRY,NONE,Multicentre Open-Label Single Ascending Dose Dose-Ranging Phase I/IIa Study to Evaluate Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor TRegulatory Cell Therapy in Living Donor Renal Transplant Recipients,2024-07-11,ACTUAL,Safety and Tolerability,PREVENTION,ALL,2021-03-17,ACTUAL,INTERVENTIONAL
SGMO,"Sangamo Therapeutics, Inc.",NCT05145062,,ACTIVE_NOT_RECRUITING,Blood and Lymphatic Diseases,"BIVV003, ST-400",,,2,BIVV003 Cohort | ST-400 Cohort, | ,"Primary Objectives:

Long-term safety of BIVV003 in participants with severe sickle cell disease (SCD) and ST- 400 in participants with transfusion-dependent beta-thalassemia (TDT)

Secondary Objectives:

* Long-term efficacy of the biological treatment effect of BIVV003 in SCD
* Long-term efficacy of the clinical treatment effect of BIVV003 on SCD-related clinical events
* Long-term efficacy of the biological treatment effect of ST-400 in TDT
* Long-term efficacy of the clinical treatment effec",,2038-07-14,ESTIMATED,18 Years - 45 Years,8,ACTUAL,,INDUSTRY,,An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant,2038-07-14,ESTIMATED,Adverse Events | Overall Survival,,ALL,2021-12-21,ACTUAL,OBSERVATIONAL
SGMO,"Sangamo Therapeutics, Inc.",NCT06980948,"PHASE1, PHASE2",RECRUITING,Chronic Neuropathic Pain,,,RANDOMIZED,2,Sham Controlled Study | Investigational Agent,SHAM_COMPARATOR | EXPERIMENTAL,"This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).",,2028-07,ESTIMATED,18 Years - N/A,27,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Multicenter Phase 1 / 2 Double-blind, Randomized, Sham-controlled Dose Escalation Study to Determine Safety and Tolerability of Single Dose Intrathecal ST-503 Gene Therapy for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)",2027-07,ESTIMATED,Incidence and severity of treatment emergent adverse events (TEAEs),TREATMENT,ALL,2025-10,ESTIMATED,INTERVENTIONAL
EDIT,"Editas Medicine, Inc.",NCT05444894,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia",,,,1,EDIT-301,EXPERIMENTAL,"The purpose of this study is to evaluate the safety, tolerability, and efficacy of treatment with EDIT-301 in adult participants with Transfusion Dependent beta Thalassemia",,2025-12,ESTIMATED,18 Years - 35 Years,9,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,"A Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited Cluster of Differentiation 34 (CD34+) Human Hematopoietic Stem and Progenitor Cells (HSPC) (EDIT-301) in Transfusion-Dependent Beta Thalassemia (TDT)",2025-09,ESTIMATED,"Proportion of participants achieving engraftment defined as neutrophil engraftment (defined as demonstrating absolute neutrophil count (ANC) ≥ 0.5 x 10^9/L post EDIT-301 infusion for 3 consecutive measurements obtained on different days) | Frequency and severity of adverse events (AEs) (incidence of AEs and Grade 3 or higher serious adverse events, using National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v.5.0)",TREATMENT,ALL,2022-04-29,ACTUAL,INTERVENTIONAL
EDIT,"Editas Medicine, Inc.",NCT04853576,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Sickle Cell Disease, Hemoglobinopathies",,,,1,EDIT-301,EXPERIMENTAL,"The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult and adolescent participants with severe sickle cell disease (SCD).",,2025-08,ESTIMATED,12 Years - 50 Years,45,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease,2025-08,ESTIMATED,Proportion of subjects achieving complete resolution of severe vaso-occlusive events (VOEs),TREATMENT,ALL,2021-05-04,ACTUAL,INTERVENTIONAL
PRQR,ProQR Therapeutics N.V.,NCT04123626,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders",QR-1123,AURORA,RANDOMIZED,6,QR-1123 Single dose - dose level 1 | QR-1123 Single dose - dose level 2 | QR-1123 Single dose - dose level 3 | QR-1123 Single dose - dose level 4 | QR-1123 Single dose - dose level 5 | Repeat dose cohort 1,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This study evaluates the safety, tolerability and efficacy of QR-1123 injection in the eye (intravitreal; IVT) injections (one eye/unilateral) in subjects receiving a single dose or repeat doses. Single injections will be assessed in an open label way, and repeat injections will be assessed in a double-masked, randomized, sham-controlled fashion.",,2022-06-07,ESTIMATED,18 Years - N/A,11,ACTUAL,SEQUENTIAL,INDUSTRY,TRIPLE,A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene,2022-06-07,ESTIMATED,Incidence and Severity of ocular AEs | Incidence and Severity of non-ocular AEs,TREATMENT,ALL,2019-10-07,ACTUAL,INTERVENTIONAL
PRQR,ProQR Therapeutics N.V.,NCT03913143,"PHASE2, PHASE3",ACTIVE_NOT_RECRUITING,"Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease",sepofarsen,ILLUMINATE,RANDOMIZED,3,Group 1: Dose 1 sepofarsen (QR-110) | Group 2: Dose 2 sepofarsen (QR-110) | Group 3: Sham,EXPERIMENTAL | ACTIVE_COMPARATOR | SHAM_COMPARATOR,"The purpose of this double-masked, randomized, controlled, multiple-dose study is to evaluate the efficacy, safety, tolerability and systemic exposure of sepofarsen (QR-110) administered via intravitreal injection in subjects with Leber's Congenital Amaurosis (LCA) due to the CEP290 p.Cys998X mutation after 24 months of treatment",,2023-03,ESTIMATED,8 Years - N/A,36,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene",2022-01-31,ACTUAL,Change in BCVA,TREATMENT,ALL,2019-04-04,ACTUAL,INTERVENTIONAL
EOLS,"Evolus, Inc.",NCT05481931,,ACTIVE_NOT_RECRUITING,Glabellar Frown Lines,prabotulinumtoxinA,,,3,Safety Population | Botulinum Toxin Naïve | Botulinum Toxin Exposed, |  | ,Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.,Avania,2026-01,ESTIMATED,18 Years - 64 Years,756,ACTUAL,,INDUSTRY,,Non-Interventional Post-Authorisation Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines,2026-01,ESTIMATED,Treatment Emergent Adverse Events,,ALL,2023-03-15,ACTUAL,OBSERVATIONAL
EOLS,"Evolus, Inc.",NCT06903975,PHASE4,RECRUITING,Neck Muscle Issue,prabotulinumtoxinA-xvfs,,,1,Botulinum injection into SCM,EXPERIMENTAL,"Botulinum toxin injections have been used both in the face and neck for many years. However, injection into the sternocleidomastoid muscle (SCM) has only been done to treat neck spasms. In this study botulinum toxin will be injected into the SCM to determine if this will result in a temporary slimming effect on the neck and produce a more feminine, youthful neck contour.","Evolus, Inc.",2026-03,ESTIMATED,18 Years - 65 Years,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,The Effect of Injection of prabotulinumtoxinA-xvfs (Jeuveau) Into the Bilateral Sternocleidomastoid Muscles on Neck Circumference and Aesthetics,2026-03,ESTIMATED,Neck circumference,TREATMENT,ALL,2025-05-14,ACTUAL,INTERVENTIONAL
ALPS,Alps Group Inc,NCT05128123,,ACTIVE_NOT_RECRUITING,Hepatocellular Carcinoma,,SOCIAL-CHIEF,,0,,,"With 8,000 related deaths per year, HCC is one of the most dangerous cancers in France. The main reason for the poor prognosis of HCC is most often a diagnosis at an advanced stage ineligible for curative treatment. In the field of oncology, low participation to screening is closely linked to socioeconomic status (e.g. level of education, income, employment). In HCC, the socioeconomic status is linked to incidence, overall survival and treatment allocation in US, UK and Australia. This suggests ","University Grenoble Alps, University Hospital, Caen, Amiens University Hospital, National Cancer Institute, France",2026-12-31,ESTIMATED,18 Years - N/A,1600,ESTIMATED,,OTHER,,Influence of Social Determinants of Health on the Management of Hepatocellular Carcinoma in the French National Cohort Study CHIEF,2024-12-31,ACTUAL,"The primary objective will be to assess the rates of curative treatment (either resection, ablation or liver transplantation) according to the social determinants of health",,ALL,2022-01-21,ACTUAL,OBSERVATIONAL
ALPS,Alps Group Inc,NCT06650813,,RECRUITING,"Fatigue Symptom, Sickle Cell Disease",,Drépa-FACETS,,1,Patients with sickle cell disease,EXPERIMENTAL,Adaptation of a fatigue management program combining the principles of cognitive-behavioral therapy and energy conservation strategies (FACETS program) for a population of adult patients with sickle cell disease (Drépa-FACETS program).,"University Hospital, Grenoble, University Grenoble Alps, Paris Nanterre University",2026-05-02,ESTIMATED,18 Years - N/A,24,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Adapting the FACETS Fatigue Management Program to Sickle Cell Disease,2026-05-02,ESTIMATED,Feasibility of the FACETS program for adult sickle-cell patients,PREVENTION,ALL,2025-01-10,ACTUAL,INTERVENTIONAL
ALPS,Alps Group Inc,NCT06253793,,NOT_YET_RECRUITING,Autism Spectrum Disorder,,FACECOM,,3,ASD Experimental group | ASD Control group | TD control group, |  | ,"Early remediation of the communicative and social difficulties of children with autism spectrum disorders (ASD) is central. However, from the age of 6-8 months, children with ASD show a lack of attention to social stimuli such as faces: such early avoidance behavior could be at the root of later communicative difficulties (language, attention). The Denver program aims to stimulate social communication and attention to faces in children with ASD aged between 18 and 60 months. Although the Denver ",University Grenoble Alps,2028-05-31,ESTIMATED,18 Months - 5 Years,90,ESTIMATED,,OTHER,,Tool for Evaluating the Effectiveness of the DENVER Protocol for Attention to Faces (Face) and the Development of Social Communication (Com) in Young Children With Autism Spectrum Disorder (ASD),2027-05-31,ESTIMATED,looking time during natural social scenes | looking time to social scenes presented on a screen,,ALL,2024-05-13,ESTIMATED,OBSERVATIONAL
ALPS,Alps Group Inc,NCT03570450,PHASE1,RECRUITING,Stroke,Adipose derived Stem Cell,,RANDOMIZED,5,"Adipose derived Stem Cells - 1.10^6cells/kg | Adipose derived Stem Cells - 2.10^6cells/kg | Adipose derived Stem Cells - 2,5.10^6cells/kg | Adipose derived Stem Cells - 3.10^6cells/kg | placebo",EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | PLACEBO_COMPARATOR,"Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life.","Horizon 2020 - European Commission, University Grenoble Alps, Servicio Madrileño de Salud, Madrid, Spain, St. Anne's University Hospital Brno, Czech Republic, Andaluz Health Service, University of Glasgow, University of Eastern Finland, Etablissement Français du Sang, Tampere University, Histocell SL, Spain, Oy Medfiles Ltd, Institut National de la Santé Et de la Recherche Médicale, France, Hospices Civils de Lyon, Association Groupe ESSEC, NOVADISCOVERY SAS, France, Finovatis, Centre Hospitalier Universitaire de Besancon, Assistance Publique - Hôpitaux de Paris, University Hospital, Toulouse, University Hospital, Bordeaux, University Hospital, Caen, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Servicio de Salud de Castilla La Mancha, Albacete, Spain, Servicio Gallego de Salud, Pirkanmaa Hospital District, Tampere, Finland, Hospital Vall d'Hebron, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, CH Sainte-Anne, Paris, France",2027-07-01,ESTIMATED,18 Years - N/A,95,ESTIMATED,SEQUENTIAL,OTHER,DOUBLE,Regenerative Stem Cell Therapy for Stroke in Europe 1,2025-07-01,ESTIMATED,Phase Ia (Toxicity study) | Phase Ib (Dose-effect study),TREATMENT,ALL,2018-06-02,ACTUAL,INTERVENTIONAL
ALPS,Alps Group Inc,NCT06822127,,RECRUITING,Orthognathic Surgery,,SPOC,,1,"Patients undergoing orthognathic surgery,",OTHER,"Orthognathic surgery consists of rebalancing the position of the jaws, taking into account functional criteria (tooth engagement, tooth/lip ratio, breathing, etc.) and aesthetic criteria. It has become much more accurate in recent years thanks to the advent of osteosynthesis plates and the contribution of three-dimensional imaging. Three-dimensional imaging makes it possible to simulate fairly accurately the surgical procedures and bone displacements required. However, the effect of these bone d",University Grenoble Alps,2027-10-31,ESTIMATED,18 Years - N/A,30,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Simulation of Facial Soft Tissue in Orthognathic Surgery,2027-10-31,ESTIMATED,Validation of the predictions provided by the digital face model (SPOC).,OTHER,ALL,2025-04-28,ACTUAL,INTERVENTIONAL
ALPS,Alps Group Inc,NCT06633003,,RECRUITING,Spinocerebellar Ataxia,,,RANDOMIZED,2,Stage I: Antrodia Cinnamomea Products + Stage II: Placebo | Stage I: Placebo + Stage II: Antrodia Cinnamomea Products,ACTIVE_COMPARATOR | PLACEBO_COMPARATOR,This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients. To investigate the advancements in neurodegenerative diseases.,,2027-08-31,ESTIMATED,30 Years - 70 Years,60,ESTIMATED,CROSSOVER,INDUSTRY,DOUBLE,Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients,2027-08-31,ESTIMATED,Change from Baseline in the total score of the Scale for the Assessment and Rating of Ataxia (SARA) at 48 weeks in subjects is compared to natural history.,HEALTH_SERVICES_RESEARCH,ALL,2024-09-16,ACTUAL,INTERVENTIONAL
ALPS,Alps Group Inc,NCT06178276,,RECRUITING,"Learning, Language, Comprehension",,COraIL,,2,A2 level | B2 level, | ,"The oral comprehension (OC) of a second language (L2) involves different cognitive processes, specially during the learning phase. This study aims at investigating the neurophysiological functioning of different steps involved in this oral understanding.","University Grenoble Alps, Institut National de la Santé Et de la Recherche Médicale, France",2026-02,ESTIMATED,18 Years - 35 Years,70,ESTIMATED,,OTHER,,Investigation of Neurophysiological Functioning During Oral Comprehension Task. An Exploratory Study in Second Language (Italian) Learning in French Students Using Autonomic and Cerebral Investigation,2026-02,ESTIMATED,Sympathetic activity,,ALL,2024-02-14,ACTUAL,OBSERVATIONAL
ALPS,Alps Group Inc,NCT06057233,,NOT_YET_RECRUITING,"Epilepsy, Temporal Lobe",,EPI-CATCHER,,2,Patients | Volunteers, | ,"The goal of EPI-CATCHER is to outline the clinical potential of multiparametric quantitative MRI (mqMRI) and of GABA-edited magnetic resonance spectroscopy (GABA-MRS), combined with machine learning tools, as imaging biomarkers to localize and delineate the EZ.","University Grenoble Alps, Institut National de la Santé Et de la Recherche Médicale, France",2028-11,ESTIMATED,18 Years - 65 Years,40,ESTIMATED,,OTHER,,Quantitative MRI and GABA Spectroscopy to Localize the Epileptic Zone,2028-11,ESTIMATED,EZmri vs EZsdt,,ALL,2024-10,ESTIMATED,OBSERVATIONAL
ALPS,Alps Group Inc,NCT06907368,,NOT_YET_RECRUITING,Total Knee Arthroplasty for Gonarthrosis,,ARTHROPROMA,,0,,,"Total knee arthroplasty remains the gold standard in the management of disabling gonarthrosis. Improved functional results, increased availability of care and an ageing population have all contributed to the rise in total knee replacement surgery in Western countries. Surgical techniques have been steadily improving for several decades in terms of implant positioning and joint alignment. However, 10% of patients are dissatisfied with the clinical and functional results. The challenge is to under",University Grenoble Alps,2027-10-01,ESTIMATED,18 Years - N/A,15,ESTIMATED,,OTHER,,"Analysis of the Functional Impact of Total Knee Arthroplasty Using Quantified Gait Analysis and Proprioceptive Evaluation. Prospective, Single-center, Open-label Study, Cohort Follow-up.",2027-10-01,ESTIMATED,Post-operative functional recovery of patients who have undergone total knee arthroplasty for gonarthrosis by analyzing their locomotion ability,,ALL,2025-04-01,ESTIMATED,OBSERVATIONAL
ALPS,Alps Group Inc,NCT06835205,,ACTIVE_NOT_RECRUITING,"Bullying of Child, Child Behavior Disorders, Social Behavior, Mental Health, Interpersonal Relations, School Health Services, Prevention and Control",,APACHES,RANDOMIZED,2,Intervention Group (TEAL Program) | Control Group (Standard Health Education),EXPERIMENTAL | ACTIVE_COMPARATOR,"This study, titled APACHES, is a cluster randomized controlled trial aimed at evaluating the effectiveness of a school-based prevention program, ""Tous Épanouis à l'École"" (TEAL), conducted by healthcare students as part of their mandatory public health service curriculum. The TEAL program consists of five interactive sessions focused on developing psychosocial skills (e.g., communication, empathy, collaboration) among elementary school students (grades CE2-CM1-CM2) in the Grenoble Academy. The p","Université Lumière Lyon 2, University Grenoble Alps, Maison des Sciences de l'Homme et de la société, Grenoble Academy",2025-06-30,ESTIMATED,8 Years - 11 Years,900,ESTIMATED,PARALLEL,OTHER,NONE,Prevention Workshop to Address Bullying Behaviors in Schools: A Cluster Randomized Controlled Trial,2025-06-30,ESTIMATED,Prevalence of Bullying Behaviors (Victims and/or Aggressors),PREVENTION,ALL,2024-10-01,ACTUAL,INTERVENTIONAL
ALPS,Alps Group Inc,NCT06266936,,NOT_YET_RECRUITING,"Mental Health Issue, Student Burnout",,SL2i-MSC,,1,Cohort with health students,,"The question of the well-being, quality of life and mental health of care students is unanimously considered to be a central issue among young adults. According to the French Ministry of Higher Education and Research, there will be 194,752 care students in France in 2021-2022. The quality of life and well-being of health students can be affected at several levels. The first is mental health. In France, the mental health of these students has deteriorated considerably in recent years. According t",University Grenoble Alps,2044-12,ESTIMATED,18 Years - N/A,1564,ESTIMATED,,OTHER,,Smart Life Smart Living Intercontinental - Medical Students' Cohort,2044-09,ESTIMATED,Synthetic score on standardized assessment scale of anxiety,,ALL,2024-09,ESTIMATED,OBSERVATIONAL
ALPS,Alps Group Inc,NCT06735911,,RECRUITING,Psoriasis,,BAREGES,,1,Experimental: patient treated with a dermatology-oriented spa therapy,EXPERIMENTAL,Evaluation of the effect of a dermatology-oriented spa therapy at 4.5 months on the quality of life of patients suffering from psoriasis,"Floralis, University Grenoble Alps",2028-05-01,ESTIMATED,18 Years - N/A,70,ESTIMATED,SINGLE_GROUP,OTHER,NONE,Assessment at 4.5 Months of the Effect of a Dermatology-Oriented Spa Therapy on the Quality of Life of Patients With Psoriasis (BAREGES),2026-07,ESTIMATED,To evaluate the effect of a complete thermal treatment (moderate impact) for a dermatological indication on the quality of life of patients with psoriasis,TREATMENT,ALL,2025-04-28,ACTUAL,INTERVENTIONAL
ALPS,Alps Group Inc,NCT05857319,,NOT_YET_RECRUITING,"Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2, Sleep Apnea, Obstructive, NAFLD, NASH",,SCOOP-RNPC,,4,General Cohort | Connected Objects Group | Obstructive Sleep Apnea Syndrome (OSAS) Group | Neuropathies Group, |  |  | ,"The investigators hypothesize that weight loss obtained with the French RNPC weight reduction program is beneficial for the general health of overweight/obese patients in the medium term.

The objective of this cohort study is to demonstrate the effectiveness of the RNPC program on the reduction of drug or instrumental treatments (for example, continuous positive pressure ventilation for the treatment of sleep apnea syndrome) and the improvement of overweight/obesity-associated comorbidities in ","University Grenoble Alps, Novo Nordisk A/S, Lyon Est University",2030-07-15,ESTIMATED,18 Years - 85 Years,10000,ESTIMATED,,INDUSTRY,,"Assessment of the Impact of Short, Medium and Long-term Weight Loss, Obtained by a Standardized Nutritional and Psycho-Behavioral Rehabilitation Program (RNPC Program) and in Real Life Conditions, in Obese or Overweight Patients",2030-07-15,ESTIMATED,Effectiveness of the national RNPC weight reduction program on the change of treatments (drug or instrumental treatments) or in the comorbidities of overweight/obesity.,,ALL,2023-07-15,ESTIMATED,OBSERVATIONAL
ALPS,Alps Group Inc,NCT06321380,,NOT_YET_RECRUITING,"Alzheimer Disease, Vascular Dementia, Mixed Dementias",,MEMTRAV-COG,,4,Alzheimer disease | Vascular dementia | Mixed dementia | Control group, |  |  | ,"The aim of the present study is to investigate potential cognitive mechanisms contributing to working memory impairment in Alzheimer's disease and vascular dementia. The investigators consider a new hypothesis suggesting that difficulties in mobilizing maintenance strategies of information could explain this working memory deficit. More specifically, the investigators assume that patient groups will have difficulties in employing both refreshing and elaborative strategies during a working memory","University Grenoble Alps, Université Savoie Mont Blanc, Centre National de la Recherche Scientifique, France, Laboratoire de Psychologie et NeuroCognition",2025-10,ESTIMATED,65 Years - N/A,120,ESTIMATED,,OTHER,,Efficacy of Working Memory Maintenance Mechanisms in Alzheimer's Disease and Vascular Dementia,2025-09,ESTIMATED,Memory performance in the Working memory task | Processing performance in the Working memory task | Reaction time,,ALL,2024-04,ESTIMATED,OBSERVATIONAL
ALPS,Alps Group Inc,NCT06742775,,NOT_YET_RECRUITING,"Aging, Diagnostic Techniques, Cardiovascular",,EvolVOAge,,3,Under 30 | Between 30 and 50 | More than 50, |  | ,"Acquisition of synchronized cardiovascular signals from non-invasive measurements (ECG, photoplethysmography pulse sensors, inductance plethysmography) in healthy volunteers aged from 18 to 75, during spontaneous ventilation with apneas (20 seconds) for a total acquisition time of 30 minutes.",University Grenoble Alps,2027-02,ESTIMATED,18 Years - 75 Years,60,ESTIMATED,,OTHER,,Evolution of the Relationship Between Central and Peripheral Arterial Wave Velocities as a Function of Age,2026-08,ESTIMATED,Electrocardiogram | Photoplethysmography | inductive plethysmography,,ALL,2025-02,ESTIMATED,OBSERVATIONAL
CDBKF,Cloudbreak Pharma Inc.,NCT05456425,PHASE3,ACTIVE_NOT_RECRUITING,Pterygium,"CBT-001, Vehicle",,RANDOMIZED,3,Vehicle | CBT-001 Low Dose | CBT-001 High Dose,PLACEBO_COMPARATOR | EXPERIMENTAL | EXPERIMENTAL,The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.,,2027-12-31,ESTIMATED,12 Years - N/A,660,ACTUAL,PARALLEL,INDUSTRY,QUADRUPLE,"Multicenter, Double-Masked, Randomized, Vehicle-Controlled 12-Month Parallel Comparison of the Safety and Efficacy of 0.1% and 0.2% CBT-001 Versus Vehicle, Dosed Twice-Daily, in Patients With Pterygium",2026-12-31,ESTIMATED,conjunctival hyperemia | pterygium length,TREATMENT,ALL,2022-06-30,ACTUAL,INTERVENTIONAL
CNTN,"Canton Strategic Holdings, Inc.",NCT05522205,,ACTIVE_NOT_RECRUITING,"Cannabis Use Disorder, Mental Health Disorder, Physical Illness",,,RANDOMIZED,2,Experimental group | Control group,EXPERIMENTAL | NO_INTERVENTION,The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.,"University of Basel, University Psychiatric Clinics Basel, Psychiatric Services Aargau AG",2025-07-31,ESTIMATED,18 Years - N/A,374,ACTUAL,PARALLEL,OTHER_GOV,NONE,WEED CARE - Randomized Controlled Study on Regulated Cannabis Access for Recreational Use in Pharmacies in Basel,2025-07-31,ESTIMATED,Change in problematic cannabis consumption behaviour,OTHER,ALL,2023-01-31,ACTUAL,INTERVENTIONAL
CNTN,"Canton Strategic Holdings, Inc.",NCT07271524,,NOT_YET_RECRUITING,Traumatic Brain Injury,,,RANDOMIZED,2,Active stimulation | Control stimulation,EXPERIMENTAL | PLACEBO_COMPARATOR,"Impairments in spatial memory and spatial navigation are commonly reported amongst patients presenting post-traumatic brain injury (TBI). In this study, the investigators examine the effect of non-invasive deep brain stimulation of the hippocampal-entorhinal complex (HC-EC), a key region supporting navigation abilities, on spatial navigation performance in TBI patients. Using a virtual reality task where participants must first encode and later recall the location of objects in a virtual arena, ","Fondation Bertarelli, The Novartis Foundation, Clinique Romande de Readaptation, HUG University hospital, SNF Swiss National Foundation, Wyss Center for Bio and Neuroengineering, Fondation Akiva, Canton du Valais",2027-12,ESTIMATED,18 Years - N/A,25,ESTIMATED,CROSSOVER,OTHER,QUADRUPLE,Investigation of the Plasticity of Deep Brain Structures in Mild Cognitive Impairment and Healthy Aging (PlasMA),2027-12,ESTIMATED,Speed in the spatial navigation task | Accuracy in the spatial navigation task,BASIC_SCIENCE,ALL,2025-12,ESTIMATED,INTERVENTIONAL
CNTN,"Canton Strategic Holdings, Inc.",NCT06190288,,RECRUITING,"Transitional Care, Multimorbidity, Geriatric Care",,AdvantAGE,,1,Intervention group,EXPERIMENTAL,"This clinical trial at the University Department of Geriatric Medicine FELIX Platter in Basel, Switzerland, is designed to evaluate a new transitional care model aimed at helping frail older adults after they get discharged from the hospital. The AdvantAGE study aims to explore the following questions:

* Does the new care model help reduce the number of patients who need to return to the hospital within 90 days?
* How effective is the implementation of this care model?

Participants in the tria",Health Department of the Canton of Basel-Stadt,2026-06-30,ESTIMATED,65 Years - N/A,250,ESTIMATED,SINGLE_GROUP,OTHER,NONE,AdvantAGE: Implementation and Evaluation of an Interprofessional Transitional Care Model for Frail Older Adults at the University Department of Geriatric Medicine FELIX PLATTER,2026-06-30,ESTIMATED,90-days rehospitalization rate,HEALTH_SERVICES_RESEARCH,ALL,2024-01-08,ACTUAL,INTERVENTIONAL
DVYSF,Devyser Diagnostics AB (publ),NCT07006831,,RECRUITING,"Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function, Cell-free DNA, NGS",,Accept cfDNA,,1,Kidney transplant recipients,,The purpose of this research is to collect blood samples and data from kidney transplant patients. The samples and data will be used for research and development of non-invasive test to detect donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients to evaluate the status of the transplanted organ.,,2027-03,ESTIMATED,18 Years - N/A,400,ESTIMATED,,INDUSTRY,,"A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population",2026-12,ESTIMATED,Detection of donor-derived cell-free DNA (dd-cfDNA) from whole blood,,ALL,2025-11-14,ACTUAL,OBSERVATIONAL
DVYSF,Devyser Diagnostics AB (publ),NCT06690099,,RECRUITING,"Rhesus D Genotype, Pregnancy",,,,1,Pregnant women,,The purpose of this research is to collect blood samples and data from pregnant women who are Rh negative. The blood will be used for the future research and the development of non-invasive prenatal tests to identify Rh blood type status of the baby during pregnancy.,,2026-12,ESTIMATED,18 Years - N/A,500,ESTIMATED,,INDUSTRY,,Prospective Collection of Whole Blood Specimens From RhD Negative Pregnant Women,2026-06,ESTIMATED,Fetal RhD determination from maternal whole blood,,FEMALE,2025-04-07,ACTUAL,OBSERVATIONAL
DYMDF,Diamyd Medical AB (publ),NCT05683990,PHASE2,RECRUITING,"Diabetes Mellitus, Type 1, Autoimmune Diseases, Prevention",Diamyd,,RANDOMIZED,2,Arm 1 | Arm 2,EXPERIMENTAL | EXPERIMENTAL,A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® (Diamyd) also known as retogatein in individuals at risk of Type 1 diabetes carrying the HLA DR3-DQ2 haplotype.,,2026-12-31,ESTIMATED,8 Years - 18 Years,16,ESTIMATED,PARALLEL,INDUSTRY,NONE,"DiaPrecise, A Phase II Open Label Study to Evaluate the Safety and Feasibility of Intralymphatic Administration of Diamyd® in Individuals at Risk for Type 1 Diabetes Carrying the HLA DR3-DQ2 Haplotype",2026-12-31,ESTIMATED,"Occurrence of AEs (including Injection site reactions) and SAEs | Number of Clinically Significant Abnormal Results from Physical examinations, including neurological and Vital Signs assessments | Number of Clinically Significant Abnormal Results From Laboratory measurements, including hematology, clinical chemistry, metabolic status parameters (fasting C-peptide, HbA1c, fasting glucose) and urine analysis",PREVENTION,ALL,2024-07-09,ACTUAL,INTERVENTIONAL
DYMDF,Diamyd Medical AB (publ),NCT05018585,PHASE3,ACTIVE_NOT_RECRUITING,Type 1 Diabetes Mellitus,"Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Placebo",DIAGNODE-3,RANDOMIZED,2,Diamyd | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.",,2027-12,ESTIMATED,12 Years - 28 Years,330,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype",2027-12,ESTIMATED,Beta cell function | Glycemic control,TREATMENT,ALL,2022-05-19,ACTUAL,INTERVENTIONAL
HRTDF,Heartseed Inc.,NCT07347197,"PHASE1, PHASE2",NOT_YET_RECRUITING,"Heart Failure, Ischemic Heart Failure, Ischemic Heart Disease, Dilated Cardiomyopathy (DCM)",,EMERALD,,1,Treatment,EXPERIMENTAL,The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.,,2030-01-31,ESTIMATED,20 Years - 80 Years,14,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,A Phase I/II Study of Endocardial Delivery for Myocardial Regeneration Using Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids for Heart Failure Reduced Ejection Fraction,2028-01-01,ESTIMATED,Safety and Tolerability,TREATMENT,ALL,2026-01-01,ESTIMATED,INTERVENTIONAL
HRTDF,Heartseed Inc.,NCT04945018,"PHASE1, PHASE2",ACTIVE_NOT_RECRUITING,"Heart Failure, Ischemic Heart Disease",HS-001 CS,LAPiS,NON_RANDOMIZED,2,HS-001 Low dose | HS-001 High dose,EXPERIMENTAL | EXPERIMENTAL,The purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.,,2026-01-31,ESTIMATED,20 Years - 80 Years,10,ESTIMATED,SEQUENTIAL,INDUSTRY,NONE,"A Phase I/II Study of Human Induced Pluripotent Stem (iPS) Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Severe Heart Failure, Secondary to Ischemic Heart Disease",2025-07-31,ACTUAL,Safety and Tolerability,TREATMENT,ALL,2022-04-19,ACTUAL,INTERVENTIONAL
KBBTF,"Kubota Pharmaceutical Holdings Co., Ltd.",NCT06034379,,RECRUITING,Myopia,0.01% atropine,,RANDOMIZED,3,Clinical prototype (CP1) device | CP1 and 0.01% atropine | 0.01% atropine,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"This is a bilateral, dispensing, masked, randomized clinical trial. Myopic children will be randomly assigned to one of the following: (1) Investigational clinical prototype (CP1) device without atropine, (2) Investigational CP1 device with daily instillation of 0.01% atropine, or (3) daily instillation of 0.01% atropine without use of the investigational CP1 device. Primary endpoint: Difference in the 12-month change of cycloplegic spherical refractive error and axial length between each of the",China Medical University Hospital,2025-12,ESTIMATED,6 Years - 13 Years,45,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,Kubota Corrective Spectacles and Low Dose Atropine for Slowing Myopic Progression in Taiwanese Children,2025-12,ESTIMATED,CSER | AL,TREATMENT,ALL,2023-10-01,ACTUAL,INTERVENTIONAL
RLFTY,MindMaze Therapeutics Holding SA,NCT05728840,,RECRUITING,"Stroke, Attention Disorder",,,RANDOMIZED,3,Rehabilitation intervention group | Dose-match control group | Retrospective standard of care group,EXPERIMENTAL | ACTIVE_COMPARATOR | NO_INTERVENTION,"Stroke is the leading cause of long-term disability with an increasing incidence, especially in young adults. Among the cognitive difficulties following brain damage, deficits in attention are frequent and pervasive, affecting between 46% and 92% of stroke survivors. The current project targets patients with acquired brain injury, including stroke, traumatic brain injury, and brain tumor. The main objective of this study is to evaluate the use and the efficacy of a training program targeting att",University of Lausanne Hospitals,2026-07-31,ESTIMATED,18 Years - N/A,135,ESTIMATED,PARALLEL,INDUSTRY,DOUBLE,Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury,2026-07-31,ESTIMATED,Change from baseline in Test of Attentional Performance (TAP),TREATMENT,ALL,2023-02-15,ACTUAL,INTERVENTIONAL
RLFTY,MindMaze Therapeutics Holding SA,NCT07427511,,NOT_YET_RECRUITING,Stroke,,SNR-HDHI,,1,Device assisted high-dose therapy,EXPERIMENTAL,"High-dose, high-intensity (HDHI) neurorehabilitation has shown promise for improving functional outcomes after acquired brain injury (ABI), yet its feasibility and impact across different stages of care and real-world clinical settings remain insufficiently understood.

The SwissNeuroRehab (SNR) initiative, bringing together Swiss rehabilitation centres to develop and evaluate innovative, technology-supported models of neurorehabilitation, provides the broader framework within which this study i","Mindmaze SA, Innosuisse - Swiss Innovation Agency, Cereneo AG",2028-05-31,ESTIMATED,18 Years - 85 Years,120,ESTIMATED,SINGLE_GROUP,OTHER,NONE,SwissNeuroRehab - High Dose High Intensity Neurorehabilitation Along the Continuum of Care,2028-05-31,ESTIMATED,"HDHI training adherence (Active Training Time, ATT) | Feasibility and satisfaction with the HDHI program (Program Feasibility and Satisfaction Questionnaire)",TREATMENT,ALL,2026-02-10,ESTIMATED,INTERVENTIONAL
SPHDF,Santhera Pharmaceuticals Holding AG,NCT06713135,PHASE4,ACTIVE_NOT_RECRUITING,Duchenne Muscular Dystrophy,vamorolone 40 mg/mL oral suspension,GUARDIAN,,1,vamorolone,EXPERIMENTAL,This study aims to assess safety and effectivness of long-term treatment with vamorolone in boys with Duchenne Muscular Dystrophy (DMD) who have completed prior studies with vamorolone.,,2028-09,ESTIMATED,N/A - N/A,80,ESTIMATED,SINGLE_GROUP,INDUSTRY,NONE,An Open-label Study to Collect Safety and Effectiveness Information on Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy Who Have Completed Prior Studies With Vamorolone,2028-09,ESTIMATED,Number of vertebral fractures per 1000 person-years based on X-ray central reading.,TREATMENT,MALE,2024-11-10,ACTUAL,INTERVENTIONAL
XFORW,"X4 Pharmaceuticals, Inc. WT EXP A 041624",NCT06056297,PHASE3,RECRUITING,Neutropenia,"Mavorixafor, Placebo",,RANDOMIZED,2,Mavorixafor | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.,,2027-11,ESTIMATED,12 Years - N/A,176,ESTIMATED,PARALLEL,INDUSTRY,QUADRUPLE,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections",2027-09,ESTIMATED,Co-primary Endpoint: Annualized Infection Rate Based on Infections Adjudicated by Blinded Infection Adjudication Committee (BIAC) During the Treatment Period | Co-primary Endpoint: Number of Participants Meeting the Definition of a Positive Absolute Neutrophil Count (ANC) Response,TREATMENT,ALL,2024-06-06,ACTUAL,INTERVENTIONAL
XFORW,"X4 Pharmaceuticals, Inc. WT EXP A 041624",NCT06858696,PHASE1,RECRUITING,Hepatic Insufficiency,Mavorixafor,,NON_RANDOMIZED,6,Group 1: Child-Pugh A | Group 2: Child-Pugh B | Group 3: Child-Pugh C | Group 4: HVs | Group 5: HVs | Group 6: HVs,EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL | EXPERIMENTAL,"The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.",,2026-04,ESTIMATED,18 Years - 75 Years,48,ESTIMATED,PARALLEL,INDUSTRY,NONE,"An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function",2026-03,ESTIMATED,Maximum Observed Plasma Concentration (Cmax) of Mavorixafor | Area Under the Serum Concentration Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mavorixafor,TREATMENT,ALL,2025-02-28,ACTUAL,INTERVENTIONAL
XFORW,"X4 Pharmaceuticals, Inc. WT EXP A 041624",NCT03995108,PHASE3,ACTIVE_NOT_RECRUITING,WHIM Syndrome,"Mavorixafor, Placebo",,RANDOMIZED,2,Mavorixafor | Placebo,EXPERIMENTAL | PLACEBO_COMPARATOR,"This study has a double-blind, Randomized Placebo-Controlled Period and an Open-Label Period. The primary objective of the Randomized Placebo-Controlled Period is to demonstrate the efficacy of mavorixafor in participants with WHIM syndrome as assessed by increasing levels of circulating neutrophils compared with placebo, and relative to a clinically meaningful threshold. The primary objective of the Open-Label Period is to evaluate the safety and tolerability of mavorixafor in participants with",,2025-12,ESTIMATED,12 Years - N/A,31,ACTUAL,PARALLEL,INDUSTRY,DOUBLE,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients With WHIM Syndrome With Open-Label Extension",2025-12,ESTIMATED,Randomized Placebo-Controlled Period: Time (in Hours) Above Threshold-Absolute Neutrophil Count (TAT-ANC in hours) of ≥ 500 Cells/Microliter (µL) over a 24-hour period | Open-Label Period: Percentage of Participants With Adverse Events (AEs),TREATMENT,ALL,2019-10-24,ACTUAL,INTERVENTIONAL
